temozolomide has been researched along with Brain Neoplasms in 3270 studies
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit." | 9.69 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. ( Baehring, J; Bähr, O; Brandes, AA; Butowski, N; Carpentier, AF; Chalamandaris, AG; Cloughesy, T; Di Giacomo, AM; Fu, AZ; Idbaih, A; Khasraw, M; Lassen, U; Lim, M; Liu, Y; Lombardi, G; Mulholland, P; Muragaki, Y; Omuro, A; Potter, V; Qian, X; Reardon, DA; Roth, P; Sepulveda, JM; Sumrall, A; Tabatabai, G; Tatsuoka, K; van den Bent, M; Vauleon, E; Weller, M, 2023) |
| "Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high." | 9.69 | Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. ( Abad, AP; Ahluwalia, MS; Belal, AN; Birkemeier, MT; Casucci, DM; Ciesielski, MJ; Curry, WT; Dharma, SS; Dhawan, A; Fenstermaker, RA; Figel, SA; Hutson, AD; Liu, S; Mechtler, LL; Mogensen, KM; Peereboom, DM; Qiu, J; Reardon, DA; Withers, HG; Wong, ET, 2023) |
| "Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis." | 9.69 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. ( Anders, CK; Arisa, O; Armstrong, TS; Brastianos, P; Burton, E; Carter, S; Connolly, RM; Figg, WD; Gilbert, MR; Houston, N; Jenkins, S; Khan, I; Lipkowitz, S; Mendoza, TR; Mozarsky, B; Nousome, D; Peer, CJ; Shah, R; Smart, DD; Smith, KL; Steeg, PS; Steinberg, SM; Tweed, C; Vera, E; Wu, X; Zhang, W; Zimmer, AS, 2023) |
| "Despite standard treatments including chemoradiotherapy with temozolomide (TMZ) (STUPP protocol), the prognosis of glioblastoma patients remains poor." | 9.69 | Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). ( Biau, J; Casile, M; De Beaumont, O; Dufort, S; Durando, X; Le Duc, G; Loeffler, M; Molnar, I; Moreau, J; Seddik, K; Thivat, E, 2023) |
| "This study was aimed at analyzing the efficacy and safety of an injectable form of chlorogenic acid (CGA) in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation phase I trial." | 9.69 | Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up. ( Chen, F; Deng, J; Jiang, J; Kang, X; Kang, Z; Li, S; Li, W; Yang, H; Zhang, J, 2023) |
| "In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiotherapy, and overall survival at 12 months was not significantly different (61% in the TMZ arm and 55% in the TMZ + BEV arm)." | 9.69 | Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen ( Bottomley, A; Clement, PM; Coens, C; de Vos, FYF; Ghislain, I; Golfinopoulos, V; Idbaih, A; Klein, M; Lewis, J; Machingura, A; Mulholland, PJ; Reijneveld, JC; Taal, W; Taphoorn, MJB; van den Bent, MJ; Wick, W, 2023) |
| "In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]." | 9.51 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. ( Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W, 2022) |
| "Temozolomide is applied as the standard chemotherapy agent in patients with glioblastoma (GBM) after surgery." | 9.51 | The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial. ( Cheng, Y; Huang, N; Liu, G; Mao, J; Sun, M; Tao, Y; Wen, R; Xie, Z; Zhang, X; Zhao, G, 2022) |
| "Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ)." | 9.51 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. ( Ansstas, G; Baehring, J; De Vos, F; Finocchiaro, G; Honnorat, J; Idbaih, A; Kinoshita, M; Lee, M; Leung, D; Lim, M; Mellinghoff, IK; Omuro, A; Petrecca, K; Raval, RR; Reardon, DA; Roberts, M; Sahebjam, S; Slepetis, R; Steinbach, J; Sumrall, A; Taylor, JW; Warad, D; Weller, M; Wick, A, 2022) |
| "The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas." | 9.51 | Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). ( Ahn, GS; Chang, JH; Choe, G; Choi, BS; Hong, YK; Hwang, K; Joo, J; Jung, TY; Kang, SG; Kim, CY; Kim, EY; Kim, JH; Kim, SH; Kim, TM; Kim, YJ; Lee, DE; Nam, DH; Park, CK; Yoo, H, 2022) |
| "Patients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib." | 9.41 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. ( Aldape, K; Armstrong, TS; Gerstner, ER; Gilbert, MR; Lieberman, F; Mendoza, T; Mikkelsen, T; Omuro, A; Robins, HI; Vera, E; Wen, PY; Wu, J; Yuan, Y, 2021) |
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 9.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma." | 9.41 | Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. ( Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021) |
| "Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies." | 9.41 | A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. ( Ashley, DM; Back, M; Barnes, EH; Buckland, ME; Fisher, L; Foote, MC; Hall, M; Khasraw, M; Koh, ES; Leonard, R; Lwin, Z; McDonald, KL; Rosenthal, M; Sim, HW; Simes, J; Sulman, EP; Wheeler, H; Yip, S, 2021) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| " We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma." | 9.34 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020) |
| "We sought to determine the maximum tolerated dose (MTD) of 5-fraction stereotactic radiosurgery (SRS) with 5-mm margins delivered with concurrent temozolomide in newly diagnosed glioblastoma (GBM)." | 9.34 | A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Hayden Gephart, M; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Usoz, M; von Eyben, R; Wynne, J, 2020) |
| "A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)." | 9.34 | A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. ( Adesina, A; Ansell, P; Baxter, PA; Billups, CA; Blaney, SM; Broniscer, A; Dunkel, IJ; Fouladi, M; Giranda, V; Kilburn, L; Li, XN; Onar-Thomas, A; Paulino, A; Poussaint, TY; Quaddoumi, I; Smith, ER; Su, JM; Thompson, P, 2020) |
| " TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial." | 9.34 | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. ( Chang, JH; Hong, YK; Kim, CY; Kim, JH; Kim, OL; Kim, SH; Nam, DH; Paek, SH, 2020) |
| "Ipi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma." | 9.34 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. ( Blagden, S; Brooks, C; Brown, NF; Coutts, T; Elhussein, L; Holmes, J; Hoskin, P; Maughan, T; Mulholland, P; Ng, SM; Roberts, C, 2020) |
| "Standard of care for glioblastoma includes concurrent chemoradiation and maintenance temozolomide with tumor treatment fields (TTFields)." | 9.34 | Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. ( Andrews, DW; Bar-Ad, V; Chervoneva, I; Evans, JJ; Farrell, CJ; Glass, J; Judy, K; Liu, H; Ly, M; Martinez, N; Palmer, JD; Shi, W; Song, A; Werner-Wasik, M, 2020) |
| "Temozolomide (TMZ) has been the standard-of-care chemotherapy for glioblastoma (GBM) patients for more than a decade." | 9.34 | Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. ( Bendok, BR; Doyle, T; Hawkins-Daarud, A; Hu, LS; Jackson, PR; Johnston, SK; Massey, SC; Mrugala, MM; Porter, AB; Sarkaria, JN; Singleton, KW; Swanson, KR; Vora, S; White, H; Whitmire, P, 2020) |
| "To report the long-term outcomes of the RTOG 0424 study of a high-risk, low-grade glioma population treated with concurrent and adjuvant temozolomide (TMZ) and radiation therapy (RT)." | 9.34 | Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Barani, IJ; Bovi, JA; Chakravatri, A; D'Souza, D; Doyle, T; Fisher, BJ; Fiveash, JB; Fox, S; Howard, SP; Kwok, Y; Laack, NN; Lesser, GJ; Macdonald, DR; Mehta, MP; Michael Yu, HH; Pugh, SL; Rogers, CL; Strasser, JF; Wahl, DR; Werner-Wasik, M; Won, M, 2020) |
| "Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate." | 9.34 | A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). ( Alonso, M; Balana, C; Berrocal, A; Carrato, C; Covela, M; de Las Peñas, R; Del Barco, S; Domenech, M; Esteve, A; Estival, A; Fuster, J; Gallego, O; Gil-Gil, M; Gironés, R; Herrero, A; Luque, R; Manuel Sepúlveda, J; Martinez-García, M; Mesia, C; Munne, N; Muñoz-Langa, J; Navarro, LM; Olier, C; Peralta, S; Perez-Martín, FJ; Perez-Segura, P; Pineda, E; Sanz, C; Vaz, MA; Villa, S, 2020) |
| "This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone." | 9.34 | Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. ( Abe, T; Adilijiang, A; Aoki, K; Aoki, T; Arakawa, Y; Asai, A; Asano, K; Beppu, T; Hashimoto, N; Hirano, H; Hirano, M; Ishikawa, E; Ito, T; Iwadate, Y; Kayama, T; Kobayashi, H; Kumabe, T; Kurisu, K; Maeda, S; Maruyama, T; Matsumura, A; Matsuo, T; Mishima, K; Motomura, K; Mukasa, A; Muragaki, Y; Nagane, M; Nakamura, H; Nakasu, Y; Narita, Y; Natsume, A; Nishikawa, R; Ohka, F; Okuno, Y; Onishi, T; Sasaki, H; Sato, S; Shibui, S; Shinoura, N; Sugiyama, K; Sumi, M; Terasaki, M; Wakabayashi, T; Yamasaki, F; Yoshimoto, K; Yoshino, A, 2020) |
| " In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone." | 9.34 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020) |
| "The optimal management of high risk WHO grade II gliomas after surgery is debated including the role of initial temozolomide to delay radiotherapy and risk of cognitive defects." | 9.30 | Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. ( Bello, L; Bertero, L; Carapella, CM; Caroli, M; Cassoni, P; Dealis, C; Faedi, M; Marchese, G; Migliore, E; Pace, A; Pellerino, A; Rudà, R; Soffietti, R, 2019) |
| "To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma." | 9.30 | Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. ( Cartalat, S; Chinot, O; Devos, P; Di Stefano, AL; Dubois, F; Houillier, C; Le Rhun, E; Lepage, C; Reyns, N; Weller, M, 2019) |
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 9.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| " We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma (GBM)." | 9.30 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. ( Ahluwalia, MS; Blakeley, JO; Chi, AS; Desideri, S; Eichler, A; Grossman, SA; Mikkelsen, T; Nabors, LB; Ribas, IG; Rosenfeld, MR; Ye, X, 2019) |
| "Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma." | 9.30 | Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019) |
| " Gliomas, which are common in dogs and also represent the majority of fatal brain tumours in humans, can be amenable to chemotherapy with temozolomide." | 9.30 | Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders. ( Hicks, J; Holmes, S; Howerth, E; Kaplan, E; Kaplan, J; Kent, M; Platt, S; Senneca, C; Stewart, G, 2019) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 9.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "The treatment using hypofractionated stereotactic radiotherapy concurrent with temozolomide appeared to be safe and could significantly extend overall survival compared with historical control in complex brain metastases." | 9.30 | A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. ( Bi, N; Chen, X; Deng, L; Hu, C; Huang, X; Li, J; Li, Y; Liu, F; Liu, Q; Ma, Y; Tian, Y; Wang, K; Wang, W; Xiao, J; Xu, Y; Yang, S; Yi, J; Zhang, H; Zhang, Y; Zhao, R, 2019) |
| "In RPA V-VI glioblastoma patients both hypofractionated radiotherapy and exclusive temozolomide can be used; the purpose of this trial is to compare these treatment regimens in terms of survival and quality of life." | 9.30 | Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. ( Borghetti, P; Bruni, A; Buglione, M; Fusco, V; Gatta, R; Krengli, M; Magrini, SM; Masini, L; Meduri, B; Pedretti, S; Pegurri, L; Pirtoli, L; Ricardi, U; Riva, N; Santoni, R; Scoccianti, S; Triggiani, L; Turco, E, 2019) |
| "A multicenter phase II study for assessing the efficacy and the toxicity of hypofractionated radiotherapy with SIB plus temozolomide in patients with glioblastoma was carried out by the Brain Study Group of the Italian Association of Radiation Oncology." | 9.27 | Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). ( Buglione, M; Detti, B; Doino, D; Fiorentino, A; Fusco, V; Greto, D; Krengli, M; Livi, L; Lonardi, F; Magrini, SM; Marrazzo, L; Marzano, S; Masini, L; Migliaccio, F; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S, 2018) |
| "Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma." | 9.27 | Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. ( Ahluwalia, MS; Anderson, SK; Ballman, KV; Buckner, JC; Cerhan, J; Galanis, E; Gerstner, ER; Giannini, C; Grossman, SA; Jaeckle, K; Lee, EQ; Lesser, GJ; Ligon, KL; Loboda, A; Miller, CR; Moore, DF; Nebozhyn, M; Prados, M; Sarkaria, JN; Schiff, D; Wen, PY, 2018) |
| "We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A)." | 9.27 | Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ( Ansell, PJ; Butowski, N; Fichtel, L; Fischer, J; Gan, HK; Gomez, EJ; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Mandich, H; Merrell, R; Munasinghe, WP; Reardon, DA; Roberts-Rapp, LA; Scott, AM; van den Bent, M; Wheeler, H; Xiong, H, 2018) |
| "The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O6-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms." | 9.27 | Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. ( Belka, C; Friedrich, F; Glas, M; Goldbrunner, R; Grau, S; Grauer, O; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Krex, D; Leutgeb, B; Mack, F; Nießen, M; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A, 2018) |
| "This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma." | 9.27 | A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. ( Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M, 2018) |
| " We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs)." | 9.27 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. ( Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Peters, KB; Reardon, DA, 2018) |
| "Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 9.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
| "Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is considered as standard therapy for adults with newly diagnosed glioblastoma." | 9.27 | Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. ( Arefian, H; Hartmann, M; Kalff, R; Maschmann, J; Walter, J; Waschke, A, 2018) |
| "1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas." | 9.27 | Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. ( Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC, 2018) |
| "In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM)." | 9.27 | Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. ( Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M, 2018) |
| "Adult patients with intermediate- to high-grade glioma on adjuvant temozolomide (TMZ) with facilities for live video call were invited to participate in the study." | 9.27 | Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy. ( Chakraborty, S; Chandrasekharan, A; Dsouza, H; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; M, C; Pande, N; Patil, VM; Tonse, R; Vallathol, DH, 2018) |
| "In this study, MGMT promoter methylation was an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiotherapy." | 9.27 | Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. ( Aldape, KD; Ashby, LS; Bahary, JP; Becker, AP; Bell, EH; Chakraborty, AR; Chakravarti, A; Fabian, D; Fisher, BJ; Fleming, J; Gray, HJ; Kwok, Y; Laack, NN; Lesser, GJ; Liu, Z; Macdonald, DR; McElroy, JP; Mehta, MP; Robins, HI; Schultz, CJ; Walker, EM; Werner-Wasik, M; Yu, HM; Zhang, P, 2018) |
| "Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs)." | 9.24 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. ( Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X, 2017) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 9.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 9.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "We characterized health-related quality of life (HRQoL), cognitive, and functional status in newly diagnosed glioblastoma (GBM) patients receiving Tumor treating fields (TTFields) with temozolomide (TMZ) versus TMZ alone in a planned interim analysis of a randomized phase III trial [NCT00916409], which showed significant improvement in progression-free and overall survival with TTFields/TMZ." | 9.24 | Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. ( Avgeropoulos, N; Benouaich-Amiel, A; David, C; Demireva, P; Goldlust, S; Kanner, AA; Mehdorn, M; Pannullo, S; Salmaggi, A; Silvani, A; Zhu, JJ, 2017) |
| "While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy." | 9.24 | Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. ( Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M, 2017) |
| "The primary objective of this study was to compare the overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU)." | 9.24 | Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( Aldape, KD; Bahary, JP; Barger, GR; Belanger, K; Bell, EH; Brachman, D; Brown, PD; Cairncross, JG; Chakravarti, A; Chang, S; Dolinskas, CA; Gilbert, MR; Hunter, G; Jaeckle, K; Mehta, M; Penas-Prado, M; Robins, HI; Schiff, D; Schultz, C; Shih, H; Werner-Wasik, M; Zhang, P, 2017) |
| "We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy." | 9.24 | A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. ( Abdulkarim, B; Corredor, AG; Guiot, MC; Owen, S; Panet-Raymond, V; Petrecca, K; Shenouda, G; Souhami, L, 2017) |
| "The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma." | 9.24 | Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. ( Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H, 2017) |
| "There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era." | 9.24 | Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. ( Aldape, K; Barnholtz-Sloan, JS; Becker, AP; Bell, EH; Blumenthal, DT; Brachman, D; Bredel, M; Brown, PD; Chakravarti, A; Curran, W; Flickinger, J; Gilbert, MR; Glass, J; Grosu, AL; Klimowicz, AC; Lee, RJ; Magliocco, A; McElroy, JP; Mehta, M; Pugh, SL; Robe, P; Salavaggione, AL; Souhami, L; Stupp, R; Won, M, 2017) |
| "Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating agent used as a first-line treatment of glioblastoma multiforme (GBM)." | 9.22 | Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. ( Chitkara, D; Jatyan, R; Karthik, YG; Mittal, A; Sahel, DK; Singh, P, 2022) |
| "To evaluate the safety and efficacy of nimotuzumab, a humanized monoclonal antibody specific for the epidermal growth factor receptor (EGFR), in combination with temozolomide (TMZ) and radiation therapy (RT) in the treatment of newly diagnosed glioblastoma (GBM) in Chinese patients." | 9.22 | Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. ( Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y, 2016) |
| "We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients." | 9.22 | A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. ( Beauchesne, P; Bernier, V; Carnin, C; Faure, G; Gorlia, T; Noel, G; Pedeux, R; Quetin, P; Quillien, V, 2016) |
| "This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients." | 9.22 | A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. ( Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P, 2016) |
| "This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse." | 9.22 | Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V, 2016) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns." | 9.22 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. ( Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 9.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| "To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma." | 9.22 | A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. ( Bernier, V; Blanchard, N; Bonnetain, F; Dalban, C; Lagneau, É; Maingon, P; Mazoyer, F; Mirjolet, C; Noël, G; Truc, G, 2016) |
| " Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg)." | 9.22 | Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). ( Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2016) |
| "Overall, there was no significant difference in progression-free survival in patients with low-grade glioma when treated with either radiotherapy alone or temozolomide chemotherapy alone." | 9.22 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. ( Balana, C; Baumert, BG; Brandes, AA; Bravo-Marques, J; Bromberg, JE; Capper, D; Chinot, O; Clement, PM; Dhermain, F; Dif, N; Enting, R; Feuvret, L; Gijtenbeek, JMM; Gorlia, T; Hartmann, C; Hassel, MB; Hegi, ME; Hoang-Xuan, K; Kantor, G; Kros, JM; Kurscheid, S; Lacombe, D; Marosi, C; Mason, WP; Nordal, RA; Rees, J; Reijneveld, JC; Reni, M; Rossiter, JP; Ryan, G; Stupp, R; Taphoorn, MJB; Thiessen, B; Tzuk-Shina, T; van den Bent, MJ; von Deimling, A; Wick, W, 2016) |
| "Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients." | 9.20 | Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. ( Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015) |
| "This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM)." | 9.20 | Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. ( Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S, 2015) |
| "Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma." | 9.20 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015) |
| "To improve the therapeutic index of whole-brain radiation therapy (WBRT) in the treatment of brain metastases (BM) from breast cancer, we investigated the efficacy and safety of WBRT combined with temozolomide (TMZ) in this population." | 9.20 | Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. ( Bourgier, C; Cao, KI; Gerber, S; Gobillion, A; Kirova, YM; Le Scodan, R; Lebas, N; Levy, C; Pierga, JY; Savignoni, A, 2015) |
| " We evaluated the efficacy and toxicity of hypofractionated intensity-modulated radiation therapy with concurrent and adjuvant temozolomide and bevacizumab in patients with newly diagnosed glioblastoma." | 9.20 | Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. ( Carlson, JA; Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, KO; Ney, DE; Reddy, K; Waziri, AE, 2015) |
| "Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent." | 9.20 | Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ, 2015) |
| "Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules." | 9.20 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. ( Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG, 2015) |
| "Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls." | 9.20 | Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Brachman, DG; Chakravarti, A; Coons, SW; Fisher, BJ; Hu, C; Lesser, GJ; Liu, J; Macdonald, DR; Mehta, M; Ryu, S; Werner-Wasik, M, 2015) |
| "To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed." | 9.20 | Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2015) |
| "The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM)." | 9.20 | Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. ( Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M, 2015) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 9.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "This phase I study aimed to evaluate safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, in combination with temozolomide (TMZ), with or without radiation therapy (RT), in patients with high-grade glioma." | 9.20 | Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. ( Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 9.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma." | 9.20 | Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. ( Brachman, DG; Giannini, C; Hu, C; Jenkins, RB; Laack, NN; Macdonald, DR; Mehta, MP; Peereboom, DM; Shrieve, DC; Souhami, L; Suh, JH; Vogelbaum, MA, 2015) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 9.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily." | 9.20 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. ( Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M, 2015) |
| "Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models." | 9.20 | Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. ( Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 9.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 9.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| "Adult patients with newly surgical diagnosed glioblastoma were randomly assigned to receive either temozolomide or semustine after radiation treatment." | 9.19 | Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. ( Chen, JX; Liu, JP; Liu, YH; Mao, Q; Wang, X; You, C, 2014) |
| " We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT." | 9.19 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. ( Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY, 2014) |
| "We conducted a phase I study to determine (a) the maximum tolerated dose of peri-radiation therapy temozolomide (TMZ) and (b) the safety of a selected hypofractionated intensity modulated radiation therapy (HIMRT) regimen in glioblastoma multiforme (GBM) patients." | 9.19 | Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. ( Ammirati, M; Chotai, S; Grecula, J; Lamki, T; Newton, H; Wei, L, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 9.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "Surgery followed by radiotherapy and concomitant and adjuvant temozolomide is standard therapy in newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. ( Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C, 2014) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide." | 9.19 | Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. ( Abrey, L; Brandes, AA; Carpentier, AF; Cernea, D; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Hoang-Xuan, K; Kavan, P; Mason, W; Nishikawa, R; Saran, F; Wick, W, 2014) |
| "Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation." | 9.19 | Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. ( Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I, 2014) |
| "The objective of this study was to report the patterns of failure in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 9.19 | Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. ( Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K, 2014) |
| " The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GB)." | 9.19 | A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. ( Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X, 2014) |
| "Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM)." | 9.19 | Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. ( Abe, T; Hashimoto, K; Ikuta, S; Ishihara, T; Ishikawa, E; Karasawa, K; Maruyama, T; Matsuda, M; Matsumura, A; Matsutani, M; Muragaki, Y; Nakazato, Y; Ohno, T; Tsuboi, K; Uemae, Y; Yamamoto, T, 2014) |
| " We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab." | 9.19 | Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. ( Abrey, LE; Barradas-Panchal, R; Baser, RE; Beal, K; Brennan, CW; Chan, TA; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, C; Gutin, P; Hormigo, A; Huse, JT; Kaley, TJ; Karimi, S; Lassman, AB; Mellinghoff, I; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Reiner, AS; Sanchez, J; Tabar, V; Zhang, J, 2014) |
| " Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter)." | 9.19 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. ( Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T, 2014) |
| " The primary objective of this study was to determine the safety of the combination of PPX with temozolomide and concurrent radiation for high-grade gliomas." | 9.19 | Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. ( Boxerman, J; Cielo, D; Constantinou, M; Dipetrillo, T; Donahue, J; Elinzano, H; Evans, D; Goldman, M; Isdale, D; Jeyapalan, S; Kinsella, T; Mantripragada, K; Oyelese, A; Puthawala, Y; Rosati, K; Safran, H; Santaniello, A; Stopa, E, 2014) |
| "To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM)." | 9.17 | Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. ( Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W, 2013) |
| "A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma." | 9.17 | A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. ( Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X, 2013) |
| "The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas." | 9.17 | Secondary hematological malignancies associated with temozolomide in patients with glioma. ( Miyakita, Y; Momota, H; Narita, Y; Shibui, S, 2013) |
| "Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown." | 9.17 | Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. ( Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ, 2013) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 9.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 9.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "To determine the safety of the mammalian target of rapamycin inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients." | 9.17 | RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ( Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M, 2013) |
| "To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ)." | 9.17 | Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. ( Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, KO; Ney, D; Reddy, K; Waziri, A, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 9.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| "To investigate the impact of nonstandard concomitant temozolomide (TMZ) administration in two prospective phase II studies for glioblastoma (GBM)." | 9.17 | Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. ( Alitto, AR; Anile, C; Balducci, M; Chiesa, S; Colosimo, C; D'Agostino, GR; De Bonis, P; Fiorentino, A; Frascino, V; Mangiola, A; Mantini, G; Mattiucci, GC; Valentini, V, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM)." | 9.17 | Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. ( Aldape, KD; Armstrong, TS; Baumert, B; Blumenthal, DT; Brown, PD; Chakravarti, A; Curran, WJ; Erridge, S; Gilbert, MR; Hegi, ME; Hopkins, KI; Jaeckle, KA; Mahajan, A; Mehta, MP; Schultz, CJ; Stupp, R; Tzuk-Shina, T; Wang, M; Wefel, JS; Won, M, 2013) |
| "Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma." | 9.17 | Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. ( Armstrong, TS; Bottomley, A; Brachman, DG; Choucair, AK; Coens, C; Gilbert, MR; Mehta, M; Mendoza, TR; Wang, M; Wefel, JS; Werner-Wasik, M; Won, M, 2013) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 9.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme." | 9.17 | Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). ( Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V, 2013) |
| "In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)." | 9.17 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. ( Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C, 2013) |
| "We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas." | 9.17 | A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. ( Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 9.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)." | 9.16 | Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. ( Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ, 2012) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | 9.16 | Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide." | 9.16 | Bevacizumab and daily temozolomide for recurrent glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ, 2012) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 9.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "This phase I trial was designed to determine the recommended phase II dose(s) of everolimus (RAD001) with temozolomide (TMZ) in patients with glioblastoma (GBM)." | 9.16 | A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. ( Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S, 2012) |
| "To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 9.16 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A, 2012) |
| " The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing." | 9.16 | A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). ( Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X, 2012) |
| " We did a randomised trial to compare the efficacy and safety of dose-dense temozolomide alone versus radiotherapy alone in elderly patients with anaplastic astrocytoma or glioblastoma." | 9.16 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. ( Braun, C; Combs, SE; Felsberg, J; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Nikkhah, G; Papsdorf, K; Platten, M; Reifenberger, G; Sabel, M; Simon, M; Steinbach, JP; Tabatabai, G; Vesper, J; Weller, M; Wick, W, 2012) |
| "To evaluate the efficacy of adding bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, and everolimus, a mammalian target of rapamycin (mTOR inhibitor), to standard radiation therapy/temozolomide in the first-line treatment of patients with glioblastoma." | 9.16 | Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. ( Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW, 2012) |
| "To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas." | 9.16 | Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. ( Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ, 2012) |
| " Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma." | 9.16 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. ( Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B, 2012) |
| "The assessment of the therapeutic response of high-grade gliomas treated with concomitant chemoradiotherapy (CCRT) using temozolomide is difficult because of the frequent occurrence of early imaging changes that are indistinguishable from tumor progression, termed pseudoprogression." | 9.16 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS, 2012) |
| "A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)." | 9.16 | Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. ( Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012) |
| "To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone." | 9.16 | The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. ( Bressel, M; Gunjur, A; Ryan, G, 2012) |
| "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment." | 9.15 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. ( Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B, 2011) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 9.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "To determine the maximum tolerated dose (MTD) of tipifarnib in combination with conventional radiotherapy for patients with newly diagnosed glioblastoma." | 9.15 | A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. ( Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY, 2011) |
| "This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM)." | 9.15 | Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. ( Black, K; Cloughesy, T; Elashoff, R; Fehrenbacher, L; Filka, E; Green, RM; Kolevska, T; Lai, A; Liau, LM; Mischel, PS; Nghiemphu, PL; Peak, S; Phuphanich, S; Polikoff, J; Pope, WB; Selch, M; Solis, OE; Spier, CE; Tran, A; Yong, WH, 2011) |
| "The objective of this prospective, monocentric phase-II pilot study was to evaluate toxicity and efficacy of neoadjuvant temozolomide (TMZ) and 13-cis retinoic acid (13-cRA) treatment in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection." | 9.15 | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). ( Bogdahn, U; Brawanski, A; Grauer, O; Hartmann, C; Hau, P; Pascher, C; Pietsch, T; Proescholdt, M; Weller, M; Wick, W; Zeman, F, 2011) |
| "To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide." | 9.15 | Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. ( Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA, 2011) |
| "This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients." | 9.15 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. ( Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A, 2011) |
| "Concurrent and post-radiotherapy temozolomide (T) significantly improves survival in patient with newly diagnosed glioblastoma multiforme." | 9.15 | Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. ( Ananda, S; Brown, C; Cher, L; Dowling, A; Nowak, AK; Rosenthal, MA; Simes, J, 2011) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 9.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma." | 9.15 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. ( Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S, 2011) |
| "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)." | 9.14 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009) |
| "To determine whether increased uptake on 11C-methionine-PET (MET-PET) imaging obtained before radiation therapy and temozolomide is associated with the site of subsequent failure in newly diagnosed glioblastoma multiforme (GBM)." | 9.14 | Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. ( Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C, 2009) |
| "In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin." | 9.14 | Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. ( Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE, 2009) |
| "This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma." | 9.14 | Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. ( Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S, 2009) |
| "Patients with newly diagnosed oligodendroglioma or oligoastrocytoma with a MIB-1 index of >5% or recurrent low-grade gliomas received temozolomide (75 mg/m(2)/day in 11-week cycles of 7 weeks on/4 weeks off)." | 9.14 | Phase II study of protracted daily temozolomide for low-grade gliomas in adults. ( Black, PM; Bradshaw, J; Ciampa, A; Doherty, L; Drappatz, J; Kesari, S; LaFrankie, D; Levy, B; Ligon, KL; Macklin, EA; Muzikansky, A; Norden, AD; Radakovic, G; Ramakrishna, N; Santagata, S; Schiff, D; Wen, PY, 2009) |
| "Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide." | 9.14 | Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy." | 9.14 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| " We investigated the time course of tumor metabolism in low-grade gliomas (LGG) during temozolomide chemotherapy, and compared metabolic responses as measured with positron emission tomography (PET) with volume responses as revealed by magnetic resonance imaging (MR)." | 9.14 | Early metabolic responses in temozolomide treated low-grade glioma patients. ( Bärtschi, E; Bruehlmeier, M; Buettner, UW; Hefti, M; Hofer, S; Roelcke, U; Uhlmann, C; Wyss, M, 2009) |
| "Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both." | 9.14 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. ( Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009) |
| "This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.14 | Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2009) |
| "This trial was designed to estimate overall survival in adults with newly diagnosed glioblastoma treated with talampanel in addition to standard radiation (RT) and temozolomide (TMZ)." | 9.14 | Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. ( Batchelor, T; Chamberlain, M; Desideri, S; Fine, HA; Fisher, J; Grossman, SA; Mikkelsen, T; Piantadosi, S; Ye, X, 2009) |
| "To present outcome data in a prospective study of radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in children with diffuse intrinsic pontine gliomas (DIPGs)." | 9.14 | Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. ( Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R, 2010) |
| "This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma." | 9.14 | Extended-schedule dose-dense temozolomide in refractory gliomas. ( Balaña, C; Berrocal, A; Gallego, O; Garcia Lopez, J; Gil, M; Iglesias, L; Perez Segura, P; Reynes, G; Rodríguez, J; Yaya, R, 2010) |
| "Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon alpha2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls." | 9.14 | Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. ( Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK, 2009) |
| "To determine the maximum tolerated dose (MTD) of fractionated intensity-modulated radiotherapy (IMRT) with temozolomide (TMZ) in patients with glioblastoma." | 9.14 | A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. ( Balducci, M; Calista, F; Cantore, GP; Cellini, N; Cilla, S; Deodato, F; Digesù, C; Esposito, V; Ferro, M; Ianiri, M; Macchia, G; Morganti, AG; Piermattei, A; Romanelli, P; Salvati, M; Valentini, V, 2010) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 9.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma." | 9.14 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. ( Bähr, O; Bamberg, M; Gorlia, T; Hartmann, C; Herrlinger, U; Meyermann, R; Tatagiba, M; von Deimling, A; Weiler, M; Weller, M; Wick, W; Wiewrodt, D, 2010) |
| "Heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma received cisplatin at a dose of 75 mg/m(2) on day 1 and temozolomide at a dose of 150 mg/m(2) on days 1 to 5 every 21 days until progression or major toxicity." | 9.14 | A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. ( Della Puppa, A; Lombardi, G; Pastorelli, D; Rotilio, A; Scienza, R; Zustovich, F, 2009) |
| "We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy." | 9.14 | IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kros, JM; Postma, TJ; Smitt, PA; Taal, W; van den Bent, MJ; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2009) |
| "To investigate the efficacy and safety of temozolomide (TMZ) and lomustine (CCNU) in malignant brain gliomas." | 9.14 | [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. ( Chang, Y; Fu, Z; Liu, XM; Liu, XY; Qian, ZZ; Wang, HQ; Yang, SY; Yu, H, 2009) |
| "We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma." | 9.14 | Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. ( Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE, 2010) |
| "We assessed six-month progression-free survival (PFS) as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ)." | 9.14 | Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. ( Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M, 2010) |
| "To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 9.14 | A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. ( Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB, 2010) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 9.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "Twenty-two patients with newly diagnosed malignant glioma who received standard radiation/temozolomide therapy were recruited for the study." | 9.14 | Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. ( Chiba, Y; Hashimoto, N; Hosen, N; Kagawa, N; Kinoshita, M; Murao, A; Nishida, S; Oji, Y; Oka, Y; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2010) |
| "The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM)." | 9.14 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. ( Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M, 2010) |
| "Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation." | 9.14 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ( Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M, 2010) |
| "The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme." | 9.14 | Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010) |
| "The objectives of this study were to determine the safety and efficacy of polyinosinic-polycytidylic acid stabilized with poly-l-lysine and carboxymethylcellulose (poly-ICLC) when added to radiation and temozolomide (TMZ) in adults with newly diagnosed glioblastoma (GB)." | 9.14 | A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. ( Batchelor, TT; Chamberlain, MC; Desideri, S; Grossman, SA; Lesser, GJ; Peereboom, DM; Rosenfeld, MR; Salazar, AM; Ye, X, 2010) |
| "Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ)." | 9.14 | Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. ( Combs, SE; Debus, J; Haberer, T; Habermehl, D; Haselmann, R; Jäkel, O; Kieser, M; Nikoghosyan, A; Rieken, S; Unterberg, A; Wick, W, 2010) |
| "To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM)." | 9.13 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. ( Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S, 2008) |
| "We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy." | 9.13 | Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. ( D'Amico, A; Dall'oglio, S; Gabbani, M; Maluta, S; Pasini, F; Passarin, MG; Pioli, F; Talacchi, A; Turazzi, S, 2008) |
| "The combination of temozolomide (TMZ) and thalidomide was reported to produce a high response rate, including shrinkage of brain metastases, in patients with metastatic melanoma." | 9.13 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008) |
| "A multicenter phase I clinical trial, namely, Integrated Japanese Multicenter Clinical Trial: A Phase I Study of Interferon-beta and Temozolomide for Glioma in Combination with Radiotherapy (INTEGRA Study), is being conducted for patients with high-grade glioma in order to evaluate the safety, feasibility and preliminary clinical effectiveness of the combination of interferon-beta and temozolomide." | 9.13 | A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). ( Aoki, T; Hashimoto, N; Kayama, T; Kurisu, K; Natsume, A; Nishikawa, R; Ogura, M; Takahashi, H; Wakabayashi, T; Yoshida, J; Yoshimine, T, 2008) |
| "To evaluate the efficacy of simultaneous postoperative temozolomide radiochemotherapy in glioblastoma patients." | 9.13 | Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. ( Becker, G; Borberg, SK; Fischedick, AR; Frommolt, P; Grauthoff, H; Herfarth, K; Kocher, M; Müller, RP; Niewald, M; Rühl, U; Staar, S; Steingräber, M; Stuschke, M, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 9.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| "The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective." | 9.13 | Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. ( Al, MJ; Crott, R; Gorlia, T; Jin Seung, S; Lamers, LM; Mittmann, N; Stupp, R; Uyl-de Groot, CA; van den Bent, MJ; Wasserfallen, JB, 2008) |
| "Twice-daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity." | 9.13 | Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. ( Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M, 2008) |
| "To evaluate toxicity and outcomes in patients with primary glioblastoma (GB) treated with postoperative radiochemotherapy (RCHT) with temozolomide (TMZ) comparing two dose regimens." | 9.13 | Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. ( Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A, 2008) |
| "We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma." | 9.13 | Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. ( Bael, TE; Gollob, JA; Peterson, BL, 2008) |
| "To assess interim safety and tolerability of a 10-patient, Phase II pilot study using bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy (RT) in the up-front treatment of patients with newly diagnosed glioblastoma." | 9.13 | Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. ( Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH, 2008) |
| "We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combination with temozolomide (TMZ) to malignant glioma (MG) patients." | 9.13 | Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ( Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ, 2008) |
| "The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)." | 9.13 | Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. ( Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD, 2008) |
| "We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma." | 9.13 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008) |
| "The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status." | 9.13 | Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A, 2008) |
| "To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas." | 9.13 | Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. ( Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T, 2008) |
| "A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)." | 9.13 | CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 9.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide." | 9.12 | MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C, 2021) |
| "Recent developments in pharmacogenomics have created opportunities for predicting temozolomide response in gliomas." | 9.12 | Comprehensive pharmacogenomics characterization of temozolomide response in gliomas. ( Long, J; Tong, S; Wang, B; Wang, Y; Wu, J; Zhong, P, 2021) |
| "We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line." | 9.12 | Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies. ( Brennan, PM; Bruce, M; Hannan, CJ; Poon, MTC; Simpson, JE, 2021) |
| "To determine which method for assessing MGMT methylation status best predicts overall survival in people diagnosed with glioblastoma who are treated with temozolomide." | 9.12 | Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Howell, A; Jefferies, S; Kelly, C; Kernohan, A; Kurian, KM; McAleenan, A; Robinson, T; Schmidt, L; Spiga, F; Vale, L; Wragg, C, 2021) |
| "In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas." | 9.12 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. ( Sun, X; Turcan, S, 2021) |
| "(1) Background: Studies in elderly patients over the age of 65 with glioblastoma have shown survival benefits of short-course radiation therapy with concurrent and adjuvant temozolomide, making it the standard of care adopted at Juravinski Cancer Center." | 9.12 | Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. ( Greenspoon, JN; Mir, T; Pond, G, 2021) |
| "The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma." | 9.12 | Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006) |
| "A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)." | 9.12 | Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2006) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 9.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases." | 9.12 | A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. ( Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S, 2006) |
| "The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas." | 9.12 | Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. ( Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006) |
| "Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes." | 9.12 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ( Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK, 2006) |
| "The implementation of combined radiochemotherapy (RCHT) with temozolomide (TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma multiforme (GBM), however, outcome still remains unsatisfactory." | 9.12 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. ( Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D, 2006) |
| "The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide (TMZ) and radiotherapy (RT) in glioblastoma (GBM) has demonstrated that the combination of TMZ and RT conferred a significant and meaningful survival advantage compared with RT alone." | 9.12 | Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. ( Allgeier, A; Brandes, AA; Cairncross, G; Curschmann, J; Fisher, B; Gorlia, T; Kortmann, RD; Lacombe, D; Mason, W; Mirimanoff, RO; Reni, M; Stupp, R; Van den Bent, MJ; Villa, S, 2006) |
| "To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy." | 9.12 | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006) |
| "The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse." | 9.12 | [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 9.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 9.12 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours." | 9.12 | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. ( Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T, 2006) |
| " The aim of this pilot study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) treatment in twelve consecutive patients with recurrent TMZ-refractory glioblastoma." | 9.12 | A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. ( Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ, 2006) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 9.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 9.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 9.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide." | 9.12 | MGMT methylation: a marker of response to temozolomide in low-grade gliomas. ( Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J, 2006) |
| "We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma." | 9.12 | Temozolomide in children with progressive low-grade glioma. ( Allen, JC; Desjardins, A; Fisher, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Krauser, JM; Phillips, PC; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Watral, MA, 2007) |
| "To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases." | 9.12 | Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? ( Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A, 2007) |
| "This phase II study evaluated the efficacy and safety of a 7-day on/7-day off regimen of temozolomide before radiotherapy (RT) in patients with inoperable newly diagnosed glioblastoma." | 9.12 | Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. ( Barrié, M; Braguer, D; Chinot, OL; Dufour, H; Eudes, N; Figarella-Branger, D; Fuentes, S; Lancelot, S; Martin, PM; Metellus, P; Muracciole, X; Ouafik, L, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 9.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites." | 9.12 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ( Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK, 2007) |
| "Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose of 150 mg/m2 per day on a 5-day schedule every 28 days." | 9.11 | Temozolomide in the treatment of recurrent malignant glioma. ( Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P, 2004) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 9.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM)." | 9.11 | Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. ( Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM, 2004) |
| "We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients." | 9.11 | Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. ( Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A, 2004) |
| "The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)." | 9.11 | Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. ( Chamberlain, MC; Tsao-Wei, DD, 2004) |
| "In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide." | 9.11 | Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. ( de Tribolet, N; Dietrich, PY; Diserens, AC; Godard, S; Hegi, ME; Ostermann, S; Otten, P; Regli, L; Stupp, R; Van Melle, G, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 9.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity." | 9.11 | First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004) |
| "To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma." | 9.11 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004) |
| "This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma." | 9.11 | Temozolomide in paediatric high-grade glioma: a key for combination therapy? ( Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC, 2004) |
| "The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma." | 9.11 | Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004) |
| "Thirty-two patients with relapsing glioma were treated with temozolomide in two university hospitals in Finland." | 9.11 | Temozolomide treatment in glioma--experiences in two university hospitals in Finland. ( Aaltonen, K; Mäenpää, HO; Mäntylä, R; Minn, H, 2004) |
| "An analysis of 73 patients with hystologically confirmed glioblastoma multiforme (GBM), treated with the ''3 step'' (90)Y-biotin based LR-RIT, is herein reported." | 9.11 | Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. ( Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 9.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival." | 9.11 | Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). ( Balaña, C; Balart, J; Ballester, R; Benavides, M; Berrocal, A; Capellades, J; Cerdá-Nicolás, M; García, JL; Herrero, A; López-Pousa, A; Martín-Broto, J; Yaya-Tur, R, 2004) |
| "Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle)." | 9.11 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. ( Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M, 2005) |
| "Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma." | 9.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)." | 9.11 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. ( Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J, 2005) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 9.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma." | 9.11 | Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. ( Chan, DT; Chan, YL; Ng, HK; Poon, WS, 2005) |
| "In an effort to reduce the frequency of central nervous system (CNS) progression in patients with metastatic melanoma with ongoing systemic response to biochemotherapy, we modified our standard concurrent biochemotherapy regimen by replacing dacarbazine (DTIC) with oral temozolomide." | 9.10 | A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. ( Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L, 2002) |
| "To determine the response rate of the malignant gliomas of childhood to an oral, daily schedule of temozolomide." | 9.10 | Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. ( Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G, 2002) |
| "Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short-lived." | 9.10 | Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. ( Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA, 2003) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases." | 9.10 | Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 9.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 9.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "Temozolomide is an effective agent in the treatment of recurrent malignant gliomas." | 9.10 | A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. ( Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002) |
| "Temozolomide is a novel oral alkylating agent that is effective against melanoma." | 9.10 | Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002) |
| "Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 9.10 | Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. ( de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R, 2002) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 9.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain." | 9.10 | Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. ( Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002) |
| "To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse." | 9.09 | Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 9.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 9.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)." | 9.09 | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 9.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70." | 9.09 | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. ( Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA, 2001) |
| " A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma." | 9.09 | Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001) |
| "Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas." | 9.08 | The Charing Cross Hospital experience with temozolomide in patients with gliomas. ( Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1996) |
| "Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity of temozolomide." | 9.08 | Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. ( Begent, RJ; Bleehen, NM; Bower, M; Brada, M; Brampton, MH; Calvert, H; Colquhoun, I; Lewis, P; Newlands, ES, 1997) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "The efficacy of radiotherapy with adjuvant temozolomide for glioblastoma remains controversial." | 9.05 | The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies. ( Feng, Y; Wang, Y, 2020) |
| "Glioblastoma (GB) is one of the most common malignancies with limited standard therapies such as surgery, radiotherapy (RT) plus temozolomide (TMZ)." | 9.01 | Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis. ( Aru, N; Ding, YM; Jin, WY; Liu, Z; Qin, HH; Shen, X; Wang, WL; Wu, SJ, 2019) |
| "Temozolomide is a first-line treatment for newly diagnosed glioblastoma." | 9.01 | Evidence-Based Practice: Temozolomide Beyond Glioblastoma. ( Chua, J; Leung, D; Nafziger, E, 2019) |
| "Here we review tumoricidal efficacy of Vitamin D analogues in glioblastoma multiforme (GBM) and potential synergisms with retinoic acid and temozolomide based on epidemiological and cellular studies." | 9.01 | From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. ( Altinoz, MA; Elmaci, I; Ozpinar, A; Perez, JL, 2019) |
| "Although reoperation likely confers survival benefit for glioblastoma, whether the extent of resection (EOR) of the reoperation affects survival outcome has yet to be thoroughly evaluated in the current temozolomide (TMZ) era." | 9.01 | Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis. ( Burns, TC; Chaichana, KL; Goyal, A; Graffeo, CS; Lu, VM; Parney, IF; Perry, A; Quinones-Hinojosa, A, 2019) |
| "Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy." | 8.98 | Temozolomide for immunomodulation in the treatment of glioblastoma. ( Dastmalchi, F; Karachi, A; Mitchell, DA; Rahman, M, 2018) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 8.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ)." | 8.95 | Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis. ( Feng, E; Sui, C; Sun, G; Wang, T, 2017) |
| "This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas." | 8.91 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| "Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma, especially with deep-seated structure involvement." | 8.91 | Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. ( Gao, Z; Hao, S; Liu, Y; Yu, L, 2015) |
| "The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG)." | 8.91 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. ( Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W, 2015) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 8.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "Temozolomide (TMZ) alone has been proposed as a promising alternative to radiotherapy (RT) in elderly glioblastoma (GBM) patients." | 8.90 | A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. ( Cai, S; Cheng, JX; Dong, Y; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2014) |
| "This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma." | 8.90 | Comprehensive analysis of temozolomide treatment for patients with glioma. ( Liang, H; Xing, BZ; Yang, WB, 2014) |
| "Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas treatment due to its DNA-damaging effect." | 8.89 | O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. ( Cao, H; Chen, L; Fan, CH; Jiang, G; Liu, WL; Wen, C, 2013) |
| "The efficacy of temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM) has been evaluated by several clinical trials." | 8.89 | The efficacy of temozolomide for recurrent glioblastoma multiforme. ( Chen, C; Chen, J; Lu, Y; Wu, S; Xu, T, 2013) |
| "We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma." | 8.89 | Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| "The landmark Stupp study demonstrated a survival advantage with concomitant and adjuvant temozolomide (TMZ) with standard radiotherapy (RT) in glioblastoma multiforme (GBM) patients but excluded those older than 70 years." | 8.88 | Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. ( Bauman, GS; Cao, JQ; Fisher, BJ; Macdonald, DR; Megyesi, JF; Watling, CJ, 2012) |
| "This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme." | 8.88 | Temozolomide and other potential agents for the treatment of glioblastoma multiforme. ( Chow, F; Cremer, N; Kim, W; Nagasawa, DT; Yang, I; Yew, A, 2012) |
| "The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy." | 8.87 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. ( Kyritsis, AP; Levin, VA, 2011) |
| "Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas." | 8.86 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010) |
| "One barrier to successful treatment of malignant glioma is resistance to alkylating agents such as temozolomide." | 8.85 | New (alternative) temozolomide regimens for the treatment of glioma. ( Platten, M; Weller, M; Wick, W, 2009) |
| "Patients with brain metastasis were identified from 3 prospective studies of temozolomide (with or without immunotherapy) for metastatic melanoma." | 8.84 | Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? ( Boogerd, W; Dalesio, O; de Gast, GC, 2007) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "Temozolomide (TMZ) has been used as standard-of-care for glioblastoma multiforme (GBM), but the resistance to TMZ develops quickly and frequently." | 8.31 | Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. ( An, YJ; Choo, M; Kim, DH; Kim, HS; Ku, JL; Lee, SK; Mai, VH; Park, CK; Park, S, 2023) |
| "Temozolomide (TMZ) is the recommended drug for glioblastoma (GBM) treatment, but its clinical effect is restricted due to drug resistance." | 8.31 | Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma. ( Dong, J; Jiang, Z; Peng, Y; Wang, K; Wu, Y; Xie, Z; Zhong, M, 2023) |
| "Temozolomide (TMZ) has been determined to be the chemotherapeutic drug with efficacy for glioblastoma (GBM)." | 8.31 | Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma. ( Song, S; Tong, X; Wang, F; Wang, Y; Wen, B; Wu, H; Wu, Q; Xu, L; Yan, H; Zhou, Y, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 8.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Temozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties." | 8.31 | The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. ( Li, L; Liu, H; Ma, H; Qian, F; Quan, A; Ren, Y; Wang, L; Xu, H; Yu, R; Zhang, Y, 2023) |
| " In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs)." | 8.31 | Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. ( Alejo, S; Brenner, AJ; Chen, Y; Clarke, K; Gilbert, AR; He, Y; Jayamohan, S; Johnson, JD; Lai, Z; Li, W; Lv, Y; Palacios, BE; Pratap, UP; Sareddy, GR; Suzuki, T; Tekmal, RR; Vadlamudi, RK; Venkata, PP; Viswanadhapalli, S; Weldon, K; Ye, Z; Zhao, W; Zheng, S; Zou, Y, 2023) |
| "Although temozolomide (TMZ) provides significant clinical benefit for glioblastoma (GBM), responses are limited by the emergence of acquired resistance." | 8.31 | Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. ( Cao, Z; Gao, G; Gu, J; Guan, Z; Guo, Q; Hao, Q; Jia, B; Li, M; Li, W; Liu, X; Wang, S; Wang, W; Zhang, K; Zhang, W; Zhang, Y, 2023) |
| "The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM)." | 8.31 | The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. ( Kucheryavykh, L; Kucheryavykh, Y; Nuñez, R; Ortiz-Rivera, J, 2023) |
| " We aimed to clarify the interplay between purinergic signaling and chemotherapeutic drug temozolomide (TMZ) in human glioma cell line." | 8.31 | Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor. ( Czach, S; Czarnecka, J; Nowak, W; Roszek, K; Szymczak, B, 2023) |
| "Temozolomide (TMZ) is one of the best choices for treating glioblastoma." | 8.31 | Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. ( Laxmi Swetha, K; Narayan Saha, R; Roy, A; Singhvi, G; Waghule, T, 2023) |
| "Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy." | 8.31 | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. ( Deng, Y; Du, H; Hou, X; Liu, J; Liu, W; Liu, Y; Qiao, J; Shu, X; Sun, B; Wang, H, 2023) |
| " Protein disulfide isomerase (PDI) is a molecular chaperone known to be highly expressed in glioblastomas with acquired resistance to temozolomide (TMZ)." | 8.31 | Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma. ( Kiang, KM; Lam, TL; Leung, GK; Li, N; Liu, J; Shum, HC; Song, Q; Tang, W; Zhu, Z, 2023) |
| "The chemoresistance of temozolomide-based therapy is a serious limitation for lasting effective treatment of gliomas, while the underlying mechanisms remain unclear." | 8.31 | Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis. ( Chen, S; Li, J; Li, M; Li, X; Li, Z; Liao, X; Qian, W; Song, L; Tang, M; Xu, Y; Yu, R; Zhang, S; Zheng, H, 2023) |
| "Temozolomide (TMZ)-based chemotherapy plays a central part in glioma treatment." | 8.31 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. ( Liu, X; Sun, Y; Wang, X; Wu, Z; Yan, W; You, Y; Zhang, Y, 2023) |
| " TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)." | 8.31 | Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023) |
| "Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ)." | 8.31 | ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression. ( Chen, JC; Chong, ZY; Huang, C; Huang, HC; Lee, IN; Wu, YP; Yang, JT, 2023) |
| "Patients with glioblastoma (GBM) have poor prognosis and limited therapeutic options, largely because of chemoresistance to temozolomide (TMZ) treatment." | 8.31 | UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. ( Gao, G; Wang, Y; Wei, X; Yu, J; Zhang, Y, 2023) |
| "Temozolomide resistance remains a major obstacle in the treatment of glioblastoma (GBM)." | 8.31 | The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma. ( Chen, H; Chen, K; Chen, L; Huang, A; Huang, Y; Li, C; Li, H; Lu, Y; Qi, S; Shi, L; Song, C; Wang, T; Zhong, C, 2023) |
| "Chemoresistance blunts the efficacy of temozolomide (TMZ) in the treatment of glioblastoma (GBM)." | 8.31 | Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation. ( Ahmad, N; Cheng, X; Deng, S; Li, H; Shu, X; Song, D; Wang, Q; Wu, M; Xu, H; Yang, X, 2023) |
| "Glioblastoma multiforme (GBM) is the deadliest glioma and its resistance to temozolomide (TMZ) remains intractable." | 8.31 | HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. ( Cao, YY; Chen, JX; Chen, QZ; Huang, GH; Li, Y; Liu, GL; Lv, SQ; Pei, YC; Ren, P; Wang, TT; Xiang, Y; Yang, L; Yang, W; Zhang, ZX; Zhou, S, 2023) |
| "To explore the role of forkhead box protein O1 (FOXO1) in the progression of glioblastoma multiforme (GBM) and related drug resistance, we deciphered the roles of FOXO1 and miR-506 in proliferation, apoptosis, migration, invasion, autophagy, and temozolomide (TMZ) sensitivity in the U251 cell line using in vitro and in vivo experiments." | 8.31 | FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1. ( Chen, C; Chen, J; Liu, Y; Shi, Y; Wang, H; Zhang, X, 2023) |
| "The cytotoxic effects of shikonin against murine glioblastoma cells, SB28 and CT-2A, were reported resistance to temozolomide, were evaluated using an allophycocyanin-conjugated annexin V and propidium iodide assay with flow cytometry." | 8.31 | Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance. ( Maeoka, R; Matsuda, R; Morimoto, T; Nakagawa, I; Nakase, H; Nakazawa, T; Nishimura, F; Ouji, Y; Park, YS; Yamada, S; Yokoyama, S; Yoshikawa, M, 2023) |
| "To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation." | 8.31 | Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma. ( Antonelli, M; Arcella, A; Bozzao, A; Capone, L; De Pietro, R; Esposito, V; Gianno, F; Giraffa, M; Lanzetta, G; Minniti, G; Paolini, S; Romano, A; Tini, P, 2023) |
| "In our previous study, we found for the first time that temozolomide (TMZ), the first-line chemotherapeutic agent for glioblastoma (GBM), can generate a large amount of reactive oxygen species (ROS) under ultrasound irradiation." | 8.31 | Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. ( Jiao, J; Tong, X; Wen, B; Wu, Q; Xu, L; Yan, H; Yang, R; Zhou, Y, 2023) |
| "To investigate the effect of Temozolomide combined with intensity modulated radiation therapy on serum factor, immune function and clinical efficacy in postoperative glioma patients." | 8.31 | Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients. ( Fan, R; Liu, J; Liu, Z; Yuan, J, 2023) |
| "Altogether, our results indicate that using nanoemulsion containing temozolomide in combination with ferrocene is an effective approach to improve glioblastoma therapy outcomes." | 8.31 | Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models. ( Bernardes Ferro, M; da Rosa, RG; da Silva, LF; de Oliveira, JVR; de Souza, BM; Henn, JG; Lopes Alves, GA; Morás, AM; Moura, DJ; Nugent, M; Pires Peña, F; Rapack Jacinto Silva, V; Silva Pinheiro, AC; Silveira Aguirre, TA; Steffens Reinhardt, L, 2023) |
| "Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) patients has been limited by resistance in the clinic." | 8.31 | Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. ( Huang, G; Li, Z; Qi, S; Qu, S; Wang, K; Ye, R; Yi, GZ; Zhang, H; Zhang, W; Zhu, T, 2023) |
| "To explore the mechanism through which curcumol reverses primary drug resistance in glioma cells." | 8.31 | [Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis]. ( Qian, Y; Sun, J; Tan, R; Tian, N; Xing, J, 2023) |
| "Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma." | 8.31 | Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. ( Arijs, I; Beerens, C; Biswas, A; Byrne, AT; Chien, MP; Connor, K; Dilcan, G; Fabro, F; Feller, KJ; Idbaih, A; Kers, TV; Kremer, A; Lambrechts, D; Lamfers, MLM; Leenstra, S; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Tching Chi Yen, R; Verreault, M, 2023) |
| "The standard treatment of glioblastoma patients consists of surgery followed by normofractionated radiotherapy (NFRT) with concomitant and adjuvant temozolomide chemotherapy." | 8.12 | Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. ( Ehret, F; Grosu, AL; Kaul, D; Klement, RJ; Lewitzki, V; Polat, B; Popp, I; Sweeney, RA, 2022) |
| " With novel strategies focused on targeting hypoxia-inducible factor (HIF) regulatory pathways, recent evidence has shown that Acriflavine (ACF) can effectively target glioma invasiveness and recurrence." | 8.12 | Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model. ( Alomari, S; Brem, H; Cecia, A; Darjee, N; Domb, AJ; Gorelick, NL; Mangraviti, A; Rottenberg, Y; Serra, R; Shapira-Furman, T; Tyler, B, 2022) |
| "Resistance to temozolomide (TMZ) chemotherapy is the main reason for treatment failure in patients with glioblastoma (GBM)." | 8.12 | Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. ( Dong, Q; Duan, L; Li, L; Li, Q; Liu, Y; Pan, Y; Wang, D; Wang, J; Wang, X; Yin, H; Yuan, G, 2022) |
| "Nearly 10% of patients with adult diffuse glioma develop clinically significant myelotoxicity while on temozolomide (TMZ) leading to treatment interruptions." | 8.12 | Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. ( Chatterjee, A; Dasgupta, A; Epari, S; Gupta, T; Kota, PK; Kowtal, P; Moitra, P; Patil, V; Sarin, R, 2022) |
| "It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms." | 8.12 | The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. ( Alonso, MM; Balnytė, I; Damanskienė, E; Preikšaitis, A; Stakišaitis, D; Valančiūtė, A, 2022) |
| "Temozolomide (TMZ) is a standard-of-care chemotherapeutic drug for the treatment of glioblastoma (GBM), but TMZ-acquired resistance limits its therapeutic effect." | 8.12 | Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. ( Chu, L; Liu, X; Sha, C; Sun, K; Sun, Y; Wang, A; Wang, S; Xu, L; Yang, X; Yu, Y; Zhou, L, 2022) |
| "Temozolomide (TMZ) monotherapy is known to be insufficient for resistant/relapsed glioblastoma (GBM), thus seeking a sensitization agent for TMZ is necessary." | 8.12 | Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. ( Ali, AAA; Chiang, IT; Chou, SY; Hsu, FT; Hsu, TI; Liu, HS; Liu, YC, 2022) |
| "This retrospective study enrolled 65 patients with IDH wild-type recurrent glioblastoma who received standard therapy and then received either bevacizumab (46 patients) or temozolomide (19 patients) as a secondary treatment." | 8.12 | Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. ( Kim, HS; Kim, JH; Kim, YH; Moon, HH; Park, JE, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for the treatment of glioma." | 8.12 | The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis. ( Duan, S; Gong, F; Li, Q; Wei, Y, 2022) |
| "We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy in 492 patients with glioma." | 8.12 | Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. ( Filipski, K; Filmann, N; Fokas, E; Forster, MT; Harter, PN; Herrlinger, U; Ronellenfitsch, MW; Steinbach, JP; Voss, M; Zeiner, PS, 2022) |
| " Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitable." | 8.12 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| " We herein investigate the therapeutic potential of bioinformatically identified HOTAIR transferred by serum-derived EVs (serum-EVs) in temozolomide (TMZ) resistance of glioblastoma (GBM) and the downstream mechanisms." | 8.12 | Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism. ( Han, J; Wang, S; Wang, X; Wang, Y; Wei, K; Xu, H; Yu, X, 2022) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 8.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| "Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear." | 8.12 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. ( Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY, 2022) |
| "We sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG)." | 8.12 | Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. ( Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Chen, Y; Hogan, T; Kissel, C; Lapin, B; Mohammadi, A; Murphy, ES; Naugle, R; Park, DY; Parsons, MW; Peereboom, DM; Schuermeyer, I; Stevens, GHJ; Suh, JH; Tewari, S; Tom, MC; Yu, JS, 2022) |
| "Temozolomide (TMZ) is generally applied for glioma treatment, while drug resistance of TMZ limits its therapeutic efficacy." | 8.12 | Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway. ( Fei, YQ; Shi, RT; Song, Z; Wu, JZ; Zhou, YF, 2022) |
| "To study the relationship between temozolomide (TMZ) chemotherapy-resistant cells and stem cells in gliomas." | 8.12 | Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas. ( Cunzu, W; Dingchao, X; Min, X; Xun, Z, 2022) |
| "To investigate the function of primary cilia in regulating the cellular response to temozolomide (TMZ) and ionizing radiation (IR) in glioblastoma (GBM)." | 8.12 | Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells. ( Cai, H; Gao, L; He, JP; Ma, W; Peng, SP; Tian, HB; Wang, JF; Wei, L, 2022) |
| "Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)." | 8.12 | Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022) |
| "Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ." | 8.12 | SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy. ( Han, L; Hu, L; Yang, F; Yu, J; Zhao, M; Zhou, H, 2022) |
| "Temozolomide (TMZ) is the first-line drug for the clinical treatment of glioblastoma (GBM), but drug resistance limits its treatment benefits." | 8.12 | Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. ( Yun, K; Zhao, W, 2022) |
| "The mechanism by which glioblastoma evades temozolomide (TMZ)-induced cytotoxicity is largely unknown." | 8.12 | SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma. ( Chang, KY; Chen, PY; Chen, SH; Cheng, SM; Chi, PI; Chien, CH; Chu, JM; Chuang, JY; Huang, CY; Hwang, DY; Lai, CC; Lee, JS; Liao, WA; Liu, CC; Wu, AC; Yang, ST; Yang, WB, 2022) |
| "Resistance to temozolomide (TMZ) is a major obstacle to preventing glioblastoma (GBM) recurrence after surgery." | 8.12 | PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. ( Deng, L; Fan, Y; Gao, Z; Guo, X; Li, G; Qi, Y; Sun, C; Wang, S; Xu, J; Xue, H; Zhang, P; Zhao, R; Zhao, S, 2022) |
| "Temozolomide (TMZ) resistance remains the main therapy challenge in patients with glioblastoma multiforme (GBM)." | 8.12 | TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. ( Gao, G; Wang, Y; Wei, X; Yu, J, 2022) |
| "We included 41 patients with isocitrate dehydrogenase 1/2-wildtype glioblastoma, who received 12 or more cycles of temozolomide therapy between June 2006 and December 2019." | 8.12 | Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. ( Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S, 2022) |
| " Optical microscopy and flow cytometry were employed to assess the differences in glioblastoma cells morphology, proliferation, and cytotoxicity of anticancer drug temozolomide (TMZ) due to increased substrate viscosity." | 8.12 | Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. ( Bucki, R; Cieśluk, M; Kochanowicz, J; Kułakowska, A; Piktel, E; Pogoda, K; Skłodowski, K; Wnorowska, U, 2022) |
| " Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence." | 8.12 | Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. ( Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN, 2022) |
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 8.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "The complex of formononetin and calycosin (FMN/CAL) shows a synergistic effect on temozolomide in the treatment of malignant glioma, however the mechanism is unclear." | 8.12 | The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology. ( Fan, H; Fan, Y; Huang, T; Li, J; Li, S; Qiu, R; Zhang, Q; Zhou, Y, 2022) |
| "A MEX3A/CCR4-NOT/MSH2 axis plays a crucial role in promoting temozolomide resistance, providing new insights into the function of MEX3A and suggesting MEX3A as a potential therapeutic target in therapy-resistant glioblastoma." | 8.12 | MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. ( Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S, 2022) |
| "The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined." | 8.12 | Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3. ( Becker, H; Blobner, J; Egensperger, R; Katzendobler, S; Niyazi, M; Quach, S; Suchorska, B; Thiele, F; Thon, N; Tonn, JC; Weller, J; Weller, M, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 8.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| "Temozolomide (TMZ) resistance limits its use in glioblastoma (GBM)." | 8.12 | Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma. ( Leng, H; Li, X; Wang, N; Xu, L; Yuan, H, 2022) |
| "Brain radiotherapy combined with concomitant and six cycles of adjuvant temozolomide (TMZ) is the standard treatment for newly diagnosed high-grade gliomas (HGGs)." | 8.12 | Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. ( Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F, 2022) |
| "Although temozolomide is the primary chemotherapeutic agent in glioblastoma, current studies have focused on its combinational applications to overcome resistance by targeting multiple pathways." | 8.12 | Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. ( Biray Avci, C; Goker Bagca, B; Ozates, NP, 2022) |
| "It has been noted that temozolomide resistance occurs in a number of malignancies, including glioma, although the underlying cause of this is unknown." | 8.12 | CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study. ( Bai, S; Chen, H; Fan, LL; Hu, Y; Luo, GQ; Yan, ZJ, 2022) |
| " The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment." | 8.12 | TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. ( Amantini, C; Maggi, F; Morelli, MB; Nabissi, M; Pallini, R; Ricci-Vitiani, L; Santoni, G, 2022) |
| "It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion." | 8.12 | Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| "Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)." | 8.12 | Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022) |
| " Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)." | 8.12 | Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022) |
| "Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor." | 8.02 | AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 8.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| " Here, we show that NSUN6 methylates both large and small RNA in glioblastoma and controls glioblastoma response to temozolomide with or without influence of the MGMT promoter status, with high NSUN6 expression conferring survival benefit to glioblastoma patients and in other cancers." | 8.02 | NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. ( Awah, CU; Mazdoom, CM; Ogunwobi, OO; Winter, J, 2021) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 8.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ)." | 8.02 | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. ( Bartsch, JW; Culmsee, C; Elsässer, K; Nimsky, C; Pagenstecher, A; Schäfer, A; Zhang, Z; Zhao, K; Zhong, L, 2021) |
| "To explore whether or not aberrant expression of miR-29b in glioblastoma multiforme (GBM) cells was associated with temozolomide (TMZ) resistance and to elucidate potential underlying mechanisms." | 8.02 | Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy. ( Luan, XP; Xu, JX; Yang, Y; Zhang, X, 2021) |
| "Temozolomide (TMZ) is widely used for glioma therapy in the clinic." | 8.02 | LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma. ( He, X; Liu, Q; Sheng, J; Wang, K; Yu, W; Zhu, S, 2021) |
| "The study includes 132 IDH-wildtype glioblastoma patients treated between 2013 and 2017 with open resection followed by radiotherapy with concomitant and maintenance temozolomide." | 8.02 | Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. ( Berger, K; Budach, W; Felsberg, J; Hänggi, D; Haussmann, J; Kamp, MA; Knipps, J; Malzkorn, B; Mijderwijk, HJ; Rapp, M; Reifenberger, G; Sabel, M; Steiger, HJ; Turowski, B, 2021) |
| "We report a case of acute interstitial nephritis with associated nephrogenic diabetes insipidus in a patient treated with temozolomide and sulfamethoxazole-trimethoprim for glioblastoma multiforme." | 8.02 | Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. ( Athavale, A; Gallagher, M; Jardine, M; Morris, J; Ritchie, A; Sen, S; Wang, AY, 2021) |
| " Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers." | 8.02 | Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021) |
| "Temozolomide (TMZ) is the major chemotherapy agent in glioma, and isocitrate dehydrogenase (IDH) is a well-known prognostic marker in glioma." | 8.02 | Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas. ( Chen, W; Jing, J; Li, R; Mao, P; Sun, Q; Wang, J; Wang, M; Yu, X, 2021) |
| "The purpose of this study is to clarify the clinical features of temozolomide (TMZ)-related hepatitis B virus (HBV) reactivation and to identify HBV reactivation predictive factors." | 8.02 | Hepatitis B virus reactivation during temozolomide administration for malignant glioma. ( Chonan, M; Inoue, J; Kanamori, M; Masamune, A; Osada, Y; Saito, R; Shimoda, Y; Shoji, T; Tominaga, T; Uenohara, H, 2021) |
| "8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide." | 8.02 | Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. ( Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021) |
| "EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment." | 8.02 | Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. ( Baumert, BG; Ben Hassel, M; Bromberg, JC; Drijver, AJ; Eekers, DBP; Freixa, SV; Golfinopoulos, V; Gorlia, T; Hoang-Xuan, K; Hottinger, AF; Klein, M; Lucas, A; Reijneveld, JC; Stupp, R; Taphoorn, MJB; Tzuk-Shina, T; van den Bent, MJ; Vauleon, E, 2021) |
| "Limited therapeutic efficacy of temozolomide (TMZ) against glioblastomas highlights the importance of exploring new drugs for clinical therapy." | 8.02 | Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling. ( Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, YT; Shih, CM, 2021) |
| "Temozolomide (TMZ) is a first-line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge." | 8.02 | Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. ( Hu, YH; Jiao, BH; Wang, CY; Wu, JL, 2021) |
| " Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality." | 8.02 | Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ( Abbaszade, Z; Avci, CB; Bagca, BG, 2021) |
| " Treatment of patients suffering from relapsed/refractory glioblastoma (GBM) with a combination of depatux-m and temozolomide (TMZ) tended to increase overall survival." | 8.02 | Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. ( Alvey, C; Anderson, M; Ansell, P; Boghaert, ER; Falls, HD; Mishra, S; Mitten, MJ; Oleksijew, A; Palma, J; Phillips, AC; Reilly, EB; Vaidya, KS; Zelaya-Lazo, AL, 2021) |
| "IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear." | 8.02 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021) |
| "Temozolomide (TMZ), an alkylating agent with a broad-spectrum antitumor activity, ability to cross blood-brain barrier (BBB), shown to be effective against malignant glioma." | 8.02 | Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. ( Baburaj, G; Jose, A; Kumar, JP; Munisamy, M; Munisamy, S; Subbiah, V; Thomas, L, 2021) |
| "Previous studies showed that the chemotherapeutic effect of temozolomide (TMZ) and vincristine (VCR) against glioma might be blunted by the co-culture with astrocytes, and connexin-43 (CX43) was thought to play a vital role in the communication between glioma cells and astrocytes." | 8.02 | AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes. ( Fan, T; Fu, X; Gong, Y; Huang, Y; Li, Z; Wang, H; Xiang, P; Zhang, S, 2021) |
| " However, whether glioma stem cells (GSCs) can be sensitized to chemotherapy via combined treatment with temozolomide (TMZ) and nicardipine is unclear." | 8.02 | Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. ( Dong, J; Dong, X; Jiang, Q; Li, H; Liu, L; Shi, J; Wang, H; Wang, L, 2021) |
| "To assess the recurrence interval and predictive significance of TP53 expression and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas treated with radiotherapy and combined chemotherapies, including temozolomide, lomustine, procarbazine and bevacizumab." | 8.02 | Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies. ( Alghamdi, B; Alkhayyat, S; Baeesa, S; Bardeesi, A; Bari, MO; Butt, NS; Dallol, A; Kurdi, M; Lary, AI; Maghrabi, Y; Mohamed, F; Saeedi, R; Samkari, A, 2021) |
| "Temozolomide (TMZ) is the internationally recognized and preferred drug for glioma chemotherapy treatment." | 8.02 | Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p. ( Chen, Z; Li, H; Li, Y; Liu, Q; Su, J; Wu, M; Zhang, C, 2021) |
| "The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM)." | 8.02 | CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. ( Arina, A; Bernal, GM; Cahill, KE; Campbell, PS; Crawley, CD; Mansour, N; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B, 2021) |
| "Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation." | 8.02 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. ( Berger, MS; Butowski, N; Chang, SM; Choi, S; Clarke, JL; Costello, JF; Grimmer, MR; Haas-Kogan, D; Hilz, S; Hong, C; Mazor, T; McDermott, M; Molinaro, AM; Oberheim Bush, NA; Phillips, JJ; Shai, A; Solomon, DA; Taylor, JW; Villanueva-Meyer, J; Wahl, M; Wainer, BH; Yu, Y, 2021) |
| " However, the alterations in gut microbiota observed during glioma growth and temozolomide (TMZ) therapy remain poorly understood." | 8.02 | Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma. ( Jiang, Y; Jin, XQ; Li, J; Li, XC; Li, YR; Li, ZQ; Ma, C; Wang, ZF; Wu, BS; Yao, J, 2021) |
| "Our data revealed (i) a clinical association of the EMT-like process with glioma malignancy and a poor survival and (ii) an anticancer and temozolomide sensitizing effect of rabeprazole by repressing EMT." | 8.02 | Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. ( Babu, D; Mudiraj, A; Panigrahi, M; Prakash Babu, P; Y B V K, C; Yadav, N, 2021) |
| "Temozolomide (TMZ) resistance limits its application in glioma." | 8.02 | Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. ( Bu, X; Chen, X; Ding, C; Gu, J; Kang, D; Lin, Y; Lin, Z; Sun, Y; Wu, X; Wu, Z; Yi, X; You, H; Zhang, G, 2021) |
| " This study investigated whether the improved oxygenation and perfusion that has been previously observed with RRx-001 both preclinically and clinically in the context of a brain metastasis trial was correlated with increased penetration and accumulation of the cytotoxic chemotherapies, irinotecan and temozolomide, in orthotopically implanted gliomas, priming tumours for improved response." | 8.02 | Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. ( Cabrales, P; Oronsky, B; Reid, T, 2021) |
| "Temozolomide (TMZ) resistance is the main challenge in the management of glioma patients." | 8.02 | Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. ( Cao, L; Chen, Z; Jiang, Z; Li, W; Li, X; Si, J, 2021) |
| "To clarify whether differential compartmentalization of Survivin impacts temozolomide (TMZ)-triggered end points, we established a well-defined glioblastoma cell model in vitro (LN229 and A172) and in vivo, distinguishing between its nuclear and cytoplasmic localization." | 8.02 | Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. ( Baymaz, HI; Beli, P; Christmann, M; Mühlhäusler, F; Nikolova, T; Poplawski, A; Reich, TR; Schwarzenbach, C; Tomicic, MT; Unger, S; Vilar, JB, 2021) |
| "Glioblastoma multiforme (GBM) is the most fatal cancer among brain tumors, and the standard treatment of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ) chemotherapy." | 8.02 | 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma. ( Chen, GY; Hsu, SP; Hsu, TI; Hung, CY; Ko, CY; Liao, KH; Lin, HY, 2021) |
| "Following captopril treatment, MMP-2 protein expression and migratory capabilities of 9 L gliosarcoma cells were assessed in vitro via western blots and scratch wound assays, respectively." | 8.02 | Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. ( Brem, H; Casaos, J; Huq, S; Mangraviti, A; Paldor, I; Perdomo-Pantoja, A; Pinheiro, L; Tyler, B; Vigilar, V; Wang, Y; Witham, TF, 2021) |
| "To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)." | 8.02 | Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021) |
| "A maximal surgical resection followed by radiotherapy and chemotherapy with temozolomide (TMZ) as the representative agent is the standard therapy for gliomas." | 8.02 | The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ). ( Chen, Y; Jiang, W; Kuang, W; Liu, Z; Tian, Y, 2021) |
| "Apatinib and TMZ may represent an alternative treatment option for patients with recurrent high-gradeglioma, especially those with a low Karnofsky performance status." | 8.02 | Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. ( Feng, M; Gan, W; Huang, Y; Li, X; Liu, J; Shao, Y; Wang, X; Yao, H; Zhang, C; Zhou, Y, 2021) |
| "Intrinsic or acquired resistance to temozolomide (TMZ) is a frequent occurrence in patients with glioblastoma (GBM)." | 8.02 | Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. ( Li, T; Wang, B; Wang, J, 2021) |
| "To evaluate the predictive significance of the duration of temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) who were treated with bevacizumab (Beva) as second-line setting." | 8.02 | Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting? ( Besiroglu, M; Demir, T; Shbair, ATM; Topcu, A; Turk, HM; Yasin, AI, 2021) |
| " We investigated the effects of dopamine in combination with platinum on human glioblastoma U-251MG cells upon X-ray irradiation, comparing with L-DOPA, 2-phenylethylamine and temozolomide." | 8.02 | Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. ( Kato, S, 2021) |
| "Improving the chemotherapy resistance of temozolomide (TMZ) is of great significance in the treatment of glioblastoma multiforme (GBM)." | 8.02 | Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. ( Jiang, XB; Li, XD; Wang, MJ; Wang, X; Wu, YH; Zheng, JL, 2021) |
| "Standard treatment for glioblastoma (GBM) patients is surgery and radiochemotherapy (RCT) with temozolomide (TMZ)." | 7.96 | ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. ( Åkesson, L; Bratthäll, C; Broholm, H; Fomichov, V; Green, H; Grunnet, K; Hallbeck, M; Jakobsen, I; Malmström, A; Milos, P; Mudaisi, M; Papagiannopoulou, A; Poulsen, HS; Söderkvist, P; Stenmark-Askmalm, M; Strandeus, M; Łysiak, M, 2020) |
| "Temozolomide (TMZ) is one of the most common drugs selected for glioma chemotherapy, but the therapeutic effect of glioma treatment is usually limited due to its resistance." | 7.96 | LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis. ( Chen, M; Li, B; Song, J; Wang, F; Zhao, H, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 7.96 | Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma. ( Gao, Y; Guo, R; Li, H; Yang, B; Zhao, C, 2020) |
| "In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)." | 7.96 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020) |
| "This analysis aimed to investigate whether the long-term administration of temozolomide (TMZ) claimed a survival advantage for patients with glioblastoma in China." | 7.96 | Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. ( Li, X; Li, Z; Quan, R; Zhang, H, 2020) |
| " Here, we detail anti-PD-L1 antibody effects on the tumor microenvironment, including Mϕ infiltration, using a temozolomide (TMZ)-treated glioma model." | 7.96 | Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell ( Akutsu, H; Ishikawa, E; Kohzuki, H; Matsuda, M; Matsumura, A; Miyazaki, T; Sakamoto, N; Sugii, N; Takano, S, 2020) |
| "Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma." | 7.96 | Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020) |
| "The isocitrate dehydrogenase (IDH) 1 wild-type glioblastoma (GBM) is a major population of GBM that should be of concern in terms of the efficacy of using Temozolomide (TMZ) in adjuvant treatment." | 7.96 | Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. ( Sangkhathat, S; Tunthanathip, T, 2020) |
| "This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma." | 7.96 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ( Bamberg, M; Bölting, H; Debus, J; Felsberg, J; Herrlinger, U; Hertler, C; Kessler, T; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Papsdorf, K; Platten, M; Reifenberger, G; Reuss, D; Sabel, M; Sahm, F; Steinbach, JP; Vesper, J; von Deimling, A; Weisang, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 7.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults and Temozolomide (TMZ) is an effective chemotherapeutic agent for its treatment." | 7.96 | Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide. ( Ebrahimi Zade, A; Shahabi Haghighi, S; Soltani, M, 2020) |
| "Temozolomide (TMZ) resistance is a major cause of recurrence and poor prognosis in glioblastoma (GBM)." | 7.96 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. ( Chi, Y; Fu, Z; Guo, H; Huang, Q; Lian, C; Liao, C; Liu, B; Wang, C; Wei, Q; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2020) |
| "To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice." | 7.96 | New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221. ( Chen, H; Chen, Y; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Yang, Y; Zhan, W; Zhang, Z, 2020) |
| "Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months." | 7.96 | Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. ( Martuza, RL; Rabkin, SD; Saha, D, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 7.96 | MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. ( Guan, F; Guo, R; Li, H; Li, M; Liu, X; Ma, S; Wu, J; Yang, B; Zhao, C, 2020) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for chemo-radiotherapy of glioblastoma, which is also a target cancer for boron neutron capture therapy (BNCT)." | 7.96 | The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status. ( Ikawa, T; Kinashi, Y; Takahashi, S, 2020) |
| "To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide." | 7.96 | Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. ( Besen, AA; Kucuk, A; Mertsoylu, H; Ozdemir, Y; Pehlivan, B; Selek, U; Topkan, E, 2020) |
| "5, 1 g/kg) or temozolomide (10 mg/kg) treatment alone inhibited tumor growth in glioblastoma U87 and U251 xenografts." | 7.96 | Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. ( Fu, J; Kong, PS; Wang, J; Wang, X; Xu, HB; Xu, YQ; Zhu, SH, 2020) |
| "Temozolomide (TMZ) is a chemotherapeutic used for the treatment of glioblastoma." | 7.96 | A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status. ( Bello-Rivero, I; Leenstra, S; van der Kaaij, M; Vázquez-Blomquist, D; Villarreal, A, 2020) |
| "We designed a conjugated compound by coupling temozolomide (TMZ) with doxorubicin (DOX) via an acylhydrazone linkage as a potential prodrug used for glioblastoma multiforme (GBM) treatment." | 7.96 | Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy. ( Du, K; Feng, F; Heng, H; Xia, Q, 2020) |
| "Resistance of glioblastoma to the chemotherapeutic compound temozolomide is associated with the presence of glioblastoma stem cells in glioblastoma and is a key obstacle for the poor prognosis of glioblastoma." | 7.96 | Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity. ( Hwang, WC; Kang, DW; Min, DS; Noh, YN; Park, KS, 2020) |
| "Temozolomide is the most effective chemotherapy for malignant glioma." | 7.96 | Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. ( Divekar, RD; Johnson, DR; Maddox, DE; Neth, BJ; Ruff, MW; Uhm, JH, 2020) |
| "Temozolomide (TMZ) therapy is the standard of care for patients with glioblastoma (GBM)." | 7.96 | Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. ( Alshareef, M; Cachia, D; Das, A; Infinger, LK; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK, 2020) |
| " Concurrent temozolomide (TMZ) radiation-the cornerstone of glioma control-extends the overall median survival of GB patients by only a few months over radiotherapy alone." | 7.96 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Duc, TC; Hartman, H; Hofman, FM; Huang, M; Minea, RO; Schönthal, AH; Swenson, SD, 2020) |
| " In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly‑ADP‑ribose polymerase inhibitor (PARPi) remain largely unidentified." | 7.96 | PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. ( Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ, 2020) |
| " The transfection efficiency was determined with flow cytometry, and the therapeutic efficacy of CD::UPRT::GFP expressing MSCs was evaluated in cocultures with temozolomide (TMZ)-sensitive or TMZ-resistant human glioblastoma cell lines." | 7.96 | A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth. ( Ho, YK; Ng, ZX; Teo, KJ; Too, HP; Tu, GXE; Yeo, TT, 2020) |
| "To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ)." | 7.96 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. ( Faustino, AC; Hamamura, AC; Viani, GA, 2020) |
| " In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG)." | 7.96 | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. ( Gjika, E; Keidar, M; Kirschner, ME; Lin, L; Pal-Ghosh, S; Sherman, JH; Stepp, MA, 2020) |
| "Glioma, especially glioblastoma (GBM), is the most aggressive malignant brain tumor and its standard therapy is often ineffective because of temozolomide (TMZ) resistance." | 7.96 | Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. ( Cai, HP; Chen, FR; Chen, ZP; Guo, CC; Ma, JX; Ni, XR; Wang, J; Wu, WC; Yu, YJ; Yu, ZH, 2020) |
| "Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival." | 7.96 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "Glioblastoma (GBM) is a malignant brain tumour with a dismal prognosis, despite best treatment by surgical resection, radiation therapy (RT) and chemotherapy with temozolomide (TMZ)." | 7.96 | Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies. ( Jue, TR; Lu, VM; McDonald, KL, 2020) |
| "Objective To investigate the expression of cathepsin S (CTSS) in temozolomide-resistant glioblastoma T98G (T98G-R) cells." | 7.96 | [Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis]. ( Guo, Q; Jia, B; Liu, W; Lyu, W, 2020) |
| " However, the function of circ_0005198 in the temozolomide (TMZ) resistance of glioma has not been well elucidated." | 7.96 | Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis. ( Deng, Y; Liu, C; Meng, X; Xiao, L; Zhu, H, 2020) |
| " In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ)." | 7.96 | The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. ( Hirata, K; Houkin, K; Ishi, Y; Kobayashi, H; Motegi, H; Oda, Y; Okamoto, M; Tanaka, S; Terasaka, S; Yamaguchi, S, 2020) |
| "The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor." | 7.91 | Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. ( Bua, S; Kopecka, J; Mujumdar, P; Poulsen, SA; Riganti, C; Supuran, CT, 2019) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent used against glioblastoma multiforme (GBM), but this disease exhibits recurrence and high lethality." | 7.91 | miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. ( Chen, KC; Chen, PH; Cheng, CH; Chou, CM; Ho, KH; Lin, CW; Liu, AJ; Shih, CM, 2019) |
| "Our study elucidated the role of oncogenic LINC01198 in glioma proliferation and temozolomide resistance, and this role may serve as a promising target for glioma therapy." | 7.91 | LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma. ( Chen, HJ; Chen, WL; Ge, JW; Hou, GQ; Zhang, XH, 2019) |
| " In this study, we investigate the underlying mechanism by which glioblastoma (GBM) cells acquire resistance to Temozolomide (TMZ) through Aurora kinase B (AURKB) thus to identify novel therapeutic targets and prognostic biomarkers for GBM." | 7.91 | Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. ( Alafate, W; Liu, C; Sun, L; Wang, J; Wang, M; Wu, W; Xie, W; Zuo, J, 2019) |
| " However, the role of circular RNA CEP128 in the resistance of glioma cells to temozolomide has not yet been characterized." | 7.91 | Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p. ( Feng, H; Hua, L; Huang, L; Shen, B; Zhang, X, 2019) |
| "To investigate the underlying mechanism by which glioblastoma (GBM) cells gain temozolomide (TMZ) resistance and to clarify novel therapeutic targets and new prognostic biomarkers for GBM." | 7.91 | Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. ( Li, R; Mao, P; Wahafu, A; Wang, J; Wang, M; Wu, W; Xie, W; Yu, X; Zuo, J, 2019) |
| "Current treatment of recurrent glioblastoma multiforme (GBM) demands dose-intense temozolomide (TMZ), a prodrug of 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC), based on the spontaneous hydrolysis of TMZ at basic pH." | 7.91 | Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme. ( Du, K; Feng, F; Li, X; Shao, F; Sun, J; Sun, Y, 2019) |
| "Drug resistance to temozolomide (TMZ) contributes to the majority of tumor recurrence and treatment failure in patients with glioblastoma multiforme (GBM)." | 7.91 | Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells. ( Cheng, SY; Kiang, KMY; Leung, GK; Li, N; Wong, VK; Zhang, P; Zhu, Z, 2019) |
| "The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (TMZ/Bev)." | 7.91 | Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. ( Ichimura, K; Igaki, H; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M, 2019) |
| "Temozolomide (TMZ) is the most commonly used chemotherapeutic agent used to treat glioblastoma (GBM), which causes significant DNA damage to highly proliferative cells." | 7.91 | Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. ( Harder, BG; Kitange, GJ; Loftus, JC; Peng, S; Sarkaria, JN; Sereduk, CP; Sodoma, AM; Tran, NL, 2019) |
| "In the management of patients with newly diagnosed glioblastoma, there is no standard duration for adjuvant temozolomide treatment." | 7.91 | Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. ( Hasegawa, Y; Hatano, K; Hirono, S; Iuchi, T; Sakaida, T; Uchino, Y, 2019) |
| "Bortezomib was found to inhibit glioma growth and improved TMZ chemotherapy efficacy, probably via down-regulating the FOXM1-Survivin axis." | 7.91 | Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. ( Chen, JX; Du, L; Huang, GH; Li, QR; Lv, SQ; Tang, JH; Xiang, Y; Xu, QF; Yang, L; Zhang, ZX; Zhou, Z; Zhu, LR, 2019) |
| "Current standard of treatment for newly diagnosed patients with glioblastoma (GBM) is surgical resection with adjuvant normofractionated radiotherapy (NFRT) combined with temozolomide (TMZ) chemotherapy." | 7.91 | Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. ( Flentje, M; Klement, RJ; Kosmala, R; Lewitzki, V; Lisowski, D; Polat, B, 2019) |
| "Temozolomide (TMZ) is known to induce thrombocytopenia but no early predictive test has yet been clearly established." | 7.91 | Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. ( Alexandru, C; Clatot, F; David, M; Di Fiore, F; Fontanilles, M; Gilard, V; Hanzen, C; Langlois, O; Laquerriere, A; Marguet, F; Tennevet, I; Veresezan, O, 2019) |
| "Glioblastoma multiforme (GBM) has a poor prognosis with an overall survival of 14-15 months after surgery, radiation and chemotherapy using temozolomide (TMZ)." | 7.91 | Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. ( Bjerkvig, R; Denisova, O; Grudic, A; Hasan-Olive, MM; Janji, B; Johannessen, TC; Latif, MA; Lund-Johansen, M; Nordal, A; Prestegarden, L; Røsland, GV; Saed, H; Simonsen, A; Sundstrøm, T; Tronstad, KJ; Varughese, JK; Wang, J; Westermarck, J; Yang, N; Zhu, H, 2019) |
| "To describe oncological patterns of care, prognostic factors, and survival for all patients in France with newly-diagnosed and histologically confirmed glioblastoma, and evaluate the impact of extended temozolomide use at the population level." | 7.91 | Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. ( Amelot, A; Bauchet, F; Bauchet, L; Bessaoud, F; Charissoux, M; Darlix, A; Duffau, H; Fabbro, M; Fabbro-Peray, P; Figarella-Branger, D; Mandonnet, E; Mathieu-Daude, H; Pallud, J; Rigau, V; Riondel, A; Sorbets, E; Taillandier, L; Tretarre, B; Zouaoui, S, 2019) |
| "Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM)." | 7.91 | PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. ( Han, L; Huang, K; Liang, H; Liu, Y; Wang, G; Wang, Q; Wang, Z; Wei, C; Zhang, A; Zhang, W; Zhang, Z; Zhen, Y; Zhou, J, 2019) |
| "Chemotherapy is the main postsurgical and adjuvant therapy for glioma, and intrinsic or acquired temozolomide (TMZ) resistance may result in poor prognosis." | 7.91 | MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. ( Feng, B; Ren, H; Wang, J; Yu, J; Yuan, Z; Zhang, B; Zhang, X; Zhao, C; Zhuang, J, 2019) |
| "For our studies, we have particularly chosen C6 rat glioma cell line due to several reasons: i) We previously showed that MPA reduced growth and induced procarbazine-sensitization in C6 cells; ii) temozolomide has a triazene-type molecular structure like procarbazine; iii) other groups previously showed that C6 glioma cell line is more resistant to temozolomide than human glioma cells; hence it may provide a native model of chemoresistance." | 7.91 | Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature. ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Chemotherapy with temozolomide (TMZ) is the traditional treatment for glioblastoma (GBM)." | 7.91 | MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic agent for glioblastoma multiforme (GBM)." | 7.91 | Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| "Despite advances in cancer therapies, glioblastoma multiforme treatment remains inefficient due to the brain-blood barrier (BBB) inhibitory activity and to the low temozolomide (TMZ) chemotherapeutic selectivity." | 7.91 | Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. ( de Melo, MT; Paula, LB; Pellosi, DS; Tedesco, AC, 2019) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | 7.91 | Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "The aims of the present study were to compare the longitudinal changes of glioblastoma multiforme after radiotherapy (RT) between 11C-methionine positron emission tomography (MET-PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) and to clarify whether these changes were predictive of survival." | 7.91 | Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy. ( Asano, Y; Ikegame, Y; Iwama, T; Kawasaki, T; Miwa, K; Shinoda, J; Takei, H; Yano, H; Yokoyama, K, 2019) |
| "When only treated with D,L-methadone, 1 µM of the opioid was sufficient to reduce viability of fibroblasts, whereas 10 µM was needed to significantly reduce glioblastoma cell viability." | 7.91 | D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. ( Baran-Schmidt, R; Dietterle, J; Gaunitz, F; Glasow, A; Matusova, M; Meixensberger, J; Neumann, K; Oppermann, H, 2019) |
| "Although temozolomide (TMZ) resistance is a significant clinical problem in glioblastoma (GBM), its underlying molecular mechanisms are poorly understood." | 7.91 | Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. ( Shi, Z; Yan, W; Yin, J; You, Y; Zeng, A; Zhang, Z, 2019) |
| "Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer." | 7.91 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? ( He, Y; Kaina, B, 2019) |
| " In this preliminary study, the purpose was to evaluate the feasibility of APT imaging in monitoring the early therapeutic response to nitroxoline (NTX) in a temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) mouse model, which was compared with diffusion-weighted imaging (DWI)." | 7.91 | Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. ( Cho, HR; Choi, SH; Kumari, N; Thakur, N, 2019) |
| "The acquired drug resistance has been regarded as a main barrier for the effective treatment of temozolomide (TMZ) in glioblastoma (GBM)." | 7.91 | miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. ( Li, X; Liu, X; Luo, W; Song, Z; Yan, D; Zhao, S; Zhu, X, 2019) |
| "The aim of this current work was to study the therapeutic enhancement of temozolomide (TMZ) on gliomavia combining with calycosin and FMN." | 7.91 | In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin. ( Fan, H; Fan, Y; Li, Y; Ni, Q; Zhang, X, 2019) |
| "To identify novel epigenetic signatures that could provide predictive information that is complementary to promoter methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene for predicting temozolomide (TMZ) response, among glioblastomas (GBMs) without glioma-CpGs island methylator phenotype (G-CIMP) METHODS: Different cohorts of primary non-G-CIMP GBMs with genome-wide DNA methylation microarray data were included for discovery and validation of a multimarker signature, combined using a RISK score model." | 7.91 | Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. ( Aubry, M; Barnholtz-Sloan, J; Etcheverry, A; He, YL; Liu, BL; Liu, YH; Lu, ZF; Mosser, J; Yin, AA; Zhang, X, 2019) |
| "Despite the increased understanding of the oncological mechanisms underlying Glioblastoma multiforme (GBM) pathophysiology, and recent advances in therapeutic strategies such as maximal surgical resection and post-operative radiotherapy with concomitant and adjuvant temozolomide chemotherapy, the prognosis for patients with brain tumors remains limited." | 7.91 | microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide. ( Carlotti, CG; de Assis Cirino, ML; Lizarte Neto, FS; Matias, CCMS; Pereira-da-Silva, G; Peria, FM; Rodrigues, AR; Tirapelli, DPDC; Trevisan, FA, 2019) |
| "We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model." | 7.91 | Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. ( Appelboom, G; Barbier, EL; Bräuer-Krisch, E; Chang, SD; Dufort, S; Le Duc, G; Lux, F; Roux, S; Sancey, L; Tillement, O; Verry, C; Zhang, M, 2019) |
| "The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment." | 7.91 | Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. ( Chen, Z; Deng, S; Guo, M; Huang, G; Lei, B; Li, Y; Li, Z; Liu, Y; Pan, J; Qi, S; Wang, H; Xiang, W; Yi, GZ; Yu, L; Zhang, X, 2019) |
| "This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time." | 7.88 | The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. ( Glumac, M; Jakimov, D; Kojic, V; Pejin, B; Tommonaro, G, 2018) |
| "Glioblastoma (GBM) is an aggressive brain tumor with temozolomide (TMZ)-based chemotherapy as the main therapeutic strategy." | 7.88 | Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells. ( Kipper, FC; Lenz, G; Lopez, PLDC; Silva, AO; Villodre, ES, 2018) |
| "We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation." | 7.88 | Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. ( Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G, 2018) |
| "Standard treatment for patients with primary glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 7.88 | Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. ( Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2018) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 7.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| " By manipulation of Cx43 expression or gap junction function, we found that there were gap junction-dependent and independent effect of Cx43 on temozolomide (TMZ) sensitivity in U87 glioblastoma cells." | 7.88 | Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication. ( Huang, H; Ma, L; Peng, J; Peng, Y; Shao, M; Wang, L; Xia, Z; Zhong, G; Zhu, Z, 2018) |
| "Numerous studies suggested autophagy was involved in temozolomide (TMZ) resistance in glioma." | 7.88 | Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. ( Du, J; Fang, X; Huang, X; Jiang, C; Li, X; Liu, Z; Shen, F; Su, J; Wang, X, 2018) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 7.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo." | 7.88 | High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. ( Hong, YK; Lee, JE; Lim, JH; Yang, SH, 2018) |
| "The impact of DNA mismatch repair (MMR) on resistance to temozolomide (TMZ) therapy in patients with glioblastoma (GBM) is recently reported but the mechanisms are not understood." | 7.88 | Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. ( Dong, T; Dong, Y; Gao, Y; Gong, Y; Li, Q; Pei, C; Ren, H; Su, J; Sun, Q; Xiao, Y; Xing, W; Zhen, Z; Zhou, P, 2018) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 7.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 7.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG)." | 7.88 | Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). ( Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC, 2018) |
| " This phenomenon, which has deleterious outcomes for the patient, has long been observed in patients with glioblastoma receiving temozolomide (TMZ)-based radiochemotherapy." | 7.88 | Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray. ( Cui, Y; Feng, H; He, H; Li, J; Li, S; Lin, J; Qiu, G; Song, C; Wei, W; Wu, X; Xu, Q; Zuo, J, 2018) |
| "Multi-institutional data from 159 patients with newly diagnosed glioblastoma who received adjuvant temozolomide concomitant chemoradiotherapy (CCRT) were collected." | 7.88 | A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. ( Chan, D; Chan, KY; Ho, J; Lam, S; Lee, M; Ma, E; Mak, C; Poon, WS; Wong, ST; Wong, WK; Woo, P, 2018) |
| "To evaluate the prognostic value of the Glasgow Prognostic Score (GPS), the combination of C-reactive protein (CRP) and albumin, in glioblastoma multiforme (GBM) patients treated with radiotherapy (RT) and concurrent plus adjuvant temozolomide (GPS)." | 7.88 | Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. ( Ciner, F; Guler, OC; Mertsoylu, H; Ozdemir, Y; Selek, U; Topkan, E; Tufan, K; Yildirim, BA, 2018) |
| "To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression." | 7.88 | Temozolomide rechallenge in recurrent glioblastoma: when is it useful? ( Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M, 2018) |
| "Temozolomide (TMZ) is the most frequent adjuvant chemotherapy drug in gliomas." | 7.88 | Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. ( Dai, B; Li, J; Qi, N; Zhang, G, 2018) |
| "To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma." | 7.88 | [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. ( Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018) |
| "Human glioblastoma U251 and T98 cells and normal astrocytes C8D1A were loaded with coenzyme Q10 (CoQ)." | 7.88 | Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide. ( Alcaín, FJ; Ariza, J; Arjona-Gutiérrez, J; De la Mata, M; Durán-Prado, M; Ferrín, G; Frontiñán-Rubio, J; Gil-Agudo, A; Gómez, MV; Lozano, E; Martínez-González, A; Moreno, M; Nieva-Velasco, CM; Peinado, JR; Pérez-García, VM; Pérez-Romasanta, L; Pesic, M; Santiago-Mora, RM; Villalba, JM, 2018) |
| "We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years." | 7.88 | Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. ( Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y, 2018) |
| "Temozolomide (TMZ) is currently the first-line drug used for clinical postoperative or non-surgical chemotherapy for glioma, but acquired and intrinsic resistance to TMZ limits its application." | 7.88 | Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells. ( Fan, H; Li, Y; Ni, Q; Wang, Y; Zhang, X, 2018) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic drug approved for the Glioblastoma multiforme (GBM) treatment." | 7.88 | miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. ( Deng, S; Guo, M; Li, Y; Liu, Y; Peng, Y; Qi, S; Ren, J; Shu, S; Yi, G; Zhao, L, 2018) |
| "Recently, D,L-methadone has been put forward as adjuvant treatment in glioblastoma (GBM)." | 7.88 | Efficacy of D,L-methadone in the treatment of glioblastoma in vitro. ( Brawanski, A; Brawanski, K; Brockhoff, G; Freyschlag, C; Hau, P; Lohmeier, A; Proescholdt, MA; Riemenschneider, MJ; Thomé, C; Vollmann-Zwerenz, A, 2018) |
| "Temozolomide (TMZ) is the current first-line chemotherapy for treatment of glioblastoma multiforme (GBM)." | 7.88 | Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells. ( Arcella, A; Capriotti, AL; Caracciolo, G; Digiacomo, L; Frati, L; Mahmoudi, M; Oliva, MA; Palchetti, S; Pozzi, D; Rota, R; Screpanti, I; Tsaouli, G, 2018) |
| " Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed." | 7.88 | Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. ( Bai, Y; Chen, Y; Dong, X; Hong, X; Li, S; Li, Y; Liu, X; Su, X; Zhao, G, 2018) |
| " For example, temozolomide (TMZ), of use for glioblastoma (GBM) treatment, appears as capable of inducing autophagy partially inhibiting cancer cell proliferation." | 7.88 | Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. ( Ascione, B; Buccarelli, M; D'Alessandris, QG; De Pascalis, I; Larocca, LM; Malorni, W; Marconi, M; Martini, M; Matarrese, P; Pacioni, S; Pallini, R; Ricci-Vitiani, L, 2018) |
| "Chemoresistance blunts the effect of Temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 7.88 | Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. ( Huang, X; Li, R; Shen, F; Wang, X; Wei, Z; Wu, W; Yan, W; Yin, J; You, Y; Zeng, A; Zhou, X, 2018) |
| "In this study, we aimed to evaluate the expression and functions of MAPK8 in temozolomide (TMZ) -resistant glioblastoma cells as well as to explore the mechanism of TMZ resistance in glioblastoma cells." | 7.88 | MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway. ( Hou, S; Sha, LG; Xu, P; Zhang, G, 2018) |
| "To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients." | 7.88 | Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. ( Guzauskas, GF; Salzberg, M; Wang, BC, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 7.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted." | 7.88 | Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 7.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by 60 Gray of radiation with concomitant and adjuvant TMZ (standard radiotherapy and TMZ)." | 7.88 | Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. ( Carter, TC; Lawler, BE; Medina-Flores, R, 2018) |
| "Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM)." | 7.85 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. ( Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P, 2017) |
| "To determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide." | 7.85 | Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide. ( Algara, M; Foro Arnalot, P; Granados, R; Membrive, I; Ortiz, A; Pera, O; Reig, A; Rodriguez, N; Sanz, X, 2017) |
| "To compare various pro-apoptotic effects of synthetic 4-thiazolidinone derivative (Les-3288), doxorubicin (Dox) and temozolomide (TMZ) in the treatment of human glioma U251 cells to improve treatment outcomes of glioblastoma and avoid anticancer drug resistance." | 7.85 | Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells. ( Finiuk, N; Grytsyna, II; Klyuchivska, OY; Lehka, L; Lesyk, RB; Panchuk, RR; Starykovych, MO; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI, 2017) |
| "In glioblastoma several histone demethylase genes (KDM) are overexpressed compared to normal brain tissue and the development of Temozolomide (TMZ) resistance is accompanied by the transient further increased expression of KDM5A and other KDMs following a mechanism that we defined as "epigenetic resilience"." | 7.85 | Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. ( Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M, 2017) |
| "Glioblastoma multiforme (GBM) exhibits high resistance to the standard treatment of temozolomide (TMZ) combined with radiotherapy, due to its remarkable cell heterogeneity." | 7.85 | Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines. ( Abdollahi, A; Dokic, I; Klein, C; Oancea-Castillo, LR; Régnier-Vigouroux, A; Weber, KJ, 2017) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM)." | 7.85 | MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J, 2017) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 7.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "Limited benefits and clinical utility of temozolomide (TMZ) for glioblastoma (GB) are frequently compromised by the development of acquired drug resistance." | 7.85 | Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling. ( Fu, Z; Guo, H; Lian, C; Liu, B; Xu, N; Yang, Z; Zeng, H, 2017) |
| " In the present study, whether MALAT1 contributes to the resistance of glioblastoma cell lines to temozolomide (TMZ) was investigated." | 7.85 | Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. ( Dong, Y; Guan, F; Li, D; Li, H; Liu, X; Wang, H; Yan, D; Yang, B; Yuan, X, 2017) |
| "The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution." | 7.85 | Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. ( Ahn, SS; Chang, JH; Cho, J; Choi, HJ; Hong, CK; Kang, SG; Kim, DS; Kim, EH; Kim, SH; Lee, KS; Lee, SK; Moon, JH; Park, HH; Roh, TH; Suh, CO, 2017) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 7.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Temozolomide is the first chemotherapeutic agent proven effective for patients with newly diagnosed glioblastoma." | 7.85 | Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. ( Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK, 2017) |
| "Acquisition of temozolomide (TMZ) resistance is a major factor leading to the failure of glioblastoma (GBM) treatment." | 7.85 | Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O ( Chang, KY; Chang, WC; Chen, KY; Chou, SW; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Hung, JJ; Kao, TJ; Ko, CY; Liou, JP; Liu, JJ; Liu, MS; Tsai, SY, 2017) |
| "To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM)." | 7.85 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison ( Roussakow, SV, 2017) |
| " Standard of care for glioblastoma (GBM) includes temozolomide chemotherapy, which is not curative, due, in part, to residual therapy-resistant brain tumor-initiating cells (BTICs)." | 7.85 | Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. ( Audia, A; Bar, EE; Benavides, GA; Bevensee, MO; Bhat, KP; Boyd, NH; Cooper, SJ; Darley-Usmar, V; Dedhar, S; Fried, J; Gillespie, GY; Gordon, E; Griguer, C; Hackney, JR; Hjelmeland, AB; Landis, CJ; McDonald, PC; Nabors, B; Nozell, S; Scott, SE; Spina, R; Tran, AN; Walker, K; Xu, B, 2017) |
| "It is controversial whether concurrent chemoradiotherapy (CRT) with temozolomide is feasible and beneficial in elderly patients with glioblastoma." | 7.85 | A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65. ( Fietkau, R; Knippen, S; Lahmer, G; Putz, F; Semrau, S, 2017) |
| "The current standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 7.85 | Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide. ( Ikawa, F; Ishifuro, M; Kawamata, T; Kurisu, K; Muragaki, Y; Nishibuchi, I; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2017) |
| "It is unknown whether the addition of temozolomide (TMZ) to radiotherapy (RT) is associated with improved overall survival (OS) among older glioblastoma patients." | 7.85 | Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. ( Arvold, ND; Cefalu, M; Dominici, F; Schrag, D; Wang, Y; Zigler, C, 2017) |
| " In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells." | 7.85 | Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. ( Chen, H; Gong, Z; Gui, Q; Guo, X; Liang, P; Meng, J; Shi, H; Xu, Y; Zhu, W, 2017) |
| "The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major burden for patients suffering from glioma." | 7.85 | Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. ( Cai, L; Su, Z; Tu, M; Yu, Z; Zeng, B; Zheng, W; Zhu, D, 2017) |
| "The present study aimed to investigate whether overexpression of integrin-linked kinase (ILK) affects drug resistance to temozolomide (TMZ) in glioma cells." | 7.85 | Overexpression of ILK promotes temozolomide resistance in glioma cells. ( Bao, L; Liang, F; Wang, B; Zhang, SM; Zhang, SQ; Zhao, YS, 2017) |
| "Temozolomide-(TMZ)-based chemoradiotherapy defines the current gold standard for the treatment of newly diagnosed glioblastoma." | 7.85 | Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival. ( Ballhausen, H; Belka, C; Nachbichler, SB; Niyazi, M; Schupp, G, 2017) |
| "Glioblastoma multiforme (GBM), the most common malignant brain tumor, is currently treated with temozolomide (TMZ), but GBM often exhibits resistance to TMZ." | 7.85 | FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation. ( Li, L; Pei, H; Wang, H; Xia, Q; Xu, K; Zhang, Z, 2017) |
| "The chemotherapeutic agent temozolomide (TMZ) is widely used in the treatment of glioblastoma multiforme (GBM)." | 7.85 | Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. ( Cheng, YS; Ho, ASW; Kiang, KMY; Lee, D; Leung, GKK; Li, N; Poon, MW; Pu, JKS; Sun, S; Zhang, P; Zhang, X, 2017) |
| "To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles." | 7.85 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. ( Bendszus, M; Felsberg, J; Gramatzki, D; Hentschel, B; Herrlinger, U; Kickingereder, P; Loeffler, M; Pietsch, T; Reifenberger, G; Sabel, M; Schackert, G; Schlegel, U; Tonn, JC; Weller, M; Westphal, M; Wick, W, 2017) |
| "Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment." | 7.83 | Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. ( Du, J; Mao, G; Song, S; Zhu, X, 2016) |
| "Few data are available on temozolomide (TMZ) in ependymomas." | 7.83 | Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. ( Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M, 2016) |
| "Temozolomide is a standard chemotherapy agent for malignant gliomas, but the efficacy is still not satisfactory." | 7.83 | Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. ( Kanamori, M; Saito, R; Shibahara, I; Sonoda, Y; Sugiyama, S; Tominaga, T; Zhang, R, 2016) |
| "Resistance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to challenge GBM treatment efforts." | 7.83 | Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. ( Gourdie, RG; Guo, S; Jourdan, J; Kanabur, P; Lamouille, S; Murphy, SF; Osimani, AM; Pridham, KJ; Rodgers, CM; Sharma, S; Sheng, Z; Simonds, GR; Varghese, RT, 2016) |
| "We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy." | 7.83 | Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016) |
| "The survival benefits of patients with glioblastoma (GBM) remain unsatisfactory due to the intrinsic or acquired resistance to temozolomide (TMZ)." | 7.83 | Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. ( Han, J; Lan, F; Wu, Q; Yang, Y; Yu, H; Yue, X, 2016) |
| "Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM)." | 7.83 | Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. ( Boyd, AW; Byrne, AT; Day, BW; Flanagan, L; Kögel, D; Murray, DW; O'Brien, DF; Prehn, JH; Rehm, M; Salvucci, M; Stringer, BW; Tivnan, A; Zakaria, Z, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ)." | 7.83 | Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. ( El-Shorbagy, SH; Khedr, RA; Younis, SG, 2016) |
| "A gene drug delivery system for glioma therapy based on transferrin (Tf)-modified polyamidoamine dendrimer (PAMAM) was prepared." | 7.83 | Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. ( Gao, S; Hao, B; Hong, B; Jiang, C; Li, J, 2016) |
| " Human glioma U87MG or LNZ308 cells overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both." | 7.83 | Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. ( Nagane, M; Nitta, Y; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| " Triple-mutant astrocytes formed serially transplantable glioblastoma allografts that were sensitive to radiation but expressed MGMT and were resistant to temozolomide." | 7.83 | Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. ( Bash, RE; Ewend, MG; Huey, L; McNeill, RS; Miller, CR; Schmid, RS; Simon, JM; Vitucci, M; Werneke, AM; White, KK; Wu, J, 2016) |
| "The current standard of care for glioblastoma (GBM) is surgical resection, radiotherapy, and treatment with temozolomide (TMZ)." | 7.83 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. ( Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS, 2016) |
| "The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear." | 7.83 | Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. ( Baruzzi, A; Bertolini, F; Biasini, C; Brandes, AA; Cavallo, MA; Crisi, G; Dazzi, C; Depenni, R; Ermani, M; Faedi, M; Franceschi, E; Michiara, M; Mucciarini, C; Paccapelo, A; Pasini, G; Pavesi, G; Pisanello, A; Servadei, F; Sturiale, C; Urbini, B, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 7.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| "Clinical guidelines for gliosarcoma (GSM) are poorly defined and GSM patients are usually treated in accordance with existing guidelines for glioblastoma (GBM), with maximal surgical resection followed by chemoradiation with temozolomide (TMZ)." | 7.83 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( Adeberg, S; Bernhardt, D; Debus, J; Diehl, C; Harrabi, SB; Koelsche, C; Rieken, S; Unterberg, A; von Deimling, A, 2016) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 7.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| "The effects of KLF8 on glioma cell proliferation, apoptosis and chemosensitivity to temozolomide (TMZ) were analyzed by Cell Counting Kit 8 assay and flow cytometry assay." | 7.83 | KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation. ( Wang, E; Wu, F; Yu, G, 2016) |
| "HIF-1α downregulation sensitizes U251 glioma cells to the temozolomide treatment via inhibiting MGMT expression and Notch1 pathway activation." | 7.83 | Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. ( Huang, GH; Li, N; Lv, SQ; Ma, ZX; Sidlauskas, K; Tang, JH; Xiang, Y; Xu, QF; Zhang, EE, 2016) |
| "Although temozolomide (TMZ) is the most effective chemotherapy agent for glioma, chemotherapy resistance has limited its clinical use." | 7.83 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. ( Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR, 2016) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 7.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy." | 7.83 | miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. ( Liao, Y; Liu, J; Liu, Q; Lv, R; Qiu, X; Wu, M; Xiao, S; Yang, Z, 2016) |
| "Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients." | 7.83 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. ( Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 7.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM)." | 7.83 | Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. ( Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M, 2016) |
| " The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ)." | 7.83 | Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). ( Chang, JH; Cheong, JH; Choi, J; Huh, YM; Jeon, JY; Kang, SG; Kim, EH; Kim, P; Kim, SH; Koh, I; Lee, JH; Lee, SJ; Park, J; Pollak, M; Shim, JK; Yook, JI; Yun, M, 2016) |
| " In the OP group with GBM and anaplastic glioma, patients treated with RT combined with temozolomide (TMZ) manifested significantly longer OS and PFS compared with patients assigned to RT alone (P < 0." | 7.83 | Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. ( Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W, 2016) |
| "Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide." | 7.83 | MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016) |
| "Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration." | 7.83 | Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016) |
| "It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)." | 7.83 | Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016) |
| "Temozolomide (TMZ), an alkylating agent of the imidazotetrazine series, is a first-line chemotherapeutic drug used in the clinical therapy of glioblastoma multiforme, the most common and high-grade primary glioma in adults." | 7.83 | The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death. ( Chang, CK; Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shih, CM, 2016) |
| "The aim of this study was to investigate the effect of downregulating Hedgehog pathway by GANT61 on human glioma cells, examine the consequent changes of temozolomide (TMZ)-induced effects and explore the molecular mechanisms." | 7.83 | GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. ( Cai, J; Chen, L; Jiang, C; Li, J; Li, R; Li, Y; Sun, Y; Yao, K; Zhai, X; Zhang, J; Zhao, S, 2016) |
| "Concurrent chemoradiotherapy with temozolomide, the current standard treatment after surgery for glioblastoma, could be shortened without increasing side effects for patients with poor prognostic features." | 7.81 | Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. ( Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH, 2015) |
| "To explore the role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the differentiation of true progression from pseudoprogression in patients with glioblastoma on the basis of findings in entirely newly developed or enlarged enhancing lesions after concurrent radiation therapy and chemotherapy with temozolomide and to evaluate the diagnostic performance of the quantitative pharmacokinetic parameters obtained at dynamic contrast-enhanced MR imaging, such as the volume transfer constant (K(trans)), the extravascular extracellular space per unit volume of tissue(ve), and the blood plasma volume per unit volume of tissue(vp)." | 7.81 | Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ, 2015) |
| "The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported." | 7.81 | Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. ( Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015) |
| "The present in vitro study aimed to assess the effects of combining the mTOR inhibitor RAD001 and temozolomide (TMZ) together with irradiation by either low-linear energy transfer (LET) radiation (γ-rays) or high-LET radiation (fast neutrons) on the growth and cell survival of the human glioblastoma cell line U-87." | 7.81 | Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture. ( Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J, 2015) |
| "To evaluate 2 specific radiation schedules, each combined with temozolomide (TMZ), assessing their efficacy and safety in patients aged ≥65 years with newly diagnosed glioblastoma (GBM)." | 7.81 | Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. ( Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I, 2015) |
| "Glioblastoma Multiforme (GBM), the most common and lethal adult primary tumor of the brain, showed a link between Sonic Hedgehog (SHH) pathway in the resistance to temozolomide (TMZ)." | 7.81 | Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. ( Greco, SJ; Ligon, KL; Munoz, JL; Rameshwar, P; Ramkissoon, SH; Rodriguez-Cruz, V, 2015) |
| " Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome." | 7.81 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. ( Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X, 2015) |
| "Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined." | 7.81 | Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. ( Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B, 2015) |
| "Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict." | 7.81 | EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. ( Bonetti, MF; Branca, C; Buglione, M; Buttolo, L; Cominelli, M; Dalerba, P; Facchetti, F; Finocchiaro, G; Furlan, D; Galli, R; Grisanti, S; Liserre, B; Liserre, R; Mazzoleni, S; Medicina, D; Pellegatta, S; Pellegrini, V; Pizzi, M; Poliani, PL, 2015) |
| " In this project, we evaluated the effects of silibinin, a natural plant component of milk thistle seeds, to potentiate toxic effects of chemotherapy drugs such as temozolomide, etoposide and irinotecan on LN229, U87 and A172 (P53 and phosphatase and tensin homolog (PTEN) -tumor suppressor-mutated) glioma cell lines." | 7.81 | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. ( Elhag, R; Mazzio, EA; Soliman, KF, 2015) |
| "In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy." | 7.81 | Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. ( Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH, 2015) |
| "Temozolomide (TMZ) is the first line drug in the care of high grade gliomas." | 7.81 | Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. ( Clemente, MA; Corsa, P; Cossa, S; Donno, E; Munafò, T; Parisi, F; Parisi, S; Perrone, A; Piombino, M; Raguso, A; Sanpaolo, G; Valle, G, 2015) |
| "Despite multimodal treatment, glioblastoma (GBM) therapy with temozolomide (TMZ) remains inefficient due to chemoresistance." | 7.81 | The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. ( Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H, 2015) |
| "High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy." | 7.81 | Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. ( Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM, 2015) |
| "We examined whether the amino acid PET tracers, trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) and (11)C-methyl-l-methionine ((11)C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-β (IFN), and bevacizumab (Bev) in glioblastoma." | 7.81 | Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H, 2015) |
| "Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied." | 7.81 | The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. ( Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F, 2015) |
| "Resistance to temozolomide (TMZ) is a major obstacle in the treatment of glioblastoma multiforme (GBM)." | 7.81 | miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. ( Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhan, Q; Zhou, D, 2015) |
| " The objective of this study was to assess the survival benefit of LEV compared with other antiepileptic drugs as a chemosensitizer to temozolomide for patients with glioblastoma." | 7.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "It is currently unclear whether adjuvant therapy for WHO grade III anaplastic astrocytomas (AA) should be carried out as combined chemoradiotherapy with temozolomide (TMZ)--analogous to the approach for glioblastoma multiforme--or as radiotherapy (RT) alone." | 7.81 | Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. ( Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P, 2015) |
| "Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival." | 7.81 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. ( Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD, 2015) |
| "The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide." | 7.81 | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. ( Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Garcia, J; Hegde, P; Henriksson, R; Kharbanda, S; Lai, A; Li, C; Mason, W; Moore, N; Nishikawa, R; Peale, F; Phillips, HS; Sandmann, T; Saran, F; Wick, W, 2015) |
| " The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 7.81 | NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. ( Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G, 2015) |
| "Temozolomide plays a critical role in curing glioma at present." | 7.81 | Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ( Gao, J; Huang, G; Liu, H; Wang, L; Wang, Z, 2015) |
| " Glioblastoma (GBM) has poor survival rate and uniformly acquired chemoresistance to its frontline agent, Temozolomide (TMZ)." | 7.81 | Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. ( Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND, 2015) |
| " The present study was undertaken to determine whether the cytotoxicity of curcumin (diferuloylmethane), a natural polyphenolic compound isolated from turmeric (Curcuma longa Linn), in glioblastoma cells is mediated through upregulation of miR‑146a." | 7.81 | Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. ( Cai, T; Chen, YD; Liu, Q; Wang, ZF; Wu, H, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 7.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| "Although temozolomide (TMZ) is the current first-line chemotherapy for glioblastoma multiforme (GBM), most patients either do not respond or ultimately fail TMZ treatment." | 7.81 | Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. ( Chang, EH; DeMarco, J; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| " Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations." | 7.81 | Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015) |
| "Mesoporous silica nanoparticles (MSNPs), 100 nm in size, incorporating a Cy5 fluorophore within the silica framework, are synthesized and loaded with the anti-cancer drug temozolomide (TMZ), used in the treatment of gliomas." | 7.81 | Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. ( Bertucci, A; Brognara, E; Corradini, R; De Cola, L; Gambari, R; Manicardi, A; Prasetyanto, EA; Septiadi, D, 2015) |
| "The efficacy of temozolomide (TMZ) plus radiation therapy (RT) in elderly patients with glioblastoma is unclear." | 7.81 | Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). ( Anghileri, E; Bazzoli, E; Bellu, L; Berti, F; D'Avella, D; Dall'Agata, M; Della Puppa, A; Eoli, M; Fabi, A; Faedi, M; Ferrazza, P; Gurrieri, L; Lombardi, G; Nicolotto, E; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Villani, V; Zagonel, V, 2015) |
| "Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with vascular normalization within the tumor." | 7.81 | Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. ( Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015) |
| "This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol." | 7.81 | Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. ( Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH, 2015) |
| "Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ)." | 7.81 | Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2015) |
| "Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment." | 7.81 | The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. ( Allemanni, G; Banelli, B; Barbieri, F; Carosio, R; Carra, E; Daga, A; Florio, T; Forlani, A; Marubbi, D; Parodi, F; Pattarozzi, A; Romani, M; Würth, R, 2015) |
| "Glioma stem cells are associated for temozolomide-resistance in glioblastoma." | 7.81 | Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. ( Leung, GK; Poon, MW; Sun, S; Wong, ST; Zhang, XQ; Zhuang, JT, 2015) |
| "Temozolomide (TMZ) with radiotherapy is the current standard of care for newly diagnosed glioma." | 7.81 | MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. ( Chen, Q; Han, J, 2015) |
| "The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide." | 7.80 | Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. ( Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA, 2014) |
| "To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6)." | 7.80 | Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). ( Arza, C; Díez Valle, R; Galván, J; Romariz, C; Slof, J; Vidal, C, 2014) |
| "Although temozolomide (TMZ) replaced nitrosoureas as the standard initial chemotherapy for glioblastoma (GBM), no studies have compared TMZ with nimustine (ACNU), a nitrosourea agent widely used in central Europe and most Asian regions." | 7.80 | Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. ( Chen, B; Chen, L; Chen, X; Jiang, T; Li, S; Wang, J; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhang, Z, 2014) |
| "The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth." | 7.80 | The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. ( Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J, 2014) |
| " This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival." | 7.80 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. ( Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P, 2014) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 7.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclinical proof-of-concept studies of the effects of temozolomide-containing regimens." | 7.80 | Mechanism of temozolomide-induced antitumour effects on glioma cells. ( Hu, JA; Shen, W; Zheng, JS, 2014) |
| "Present work mainly evaluated the inhibitory effects of lidamycin (LDM), an enediyne antibiotic, on angiogenesis or glioma-induced angiogenesis in vitro and in vivo, especially its synergistic anti-angiogenesis with temozolomide (TMZ)." | 7.80 | Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| "With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14." | 7.80 | Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. ( Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A, 2014) |
| " In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients." | 7.80 | MGMT promoter methylation in plasma of glioma patients receiving temozolomide. ( Cassoni, P; Castiglione, A; De Marco, L; Fiano, V; Gillio-Tos, A; Grasso, C; Magistrello, M; Merletti, F; Rudà, R; Sacerdote, C; Senetta, R; Soffietti, R; Tondat, F; Trevisan, E; Trevisan, M, 2014) |
| "Temozolomide profoundly prevented the outgrowth of experimental brain metastases of breast cancer in an MGMT-dependent manner." | 7.80 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. ( Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014) |
| "Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells." | 7.80 | Antitumor effect of fibrin glue containing temozolomide against malignant glioma. ( Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S, 2014) |
| "Autophagy is a cytoprotective process, which occurs following temozolomide (TMZ) treatment, and contributes to glioma chemoresistance and TMZ treatment failure." | 7.80 | Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma. ( Li, B; Wang, Q; Wang, W; Xie, B; Zou, Y, 2014) |
| " We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012." | 7.80 | IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. ( Arcella, A; Bozzao, A; Di Stefano, D; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Salvati, M; Scaringi, C; Scarpino, S; Villani, V, 2014) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 7.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance." | 7.80 | Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. ( Anderson, JC; Bonner, JA; Bredel, M; Choradia, NV; Duarte, CW; Rohrbach, TD; Thottassery, JV; Welaya, K; Willey, CD; Yancey Gillespie, G; Yang, ES, 2014) |
| "Effective sensitizing strategies potentially can extend the benefit of temozolomide (TMZ) therapy in patients with glioblastoma (GBM)." | 7.80 | Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. ( Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA, 2014) |
| "The present work evaluated the synergistic efficacy of an enediyne antibiotic lidamycin (LDM) plus temozolomide (TMZ) against glioma in vitro and in vivo." | 7.80 | Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| "To study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts." | 7.80 | [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats]. ( Gao, Y; Li, Y; Liu, G; Ma, L; Wang, Y; Zhou, X, 2014) |
| " The aim of this study was to investigate whether quercetin could sensitize human glioblastoma cells to temozolomide (TMZ) in vitro." | 7.80 | Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. ( Lan, Q; Li, RJ; Sang, DP, 2014) |
| "To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide." | 7.80 | Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. ( Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM, 2014) |
| "We examined changes to key UPR modulators in temozolomide-sensitive and -resistant human GBM cells (D54 and U87) treated with/without temozolomide at different oxygen concentrations using western blotting, and cytotoxic benefits of overexpressing key chaperone, P4HB, in GBM cells (U87 and U251) under normoxia and hyperoxia." | 7.80 | Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. ( Ho, AS; Kiang, KM; Lee, D; Leung, GK; Sun, S; Xu, FF; Zhang, XQ, 2014) |
| "This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas." | 7.80 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. ( Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X, 2014) |
| "This study assesses the controversial role of temozolomide (TMZ) concurrent with adjuvant radiation (RT) in patients with anaplastic astrocytoma (AA)." | 7.80 | The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. ( Buckner, JC; Decker, PA; Giannini, C; Hardie, J; Jenkins, RB; Kizilbash, SH; Laack, NN; Parney, IF; Uhm, JH; Voss, JS, 2014) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 7.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "The combined application of aplysin and TMZ significantly sensitizes glioma cells to TMZ action, compared with TMZ alone." | 7.80 | Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. ( Ge, N; Gong, A; Liang, H; Lu, L; Yao, W, 2014) |
| "The aim of the present study was to evaluate the toxicity and clinical outcome of radio-chemotherapy with temozolomide in patients with glioblastoma aged more than 65 years." | 7.80 | Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience. ( Cocuzza, P; Fabbrini, MG; Fatigante, L; Ferrazza, P; Monzani, F; Pasqualetti, F; Pasqualetti, G, 2014) |
| "The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control." | 7.80 | Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S, 2014) |
| "To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT)." | 7.80 | Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. ( Badiyan, SN; Chicoine, MR; Dacey, R; DeWees, T; Dowling, JL; Huang, J; Jalalizadeh, R; Kim, AH; Leuthardt, EC; Linette, G; Markovina, S; Rich, KM; Robinson, CG; Simpson, JR; Tran, DD; Zipfel, GJ, 2014) |
| "These results suggest that concomitant treatment with NPe6-PDT and temozolomide is a potentially useful therapy for glioma." | 7.80 | Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium. ( Akimoto, J; Beppu, M; Fujiwara, Y; Hiranuma, M; Hironaka, C; Miki, Y; Moritake, K; Omata, H, 2014) |
| "We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas." | 7.80 | Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. ( Brown, BD; Brown, T; Juarez, T; Kesari, S; Piccioni, DE; Saria, MG; van Vugt, VA, 2014) |
| "To assess the prognosis predictability of a measurable enhancing lesion using histogram parameters produced by the normalized cerebral blood volume (nCBV) and normalized apparent diffusion coefficient (nADC) after completion of standard concomitant chemoradiotherapy (CCRT) and adjuvant temozolomide (TMZ) medication in glioblastoma multiforme (GBM) patients." | 7.80 | Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Ryoo, I; Sohn, CH; Yun, TJ, 2014) |
| "Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma." | 7.80 | Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014) |
| "The objective of this study was to report the authors' experience with the long-term administration of temozolomide (TMZ; > 6 cycles, up to 101) in patients with newly diagnosed glioblastoma and to analyze its feasibility and safety as well as its impact on survival." | 7.80 | Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. ( Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G, 2014) |
| "For glioma, temozolomide (TMZ) is a commonly used chemotherapy drug and photodynamic therapy (PDT) is an important adjuvant therapy." | 7.80 | Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. ( Guo, M; Hu, S; Shen, L; Zhang, X, 2014) |
| "Nine post-temozolomide recurrent or progressive high-grade glioma patients (seven with glioblastoma and two with anaplastic astrocytoma) were treated with BV monotherapy." | 7.80 | Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. ( Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K, 2014) |
| "The benefit of the introduction of alkylating chemotherapy in the treatment of glioblastoma multiforme (GBM) patients has been demonstrated by comparing radiotherapy with concomitant plus intermittent temozolomide (iTMZ) to radiation therapy." | 7.79 | The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. ( Felsberg, J; Goeppert, M; Rapp, M; Sabel, M; Steiger, HJ, 2013) |
| " In this study, we investigated the predictive value of SLC22A18 promoter methylation and protein expression in glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) therapy." | 7.79 | Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. ( Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB, 2013) |
| "Temozolomide (TMZ) is commonly used in the treatment of glioblastoma (GBM)." | 7.79 | Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. ( Canpinar, H; Castresana, JS; Ilgaz, S; Ozdemir, M; Ozkan, T; Oztuna, D; Rey, JA; Sunguroğlu, A; Taspinar, M; Ugur, HC, 2013) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 7.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "The purpose of this study is to assess the preclinical therapeutic efficacy of magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption to enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment." | 7.79 | Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. ( Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC, 2013) |
| "We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ)." | 7.79 | Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. ( Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW, 2013) |
| "We have studied the consequences of the combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 and temozolomide on the growth and cell death of the glioblastoma cell line U-87 in vitro." | 7.79 | The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. ( Bischoff, P; Burckel, H; Josset, E; Noël, G, 2013) |
| "To determine whether immediate post-operative brachytherapy can be safely applied to newly diagnosed glioblastomas to retard tumor progression prior to initiation of external beam radiation therapy (EBRT) and temozolomide." | 7.79 | Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. ( Alksne, JF; Carter, BS; Chen, CC; Gonda, DD; Lawson, J; Murphy, K; Rose, B; Russell, M; Scanderbeg, DJ; Waters, JD, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Global gene expressions and drug sensitivities to three chemotherapeutic drugs (imatinib, camptothecin and temozolomide) were measured in six human glioblastoma-derived cell lines." | 7.79 | Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. ( Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L, 2013) |
| "To explore the role of histogram analysis of apparent diffusion coefficient (ADC) maps obtained at standard- and high-b-value (1000 and 3000 sec/mm(2), respectively) diffusion-weighted (DW) imaging in the differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide." | 7.79 | Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. ( Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ, 2013) |
| "Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance mechanisms limit benefits." | 7.79 | Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. ( Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P, 2013) |
| "To evaluate the efficacy of pulsed low-dose radiation therapy (PLRT) combined with temozolomide (TMZ) as a novel treatment approach for radioresistant glioblastoma multiforme (GBM) in a murine model." | 7.79 | Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. ( Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD, 2013) |
| "Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM)." | 7.79 | Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. ( Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S, 2013) |
| " Such chemoresistance was overcome by apparently noncytotoxic doses of temozolomide, which chemosensitized glioblastoma cells to doxorubicin, vinblastine, and etoposide." | 7.79 | Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway. ( Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Ghigo, D; Kopecka, J; Mellai, M; Riganti, C; Salaroglio, IC; Schiffer, D, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients." | 7.79 | Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. ( Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S, 2013) |
| "To compare retrospectively outcome after photon radiotherapy alone, radiochemotherapy with temozolomide (TMZ), and carbon ion radiotherapy in patients with high-grade gliomas and to generate a hypothetical outcome curve for C12 and TMZ." | 7.79 | Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. ( Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H, 2013) |
| "The recent progress in chemotherapy for malignant gliomas is attributable to the introduction of the DNA-methylating agent temozolomide (TMZ); however, drug resistance remains a major issue." | 7.79 | The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. ( Adachi, K; Hayashi, T; Hirose, Y; Ohba, S, 2013) |
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 7.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Temozolomide (TMZ) during and after radiotherapy (RT) is recommended for patients with newly diagnosed glioblastoma (GBM)." | 7.79 | Glioblastoma management in the temozolomide era: have we improved outcome? ( Al-Zahrani, A; Atenafu, E; Laperriere, N; Lwin, Z; MacFadden, D; Mason, WP; Menard, C; Miller, BA; Sahgal, A, 2013) |
| "The effect of concomitant and adjuvant temozolomide in glioblastoma patients above the age of 65 years lacks evidence." | 7.79 | Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. ( Behm, T; Bock, HC; Horowski, A; Mielke, D; Rohde, V; Schneider, S; Stockhammer, F, 2013) |
| "In 2005, maximum safe surgical resection, followed by radiotherapy with concomitant temozolomide (TMZ), followed by adjuvant TMZ became the standard of care for glioblastoma (GBM)." | 7.79 | Time trends in glioblastoma multiforme survival: the role of temozolomide. ( Darefsky, AS; Dubrow, R; Jacobs, DI; King, JT; Laurans, MS; Park, LS; Rose, MG, 2013) |
| "To examine whether adjuvant temozolomide treatment improved glioblastoma patients` survival in a large Canadian cohort." | 7.79 | Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma. ( Al-Nuaimi, SK; Alnaami, IM; Gourishankar, S; Mehta, V; Murtha, AD; Senthilselvan, A; Walling, S, 2013) |
| "To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy." | 7.79 | Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. ( Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K, 2013) |
| " Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma." | 7.79 | Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. ( Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Karl, S; Marschall, V; Vucic, D; Wagner, L; Zobel, K, 2013) |
| " We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)." | 7.79 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013) |
| "We investigated whether high levels of activated mitogen-activated protein kinase (p-MAPK) were associated with poor survival among patients with newly diagnosed glioblastoma during the temozolomide era." | 7.79 | High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. ( Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Fan, X; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Yu, JS, 2013) |
| " This study aimed to investigate the possible mechanism of mutant TP53 inducing temozolomide resistance in glioblastoma cells." | 7.79 | Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. ( Chen, JX; Liu, YH; Mao, Q; Wang, X; You, C, 2013) |
| " In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model." | 7.79 | Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. ( Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y, 2013) |
| "To compare survival and hematological toxicity rates between two postoperative therapy regimens in patients with primary glioblastoma (GBM), namely temozolomide (TMZ) concomitant to radiation, followed by adjuvant TMZ, versus adjuvant TMZ after radiation only." | 7.79 | Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. ( Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G, 2013) |
| "We retrospectively reviewed nine cases of relapsed medulloblastoma treated with bevacizumab, irinotecan, ± temozolomide." | 7.79 | Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. ( Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY, 2013) |
| "For elderly patients with glioblastoma multiforme (GBM), radiotherapy plus concomitant and adjuvant temozolomide has resulted in longer survival." | 7.79 | Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. ( Jang, WY; Jeong, EH; Jung, S; Jung, TY; Kim, IY; Lee, JH; Moon, KS, 2013) |
| "To evaluate pathologically confirmed incidence of pseudoprogression and its impact on survival in glioblastoma multiforme (GBM) patients treated with radiotherapy and concurrent temozolomide (TMZ), followed by 6 months of TMZ maintenance therapy." | 7.78 | Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. ( Oymak, E; Parlak, C; Pehlivan, B; Topkan, E; Topuk, S, 2012) |
| "We report retrospective data on the feasibility and efficacy of prolonging adjuvant temozolomide (TMZ) more than 6 months after chemoradiotherapy completion in patients with glioblastoma (GBM)." | 7.78 | Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2012) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 7.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone." | 7.78 | Glioblastoma survival in the United States before and during the temozolomide era. ( Johnson, DR; O'Neill, BP, 2012) |
| "To determine the maximum-tolerated dose (MTD) of radiation (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma (GBM), to estimate their progression-free (PFS) and overall survival (OS), and to assess the role of (11)C methionine PET (MET-PET) imaging in predicting recurrence." | 7.78 | Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. ( Brown, D; Cao, Y; Chenevert, T; Gomez-Hassan, D; Heth, J; Junck, L; Lawrence, T; Normolle, D; Piert, M; Schipper, M; Ten Haken, RK; Tsien, CI, 2012) |
| "The alkylating agent temozolomide (TMZ) is the major chemotherapeutic drug used clinically in the treatment of malignant gliomas." | 7.78 | Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. ( Lee, CC; Lin, CJ; Lin, TY; Lin, YF; Shih, CM; Shih, YL; Wang, SH, 2012) |
| "The standard of care for newly diagnosed glioblastoma multiforme (GBM) is temozolomide (TMZ) chemotherapy given concurrently with radiation for 6 weeks followed by 6 months of adjuvant TMZ." | 7.78 | Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. ( Easaw, JC; Roldán Urgoiti, GB; Singh, AD, 2012) |
| "Alkylating agents, such as temozolomide (TMZ) and fotemustine (FTM) are widely used in recurrent glioblastoma (GBM) regimes." | 7.78 | Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. ( Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M, 2012) |
| "Polysorbate 80 coated temozolomide-loaded PLGA-based superparamagnetic nanoparticles (P80-TMZ/SPIO-NPs) were successfully synthesized and characterized as drug carriers and diagnosis agent for malignant brain glioma." | 7.78 | Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. ( Ling, Y; Wei, K; Zhong, S; Zou, F, 2012) |
| "Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT." | 7.78 | Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. ( Hara, K; Kageji, T; Kitazato, KT; Kuwayama, K; Matsuzaki, K; Mizobuchi, Y; Morigaki, R; Mure, H; Nagahiro, S; Okazaki, T, 2012) |
| "The effectiveness of temozolomide (TMZ) dosing schemes and the "rechallenge" of recurrent glioblastoma (GBM) with TMZ are controversial." | 7.78 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. ( Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J, 2012) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma." | 7.78 | Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. ( Florea, AM; Happold, C; Reifenberger, G; Roth, P; Schmidt, N; Silginer, M; Weller, M; Wick, W, 2012) |
| "We analyzed the usefulness of initial or recurrent treatment of temozolomide (TMZ) in pediatric high-grade gliomas (HGGs)." | 7.78 | Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study. ( Baek, HJ; Choi, HS; Jung, TY; Kim, CY; Kim, DS; Kim, IA; Kim, SH; Ra, YS, 2012) |
| "Radiotherapy plus concomitant and adjuvant temozolomide (RCAT) is now standard treatment for grade IV glioblastoma (GBM)." | 7.78 | Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. ( Hargreaves, S; Kooner, I; Liu, ZW; Menashy, R; Michalarea, V; Williams, M; Wilson, E; Woolf, D, 2012) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 7.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 7.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| "Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM)." | 7.78 | Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. ( Fung, CF; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Wong, ST, 2012) |
| "Currently, treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy." | 7.78 | Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. ( Chen, Y; Cui, B; Dai, X; Dong, J; Huang, Q; Lan, Q; Tang, D; Zhang, J; Zhou, G, 2012) |
| "The effect of temozolomide (TMZ) and radiotherapy (RT) in the treatment of glioblastoma multiforme (GBM) has been well documented in randomized controlled trials." | 7.78 | A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. ( Helseth, E; Johannesen, TB; Meling, TR; Rønning, PA, 2012) |
| "Temozolomide (TMZ) is an oral alkylating agent widely used in the treatment of refractory glioma." | 7.78 | The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels. ( Cao, K; Li, QY; Lu, PS; Lu, XY; Yuan, ZC, 2012) |
| " Recently, in a phase II trial in Brazil for the treatment of temozolomide (TMZ)-resistant malignant gliomas, POH was well tolerated when administered intranasally." | 7.78 | Perillyl alcohol for the treatment of temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012) |
| "Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy." | 7.78 | A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. ( Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012) |
| "Implementation of chemotherapy with the drug temozolomide increased the overall survival of patients with glioblastoma multiforme (GBM; WHO grade IV), in particular when the O(6)-methylguanine DNA methyltransferase (MGMT) promoter is epigenetically silenced." | 7.78 | Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. ( Beier, CP; Bettstetter, M; Gempt, J; Hoepner, I; Koeritzer, J; Meyer, B; Rasper, M; Ringel, F; Schäfer, A; Schlegel, J; Schmidt-Graf, F; Teufel, J, 2012) |
| "Implantable and poly (d,l-lactide-co-glycolide) (PLGA) microparticles were developed to deliver temozolomide (TM) continuously in interstitial chemotherapy for glioma." | 7.77 | Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. ( Liu, JM; Yue, ZJ; Zhang, H; Zhang, YH, 2011) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 7.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors." | 7.77 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. ( Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH, 2011) |
| "To evaluate the safety and efficacy of hypofractionated radiotherapy (RT) with a standard temozolomide (TMZ) regimen for adults with newly diagnosed glioblastoma multiforme (GBM), twenty-six consecutive adults (range 39-79 years) who met our enrollment criteria received short courses of hypofractionated RT (45 Gy in 15 fractions over three weeks) with concomitant TMZ at 75 mg/m(2)/d." | 7.77 | A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. ( Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T, 2011) |
| " A 56-year-old man with a left parietal glioblastoma was treated with resection, radiation and concomitant and adjuvant temozolomide chemotherapy." | 7.77 | Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma. ( Grommes, C; Papanicolaou, G; Redelman-Sidi, G, 2011) |
| "Temozolomide in combination with radiation has been in use for more than 5 years for the therapy of glioblastoma." | 7.77 | Hepatic encephalopathy after treatment with temozolomide. ( Goldbecker, A; Herrmann, J; Raab, P; Tryc, AB; Weissenborn, K; Worthmann, H, 2011) |
| "Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ→TMZ)." | 7.77 | Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. ( Belka, C; Eigenbrod, S; Grasbon-Frodl, EM; Kreth, FW; Kreth, S; Kretzschmar, HA; Lutz, J; Popperl, G; Thon, N; Tonn, JC, 2011) |
| "This prospective study was performed to determine the efficacy, safety, and tolerability of concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with WHO grade III gliomas." | 7.77 | Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. ( Bae, SH; Cha, SH; Cho, WH; Choe, G; Jung, HW; Kim, CY; Kim, DG; Kim, IA; Kim, IH; Kim, YH; Lee, MM; Moon, S; Park, CK; Park, SH, 2011) |
| "The aim of this paper is to evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) and concomitant temozolomide (TMZ) as a salvage treatment option in patients with recurrent glioblastoma (GBM)." | 7.77 | Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. ( Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M, 2011) |
| "Only a few studies examined the effect of temozolomide (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT)." | 7.77 | First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2011) |
| "The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma." | 7.77 | Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. ( Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W, 2011) |
| " Induction of autophagy by temozolomide (TMZ) has been noted in glioma cell lines." | 7.77 | Induction of autophagy in temozolomide treated malignant gliomas. ( Aoki, H; Fujii, Y; Kakita, A; Miyahara, H; Natsumeda, M; Takahashi, H; Toyoshima, Y; Uzuka, T; Yajima, N, 2011) |
| "Concomitant radiation therapy (RT) and temozolomide (TMZ) therapy after surgery is the standard treatment for glioblastoma multiforme (GBM)." | 7.77 | Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. ( Côté, AL; Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH, 2011) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic agent in the treatment of glioma following surgical resection and/or radiation." | 7.77 | N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. ( Banze, LA; Brown, AR; Goellner, EM; Hamilton, RL; Moore, B; Sobol, RW; Svilar, D; Tang, JB; Trivedi, RN; Wang, XH, 2011) |
| " Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide." | 7.77 | Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. ( Blasberg, RG; de Stanchina, E; Gamez, I; Huang, R; Kochetkov, T; Moroz, MA; Ryan, RP; Shi, W; Thaler, H, 2011) |
| "We investigated the molecular mechanisms underlying the cytotoxic effect of Temozolomide (TMZ) in both O(6)-methylguanine-DNA methyl transferase (MGMT) depleted as well as undepleted glioblastoma cell lines." | 7.77 | Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. ( Brunetti, E; Bucci, B; D'agnano, I; De Paula, U; De Salvo, M; Gagliassi, R; Marchese, R; Maresca, G; Raza, GH; Stigliano, A, 2011) |
| "To study the impact of two human glioma tissue resistance genes MGMT and ERCC(2) on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions." | 7.77 | [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship]. ( Hou, X; Sun, JH; Wang, JJ; Wu, ZC; Zhao, Y; Zheng, YR, 2011) |
| "Temozolomide has significantly improved the outcome of patients with glioblastoma." | 7.77 | [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2011) |
| "Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM." | 7.77 | Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - . ( Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T, 2011) |
| "This study was designed to evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for monitoring the WHO grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ)." | 7.77 | Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. ( Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN, 2011) |
| " In vitro Southern Blot analysis and cytopathic effect assays demonstrate high anti-glioma potency, which was significantly increased in combination with temozolomide (TMZ), daunorubicin and cisplatin." | 7.77 | YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. ( Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W, 2011) |
| "Patients with high-grade gliomas (HGG) routinely receive radiation, temozolomide, and glucocorticoids." | 7.77 | Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. ( Carraway, H; Desideri, S; Grossman, SA; Lesser, G; Piantadosi, S; Sloan, A; Ye, X, 2011) |
| "Temozolomide (TMZ) is an alkylating agent that has yielded significant benefits and is a current standard agent in the treatment of malignant gliomas." | 7.77 | Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. ( Fukushima, T; Katayama, Y; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tashiro, S; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2011) |
| "The goal of this study was to evaluate accelerated radiotherapy with and without temozolomide (TMZ) for glioblastoma multiforme (GBM)." | 7.77 | Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. ( Buttmann, M; Flentje, M; Guckenberger, M; Mayer, M; Sweeney, RA; Vince, GH, 2011) |
| "A 61-year-old man with glioblastoma and positive for hepatitis B surface antigen (HBsAg) developed acute hepatitis due to hepatitis B virus (HBV) reactivation after concomitant postoperative treatment with temozolomide (75 mg/m(2)/day) and radiation therapy (60 Gy in 30 fractions)." | 7.77 | Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report. ( Kayama, T; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Ueno, H, 2011) |
| "The objective of this retrospective analysis was to assess long-term outcome and prognostic factors of unselected patients treated for glioblastoma (GB) at a single center with surgery, standard radiotherapy (RT), and concomitant temozolomide (TMZ)." | 7.77 | Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. ( Franz, K; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 7.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "To evaluate the incidence and impact of early post-chemoradiation (cRT) 'pseudoprogression' (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of care - 60 Gy conformal radiotherapy with concurrent low-dose temozolomide, followed by six cycles of high-dose temozolomide (the 'Stupp protocol')." | 7.77 | Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. ( Gunjur, A; Lau, E; Ryan, G; Taouk, Y, 2011) |
| "To study the efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide (TMZ) for gliomas." | 7.77 | [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. ( Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011) |
| " Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases." | 7.77 | Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| "The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ)." | 7.76 | Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. ( Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ, 2010) |
| "Concomitant daily temozolomide and radiation followed by adjuvant temozolomide is a tolerable and reasonable treatment option and has a good performance status for elderly patients diagnosed with glioblastoma." | 7.76 | Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? ( Collichio, F; Ewend, MG; Grabowski, S; Kimple, RJ; Morris, DE; Papez, M, 2010) |
| "In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model." | 7.76 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. ( Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD, 2010) |
| "This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma." | 7.76 | Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? ( Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE, 2010) |
| "We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively." | 7.76 | Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. ( Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT, 2010) |
| "O(6)-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of glioblastoma multiforme (GBM) patients." | 7.76 | O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. ( Berger, W; Buchroithner, J; Filipits, M; Fischer, J; Lötsch, D; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S; Weis, S, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 7.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation." | 7.76 | Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. ( Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA, 2010) |
| "Novel agents are currently combined with radiation and temozolomide (RT + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end point." | 7.76 | Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. ( Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X, 2010) |
| " We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide." | 7.76 | Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010) |
| "Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades." | 7.76 | Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. ( Blank, A; Bobola, MS; Kolstoe, DD; Silber, JR, 2010) |
| "There is a growing evidence of using Temozolomide as upfront therapy for progressive low grade gliomas." | 7.76 | Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. ( Dehais, C; Delattre, JY; Ducray, F; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Omuro, A; Psimaras, D; Sanson, M; Sierra del Rio, M; Taillibert, S, 2010) |
| "To evaluate perfusion parameter changes in patients with glioblastoma multiforme by comparing the perfusion magnetic resonance (MR) imaging measurements obtained before combined radiation and temozolomide therapy (RT-TMZ) with the follow-up MR imaging measurements obtained 1 month after completion of this treatment." | 7.76 | Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. ( Ekholm, SE; Korones, DN; Mangla, R; Milano, MT; Singh, G; Zhong, J; Ziegelitz, D, 2010) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 7.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "O(6)-methylguanine-DNA methyltransferase (MGMT) expression in glioblastoma correlates with temozolomide resistance." | 7.76 | Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. ( Donze, J; Liu, L; McGraw, M; Palomo, JM; Rahmathulla, G; Robinson, CG; Vogelbaum, MA, 2010) |
| "The aim of the present study was to investigate the effect of Temozolomide (an alkylating chemotherapeutic agent) and quercetin (natural flavonoid) on cell death in the human astrocytoma cell line MOGGCCM (WHO grade III)." | 7.76 | Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. ( Jakubowicz-Gil, J; Langner, E; Piersiak, T; Rzeski, W; Wertel, I, 2010) |
| "We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)." | 7.76 | Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 7.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia." | 7.76 | Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. ( Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T, 2010) |
| "Temozolomide (TM) has anti-tumor activity in patients with malignant glioma." | 7.76 | Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010) |
| "The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GB) when compared to postoperative RT alone in patients up to 65 years of age." | 7.76 | Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. ( Franz, K; Fraunholz, I; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2010) |
| "To analyze the recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with conformal radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), and to compare the patterns of failure according to different target volume delineations." | 7.76 | Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. ( Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S, 2010) |
| "Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers." | 7.76 | Urticarial hypersensitivity reaction caused by temozolomide. ( Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C, 2010) |
| "Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT)." | 7.75 | A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. ( Dill, C; Ehninger, G; Illmer, T; Kestel, L; Kramer, M; Krex, D; Pfirrmann, M; Robel, K; Schackert, G; Schaich, M, 2009) |
| " In this study, we used pharmacokinetic and pharmacodynamic approaches to investigate how sunitinib at different dose levels affects brain distribution of temozolomide (TMZ), and to ascertain the relationship between intratumoral TMZ concentrations and tumor vascularity in an orthotopic human glioma model." | 7.75 | Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ( Gallo, JM; Zhou, Q, 2009) |
| "CpG methylation within the O6-methylguanine-DNA-methyltransferase (MGMT) promoter is associated with enhanced survival of glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ)." | 7.75 | Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. ( Ballman, KV; Buckner, JC; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT)." | 7.75 | Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ( Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A, 2009) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 7.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "The aim of the present study was to evaluate factors predicting the recurrence pattern after the administration of temozolomide (TMZ), initially concurrent with radiotherapy (RT) and subsequently as maintenance therapy, which has become standard treatment for patients with newly diagnosed glioblastoma (GBM)." | 7.75 | Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. ( Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 7.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 7.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| "We have completed in vivo safety and efficacy studies of the use of a novel drug delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the post-resection cavity, as a candidate for glioma therapy." | 7.75 | Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. ( Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J, 2009) |
| "Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas." | 7.75 | Glioma-associated endothelial cells are chemoresistant to temozolomide. ( Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W, 2009) |
| "A 46-year-old man developed Stevens-Johnson syndrome and toxic epidermal necrolysis overlap, with severe localized denudation of the skin on the head and neck, following radiotherapy and oral temozolomide therapy for cranial glioblastoma multiforme." | 7.75 | Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. ( Sarma, N, 2009) |
| " On the other hand, temozolomide (TMZ), an oral bioavailable alkylating agent with excellent tolerability, has demonstrated efficacy and has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 7.75 | Effect of IFN-beta on human glioma cell lines with temozolomide resistance. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Watanabe, T; Yachi, K; Yoshino, A, 2009) |
| "A recent randomized study conducted on newly diagnosed glioblastoma (GBM) patients demonstrated that concomitant and adjuvant temozolomide added to standard radiotherapy had a survival advantage compared with radiotherapy alone." | 7.75 | Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. ( Agati, R; Bacci, A; Benevento, F; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Mazzocchi, V; Scopece, L; Tosoni, A, 2009) |
| "Previous studies have revealed that p38, a member of the family of stress-activated protein kinases (SAPKs), cooperates with the Chk1-pathway to bring about temozolomide (TMZ)-induced G2 arrest, and that the inhibition of either pathway alone is sufficient to sensitize U87MG glioma cells to TMZ-induced cytotoxicity." | 7.75 | Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Sano, H, 2009) |
| "Concurrent temozolomide (TMZ) and radiation therapy (RT) followed by adjuvant TMZ is standard treatment for patients with glioblastoma multiforme (GBM), although the relative contribution of concurrent versus adjuvant TMZ is unknown." | 7.75 | Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. ( Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "Our data suggest that temozolomide is an active regimen for malignant gliomas." | 7.74 | Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Gunel, N; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2008) |
| "Although high AGT levels may mediate resistance in a portion of these samples, MMR deficiency does not seem to be responsible for mediating temozolomide resistance in adult malignant glioma." | 7.74 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. ( Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A, 2008) |
| " Convection-enhanced delivery (CED) of either the replication-defective, ICP0-producing HSV-1 mutant, d106, or the recombinant d109, devoid of all viral genome expression, was performed to determine the in vivo efficacy of ICP0 in combination with ionizing radiation (IR) or systemic temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 7.74 | Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. ( Deluca, NA; Fellows-Mayle, W; Hadjipanayis, CG, 2008) |
| "Use of antiangiogenic therapy with radiation and temozolomide in the primary management of high-grade glioma is feasible." | 7.74 | Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. ( Eagan, P; Fischer, I; Golfinos, JG; Gruber, ML; Kelly, P; Knopp, EA; Medabalmi, P; Narayana, A; Parker, E; Raza, S; Zagzag, D, 2008) |
| " In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide." | 7.74 | Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008) |
| "Human GBM-derived cell lines U87, G44, G112, and the gliosarcoma-derived line G28 were treated with EPO, with and without combinations of irradiation or temozolomide (TMZ)." | 7.74 | Erythropoietin augments survival of glioma cells after radiation and temozolomide. ( Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S, 2008) |
| "In the 4-year retrospective study, 31 patients with histologically confirmed malignant gliomas, in which 10 patients received radiotherapy followed by temozolomide (group A) and 21 patients received radiotherapy alone (group B)." | 7.74 | Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. ( Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM, 2008) |
| "In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches." | 7.74 | p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. ( Berger, MS; Dinca, EB; Haas-Kogan, DA; James, CD; Lu, KV; Pieper, RO; Prados, MD; Sarkaria, JN; Vandenberg, SR, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 7.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents." | 7.74 | MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. ( Addo-Yobo, SO; Donson, AM; Foreman, NK; Gore, L; Handler, MH, 2007) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas)." | 7.74 | Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. ( Batista, LF; Kaina, B; Menck, CF; Naumann, SC; Roos, WP; Weller, M; Wick, W, 2007) |
| "Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model." | 7.74 | Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. ( Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "The aim of this study was to investigate the effect of temozolomide (TZM) in combination with X-rays on proliferation and migration in human glioma spheroids." | 7.74 | The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation. ( Fehlauer, F; Muench, M; Rades, D; Richter, E, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 7.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations." | 7.74 | Dynamic history of low-grade gliomas before and after temozolomide treatment. ( Amiel-Benouaich, A; Capelle, L; Carpentier, AF; Cornu, P; Delattre, JY; Duffau, H; Guillevin, R; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Laigle-Donadey, F; Lejeune, J; Mandonnet, E; Marie, Y; Mokhtari, K; Omuro, A; Ricard, D; Sanson, M; Taillibert, S, 2007) |
| "We report the case of a 30-year-old woman with glioblastoma multiforme (GBM) treated with surgery followed by concomitant Temozolomide (TMZ) and external beam radiation, which she tolerated well without any interruptions." | 7.74 | Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. ( Gujral, S; Jalali, R; Menon, H; Singh, P, 2007) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 7.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "The use of adjuvant temozolomide (TMZ) in patients managed with surgery and adjuvant radiation therapy (RT) for glioblastoma multiforme (GBM) has been demonstrated to improve median and 2-year survival in a recent large international multicentre study." | 7.74 | Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. ( Ang, EL; Back, MF; Chan, SP; Lim, CC; Ng, WH; See, SJ; Yeo, TT, 2007) |
| " In this study, as we determined p53 gene mutation occurring in multinucleated giant cell glioblastoma, we investigated the role of Aurora-B in formation of multinucleated cells in human neoplasm cells with various p53 statuses as well as cytotoxity of glioma cells to temozolomide (TMZ), a common oral alkylating agent used in the treatment of gliomas." | 7.74 | Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. ( Fujita, M; Inagaki, M; Katsumata, S; Mizuno, M; Nakahara, N; Natsume, A; Osawa, H; Satoh, Y; Tsuno, T; Wakabayashi, T; Yoshida, J, 2007) |
| "Treatment of malignant glioma involves concomitant temozolomide and ionizing radiation (IR)." | 7.74 | Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. ( Bickenbach, K; Galanopoulos, N; Pytel, P; Rawlani, V; Veerapong, J; Weichselbaum, RR; Yamini, B; Yu, X, 2007) |
| "To investigate the radiosensitizing potential of temozolomide (TMZ) for human glioblastoma multiforme (GBM) cell lines using single-dose and fractionated gamma-irradiation." | 7.74 | Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. ( Hulsebos, TJ; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; van den Berg, J; van Nifterik, KA, 2007) |
| "To evaluate efficacy and toxicity in elderly patients with glioblastoma multiforme (GBM) treated with postoperative radiochemotherapy with temozolomide (TMZ)." | 7.74 | Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. ( Bischof, M; Combs, SE; Debus, J; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T, 2008) |
| "Diffusion tensor imaging and multiple voxel magnetic resonance spectroscopy were performed in the MRI follow-up of a patient with a glioma treated with temozolomide chemotherapy." | 7.74 | Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. ( Enting, RH; Heesters, MA; Irwan, R; Meiners, LC; Oudkerk, M; Potze, JH; Sijens, PE; van der Graaf, WT, 2007) |
| "The purpose of this study was to report our experience with concomitant and adjuvant temozolomide (TMZ) with radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 7.74 | Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. ( Basu, A; Goel, A; Gupta, T; Jalali, R; Menon, H; Munshi, A; Sarin, R, 2007) |
| " Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia." | 7.74 | Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. ( Aldape, K; Archer, GE; Bigner, DD; Crutcher, L; Dey, M; Gilbert, M; Hassenbusch, SJ; Heimberger, AB; Hussain, SF; Mitchell, DA; Sampson, JH; Sawaya, R; Schmittling, B; Sun, W, 2008) |
| "Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM)." | 7.74 | The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. ( Avutu, B; Barker, FG; Batchelor, TT; Chakravarti, A; Henson, JW; Hochberg, FH; Loeffler, JS; Martuza, RL; Sher, DJ, 2008) |
| "32 patients 70 years of age or older with a newly diagnosed glioblastoma and a Karnofsky performance status (KPS) > or = 70 were treated with RT (daily fractions of 2 Gy for a total of 60 Gy) plus temozolomide at the dose of 75 mg/m(2) per day followed by six cycles of adjuvant temozolomide (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 7.74 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. ( Bozzao, A; De Paula, U; De Sanctis, V; Filippone, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Tombolini, V; Valeriani, M, 2008) |
| "To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma." | 7.73 | Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. ( Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005) |
| "Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit." | 7.73 | MGMT gene silencing and benefit from temozolomide in glioblastoma. ( Bromberg, JE; Cairncross, JG; de Tribolet, N; Diserens, AC; Gorlia, T; Hainfellner, JA; Hamou, MF; Hau, P; Hegi, ME; Janzer, RC; Kros, JM; Mariani, L; Mason, W; Mirimanoff, RO; Stupp, R; Weller, M, 2005) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 7.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 7.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "Cimetidine added to temozolomide compared with temozolomide alone induced survival benefits in nude mice with U373 human glioblastoma multiforme (GBM) cells orthotopically xenografted in the brain." | 7.73 | Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. ( Brotchi, J; Camby, I; Darro, F; Gabius, J; Gaussin, JF; James, S; Kiss, R; Lefranc, F, 2005) |
| "There are new scientific data concerning the treatment of patients with glioblastoma multiforme with concomitant and adjuvant temozolomide following surgery and radiotherapy." | 7.73 | [Temozolomide in patients with a glioblastoma multiforme: new developments]. ( Bromberg, JE; Postma, TJ, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 7.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| "Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 7.73 | Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. ( Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P, 2005) |
| " Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 7.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 7.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 7.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma." | 7.73 | Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M, 2006) |
| "Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma." | 7.73 | Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. ( Bally, F; Christen, G; de Ribaupierre, S; Ganière, V; Guillou, L; Pica, A; Stupp, R, 2006) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 7.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma." | 7.73 | Potentiation of antiglioma effect with combined temozolomide and interferon-beta. ( Hong, YK; Joe, YA; Kim, TG; Park, JA, 2006) |
| "In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent." | 7.72 | Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. ( Barnett, G; Chahlavi, A; Elson, P; Kanner, A; Peereboom, D; Staugaitis, SM, 2003) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 7.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases." | 7.72 | Complete response of multiple melanoma brain metastases after treatment with temozolomide. ( Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J, 2004) |
| "The phase III randomised European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trail Group (NCIC) Intergroup trial (EORTC 26981/22981; CE3) compares irradiation alone with irradiation plus temozolomide for patients with glioblastoma multiforme (GBM)." | 7.72 | Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. ( Ataman, F; Fisher, B; Mirimanoff, RO; Poortmans, P; Stupp, R, 2004) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 7.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| "Temozolomide is an oral alkylating agent shown to have modest efficacy in the treatment of glioblastoma multiforme." | 7.72 | Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. ( Gillespie, GY; Kufe, DW; Weichselbaum, RR; Yamini, B; Yu, X, 2004) |
| "Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence." | 7.71 | Temozolomide as second-line chemotherapy for relapsed gliomas. ( Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S, 2002) |
| "Temozolomide (TZM) is a novel methylating agent currently under investigation for treatment of recurrent high-grade gliomas." | 7.71 | Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. ( Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F, 2002) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 7.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "A case is reported in which temozolomide, a promising new DNA alkylating agent, was successfully used to treat radiation refractory metastatic brain tumors arising from primary breast cancer." | 7.71 | Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report. ( Isaacson, BJ; Islam, R; Ratanawong, C; Tipping, SJ; Zickerman, PM, 2002) |
| "Temozolomide has an evolving role in the treatment of high grade gliomas." | 7.71 | An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. ( Ashley, DL; Cher, L; Harris, MT; Rosenthal, MA, 2001) |
| "The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days." | 7.71 | Temozolomide chemotherapy in recurrent oligodendroglioma. ( Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ, 2001) |
| "Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy." | 7.71 | Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. ( Chou, TC; Droege, JW; Fels, C; Kramm, CM; Rainov, NG; Schäfer, C, 2001) |
| "To investigate the effect of temozolomide, a 3-methyl derivative of mitozolomide in combination with X-rays in human glioma-derived cell lines." | 7.70 | Survival of human glioma cells treated with various combination of temozolomide and X-rays. ( Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J, 2000) |
| " Temozolomide is a novel methylating agent with proven efficacy against malignant gliomas (MGs) after systemic administration but with dose-limiting myelotoxicity." | 7.70 | Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. ( Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Heimberger, AB; Hulette, C; McLendon, RE; Sampson, JH, 2000) |
| "Glioblastoma is the most common and most aggressive type of primary brain tumor." | 7.30 | Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023) |
| "The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade." | 7.11 | Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. ( Amatu, A; Barault, L; Bardelli, A; Bartolini, A; Battuello, P; Bonoldi, E; Cassingena, A; Crisafulli, G; Di Nicolantonio, F; Germano, G; Idotta, L; Lazzari, L; Luraghi, P; Macagno, M; Marsoni, S; Mauri, G; Morano, F; Personeni, N; Pessei, V; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F; Valtorta, E; Vitiello, PP; Zampino, MG, 2022) |
| " Only one possibly treatment-related treatment emergent adverse event (TEAE), Grade 1 gingival swelling, was observed." | 7.01 | Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study. ( Chen, KT; Hsu, PW; Huang, HL; Jung, SM; Ke, YX; Lin, YJ; Toh, CH; Tsai, HC; Tseng, CK; Wei, KC, 2021) |
| "Glioblastoma is the most common and lethal brain tumor in adults." | 7.01 | Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. ( Iturrioz-Rodríguez, N; Matheu, A; Sampron, N, 2023) |
| "Atorvastatin was not shown to improve PFS-6." | 7.01 | Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study. ( Aldanan, S; Alghareeb, WA; Alhussain, H; AlNajjar, FH; Alsaeed, E; Alsharm, AA; Altwairgi, AK; Balbaid, AAO; Orz, Y, 2021) |
| " Methods This is an open-label, 2-arm Phase 1b/2a study (N = 56) of galunisertib (intermittent dosing: 14 days on/14 days off per cycle of 28 days) in combination with TMZ/RTX (n = 40), versus a control arm (TMZ/RTX, n = 16)." | 6.94 | Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ( Burkholder, T; Capper, D; Cleverly, AL; Desjardins, A; Estrem, ST; Forsyth, P; Guba, SC; Gueorguieva, I; Lahn, MM; Rodon, J; Suarez, C; Wang, S; Wick, A, 2020) |
| "Primary end point is freedom from new brain metastases at 1 year." | 6.94 | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. ( Armstrong, TS; Biassou, N; Brastianos, PK; Burton, E; Carter, S; Gilbert, MR; Gril, B; Houston, N; Lipkowitz, S; Lyden, D; Smart, DD; Steeg, PS; Steinberg, SM; Zimmer, AS, 2020) |
| " In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide (TMZ) to treat these patients, although large-scale prospective studies are lacking." | 6.90 | Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial. ( Guan, H; He, L; He, Y; Mu, X; Peng, X; Wang, J; Wang, Y, 2019) |
| " Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%)." | 6.90 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ( Ansell, PJ; Bain, E; Butowski, N; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Maag, D; Merrell, R; Mikkelsen, T; Nabors, LB; Papadopoulos, KP; Penas-Prado, M; Reardon, DA; Roberts-Rapp, L; Scott, AM; Simes, J; van den Bent, MJ; Walbert, T; Wheeler, H; Xiong, H, 2019) |
| " The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM." | 6.90 | Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. ( Chen, G; Chen, L; Li, G; Li, Q; Luo, W; Lv, S; Zhong, L; Zhou, P, 2019) |
| "Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 6.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
| "Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit angiogenesis." | 6.82 | Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature. ( Sun, X; Xu, X; Xu, Y; Zhan, W; Zhao, L; Zhu, Y, 2022) |
| "Glioblastoma is a fatal brain tumor with a bleak prognosis." | 6.82 | Glioblastoma and Methionine Addiction. ( Sowers, LC; Sowers, ML, 2022) |
| "Retreatment with temozolomide (TMZ) is one treatment option." | 6.80 | Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. ( Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015) |
| "Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression." | 6.80 | A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. ( Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH, 2015) |
| "Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles." | 6.80 | Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H, 2015) |
| "Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1-6), followed by TMZ maintenance therapy (TMZ/RT→TMZ)." | 6.80 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. ( Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015) |
| "The upfront approach to treatment of glioblastoma in the unresectable population warrants further investigation in randomized controlled phase III trials." | 6.78 | Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ, 2013) |
| "Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 6.77 | Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. ( Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 6.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases)." | 6.76 | Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. ( Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L, 2011) |
| " On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study." | 6.76 | North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. ( Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011) |
| " The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation." | 6.76 | Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. ( Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y, 2011) |
| "Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70." | 6.76 | Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. ( Barrie, M; Beauchesne, P; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, O; Delattre, JY; Ducray, F; Gállego Pérez-Larraya, J; Guillamo, JS; Honnorat, J; Huchet, A; Matta, M; Mokhtari, K; Monjour, A; Taillandier, L; Tanguy, ML, 2011) |
| "Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles." | 6.76 | A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. ( Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ, 2011) |
| "Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR." | 6.75 | EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. ( Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ, 2010) |
| "The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q." | 6.74 | Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. ( Anderson, J; Avedissian, R; Croteau, D; Doyle, T; Gutierrez, J; Hasselbach, L; Margolis, J; Mikkelsen, T; Paleologos, N; Schultz, L, 2009) |
| "Temozolomide treatment did not affect TPM plasma concentrations in chronically treated patients." | 6.73 | Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Pace, A; Zarabla, A, 2008) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 6.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| " CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion." | 6.73 | Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. ( Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 6.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| "GBM is the grade IV glioma brain cancer which is life-threatening to many individuals affected by this cancer." | 6.72 | Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. ( Shetty, K; Yadav, KS; Yasaswi, PS, 2021) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 6.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard." | 6.72 | Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. ( Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Temozolomide is an oral chemotherapeutic agent with efficacy against malignant gliomas and a favorable safety profile." | 6.71 | Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Frauger, E; Grisoli, F; Hoang-Xuan, K; Martin, PM; Moktari, K; Palmari, J; Peragut, JC, 2004) |
| "Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS." | 6.71 | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. ( Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N, 2004) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%." | 6.71 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. ( Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D, 2004) |
| "Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)." | 6.71 | Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004) |
| "Temozolomide was administered orally each therapy day at a dose of 50 mg/m(2)." | 6.71 | Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. ( Combs, SE; Debus, J; Edler, L; Gutwein, S; Schulz-Ertner, D; Thilmann, C; van Kampen, M; Wannenmacher, MM, 2005) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 6.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| "Temozolomide is a new cytotoxic alkylating agent that has recently been approved in Portugal for the treatment of recurrent high-grade glioma." | 6.70 | Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. ( Albano, J; Cernuda, M; Garcia, I; Lima, L; Oliveira, C; Portela, I; Teixeira, MM, 2002) |
| " The absolute bioavailability of TMZ was 0." | 6.69 | Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ( Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F, 1998) |
| "Glioblastoma (GBM), the most common primary brain tumor, is the most aggressive human cancers, with a median survival rate of only 14." | 6.61 | Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide. ( Aoki, K; Hirano, M; Natsume, A; Ranjit, M; Wakabayashi, T, 2019) |
| "Temozolomide may cause thrombocytopenia or neutropenia in 3-4% of glioblastoma patients, respectively." | 6.55 | MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case. ( Altinoz, MA; Bolukbasi, FH; Ekmekci, CG; Elmaci, I; Sari, R; Sav, A; Yenmis, G, 2017) |
| "The standard treatment for brain metastases is radiotherapy." | 6.55 | Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. ( Luo, Y; Tang, J; Tian, J; Xiang, J, 2017) |
| "Fibrosarcoma is a rare brain tumour with 33 cases reported so far." | 6.53 | Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases. ( Giridhar, P; Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK, 2016) |
| "Glioblastoma is a unique model of non-metastasising disease that kills the vast majority of patients through local growth, despite surgery and local irradiation." | 6.53 | Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. ( Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG, 2016) |
| "Many physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies." | 6.49 | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. ( Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2013) |
| " Hematotoxicity is listed as a frequent adverse drug reaction in the US prescribing information and hepatotoxicity has been reported infrequently in the postmarketing period." | 6.48 | Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. ( Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M, 2012) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 6.48 | Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. ( Caporello, P; Enrici, RM; Minniti, G; Scaringi, C, 2012) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 6.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with activity in high and LGG." | 6.47 | Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. ( Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug." | 6.45 | Temozolomide in malignant gliomas: current use and future targets. ( Bressler, LR; Seery, TE; Villano, JL, 2009) |
| " Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O(6)-guanine mimetic agents as substrates for MGMT." | 6.44 | Mechanisms of disease: temozolomide and glioblastoma--look to the future. ( Chamberlain, MC; Mrugala, MM, 2008) |
| "Temozolomide has proven benefit in grade II/III gliomas progressive following standard therapy and when added to radiation for glioblastoma." | 6.44 | Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. ( Schiff, D, 2007) |
| "Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma." | 6.43 | Optimal role of temozolomide in the treatment of malignant gliomas. ( Hegi, ME; Stupp, R; van den Bent, MJ, 2005) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 6.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| " The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules." | 6.41 | The use of temozolomide in recurrent malignant gliomas. ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "Temozolomide is a novel, oral, second-generation alkylating agent." | 6.41 | Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. ( Friedman, HS, 2000) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 6.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system." | 5.91 | Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98). ( Ahmadi-Zeidabadi, M; Amirinejad, M; Jomehzadeh, A; Khoei, S; Kordestani, Z; Larizadeh, MH; Yahyapour, R, 2023) |
| "Glioblastoma (GBM) is the most lethal primary brain tumor in adults and harbors a subpopulation of glioma stem cells (GSCs)." | 5.91 | EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. ( Li, M; Tian, W; Wang, B; Wang, Y; Xu, R; Yu, T; Zeng, A; Zhang, J; Zhou, F; Zhou, Z, 2023) |
| "Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis." | 5.91 | Role of COL6A2 in malignant progression and temozolomide resistance of glioma. ( Hong, X; Ouyang, J; Peng, X; Wang, P; Xiao, B; Zhang, J; Zou, J, 2023) |
| "Glioblastoma (GBM) is the most frequent brain cancer and more lethal than other cancers." | 5.91 | Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma. ( Agredano-Moreno, LT; Gallardo-Pérez, JC; Jimenez-García, LF; López-Marure, R; Robledo-Cadena, DX; Sánchez-Lozada, LG; Trejo-Solís, MC, 2023) |
| " Based on the genetic testing results, almonertinib combined with anlotinib and temozolomide was administered and obtained 12 months of progression-free survival after the diagnosis of recurrence as the fourth-line treatment." | 5.91 | Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. ( Dong, S; Hou, Z; Li, S; Luo, N; Tao, R; Wu, H; Zhang, H; Zhang, X; Zhu, D, 2023) |
| "Temozolomide (TMZ) is a first line agent used in the clinic for glioblastoma and it has been useful in increasing patient survival rates." | 5.91 | Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. ( Ahmed-Cox, A; Akhter, DT; Cao, Y; Fletcher, NL; Janjua, TI; Kavallaris, M; Moniruzzaman, M; Popat, A; Raza, A; Thurecht, KJ, 2023) |
| "Glioblastoma is the most common malignant brain tumor in adults." | 5.91 | Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. ( Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C, 2023) |
| "Temozolomide (TMZ) is a chemotherapy agent used to treat primary central nervous system tumors." | 5.91 | Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis. ( Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F, 2023) |
| " In this paper, we present the effects of juglone alone and in combination with temozolomide on glioblastoma cells." | 5.91 | Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. ( Barciszewska, AM; Belter, A; Gawrońska, I; Giel-Pietraszuk, M; Naskręt-Barciszewska, MZ, 2023) |
| "Glioblastoma is the most aggressive and fatal form of brain cancer." | 5.91 | The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. ( Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M, 2023) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | 5.91 | Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma. ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| " The most common adverse events were leukocytopenia (66." | 5.91 | Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. ( Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023) |
| "Neuroblastoma is the most common tumour in children under 1 year old, accounting for 12-15% of childhood cancer deaths." | 5.91 | Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma. ( Balachandar, A; Bhagirath, E; Pandey, S; Vegh, C; Wear, D, 2023) |
| "Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders." | 5.72 | Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. ( Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022) |
| "Glioblastoma multiforme (GBM) is a primary brain tumor with devastating prognosis." | 5.72 | Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. ( Huang, G; Lin, R; Liu, Y; Ni, B; Qi, ST; Song, H; Wang, H; Wang, Z; Xie, S; Xu, Y; Yi, GZ; Zhang, Y, 2022) |
| " Therefore, localised approaches that treat GB straight into the tumour site provide an alternative to enhance chemotherapy bioavailability and efficacy, reducing systemic toxicity." | 5.72 | Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. ( Arantes, PR; Borges, GR; Braganhol, E; Dalanhol, CS; de Barros Dias, MCH; de Oliveira Merib, J; de Souza, PO; Ferro, MB; Henn, JG; Morás, AM; Moura, DJ; Nugent, M; Reinhardt, LS, 2022) |
| "Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment." | 5.72 | Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. ( Belanger, K; Damek, D; Lillehei, KO; Ormond, DR; Ung, TH, 2022) |
| " Additionally, by lowering the effective dosage of TMZ, the combination liposomes reduced systemic TMZ-induced toxicity, highlighting the preclinical potential of this novel integrative strategy to deliver combination therapies to brain tumors." | 5.72 | Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. ( Chai, T; Du, Q; Hanif, S; Ismail, M; Li, Y; Muhammad, P; Shi, B; Yang, W; Zhang, D; Zheng, M, 2022) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic drug for glioma." | 5.72 | FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway. ( Guo, L; Wu, Z, 2022) |
| " Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies." | 5.72 | Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide. ( Astori, G; Belli, R; Bernardi, M; Bozza, A; Catanzaro, D; Celli, P; Chieregato, K; Menarin, M; Merlo, A; Milani, G; Peroni, D; Pozzato, A; Pozzato, G; Raneri, FA; Ruggeri, M; Volpin, L, 2022) |
| "Temozolomide (TMZ) is a chemotherapeutic drug for the treatment of GBM." | 5.72 | Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells. ( Adıgüzel, Z; Kıyga, E; Önay Uçar, E, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 5.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but the emergence of drug resistance limits its anti-tumor activity." | 5.72 | GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair. ( Chen, CC; Chen, Y; Grigore, FN; Jin, J; Lan, Q; Li, M; Li, S; Ma, J; Wang, J; Wang, Q; Wu, G; Xu, H; Zhu, H, 2022) |
| "Metformin is a biguanide drug utilized as the first-line medication in treating type 2 diabetes." | 5.72 | Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022) |
| "Gliomas are the most common type of primary brain tumors, with high recurrence rate and mortality." | 5.72 | ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12. ( Fu, J; Peng, J; Tu, G, 2022) |
| "Apatinib is a multitarget tyrosine kinase inhibitor, which has been reported to exhibit broad antitumor profiles." | 5.72 | Apatinib and temozolomide in children with recurrent ependymoma: A case report. ( Li, J; Shen, Z; Shi, L; Zhang, N; Zhao, S, 2022) |
| "Temozolomide (TMZ) is a first-line clinical chemotherapeutic drug." | 5.72 | Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment. ( Chen, KC; Chen, PH; Ho, KH; Kuo, YY; Liu, AJ; Shih, CM, 2022) |
| "Glioma is a common type of malignant and aggressive tumor in the brain." | 5.72 | Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma. ( Chen, M; Feng, W; Li, J; Li, M; Li, T; Liu, Y; Xia, X; Yang, W; Yuan, Q; Zhang, S; Zhou, X; Zuo, M, 2022) |
| "Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit." | 5.69 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. ( Baehring, J; Bähr, O; Brandes, AA; Butowski, N; Carpentier, AF; Chalamandaris, AG; Cloughesy, T; Di Giacomo, AM; Fu, AZ; Idbaih, A; Khasraw, M; Lassen, U; Lim, M; Liu, Y; Lombardi, G; Mulholland, P; Muragaki, Y; Omuro, A; Potter, V; Qian, X; Reardon, DA; Roth, P; Sepulveda, JM; Sumrall, A; Tabatabai, G; Tatsuoka, K; van den Bent, M; Vauleon, E; Weller, M, 2023) |
| " Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840)." | 5.69 | Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. ( Amoroso, B; Aronchik, I; Chang, H; Filvaroff, E; González León, P; Hanna, B; Manuel Sepúlveda, J; Mendez, C; Moreno, V; Nikolova, Z; Pérez-Núñez, Á; Reardon, DA; Sanchez-Perez, T; Stephens, D; Vogelbaum, MA; Zuraek, M, 2023) |
| "Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high." | 5.69 | Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. ( Abad, AP; Ahluwalia, MS; Belal, AN; Birkemeier, MT; Casucci, DM; Ciesielski, MJ; Curry, WT; Dharma, SS; Dhawan, A; Fenstermaker, RA; Figel, SA; Hutson, AD; Liu, S; Mechtler, LL; Mogensen, KM; Peereboom, DM; Qiu, J; Reardon, DA; Withers, HG; Wong, ET, 2023) |
| "In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity." | 5.69 | Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. ( Brehmer, S; Bullinger, L; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Hau, P; Herrlinger, U; Kowalski, T; Krex, D; Potthoff, AL; Ringel, F; Sabel, M; Schäfer, N; Schaub, C; Schmidt-Graf, F; Schneider, M; Schnell, O; Seidel, C; Steinbach, JP; Tabatabai, G; Tonn, JC; Tzaridis, T; Vajkoczy, P; Vatter, H; Weller, J; Zeiner, PS; Zeyen, T, 2023) |
| "Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis." | 5.69 | Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. ( Anders, CK; Arisa, O; Armstrong, TS; Brastianos, P; Burton, E; Carter, S; Connolly, RM; Figg, WD; Gilbert, MR; Houston, N; Jenkins, S; Khan, I; Lipkowitz, S; Mendoza, TR; Mozarsky, B; Nousome, D; Peer, CJ; Shah, R; Smart, DD; Smith, KL; Steeg, PS; Steinberg, SM; Tweed, C; Vera, E; Wu, X; Zhang, W; Zimmer, AS, 2023) |
| "Despite standard treatments including chemoradiotherapy with temozolomide (TMZ) (STUPP protocol), the prognosis of glioblastoma patients remains poor." | 5.69 | Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). ( Biau, J; Casile, M; De Beaumont, O; Dufort, S; Durando, X; Le Duc, G; Loeffler, M; Molnar, I; Moreau, J; Seddik, K; Thivat, E, 2023) |
| "This study was aimed at analyzing the efficacy and safety of an injectable form of chlorogenic acid (CGA) in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation phase I trial." | 5.69 | Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up. ( Chen, F; Deng, J; Jiang, J; Kang, X; Kang, Z; Li, S; Li, W; Yang, H; Zhang, J, 2023) |
| "In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiotherapy, and overall survival at 12 months was not significantly different (61% in the TMZ arm and 55% in the TMZ + BEV arm)." | 5.69 | Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen ( Bottomley, A; Clement, PM; Coens, C; de Vos, FYF; Ghislain, I; Golfinopoulos, V; Idbaih, A; Klein, M; Lewis, J; Machingura, A; Mulholland, PJ; Reijneveld, JC; Taal, W; Taphoorn, MJB; van den Bent, MJ; Wick, W, 2023) |
| "Glioma is the most common primary intracranial tumor." | 5.62 | FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. ( Huang, L; Jiang, T; Li, G; Liu, Y; Zhao, Z; Zhou, K, 2021) |
| "Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis." | 5.62 | Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. ( Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA, 2021) |
| "GBM (glioblastoma multiforme) is the most common and aggressive brain tumor." | 5.62 | Regorafenib in glioblastoma recurrence: A case report. ( Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA, 2021) |
| "Temozolomide (TMZ) has been widely used as a first-line treatment for GBM." | 5.62 | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. ( Li, N; Li, Y; Lv, Y; Sha, C; Sun, K; Tang, S; Wang, A; Wang, L; Yan, X; Yu, Y, 2021) |
| "Temozolomide (TMZ) is an effective chemotherapy drug for glioblastoma, but the resistance to TMZ has come to represent a major clinical problem, and its underlying mechanism has yet to be elucidated." | 5.62 | Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide. ( Bi, QC; Gan, LJ; Han, XJ; Hong, T; Jiang, LP; Lan, XM; Liu, LH; Tan, RJ; Wei, MJ; Yang, ZJ; Zhang, LL, 2021) |
| "Glioblastoma is the most malignant brain tumor and presents high resistance to chemotherapy and radiotherapy." | 5.62 | APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2021) |
| "Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics." | 5.62 | Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. ( Boockvar, J; Brahmbhatt, H; Gao, S; Gonzalez, C; Jamil, E; Khan, MB; MacDiarmid, J; Mugridge, N; Ruggieri, R; Sarkaria, JN; Symons, M; Tran, NL, 2021) |
| "Celecoxib and 2,5-DMC were the most cytotoxic." | 5.62 | COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. ( Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K, 2021) |
| "Temozolomide (TMZ) is an alkylating agent widely used for glioma treatment." | 5.62 | miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma. ( Cui, B; Gao, K; Qiao, Y; Wang, T, 2021) |
| "Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide." | 5.56 | Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. ( Batchelor, T; Beers, AL; Catana, C; Chang, K; Dietrich, J; Duda, DG; Emblem, KE; Gerstner, ER; Hooker, JM; Jain, RK; Kalpathy-Cramer, J; Plotkin, SR; Rosen, B; Vakulenko-Lagun, B; Yen, YF, 2020) |
| "Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice." | 5.56 | Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020) |
| " Because the free drug cannot pass the blood-brain barrier (BBB), we investigated the use of nanocarriers for transport of the drug through the BBB and its efficacy when combined with radiotherapy and temozolomide (TMZ) in glioma spheroids." | 5.56 | Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. ( Becerril Aragon, G; Bikhezar, F; de Kruijff, RM; de Vries, HE; Denkova, AG; Gasol Garcia, A; Narayan, RS; Slotman, BJ; Sminia, P; Torrelo Villa, G; van der Meer, AJGM; van der Pol, SMA, 2020) |
| "Glioblastoma is the most common primary tumor of the central nervous system that develops chemotherapy resistance." | 5.56 | Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT. ( Chen, J; Chen, L; Hao, B; He, M; Li, X; Wang, C; Wu, H; Zhang, G; Zhang, T, 2020) |
| "Calpeptin could inhibit the effect." | 5.56 | Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. ( Cai, L; Li, Q; Li, W; Lu, X; Su, Z; Tu, M; Wang, C; Zhu, Z, 2020) |
| "Temozolomide (TMZ) is an effective drug for prolonging the overall survival time of patients, while drug-resistance is an important clinical problem at present." | 5.56 | A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway. ( Fang, F; Ji, Y; Li, H; Lu, Y; Qiu, P; Tang, H; Zhang, S, 2020) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | 5.56 | MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Glioma is a common cancer that affects people worldwide with high morbidity and mortality." | 5.56 | miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells. ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B, 2020) |
| "In adults, glioma is the most commonly occurring and invasive brain tumour." | 5.56 | CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. ( Cao, Y; Kong, S; Li, X; Qi, Y; Shang, S, 2020) |
| "Glioblastoma is the most devastating primary brain tumor and effective therapies are not available." | 5.56 | CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Gelsleichter, NE; Lenz, GS; Michels, LR; Schuh, RS; Stefani, MA; Teixeira, HF; Wink, MR, 2020) |
| "Osthole was the most effective." | 5.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
| "Glioma is one of the most aggressive forms of brain tumor and is hallmarked by high rate of mortality, metastasis and drug resistance." | 5.56 | Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294. ( Feng, H; Hua, L; Huang, L; Zhang, X, 2020) |
| "Glioma is the most malignant tumour of the human brain still lacking effective treatment modalities." | 5.56 | Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells ( Bębenek, E; Boryczka, S; Dmoszyńska-Graniczka, M; Król, SK; Stepulak, A; Sławińska-Brych, A, 2020) |
| "Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults." | 5.56 | Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. ( Arús, C; Candiota, AP; Julià-Sapé, M; Ledesma-Carbayo, MJ; Núñez, LM; Romero, E; Santos, A; Vellido, A, 2020) |
| "Metformin has been linked to improve survival of patients with various cancers." | 5.56 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. ( Chinot, O; Genbrugge, E; Gorlia, T; Hau, P; Nabors, B; Seliger, C; Stupp, R; Weller, M, 2020) |
| "In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]." | 5.51 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. ( Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W, 2022) |
| "Temozolomide is applied as the standard chemotherapy agent in patients with glioblastoma (GBM) after surgery." | 5.51 | The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial. ( Cheng, Y; Huang, N; Liu, G; Mao, J; Sun, M; Tao, Y; Wen, R; Xie, Z; Zhang, X; Zhao, G, 2022) |
| "Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ)." | 5.51 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. ( Ansstas, G; Baehring, J; De Vos, F; Finocchiaro, G; Honnorat, J; Idbaih, A; Kinoshita, M; Lee, M; Leung, D; Lim, M; Mellinghoff, IK; Omuro, A; Petrecca, K; Raval, RR; Reardon, DA; Roberts, M; Sahebjam, S; Slepetis, R; Steinbach, J; Sumrall, A; Taylor, JW; Warad, D; Weller, M; Wick, A, 2022) |
| "Current standard of care for glioblastoma (GBM) includes concurrent chemoradiation and maintenance temozolomide (TMZ) with Tumor Treating Fields (TTFields)." | 5.51 | Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study. ( Ali, AS; Alnahhas, I; Andrews, DW; Judy, KD; Lombardo, J; Martinez, NL; Miller, RC; Niazi, MZ; Shi, W, 2022) |
| "Fresh suspected glioblastoma tissue was collected during surgery, and patients with pathology-confirmed GBM enrolled before starting concurrent Radiation Therapy and Temozolomide (RT/TMZ) with Intent to Treat (ITT) after recovery from RT/TMZ." | 5.51 | Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. ( Abedi, M; Aiken, RD; Bota, DA; Bota, PG; Carrillo, JA; Dillman, RO; Duma, CM; Hsieh, C; Hsu, FPK; Keirstead, HS; Kesari, S; Kong, XT; LaRocca, RV; Nistor, GI; Piccioni, DE; Taylor, TH, 2022) |
| "Palbociclib treatment significantly reduced tumorigenesis in TMZ-R/HMC3 bearing mice and SNHG15 and CDK6 expression was significantly reduced while miR-627-5p level was increased." | 5.51 | Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. ( Bao, H; Jin, H; Li, C; Li, Z; Liang, P; Wang, W; Xiong, J; Zhang, J; Zheng, H, 2019) |
| "Glioma is one of the most lethal malignancies and molecular regulators driving gliomagenesis are incompletely understood." | 5.51 | DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. ( Dai, X; He, Q; Shao, Y; Tan, B; Wang, J; Weng, Q; Yang, B; Zhao, M, 2019) |
| "Papaverine is a potential anticancer drug in GBM treatment." | 5.51 | Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth. ( Akasaki, Y; Ichimura, K; Inada, M; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019) |
| "The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas." | 5.51 | Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). ( Ahn, GS; Chang, JH; Choe, G; Choi, BS; Hong, YK; Hwang, K; Joo, J; Jung, TY; Kang, SG; Kim, CY; Kim, EY; Kim, JH; Kim, SH; Kim, TM; Kim, YJ; Lee, DE; Nam, DH; Park, CK; Yoo, H, 2022) |
| "Euphol is a tetracyclic triterpene alcohol, and it is the main constituent of the sap of the medicinal plant Euphorbia tirucalli." | 5.51 | Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. ( Carloni, AC; Costa, AM; Evangelista, AF; Jones, C; Lima, JP; Martinho, O; Miranda-Gonçalves, V; Pianowski, LF; Reis, RM; Rosa, MN; Silva, VAO; Tansini, A, 2019) |
| "Malignant gliomas are aggressive primary neoplasms that originate in the glial cells of the brain or the spine with notable resistance to standard treatment options." | 5.51 | Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway. ( Bu, XY; Gao, YS; Han, SY; Hu, S; Qu, MQ; Wang, BQ; Wang, JY; Yan, ZY; Yang, B; Yang, HC, 2019) |
| "Malignant glioma is a lethal brain tumor with a low survival rate and poor prognosis." | 5.51 | Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. ( Lan, Q; Mao, J; Shao, N; Wang, R; Xue, L; Zhi, F, 2019) |
| "Glioma is the most common brain malignancy." | 5.51 | Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. ( Fedulov, A; Karlsson, I; Lokot, I; Pejler, G; Veevnik, D; Yurkshtovich, N; Yurkshtovich, T, 2019) |
| "Glioma is a primary intracranial malignant tumor with poor prognosis." | 5.51 | Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy. ( Liu, G; Mao, J; Meng, X; Yang, Y; Zhao, C, 2019) |
| "The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to determine if the malignant phenotype may be reverted." | 5.51 | Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells. ( Castresana, JS; Erausquin, E; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A, 2019) |
| " Combinatorial therapy of diosgenin and TMZ significantly reduced the dosage regimen of TMZ and also showed affectivity in hitherto TMZ resistant GBM cells." | 5.51 | Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. ( Banerjee, I; Banik, P; Bharti, R; Biswas, A; Das, S; Ghosh, SK; Kumar, U; Mandal, M; Nayak, S; Rajesh, Y, 2019) |
| "Temozolomide treatment inhibited p50 recruitment to its cognate element as a function of Ser329 phosphorylation while concomitantly increasing p53 recruitment." | 5.51 | Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. ( Bernal, GM; Cahill, KE; Crawley, CD; Khodarev, NN; Larsen, G; Mansour, NM; Nunez, L; Raleigh, DR; Spretz, R; Szymura, SJ; Uppal, A; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W, 2019) |
| "Temozolomide (TMZ) is an important agent against GBM." | 5.51 | Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. ( Chen, Z; Liang, H; Sun, L, 2019) |
| "Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect." | 5.51 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. ( Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T, 2019) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | 5.51 | Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 5.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| " Proliferation, cell cycle, and apoptotic assays were performed with ML00253764, whereas the synergism of the simultaneous combination with temozolomide was evaluated by the combination index method." | 5.48 | Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. ( Bocci, G; Di Desidero, T; Giuliani, D; Guarini, S; Orlandi, P; Ottani, A; Pacini, S; Pardini, C; Pasqualetti, F; Vaglini, F, 2018) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 5.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Temozolomide (TMZ) has been considered to be one of the most effective chemotherapeutic agents to prolong the survival of patients with glioblastoma." | 5.48 | Differential Characterization of Temozolomide-Resistant Human Glioma Cells. ( Chen, CC; Huang, BR; Lai, SW; Lin, C; Lin, HY; Liu, YS; Lu, DY; Tsai, CF, 2018) |
| "Glioma is the most common intracranial malignant tumors, accounting for about 40% of intracranial tumors." | 5.48 | MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. ( Jiang, Y; Tan, Z; Zhao, J, 2018) |
| "Glioblastoma is the most frequent and aggressive form of high-grade malignant glioma." | 5.48 | XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. ( Frohnapfel, L; Kaina, B; Quiros, S; Ringel, F; Roos, WP, 2018) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | 5.48 | Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| " Our results demonstrate benefit of ddTMZ after previous treatment with standard TMZ dosing with no apparent increase in treatment-related toxicities." | 5.48 | Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ( Garcia, CR; Gruber, L; Kumar, SS; Lightner, DD; Morgan, RM; Slone, SA; Villano, JL, 2018) |
| "Glioblastoma is the most common malignant brain tumor." | 5.48 | Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. ( Chu, L; Liu, S; Mu, H; Ni, L; Song, Y; Sun, K; Wang, A; Wu, Z; Yan, X; Zhang, C; Zhao, M, 2018) |
| "Human glioma is the most common type of primary brain tumor." | 5.48 | Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy. ( Liu, J; Lv, H; Ma, R; Shao, C; Zhang, G; Zheng, G, 2018) |
| " ATOR showed similar cytotoxic effect as TMZ to glioma cells, and it may be a safer drug, regarding side effect induction, than chemotherapic agents." | 5.48 | Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. ( Dal-Cim, T; Lopes, FG; Ludka, FK; Nedel, CB; Oliveira, KA; Tasca, CI, 2018) |
| "Glioblastoma (GBM) is one of the lethal central nervous system tumors." | 5.48 | The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. ( Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM, 2018) |
| "Glioma is the most common primary brain tumor and has an undesirable prognosis due to the blood-brain barrier (BBB) and drug resistance." | 5.46 | β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1. ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2017) |
| "Glioblastomas (GBM) comprise 17% of all primary brain tumors." | 5.46 | Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. ( Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB, 2017) |
| "Glioblastoma is one of the most frequent and aggressive brain tumors." | 5.46 | MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. ( Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X, 2017) |
| "Chlorpromazine is a United States Food and Drug Administration-approved phenothiazine widely used as a psychotropic in clinical practice." | 5.46 | Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. ( Griguer, CE; Langford, C; Oliva, CR; Suto, MJ; Zhang, W, 2017) |
| "Guanosine (GUO) is an endogenous nucleoside involved in extracellular signaling that presents neuroprotective effects and also shows the effect of inducing differentiation in cancer cells." | 5.46 | Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells. ( Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI, 2017) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent widely used in anti-glioma treatment." | 5.46 | Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells. ( Fu, Z; Guo, H; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H, 2017) |
| " In vivo, we implanted the cells orthotopically in nude mice and administered CBL0137 in various dosing regimens to assess brain and tumor accumulation of CBL0137, its effect on tumor cell proliferation and apoptosis, and on survival of mice with and without temozolomide (TMZ)." | 5.46 | Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. ( Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A, 2017) |
| "Temozolomide is a commonly used chemotherapy drug and frequently causes lymphocytopenia." | 5.46 | Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy. ( Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H, 2017) |
| "Temozolomide (TMZ) is a novel cytotoxic agent used as first-line chemotherapy for GBM, however, some individual cells can't be isolated for surgical resection and show treatment-resistance, thus inducing poor prognosis." | 5.46 | MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. ( Chen, C; Chen, W; Ge, XS; He, J; Kong, KK; Li, FC; Li, H; Li, JL; Li, P; Wang, F; Xu, XK, 2017) |
| "A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles." | 5.46 | A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 5.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 5.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 5.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | 5.43 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| " We show that GSI in combination with RT and TMZ attenuates proliferation, decreases 3D spheroid growth and results into a marked reduction in clonogenic survival in primary and established glioma cell lines." | 5.43 | NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. ( Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2016) |
| "Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0." | 5.43 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. ( Arnal, AV; Donovan, LE; Odia, Y; Wang, SH, 2016) |
| "Glioblastoma multiforme is the most aggressive malignant primary brain tumor in adults." | 5.43 | Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. ( Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF, 2016) |
| "Gliomas are the most common primary intracranial malignant tumors in adults." | 5.43 | Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. ( Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G, 2016) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of aggressive forms of brain tumor based on its antitumor actions." | 5.43 | Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells. ( Gao, S; Liang, J; Wang, W; Wang, Y, 2016) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 5.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 5.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Malignant glioma is a common and lethal primary brain tumor in adults." | 5.42 | VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. ( Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y, 2015) |
| "These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway." | 5.42 | Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway. ( Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S, 2015) |
| "Glioblastoma is a devastating primary brain tumor resistant to conventional therapies." | 5.42 | Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. ( Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 5.42 | Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. ( Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 5.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Glioblastoma is the most malignant brain tumor, exhibiting remarkable resistance to treatment." | 5.42 | A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. ( Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 5.42 | Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. ( Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K, 2015) |
| "Evidence suggests hyperglycemia is associated with worse outcomes in glioblastoma (GB)." | 5.42 | Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. ( Chung, C; Kiehl, TR; Laperriere, N; Lovblom, LE; Mason, W; McNamara, MG; Ménard, C; Millar, BA; Perkins, BA; Tieu, MT, 2015) |
| " Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ)." | 5.42 | Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. ( Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN, 2015) |
| "Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM)." | 5.42 | A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. ( Barciszewska, AM; Gurda, D; Głodowicz, P; Naskręt-Barciszewska, MZ; Nowak, S, 2015) |
| "Glioma is one of the most common primary tumors of the central nervous system in adults." | 5.42 | Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. ( Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY, 2015) |
| "Gliomas are the most common primary brain tumors." | 5.42 | Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. ( Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L, 2015) |
| "Chemotherapy with the oral alkylating agent temozolomide still prevails as a linchpin in the therapeutic regimen of glioblastoma alongside radiotherapy." | 5.41 | Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond ( Chamallamudi, MR; Kumar, G; Kumar, N; Nandakumar, K; Rao, V; Thorat, ND; Vibhavari, RJA, 2023) |
| " Temozolomide (TMZ) has anti-proliferative and cytotoxic effects and is indicated for glioblastoma multiforme and recurrent mesenchymal astrocytoma." | 5.41 | Progress in research and development of temozolomide brain-targeted preparations: a review. ( Chen, J; Fan, W; Fu, Z; Wu, X; Xu, Y; Yang, J, 2023) |
| "Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy." | 5.41 | Modeling glioblastoma complexity with organoids for personalized treatments. ( Babak, MV; Balyasnikova, IV; Duffy, JT; Pawlowski, KD, 2023) |
| "Temozolomide is an oral alkylating agent that is used as the first line treatment for glioblastoma multiform, and in recurrent anaplastic astrocytoma, as well as having demonstrable activity in patients with metastatic melanoma." | 5.41 | Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy? ( Elshazly, AM; Gewirtz, DA, 2023) |
| "A significant proportion of the human transcriptome, long noncoding RNAs (lncRNAs) play pivotal roles in several aspects of glioblastoma (GBM) pathophysiology including proliferation, invasion, radiation and temozolomide resistance, and immune modulation." | 5.41 | The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know. ( Chiocca, EA; Villa, GR, 2023) |
| "Standard treatment for glioblastoma includes maximal safe resection followed by adjuvant radiation and concurrent temozolomide for 6 weeks, followed by 6 months of maintenance temozolomide; additionally, concurrent high doses of corticosteroids are required for many patients to reduce intracranial pressure and reduce inflammatory side effects." | 5.41 | Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review. ( Kleinberg, L; Kut, C, 2023) |
| "Glioblastoma (GBM) is a highly aggressive and lethal brain tumor with limited treatment options, such as the chemotherapeutic agent, temozolomide (TMZ)." | 5.41 | Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities. ( Hsu, TI; Kao, TJ; Li, HY; Lin, CL; Yang, WB, 2023) |
| "Adults (>18) with newly diagnosed 1p/19q World Health Organization (WHO) grade III oligodendroglioma were randomized to radiotherapy (RT; 5940 centigray ) alone (arm A); RT with concomitant and adjuvant temozolomide (TMZ) (arm B); or TMZ alone (arm C)." | 5.41 | CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. ( Aldape, KD; Anderson, SK; Ballman, KV; Brown, PD; Cairncross, JG; Cerhan, JH; Dhermain, F; Dixon, JG; Flynn, PJ; Galanis, E; Giannini, C; Grossman, SA; Jaeckle, KA; Jenkins, RB; Klein, M; Nordstrom, DG; Raizer, JJ; Schiff, D; van den Bent, M; Vogelbaum, MA; Wefel, JS; Weller, M; Wick, W, 2021) |
| "Patients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib." | 5.41 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. ( Aldape, K; Armstrong, TS; Gerstner, ER; Gilbert, MR; Lieberman, F; Mendoza, T; Mikkelsen, T; Omuro, A; Robins, HI; Vera, E; Wen, PY; Wu, J; Yuan, Y, 2021) |
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 5.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma." | 5.41 | Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. ( Aboud, O; Ahmad, S; Antony, R; Armstrong, TS; Boris, L; Bryla, C; Burton, EM; Butler, MK; Calvo, KR; Cordova, C; Figg, WD; Fink, D; Gallin, JI; Garren, N; Gilbert, MR; Gonzales, J; Grajkowska, E; Kuhns, DB; Leeper, H; Lindsley, M; Lollo, N; Long Priel, DA; Mendoza, TR; Mentges, K; Pang, Y; Peer, CJ; Penas-Prado, M; Siegel, C; Sissung, TM; Su, YT; Theeler, BJ; Vera, E; Wu, J; Yu, G; Yuan, Y, 2021) |
| "Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies." | 5.41 | A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. ( Ashley, DM; Back, M; Barnes, EH; Buckland, ME; Fisher, L; Foote, MC; Hall, M; Khasraw, M; Koh, ES; Leonard, R; Lwin, Z; McDonald, KL; Rosenthal, M; Sim, HW; Simes, J; Sulman, EP; Wheeler, H; Yip, S, 2021) |
| " This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells." | 5.40 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. ( Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014) |
| " We report five patients who received long-term treatment with TMZ chemotherapy at normal dosing levels." | 5.40 | Long-term treatment with temozolomide in malignant glioma. ( Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL, 2014) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 5.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Glioblastoma is the most common malignant primary brain tumor." | 5.40 | EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. ( Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "optimal treatment of glioblastoma (gBM) in the elderly remains unclear." | 5.40 | Glioblastoma treatment in the elderly in the temozolomide therapy era. ( Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A, 2014) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma multiforme (GBM), the main form of human brain tumours in adults." | 5.40 | Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. ( Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM, 2014) |
| "Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of GBM following surgery." | 5.40 | miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. ( Cui, Y; Lei, Q; Li, G; She, X; Wang, Z; Wu, M; Xiang, J; Xu, G; Yu, Z, 2014) |
| "Non-invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI." | 5.40 | Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. ( Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M, 2014) |
| " In the present work, TMZ was combined with a specific SKI, and the cytotoxic effect of each drug alone or in combination was tested on GBM cell lines." | 5.40 | A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. ( Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K, 2014) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | 5.40 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf)." | 5.40 | Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. ( Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S, 2014) |
| "Temozolomide was used almost exclusively during CRT (94." | 5.39 | Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. ( Cahill, D; Gilbert, MR; Lei, X; Shonka, NA; Smith, L; Theeler, B; Yung, A, 2013) |
| "Glioblastoma multiforme is the most aggressive primary brain tumour." | 5.39 | Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2013) |
| "C6 rat gliomas were incubated with low-dose TMZ to induce chemoresistance." | 5.39 | Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, T; Sasajima, T; Shimada, N, 2013) |
| "Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system." | 5.39 | Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | 5.39 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "Anaplastic ependymomas are rare tumors in adult patients." | 5.39 | Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( Bellu, L; Della Puppa, A; Gardiman, MP; Lombardi, G; Pambuku, A; Pomerri, F; Rumanò, L; Zagonel, V, 2013) |
| "Temozolomide is an attractive candidate treatment in neuroblastoma with methylated MGMT, especially in central nervous system relapsed cases." | 5.39 | Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation. ( Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K, 2013) |
| "Gliosarcoma was more common in males (n = 31, 67." | 5.39 | Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. ( Brown, PD; Gilbert, MR; McAleer, MF; Prabhu, SS; Walker, GV, 2013) |
| "The tumor was partially resected and anaplastic astrocytoma was diagnosed." | 5.38 | Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. ( Fujimoto, Y; Hashimoto, N; Kagawa, N; Kinoshita, M; Miyazaki, Y; Takehara, T; Tanaka, S; Yakushijin, T; Yoshimine, T, 2012) |
| "Primary malignant brain tumors (BT) are the most common and aggressive malignant brain tumor." | 5.38 | Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. ( Bow, H; Brem, H; Cima, MJ; Langer, R; Masi, BC; Tyler, BM; Wicks, RT; Xue, Y, 2012) |
| " These data reassuringly suggest that BEV does not significantly change the ECF tumor concentrations of TMZ in either tumor-bearing or normal brain when dosed 36 h prior to TMZ." | 5.38 | The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ( Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P, 2012) |
| "The management of brain metastases (BM) from breast cancer (BC) needs to be improved, and new therapeutic strategies are urgently requested." | 5.38 | Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. ( Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; Iodice, P; Lombardi, A; Montella, L; Parlato, C; Prete, SD; Russo, P; Salzano, A; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2012) |
| "These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 5.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
| "All patients had seizure disorders that were treated with anticonvulsants." | 5.37 | Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | 5.37 | Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| " We evaluated the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor (XL765) in in vitro and in vivo studies." | 5.37 | Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. ( Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X, 2011) |
| "The long-term TMZ-treated astroglioma cells, but not the Hs683 oligodendroglioma cells, developed in vivo a certain level of resistance to TMZ, which correlated with the up- regulation of CXCL2, CXCL3 and CXCL8 expression in the U373 and T98G astroglioma cells." | 5.37 | Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. ( Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S, 2011) |
| "The prognostic value of postoperative residual tumor volume in FET PET, TBR(mean,) TBR(max) and Gd-volume was evaluated using Kaplan-Maier estimates for disease-free survival (DFS) and overall survival (OS)." | 5.37 | Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. ( Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G, 2011) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 5.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| "Cediranib is a highly potent receptor tyrosine kinase inhibitor that inhibits all three VEGF receptors." | 5.37 | Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. ( Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X, 2011) |
| " The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment." | 5.37 | Rechallenge with temozolomide in recurrent glioma. ( Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011) |
| "Gliomas account for more than 50% of all primary brain tumors." | 5.36 | Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. ( Bontempi, G; Bruyère, C; Decaestecker, C; Dubois, J; Haibe-Kains, B; Kiss, R; Lamoral-Theys, D; Le Calvé, B; Le Mercier, M; Lefranc, F; Rynkowski, MA, 2010) |
| "Glioblastoma multiforme is the most common and most malignant primary brain tumour." | 5.36 | Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. ( Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P, 2010) |
| "Temozolomide (TMZ) is a recently introduced alkylating agent that has yielded significant benefits and become a key agent in the treatment of high-grade gliomas." | 5.36 | Gene expression profiling predicts response to temozolomide in malignant gliomas. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2010) |
| "High-grade gliomas are among the most lethal of all cancers." | 5.36 | Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. ( Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M, 2010) |
| "Glioblastomas (GBM) are lethal brain tumors that are highly resistant to therapy." | 5.36 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. ( Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N, 2010) |
| "A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting." | 5.36 | Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. ( Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H, 2010) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 5.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| " The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d)." | 5.35 | A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. ( Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE, 2009) |
| "Glioblastoma multiforme is a primary malignant brain tumor with a prognosis of typically less than 2 years." | 5.35 | Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? ( Binello, E; Germano, IM, 2009) |
| "Cilengitide is a cyclic peptide antagonist of integrins alphavbeta3 and alphavbeta5 that is currently being evaluated as a novel therapeutic agent for recurrent and newly diagnosed glioblastoma." | 5.35 | Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. ( Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W, 2009) |
| "Carmustine wafer was not an independent predictor (P=." | 5.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| " After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7." | 5.35 | Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ( Buhk, JH; Hoffmann, AL; Strik, H, 2009) |
| " The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide." | 5.35 | Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. ( Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 5.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | 5.35 | Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. ( Banik, NL; Das, A; Ray, SK, 2008) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| " We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma." | 5.34 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020) |
| "We sought to determine the maximum tolerated dose (MTD) of 5-fraction stereotactic radiosurgery (SRS) with 5-mm margins delivered with concurrent temozolomide in newly diagnosed glioblastoma (GBM)." | 5.34 | A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Hayden Gephart, M; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Usoz, M; von Eyben, R; Wynne, J, 2020) |
| "A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)." | 5.34 | A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. ( Adesina, A; Ansell, P; Baxter, PA; Billups, CA; Blaney, SM; Broniscer, A; Dunkel, IJ; Fouladi, M; Giranda, V; Kilburn, L; Li, XN; Onar-Thomas, A; Paulino, A; Poussaint, TY; Quaddoumi, I; Smith, ER; Su, JM; Thompson, P, 2020) |
| " TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial." | 5.34 | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. ( Chang, JH; Hong, YK; Kim, CY; Kim, JH; Kim, OL; Kim, SH; Nam, DH; Paek, SH, 2020) |
| "We performed the first clinical trial to assess VEGFR1 and 2 vaccination along with temozolomide (TMZ) -based chemoradiotherapy for the patients with primary glioblastomas." | 5.34 | Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. ( Hikichi, T; Kawakami, Y; Kikuchi, R; Kosugi, K; Morimoto, Y; Nagashima, H; Noji, S; Oishi, Y; Sasaki, H; Sato, M; Tamura, R; Toda, M; Ueda, R; Yoshida, K, 2020) |
| "Ipi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma." | 5.34 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. ( Blagden, S; Brooks, C; Brown, NF; Coutts, T; Elhussein, L; Holmes, J; Hoskin, P; Maughan, T; Mulholland, P; Ng, SM; Roberts, C, 2020) |
| "Standard of care for glioblastoma includes concurrent chemoradiation and maintenance temozolomide with tumor treatment fields (TTFields)." | 5.34 | Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. ( Andrews, DW; Bar-Ad, V; Chervoneva, I; Evans, JJ; Farrell, CJ; Glass, J; Judy, K; Liu, H; Ly, M; Martinez, N; Palmer, JD; Shi, W; Song, A; Werner-Wasik, M, 2020) |
| "Temozolomide (TMZ) has been the standard-of-care chemotherapy for glioblastoma (GBM) patients for more than a decade." | 5.34 | Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. ( Bendok, BR; Doyle, T; Hawkins-Daarud, A; Hu, LS; Jackson, PR; Johnston, SK; Massey, SC; Mrugala, MM; Porter, AB; Sarkaria, JN; Singleton, KW; Swanson, KR; Vora, S; White, H; Whitmire, P, 2020) |
| "To report the long-term outcomes of the RTOG 0424 study of a high-risk, low-grade glioma population treated with concurrent and adjuvant temozolomide (TMZ) and radiation therapy (RT)." | 5.34 | Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Barani, IJ; Bovi, JA; Chakravatri, A; D'Souza, D; Doyle, T; Fisher, BJ; Fiveash, JB; Fox, S; Howard, SP; Kwok, Y; Laack, NN; Lesser, GJ; Macdonald, DR; Mehta, MP; Michael Yu, HH; Pugh, SL; Rogers, CL; Strasser, JF; Wahl, DR; Werner-Wasik, M; Won, M, 2020) |
| "Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate." | 5.34 | A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). ( Alonso, M; Balana, C; Berrocal, A; Carrato, C; Covela, M; de Las Peñas, R; Del Barco, S; Domenech, M; Esteve, A; Estival, A; Fuster, J; Gallego, O; Gil-Gil, M; Gironés, R; Herrero, A; Luque, R; Manuel Sepúlveda, J; Martinez-García, M; Mesia, C; Munne, N; Muñoz-Langa, J; Navarro, LM; Olier, C; Peralta, S; Perez-Martín, FJ; Perez-Segura, P; Pineda, E; Sanz, C; Vaz, MA; Villa, S, 2020) |
| "This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone." | 5.34 | Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. ( Abe, T; Adilijiang, A; Aoki, K; Aoki, T; Arakawa, Y; Asai, A; Asano, K; Beppu, T; Hashimoto, N; Hirano, H; Hirano, M; Ishikawa, E; Ito, T; Iwadate, Y; Kayama, T; Kobayashi, H; Kumabe, T; Kurisu, K; Maeda, S; Maruyama, T; Matsumura, A; Matsuo, T; Mishima, K; Motomura, K; Mukasa, A; Muragaki, Y; Nagane, M; Nakamura, H; Nakasu, Y; Narita, Y; Natsume, A; Nishikawa, R; Ohka, F; Okuno, Y; Onishi, T; Sasaki, H; Sato, S; Shibui, S; Shinoura, N; Sugiyama, K; Sumi, M; Terasaki, M; Wakabayashi, T; Yamasaki, F; Yoshimoto, K; Yoshino, A, 2020) |
| "In this open-label, randomized, phase 3 clinical trial, 439 patients with glioblastoma at first recurrence following standard radiation and temozolomide therapy were enrolled, and 369 were randomized." | 5.34 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. ( Ahluwalia, MS; Baehring, J; Bähr, O; Brandes, AA; Carleton, M; De Souza, P; Lim, M; Mulholland, P; Omuro, A; Phuphanich, S; Reardon, DA; Roth, P; Sahebjam, S; Sampson, J; Sepulveda, JM; Taitt, C; Tatsuoka, K; Weller, M; Wick, A; Zwirtes, R, 2020) |
| " In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone." | 5.34 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020) |
| " Three patients (12%) were changed to standard temozolomide dosing due to side effects, including intractable nausea (n = 2) and multiple cytopenias (n = 1)." | 5.34 | Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. ( Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH, 2007) |
| "Glioblastomas are malignant brain tumors that are very difficult to cure, even with aggressive therapy consisting of surgery, chemotherapy, and radiation." | 5.34 | Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. ( Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N, 2007) |
| "Temozolomide treatment of high-grade tv-a gliomas provided a 14-day growth delay compared with vehicle controls." | 5.34 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. ( Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ, 2007) |
| "The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h." | 5.34 | Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ( Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 5.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 5.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 5.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 5.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma." | 5.33 | Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. ( Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R, 2006) |
| "Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components." | 5.33 | Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. ( Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W, 2006) |
| "Temozolomide (TMZ) displays efficacy for the treatment of metastatic melanoma." | 5.32 | [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation]. ( Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M, 2004) |
| " The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software." | 5.32 | Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ( Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R, 2004) |
| " In this work we investigated the effect of association of temozolomide (TMZ), an orally bioavailable alkylating agent, with three chemotherapeutic drugs, liposomal doxorubicin (DOXO), cis-platinum (CDDP)." | 5.32 | Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A, 2004) |
| "Temozolomide (TMZ) is a methylating agent with promising antitumor efficacy for the treatment of melanomas and intermediate-grade gliomas." | 5.32 | The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. ( Cereda, E; Gariboldi, MB; Monti, E; Ravizza, R, 2004) |
| "Glioblastoma is the deadliest and most prevalent brain tumor." | 5.32 | Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. ( Banik, NL; Das, A; Patel, SJ; Ray, SK, 2004) |
| "The optimal management of high risk WHO grade II gliomas after surgery is debated including the role of initial temozolomide to delay radiotherapy and risk of cognitive defects." | 5.30 | Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. ( Bello, L; Bertero, L; Carapella, CM; Caroli, M; Cassoni, P; Dealis, C; Faedi, M; Marchese, G; Migliore, E; Pace, A; Pellerino, A; Rudà, R; Soffietti, R, 2019) |
| "To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma." | 5.30 | Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. ( Cartalat, S; Chinot, O; Devos, P; Di Stefano, AL; Dubois, F; Houillier, C; Le Rhun, E; Lepage, C; Reyns, N; Weller, M, 2019) |
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 5.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| " We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma (GBM)." | 5.30 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. ( Ahluwalia, MS; Blakeley, JO; Chi, AS; Desideri, S; Eichler, A; Grossman, SA; Mikkelsen, T; Nabors, LB; Ribas, IG; Rosenfeld, MR; Ye, X, 2019) |
| "Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ)." | 5.30 | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. ( Bendszus, M; Berberich, A; Brors, B; Debus, J; Dettmer, S; Eisenmenger, A; Herold-Mende, C; Jones, DTW; Karapanagiotou-Schenkel, I; Kessler, T; Pfaff, E; Pfister, SM; Platten, M; Sahm, F; Unterberg, A; von Deimling, A; Wick, A; Wick, W; Winkler, F, 2019) |
| "Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma." | 5.30 | Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019) |
| " Gliomas, which are common in dogs and also represent the majority of fatal brain tumours in humans, can be amenable to chemotherapy with temozolomide." | 5.30 | Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders. ( Hicks, J; Holmes, S; Howerth, E; Kaplan, E; Kaplan, J; Kent, M; Platt, S; Senneca, C; Stewart, G, 2019) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 5.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "The treatment using hypofractionated stereotactic radiotherapy concurrent with temozolomide appeared to be safe and could significantly extend overall survival compared with historical control in complex brain metastases." | 5.30 | A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. ( Bi, N; Chen, X; Deng, L; Hu, C; Huang, X; Li, J; Li, Y; Liu, F; Liu, Q; Ma, Y; Tian, Y; Wang, K; Wang, W; Xiao, J; Xu, Y; Yang, S; Yi, J; Zhang, H; Zhang, Y; Zhao, R, 2019) |
| "In RPA V-VI glioblastoma patients both hypofractionated radiotherapy and exclusive temozolomide can be used; the purpose of this trial is to compare these treatment regimens in terms of survival and quality of life." | 5.30 | Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. ( Borghetti, P; Bruni, A; Buglione, M; Fusco, V; Gatta, R; Krengli, M; Magrini, SM; Masini, L; Meduri, B; Pedretti, S; Pegurri, L; Pirtoli, L; Ricardi, U; Riva, N; Santoni, R; Scoccianti, S; Triggiani, L; Turco, E, 2019) |
| "The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ)." | 5.30 | Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. ( Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A, 2019) |
| "Combined PET-MRI with the tracer O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) prior to re-RT was performed in recurrent glioma patients in a phase I trial." | 5.30 | Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. ( Albert, NL; Bartenstein, P; Belka, C; Corradini, S; Fleischmann, DF; Förster, S; la Fougère, C; Niyazi, M; Rottler, M; Schwaiger, M; Siepmann, T; Unterrainer, M, 2019) |
| "A multicenter phase II study for assessing the efficacy and the toxicity of hypofractionated radiotherapy with SIB plus temozolomide in patients with glioblastoma was carried out by the Brain Study Group of the Italian Association of Radiation Oncology." | 5.27 | Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). ( Buglione, M; Detti, B; Doino, D; Fiorentino, A; Fusco, V; Greto, D; Krengli, M; Livi, L; Lonardi, F; Magrini, SM; Marrazzo, L; Marzano, S; Masini, L; Migliaccio, F; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S, 2018) |
| "Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma." | 5.27 | Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. ( Ahluwalia, MS; Anderson, SK; Ballman, KV; Buckner, JC; Cerhan, J; Galanis, E; Gerstner, ER; Giannini, C; Grossman, SA; Jaeckle, K; Lee, EQ; Lesser, GJ; Ligon, KL; Loboda, A; Miller, CR; Moore, DF; Nebozhyn, M; Prados, M; Sarkaria, JN; Schiff, D; Wen, PY, 2018) |
| "In this exploratory analysis of AVAglio, a randomized phase III clinical study that investigated the addition of bevacizumab (Bev) to radiotherapy/temozolomide in newly diagnosed glioblastoma, we aim to radiologically characterize glioblastoma on therapy until progression and investigate whether the type of radiologic progression differs between treatment arms and is related to survival and molecular data." | 5.27 | Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. ( Abrey, LE; Bendszus, M; Chinot, OL; Cloughesy, TF; Ellingson, BM; Garcia, J; Henriksson, R; Kickingereder, P; Mason, WP; Nishikawa, R; Nowosielski, M; Platten, M; Radbruch, A; Revil, C; Sandmann, T; Saran, F; Wick, W, 2018) |
| "We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A)." | 5.27 | Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ( Ansell, PJ; Butowski, N; Fichtel, L; Fischer, J; Gan, HK; Gomez, EJ; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Mandich, H; Merrell, R; Munasinghe, WP; Reardon, DA; Roberts-Rapp, LA; Scott, AM; van den Bent, M; Wheeler, H; Xiong, H, 2018) |
| "To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma." | 5.27 | Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. ( Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF, 2018) |
| "The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O6-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms." | 5.27 | Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. ( Belka, C; Friedrich, F; Glas, M; Goldbrunner, R; Grau, S; Grauer, O; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Krex, D; Leutgeb, B; Mack, F; Nießen, M; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A, 2018) |
| "This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma." | 5.27 | A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. ( Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M, 2018) |
| " We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs)." | 5.27 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. ( Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Peters, KB; Reardon, DA, 2018) |
| "Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 5.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
| "This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy." | 5.27 | Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. ( Bruna, J; Chen, TC; David, C; Desai, R; Dirven, L; Easaw, JC; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kew, Y; Kim, CY; Kirson, ED; Lavy-Shahaf, G; Ram, Z; Roth, P; Sroubek, J; Stupp, R; Taillibert, S; Taphoorn, MJB; Toms, SA; Villano, JL; Weinberg, U, 2018) |
| "Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is considered as standard therapy for adults with newly diagnosed glioblastoma." | 5.27 | Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. ( Arefian, H; Hartmann, M; Kalff, R; Maschmann, J; Walter, J; Waschke, A, 2018) |
| "The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade glioma (LGG) patients." | 5.27 | Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. ( Balana, C; Baumert, BG; Ben Hassel, M; Brandes, AA; Chinot, O; Dhermain, F; Enting, R; Erdem-Eraslan, L; French, PJ; Gao, Y; Gijtenbeek, JMM; Gorlia, T; Hegi, ME; Hoang-Xuan, K; Kros, JM; Mason, WP; Ryan, GF; Sillevis Smitt, P; Stupp, R; van den Bent, MJ; van Linde, ME; von Deimling, A; Vos, M; Weenink, B, 2018) |
| "ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma." | 5.27 | Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. ( Barboriak, DP; Boxerman, JL; Gilbert, MR; Marques, H; Mohan, S; Rogg, JM; Safriel, Y; Sorensen, AG; Wolf, RL; Zhang, Z, 2018) |
| "1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas." | 5.27 | Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. ( Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC, 2018) |
| "In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM)." | 5.27 | Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. ( Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M, 2018) |
| "Adult patients with intermediate- to high-grade glioma on adjuvant temozolomide (TMZ) with facilities for live video call were invited to participate in the study." | 5.27 | Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy. ( Chakraborty, S; Chandrasekharan, A; Dsouza, H; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; M, C; Pande, N; Patil, VM; Tonse, R; Vallathol, DH, 2018) |
| "In this study, MGMT promoter methylation was an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiotherapy." | 5.27 | Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. ( Aldape, KD; Ashby, LS; Bahary, JP; Becker, AP; Bell, EH; Chakraborty, AR; Chakravarti, A; Fabian, D; Fisher, BJ; Fleming, J; Gray, HJ; Kwok, Y; Laack, NN; Lesser, GJ; Liu, Z; Macdonald, DR; McElroy, JP; Mehta, MP; Robins, HI; Schultz, CJ; Walker, EM; Werner-Wasik, M; Yu, HM; Zhang, P, 2018) |
| "Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs)." | 5.24 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. ( Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X, 2017) |
| "This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence." | 5.24 | Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. ( Kesari, S; Ram, Z, 2017) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 5.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 5.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "We characterized health-related quality of life (HRQoL), cognitive, and functional status in newly diagnosed glioblastoma (GBM) patients receiving Tumor treating fields (TTFields) with temozolomide (TMZ) versus TMZ alone in a planned interim analysis of a randomized phase III trial [NCT00916409], which showed significant improvement in progression-free and overall survival with TTFields/TMZ." | 5.24 | Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. ( Avgeropoulos, N; Benouaich-Amiel, A; David, C; Demireva, P; Goldlust, S; Kanner, AA; Mehdorn, M; Pannullo, S; Salmaggi, A; Silvani, A; Zhu, JJ, 2017) |
| "While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy." | 5.24 | Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. ( Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M, 2017) |
| " We evaluated the efficacy and safety of CIK cell immunotherapy with radiotherapy-temozolomide (TMZ) for the treatment of newly diagnosed glioblastomas." | 5.24 | Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. ( Chang, JH; Chung, YG; Kang, SH; Kim, CH; Kim, JH; Kim, JM; Koh, YC; Kong, DS; Lee, JW; Lim, YJ; Nam, DH, 2017) |
| "The primary objective of this study was to compare the overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU)." | 5.24 | Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( Aldape, KD; Bahary, JP; Barger, GR; Belanger, K; Bell, EH; Brachman, D; Brown, PD; Cairncross, JG; Chakravarti, A; Chang, S; Dolinskas, CA; Gilbert, MR; Hunter, G; Jaeckle, K; Mehta, M; Penas-Prado, M; Robins, HI; Schiff, D; Schultz, C; Shih, H; Werner-Wasik, M; Zhang, P, 2017) |
| "We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy." | 5.24 | A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. ( Abdulkarim, B; Corredor, AG; Guiot, MC; Owen, S; Panet-Raymond, V; Petrecca, K; Shenouda, G; Souhami, L, 2017) |
| "The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma." | 5.24 | Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. ( Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H, 2017) |
| "There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era." | 5.24 | Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. ( Aldape, K; Barnholtz-Sloan, JS; Becker, AP; Bell, EH; Blumenthal, DT; Brachman, D; Bredel, M; Brown, PD; Chakravarti, A; Curran, W; Flickinger, J; Gilbert, MR; Glass, J; Grosu, AL; Klimowicz, AC; Lee, RJ; Magliocco, A; McElroy, JP; Mehta, M; Pugh, SL; Robe, P; Salavaggione, AL; Souhami, L; Stupp, R; Won, M, 2017) |
| "Temozolomide (TMZ) is an imidazotetrazine prodrug used to treat glioblastoma multiforme." | 5.22 | Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods. ( Carvalho, SG; Chorilli, M; Di Filippo, LD; Dutra, JAP; Luiz, MT; Tavares Junior, AG, 2022) |
| "Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating agent used as a first-line treatment of glioblastoma multiforme (GBM)." | 5.22 | Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. ( Chitkara, D; Jatyan, R; Karthik, YG; Mittal, A; Sahel, DK; Singh, P, 2022) |
| "To evaluate the safety and efficacy of nimotuzumab, a humanized monoclonal antibody specific for the epidermal growth factor receptor (EGFR), in combination with temozolomide (TMZ) and radiation therapy (RT) in the treatment of newly diagnosed glioblastoma (GBM) in Chinese patients." | 5.22 | Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. ( Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y, 2016) |
| "Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited." | 5.22 | A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. ( Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK, 2016) |
| "We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients." | 5.22 | A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. ( Beauchesne, P; Bernier, V; Carnin, C; Faure, G; Gorlia, T; Noel, G; Pedeux, R; Quetin, P; Quillien, V, 2016) |
| "This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients." | 5.22 | A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. ( Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P, 2016) |
| "This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse." | 5.22 | Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V, 2016) |
| "Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma." | 5.22 | Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns." | 5.22 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. ( Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 5.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| "To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma." | 5.22 | A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. ( Bernier, V; Blanchard, N; Bonnetain, F; Dalban, C; Lagneau, É; Maingon, P; Mazoyer, F; Mirjolet, C; Noël, G; Truc, G, 2016) |
| " Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg)." | 5.22 | Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). ( Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2016) |
| "Temozolomide chemotherapy versus radiotherapy in patients with a high-risk low-grade glioma has been shown to have no significant effect on progression-free survival." | 5.22 | Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. ( Back, M; Baumert, BG; Borchers, C; Bottomley, A; Brandes, AA; Bromberg, JEC; Chinot, O; Coens, C; Enting, RH; Golfinopoulos, V; Gorlia, T; Hassel, MB; Hau, P; Hoang-Xuan, K; Kantor, G; Klein, M; Mason, WP; Reijneveld, JC; Reni, M; Ryan, G; Smits, A; Stupp, R; Taphoorn, MJB; Thiessen, B; Verger, E; Wick, A, 2016) |
| "Overall, there was no significant difference in progression-free survival in patients with low-grade glioma when treated with either radiotherapy alone or temozolomide chemotherapy alone." | 5.22 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. ( Balana, C; Baumert, BG; Brandes, AA; Bravo-Marques, J; Bromberg, JE; Capper, D; Chinot, O; Clement, PM; Dhermain, F; Dif, N; Enting, R; Feuvret, L; Gijtenbeek, JMM; Gorlia, T; Hartmann, C; Hassel, MB; Hegi, ME; Hoang-Xuan, K; Kantor, G; Kros, JM; Kurscheid, S; Lacombe, D; Marosi, C; Mason, WP; Nordal, RA; Rees, J; Reijneveld, JC; Reni, M; Rossiter, JP; Ryan, G; Stupp, R; Taphoorn, MJB; Thiessen, B; Tzuk-Shina, T; van den Bent, MJ; von Deimling, A; Wick, W, 2016) |
| "Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients." | 5.20 | Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. ( Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015) |
| "This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM)." | 5.20 | Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. ( Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S, 2015) |
| "Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma." | 5.20 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015) |
| "To improve the therapeutic index of whole-brain radiation therapy (WBRT) in the treatment of brain metastases (BM) from breast cancer, we investigated the efficacy and safety of WBRT combined with temozolomide (TMZ) in this population." | 5.20 | Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. ( Bourgier, C; Cao, KI; Gerber, S; Gobillion, A; Kirova, YM; Le Scodan, R; Lebas, N; Levy, C; Pierga, JY; Savignoni, A, 2015) |
| " We evaluated the efficacy and toxicity of hypofractionated intensity-modulated radiation therapy with concurrent and adjuvant temozolomide and bevacizumab in patients with newly diagnosed glioblastoma." | 5.20 | Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. ( Carlson, JA; Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, KO; Ney, DE; Reddy, K; Waziri, AE, 2015) |
| "Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent." | 5.20 | Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ, 2015) |
| "Rindopepimut and standard adjuvant temozolomide chemotherapy were administered to 65 patients with newly diagnosed EGFRvIII-expressing (EGFRvIII+) glioblastoma after gross total resection and chemoradiation." | 5.20 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. ( Archer, GE; Baehring, JM; Bigner, DD; Cruickshank, S; Davis, TA; Green, JA; Groves, MD; Heimberger, AB; Jensen, R; Keler, T; Lai, RK; Mrugala, MM; Paleologos, NA; Reardon, DA; Recht, LD; Sampson, JH; Schuster, J; Sloan, A, 2015) |
| "Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules." | 5.20 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. ( Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG, 2015) |
| "Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls." | 5.20 | Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Brachman, DG; Chakravarti, A; Coons, SW; Fisher, BJ; Hu, C; Lesser, GJ; Liu, J; Macdonald, DR; Mehta, M; Ryu, S; Werner-Wasik, M, 2015) |
| "To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed." | 5.20 | Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2015) |
| "The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM)." | 5.20 | Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. ( Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M, 2015) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 5.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "This phase I study aimed to evaluate safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, in combination with temozolomide (TMZ), with or without radiation therapy (RT), in patients with high-grade glioma." | 5.20 | Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. ( Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 5.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma." | 5.20 | Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. ( Brachman, DG; Giannini, C; Hu, C; Jenkins, RB; Laack, NN; Macdonald, DR; Mehta, MP; Peereboom, DM; Shrieve, DC; Souhami, L; Suh, JH; Vogelbaum, MA, 2015) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 5.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily." | 5.20 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. ( Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M, 2015) |
| "Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models." | 5.20 | Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. ( Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 5.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 5.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| "Adult patients with newly surgical diagnosed glioblastoma were randomly assigned to receive either temozolomide or semustine after radiation treatment." | 5.19 | Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. ( Chen, JX; Liu, JP; Liu, YH; Mao, Q; Wang, X; You, C, 2014) |
| " We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT." | 5.19 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. ( Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY, 2014) |
| "We conducted a phase I study to determine (a) the maximum tolerated dose of peri-radiation therapy temozolomide (TMZ) and (b) the safety of a selected hypofractionated intensity modulated radiation therapy (HIMRT) regimen in glioblastoma multiforme (GBM) patients." | 5.19 | Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. ( Ammirati, M; Chotai, S; Grecula, J; Lamki, T; Newton, H; Wei, L, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 5.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "Surgery followed by radiotherapy and concomitant and adjuvant temozolomide is standard therapy in newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. ( Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C, 2014) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide." | 5.19 | Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. ( Abrey, L; Brandes, AA; Carpentier, AF; Cernea, D; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Hoang-Xuan, K; Kavan, P; Mason, W; Nishikawa, R; Saran, F; Wick, W, 2014) |
| "Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma." | 5.19 | A randomized trial of bevacizumab for newly diagnosed glioblastoma. ( Aldape, KD; Armstrong, TS; Blumenthal, DT; Brachman, DG; Brown, PD; Chakravarti, A; Colman, H; Curran, WJ; Dignam, JJ; Gilbert, MR; Jaeckle, KA; Jeraj, R; Mehta, MP; Pugh, S; Schiff, D; Stieber, VW; Sulman, EP; Tremont-Lukats, IW; Vogelbaum, MA; Wefel, JS; Werner-Wasik, M; Won, M, 2014) |
| "A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG)." | 5.19 | Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. ( Berger, MS; Butowski, NA; Chang, SM; Clarke, JL; DeSilva, A; Han, SJ; Molinaro, AM; Prados, MD; Rolston, JD, 2014) |
| "Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation." | 5.19 | Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. ( Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I, 2014) |
| "We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy." | 5.19 | Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. ( Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC, 2014) |
| "The objective of this study was to report the patterns of failure in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 5.19 | Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. ( Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K, 2014) |
| " The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GB)." | 5.19 | A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. ( Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X, 2014) |
| "Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM)." | 5.19 | Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. ( Abe, T; Hashimoto, K; Ikuta, S; Ishihara, T; Ishikawa, E; Karasawa, K; Maruyama, T; Matsuda, M; Matsumura, A; Matsutani, M; Muragaki, Y; Nakazato, Y; Ohno, T; Tsuboi, K; Uemae, Y; Yamamoto, T, 2014) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| " We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab." | 5.19 | Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. ( Abrey, LE; Barradas-Panchal, R; Baser, RE; Beal, K; Brennan, CW; Chan, TA; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, C; Gutin, P; Hormigo, A; Huse, JT; Kaley, TJ; Karimi, S; Lassman, AB; Mellinghoff, I; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Reiner, AS; Sanchez, J; Tabar, V; Zhang, J, 2014) |
| " Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter)." | 5.19 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. ( Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T, 2014) |
| "We investigate the patterns of failure in the treatment of glioblastoma (GBM) based on clinical target volume (CTV) margin size, dose delivered to the site of initial failure, and the use of temozolomide and intensity-modulated radiotherapy (IMRT)." | 5.19 | Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. ( Chan, MD; Debinski, W; Ellis, TL; Hinson, WH; Johnson, AJ; Kearns, WT; Lesser, GJ; McMullen, KP; Paulsson, AK; Peiffer, AM; Shaw, EG; Tatter, SB, 2014) |
| " The primary objective of this study was to determine the safety of the combination of PPX with temozolomide and concurrent radiation for high-grade gliomas." | 5.19 | Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. ( Boxerman, J; Cielo, D; Constantinou, M; Dipetrillo, T; Donahue, J; Elinzano, H; Evans, D; Goldman, M; Isdale, D; Jeyapalan, S; Kinsella, T; Mantripragada, K; Oyelese, A; Puthawala, Y; Rosati, K; Safran, H; Santaniello, A; Stopa, E, 2014) |
| "To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM)." | 5.17 | Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. ( Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W, 2013) |
| "A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma." | 5.17 | A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. ( Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X, 2013) |
| "The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas." | 5.17 | Secondary hematological malignancies associated with temozolomide in patients with glioma. ( Miyakita, Y; Momota, H; Narita, Y; Shibui, S, 2013) |
| "Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown." | 5.17 | Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. ( Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ, 2013) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 5.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "Thirteen patients with recurrent glioblastoma were enrolled in RTOG 0625/ACRIN 6677, a prospective multicenter trial in which bevacizumab was used in combination with either temozolomide or irinotecan." | 5.17 | Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. ( Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 5.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "To determine the safety of the mammalian target of rapamycin inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients." | 5.17 | RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ( Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M, 2013) |
| "To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ)." | 5.17 | Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. ( Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, KO; Ney, D; Reddy, K; Waziri, A, 2013) |
| "RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM)." | 5.17 | Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. ( Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 5.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| "To investigate the impact of nonstandard concomitant temozolomide (TMZ) administration in two prospective phase II studies for glioblastoma (GBM)." | 5.17 | Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. ( Alitto, AR; Anile, C; Balducci, M; Chiesa, S; Colosimo, C; D'Agostino, GR; De Bonis, P; Fiorentino, A; Frascino, V; Mangiola, A; Mantini, G; Mattiucci, GC; Valentini, V, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM)." | 5.17 | Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. ( Aldape, KD; Armstrong, TS; Baumert, B; Blumenthal, DT; Brown, PD; Chakravarti, A; Curran, WJ; Erridge, S; Gilbert, MR; Hegi, ME; Hopkins, KI; Jaeckle, KA; Mahajan, A; Mehta, MP; Schultz, CJ; Stupp, R; Tzuk-Shina, T; Wang, M; Wefel, JS; Won, M, 2013) |
| "Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma." | 5.17 | Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. ( Armstrong, TS; Bottomley, A; Brachman, DG; Choucair, AK; Coens, C; Gilbert, MR; Mehta, M; Mendoza, TR; Wang, M; Wefel, JS; Werner-Wasik, M; Won, M, 2013) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 5.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme." | 5.17 | Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). ( Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V, 2013) |
| "In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)." | 5.17 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. ( Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C, 2013) |
| "We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas." | 5.17 | A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. ( Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D, 2013) |
| "To evaluate in a single center retrospectively the efficacy and tolerability of a weekly regimen, which alternates temozolomide (TMZ) in patients with recurrent or progressive high-grade glioma (HGG)." | 5.17 | "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. ( Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 5.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)." | 5.16 | Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. ( Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ, 2012) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | 5.16 | Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "This paper aims to study the value of MRI and Thallium 201 ((201)Tl) single-photon emission computed tomography (SPECT) in the prediction of overall survival (OS) in glioma patients treated with temozolomide (TMZ) and to evaluate timing of radiological follow-up." | 5.16 | MRI and thallium-201 SPECT in the prediction of survival in glioma. ( Berkhof, J; Bosma, I; Buter, J; Heimans, JJ; Hoekstra, OS; Lagerwaard, FJ; Noske, DP; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Vos, MJ, 2012) |
| "The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide." | 5.16 | Bevacizumab and daily temozolomide for recurrent glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ, 2012) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 5.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "This phase I trial was designed to determine the recommended phase II dose(s) of everolimus (RAD001) with temozolomide (TMZ) in patients with glioblastoma (GBM)." | 5.16 | A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. ( Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S, 2012) |
| "To compare the therapeutic efficacy of two regimens of postoperative radiotherapy with concurrent chemotherapy using temozolomide (TMZ) and teniposide (VM-26) plus semustine (Me-CCNU) in adult patients with grade III-IV cerebral gliomas." | 5.16 | [Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas]. ( Gu, K; Wang, J; Zhai, X; Zhang, J, 2012) |
| "To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 5.16 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A, 2012) |
| " The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing." | 5.16 | A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). ( Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X, 2012) |
| "4 Gy radiotherapy with up-front temozolomide in previously untreated low-grade glioma." | 5.16 | Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. ( Bar-Deroma, R; Baumert, BG; Fairchild, A; Fenton, PA; Gulyban, A; Stupp, R; Weber, DC, 2012) |
| " We did a randomised trial to compare the efficacy and safety of dose-dense temozolomide alone versus radiotherapy alone in elderly patients with anaplastic astrocytoma or glioblastoma." | 5.16 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. ( Braun, C; Combs, SE; Felsberg, J; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Nikkhah, G; Papsdorf, K; Platten, M; Reifenberger, G; Sabel, M; Simon, M; Steinbach, JP; Tabatabai, G; Vesper, J; Weller, M; Wick, W, 2012) |
| "To evaluate the efficacy of adding bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, and everolimus, a mammalian target of rapamycin (mTOR inhibitor), to standard radiation therapy/temozolomide in the first-line treatment of patients with glioblastoma." | 5.16 | Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. ( Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW, 2012) |
| "To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas." | 5.16 | Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. ( Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ, 2012) |
| " Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma." | 5.16 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. ( Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B, 2012) |
| "The assessment of the therapeutic response of high-grade gliomas treated with concomitant chemoradiotherapy (CCRT) using temozolomide is difficult because of the frequent occurrence of early imaging changes that are indistinguishable from tumor progression, termed pseudoprogression." | 5.16 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS, 2012) |
| "A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)." | 5.16 | Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. ( Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012) |
| "To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone." | 5.16 | The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. ( Bressel, M; Gunjur, A; Ryan, G, 2012) |
| "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment." | 5.15 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. ( Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B, 2011) |
| "We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial." | 5.15 | Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, R; Peters, K; Reardon, DA; Rich, JN; Sampson, J; Threatt, S; Vredenburgh, JJ, 2011) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 5.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "To determine the maximum tolerated dose (MTD) of tipifarnib in combination with conventional radiotherapy for patients with newly diagnosed glioblastoma." | 5.15 | A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. ( Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY, 2011) |
| "This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM)." | 5.15 | Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. ( Black, K; Cloughesy, T; Elashoff, R; Fehrenbacher, L; Filka, E; Green, RM; Kolevska, T; Lai, A; Liau, LM; Mischel, PS; Nghiemphu, PL; Peak, S; Phuphanich, S; Polikoff, J; Pope, WB; Selch, M; Solis, OE; Spier, CE; Tran, A; Yong, WH, 2011) |
| "The objective of this prospective, monocentric phase-II pilot study was to evaluate toxicity and efficacy of neoadjuvant temozolomide (TMZ) and 13-cis retinoic acid (13-cRA) treatment in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection." | 5.15 | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). ( Bogdahn, U; Brawanski, A; Grauer, O; Hartmann, C; Hau, P; Pascher, C; Pietsch, T; Proescholdt, M; Weller, M; Wick, W; Zeman, F, 2011) |
| "To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide." | 5.15 | Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. ( Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA, 2011) |
| "The quantitative expression of CD133 stem cell antigen mRNA using real-time QRT-PCR was assessed in a cohort of 48 consecutive primary glioblastoma patients treated by chemoradiation with temozolomide." | 5.15 | Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. ( Barrie, M; Chinot, O; Colin, C; Coulibaly, B; Delfino, C; Figarella-Branger, D; Fina, F; Loundou, A; Metellus, P; Nanni-Metellus, I; Ouafik, L; Tchogandjian, A, 2011) |
| "Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse." | 5.15 | Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. ( Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK, 2011) |
| "This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients." | 5.15 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. ( Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A, 2011) |
| " We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vaccine-driven immune responses and significantly reduces malignant growth in an established model of murine tumorigenesis." | 5.15 | Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. ( Archer, GE; Bigner, DD; Congdon, KL; Cui, X; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sanchez-Perez, L; Schmittling, RJ; Snyder, DJ; Vredenburgh, JJ, 2011) |
| "Concurrent and post-radiotherapy temozolomide (T) significantly improves survival in patient with newly diagnosed glioblastoma multiforme." | 5.15 | Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. ( Ananda, S; Brown, C; Cher, L; Dowling, A; Nowak, AK; Rosenthal, MA; Simes, J, 2011) |
| "Patients with newly diagnosed malignant glioma received AdV-tk at 3 × 10(10), 1 × 10(11), or 3 × 10(11) vector particles (vp) via tumor bed injection at time of surgery followed by 14 days of valacyclovir." | 5.15 | Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. ( Aguilar, LK; Aguilar-Cordova, E; Baskin, DS; Bell, SD; Cavaliere, R; Chakravarti, A; Chiocca, EA; Grecula, J; Grossman, RG; Hardcastle, J; Harris, KS; Kaur, B; Lo, S; Manzanera, AG; McGregor, J; Monterroso, C; New, PZ; Newton, H; Ray-Chaudhuri, A; Trask, TW, 2011) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 5.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma." | 5.15 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. ( Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S, 2011) |
| "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)." | 5.14 | Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009) |
| "To determine whether increased uptake on 11C-methionine-PET (MET-PET) imaging obtained before radiation therapy and temozolomide is associated with the site of subsequent failure in newly diagnosed glioblastoma multiforme (GBM)." | 5.14 | Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. ( Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C, 2009) |
| "In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin." | 5.14 | Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. ( Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE, 2009) |
| "This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma." | 5.14 | Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. ( Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S, 2009) |
| "Patients with newly diagnosed oligodendroglioma or oligoastrocytoma with a MIB-1 index of >5% or recurrent low-grade gliomas received temozolomide (75 mg/m(2)/day in 11-week cycles of 7 weeks on/4 weeks off)." | 5.14 | Phase II study of protracted daily temozolomide for low-grade gliomas in adults. ( Black, PM; Bradshaw, J; Ciampa, A; Doherty, L; Drappatz, J; Kesari, S; LaFrankie, D; Levy, B; Ligon, KL; Macklin, EA; Muzikansky, A; Norden, AD; Radakovic, G; Ramakrishna, N; Santagata, S; Schiff, D; Wen, PY, 2009) |
| "Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide." | 5.14 | Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy." | 5.14 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| " We investigated the time course of tumor metabolism in low-grade gliomas (LGG) during temozolomide chemotherapy, and compared metabolic responses as measured with positron emission tomography (PET) with volume responses as revealed by magnetic resonance imaging (MR)." | 5.14 | Early metabolic responses in temozolomide treated low-grade glioma patients. ( Bärtschi, E; Bruehlmeier, M; Buettner, UW; Hefti, M; Hofer, S; Roelcke, U; Uhlmann, C; Wyss, M, 2009) |
| "Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both." | 5.14 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. ( Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009) |
| "This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.14 | Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2009) |
| "This trial was designed to estimate overall survival in adults with newly diagnosed glioblastoma treated with talampanel in addition to standard radiation (RT) and temozolomide (TMZ)." | 5.14 | Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. ( Batchelor, T; Chamberlain, M; Desideri, S; Fine, HA; Fisher, J; Grossman, SA; Mikkelsen, T; Piantadosi, S; Ye, X, 2009) |
| "The use of radiotherapy plus temozolomide administered concomitantly with and after radiotherapy for glioblastoma was recently shown to improve median and 2-year survival in a large international multicenter study." | 5.14 | Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. ( Jeon, HJ; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Park, KB, 2009) |
| "To present outcome data in a prospective study of radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in children with diffuse intrinsic pontine gliomas (DIPGs)." | 5.14 | Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. ( Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R, 2010) |
| "This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma." | 5.14 | Extended-schedule dose-dense temozolomide in refractory gliomas. ( Balaña, C; Berrocal, A; Gallego, O; Garcia Lopez, J; Gil, M; Iglesias, L; Perez Segura, P; Reynes, G; Rodríguez, J; Yaya, R, 2010) |
| "Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon alpha2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls." | 5.14 | Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. ( Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK, 2009) |
| "To determine the maximum tolerated dose (MTD) of fractionated intensity-modulated radiotherapy (IMRT) with temozolomide (TMZ) in patients with glioblastoma." | 5.14 | A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. ( Balducci, M; Calista, F; Cantore, GP; Cellini, N; Cilla, S; Deodato, F; Digesù, C; Esposito, V; Ferro, M; Ianiri, M; Macchia, G; Morganti, AG; Piermattei, A; Romanelli, P; Salvati, M; Valentini, V, 2010) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 5.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "Chemoradiotherapy followed by monthly temozolomide (TMZ) is the standard of care for patients with glioblastoma multiforme (GBM)." | 5.14 | Population-based study of pseudoprogression after chemoradiotherapy in GBM. ( Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES, 2009) |
| "To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma." | 5.14 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. ( Bähr, O; Bamberg, M; Gorlia, T; Hartmann, C; Herrlinger, U; Meyermann, R; Tatagiba, M; von Deimling, A; Weiler, M; Weller, M; Wick, W; Wiewrodt, D, 2010) |
| "Heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma received cisplatin at a dose of 75 mg/m(2) on day 1 and temozolomide at a dose of 150 mg/m(2) on days 1 to 5 every 21 days until progression or major toxicity." | 5.14 | A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. ( Della Puppa, A; Lombardi, G; Pastorelli, D; Rotilio, A; Scienza, R; Zustovich, F, 2009) |
| "We retrospectively investigated the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas treated with temozolomide at the time of progression after radiotherapy." | 5.14 | IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kros, JM; Postma, TJ; Smitt, PA; Taal, W; van den Bent, MJ; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2009) |
| "To investigate the efficacy and safety of temozolomide (TMZ) and lomustine (CCNU) in malignant brain gliomas." | 5.14 | [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. ( Chang, Y; Fu, Z; Liu, XM; Liu, XY; Qian, ZZ; Wang, HQ; Yang, SY; Yu, H, 2009) |
| "Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year." | 5.14 | Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. ( Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA, 2010) |
| "We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma." | 5.14 | Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. ( Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE, 2010) |
| "We assessed six-month progression-free survival (PFS) as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ)." | 5.14 | Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. ( Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M, 2010) |
| "To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 5.14 | A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. ( Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB, 2010) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 5.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "Twenty-two patients with newly diagnosed malignant glioma who received standard radiation/temozolomide therapy were recruited for the study." | 5.14 | Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. ( Chiba, Y; Hashimoto, N; Hosen, N; Kagawa, N; Kinoshita, M; Murao, A; Nishida, S; Oji, Y; Oka, Y; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2010) |
| " Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles)." | 5.14 | A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. ( Algar, E; Benson, A; Cher, L; Dowling, A; Gan, HK; Kalnins, R; Rosenthal, MA; Wong, N; Woods, AM, 2010) |
| "The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM)." | 5.14 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. ( Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M, 2010) |
| "Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation." | 5.14 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ( Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M, 2010) |
| "The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme." | 5.14 | Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010) |
| "The objectives of this study were to determine the safety and efficacy of polyinosinic-polycytidylic acid stabilized with poly-l-lysine and carboxymethylcellulose (poly-ICLC) when added to radiation and temozolomide (TMZ) in adults with newly diagnosed glioblastoma (GB)." | 5.14 | A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. ( Batchelor, TT; Chamberlain, MC; Desideri, S; Grossman, SA; Lesser, GJ; Peereboom, DM; Rosenfeld, MR; Salazar, AM; Ye, X, 2010) |
| "Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ)." | 5.14 | Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. ( Combs, SE; Debus, J; Haberer, T; Habermehl, D; Haselmann, R; Jäkel, O; Kieser, M; Nikoghosyan, A; Rieken, S; Unterberg, A; Wick, W, 2010) |
| "Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 5.14 | The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study. ( Abo Hamar, AH; El-Shorbagy, D; Galal, S; Shawky, H; Zakaria, F, 2009) |
| "To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM)." | 5.13 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. ( Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S, 2008) |
| "We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy." | 5.13 | Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. ( D'Amico, A; Dall'oglio, S; Gabbani, M; Maluta, S; Pasini, F; Passarin, MG; Pioli, F; Talacchi, A; Turazzi, S, 2008) |
| "The combination of temozolomide (TMZ) and thalidomide was reported to produce a high response rate, including shrinkage of brain metastases, in patients with metastatic melanoma." | 5.13 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008) |
| "A multicenter phase I clinical trial, namely, Integrated Japanese Multicenter Clinical Trial: A Phase I Study of Interferon-beta and Temozolomide for Glioma in Combination with Radiotherapy (INTEGRA Study), is being conducted for patients with high-grade glioma in order to evaluate the safety, feasibility and preliminary clinical effectiveness of the combination of interferon-beta and temozolomide." | 5.13 | A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). ( Aoki, T; Hashimoto, N; Kayama, T; Kurisu, K; Natsume, A; Nishikawa, R; Ogura, M; Takahashi, H; Wakabayashi, T; Yoshida, J; Yoshimine, T, 2008) |
| "To evaluate the efficacy of simultaneous postoperative temozolomide radiochemotherapy in glioblastoma patients." | 5.13 | Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. ( Becker, G; Borberg, SK; Fischedick, AR; Frommolt, P; Grauthoff, H; Herfarth, K; Kocher, M; Müller, RP; Niewald, M; Rühl, U; Staar, S; Steingräber, M; Stuschke, M, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 5.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| "The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective." | 5.13 | Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. ( Al, MJ; Crott, R; Gorlia, T; Jin Seung, S; Lamers, LM; Mittmann, N; Stupp, R; Uyl-de Groot, CA; van den Bent, MJ; Wasserfallen, JB, 2008) |
| "Twice-daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity." | 5.13 | Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. ( Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M, 2008) |
| "To evaluate toxicity and outcomes in patients with primary glioblastoma (GB) treated with postoperative radiochemotherapy (RCHT) with temozolomide (TMZ) comparing two dose regimens." | 5.13 | Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. ( Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A, 2008) |
| "We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma." | 5.13 | Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. ( Bael, TE; Gollob, JA; Peterson, BL, 2008) |
| "To assess interim safety and tolerability of a 10-patient, Phase II pilot study using bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy (RT) in the up-front treatment of patients with newly diagnosed glioblastoma." | 5.13 | Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. ( Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH, 2008) |
| "We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combination with temozolomide (TMZ) to malignant glioma (MG) patients." | 5.13 | Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ( Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ, 2008) |
| "The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)." | 5.13 | Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. ( Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD, 2008) |
| "We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma." | 5.13 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008) |
| "The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status." | 5.13 | Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A, 2008) |
| "To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas." | 5.13 | Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. ( Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T, 2008) |
| "A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)." | 5.13 | CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 5.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide." | 5.12 | MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C, 2021) |
| "Temozolomide is an oral alkylating agent incorporated in the treatment of glioblastoma multiforme (GBM) that can lead to lymphopenia." | 5.12 | Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review. ( Brault, C; Chouaki, T; Maizel, J; Nyga, R; Zerbib, Y, 2021) |
| "Recent developments in pharmacogenomics have created opportunities for predicting temozolomide response in gliomas." | 5.12 | Comprehensive pharmacogenomics characterization of temozolomide response in gliomas. ( Long, J; Tong, S; Wang, B; Wang, Y; Wu, J; Zhong, P, 2021) |
| "We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line." | 5.12 | Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies. ( Brennan, PM; Bruce, M; Hannan, CJ; Poon, MTC; Simpson, JE, 2021) |
| "Steroids are commonly used for managing brain edema in patients with glioblastoma multiforme (GBM), treated with surgery and concomitant temozolomide-based chemoradiotherapy (CTRT)." | 5.12 | Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis. ( Bruschieri, L; De Stefani, A; Dottorini, L; Ghidini, A; Iaculli, A; Petrelli, F; Riboldi, V; Trevisan, F; Zaniboni, A, 2021) |
| "Temozolomide (TMZ) is an oral alkylating agent principally indicated for neurological malignancies including glioblastoma (GBM) and astrocytoma." | 5.12 | Temozolomide-induced aplastic anaemia: Case report and review of the literature. ( Gilbar, PJ; Mangos, HM; Pokharel, K, 2021) |
| "To determine which method for assessing MGMT methylation status best predicts overall survival in people diagnosed with glioblastoma who are treated with temozolomide." | 5.12 | Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Howell, A; Jefferies, S; Kelly, C; Kernohan, A; Kurian, KM; McAleenan, A; Robinson, T; Schmidt, L; Spiga, F; Vale, L; Wragg, C, 2021) |
| "The standard of care treatment for glioblastoma is surgical resection followed by radiotherapy to 60 Gy with concurrent and adjuvant temozolomide with or without tumor-treating fields." | 5.12 | Novel Radiation Approaches. ( Kotecha, R; Mehta, MP; Tom, MC, 2021) |
| "Limited evidence is available on the utility of dose-escalated radiation therapy (DE-RT) with or without temozolomide (TMZ) versus standard-of-care radiation therapy (SoC-RT) for patients with newly diagnosed glioblastoma multiforme." | 5.12 | Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. ( Bovi, J; Brown, PD; Gondi, V; Lehrer, EJ; Navarria, P; Palmer, JD; Perlow, HK; Scoccianti, S; Singh, R; Trifiletti, DM; Wang, M; Zaorsky, NG, 2021) |
| "In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas." | 5.12 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. ( Sun, X; Turcan, S, 2021) |
| "(1) Background: Studies in elderly patients over the age of 65 with glioblastoma have shown survival benefits of short-course radiation therapy with concurrent and adjuvant temozolomide, making it the standard of care adopted at Juravinski Cancer Center." | 5.12 | Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. ( Greenspoon, JN; Mir, T; Pond, G, 2021) |
| "The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma." | 5.12 | Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006) |
| "A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)." | 5.12 | Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2006) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 5.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases." | 5.12 | A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. ( Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S, 2006) |
| "The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas." | 5.12 | Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. ( Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006) |
| "Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes." | 5.12 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ( Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK, 2006) |
| "The implementation of combined radiochemotherapy (RCHT) with temozolomide (TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma multiforme (GBM), however, outcome still remains unsatisfactory." | 5.12 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. ( Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D, 2006) |
| "The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide (TMZ) and radiotherapy (RT) in glioblastoma (GBM) has demonstrated that the combination of TMZ and RT conferred a significant and meaningful survival advantage compared with RT alone." | 5.12 | Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. ( Allgeier, A; Brandes, AA; Cairncross, G; Curschmann, J; Fisher, B; Gorlia, T; Kortmann, RD; Lacombe, D; Mason, W; Mirimanoff, RO; Reni, M; Stupp, R; Van den Bent, MJ; Villa, S, 2006) |
| "A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
| "Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma." | 5.12 | Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. ( Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A, 2007) |
| "To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy." | 5.12 | Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006) |
| "The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse." | 5.12 | [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 5.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 5.12 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours." | 5.12 | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. ( Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T, 2006) |
| " The aim of this pilot study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) treatment in twelve consecutive patients with recurrent TMZ-refractory glioblastoma." | 5.12 | A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. ( Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ, 2006) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 5.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 5.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 5.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide." | 5.12 | MGMT methylation: a marker of response to temozolomide in low-grade gliomas. ( Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J, 2006) |
| "We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma." | 5.12 | Temozolomide in children with progressive low-grade glioma. ( Allen, JC; Desjardins, A; Fisher, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Krauser, JM; Phillips, PC; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Watral, MA, 2007) |
| "To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases." | 5.12 | Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? ( Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A, 2007) |
| "This phase II study evaluated the efficacy and safety of a 7-day on/7-day off regimen of temozolomide before radiotherapy (RT) in patients with inoperable newly diagnosed glioblastoma." | 5.12 | Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. ( Barrié, M; Braguer, D; Chinot, OL; Dufour, H; Eudes, N; Figarella-Branger, D; Fuentes, S; Lancelot, S; Martin, PM; Metellus, P; Muracciole, X; Ouafik, L, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 5.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy." | 5.12 | Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007) |
| "To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites." | 5.12 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ( Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose of 150 mg/m2 per day on a 5-day schedule every 28 days." | 5.11 | Temozolomide in the treatment of recurrent malignant glioma. ( Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P, 2004) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 5.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM)." | 5.11 | Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. ( Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM, 2004) |
| "We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients." | 5.11 | Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. ( Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A, 2004) |
| "The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)." | 5.11 | Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. ( Chamberlain, MC; Tsao-Wei, DD, 2004) |
| "In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide." | 5.11 | Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. ( de Tribolet, N; Dietrich, PY; Diserens, AC; Godard, S; Hegi, ME; Ostermann, S; Otten, P; Regli, L; Stupp, R; Van Melle, G, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 5.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity." | 5.11 | First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004) |
| "To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma." | 5.11 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004) |
| "This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma." | 5.11 | Temozolomide in paediatric high-grade glioma: a key for combination therapy? ( Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC, 2004) |
| "The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma." | 5.11 | Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004) |
| "Thirty-two patients with relapsing glioma were treated with temozolomide in two university hospitals in Finland." | 5.11 | Temozolomide treatment in glioma--experiences in two university hospitals in Finland. ( Aaltonen, K; Mäenpää, HO; Mäntylä, R; Minn, H, 2004) |
| "An analysis of 73 patients with hystologically confirmed glioblastoma multiforme (GBM), treated with the ''3 step'' (90)Y-biotin based LR-RIT, is herein reported." | 5.11 | Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. ( Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 5.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival." | 5.11 | Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). ( Balaña, C; Balart, J; Ballester, R; Benavides, M; Berrocal, A; Capellades, J; Cerdá-Nicolás, M; García, JL; Herrero, A; López-Pousa, A; Martín-Broto, J; Yaya-Tur, R, 2004) |
| "Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle)." | 5.11 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. ( Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M, 2005) |
| "Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma." | 5.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)." | 5.11 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. ( Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J, 2005) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 5.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma." | 5.11 | Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. ( Chan, DT; Chan, YL; Ng, HK; Poon, WS, 2005) |
| "In an effort to reduce the frequency of central nervous system (CNS) progression in patients with metastatic melanoma with ongoing systemic response to biochemotherapy, we modified our standard concurrent biochemotherapy regimen by replacing dacarbazine (DTIC) with oral temozolomide." | 5.10 | A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. ( Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L, 2002) |
| "To determine the response rate of the malignant gliomas of childhood to an oral, daily schedule of temozolomide." | 5.10 | Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. ( Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G, 2002) |
| "Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short-lived." | 5.10 | Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. ( Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA, 2003) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases." | 5.10 | Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 5.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 5.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "Temozolomide is an effective agent in the treatment of recurrent malignant gliomas." | 5.10 | A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. ( Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002) |
| "Temozolomide is a novel oral alkylating agent that is effective against melanoma." | 5.10 | Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002) |
| "Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 5.10 | Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. ( de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R, 2002) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 5.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain." | 5.10 | Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. ( Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002) |
| "To determine the antitumor efficacy and safety profile of temozolomide in patients with malignant astrocytoma at first relapse." | 5.09 | Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( Albright, R; Brada, M; Bruner, J; Chang, SM; Dugan, M; Friedman, AH; Friedman, HS; Levin, VA; O'Neill, AM; Olson, J; Prados, MD; Rosenfeld, SS; Yaya-Tur, R; Yue, N; Yung, WK; Zaknoen, S, 1999) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 5.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 5.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)." | 5.09 | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 5.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70." | 5.09 | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. ( Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA, 2001) |
| " A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma." | 5.09 | Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001) |
| "Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas." | 5.08 | The Charing Cross Hospital experience with temozolomide in patients with gliomas. ( Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1996) |
| "Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity of temozolomide." | 5.08 | Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. ( Begent, RJ; Bleehen, NM; Bower, M; Brada, M; Brampton, MH; Calvert, H; Colquhoun, I; Lewis, P; Newlands, ES, 1997) |
| "Temozolomide, a methylating imidazotetrazinone, has antitumor activity against gliomas, malignant melanoma, and mycosis fungoides and is presently administered as a 5-day oral schedule every 4 weeks." | 5.08 | Phase I trial of temozolomide using an extended continuous oral schedule. ( Bower, M; Brampton, MH; Brock, CS; Colquhoun, I; Evans, H; Glaser, M; Newlands, ES; Roddie, M; Rustin, GJ; Wedge, SR, 1998) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "The efficacy of radiotherapy with adjuvant temozolomide for glioblastoma remains controversial." | 5.05 | The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies. ( Feng, Y; Wang, Y, 2020) |
| "The association of radiotherapy and procarbazine, lomustine (CCNU), vincristine chemotherapy in low-grade oligodendrogliomas is definitely superior over radiotherapy alone, and yields median progression-free survival and overall survival values exceeding by far 10 years." | 5.05 | Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? ( Rudà, R; Soffietti, R; Touat, M, 2020) |
| "Glioblastoma (GB) is one of the most common malignancies with limited standard therapies such as surgery, radiotherapy (RT) plus temozolomide (TMZ)." | 5.01 | Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis. ( Aru, N; Ding, YM; Jin, WY; Liu, Z; Qin, HH; Shen, X; Wang, WL; Wu, SJ, 2019) |
| "Temozolomide is a first-line treatment for newly diagnosed glioblastoma." | 5.01 | Evidence-Based Practice: Temozolomide Beyond Glioblastoma. ( Chua, J; Leung, D; Nafziger, E, 2019) |
| "Here we review tumoricidal efficacy of Vitamin D analogues in glioblastoma multiforme (GBM) and potential synergisms with retinoic acid and temozolomide based on epidemiological and cellular studies." | 5.01 | From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. ( Altinoz, MA; Elmaci, I; Ozpinar, A; Perez, JL, 2019) |
| "Although reoperation likely confers survival benefit for glioblastoma, whether the extent of resection (EOR) of the reoperation affects survival outcome has yet to be thoroughly evaluated in the current temozolomide (TMZ) era." | 5.01 | Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis. ( Burns, TC; Chaichana, KL; Goyal, A; Graffeo, CS; Lu, VM; Parney, IF; Perry, A; Quinones-Hinojosa, A, 2019) |
| " For glioblastoma, the irradiation dose of 60 Gy in 30 fractions with concomitant and adjuvant temozolomide is currently considered as a standard of treatment, and further dose escalation has failed to be of benefit in clinical trials." | 4.98 | Fractionated Radiotherapy of Intracranial Gliomas. ( Ghia, AJ, 2018) |
| " Temozolomide, a monofunctional alkylator, was the first chemotherapeutic agent to definitively improve survival in adults with newly diagnosed glioblastoma used in combination with radiation therapy with the most pronounced effect being in a subgroup of tumors with MGMT promoter methylation." | 4.98 | Chemotherapy of High-Grade Astrocytomas in Adults. ( Hoang, N; Puduvalli, VK, 2018) |
| "Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy." | 4.98 | Temozolomide for immunomodulation in the treatment of glioblastoma. ( Dastmalchi, F; Karachi, A; Mitchell, DA; Rahman, M, 2018) |
| "This review focuses on a carotenoid and a phlorotannin present in seaweed, namely fucoxanthin and phloroglucinol, and their anticancer activity against glioblastoma." | 4.98 | Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review. ( Almeida, T; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E, 2018) |
| "New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma." | 4.95 | The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. ( Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J, 2017) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 4.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "Tumor treating fields (TTFields) are an integral treatment modality in the management of glioblastoma and extend overall survival when combined with maintenance temozolomide in newly diagnosed patients." | 4.95 | A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. ( Battiste, J; Bota, DA; Connelly, J; Damek, D; Dunbar, E; Iwamoto, F; Mohile, N; Trusheim, J, 2017) |
| "The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ)." | 4.95 | Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis. ( Feng, E; Sui, C; Sun, G; Wang, T, 2017) |
| "Since 2005, the standard of care for patients with newly diagnosed glioblastoma (GBM) has consisted of maximal resection followed by radiotherapy plus daily temozolomide (TMZ), followed by maintenance TMZ." | 4.95 | Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. ( Mehta, M; Nishikawa, R; Peters, K; Reardon, D; Wen, P, 2017) |
| "Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ)." | 4.95 | Single vs. combination immunotherapeutic strategies for glioma. ( Asad, AS; Candolfi, M; Castro, MG; Chandran, M; Koschmann, C; Lowenstein, PR; Mineharu, Y; Shah, D; Yadav, VN, 2017) |
| "In the last decade, phase III trials on novel compounds largely failed to introduce efficacious pharmacotherapies beyond temozolomide in glioblastoma." | 4.93 | Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. ( Gramatzki, D; Roth, P; Seystahl, K; Weller, M, 2016) |
| "This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas." | 4.91 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| "Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy." | 4.91 | Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature. ( Balducci, N; Biolato, M; Di Napoli, N; Diletto, B; Grieco, A; Miele, L; Tafuri, MA; Vecchio, FM, 2015) |
| "Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma, especially with deep-seated structure involvement." | 4.91 | Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. ( Gao, Z; Hao, S; Liu, Y; Yu, L, 2015) |
| "The Avastin in Glioblastoma trial has shown that patients newly diagnosed with glioblastoma multiforme (GBM) treated with bevacizumab plus radiotherapy and temozolomide versus radiotherapy and temozolomide alone showed improvement in progression-free survival, possibly leading to a new indication for first-line use of bevacizumab in GBM." | 4.91 | Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. ( Kovic, B; Xie, F, 2015) |
| "The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG)." | 4.91 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. ( Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W, 2015) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 4.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion." | 4.91 | Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? ( Lassman, AB, 2015) |
| "Temozolomide (TMZ) alone has been proposed as a promising alternative to radiotherapy (RT) in elderly glioblastoma (GBM) patients." | 4.90 | A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. ( Cai, S; Cheng, JX; Dong, Y; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2014) |
| "Postoperative external beam radiotherapy was considered the standard adjuvant treatment for patients with glioblastoma multiforme until the advent of using the drug temozolomide (TMZ) in addition to radiotherapy." | 4.90 | Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. ( Balañà, C; Comas, S; Villà, S, 2014) |
| "Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy." | 4.90 | The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. ( Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY, 2014) |
| " While temozolomide, an alkylating agent, has demonstrated a survival benefit, median survival in the past decade of patients with glioblastoma (GBM) remains an obdurate 15 months and add-on therapies have not significantly prolonged life." | 4.90 | Molecular neuro-oncology and the challenge of the blood-brain barrier. ( Aiken, R, 2014) |
| "Glioblastoma is the most common primary malignant brain tumor, but despite multimodal treatment with surgery, radiotherapy, and temozolomide chemotherapy, the prognosis is poor, with a median survival of 16 to 19 months and poor quality of life throughout the disease course." | 4.90 | Emerging therapies for glioblastoma. ( Brennan, CW; DeAngelis, LM; Omuro, AM; Thomas, AA, 2014) |
| "This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma." | 4.90 | Comprehensive analysis of temozolomide treatment for patients with glioma. ( Liang, H; Xing, BZ; Yang, WB, 2014) |
| "For primary therapy three RCTs were identified, enrolling a total of 745 patients, that investigated temozolomide in combination with radiotherapy versus radiotherapy alone for glioblastoma multiforme (GBM)." | 4.89 | Temozolomide for high grade glioma. ( Garside, R; Grant, R; Hart, MG; Rogers, G; Stein, K, 2013) |
| "Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas treatment due to its DNA-damaging effect." | 4.89 | O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. ( Cao, H; Chen, L; Fan, CH; Jiang, G; Liu, WL; Wen, C, 2013) |
| "The efficacy of temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM) has been evaluated by several clinical trials." | 4.89 | The efficacy of temozolomide for recurrent glioblastoma multiforme. ( Chen, C; Chen, J; Lu, Y; Wu, S; Xu, T, 2013) |
| "We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma." | 4.89 | Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| "The landmark Stupp study demonstrated a survival advantage with concomitant and adjuvant temozolomide (TMZ) with standard radiotherapy (RT) in glioblastoma multiforme (GBM) patients but excluded those older than 70 years." | 4.88 | Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. ( Bauman, GS; Cao, JQ; Fisher, BJ; Macdonald, DR; Megyesi, JF; Watling, CJ, 2012) |
| "This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme." | 4.88 | Temozolomide and other potential agents for the treatment of glioblastoma multiforme. ( Chow, F; Cremer, N; Kim, W; Nagasawa, DT; Yang, I; Yew, A, 2012) |
| " Attempted gross total surgical resection followed by concurrent temozolomide and radiation therapy has become standard of care for glioblastoma." | 4.88 | Potential usefulness of radiosensitizers in glioblastoma. ( Harasaki, Y; Waziri, A, 2012) |
| "Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances." | 4.88 | [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. ( Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R, 2012) |
| "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol')." | 4.87 | The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. ( Achawal, S; Dixit, S; Hingorani, M; Scott, I, 2011) |
| "The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy." | 4.87 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. ( Kyritsis, AP; Levin, VA, 2011) |
| "Loco-regional chemotherapy with carmustine wafers (Gliadel) positioned at surgery and followed by radiotherapy has been shown to prolong survival in first-diagnosis glioblastoma, as well as concomitant radiochemotherapy with temozolomide." | 4.87 | Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. ( Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A, 2011) |
| "Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas." | 4.86 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010) |
| "One barrier to successful treatment of malignant glioma is resistance to alkylating agents such as temozolomide." | 4.85 | New (alternative) temozolomide regimens for the treatment of glioma. ( Platten, M; Weller, M; Wick, W, 2009) |
| " The standard care for glioblastoma is surgery and concomitant radio- and chemotherapy with temozolomide (TMZ), followed by adjuvant treatment with TMZ." | 4.85 | Insights into pharmacotherapy of malignant glioma in adults. ( D'Elia, A; Formichella, AI; Frati, A; Salvati, M, 2009) |
| "Temozolomide (TMZ) offers substantial therapeutic benefits for glioblastoma (GB), yet its efficacy is hindered the development of chemoresistance." | 4.84 | CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding. ( Fang, X; Feng, M; Jiang, CM; Jiang, LY; Li, XL; Lin, XY; Wang, GH; Xu, JJ; Zhang, HX, 2024) |
| "In primary disease two RCTs were identified, enrolling a total of 703 patients, that investigated concomitant and adjuvant temozolomide in Glioblastoma Multiforme (GBM)." | 4.84 | Temozolomide for high grade glioma. ( Garside, R; Grant, R; Hart, MG; Rogers, G; Somerville, M; Stein, K, 2008) |
| "Patients with brain metastasis were identified from 3 prospective studies of temozolomide (with or without immunotherapy) for metastatic melanoma." | 4.84 | Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? ( Boogerd, W; Dalesio, O; de Gast, GC, 2007) |
| "Carmustine wafers (Gliadel) and temozolomide (Temodal) were recently approved for initial management of glioblastoma." | 4.84 | [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]. ( Ducray, F; Honnorat, J, 2007) |
| " Temozolomide is a novel second-generation alkylating agent that has shown efficacy for the treatment of high-grade gliomas." | 4.84 | [Glioma therapy up-date]. ( Dalmau, J; de la Fuente, BP; Rosenfeld, M, 2007) |
| "The dismal prognosis of glioblastoma had remained unchanged for the past 30 years until the association of temozolomide and radiotherapy in the breakthrough European Organization for Cancer/National Cancer Institute of Canada (EORTC/NCIC) trial brought new hope for patients." | 4.83 | The evolution of chemoradiation for glioblastoma: a modern success story. ( Mirimanoff, RO, 2006) |
| "Following the seminal trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC), concurrent temozolomide and radiotherapy has become the new standard of care for patients with newly diagnosed glioblastoma multiforme (GBM)." | 4.83 | Treatment options for glioblastoma. ( Chamberlain, MC, 2006) |
| "Concomitant and adjuvant treatment with Temozolomide, an oral alkylating agent, has significantly improved the survival of patients with newly diagnosed glioblastoma multiforme (study EORTC 26981/22981, NCIC CE3)." | 4.83 | Chemotherapy for malignant gliomas. ( Marosi, C, 2006) |
| "Surgery and radiation have been the mainstays of therapy for most glioma patients, but temozolomide chemotherapy has recently been proven to prolong overall survival in patients with glioblastoma." | 4.83 | Glioma therapy in adults. ( Norden, AD; Wen, PY, 2006) |
| "The current standard of care for malignant gliomas is surgical resection and radiotherapy followed by extended adjuvant treatment with the alkylating agent temozolomide." | 4.83 | Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. ( Alonso, MM; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y, 2006) |
| " The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide." | 4.83 | [Pattern of care of high-grade gliomas]. ( Laigle-Donadey, F; Sanson, M, 2006) |
| " We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)." | 4.82 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| " Temozolomide, an alkylating agent that can be administered orally, has been approved for the treatment of recurrent malignant glioma on a daily schedule for 5-day cycles." | 4.81 | Current and future developments in the use of temozolomide for the treatment of brain tumours. ( Gander, M; Leyvraz, S; Newlands, E; Stupp, R, 2001) |
| "Temozolomide (TMZ) is a new, orally administered, second-generation imidazotetrazine prodrug with essentially 100% oral bioavailability that has demonstrated meaningful efficacy and an acceptable safety profile in the treatment of patients with recurrent glioblastoma multiforme." | 4.80 | Future directions in the treatment of malignant gliomas with temozolomide. ( Prados, MD, 2000) |
| "Temozolomide (TMZ) has been used as standard-of-care for glioblastoma multiforme (GBM), but the resistance to TMZ develops quickly and frequently." | 4.31 | Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. ( An, YJ; Choo, M; Kim, DH; Kim, HS; Ku, JL; Lee, SK; Mai, VH; Park, CK; Park, S, 2023) |
| "Temozolomide (TMZ) is the recommended drug for glioblastoma (GBM) treatment, but its clinical effect is restricted due to drug resistance." | 4.31 | Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma. ( Dong, J; Jiang, Z; Peng, Y; Wang, K; Wu, Y; Xie, Z; Zhong, M, 2023) |
| "Temozolomide (TMZ) has been determined to be the chemotherapeutic drug with efficacy for glioblastoma (GBM)." | 4.31 | Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma. ( Song, S; Tong, X; Wang, F; Wang, Y; Wen, B; Wu, H; Wu, Q; Xu, L; Yan, H; Zhou, Y, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 4.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| " Based on CRISPR-Cas9 library screening, we found that mucin1 (MUC1) is essential for EGFRvIII glioma cell survival and temozolomide (TMZ) resistance." | 4.31 | MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII. ( Cui, XT; Fang, ZY; Fu, JQ; Kang, CS; Liu, SZ; Liu, X; Qiu, ZJ; Su, DY; Tong, F; Wang, GX; Wang, JC; Wang, QX; Zhao, JX; Zhou, JH, 2023) |
| "Temozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties." | 4.31 | The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. ( Li, L; Liu, H; Ma, H; Qian, F; Quan, A; Ren, Y; Wang, L; Xu, H; Yu, R; Zhang, Y, 2023) |
| "Temozolomide (TMZ) delivery was investigated in CT2A and PDGFB-driven RCAS/tv-a orthotopic glioma models." | 4.31 | Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma. ( Cao, H; Chao, M; Dimberg, A; He, L; Huang, H; Li, Y; Shi, X; Tang, J; Uhrbom, L; Wang, J; Wang, L; Xiao, B; Xie, Y; Xin, L; Yang, F; Zhang, L; Zhang, X; Zhang, Y, 2023) |
| " In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs)." | 4.31 | Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. ( Alejo, S; Brenner, AJ; Chen, Y; Clarke, K; Gilbert, AR; He, Y; Jayamohan, S; Johnson, JD; Lai, Z; Li, W; Lv, Y; Palacios, BE; Pratap, UP; Sareddy, GR; Suzuki, T; Tekmal, RR; Vadlamudi, RK; Venkata, PP; Viswanadhapalli, S; Weldon, K; Ye, Z; Zhao, W; Zheng, S; Zou, Y, 2023) |
| "Hypofractionated radiotherapy (HypoRT) has recently been implemented in patients with glioblastoma (GBM) receiving concurrent temozolomide." | 4.31 | Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma. ( Choi, JW; Kim, N; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Seol, HJ, 2023) |
| "Our study aimed to assess the benefit of prolonging adjuvant temozolomide (TMZ) therapy beyond 6 cycles in glioblastoma multiform patients." | 4.31 | Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients. ( Elsaid, AA; Elsaka, R; Kitagwa, JM; Mahmoud, AA; Meheissen, MAM; Refaat, T; Shaikh, H, 2023) |
| "Although temozolomide (TMZ) provides significant clinical benefit for glioblastoma (GBM), responses are limited by the emergence of acquired resistance." | 4.31 | Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. ( Cao, Z; Gao, G; Gu, J; Guan, Z; Guo, Q; Hao, Q; Jia, B; Li, M; Li, W; Liu, X; Wang, S; Wang, W; Zhang, K; Zhang, W; Zhang, Y, 2023) |
| "The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM)." | 4.31 | The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. ( Kucheryavykh, L; Kucheryavykh, Y; Nuñez, R; Ortiz-Rivera, J, 2023) |
| " We aimed to clarify the interplay between purinergic signaling and chemotherapeutic drug temozolomide (TMZ) in human glioma cell line." | 4.31 | Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor. ( Czach, S; Czarnecka, J; Nowak, W; Roszek, K; Szymczak, B, 2023) |
| "Although temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate dehydrogenase wild-type (IDH-wt) cases remains challenging due to intrinsic and acquired drug resistance." | 4.31 | Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. ( Cho, HJ; Choi, SW; Kim, D; Kim, Y; Kong, DS; Koo, H; Kwon, YJ; Lee, HW; Lee, JI; Lee, K; Mu, Q; Nam, Y; Oh, JW; Park, CK; Park, WY; Sa, JK; Seo, YJ; Seol, HJ; Shin, S; Wang, J; Yang, Y; Yoon, Y; Zhu, Z, 2023) |
| "Temozolomide (TMZ) is one of the best choices for treating glioblastoma." | 4.31 | Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. ( Laxmi Swetha, K; Narayan Saha, R; Roy, A; Singhvi, G; Waghule, T, 2023) |
| "Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy." | 4.31 | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. ( Deng, Y; Du, H; Hou, X; Liu, J; Liu, W; Liu, Y; Qiao, J; Shu, X; Sun, B; Wang, H, 2023) |
| " Protein disulfide isomerase (PDI) is a molecular chaperone known to be highly expressed in glioblastomas with acquired resistance to temozolomide (TMZ)." | 4.31 | Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma. ( Kiang, KM; Lam, TL; Leung, GK; Li, N; Liu, J; Shum, HC; Song, Q; Tang, W; Zhu, Z, 2023) |
| "The chemoresistance of temozolomide-based therapy is a serious limitation for lasting effective treatment of gliomas, while the underlying mechanisms remain unclear." | 4.31 | Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis. ( Chen, S; Li, J; Li, M; Li, X; Li, Z; Liao, X; Qian, W; Song, L; Tang, M; Xu, Y; Yu, R; Zhang, S; Zheng, H, 2023) |
| "Temozolomide (TMZ)-based chemotherapy plays a central part in glioma treatment." | 4.31 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. ( Liu, X; Sun, Y; Wang, X; Wu, Z; Yan, W; You, Y; Zhang, Y, 2023) |
| " TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)." | 4.31 | Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023) |
| "Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ)." | 4.31 | ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression. ( Chen, JC; Chong, ZY; Huang, C; Huang, HC; Lee, IN; Wu, YP; Yang, JT, 2023) |
| "Patients with glioblastoma (GBM) have poor prognosis and limited therapeutic options, largely because of chemoresistance to temozolomide (TMZ) treatment." | 4.31 | UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. ( Gao, G; Wang, Y; Wei, X; Yu, J; Zhang, Y, 2023) |
| "This study aims to elucidate the mechanism underlying temozolomide resistance in patients with MGMT promoter hypomethylated glioblastoma, which is correlated with poor prognosis." | 4.31 | AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma. ( Bian, Y; Li, P; Li, S; Liu, J; Liu, Z; Pan, J; Song, S; Sun, Z; Tan, N; Wang, Y; Zhao, W, 2023) |
| "Temozolomide resistance remains a major obstacle in the treatment of glioblastoma (GBM)." | 4.31 | The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma. ( Chen, H; Chen, K; Chen, L; Huang, A; Huang, Y; Li, C; Li, H; Lu, Y; Qi, S; Shi, L; Song, C; Wang, T; Zhong, C, 2023) |
| "Chemoresistance blunts the efficacy of temozolomide (TMZ) in the treatment of glioblastoma (GBM)." | 4.31 | Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation. ( Ahmad, N; Cheng, X; Deng, S; Li, H; Shu, X; Song, D; Wang, Q; Wu, M; Xu, H; Yang, X, 2023) |
| "Glioblastoma multiforme (GBM) is the deadliest glioma and its resistance to temozolomide (TMZ) remains intractable." | 4.31 | HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. ( Cao, YY; Chen, JX; Chen, QZ; Huang, GH; Li, Y; Liu, GL; Lv, SQ; Pei, YC; Ren, P; Wang, TT; Xiang, Y; Yang, L; Yang, W; Zhang, ZX; Zhou, S, 2023) |
| "Dacarbazine is an important drug in the therapeutic landscape of leiomyosarcoma (LMS)." | 4.31 | The Impact of O6-Methylguanine-DNA Methyltransferase ( ( Badalamenti, G; Barretta, ML; Buonaiuto, M; Cannella, L; Chiariotti, L; Clemente, O; De Chiara, AR; Della Monica, R; Di Marzo, M; Di Mauro, A; Guida, M; Iervolino, D; Marretta, AL; Tafuto, S; Vincenzi, B, 2023) |
| "The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide." | 4.31 | [Regional variation in usage of TTF (Optune)]. ( Henriksson, R; Kinhult, S; Löfgren, D; Rosenlund, L; Sandström, M; Strandeus, M; Tavelin, B, 2023) |
| "Temozolomide (TMZ) is considered a first line chemotherapy drug for glioblastoma (GBM)." | 4.31 | Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma. ( Ji, N; Wang, J; Wang, N; Wang, P; Yue, S, 2023) |
| "The potential targets and mechanisms of quercetin in glioma treatment were predicted based on network pharmacology and molecular docking." | 4.31 | Quercetin induces MGMT ( Chen, J; Li, B; Mu, J; Wang, Q; Wang, W; Wu, X; Xu, L; Yin, Z; Yuan, X; Zeng, Z; Zhu, X; Zou, Y, 2023) |
| "In our study, we included 169 glioblastoma patients who were admitted to our clinic between 2009 and 2019 and received concurrent radiotherapy (RT) + temozolomide (TMZ) after surgery." | 4.31 | The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients. ( Bora, H; Demircan, NV; Erpolat, OP; Guzel, C; Karahacioglu, E; Senturk, E, 2023) |
| "To explore the role of forkhead box protein O1 (FOXO1) in the progression of glioblastoma multiforme (GBM) and related drug resistance, we deciphered the roles of FOXO1 and miR-506 in proliferation, apoptosis, migration, invasion, autophagy, and temozolomide (TMZ) sensitivity in the U251 cell line using in vitro and in vivo experiments." | 4.31 | FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1. ( Chen, C; Chen, J; Liu, Y; Shi, Y; Wang, H; Zhang, X, 2023) |
| "The cytotoxic effects of shikonin against murine glioblastoma cells, SB28 and CT-2A, were reported resistance to temozolomide, were evaluated using an allophycocyanin-conjugated annexin V and propidium iodide assay with flow cytometry." | 4.31 | Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance. ( Maeoka, R; Matsuda, R; Morimoto, T; Nakagawa, I; Nakase, H; Nakazawa, T; Nishimura, F; Ouji, Y; Park, YS; Yamada, S; Yokoyama, S; Yoshikawa, M, 2023) |
| "To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation." | 4.31 | Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma. ( Antonelli, M; Arcella, A; Bozzao, A; Capone, L; De Pietro, R; Esposito, V; Gianno, F; Giraffa, M; Lanzetta, G; Minniti, G; Paolini, S; Romano, A; Tini, P, 2023) |
| "In our previous study, we found for the first time that temozolomide (TMZ), the first-line chemotherapeutic agent for glioblastoma (GBM), can generate a large amount of reactive oxygen species (ROS) under ultrasound irradiation." | 4.31 | Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. ( Jiao, J; Tong, X; Wen, B; Wu, Q; Xu, L; Yan, H; Yang, R; Zhou, Y, 2023) |
| "In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma." | 4.31 | Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. ( Duffy, C; Galldiks, N; Glas, M; Goldbrunner, R; Grauer, O; Hattingen, E; Hau, P; Herrlinger, U; Krex, D; Nitsch, L; Paech, D; Potthoff, AL; Radbruch, A; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Weller, J; Zeiner, PS; Zeyen, T, 2023) |
| "Temozolomide (TMZ) is a commonly used chemotherapeutic agent for glioblastoma (GBM), but acquired drug resistance prevents its therapeutic efficacy." | 4.31 | NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2. ( Huang, H; Liu, P; Xie, Y; Zhang, Y, 2023) |
| "To investigate the effect of Temozolomide combined with intensity modulated radiation therapy on serum factor, immune function and clinical efficacy in postoperative glioma patients." | 4.31 | Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients. ( Fan, R; Liu, J; Liu, Z; Yuan, J, 2023) |
| "Altogether, our results indicate that using nanoemulsion containing temozolomide in combination with ferrocene is an effective approach to improve glioblastoma therapy outcomes." | 4.31 | Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models. ( Bernardes Ferro, M; da Rosa, RG; da Silva, LF; de Oliveira, JVR; de Souza, BM; Henn, JG; Lopes Alves, GA; Morás, AM; Moura, DJ; Nugent, M; Pires Peña, F; Rapack Jacinto Silva, V; Silva Pinheiro, AC; Silveira Aguirre, TA; Steffens Reinhardt, L, 2023) |
| "Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) patients has been limited by resistance in the clinic." | 4.31 | Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. ( Huang, G; Li, Z; Qi, S; Qu, S; Wang, K; Ye, R; Yi, GZ; Zhang, H; Zhang, W; Zhu, T, 2023) |
| "To explore the mechanism through which curcumol reverses primary drug resistance in glioma cells." | 4.31 | [Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis]. ( Qian, Y; Sun, J; Tan, R; Tian, N; Xing, J, 2023) |
| "The therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) include chemotherapy with cyclophosphamide/vincristine/dacarbazine (CVD), temozolomide monotherapy, radionuclide therapies, and tyrosine kinase inhibitors such as sunitinib." | 4.31 | Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. ( Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bornstein, SR; Dischinger, U; Fischer, A; Fliedner, SMJ; Grossman, AB; Hantel, C; Kloos, S; Kroiss, M; Maurer, J; Mohr, H; Nölting, S; Pacak, K; Pamporaki, C; Pellegata, NS; Reincke, M; Remde, H; Reul, A; Robledo, M; Timmers, HJLM; Wang, K, 2023) |
| "Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma." | 4.31 | Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. ( Arijs, I; Beerens, C; Biswas, A; Byrne, AT; Chien, MP; Connor, K; Dilcan, G; Fabro, F; Feller, KJ; Idbaih, A; Kers, TV; Kremer, A; Lambrechts, D; Lamfers, MLM; Leenstra, S; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Tching Chi Yen, R; Verreault, M, 2023) |
| "Low-grade gliomas are primary brain tumors that arise from glial cells and are usually treated with temozolomide (TMZ) as a chemotherapeutic option." | 4.31 | Overcoming chemotherapy resistance in low-grade gliomas: A computational approach. ( Ayala-Hernández, LE; Bosque, JJ; Chulián, S; Delobel, T; García-Ferrer, M; Murek, M; Pérez-Beteta, J; Pérez-García, VM; Piñero, P; Schucht, P, 2023) |
| "In this study, to screen for candidate markers of temozolomide (TMZ) resistance in glioblastoma, we artificially established TMZ drug-resistant glioblastoma (GBM) cell lines, U251-TMZ and U87-TMZ." | 4.31 | Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics. ( Bian, L; Li, D; Li, K; Lin, B; Liu, X; Xi, Z; Yan, J; Yang, Q, 2023) |
| "Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TMZ)." | 4.12 | Hematological adverse events in the management of glioblastoma. ( Butts, AR; Garcia, CR; Jayswal, R; Morgan, RM; Myint, ZW; Villano, JL; Wang, C; Weiss, HL, 2022) |
| "Survival of patients with glioblastoma (GBM) increased in the 2000s, most prominently after the addition of temozolomide to the standard-of-care treatment protocol." | 4.12 | Temporal Trends in Glioblastoma Survival: Progress then Plateau. ( Carabenciov, ID; Johnson, DR; Neth, BJ; Ruff, MW, 2022) |
| "The standard treatment of glioblastoma patients consists of surgery followed by normofractionated radiotherapy (NFRT) with concomitant and adjuvant temozolomide chemotherapy." | 4.12 | Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. ( Ehret, F; Grosu, AL; Kaul, D; Klement, RJ; Lewitzki, V; Polat, B; Popp, I; Sweeney, RA, 2022) |
| " With novel strategies focused on targeting hypoxia-inducible factor (HIF) regulatory pathways, recent evidence has shown that Acriflavine (ACF) can effectively target glioma invasiveness and recurrence." | 4.12 | Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model. ( Alomari, S; Brem, H; Cecia, A; Darjee, N; Domb, AJ; Gorelick, NL; Mangraviti, A; Rottenberg, Y; Serra, R; Shapira-Furman, T; Tyler, B, 2022) |
| "Resistance to temozolomide (TMZ) chemotherapy is the main reason for treatment failure in patients with glioblastoma (GBM)." | 4.12 | Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. ( Dong, Q; Duan, L; Li, L; Li, Q; Liu, Y; Pan, Y; Wang, D; Wang, J; Wang, X; Yin, H; Yuan, G, 2022) |
| "The standard of care for elderly glioblastoma patients is 40 Gy in 15 fraction radiotherapy with temozolomide (TMZ)." | 4.12 | Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. ( Ammirati, M; Arnett, A; Beyer, S; Blakaj, DM; Brown, PD; Chakravarti, A; Elder, JB; Giglio, P; Gondi, V; Goranovich, J; Grecula, J; Hardesty, D; Klamer, B; Lonser, R; Matsui, J; Ong, S; Palmer, JD; Perlow, HK; Pillainayagam, C; Raval, RR; Yaney, A; Yang, M, 2022) |
| "Patients with glioblastoma (GBM) are treated with radiotherapy (RT) and temozolomide (TMZ)." | 4.12 | Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. ( Campian, JL; Chheda, MG; Ferrando-Martinez, S; Ghosh, S; Hallahan, D; Hu, T; Jash, A; Kapoor, V; Lee, BH; Mahadevan, A; Page, L; Rifai, K; Thotala, D; Thotala, S; Wolfarth, AA; Yan, R; Yang, SH, 2022) |
| "Nearly 10% of patients with adult diffuse glioma develop clinically significant myelotoxicity while on temozolomide (TMZ) leading to treatment interruptions." | 4.12 | Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. ( Chatterjee, A; Dasgupta, A; Epari, S; Gupta, T; Kota, PK; Kowtal, P; Moitra, P; Patil, V; Sarin, R, 2022) |
| "We report a case of oligodendroglioma that had consistent histopathological features as well as a distinct change in 1p/19q status in the second recurrence, after temozolomide chemotherapy and radiotherapy." | 4.12 | Recurrent oligodendroglioma with changed 1p/19q status. ( Barresi, V; Calicchia, M; Ghimenton, C; Mafficini, A; Musumeci, A; Piredda, ML; Scarpa, A, 2022) |
| " The present study was designed to investigate the role of hsa_circ_0072309 in autophagy and temozolomide (TMZ) sensitivity in glioblastoma (GBM)." | 4.12 | Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma. ( Chen, Q; Deng, G; Liu, B; Sun, Q; Xu, Y; Xu, Z; Ye, L; Yuan, F; Zhang, S, 2022) |
| "It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms." | 4.12 | The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. ( Alonso, MM; Balnytė, I; Damanskienė, E; Preikšaitis, A; Stakišaitis, D; Valančiūtė, A, 2022) |
| "A broad panel of primary and temozolomide (TMZ)-resistant human glioma cell lines were screened by cell viability assays, flow cytometry, and crystal violet assays to investigate the therapeutic efficacy of Gamitrinib." | 4.12 | Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. ( Abdullah, K; Ashley, DM; Bowie, M; Chen, Y; Deek, RA; Du, K; Flaherty, KT; Hariharan, S; Herlyn, M; Keir, ST; Khasraw, M; Ku, Y; Labrie, M; Li, S; Lin, X; Liu, H; Liu, L; Lu, Y; Mills, GB; Savani, MR; Sugarman, ET; Tian, M; Waitkus, M; Wei, S; Wei, Z; Wu, D; Wu, K; Yin, D; Yu, S; Zhang, G, 2022) |
| "Temozolomide (TMZ) is a standard-of-care chemotherapeutic drug for the treatment of glioblastoma (GBM), but TMZ-acquired resistance limits its therapeutic effect." | 4.12 | Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. ( Chu, L; Liu, X; Sha, C; Sun, K; Sun, Y; Wang, A; Wang, S; Xu, L; Yang, X; Yu, Y; Zhou, L, 2022) |
| "Temozolomide (TMZ) monotherapy is known to be insufficient for resistant/relapsed glioblastoma (GBM), thus seeking a sensitization agent for TMZ is necessary." | 4.12 | Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. ( Ali, AAA; Chiang, IT; Chou, SY; Hsu, FT; Hsu, TI; Liu, HS; Liu, YC, 2022) |
| "This retrospective study enrolled 65 patients with IDH wild-type recurrent glioblastoma who received standard therapy and then received either bevacizumab (46 patients) or temozolomide (19 patients) as a secondary treatment." | 4.12 | Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. ( Kim, HS; Kim, JH; Kim, YH; Moon, HH; Park, JE, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for the treatment of glioma." | 4.12 | The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis. ( Duan, S; Gong, F; Li, Q; Wei, Y, 2022) |
| "Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma." | 4.12 | Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. ( Chinot, O; Gorlia, T; Le Rhun, E; Nabors, B; Oppong, FB; Preusser, M; Stupp, R; Vanlancker, M; Weller, M; Wick, W, 2022) |
| "We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy in 492 patients with glioma." | 4.12 | Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. ( Filipski, K; Filmann, N; Fokas, E; Forster, MT; Harter, PN; Herrlinger, U; Ronellenfitsch, MW; Steinbach, JP; Voss, M; Zeiner, PS, 2022) |
| " Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitable." | 4.12 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| " We herein investigate the therapeutic potential of bioinformatically identified HOTAIR transferred by serum-derived EVs (serum-EVs) in temozolomide (TMZ) resistance of glioblastoma (GBM) and the downstream mechanisms." | 4.12 | Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism. ( Han, J; Wang, S; Wang, X; Wang, Y; Wei, K; Xu, H; Yu, X, 2022) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 4.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| "Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear." | 4.12 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. ( Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY, 2022) |
| "We sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG)." | 4.12 | Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. ( Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Chen, Y; Hogan, T; Kissel, C; Lapin, B; Mohammadi, A; Murphy, ES; Naugle, R; Park, DY; Parsons, MW; Peereboom, DM; Schuermeyer, I; Stevens, GHJ; Suh, JH; Tewari, S; Tom, MC; Yu, JS, 2022) |
| "Temozolomide (TMZ) is generally applied for glioma treatment, while drug resistance of TMZ limits its therapeutic efficacy." | 4.12 | Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway. ( Fei, YQ; Shi, RT; Song, Z; Wu, JZ; Zhou, YF, 2022) |
| "The standard treatment for glioblastoma is maximal surgical resection followed by postoperative temozolomide administration combined with radiation therapy." | 4.12 | [Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities]. ( Imai, R; Sasaki, H, 2022) |
| "To study the relationship between temozolomide (TMZ) chemotherapy-resistant cells and stem cells in gliomas." | 4.12 | Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas. ( Cunzu, W; Dingchao, X; Min, X; Xun, Z, 2022) |
| " However, the role of lncRNAs in temozolomide (TMZ) resistance in glioblastoma multiforme (GBM) remains largely undefined." | 4.12 | lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma. ( Guo, H; He, Z; Lenahan, C; Liu, B; Tang, W; Wang, C; Xu, N; Zeng, H; Zhou, J, 2022) |
| "To investigate the function of primary cilia in regulating the cellular response to temozolomide (TMZ) and ionizing radiation (IR) in glioblastoma (GBM)." | 4.12 | Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells. ( Cai, H; Gao, L; He, JP; Ma, W; Peng, SP; Tian, HB; Wang, JF; Wei, L, 2022) |
| "Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)." | 4.12 | Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022) |
| "Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ." | 4.12 | SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy. ( Han, L; Hu, L; Yang, F; Yu, J; Zhao, M; Zhou, H, 2022) |
| "Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005." | 4.12 | Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas. ( Alamillo-Ferrer, C; Cheng, SY; Drewry, DH; Erdogdu, B; Goenka, A; Goldlust, SA; Haddad, BR; Hogg, JR; Hu, B; Jin, L; Pertea, M; Pickett, JE; Razaghi, R; Riggins, RB; Sadowski, N; Song, X; Tiek, DM; Timp, W; Wells, CI; Zuercher, WJ, 2022) |
| "Temozolomide (TMZ) is the first-line drug for the clinical treatment of glioblastoma (GBM), but drug resistance limits its treatment benefits." | 4.12 | Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. ( Yun, K; Zhao, W, 2022) |
| "The mechanism by which glioblastoma evades temozolomide (TMZ)-induced cytotoxicity is largely unknown." | 4.12 | SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma. ( Chang, KY; Chen, PY; Chen, SH; Cheng, SM; Chi, PI; Chien, CH; Chu, JM; Chuang, JY; Huang, CY; Hwang, DY; Lai, CC; Lee, JS; Liao, WA; Liu, CC; Wu, AC; Yang, ST; Yang, WB, 2022) |
| "Resistance to temozolomide (TMZ) is a major obstacle to preventing glioblastoma (GBM) recurrence after surgery." | 4.12 | PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. ( Deng, L; Fan, Y; Gao, Z; Guo, X; Li, G; Qi, Y; Sun, C; Wang, S; Xu, J; Xue, H; Zhang, P; Zhao, R; Zhao, S, 2022) |
| "Temozolomide (TMZ) resistance remains the main therapy challenge in patients with glioblastoma multiforme (GBM)." | 4.12 | TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. ( Gao, G; Wang, Y; Wei, X; Yu, J, 2022) |
| "We included 41 patients with isocitrate dehydrogenase 1/2-wildtype glioblastoma, who received 12 or more cycles of temozolomide therapy between June 2006 and December 2019." | 4.12 | Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. ( Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S, 2022) |
| " Optical microscopy and flow cytometry were employed to assess the differences in glioblastoma cells morphology, proliferation, and cytotoxicity of anticancer drug temozolomide (TMZ) due to increased substrate viscosity." | 4.12 | Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. ( Bucki, R; Cieśluk, M; Kochanowicz, J; Kułakowska, A; Piktel, E; Pogoda, K; Skłodowski, K; Wnorowska, U, 2022) |
| " Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence." | 4.12 | Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. ( Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN, 2022) |
| "Our previous researches showed that essential oil (EO) of chuanxiong could promote temozolomide (TMZ) entry into glioma cells in vitro and enhance TMZ-induced anticancer efficiency in vivo, and therefore, the aim of this study was to investigate whether EO could increase the concentration accumulation of TMZ in brain or tumor of C6 glioma rats and the related mechanisms." | 4.12 | Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor. ( Hu, PY; Liu, SS; Liu, XJ; Shuai, SY; Yang, M; Yue, PF; Zhang, GS; Zheng, Q, 2022) |
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 4.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "The complex of formononetin and calycosin (FMN/CAL) shows a synergistic effect on temozolomide in the treatment of malignant glioma, however the mechanism is unclear." | 4.12 | The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology. ( Fan, H; Fan, Y; Huang, T; Li, J; Li, S; Qiu, R; Zhang, Q; Zhou, Y, 2022) |
| "A MEX3A/CCR4-NOT/MSH2 axis plays a crucial role in promoting temozolomide resistance, providing new insights into the function of MEX3A and suggesting MEX3A as a potential therapeutic target in therapy-resistant glioblastoma." | 4.12 | MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. ( Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S, 2022) |
| "The role of temozolomide chemotherapy alone in isocitrate dehydrogenase (IDH)-mutant astrocytomas has not been conclusively determined." | 4.12 | Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3. ( Becker, H; Blobner, J; Egensperger, R; Katzendobler, S; Niyazi, M; Quach, S; Suchorska, B; Thiele, F; Thon, N; Tonn, JC; Weller, J; Weller, M, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 4.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| "Temozolomide (TMZ) resistance limits its use in glioblastoma (GBM)." | 4.12 | Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma. ( Leng, H; Li, X; Wang, N; Xu, L; Yuan, H, 2022) |
| "Brain radiotherapy combined with concomitant and six cycles of adjuvant temozolomide (TMZ) is the standard treatment for newly diagnosed high-grade gliomas (HGGs)." | 4.12 | Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. ( Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F, 2022) |
| "Although temozolomide is the primary chemotherapeutic agent in glioblastoma, current studies have focused on its combinational applications to overcome resistance by targeting multiple pathways." | 4.12 | Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. ( Biray Avci, C; Goker Bagca, B; Ozates, NP, 2022) |
| "It has been noted that temozolomide resistance occurs in a number of malignancies, including glioma, although the underlying cause of this is unknown." | 4.12 | CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study. ( Bai, S; Chen, H; Fan, LL; Hu, Y; Luo, GQ; Yan, ZJ, 2022) |
| " The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment." | 4.12 | TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. ( Amantini, C; Maggi, F; Morelli, MB; Nabissi, M; Pallini, R; Ricci-Vitiani, L; Santoni, G, 2022) |
| "It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion." | 4.12 | Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| "Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)." | 4.12 | Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022) |
| " Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)." | 4.12 | Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022) |
| "Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor." | 4.02 | AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 4.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "Despite the development of new treatment protocols for glioblastoma (GBM), temozolomide (TMZ) resistance remains a primary hindrance." | 4.02 | Interplay of m ( Chen, S; Gao, Z; Li, F; Li, Y; Liu, Q; Long, T; Long, W; Pan, Y; Qin, C; Sun, Z; Yi, Y; Yu, J; Zhang, C; Zhao, W, 2021) |
| " To validate this approach, we determined ex vivo response to temozolomide in a retrospective cohort of 69 glioblastoma patient-derived neurosphere models with matched patient survival and genomics." | 4.02 | Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. ( Chow, KH; Geduldig, J; Kim, AS; Ligon, KL; Malinowski, S; Manalis, SR; Mirza, M; Stockslager, MA; Touat, M; Wen, PY; Yoon, JC, 2021) |
| " Here, we show that NSUN6 methylates both large and small RNA in glioblastoma and controls glioblastoma response to temozolomide with or without influence of the MGMT promoter status, with high NSUN6 expression conferring survival benefit to glioblastoma patients and in other cancers." | 4.02 | NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. ( Awah, CU; Mazdoom, CM; Ogunwobi, OO; Winter, J, 2021) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 4.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ)." | 4.02 | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. ( Bartsch, JW; Culmsee, C; Elsässer, K; Nimsky, C; Pagenstecher, A; Schäfer, A; Zhang, Z; Zhao, K; Zhong, L, 2021) |
| "To explore whether or not aberrant expression of miR-29b in glioblastoma multiforme (GBM) cells was associated with temozolomide (TMZ) resistance and to elucidate potential underlying mechanisms." | 4.02 | Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy. ( Luan, XP; Xu, JX; Yang, Y; Zhang, X, 2021) |
| "Temozolomide (TMZ) is widely used for glioma therapy in the clinic." | 4.02 | LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma. ( He, X; Liu, Q; Sheng, J; Wang, K; Yu, W; Zhu, S, 2021) |
| "The study includes 132 IDH-wildtype glioblastoma patients treated between 2013 and 2017 with open resection followed by radiotherapy with concomitant and maintenance temozolomide." | 4.02 | Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. ( Berger, K; Budach, W; Felsberg, J; Hänggi, D; Haussmann, J; Kamp, MA; Knipps, J; Malzkorn, B; Mijderwijk, HJ; Rapp, M; Reifenberger, G; Sabel, M; Steiger, HJ; Turowski, B, 2021) |
| "We report a case of acute interstitial nephritis with associated nephrogenic diabetes insipidus in a patient treated with temozolomide and sulfamethoxazole-trimethoprim for glioblastoma multiforme." | 4.02 | Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. ( Athavale, A; Gallagher, M; Jardine, M; Morris, J; Ritchie, A; Sen, S; Wang, AY, 2021) |
| " Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers." | 4.02 | Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021) |
| "Temozolomide (TMZ) is the major chemotherapy agent in glioma, and isocitrate dehydrogenase (IDH) is a well-known prognostic marker in glioma." | 4.02 | Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas. ( Chen, W; Jing, J; Li, R; Mao, P; Sun, Q; Wang, J; Wang, M; Yu, X, 2021) |
| "The purpose of this study is to clarify the clinical features of temozolomide (TMZ)-related hepatitis B virus (HBV) reactivation and to identify HBV reactivation predictive factors." | 4.02 | Hepatitis B virus reactivation during temozolomide administration for malignant glioma. ( Chonan, M; Inoue, J; Kanamori, M; Masamune, A; Osada, Y; Saito, R; Shimoda, Y; Shoji, T; Tominaga, T; Uenohara, H, 2021) |
| "8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide." | 4.02 | Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. ( Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021) |
| "EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment." | 4.02 | Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. ( Baumert, BG; Ben Hassel, M; Bromberg, JC; Drijver, AJ; Eekers, DBP; Freixa, SV; Golfinopoulos, V; Gorlia, T; Hoang-Xuan, K; Hottinger, AF; Klein, M; Lucas, A; Reijneveld, JC; Stupp, R; Taphoorn, MJB; Tzuk-Shina, T; van den Bent, MJ; Vauleon, E, 2021) |
| "Using data from the German multi-center E-HIT-REZ-2005 study, we examined the role of local therapy and the efficacy of chemotherapy with blockwise temozolomide (TMZ) in children and adolescents with recurrent ependymomas." | 4.02 | Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. ( Adolph, JE; Bison, B; Bode, U; Faldum, A; Fleischhack, G; Frühwald, MC; Kortmann, RD; Krauß, J; Kwiecien, R; Mikasch, R; Mynarek, M; Obrecht, D; Pajtler, KW; Pfister, SM; Pietsch, T; Rutkowski, S; Schüller, U; Timmermann, B; Tippelt, S; von Hoff, K; Warmuth-Metz, M; Witt, H; Witt, O; Zeller, J, 2021) |
| "Limited therapeutic efficacy of temozolomide (TMZ) against glioblastomas highlights the importance of exploring new drugs for clinical therapy." | 4.02 | Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling. ( Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, YT; Shih, CM, 2021) |
| "Temozolomide (TMZ) is a first-line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge." | 4.02 | Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. ( Hu, YH; Jiao, BH; Wang, CY; Wu, JL, 2021) |
| " Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality." | 4.02 | Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ( Abbaszade, Z; Avci, CB; Bagca, BG, 2021) |
| " The chemotherapy drug temozolomide (TMZ), embedded in nanobubbles (NBs) and combined with persistent luminescent nanoparticles (PLNs), has been used to treat glioblastoma (GBM) effectively through image tracking." | 4.02 | Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites. ( Chan, MH; Cheng, CL; Feng, SJ; Hsiao, M; Liu, RS, 2021) |
| " Treatment of patients suffering from relapsed/refractory glioblastoma (GBM) with a combination of depatux-m and temozolomide (TMZ) tended to increase overall survival." | 4.02 | Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. ( Alvey, C; Anderson, M; Ansell, P; Boghaert, ER; Falls, HD; Mishra, S; Mitten, MJ; Oleksijew, A; Palma, J; Phillips, AC; Reilly, EB; Vaidya, KS; Zelaya-Lazo, AL, 2021) |
| "IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear." | 4.02 | Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021) |
| "Temozolomide (TMZ), an alkylating agent with a broad-spectrum antitumor activity, ability to cross blood-brain barrier (BBB), shown to be effective against malignant glioma." | 4.02 | Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. ( Baburaj, G; Jose, A; Kumar, JP; Munisamy, M; Munisamy, S; Subbiah, V; Thomas, L, 2021) |
| "Previous studies showed that the chemotherapeutic effect of temozolomide (TMZ) and vincristine (VCR) against glioma might be blunted by the co-culture with astrocytes, and connexin-43 (CX43) was thought to play a vital role in the communication between glioma cells and astrocytes." | 4.02 | AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes. ( Fan, T; Fu, X; Gong, Y; Huang, Y; Li, Z; Wang, H; Xiang, P; Zhang, S, 2021) |
| " However, whether glioma stem cells (GSCs) can be sensitized to chemotherapy via combined treatment with temozolomide (TMZ) and nicardipine is unclear." | 4.02 | Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. ( Dong, J; Dong, X; Jiang, Q; Li, H; Liu, L; Shi, J; Wang, H; Wang, L, 2021) |
| "To assess the recurrence interval and predictive significance of TP53 expression and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas treated with radiotherapy and combined chemotherapies, including temozolomide, lomustine, procarbazine and bevacizumab." | 4.02 | Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies. ( Alghamdi, B; Alkhayyat, S; Baeesa, S; Bardeesi, A; Bari, MO; Butt, NS; Dallol, A; Kurdi, M; Lary, AI; Maghrabi, Y; Mohamed, F; Saeedi, R; Samkari, A, 2021) |
| "Temozolomide (TMZ) is the internationally recognized and preferred drug for glioma chemotherapy treatment." | 4.02 | Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p. ( Chen, Z; Li, H; Li, Y; Liu, Q; Su, J; Wu, M; Zhang, C, 2021) |
| "In this retrospective analysis, only adult patients with supratentorial IDHwt glioblastoma were included who were treated with temozolomide-based chemoradiotherapy after surgery." | 4.02 | Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma. ( Boterberg, T; Hallaert, G; Kalala, JP; Pinson, H; Sweldens, C; Van den Broecke, C; Van Roost, D, 2021) |
| "The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM)." | 4.02 | CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. ( Arina, A; Bernal, GM; Cahill, KE; Campbell, PS; Crawley, CD; Mansour, N; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B, 2021) |
| "Glioblastoma is the most common malignant brain tumor, currently treated by surgery followed by concomitant radiotherapy and temozolomide-based chemotherapy." | 4.02 | Adjuvant therapeutic potential of moderate hypothermia for glioblastoma. ( Chabardès, S; Fulbert, C; Ratel, D, 2021) |
| " The present study evaluates the effects of AT101, alone or in combination with temozolomide (TMZ), in a microenvironmental glioma stem cell niche model of two GBM cell lines (U251MG and U87MG)." | 4.02 | Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche. ( Caylioglu, D; Held-Feindt, J; Hellmold, D; Kubelt, C; Meyer, RJ; Synowitz, M, 2021) |
| " Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (protein kinase CK2 inhibitor) outperformed single treatments, provided an immune-friendly schedule was followed." | 4.02 | Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells. ( Arús, C; Candiota, AP; Martínez-Escardó, L; Villamañan, L; Yuste, VJ, 2021) |
| "Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation." | 4.02 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. ( Berger, MS; Butowski, N; Chang, SM; Choi, S; Clarke, JL; Costello, JF; Grimmer, MR; Haas-Kogan, D; Hilz, S; Hong, C; Mazor, T; McDermott, M; Molinaro, AM; Oberheim Bush, NA; Phillips, JJ; Shai, A; Solomon, DA; Taylor, JW; Villanueva-Meyer, J; Wahl, M; Wainer, BH; Yu, Y, 2021) |
| " However, the alterations in gut microbiota observed during glioma growth and temozolomide (TMZ) therapy remain poorly understood." | 4.02 | Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma. ( Jiang, Y; Jin, XQ; Li, J; Li, XC; Li, YR; Li, ZQ; Ma, C; Wang, ZF; Wu, BS; Yao, J, 2021) |
| "Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy." | 4.02 | PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. ( Egensperger, R; Karschnia, P; Katzendobler, S; Lietke, S; Suchorska, B; Thon, N; Tonn, JC; Weller, J; Weller, M, 2021) |
| "Our data revealed (i) a clinical association of the EMT-like process with glioma malignancy and a poor survival and (ii) an anticancer and temozolomide sensitizing effect of rabeprazole by repressing EMT." | 4.02 | Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. ( Babu, D; Mudiraj, A; Panigrahi, M; Prakash Babu, P; Y B V K, C; Yadav, N, 2021) |
| "Temozolomide (TMZ) resistance limits its application in glioma." | 4.02 | Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. ( Bu, X; Chen, X; Ding, C; Gu, J; Kang, D; Lin, Y; Lin, Z; Sun, Y; Wu, X; Wu, Z; Yi, X; You, H; Zhang, G, 2021) |
| " This study investigated whether the improved oxygenation and perfusion that has been previously observed with RRx-001 both preclinically and clinically in the context of a brain metastasis trial was correlated with increased penetration and accumulation of the cytotoxic chemotherapies, irinotecan and temozolomide, in orthotopically implanted gliomas, priming tumours for improved response." | 4.02 | Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. ( Cabrales, P; Oronsky, B; Reid, T, 2021) |
| "Temozolomide (TMZ) resistance is the main challenge in the management of glioma patients." | 4.02 | Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. ( Cao, L; Chen, Z; Jiang, Z; Li, W; Li, X; Si, J, 2021) |
| "Glioma stem cells (GSCs) are tumour initiating cells which contribute to treatment resistance, temozolomide (TMZ) chemotherapy and radiotherapy, in glioblastoma (GBM), the most aggressive adult brain tumour." | 4.02 | Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM. ( Düssmann, H; Juric, V; Lamfers, MLM; Murphy, BM; Prehn, JHM; Rehm, M, 2021) |
| " The nanoantidote, consisting of a dendrimer core wrapped by reductive cysteine, captures Temozolomide (TMZ, the glioblastoma standard chemotherapy)." | 4.02 | A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. ( Guan, J; Tian, M; Xing, R; Yang, B; Yang, J; Zhan, C; Zhang, S; Zhao, X, 2021) |
| "Glioblastoma (GBM) is a malignant brain tumor with a poor long-term prognosis due to recurrence from highly resistant GBM cancer stem cells (CSCs), for which the current standard of treatment with temozolomide (TMZ) alone will unlikely produce a viable cure." | 4.02 | Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. ( Ayyagari, P; Das, SK; Pollok, KE; Shannon, HE; Smiley, SB; Vannier, MW; Veronesi, MC; Yun, Y, 2021) |
| "To clarify whether differential compartmentalization of Survivin impacts temozolomide (TMZ)-triggered end points, we established a well-defined glioblastoma cell model in vitro (LN229 and A172) and in vivo, distinguishing between its nuclear and cytoplasmic localization." | 4.02 | Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. ( Baymaz, HI; Beli, P; Christmann, M; Mühlhäusler, F; Nikolova, T; Poplawski, A; Reich, TR; Schwarzenbach, C; Tomicic, MT; Unger, S; Vilar, JB, 2021) |
| "Retrospective data from IDH-wildtype glioblastoma preclinical experiments evaluating a uniform regimen of fractionated radiation (RT), temozolomide (TMZ) chemotherapy, and concurrent RT/TMZ across 27 PDX lines were used to evaluate experimental designs and empirically estimate statistical power for ANOVA and Cox regression." | 4.02 | Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines. ( Burgenske, DM; Decker, PA; Eckel-Passow, JE; Kitange, GJ; Kosel, ML; Oberg, AL; Sarkaria, JN, 2021) |
| "Glioblastoma multiforme (GBM) is the most fatal cancer among brain tumors, and the standard treatment of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ) chemotherapy." | 4.02 | 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma. ( Chen, GY; Hsu, SP; Hsu, TI; Hung, CY; Ko, CY; Liao, KH; Lin, HY, 2021) |
| "Following captopril treatment, MMP-2 protein expression and migratory capabilities of 9 L gliosarcoma cells were assessed in vitro via western blots and scratch wound assays, respectively." | 4.02 | Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. ( Brem, H; Casaos, J; Huq, S; Mangraviti, A; Paldor, I; Perdomo-Pantoja, A; Pinheiro, L; Tyler, B; Vigilar, V; Wang, Y; Witham, TF, 2021) |
| "To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)." | 4.02 | Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021) |
| "A maximal surgical resection followed by radiotherapy and chemotherapy with temozolomide (TMZ) as the representative agent is the standard therapy for gliomas." | 4.02 | The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ). ( Chen, Y; Jiang, W; Kuang, W; Liu, Z; Tian, Y, 2021) |
| "Apatinib and TMZ may represent an alternative treatment option for patients with recurrent high-gradeglioma, especially those with a low Karnofsky performance status." | 4.02 | Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. ( Feng, M; Gan, W; Huang, Y; Li, X; Liu, J; Shao, Y; Wang, X; Yao, H; Zhang, C; Zhou, Y, 2021) |
| "Intrinsic or acquired resistance to temozolomide (TMZ) is a frequent occurrence in patients with glioblastoma (GBM)." | 4.02 | Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. ( Li, T; Wang, B; Wang, J, 2021) |
| "To evaluate the predictive significance of the duration of temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) who were treated with bevacizumab (Beva) as second-line setting." | 4.02 | Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting? ( Besiroglu, M; Demir, T; Shbair, ATM; Topcu, A; Turk, HM; Yasin, AI, 2021) |
| " We investigated the effects of dopamine in combination with platinum on human glioblastoma U-251MG cells upon X-ray irradiation, comparing with L-DOPA, 2-phenylethylamine and temozolomide." | 4.02 | Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. ( Kato, S, 2021) |
| "Improving the chemotherapy resistance of temozolomide (TMZ) is of great significance in the treatment of glioblastoma multiforme (GBM)." | 4.02 | Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. ( Jiang, XB; Li, XD; Wang, MJ; Wang, X; Wu, YH; Zheng, JL, 2021) |
| "Glioblastoma (GBM) is one of the most aggressive primary brain tumors with frequent recurrences following the standard methods of treatment-temozolomide (TMZ), ionizing radiation and surgical resection." | 3.96 | TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway. ( Gonzalez-Buendia, E; Lesniak, MS; Mijanovic, O; Savchuk, S; Sonabend, A; Timashev, P; Ulasov, IV; Xiao, T, 2020) |
| "We identified patients newly diagnosed with glioblastoma who were treated with temozolomide-based chemoradiotherapy between 2006 and 2016 at three large-volume hospitals." | 3.96 | Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. ( Chang, JH; Chang, JS; Cho, J; Choe, G; Choi, SH; Hong, CK; Kang, SG; Kim, CY; Kim, E; Kim, EH; Kim, IA; Kim, IH; Kim, JH; Kim, JW; Kim, N; Kim, SH; Kim, TM; Kim, YJ; Lee, HS; Lee, ST; Park, CK; Park, SH; Suh, CO; Wee, CW; Yoon, HI, 2020) |
| "Standard treatment for glioblastoma (GBM) patients is surgery and radiochemotherapy (RCT) with temozolomide (TMZ)." | 3.96 | ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. ( Åkesson, L; Bratthäll, C; Broholm, H; Fomichov, V; Green, H; Grunnet, K; Hallbeck, M; Jakobsen, I; Malmström, A; Milos, P; Mudaisi, M; Papagiannopoulou, A; Poulsen, HS; Söderkvist, P; Stenmark-Askmalm, M; Strandeus, M; Łysiak, M, 2020) |
| "Temozolomide (TMZ) is one of the most common drugs selected for glioma chemotherapy, but the therapeutic effect of glioma treatment is usually limited due to its resistance." | 3.96 | LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis. ( Chen, M; Li, B; Song, J; Wang, F; Zhao, H, 2020) |
| " The impact of the chemotherapeutic temozolomide (TMZ) in combination with valproic acid (VPA) was tested in two pediatric glioblastoma-derived cell lines." | 3.96 | Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro. ( Gielen, G; Hüttelmaier, S; Klusmann, JH; Kramm, C; Kühnöl, CD; Pietsch, T; Pötschke, R, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 3.96 | Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma. ( Gao, Y; Guo, R; Li, H; Yang, B; Zhao, C, 2020) |
| "In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)." | 3.96 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020) |
| "In this study, we demonstrated that IKBKE enhances the resistance of glioblastoma cells to temozolomide (TMZ) by activating the AKT/NF-κB signaling pathway to upregulate the expression of the DNA repair enzyme o6-methylguanine-dna methyltransferase (MGMT)." | 3.96 | IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. ( Guo, C; Guo, G; Hong, R; Huang, Q; Liu, Y; Lu, J; Lu, Y; Nan, Y; Sun, Y; Xiong, J; Zhang, Z, 2020) |
| "This analysis aimed to investigate whether the long-term administration of temozolomide (TMZ) claimed a survival advantage for patients with glioblastoma in China." | 3.96 | Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. ( Li, X; Li, Z; Quan, R; Zhang, H, 2020) |
| "We evaluated clinical and survival data of glioblastoma patients who underwent treatment with bevacizumab after progression under temozolomide, at CHUSJ between 2010 and 2017." | 3.96 | Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients. ( Caeiro, C; Carvalho, B; Costa, A; Fernandes, AC; Linhares, P; Lopes, RG; Osório, L; Tavares, N; Vaz, R, 2020) |
| " Here, we detail anti-PD-L1 antibody effects on the tumor microenvironment, including Mϕ infiltration, using a temozolomide (TMZ)-treated glioma model." | 3.96 | Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell ( Akutsu, H; Ishikawa, E; Kohzuki, H; Matsuda, M; Matsumura, A; Miyazaki, T; Sakamoto, N; Sugii, N; Takano, S, 2020) |
| "Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma." | 3.96 | Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020) |
| "The isocitrate dehydrogenase (IDH) 1 wild-type glioblastoma (GBM) is a major population of GBM that should be of concern in terms of the efficacy of using Temozolomide (TMZ) in adjuvant treatment." | 3.96 | Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. ( Sangkhathat, S; Tunthanathip, T, 2020) |
| "This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma." | 3.96 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ( Bamberg, M; Bölting, H; Debus, J; Felsberg, J; Herrlinger, U; Hertler, C; Kessler, T; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Papsdorf, K; Platten, M; Reifenberger, G; Reuss, D; Sabel, M; Sahm, F; Steinbach, JP; Vesper, J; von Deimling, A; Weisang, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 3.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "Radiotherapy, surgery and the chemotherapeutic agent temozolomide (TMZ) are frontline treatments for glioblastoma multiforme (GBM)." | 3.96 | Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy. ( Ahmed, F; Angulo, MC; Baulch, JE; Dey, D; Goldman, J; Klein, PM; Limoli, CL; Merriott, D; Moayyad, J; Murry, A; Nguyen, B; Nguyen, QA; Parihar, VK; Piomelli, D; Soltesz, I; Szabo, GG; Tran, J, 2020) |
| "Emerging data suggest that a subset of patients with diffuse isocitrate dehydrogenase (IDH)-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors." | 3.96 | MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. ( Berger, MS; Bollam, S; Chang, SM; Clarke, J; Costello, JF; Grimmer, MR; Hong, C; Mathur, R; Molinaro, AM; Oberheim-Bush, NA; Petrecca, K; Phillips, JJ; Zhang, M; Zhang, Y, 2020) |
| " However, the standard chemotherapy drug for glioma, temozolomide (TMZ), cannot induce ICD as it cannot activate IFN-I signaling." | 3.96 | Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response. ( Cai, X; Cao, G; Du, B; Hu, J; Ke, C; Li, H; Li, L; Liu, X; Xin, X; Yin, P, 2020) |
| "Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults and Temozolomide (TMZ) is an effective chemotherapeutic agent for its treatment." | 3.96 | Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide. ( Ebrahimi Zade, A; Shahabi Haghighi, S; Soltani, M, 2020) |
| "Temozolomide (TMZ) resistance is a major cause of recurrence and poor prognosis in glioblastoma (GBM)." | 3.96 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. ( Chi, Y; Fu, Z; Guo, H; Huang, Q; Lian, C; Liao, C; Liu, B; Wang, C; Wei, Q; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2020) |
| "To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice." | 3.96 | New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221. ( Chen, H; Chen, Y; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Yang, Y; Zhan, W; Zhang, Z, 2020) |
| "Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months." | 3.96 | Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. ( Martuza, RL; Rabkin, SD; Saha, D, 2020) |
| " Here, diffusion MRI data were acquired in a GL261 glioma mouse model before and during treatment with Temozolomide." | 3.96 | Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. ( Agliardi, G; Alexander, DC; Atkinson, D; Brandner, S; Breen-Norris, JO; d'Esposito, A; Hipwell, B; Hyare, H; Ianus, A; Lythgoe, MF; Panagiotaki, E; Punwani, S; Ramasawmy, R; Rees, J; Roberts, TA; Siow, B; Taylor, V; Walker-Samuel, S, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 3.96 | MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. ( Guan, F; Guo, R; Li, H; Li, M; Liu, X; Ma, S; Wu, J; Yang, B; Zhao, C, 2020) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for chemo-radiotherapy of glioblastoma, which is also a target cancer for boron neutron capture therapy (BNCT)." | 3.96 | The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status. ( Ikawa, T; Kinashi, Y; Takahashi, S, 2020) |
| "To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide." | 3.96 | Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. ( Besen, AA; Kucuk, A; Mertsoylu, H; Ozdemir, Y; Pehlivan, B; Selek, U; Topkan, E, 2020) |
| "5, 1 g/kg) or temozolomide (10 mg/kg) treatment alone inhibited tumor growth in glioblastoma U87 and U251 xenografts." | 3.96 | Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. ( Fu, J; Kong, PS; Wang, J; Wang, X; Xu, HB; Xu, YQ; Zhu, SH, 2020) |
| "Temozolomide (TMZ) is a chemotherapeutic used for the treatment of glioblastoma." | 3.96 | A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status. ( Bello-Rivero, I; Leenstra, S; van der Kaaij, M; Vázquez-Blomquist, D; Villarreal, A, 2020) |
| "We designed a conjugated compound by coupling temozolomide (TMZ) with doxorubicin (DOX) via an acylhydrazone linkage as a potential prodrug used for glioblastoma multiforme (GBM) treatment." | 3.96 | Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy. ( Du, K; Feng, F; Heng, H; Xia, Q, 2020) |
| "Resistance of glioblastoma to the chemotherapeutic compound temozolomide is associated with the presence of glioblastoma stem cells in glioblastoma and is a key obstacle for the poor prognosis of glioblastoma." | 3.96 | Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity. ( Hwang, WC; Kang, DW; Min, DS; Noh, YN; Park, KS, 2020) |
| "Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas." | 3.96 | MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. ( Bao, Z; Galán-Ganga, M; Jiang, T; Kim, H; Kroon, P; Liu, H; Mu, Q; Nam, DH; Oldrini, B; Rabadan, R; Rodriguez-Perales, S; Sa, JK; Squatrito, M; Vaquero-Siguero, N; Verhaak, RGW; Wang, J; Wang, Z; Zhang, Y; Zhao, J, 2020) |
| "Temozolomide is the most effective chemotherapy for malignant glioma." | 3.96 | Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. ( Divekar, RD; Johnson, DR; Maddox, DE; Neth, BJ; Ruff, MW; Uhm, JH, 2020) |
| "Temozolomide (TMZ) therapy is the standard of care for patients with glioblastoma (GBM)." | 3.96 | Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. ( Alshareef, M; Cachia, D; Das, A; Infinger, LK; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK, 2020) |
| " Concurrent temozolomide (TMZ) radiation-the cornerstone of glioma control-extends the overall median survival of GB patients by only a few months over radiotherapy alone." | 3.96 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Duc, TC; Hartman, H; Hofman, FM; Huang, M; Minea, RO; Schönthal, AH; Swenson, SD, 2020) |
| " In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly‑ADP‑ribose polymerase inhibitor (PARPi) remain largely unidentified." | 3.96 | PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. ( Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ, 2020) |
| "Glioma is the most common primary malignant tumour in the brain; temozolomide (TMZ) is the most prevalent chemotherapeutic drug currently used to combat this cancer." | 3.96 | LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma. ( Li, Y; Liu, Q; Long, W; Pan, Y; Qin, C; Su, J; Wang, J; Wang, X; Wu, C; Xiao, K; Xiao, Q, 2020) |
| " The transfection efficiency was determined with flow cytometry, and the therapeutic efficacy of CD::UPRT::GFP expressing MSCs was evaluated in cocultures with temozolomide (TMZ)-sensitive or TMZ-resistant human glioblastoma cell lines." | 3.96 | A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth. ( Ho, YK; Ng, ZX; Teo, KJ; Too, HP; Tu, GXE; Yeo, TT, 2020) |
| "To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ)." | 3.96 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. ( Faustino, AC; Hamamura, AC; Viani, GA, 2020) |
| " In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG)." | 3.96 | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. ( Gjika, E; Keidar, M; Kirschner, ME; Lin, L; Pal-Ghosh, S; Sherman, JH; Stepp, MA, 2020) |
| "Glioma, especially glioblastoma (GBM), is the most aggressive malignant brain tumor and its standard therapy is often ineffective because of temozolomide (TMZ) resistance." | 3.96 | Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. ( Cai, HP; Chen, FR; Chen, ZP; Guo, CC; Ma, JX; Ni, XR; Wang, J; Wu, WC; Yu, YJ; Yu, ZH, 2020) |
| "Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival." | 3.96 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "Glioblastoma (GBM) is a malignant brain tumour with a dismal prognosis, despite best treatment by surgical resection, radiation therapy (RT) and chemotherapy with temozolomide (TMZ)." | 3.96 | Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies. ( Jue, TR; Lu, VM; McDonald, KL, 2020) |
| " This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma (n = 3) patients treated with concomitant temozolomide and radiotherapy (RT-TMZ), followed by a TMZ maintenance phase." | 3.96 | Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. ( Alexandru, C; Beaussire, L; Clatot, F; Di Fiore, F; Fontanilles, M; Hanzen, C; Jardin, F; Langlois, O; Laquerrière, A; Magne, N; Marguet, F; Pépin, LF; Sarafan-Vasseur, N; Tennevet, I, 2020) |
| "Objective To investigate the expression of cathepsin S (CTSS) in temozolomide-resistant glioblastoma T98G (T98G-R) cells." | 3.96 | [Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis]. ( Guo, Q; Jia, B; Liu, W; Lyu, W, 2020) |
| " However, the function of circ_0005198 in the temozolomide (TMZ) resistance of glioma has not been well elucidated." | 3.96 | Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis. ( Deng, Y; Liu, C; Meng, X; Xiao, L; Zhu, H, 2020) |
| " In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ)." | 3.96 | The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. ( Hirata, K; Houkin, K; Ishi, Y; Kobayashi, H; Motegi, H; Oda, Y; Okamoto, M; Tanaka, S; Terasaka, S; Yamaguchi, S, 2020) |
| " The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests)." | 3.96 | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. ( Dankó, T; Hujber, Z; Jeney, A; Krencz, I; Pápay, J; Petővári, G; Raffay, R; Rajnai, H; Sebestyén, A; Vetlényi, E, 2020) |
| "The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor." | 3.91 | Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. ( Bua, S; Kopecka, J; Mujumdar, P; Poulsen, SA; Riganti, C; Supuran, CT, 2019) |
| " We identified hybrid compounds 1d and 1e to be remarkably more potent against glioma and more efficient in decreasing invasive cell properties than temozolomide and endowed with chemical and plasma stability." | 3.91 | Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability. ( Braga, C; Brites, D; Matilde Marques, M; Moreira, R; Oliveira, MC; Perry, MJ; Vaz, AR, 2019) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent used against glioblastoma multiforme (GBM), but this disease exhibits recurrence and high lethality." | 3.91 | miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. ( Chen, KC; Chen, PH; Cheng, CH; Chou, CM; Ho, KH; Lin, CW; Liu, AJ; Shih, CM, 2019) |
| "Temozolomide is an alkylating agent used as the first line of treatment for glioblastoma." | 3.91 | Temozolomide has anti-tumor effects through the phosphorylation of cPLA ( Hara, H; Iwama, T; Nakamura, S; Noda, Y; Ohno, Y; Saio, M; Shimazawa, M; Tsuji, S; Yamada, T, 2019) |
| "Our study elucidated the role of oncogenic LINC01198 in glioma proliferation and temozolomide resistance, and this role may serve as a promising target for glioma therapy." | 3.91 | LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma. ( Chen, HJ; Chen, WL; Ge, JW; Hou, GQ; Zhang, XH, 2019) |
| " In this study, we investigate the underlying mechanism by which glioblastoma (GBM) cells acquire resistance to Temozolomide (TMZ) through Aurora kinase B (AURKB) thus to identify novel therapeutic targets and prognostic biomarkers for GBM." | 3.91 | Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. ( Alafate, W; Liu, C; Sun, L; Wang, J; Wang, M; Wu, W; Xie, W; Zuo, J, 2019) |
| " However, the role of circular RNA CEP128 in the resistance of glioma cells to temozolomide has not yet been characterized." | 3.91 | Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p. ( Feng, H; Hua, L; Huang, L; Shen, B; Zhang, X, 2019) |
| "To investigate the underlying mechanism by which glioblastoma (GBM) cells gain temozolomide (TMZ) resistance and to clarify novel therapeutic targets and new prognostic biomarkers for GBM." | 3.91 | Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. ( Li, R; Mao, P; Wahafu, A; Wang, J; Wang, M; Wu, W; Xie, W; Yu, X; Zuo, J, 2019) |
| "Current treatment of recurrent glioblastoma multiforme (GBM) demands dose-intense temozolomide (TMZ), a prodrug of 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC), based on the spontaneous hydrolysis of TMZ at basic pH." | 3.91 | Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme. ( Du, K; Feng, F; Li, X; Shao, F; Sun, J; Sun, Y, 2019) |
| "Drug resistance to temozolomide (TMZ) contributes to the majority of tumor recurrence and treatment failure in patients with glioblastoma multiforme (GBM)." | 3.91 | Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells. ( Cheng, SY; Kiang, KMY; Leung, GK; Li, N; Wong, VK; Zhang, P; Zhu, Z, 2019) |
| "The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (TMZ/Bev)." | 3.91 | Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. ( Ichimura, K; Igaki, H; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M, 2019) |
| "Temozolomide (TMZ) is the most commonly used chemotherapeutic agent used to treat glioblastoma (GBM), which causes significant DNA damage to highly proliferative cells." | 3.91 | Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. ( Harder, BG; Kitange, GJ; Loftus, JC; Peng, S; Sarkaria, JN; Sereduk, CP; Sodoma, AM; Tran, NL, 2019) |
| "In the management of patients with newly diagnosed glioblastoma, there is no standard duration for adjuvant temozolomide treatment." | 3.91 | Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. ( Hasegawa, Y; Hatano, K; Hirono, S; Iuchi, T; Sakaida, T; Uchino, Y, 2019) |
| "Bortezomib was found to inhibit glioma growth and improved TMZ chemotherapy efficacy, probably via down-regulating the FOXM1-Survivin axis." | 3.91 | Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. ( Chen, JX; Du, L; Huang, GH; Li, QR; Lv, SQ; Tang, JH; Xiang, Y; Xu, QF; Yang, L; Zhang, ZX; Zhou, Z; Zhu, LR, 2019) |
| "Current standard of treatment for newly diagnosed patients with glioblastoma (GBM) is surgical resection with adjuvant normofractionated radiotherapy (NFRT) combined with temozolomide (TMZ) chemotherapy." | 3.91 | Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. ( Flentje, M; Klement, RJ; Kosmala, R; Lewitzki, V; Lisowski, D; Polat, B, 2019) |
| "Temozolomide (TMZ) is known to induce thrombocytopenia but no early predictive test has yet been clearly established." | 3.91 | Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. ( Alexandru, C; Clatot, F; David, M; Di Fiore, F; Fontanilles, M; Gilard, V; Hanzen, C; Langlois, O; Laquerriere, A; Marguet, F; Tennevet, I; Veresezan, O, 2019) |
| "Oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic biomarker in astrocytomas, especially for temozolomide (TMZ) chemotherapy." | 3.91 | A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. ( Dong, D; Gu, D; Hao, X; Tan, Y; Tian, J; Wang, L; Wang, X; Wei, J; Yang, G; Zhang, H; Zhang, S, 2019) |
| "Glioblastoma multiforme (GBM) has a poor prognosis with an overall survival of 14-15 months after surgery, radiation and chemotherapy using temozolomide (TMZ)." | 3.91 | Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. ( Bjerkvig, R; Denisova, O; Grudic, A; Hasan-Olive, MM; Janji, B; Johannessen, TC; Latif, MA; Lund-Johansen, M; Nordal, A; Prestegarden, L; Røsland, GV; Saed, H; Simonsen, A; Sundstrøm, T; Tronstad, KJ; Varughese, JK; Wang, J; Westermarck, J; Yang, N; Zhu, H, 2019) |
| "The aromatase inhibitor, letrozole, is being investigated in experimental animal models as a novel treatment for high-grade gliomas (HGGs)." | 3.91 | Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ( Adams, CH; Arora, P; DasGupta, B; Desai, PB; Gudelsky, G, 2019) |
| " In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) improved progression free (PFS) and overall survival (OS) versus TMZ alone." | 3.91 | Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. ( Kim, CY; Nicholas, G; Ram, Z; Toms, SA, 2019) |
| "To describe oncological patterns of care, prognostic factors, and survival for all patients in France with newly-diagnosed and histologically confirmed glioblastoma, and evaluate the impact of extended temozolomide use at the population level." | 3.91 | Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. ( Amelot, A; Bauchet, F; Bauchet, L; Bessaoud, F; Charissoux, M; Darlix, A; Duffau, H; Fabbro, M; Fabbro-Peray, P; Figarella-Branger, D; Mandonnet, E; Mathieu-Daude, H; Pallud, J; Rigau, V; Riondel, A; Sorbets, E; Taillandier, L; Tretarre, B; Zouaoui, S, 2019) |
| "Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM)." | 3.91 | PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. ( Han, L; Huang, K; Liang, H; Liu, Y; Wang, G; Wang, Q; Wang, Z; Wei, C; Zhang, A; Zhang, W; Zhang, Z; Zhen, Y; Zhou, J, 2019) |
| "Chemotherapy is the main postsurgical and adjuvant therapy for glioma, and intrinsic or acquired temozolomide (TMZ) resistance may result in poor prognosis." | 3.91 | MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. ( Feng, B; Ren, H; Wang, J; Yu, J; Yuan, Z; Zhang, B; Zhang, X; Zhao, C; Zhuang, J, 2019) |
| "At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose." | 3.91 | Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report. ( Li, Y; Qie, S; Shi, HY; Yuan, L; Zhang, X, 2019) |
| "For our studies, we have particularly chosen C6 rat glioma cell line due to several reasons: i) We previously showed that MPA reduced growth and induced procarbazine-sensitization in C6 cells; ii) temozolomide has a triazene-type molecular structure like procarbazine; iii) other groups previously showed that C6 glioma cell line is more resistant to temozolomide than human glioma cells; hence it may provide a native model of chemoresistance." | 3.91 | Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature. ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Chemotherapy with temozolomide (TMZ) is the traditional treatment for glioblastoma (GBM)." | 3.91 | MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic agent for glioblastoma multiforme (GBM)." | 3.91 | Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| " Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy." | 3.91 | Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. ( Azari, H; Dastmalchi, F; Flores, C; Huang, J; Karachi, A; Long, Y; Mitchell, DA; Rahman, M; Sayour, EJ; Yang, C, 2019) |
| "Despite advances in cancer therapies, glioblastoma multiforme treatment remains inefficient due to the brain-blood barrier (BBB) inhibitory activity and to the low temozolomide (TMZ) chemotherapeutic selectivity." | 3.91 | Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. ( de Melo, MT; Paula, LB; Pellosi, DS; Tedesco, AC, 2019) |
| "Despite intensive treatments including temozolomide (TMZ) administration, glioblastoma patient prognosis remains dismal and innovative therapeutic strategies are urgently needed." | 3.91 | pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study. ( Ballesta, A; Stéphanou, A, 2019) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | 3.91 | Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "The aims of the present study were to compare the longitudinal changes of glioblastoma multiforme after radiotherapy (RT) between 11C-methionine positron emission tomography (MET-PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) and to clarify whether these changes were predictive of survival." | 3.91 | Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy. ( Asano, Y; Ikegame, Y; Iwama, T; Kawasaki, T; Miwa, K; Shinoda, J; Takei, H; Yano, H; Yokoyama, K, 2019) |
| "We identified DDIT4 as a cell-intrinsic regulator for adaptive responses and therapy resistance in glioblastoma cells which may interfere with cell death induction by temozolomide, radiotherapy or hypoxia by inhibiting mTORC1 activity." | 3.91 | The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. ( Foltyn, M; Harter, PN; Lorenz, NI; Luger, AL; Mittelbronn, M; Ronellenfitsch, MW; Sauer, B; Steinbach, JP, 2019) |
| "Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance to the standard chemotherapeutic agent, temozolomide (TMZ)." | 3.91 | Glioblastoma Recurrence and the Role of O ( Ahmed, AU; Foo, J; Hawkins-Daarud, A; Leder, K; Rockne, RC; Storey, K; Swanson, K, 2019) |
| "Together, our findings reveal the indispensable role of HERC3 in regulating canonical SMAD2/3-dependent TGFβ pathway involvement in autophagy-induced EMT, providing insights toward a better understanding of the mechanism of resistance to temozolomide and peripheral recurrence of glioblastoma." | 3.91 | HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma. ( Chen, L; Hu, Z; Huang, A; Li, H; Li, J; Lu, Y; Ma, L; Qi, S; Shi, L; Weng, Z; Xin, Z; Yu, S; Zhou, Q, 2019) |
| "When only treated with D,L-methadone, 1 µM of the opioid was sufficient to reduce viability of fibroblasts, whereas 10 µM was needed to significantly reduce glioblastoma cell viability." | 3.91 | D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. ( Baran-Schmidt, R; Dietterle, J; Gaunitz, F; Glasow, A; Matusova, M; Meixensberger, J; Neumann, K; Oppermann, H, 2019) |
| "Both of the temozolomide (TMZ)-resistant and CtIP deficient glioma cell lines were successfully generated." | 3.91 | CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells. ( Han, N; Jiang, H; Sun, J; Xu, HY; Yang, B, 2019) |
| "Although temozolomide (TMZ) resistance is a significant clinical problem in glioblastoma (GBM), its underlying molecular mechanisms are poorly understood." | 3.91 | Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. ( Shi, Z; Yan, W; Yin, J; You, Y; Zeng, A; Zhang, Z, 2019) |
| "Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer." | 3.91 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? ( He, Y; Kaina, B, 2019) |
| " In this preliminary study, the purpose was to evaluate the feasibility of APT imaging in monitoring the early therapeutic response to nitroxoline (NTX) in a temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) mouse model, which was compared with diffusion-weighted imaging (DWI)." | 3.91 | Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. ( Cho, HR; Choi, SH; Kumari, N; Thakur, N, 2019) |
| " Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses." | 3.91 | Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report. ( Bloch, O; Grimm, SA; Horbinski, CM; Kumthekar, PU; Lamano, JB; Quaggin-Smith, JA; Tate, MC, 2019) |
| "The acquired drug resistance has been regarded as a main barrier for the effective treatment of temozolomide (TMZ) in glioblastoma (GBM)." | 3.91 | miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. ( Li, X; Liu, X; Luo, W; Song, Z; Yan, D; Zhao, S; Zhu, X, 2019) |
| "The aim of this current work was to study the therapeutic enhancement of temozolomide (TMZ) on gliomavia combining with calycosin and FMN." | 3.91 | In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin. ( Fan, H; Fan, Y; Li, Y; Ni, Q; Zhang, X, 2019) |
| "Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, quetiapine, and sertraline) combined with temozolomide (TMZ)." | 3.91 | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. ( Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019) |
| " However, the mechanisms underlying lncRNA-mediated temozolomide (TMZ) resistance in glioblastoma (GBM) remain largely unknown." | 3.91 | Lnc-TALC promotes O ( Cai, J; Chen, Q; Duan, C; Han, B; Jiang, C; Kang, C; Li, Y; Li, Z; Lin, L; Meng, X; Wang, R; Wu, P, 2019) |
| "Temozolomide (TMZ) is widely used as a chemotherapeutic agent in the treatment of glioma; however, the development of drug resistance remains a major obstacle in the effective treatment of glioblastoma." | 3.91 | Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1. ( Chen, R; Tu, Y; Wang, C; Wang, L; Wang, S; Xiong, Y; Zhu, L, 2019) |
| "To identify novel epigenetic signatures that could provide predictive information that is complementary to promoter methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene for predicting temozolomide (TMZ) response, among glioblastomas (GBMs) without glioma-CpGs island methylator phenotype (G-CIMP) METHODS: Different cohorts of primary non-G-CIMP GBMs with genome-wide DNA methylation microarray data were included for discovery and validation of a multimarker signature, combined using a RISK score model." | 3.91 | Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. ( Aubry, M; Barnholtz-Sloan, J; Etcheverry, A; He, YL; Liu, BL; Liu, YH; Lu, ZF; Mosser, J; Yin, AA; Zhang, X, 2019) |
| "Gene signatures (GS) were developed from 31 orthotopic glioblastoma patient-derived xenografts (PDXs), treated with standard therapies, to predict benefit from radiotherapy (RT-GS), temozolomide (Chemo-GS), or the combination (ChemoRT-GS)." | 3.91 | Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. ( Carlson, BL; Chang, SL; Feng, FY; Kim, MM; Lawrence, TS; Mladek, AC; Sarkaria, JN; Speers, CW; Spratt, DE; Wahl, DR; Yu, M; Zhao, SG, 2019) |
| "Despite the increased understanding of the oncological mechanisms underlying Glioblastoma multiforme (GBM) pathophysiology, and recent advances in therapeutic strategies such as maximal surgical resection and post-operative radiotherapy with concomitant and adjuvant temozolomide chemotherapy, the prognosis for patients with brain tumors remains limited." | 3.91 | microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide. ( Carlotti, CG; de Assis Cirino, ML; Lizarte Neto, FS; Matias, CCMS; Pereira-da-Silva, G; Peria, FM; Rodrigues, AR; Tirapelli, DPDC; Trevisan, FA, 2019) |
| "We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model." | 3.91 | Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. ( Appelboom, G; Barbier, EL; Bräuer-Krisch, E; Chang, SD; Dufort, S; Le Duc, G; Lux, F; Roux, S; Sancey, L; Tillement, O; Verry, C; Zhang, M, 2019) |
| "The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment." | 3.91 | Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. ( Chen, Z; Deng, S; Guo, M; Huang, G; Lei, B; Li, Y; Li, Z; Liu, Y; Pan, J; Qi, S; Wang, H; Xiang, W; Yi, GZ; Yu, L; Zhang, X, 2019) |
| "This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time." | 3.88 | The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. ( Glumac, M; Jakimov, D; Kojic, V; Pejin, B; Tommonaro, G, 2018) |
| "Glioblastoma (GBM) is an aggressive brain tumor with temozolomide (TMZ)-based chemotherapy as the main therapeutic strategy." | 3.88 | Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells. ( Kipper, FC; Lenz, G; Lopez, PLDC; Silva, AO; Villodre, ES, 2018) |
| "We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation." | 3.88 | Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. ( Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G, 2018) |
| "Standard treatment for patients with primary glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 3.88 | Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. ( Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2018) |
| "Evaluate survival of patients diagnosed with glioblastoma multiforme (GBM) managed with adjuvant intensity modulated radiation therapy and temozolomide since the introduction of the European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada Clinical Trials Group (EORTC-NCIC) protocol." | 3.88 | Survival improvements with adjuvant therapy in patients with glioblastoma. ( Back, MF; Brazier, D; Cook, R; Guo, L; Jayamanne, D; Kastelan, M; Schembri, G; Teo, C; Wheeler, H, 2018) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 3.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| " By manipulation of Cx43 expression or gap junction function, we found that there were gap junction-dependent and independent effect of Cx43 on temozolomide (TMZ) sensitivity in U87 glioblastoma cells." | 3.88 | Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication. ( Huang, H; Ma, L; Peng, J; Peng, Y; Shao, M; Wang, L; Xia, Z; Zhong, G; Zhu, Z, 2018) |
| "Numerous studies suggested autophagy was involved in temozolomide (TMZ) resistance in glioma." | 3.88 | Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. ( Du, J; Fang, X; Huang, X; Jiang, C; Li, X; Liu, Z; Shen, F; Su, J; Wang, X, 2018) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 3.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo." | 3.88 | High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. ( Hong, YK; Lee, JE; Lim, JH; Yang, SH, 2018) |
| "The impact of DNA mismatch repair (MMR) on resistance to temozolomide (TMZ) therapy in patients with glioblastoma (GBM) is recently reported but the mechanisms are not understood." | 3.88 | Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. ( Dong, T; Dong, Y; Gao, Y; Gong, Y; Li, Q; Pei, C; Ren, H; Su, J; Sun, Q; Xiao, Y; Xing, W; Zhen, Z; Zhou, P, 2018) |
| "0 years) diagnosed with glioblastoma undergoing adjuvant photon (n = 47) or proton (n = 19) radiochemotherapy with temozolomide after tumor resection underwent T1-weighted and arterial spin labeling MRI." | 3.88 | Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. ( Asllani, I; Baumann, M; Beuthien-Baumann, B; Gommlich, A; Hofheinz, F; Jentsch, C; Krause, M; Krukowski, P; Maus, J; Mutsaerts, HJMM; Petr, J; Platzek, I; Seidlitz, A; Troost, EGC; van den Hoff, J; van Osch, MJP, 2018) |
| " However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival." | 3.88 | Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( Narita, Y, 2018) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 3.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 3.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "The incidence, risk factors, and outcomes of low-grade glioma patients who undergo malignant transformation (MT) in the era of temozolomide are not well known." | 3.88 | Risk Factors for Malignant Transformation of Low-Grade Glioma. ( Ahluwalia, MS; Barnett, GH; Chao, ST; Jia, X; Kotecha, R; Leyrer, CM; Murphy, ES; Parsons, M; Peereboom, DM; Prayson, RA; Stevens, GHJ; Suh, JH; Vogelbaum, MA; Yu, JS, 2018) |
| "We collected paraffin blocks from resection specimens from 114 glioblastoma patients who had received temozolomide treatment and radiotherapy." | 3.88 | Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients. ( Chen, YY; Ho, HL; Ho, TD; Hsu, CY; Lin, SC, 2018) |
| "A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG)." | 3.88 | Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). ( Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC, 2018) |
| " This phenomenon, which has deleterious outcomes for the patient, has long been observed in patients with glioblastoma receiving temozolomide (TMZ)-based radiochemotherapy." | 3.88 | Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray. ( Cui, Y; Feng, H; He, H; Li, J; Li, S; Lin, J; Qiu, G; Song, C; Wei, W; Wu, X; Xu, Q; Zuo, J, 2018) |
| "Previous studies showed Demethoxycurcumin (DMC) has stronger anti-glioma and anti-GSCs effects both in vitro and in vivo." | 3.88 | DMC is not better than TMZ on intracranial anti-glioma effects. ( Shi, L; Sun, G, 2018) |
| "Multi-institutional data from 159 patients with newly diagnosed glioblastoma who received adjuvant temozolomide concomitant chemoradiotherapy (CCRT) were collected." | 3.88 | A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. ( Chan, D; Chan, KY; Ho, J; Lam, S; Lee, M; Ma, E; Mak, C; Poon, WS; Wong, ST; Wong, WK; Woo, P, 2018) |
| "To evaluate the prognostic value of the Glasgow Prognostic Score (GPS), the combination of C-reactive protein (CRP) and albumin, in glioblastoma multiforme (GBM) patients treated with radiotherapy (RT) and concurrent plus adjuvant temozolomide (GPS)." | 3.88 | Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. ( Ciner, F; Guler, OC; Mertsoylu, H; Ozdemir, Y; Selek, U; Topkan, E; Tufan, K; Yildirim, BA, 2018) |
| "To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression." | 3.88 | Temozolomide rechallenge in recurrent glioblastoma: when is it useful? ( Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M, 2018) |
| "Temozolomide (TMZ) is the most frequent adjuvant chemotherapy drug in gliomas." | 3.88 | Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. ( Dai, B; Li, J; Qi, N; Zhang, G, 2018) |
| "To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma." | 3.88 | [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. ( Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018) |
| "Human glioblastoma U251 and T98 cells and normal astrocytes C8D1A were loaded with coenzyme Q10 (CoQ)." | 3.88 | Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide. ( Alcaín, FJ; Ariza, J; Arjona-Gutiérrez, J; De la Mata, M; Durán-Prado, M; Ferrín, G; Frontiñán-Rubio, J; Gil-Agudo, A; Gómez, MV; Lozano, E; Martínez-González, A; Moreno, M; Nieva-Velasco, CM; Peinado, JR; Pérez-García, VM; Pérez-Romasanta, L; Pesic, M; Santiago-Mora, RM; Villalba, JM, 2018) |
| "We describe the first case of a novel treatment for a newly diagnosed glioblastoma (GBM) using superselective intraarterial cerebral infusion (SIACI) of cetuximab after osmotic disruption of the blood-brain barrier (BBB) with mannitol." | 3.88 | Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma. ( Alter, RA; Boockvar, JA; Chakraborty, S; Demopoulos, A; Filippi, CG; Fralin, S; Kulason, KO; Langer, DJ; Ortiz, R; Pramanik, B; Ray, A; Schneider, JR; Tan, K; Wong, T, 2018) |
| "We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years." | 3.88 | Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. ( Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y, 2018) |
| "Temozolomide (TMZ) is currently the first-line drug used for clinical postoperative or non-surgical chemotherapy for glioma, but acquired and intrinsic resistance to TMZ limits its application." | 3.88 | Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells. ( Fan, H; Li, Y; Ni, Q; Wang, Y; Zhang, X, 2018) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic drug approved for the Glioblastoma multiforme (GBM) treatment." | 3.88 | miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. ( Deng, S; Guo, M; Li, Y; Liu, Y; Peng, Y; Qi, S; Ren, J; Shu, S; Yi, G; Zhao, L, 2018) |
| "Recently, D,L-methadone has been put forward as adjuvant treatment in glioblastoma (GBM)." | 3.88 | Efficacy of D,L-methadone in the treatment of glioblastoma in vitro. ( Brawanski, A; Brawanski, K; Brockhoff, G; Freyschlag, C; Hau, P; Lohmeier, A; Proescholdt, MA; Riemenschneider, MJ; Thomé, C; Vollmann-Zwerenz, A, 2018) |
| "Temozolomide (TMZ) is the current first-line chemotherapy for treatment of glioblastoma multiforme (GBM)." | 3.88 | Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells. ( Arcella, A; Capriotti, AL; Caracciolo, G; Digiacomo, L; Frati, L; Mahmoudi, M; Oliva, MA; Palchetti, S; Pozzi, D; Rota, R; Screpanti, I; Tsaouli, G, 2018) |
| "We assessed survival associations of anticoagulant use from baseline up to the start of temozolomide chemoradiotherapy (TMZ/RT) (period I) and from there to the start of maintenance TMZ chemotherapy (period II) by pooling data of three randomised clinical trials in newly diagnosed glioblastoma including 1273 patients." | 3.88 | Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. ( Chinot, OL; Cloughesy, T; Genbrugge, E; Gorlia, T; Le Rhun, E; Nabors, LB; Reardon, DA; Stupp, R; Weller, M; Wick, W, 2018) |
| " Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed." | 3.88 | Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. ( Bai, Y; Chen, Y; Dong, X; Hong, X; Li, S; Li, Y; Liu, X; Su, X; Zhao, G, 2018) |
| " For example, temozolomide (TMZ), of use for glioblastoma (GBM) treatment, appears as capable of inducing autophagy partially inhibiting cancer cell proliferation." | 3.88 | Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. ( Ascione, B; Buccarelli, M; D'Alessandris, QG; De Pascalis, I; Larocca, LM; Malorni, W; Marconi, M; Martini, M; Matarrese, P; Pacioni, S; Pallini, R; Ricci-Vitiani, L, 2018) |
| "Chemoresistance blunts the effect of Temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 3.88 | Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. ( Huang, X; Li, R; Shen, F; Wang, X; Wei, Z; Wu, W; Yan, W; Yin, J; You, Y; Zeng, A; Zhou, X, 2018) |
| "In this study, we aimed to evaluate the expression and functions of MAPK8 in temozolomide (TMZ) -resistant glioblastoma cells as well as to explore the mechanism of TMZ resistance in glioblastoma cells." | 3.88 | MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway. ( Hou, S; Sha, LG; Xu, P; Zhang, G, 2018) |
| "To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients." | 3.88 | Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. ( Guzauskas, GF; Salzberg, M; Wang, BC, 2018) |
| "A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation." | 3.88 | Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. ( Aoki, K; Chang, JH; Cho, O; Cho, WK; Choi, JW; Chung, WK; Dho, YS; Kim, CY; Kim, E; Kim, IA; Kim, IH; Kim, JW; Kim, N; Kim, SH; Lim, DH; Motomura, K; Nam, DH; Natsume, A; Oh, YT; Ohka, F; Park, CK; Suh, CO; Wee, CW, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 3.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted." | 3.88 | Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 3.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "The survival rate in high-grade glioma (HGG) patients receiving a combined regimen of radiotherapy (RT) and temozolomide after tumor resection was increased." | 3.88 | A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy. ( Chang, J; Di, J; Lu, X; Qi, F; Song, X; Wang, Q; Yu, Y; Zhang, L; Zhou, Y, 2018) |
| "The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by 60 Gray of radiation with concomitant and adjuvant TMZ (standard radiotherapy and TMZ)." | 3.88 | Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. ( Carter, TC; Lawler, BE; Medina-Flores, R, 2018) |
| " The aim of the present study was to investigate the effect of temozolomide and thymoquinone combination on apoptotic pathway of human glioblastoma multiforme cell line (U87MG)." | 3.85 | Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line. ( Khazaei, M; Pazhouhi, M, 2017) |
| "Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM)." | 3.85 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. ( Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P, 2017) |
| "To determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide." | 3.85 | Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide. ( Algara, M; Foro Arnalot, P; Granados, R; Membrive, I; Ortiz, A; Pera, O; Reig, A; Rodriguez, N; Sanz, X, 2017) |
| "To compare various pro-apoptotic effects of synthetic 4-thiazolidinone derivative (Les-3288), doxorubicin (Dox) and temozolomide (TMZ) in the treatment of human glioma U251 cells to improve treatment outcomes of glioblastoma and avoid anticancer drug resistance." | 3.85 | Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells. ( Finiuk, N; Grytsyna, II; Klyuchivska, OY; Lehka, L; Lesyk, RB; Panchuk, RR; Starykovych, MO; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI, 2017) |
| "Numerous studies have reported that glioma patients with isocitrate dehydrogenase 1(IDH1) R132H mutation are sensitive to temozolomide treatment." | 3.85 | IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. ( Cai, W; He, M; Li, K; Liu, A; Luo, M; Ouyang, L; Pi, R; Tu, Y, 2017) |
| "In glioblastoma several histone demethylase genes (KDM) are overexpressed compared to normal brain tissue and the development of Temozolomide (TMZ) resistance is accompanied by the transient further increased expression of KDM5A and other KDMs following a mechanism that we defined as "epigenetic resilience"." | 3.85 | Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. ( Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M, 2017) |
| "Glioblastoma multiforme (GBM) exhibits high resistance to the standard treatment of temozolomide (TMZ) combined with radiotherapy, due to its remarkable cell heterogeneity." | 3.85 | Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines. ( Abdollahi, A; Dokic, I; Klein, C; Oancea-Castillo, LR; Régnier-Vigouroux, A; Weber, KJ, 2017) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM)." | 3.85 | MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J, 2017) |
| "Resistance to temozolomide (TMZ) chemotherapy poses a significant challenge in the treatment of glioblastoma (GBM)." | 3.85 | Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. ( Dai, J; Ma, K; Niu, L; Pan, Y; Wang, X; Yin, H; Yuan, G; Zhang, Y; Zhou, W, 2017) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 3.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "Temozolomide (TMZ) chemotherapy, in combination with maximal safe resection and radiotherapy, is the current standard of care for patients with glioblastoma (GBM)." | 3.85 | Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. ( Jahan, N; Lee, JM; Shah, K; Wakimoto, H, 2017) |
| "Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide." | 3.85 | CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. ( Herrera-Rios, D; Hoerbelt, T; Jiang, T; Kahlert, UD; Koch, K; Li, G; Maciaczyk, D; Maciaczyk, J; Marquardt, V; Ouwens, DM; Pauck, D; Picard, D; Remke, M; Steiger, HJ; Zhang, W; Zhao, L, 2017) |
| "Limited benefits and clinical utility of temozolomide (TMZ) for glioblastoma (GB) are frequently compromised by the development of acquired drug resistance." | 3.85 | Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling. ( Fu, Z; Guo, H; Lian, C; Liu, B; Xu, N; Yang, Z; Zeng, H, 2017) |
| " In the present study, whether MALAT1 contributes to the resistance of glioblastoma cell lines to temozolomide (TMZ) was investigated." | 3.85 | Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. ( Dong, Y; Guan, F; Li, D; Li, H; Liu, X; Wang, H; Yan, D; Yang, B; Yuan, X, 2017) |
| "The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution." | 3.85 | Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. ( Ahn, SS; Chang, JH; Cho, J; Choi, HJ; Hong, CK; Kang, SG; Kim, DS; Kim, EH; Kim, SH; Lee, KS; Lee, SK; Moon, JH; Park, HH; Roh, TH; Suh, CO, 2017) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 3.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Temozolomide (TMZ) is used to treat adult patients with glioblastoma multiforme (GBM)." | 3.85 | Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database. ( Deitz, AC; Desai, VCA; He, J; Holick, CN; Lanes, S; Quinlan, SC, 2017) |
| "Assessment of perfusion in early post-treatment MR imaging can stratify TTP in patients with glioblastoma for adjuvant temozolomide therapy." | 3.85 | Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma. ( Choi, CG; Jung, SC; Kim, HS; Kim, HW; Kim, JH; Kim, SJ; Park, JE; Ryu, KH; Shim, WH, 2017) |
| "In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial." | 3.85 | Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. ( Bergin, P; Blackley, E; Gill, S; Haydon, A; McLean, C; Moore, M; Tay, RY, 2017) |
| "Temozolomide is the first chemotherapeutic agent proven effective for patients with newly diagnosed glioblastoma." | 3.85 | Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. ( Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK, 2017) |
| "Acquisition of temozolomide (TMZ) resistance is a major factor leading to the failure of glioblastoma (GBM) treatment." | 3.85 | Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O ( Chang, KY; Chang, WC; Chen, KY; Chou, SW; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Hung, JJ; Kao, TJ; Ko, CY; Liou, JP; Liu, JJ; Liu, MS; Tsai, SY, 2017) |
| "Temozolomide (TMZ) is the main chemotherapeutic agent used for treating newly diagnosed Glioblastoma Multiforme (GBM), the most frequent malignant brain tumors in adults." | 3.85 | HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. ( Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM, 2017) |
| "To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM)." | 3.85 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison ( Roussakow, SV, 2017) |
| " Standard of care for glioblastoma (GBM) includes temozolomide chemotherapy, which is not curative, due, in part, to residual therapy-resistant brain tumor-initiating cells (BTICs)." | 3.85 | Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. ( Audia, A; Bar, EE; Benavides, GA; Bevensee, MO; Bhat, KP; Boyd, NH; Cooper, SJ; Darley-Usmar, V; Dedhar, S; Fried, J; Gillespie, GY; Gordon, E; Griguer, C; Hackney, JR; Hjelmeland, AB; Landis, CJ; McDonald, PC; Nabors, B; Nozell, S; Scott, SE; Spina, R; Tran, AN; Walker, K; Xu, B, 2017) |
| "It is controversial whether concurrent chemoradiotherapy (CRT) with temozolomide is feasible and beneficial in elderly patients with glioblastoma." | 3.85 | A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65. ( Fietkau, R; Knippen, S; Lahmer, G; Putz, F; Semrau, S, 2017) |
| " However, vital safety and efficacy issues related to combined therapy with temozolomide, the first-line cytostatic in patients diagnosed with glioblastoma multiforme, and antidepressant drugs have yet to be addressed." | 3.85 | Antidepressant drugs can modify cytotoxic action of temozolomide. ( Bielecka, AM; Obuchowicz, E, 2017) |
| " The triazene Temozolomide (TMZ), an alkylating drug, is the classical chemotherapeutic agent for gliomas, but has been disappointing against the highly invasive and resistant nature of GBM." | 3.85 | Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference? ( Braga, C; Brites, D; Bronze, MR; Falcão, AS; Moreira, R; Perry, MJ; Pinheiro, R; Santos, G, 2017) |
| "The current standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 3.85 | Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide. ( Ikawa, F; Ishifuro, M; Kawamata, T; Kurisu, K; Muragaki, Y; Nishibuchi, I; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2017) |
| "It is unknown whether the addition of temozolomide (TMZ) to radiotherapy (RT) is associated with improved overall survival (OS) among older glioblastoma patients." | 3.85 | Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. ( Arvold, ND; Cefalu, M; Dominici, F; Schrag, D; Wang, Y; Zigler, C, 2017) |
| " This model, developed using FM-HCR and drug sensitivity measurements in 24 human lymphoblastoid cell lines, was applied to a panel of 12 patient-derived xenograft (PDX) models of glioblastoma to predict glioblastoma response to treatment with the chemotherapeutic DNA-damaging agent temozolomide." | 3.85 | DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. ( Chaim, IA; Gupta, SK; Joughin, BA; Kitange, GJ; Lauffenburger, DA; Mazzucato, P; Nagel, ZD; Samson, LD; Sarkaria, JN, 2017) |
| " In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells." | 3.85 | Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. ( Chen, H; Gong, Z; Gui, Q; Guo, X; Liang, P; Meng, J; Shi, H; Xu, Y; Zhu, W, 2017) |
| " We previously reported the immunomodulatory effects of radiation and temozolomide (TMZ) in newly diagnosed glioblastoma." | 3.85 | Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. ( Christensen, BC; Davis, MC; Ernstoff, MS; Fadul, CE; Fisher, JL; Gaur, AB; Hampton, TH; Lewis, LD; Rahme, GJ; Steel, SE; Thomas, AA; Tsongalis, GJ; Whipple, CA, 2017) |
| "Temozolomide (TMZ) is an alkylating agent used for treatment of brain neoplasms and levetiracetam (LEV) is a commonly used antiepileptic." | 3.85 | Acute liver injury induced by levetiracetam and temozolomide co-treatment. ( Abu Rmeileh, A; Benson, AA; Chen, S; Cohen, J; Daher, S; Khoury, T; Mizrahi, M; Yaari, S, 2017) |
| "The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major burden for patients suffering from glioma." | 3.85 | Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. ( Cai, L; Su, Z; Tu, M; Yu, Z; Zeng, B; Zheng, W; Zhu, D, 2017) |
| "The present study aimed to investigate whether overexpression of integrin-linked kinase (ILK) affects drug resistance to temozolomide (TMZ) in glioma cells." | 3.85 | Overexpression of ILK promotes temozolomide resistance in glioma cells. ( Bao, L; Liang, F; Wang, B; Zhang, SM; Zhang, SQ; Zhao, YS, 2017) |
| "Although methylguanine-DNA-methyltransferase (MGMT) plays an important role in resistance to temozolomide (TMZ) in glioma, 40% of gliomas with MGMT inactivation are still resistant to TMZ." | 3.85 | FoxM1-mediated RFC5 expression promotes temozolomide resistance. ( Du, FY; Ge, L; Gong, AH; Han, X; Jin, J; Peng, WX; Zhang, CL, 2017) |
| "Temozolomide-(TMZ)-based chemoradiotherapy defines the current gold standard for the treatment of newly diagnosed glioblastoma." | 3.85 | Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival. ( Ballhausen, H; Belka, C; Nachbichler, SB; Niyazi, M; Schupp, G, 2017) |
| "Glioblastoma multiforme (GBM), the most common malignant brain tumor, is currently treated with temozolomide (TMZ), but GBM often exhibits resistance to TMZ." | 3.85 | FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation. ( Li, L; Pei, H; Wang, H; Xia, Q; Xu, K; Zhang, Z, 2017) |
| "The chemotherapeutic agent temozolomide (TMZ) is widely used in the treatment of glioblastoma multiforme (GBM)." | 3.85 | Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. ( Cheng, YS; Ho, ASW; Kiang, KMY; Lee, D; Leung, GKK; Li, N; Poon, MW; Pu, JKS; Sun, S; Zhang, P; Zhang, X, 2017) |
| "To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles." | 3.85 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. ( Bendszus, M; Felsberg, J; Gramatzki, D; Hentschel, B; Herrlinger, U; Kickingereder, P; Loeffler, M; Pietsch, T; Reifenberger, G; Sabel, M; Schackert, G; Schlegel, U; Tonn, JC; Weller, M; Westphal, M; Wick, W, 2017) |
| "A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era." | 3.85 | Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. ( Chang, JH; Choe, G; Choi, SH; Kim, CY; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, JW; Kim, N; Kim, SH; Kim, TM; Kim, YJ; Lee, ST; Park, CK; Park, SH; Suh, CO; Wee, CW, 2017) |
| " Then, knockdown of hnRNP A2/B1 expression induced by RNA interference (RNAi) method was used to analyze the role of hnRNP A2/B1 in glioblastoma cell viability, adhesion, migration, invasion, and chemoresistance for temozolomide (TMZ)." | 3.83 | Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival. ( Chen, S; Cheng, Y; Deng, J; Liang, P; Wang, F; Xie, Z; Xu, Z; Zhai, X; Zhang, Q; Zhao, H, 2016) |
| "Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment." | 3.83 | Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. ( Du, J; Mao, G; Song, S; Zhu, X, 2016) |
| "Few data are available on temozolomide (TMZ) in ependymomas." | 3.83 | Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. ( Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M, 2016) |
| "The standard of care for patients with newly diagnosed glioblastoma (GBM) is maximal safe resection followed by adjuvant radiation therapy (RT) and temozolomide (TMZ)." | 3.83 | Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients. ( Bruce, JN; Cheng, SK; Chow, DS; Estrada, JP; Gartrell, R; Isaacson, SR; Jani, A; Lassman, AB; McKhann, GM; Qureshi, YH; Saad, S; Sisti, MB; Soun, JE; Ung, TH; Wang, TJ, 2016) |
| "Temozolomide is a standard chemotherapy agent for malignant gliomas, but the efficacy is still not satisfactory." | 3.83 | Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. ( Kanamori, M; Saito, R; Shibahara, I; Sonoda, Y; Sugiyama, S; Tominaga, T; Zhang, R, 2016) |
| "Resistance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to challenge GBM treatment efforts." | 3.83 | Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. ( Gourdie, RG; Guo, S; Jourdan, J; Kanabur, P; Lamouille, S; Murphy, SF; Osimani, AM; Pridham, KJ; Rodgers, CM; Sharma, S; Sheng, Z; Simonds, GR; Varghese, RT, 2016) |
| "We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy." | 3.83 | Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016) |
| "In the effort to find better treatments for glioblastoma we tested several currently marketed non-chemotherapy drugs for their ability to enhance the standard cytotoxic drug currently used to treat glioblastoma- temozolomide." | 3.83 | Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. ( Coveñas, R; Kast, RE; Lladó, S; Muñoz, M; Ramiro, S; Toro, S, 2016) |
| "The survival benefits of patients with glioblastoma (GBM) remain unsatisfactory due to the intrinsic or acquired resistance to temozolomide (TMZ)." | 3.83 | Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. ( Han, J; Lan, F; Wu, Q; Yang, Y; Yu, H; Yue, X, 2016) |
| "Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM)." | 3.83 | Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. ( Boyd, AW; Byrne, AT; Day, BW; Flanagan, L; Kögel, D; Murray, DW; O'Brien, DF; Prehn, JH; Rehm, M; Salvucci, M; Stringer, BW; Tivnan, A; Zakaria, Z, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ)." | 3.83 | Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. ( El-Shorbagy, SH; Khedr, RA; Younis, SG, 2016) |
| "A gene drug delivery system for glioma therapy based on transferrin (Tf)-modified polyamidoamine dendrimer (PAMAM) was prepared." | 3.83 | Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. ( Gao, S; Hao, B; Hong, B; Jiang, C; Li, J, 2016) |
| "Management of patients with glioblastoma (GBM) often includes radiation (RT) and temozolomide (TMZ)." | 3.83 | Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. ( Campian, JL; Gao, F; Govindan, A; Huang, J; Leong, J; Mendez, JS, 2016) |
| " Human glioma U87MG or LNZ308 cells overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both." | 3.83 | Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. ( Nagane, M; Nitta, Y; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| " Triple-mutant astrocytes formed serially transplantable glioblastoma allografts that were sensitive to radiation but expressed MGMT and were resistant to temozolomide." | 3.83 | Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. ( Bash, RE; Ewend, MG; Huey, L; McNeill, RS; Miller, CR; Schmid, RS; Simon, JM; Vitucci, M; Werneke, AM; White, KK; Wu, J, 2016) |
| "Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a predictive and prognostic marker in newly diagnosed glioblastoma patients treated with temozolomide but how MGMT methylation should be assessed to ensure optimal detection accuracy is debated." | 3.83 | Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. ( Aslan, D; Broholm, H; Christensen, IJ; Dyrbye, H; Grunnet, K; Grønbæk, K; Kristensen, LS; Michaelsen, SR; Poulsen, HS, 2016) |
| "The current standard of care for glioblastoma (GBM) is surgical resection, radiotherapy, and treatment with temozolomide (TMZ)." | 3.83 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. ( Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS, 2016) |
| "The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear." | 3.83 | Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. ( Baruzzi, A; Bertolini, F; Biasini, C; Brandes, AA; Cavallo, MA; Crisi, G; Dazzi, C; Depenni, R; Ermani, M; Faedi, M; Franceschi, E; Michiara, M; Mucciarini, C; Paccapelo, A; Pasini, G; Pavesi, G; Pisanello, A; Servadei, F; Sturiale, C; Urbini, B, 2016) |
| " O(6)-methylguanine DNA methyltransferase (MGMT), N-methylpurine DNA glycosylase (MPG), and Rad51 are DNA damage repair proteins that mediate resistance to temozolomide in glioblastoma." | 3.83 | Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. ( Acanda, AM; Alonso, MM; Aragón, T; Fueyo, J; Garzón, AG; Gomez-Manzano, C; Gonzalez-Huarriz, M; Idoate, MA; Jones, C; Lang, FF; Martínez-Irujo, JJ; Martínez-Velez, N; Vera, B; Xipell, E, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 3.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| "Clinical guidelines for gliosarcoma (GSM) are poorly defined and GSM patients are usually treated in accordance with existing guidelines for glioblastoma (GBM), with maximal surgical resection followed by chemoradiation with temozolomide (TMZ)." | 3.83 | Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( Adeberg, S; Bernhardt, D; Debus, J; Diehl, C; Harrabi, SB; Koelsche, C; Rieken, S; Unterberg, A; von Deimling, A, 2016) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 3.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| "The effects of KLF8 on glioma cell proliferation, apoptosis and chemosensitivity to temozolomide (TMZ) were analyzed by Cell Counting Kit 8 assay and flow cytometry assay." | 3.83 | KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation. ( Wang, E; Wu, F; Yu, G, 2016) |
| "HIF-1α downregulation sensitizes U251 glioma cells to the temozolomide treatment via inhibiting MGMT expression and Notch1 pathway activation." | 3.83 | Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. ( Huang, GH; Li, N; Lv, SQ; Ma, ZX; Sidlauskas, K; Tang, JH; Xiang, Y; Xu, QF; Zhang, EE, 2016) |
| "Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme." | 3.83 | Persistent bone marrow depression following short-term treatment with temozolomide. ( Brandal, P; Johannesen, TB; Tjønnfjord, GE; Vandraas, K, 2016) |
| "Although temozolomide (TMZ) is the most effective chemotherapy agent for glioma, chemotherapy resistance has limited its clinical use." | 3.83 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. ( Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR, 2016) |
| " Here, we report increased MAP kinase-interacting kinase (MNK)-regulated phosphorylation of translation initiation factor 4E (eIF4E) in glioma cells upon temozolomide (TMZ) treatment and in medullary thyroid carcinoma (MTC) cells in response to targeted radionuclide therapy." | 3.83 | Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. ( Behe, M; Frank, S; Grzmil, M; Hemmings, BA; Hess, D; Moncayo, G; Schibli, R; Seebacher, J, 2016) |
| "Twenty patients with high grade glioma relapse received a stereotactic radiation; among them two patients received temozolomide and eight patients received bevacizumab; among the latter, four received also irinotecan." | 3.83 | Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. ( Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R, 2016) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 3.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy." | 3.83 | miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. ( Liao, Y; Liu, J; Liu, Q; Lv, R; Qiu, X; Wu, M; Xiao, S; Yang, Z, 2016) |
| "Glioblastoma has a dismal prognosis, with an average overall survival of about one year despite maximal safe resection, concomitant radiochemotherapy with temozolomide followed by adjuvant temozolomide therapy." | 3.83 | Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. ( Blaes, J; Dong, Z; Green, E; Hertenstein, A; Jugold, M; Lemke, D; Löw, S; Ott, M; Platten, M; Pledl, HW; Sahm, F; Steffen, AC; Weiler, M; Wick, W; Winkler, F; Zorn, M, 2016) |
| "Maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide significantly prolonged overall survival times and was well tolerated in elderly patients with glioblastomas." | 3.83 | Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma. ( Gao, Z; Hao, S; Ji, N; Li, Y; Song, G; Su, Z; Wang, J; Wang, X; Xie, J; Yu, L; Zhang, C; Zhang, P, 2016) |
| "Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients." | 3.83 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. ( Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 3.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM)." | 3.83 | Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. ( Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M, 2016) |
| " The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ)." | 3.83 | Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). ( Chang, JH; Cheong, JH; Choi, J; Huh, YM; Jeon, JY; Kang, SG; Kim, EH; Kim, P; Kim, SH; Koh, I; Lee, JH; Lee, SJ; Park, J; Pollak, M; Shim, JK; Yook, JI; Yun, M, 2016) |
| " In the OP group with GBM and anaplastic glioma, patients treated with RT combined with temozolomide (TMZ) manifested significantly longer OS and PFS compared with patients assigned to RT alone (P < 0." | 3.83 | Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. ( Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W, 2016) |
| "Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide." | 3.83 | MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016) |
| "Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration." | 3.83 | Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016) |
| "It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)." | 3.83 | Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016) |
| "To analyze the enhancement patterns and apparent diffusion coefficient (ADC) values of non-measurable surgical cavity wall enhancement pattern, newly appearing after completion of standard concurrent chemoradiotherapy (CCRT) with temozolomide in glioblastoma patients for the prognosis prediction." | 3.83 | MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. ( Choi, SH; Kim, BR; Kim, IH; Kim, JH; Kim, TM; Lee, ST; Park, CK; Park, SH; Park, SW; Sohn, CH; Yun, TJ, 2016) |
| "Temozolomide (TMZ), an alkylating agent of the imidazotetrazine series, is a first-line chemotherapeutic drug used in the clinical therapy of glioblastoma multiforme, the most common and high-grade primary glioma in adults." | 3.83 | The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death. ( Chang, CK; Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shih, CM, 2016) |
| "The aim of this study was to investigate the effect of downregulating Hedgehog pathway by GANT61 on human glioma cells, examine the consequent changes of temozolomide (TMZ)-induced effects and explore the molecular mechanisms." | 3.83 | GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. ( Cai, J; Chen, L; Jiang, C; Li, J; Li, R; Li, Y; Sun, Y; Yao, K; Zhai, X; Zhang, J; Zhao, S, 2016) |
| "Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM)." | 3.81 | EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. ( Boothman, DA; Burma, S; Chakraborty, S; Habib, AA; Hatanpaa, KJ; Koduru, P; Li, L; Puliyappadamba, VT; Rehman, A; Saha, D; Souza, RF; Vemireddy, V, 2015) |
| "Twenty-two newly diagnosed patients with primary malignant gliomas underwent 6 weeks of combined modality treatment (CMD) with radiation and temozolomide followed by six monthly cycles of temozolomide." | 3.81 | Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. ( Case, D; Dietrich, AM; Duncan, SE; Harmon, M; Lesser, G; Mirlohi, S, 2015) |
| "Concurrent chemoradiotherapy with temozolomide, the current standard treatment after surgery for glioblastoma, could be shortened without increasing side effects for patients with poor prognostic features." | 3.81 | Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. ( Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH, 2015) |
| "To explore the role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the differentiation of true progression from pseudoprogression in patients with glioblastoma on the basis of findings in entirely newly developed or enlarged enhancing lesions after concurrent radiation therapy and chemotherapy with temozolomide and to evaluate the diagnostic performance of the quantitative pharmacokinetic parameters obtained at dynamic contrast-enhanced MR imaging, such as the volume transfer constant (K(trans)), the extravascular extracellular space per unit volume of tissue(ve), and the blood plasma volume per unit volume of tissue(vp)." | 3.81 | Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ, 2015) |
| "The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported." | 3.81 | Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. ( Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015) |
| "The upregulation of Livin expression and downregulation of caspase activity were observed under cycling and chronic hypoxia in glioblastoma cells and xenografts, concomitant with increased TR to ionizing radiation and temozolomide." | 3.81 | Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. ( Hsieh, CH; Lee, HT; Lin, YJ; Shyu, WC; Wang, CC; Wu, CP, 2015) |
| "The present in vitro study aimed to assess the effects of combining the mTOR inhibitor RAD001 and temozolomide (TMZ) together with irradiation by either low-linear energy transfer (LET) radiation (γ-rays) or high-LET radiation (fast neutrons) on the growth and cell survival of the human glioblastoma cell line U-87." | 3.81 | Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture. ( Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J, 2015) |
| "To evaluate 2 specific radiation schedules, each combined with temozolomide (TMZ), assessing their efficacy and safety in patients aged ≥65 years with newly diagnosed glioblastoma (GBM)." | 3.81 | Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. ( Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I, 2015) |
| "Glioblastoma (GBM) is a highly proliferative, angiogenic grade IV astrocytoma that develops resistance to the alkylating agents used in chemotherapy, such as temozolomide (TMZ), which is considered the gold standard." | 3.81 | Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. ( Balça-Silva, J; do Carmo, A; Girão, H; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB, 2015) |
| "We retrospectively identified 68 consecutive patients with high-grade gliomas treated by surgical resection followed by radiation therapy and temozolomide, who then developed increasing enhancing mass lesions indeterminate for treatment-related changes versus recurrent tumor." | 3.81 | Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. ( Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z, 2015) |
| "Glioblastoma Multiforme (GBM), the most common and lethal adult primary tumor of the brain, showed a link between Sonic Hedgehog (SHH) pathway in the resistance to temozolomide (TMZ)." | 3.81 | Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. ( Greco, SJ; Ligon, KL; Munoz, JL; Rameshwar, P; Ramkissoon, SH; Rodriguez-Cruz, V, 2015) |
| "The aim of this prospective longitudinal study was to identify static and dynamic O-(2-[(18)F]fluoroethyl)-L-tyrosine PET ((18)FET-PET)-derived imaging biomarkers in patients with glioblastoma (GBM)." | 3.81 | Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. ( Eigenbrod, S; Jansen, NL; Janssen, H; Kreth, FW; Kretzschmar, H; la Fougere, C; Linn, J; Pöpperl, G; Simon, M; Suchorska, B; Tonn, JC; Weller, M, 2015) |
| " Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome." | 3.81 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. ( Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X, 2015) |
| "Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined." | 3.81 | Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. ( Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B, 2015) |
| "Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict." | 3.81 | EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. ( Bonetti, MF; Branca, C; Buglione, M; Buttolo, L; Cominelli, M; Dalerba, P; Facchetti, F; Finocchiaro, G; Furlan, D; Galli, R; Grisanti, S; Liserre, B; Liserre, R; Mazzoleni, S; Medicina, D; Pellegatta, S; Pellegrini, V; Pizzi, M; Poliani, PL, 2015) |
| " In this project, we evaluated the effects of silibinin, a natural plant component of milk thistle seeds, to potentiate toxic effects of chemotherapy drugs such as temozolomide, etoposide and irinotecan on LN229, U87 and A172 (P53 and phosphatase and tensin homolog (PTEN) -tumor suppressor-mutated) glioma cell lines." | 3.81 | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. ( Elhag, R; Mazzio, EA; Soliman, KF, 2015) |
| "In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy." | 3.81 | Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. ( Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH, 2015) |
| "Temozolomide (TMZ) is the first line drug in the care of high grade gliomas." | 3.81 | Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. ( Clemente, MA; Corsa, P; Cossa, S; Donno, E; Munafò, T; Parisi, F; Parisi, S; Perrone, A; Piombino, M; Raguso, A; Sanpaolo, G; Valle, G, 2015) |
| "Despite multimodal treatment, glioblastoma (GBM) therapy with temozolomide (TMZ) remains inefficient due to chemoresistance." | 3.81 | The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. ( Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H, 2015) |
| "High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy." | 3.81 | Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. ( Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM, 2015) |
| "We examined whether the amino acid PET tracers, trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) and (11)C-methyl-l-methionine ((11)C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-β (IFN), and bevacizumab (Bev) in glioblastoma." | 3.81 | Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H, 2015) |
| "Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied." | 3.81 | The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. ( Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F, 2015) |
| "Resistance to temozolomide (TMZ) is a major obstacle in the treatment of glioblastoma multiforme (GBM)." | 3.81 | miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. ( Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhan, Q; Zhou, D, 2015) |
| " The objective of this study was to assess the survival benefit of LEV compared with other antiepileptic drugs as a chemosensitizer to temozolomide for patients with glioblastoma." | 3.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "It is currently unclear whether adjuvant therapy for WHO grade III anaplastic astrocytomas (AA) should be carried out as combined chemoradiotherapy with temozolomide (TMZ)--analogous to the approach for glioblastoma multiforme--or as radiotherapy (RT) alone." | 3.81 | Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. ( Giese, A; Mayer, A; Renovanz, M; Schmidberger, H; Schwanbeck, C; Sommer, C; Stockinger, M; Vaupel, P, 2015) |
| "Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival." | 3.81 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. ( Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD, 2015) |
| " Cutoff values of MGMT methylation specific for metastatic colorectal cancer (mCRC) tissue samples were established in a cohort of 60 patients treated with dacarbazine." | 3.81 | Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. ( Amatu, A; Barault, L; Bardelli, A; Bleeker, FE; Cassingena, A; Cassoni, P; De Braud, F; de Witt Hamer, P; Di Nicolantonio, F; Esteller, M; Falcomatà, C; Fiano, V; Milione, M; Moutinho, C; Pietrantonio, F; Rudà, R; Sartore-Bianchi, A; Siena, S; Siravegna, G; Soffietti, R; Venesio, T; Wesseling, P, 2015) |
| "The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide." | 3.81 | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. ( Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Garcia, J; Hegde, P; Henriksson, R; Kharbanda, S; Lai, A; Li, C; Mason, W; Moore, N; Nishikawa, R; Peale, F; Phillips, HS; Sandmann, T; Saran, F; Wick, W, 2015) |
| " The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 3.81 | NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. ( Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G, 2015) |
| "Temozolomide plays a critical role in curing glioma at present." | 3.81 | Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ( Gao, J; Huang, G; Liu, H; Wang, L; Wang, Z, 2015) |
| " Glioblastoma (GBM) has poor survival rate and uniformly acquired chemoresistance to its frontline agent, Temozolomide (TMZ)." | 3.81 | Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. ( Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND, 2015) |
| " The present study was undertaken to determine whether the cytotoxicity of curcumin (diferuloylmethane), a natural polyphenolic compound isolated from turmeric (Curcuma longa Linn), in glioblastoma cells is mediated through upregulation of miR‑146a." | 3.81 | Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. ( Cai, T; Chen, YD; Liu, Q; Wang, ZF; Wu, H, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 3.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| " A 48-year-old patient had supratentorial glioblastoma, treated with radiotherapy (RT) and concurrent temozolomide followed by six cycles of adjuvant temozolomide." | 3.81 | Diagnosis and Management of Spinal Metastasis of Glioblastoma. ( Dubey, A; Koul, R; Salim, M; Tai, P; Vu, K, 2015) |
| "Although temozolomide (TMZ) is the current first-line chemotherapy for glioblastoma multiforme (GBM), most patients either do not respond or ultimately fail TMZ treatment." | 3.81 | Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. ( Chang, EH; DeMarco, J; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| " Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations." | 3.81 | Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015) |
| " In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen." | 3.81 | Spatiotemporal Evolution of the Primary Glioblastoma Genome. ( Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y, 2015) |
| "Mesoporous silica nanoparticles (MSNPs), 100 nm in size, incorporating a Cy5 fluorophore within the silica framework, are synthesized and loaded with the anti-cancer drug temozolomide (TMZ), used in the treatment of gliomas." | 3.81 | Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. ( Bertucci, A; Brognara, E; Corradini, R; De Cola, L; Gambari, R; Manicardi, A; Prasetyanto, EA; Septiadi, D, 2015) |
| "The efficacy of temozolomide (TMZ) plus radiation therapy (RT) in elderly patients with glioblastoma is unclear." | 3.81 | Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). ( Anghileri, E; Bazzoli, E; Bellu, L; Berti, F; D'Avella, D; Dall'Agata, M; Della Puppa, A; Eoli, M; Fabi, A; Faedi, M; Ferrazza, P; Gurrieri, L; Lombardi, G; Nicolotto, E; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Villani, V; Zagonel, V, 2015) |
| "For glioblastoma patients who underwent Temozolomide and Radiation Therapy, OS and PFS was most favorable for those with tumors harboring both mIDH and methMGMT (median OS: 35." | 3.81 | IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. ( Chen, B; Chen, CC; Jiang, T; Li, G; Li, J; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yan, W; Yang, P; Yao, K; You, Y; Zhang, W, 2015) |
| "Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with vascular normalization within the tumor." | 3.81 | Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. ( Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015) |
| "This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol." | 3.81 | Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. ( Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH, 2015) |
| "Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ)." | 3.81 | Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2015) |
| "Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment." | 3.81 | The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. ( Allemanni, G; Banelli, B; Barbieri, F; Carosio, R; Carra, E; Daga, A; Florio, T; Forlani, A; Marubbi, D; Parodi, F; Pattarozzi, A; Romani, M; Würth, R, 2015) |
| " Here, we built protein interaction networks associated with chemoresistance to temozolomide, an alkylating agent used in glioma therapy, and analyzed their modular structure and robustness against intentional attack." | 3.81 | Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma. ( Azevedo, H; Moreira-Filho, CA, 2015) |
| "Glioma stem cells are associated for temozolomide-resistance in glioblastoma." | 3.81 | Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. ( Leung, GK; Poon, MW; Sun, S; Wong, ST; Zhang, XQ; Zhuang, JT, 2015) |
| "The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy." | 3.81 | EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients. ( Benderitter, M; Bernier, MO; Brochet, B; Delattre, JY; Douzane, H; Durand, T; Feuvret, L; Hoang-Xuan, K; Jacob, S; Lebouil, L; Leclercq, D; Lestaevel, P; Milliat, F; Noël, G; Psimaras, D; Rahimian, A; Ricard, D; Tamarat, R; Vayatis, N, 2015) |
| "Temozolomide (TMZ) with radiotherapy is the current standard of care for newly diagnosed glioma." | 3.81 | MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. ( Chen, Q; Han, J, 2015) |
| "The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide." | 3.80 | Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. ( Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA, 2014) |
| "To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6)." | 3.80 | Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). ( Arza, C; Díez Valle, R; Galván, J; Romariz, C; Slof, J; Vidal, C, 2014) |
| "Although temozolomide (TMZ) replaced nitrosoureas as the standard initial chemotherapy for glioblastoma (GBM), no studies have compared TMZ with nimustine (ACNU), a nitrosourea agent widely used in central Europe and most Asian regions." | 3.80 | Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. ( Chen, B; Chen, L; Chen, X; Jiang, T; Li, S; Wang, J; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhang, Z, 2014) |
| "The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth." | 3.80 | The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. ( Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J, 2014) |
| "It is now accepted that the concomitant administration of temozolomide with radiotherapy (Stupp regime), in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), significantly improves survival and this practice has been adopted locally since 2004." | 3.80 | A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime. ( Clark, B; Mackinnon, M; Martin, S; Nowicki, S; Owusu-Agyemang, K; Paul, J; St George, J; Stewart, W; Teo, M, 2014) |
| "Our purpose was to analyze the pattern of failure in glioblastoma (GBM) patients at first recurrence after radiotherapy and temozolomide and its relationship with different factors." | 3.80 | Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. ( Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S, 2014) |
| " This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival." | 3.80 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. ( Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P, 2014) |
| "Radiotherapy (RT) and temozolomide (TMZ) for glioblastoma (GBM) has resulted in longer survival." | 3.80 | Employment following chemoradiotherapy in glioblastoma: a prospective case series. ( Back, M; Guo, L; Gzell, C; Kastelan, M; Wheeler, H, 2014) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 3.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "Following tumor resection, the majority of high-grade glioma (HGG) patients are treated with a combined modality regimen of radiotherapy and temozolomide." | 3.80 | Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. ( Bosma, I; Buter, J; de Groot, M; Douw, L; Froklage, FE; Heimans, JJ; Klein, M; Lagerwaard, FJ; Oosterbaan, LJ; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Uitdehaag, BM, 2014) |
| "Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol." | 3.80 | Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. ( Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M, 2014) |
| "To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclinical proof-of-concept studies of the effects of temozolomide-containing regimens." | 3.80 | Mechanism of temozolomide-induced antitumour effects on glioma cells. ( Hu, JA; Shen, W; Zheng, JS, 2014) |
| "Present work mainly evaluated the inhibitory effects of lidamycin (LDM), an enediyne antibiotic, on angiogenesis or glioma-induced angiogenesis in vitro and in vivo, especially its synergistic anti-angiogenesis with temozolomide (TMZ)." | 3.80 | Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| "With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14." | 3.80 | Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. ( Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A, 2014) |
| "Wild-type or immunodeficient mice bearing intracranial glioblastoma multiforme or metastatic melanoma were treated with an intratumoral injection of Ad-Flt3L alone or in combination with the conditionally cytotoxic enzyme thymidine kinase (Ad-TK), followed by systemic administration of ganciclovir and temozolomide." | 3.80 | Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. ( Ahlzadeh, GE; Candolfi, M; Castro, MG; Ghiasi, H; Kamran, N; Lowenstein, PR; Paran, C; Puntel, M; Wibowo, M; Yagiz, K, 2014) |
| " In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients." | 3.80 | MGMT promoter methylation in plasma of glioma patients receiving temozolomide. ( Cassoni, P; Castiglione, A; De Marco, L; Fiano, V; Gillio-Tos, A; Grasso, C; Magistrello, M; Merletti, F; Rudà, R; Sacerdote, C; Senetta, R; Soffietti, R; Tondat, F; Trevisan, E; Trevisan, M, 2014) |
| "Bevacizumab (BZM) and temozolomide (TMZ) have been shown to be beneficial in the treatment of patients with glioblastoma." | 3.80 | Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. ( Wachtel, MS; Yang, S, 2014) |
| "Temozolomide profoundly prevented the outgrowth of experimental brain metastases of breast cancer in an MGMT-dependent manner." | 3.80 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. ( Biernat, W; Duchnowska, R; Gril, B; Hewitt, SM; Hua, E; Jassem, J; Liewehr, DJ; Palmieri, D; Qian, Y; Sosińska-Mielcarek, K; Stark, AM; Steeg, PS; Steinberg, SM; Woditschka, S, 2014) |
| "Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells." | 3.80 | Antitumor effect of fibrin glue containing temozolomide against malignant glioma. ( Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S, 2014) |
| "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma." | 3.80 | Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. ( Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L, 2014) |
| "Temozolomide (TMZ) is widely used to treat glioblastoma multiforme (GBM)." | 3.80 | microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. ( Bekar, A; Berghoff, AS; Budak, F; Cecener, G; Egeli, U; Kocaeli, H; Preusser, M; Ricken, G; Taskapılıoglu, MO; Tezcan, G; Tolunay, S; Tunca, B, 2014) |
| "Glioblastoma (GBM) remains the most aggressive and lethal brain tumor due to its molecular heterogeneity and high motility and invasion capabilities of its cells, resulting in high resistance to current standard treatments (surgery, followed by ionizing radiation combined with Temozolomide chemotherapy administration)." | 3.80 | Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells. ( Allavena, G; Angeletti, F; Comincini, S; Manai, F; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M, 2014) |
| "Autophagy is a cytoprotective process, which occurs following temozolomide (TMZ) treatment, and contributes to glioma chemoresistance and TMZ treatment failure." | 3.80 | Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma. ( Li, B; Wang, Q; Wang, W; Xie, B; Zou, Y, 2014) |
| " We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012." | 3.80 | IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. ( Arcella, A; Bozzao, A; Di Stefano, D; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Salvati, M; Scaringi, C; Scarpino, S; Villani, V, 2014) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 3.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to upregulation of O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.80 | A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ( Chang, EH; Dagata, JA; Farkas, N; Kim, E; Kim, SS; Nishida, M; Pirollo, KF; Rait, A, 2014) |
| "Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance." | 3.80 | Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. ( Anderson, JC; Bonner, JA; Bredel, M; Choradia, NV; Duarte, CW; Rohrbach, TD; Thottassery, JV; Welaya, K; Willey, CD; Yancey Gillespie, G; Yang, ES, 2014) |
| "Effective sensitizing strategies potentially can extend the benefit of temozolomide (TMZ) therapy in patients with glioblastoma (GBM)." | 3.80 | Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. ( Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA, 2014) |
| "The present work evaluated the synergistic efficacy of an enediyne antibiotic lidamycin (LDM) plus temozolomide (TMZ) against glioma in vitro and in vivo." | 3.80 | Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| "To study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts." | 3.80 | [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats]. ( Gao, Y; Li, Y; Liu, G; Ma, L; Wang, Y; Zhou, X, 2014) |
| " The aim of this study was to investigate whether quercetin could sensitize human glioblastoma cells to temozolomide (TMZ) in vitro." | 3.80 | Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. ( Lan, Q; Li, RJ; Sang, DP, 2014) |
| "To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide." | 3.80 | Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. ( Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM, 2014) |
| "To evaluate the role of bevacizumab and irinotecan as secondline treatment of glioblastoma in patients with progression after radiotherapy and temozolomide." | 3.80 | Bevacizumab as secondline treatment of glioblastoma - worth the effort? ( Rovere, RK, 2014) |
| "We examined changes to key UPR modulators in temozolomide-sensitive and -resistant human GBM cells (D54 and U87) treated with/without temozolomide at different oxygen concentrations using western blotting, and cytotoxic benefits of overexpressing key chaperone, P4HB, in GBM cells (U87 and U251) under normoxia and hyperoxia." | 3.80 | Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. ( Ho, AS; Kiang, KM; Lee, D; Leung, GK; Sun, S; Xu, FF; Zhang, XQ, 2014) |
| "This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas." | 3.80 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. ( Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X, 2014) |
| "Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy." | 3.80 | 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. ( Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC, 2014) |
| "This study assesses the controversial role of temozolomide (TMZ) concurrent with adjuvant radiation (RT) in patients with anaplastic astrocytoma (AA)." | 3.80 | The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. ( Buckner, JC; Decker, PA; Giannini, C; Hardie, J; Jenkins, RB; Kizilbash, SH; Laack, NN; Parney, IF; Uhm, JH; Voss, JS, 2014) |
| "The EORTC-NCIC regimen for glioblastoma requires different dosing of temozolomide (TMZ) during radiation and maintenance therapy." | 3.80 | Analyzing temozolomide medication errors: potentially fatal. ( Bressler, LR; Gabay, MP; Letarte, N; Long, KE; Stachnik, JM; Villano, JL, 2014) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 3.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "The combined application of aplysin and TMZ significantly sensitizes glioma cells to TMZ action, compared with TMZ alone." | 3.80 | Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. ( Ge, N; Gong, A; Liang, H; Lu, L; Yao, W, 2014) |
| "The aim of the present study was to evaluate the toxicity and clinical outcome of radio-chemotherapy with temozolomide in patients with glioblastoma aged more than 65 years." | 3.80 | Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience. ( Cocuzza, P; Fabbrini, MG; Fatigante, L; Ferrazza, P; Monzani, F; Pasqualetti, F; Pasqualetti, G, 2014) |
| "The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control." | 3.80 | Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S, 2014) |
| " Finally, human T98G glioblastoma cells that are resistant to the chemotherapy drug temozolomide (TMZ) showed a unique high expression of the Na+/K+-ATPase α2 and α3 subunits compared to the TMZ-sensitive cell line LN229 and normal human astrocytes." | 3.80 | Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells. ( Chen, D; Mohamad, O; Song, M; Yu, SP, 2014) |
| "To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT)." | 3.80 | Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. ( Badiyan, SN; Chicoine, MR; Dacey, R; DeWees, T; Dowling, JL; Huang, J; Jalalizadeh, R; Kim, AH; Leuthardt, EC; Linette, G; Markovina, S; Rich, KM; Robinson, CG; Simpson, JR; Tran, DD; Zipfel, GJ, 2014) |
| "These results suggest that concomitant treatment with NPe6-PDT and temozolomide is a potentially useful therapy for glioma." | 3.80 | Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium. ( Akimoto, J; Beppu, M; Fujiwara, Y; Hiranuma, M; Hironaka, C; Miki, Y; Moritake, K; Omata, H, 2014) |
| " Next, we treated all eGFP/Luc GBM cell lines with Temozolomide (TMZ) or Doxorubicin, comparing co-cultures of glioblastoma (GBM) cells and TNC-1 astrocytes with mono-cultures of eGFP/Luc GBM cells." | 3.80 | A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma. ( Costea, DE; Enger, PØ; Huang, B; Leiss, L; Li, X; Liang, X; Sakariassen, PØ; Skaftnesmo, KO; Wang, J; Yan, T; Yang, N; Zhu, H, 2014) |
| "Twenty-three consecutive high-grade glioma patients were treated with radiotherapy (2 Gy/60 Gy) with concomitant and adjuvant temozolomide." | 3.80 | ADC texture--an imaging biomarker for high-grade glioma? ( Asklund, T; Birgander, R; Brynolfsson, P; Garpebring, A; Hauksson, J; Henriksson, R; Karlsson, M; Nilsson, D; Nyholm, T; Trygg, J, 2014) |
| "We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas." | 3.80 | Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. ( Brown, BD; Brown, T; Juarez, T; Kesari, S; Piccioni, DE; Saria, MG; van Vugt, VA, 2014) |
| "Prophylaxis against Pneumocystis jiroveci pneumonia (PJP) is currently recommended for patients receiving chemoradiation with temozolomide for newly diagnosed glioblastoma multiforme." | 3.80 | Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. ( Barnes, PD; Bubalo, J; Fu, R; Gahramanov, S; Lacy, C; Nasseri, M; Neuwelt, AJ; Neuwelt, EA; Nguyen, TM; Tyson, RM, 2014) |
| "To assess the prognosis predictability of a measurable enhancing lesion using histogram parameters produced by the normalized cerebral blood volume (nCBV) and normalized apparent diffusion coefficient (nADC) after completion of standard concomitant chemoradiotherapy (CCRT) and adjuvant temozolomide (TMZ) medication in glioblastoma multiforme (GBM) patients." | 3.80 | Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Ryoo, I; Sohn, CH; Yun, TJ, 2014) |
| "Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma." | 3.80 | Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014) |
| "The objective of this study was to report the authors' experience with the long-term administration of temozolomide (TMZ; > 6 cycles, up to 101) in patients with newly diagnosed glioblastoma and to analyze its feasibility and safety as well as its impact on survival." | 3.80 | Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. ( Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G, 2014) |
| "For glioma, temozolomide (TMZ) is a commonly used chemotherapy drug and photodynamic therapy (PDT) is an important adjuvant therapy." | 3.80 | Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. ( Guo, M; Hu, S; Shen, L; Zhang, X, 2014) |
| " Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors." | 3.80 | Glioblastoma multiforme and hepatitis B: do the right thing(s). ( Begini, P; Delle Fave, G; Gallina, S; Marignani, M; Minniti, G; Purchiaroni, F, 2014) |
| "Nine post-temozolomide recurrent or progressive high-grade glioma patients (seven with glioblastoma and two with anaplastic astrocytoma) were treated with BV monotherapy." | 3.80 | Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. ( Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K, 2014) |
| "The benefit of the introduction of alkylating chemotherapy in the treatment of glioblastoma multiforme (GBM) patients has been demonstrated by comparing radiotherapy with concomitant plus intermittent temozolomide (iTMZ) to radiation therapy." | 3.79 | The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. ( Felsberg, J; Goeppert, M; Rapp, M; Sabel, M; Steiger, HJ, 2013) |
| "Temozolomide (TMZ) is important chemotherapy for glioblastoma multiforme (GBM), but the optimal dosing schedule is unclear." | 3.79 | Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. ( Anderson, SK; Ballman, KV; Carlson, BL; Cen, L; Decker, PA; Giannini, C; Grogan, PT; Kitange, GJ; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Wu, W, 2013) |
| " In this study, we investigated the predictive value of SLC22A18 promoter methylation and protein expression in glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) therapy." | 3.79 | Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. ( Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB, 2013) |
| "Temozolomide (TMZ) is commonly used in the treatment of glioblastoma (GBM)." | 3.79 | Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. ( Canpinar, H; Castresana, JS; Ilgaz, S; Ozdemir, M; Ozkan, T; Oztuna, D; Rey, JA; Sunguroğlu, A; Taspinar, M; Ugur, HC, 2013) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 3.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "The purpose of this study is to assess the preclinical therapeutic efficacy of magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption to enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment." | 3.79 | Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. ( Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC, 2013) |
| " In addition, microsatellite instability, leading to the putative mechanism of temozolomide (TMZ) resistance, was frequently detected." | 3.79 | Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics. ( Amano, T; Fujioka, Y; Hata, N; Iwaki, T; Mizoguchi, M; Murata, H; Nakamizo, A; Sasaki, T; Suzuki, SO; Yoshimoto, K, 2013) |
| "We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ)." | 3.79 | Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. ( Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW, 2013) |
| "We have studied the consequences of the combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 and temozolomide on the growth and cell death of the glioblastoma cell line U-87 in vitro." | 3.79 | The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. ( Bischoff, P; Burckel, H; Josset, E; Noël, G, 2013) |
| "To determine whether immediate post-operative brachytherapy can be safely applied to newly diagnosed glioblastomas to retard tumor progression prior to initiation of external beam radiation therapy (EBRT) and temozolomide." | 3.79 | Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. ( Alksne, JF; Carter, BS; Chen, CC; Gonda, DD; Lawson, J; Murphy, K; Rose, B; Russell, M; Scanderbeg, DJ; Waters, JD, 2013) |
| "Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients." | 3.79 | Defining pseudoprogression in glioblastoma multiforme. ( Bechter, OE; Clement, PM; De Vleeschouwer, S; Demaerel, P; Geussens, Y; Menten, J; Sciot, R; Van Calenbergh, F; Van Gool, S; Van Mieghem, E; Wilms, G; Wozniak, A, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| " The alkylating agent temozolomide (TMZ) has been shown to improve the overall survival in patients with malignant gliomas, especially in tumors with methylated promoter of the O6-methylguanine-DNA-methyltransferase (MGMT) gene." | 3.79 | Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma. ( Boxhammer, V; Klämpfl, TG; Köritzer, J; Li, YF; Morfill, GE; Schäfer, A; Schlegel, J; Schwenk-Zieger, S; Shimizu, T; Welz, C; Zimmermann, JL, 2013) |
| "Global gene expressions and drug sensitivities to three chemotherapeutic drugs (imatinib, camptothecin and temozolomide) were measured in six human glioblastoma-derived cell lines." | 3.79 | Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. ( Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L, 2013) |
| "To explore the role of histogram analysis of apparent diffusion coefficient (ADC) maps obtained at standard- and high-b-value (1000 and 3000 sec/mm(2), respectively) diffusion-weighted (DW) imaging in the differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide." | 3.79 | Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. ( Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ, 2013) |
| "Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance mechanisms limit benefits." | 3.79 | Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. ( Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P, 2013) |
| "To evaluate the efficacy of pulsed low-dose radiation therapy (PLRT) combined with temozolomide (TMZ) as a novel treatment approach for radioresistant glioblastoma multiforme (GBM) in a murine model." | 3.79 | Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. ( Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD, 2013) |
| "Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM)." | 3.79 | Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. ( Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S, 2013) |
| " Such chemoresistance was overcome by apparently noncytotoxic doses of temozolomide, which chemosensitized glioblastoma cells to doxorubicin, vinblastine, and etoposide." | 3.79 | Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway. ( Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Ghigo, D; Kopecka, J; Mellai, M; Riganti, C; Salaroglio, IC; Schiffer, D, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients." | 3.79 | Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. ( Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S, 2013) |
| "To compare retrospectively outcome after photon radiotherapy alone, radiochemotherapy with temozolomide (TMZ), and carbon ion radiotherapy in patients with high-grade gliomas and to generate a hypothetical outcome curve for C12 and TMZ." | 3.79 | Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. ( Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H, 2013) |
| "Standard treatment for glioblastoma (GBM) is surgery followed by radiation (RT) and temozolomide (TMZ)." | 3.79 | Chemoirradiation for glioblastoma multiforme: the national cancer institute experience. ( Camphausen, K; Fine, HA; Ho, J; Iwamoto, F; Kim, L; Krauze, A; Kreisl, T; McNeil, K; Ning, H; Ondos, J; Shankavaram, U; Smith, S; Sul, J, 2013) |
| "The recent progress in chemotherapy for malignant gliomas is attributable to the introduction of the DNA-methylating agent temozolomide (TMZ); however, drug resistance remains a major issue." | 3.79 | The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. ( Adachi, K; Hayashi, T; Hirose, Y; Ohba, S, 2013) |
| "A retrospective analysis was conducted to identify patients (N=117) who received standard oral temozolomide for glioblastoma at our institution from 2003 to 2010." | 3.79 | An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. ( Carter, AF; DeTroye, AT; Harmon, MS; Lesser, GJ; Morrell, RM; Tooze, JA, 2013) |
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 3.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Temozolomide (TMZ) during and after radiotherapy (RT) is recommended for patients with newly diagnosed glioblastoma (GBM)." | 3.79 | Glioblastoma management in the temozolomide era: have we improved outcome? ( Al-Zahrani, A; Atenafu, E; Laperriere, N; Lwin, Z; MacFadden, D; Mason, WP; Menard, C; Miller, BA; Sahgal, A, 2013) |
| "The effect of concomitant and adjuvant temozolomide in glioblastoma patients above the age of 65 years lacks evidence." | 3.79 | Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. ( Behm, T; Bock, HC; Horowski, A; Mielke, D; Rohde, V; Schneider, S; Stockhammer, F, 2013) |
| "Although implementation of temozolomide (TMZ) as a part of primary therapy for glioblastoma multiforme (GBM) has resulted in improved patient survival, the disease is still incurable." | 3.79 | Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. ( Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Michaelsen, SR; Poulsen, HS; Stockhausen, MT, 2013) |
| "In 2005, maximum safe surgical resection, followed by radiotherapy with concomitant temozolomide (TMZ), followed by adjuvant TMZ became the standard of care for glioblastoma (GBM)." | 3.79 | Time trends in glioblastoma multiforme survival: the role of temozolomide. ( Darefsky, AS; Dubrow, R; Jacobs, DI; King, JT; Laurans, MS; Park, LS; Rose, MG, 2013) |
| "To examine whether adjuvant temozolomide treatment improved glioblastoma patients` survival in a large Canadian cohort." | 3.79 | Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma. ( Al-Nuaimi, SK; Alnaami, IM; Gourishankar, S; Mehta, V; Murtha, AD; Senthilselvan, A; Walling, S, 2013) |
| " Human glioblastoma is highly resistant to chemotherapy with temozolomide." | 3.79 | Lobarstin enhances chemosensitivity in human glioblastoma T98G cells. ( Chung, H; Jo, S; Kim, IC; Kim, S; Kim, TU; Lee, H; Yim, JH, 2013) |
| "To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy." | 3.79 | Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. ( Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K, 2013) |
| " Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma." | 3.79 | Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. ( Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Karl, S; Marschall, V; Vucic, D; Wagner, L; Zobel, K, 2013) |
| " We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)." | 3.79 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013) |
| "Clinical studies in patients with newly diagnosed glioblastoma treated with temozolomide have shown that the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is both predictive and prognostic of outcome." | 3.79 | The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. ( Brewer, J; Hitchins, MP; Kuroiwa-Trzmielina, J; Lu, D; McDonald, KL; Nozue, K; Olivier, J; Rapkins, RW; Tiwari, S; Wheeler, HR; Zhao, L, 2013) |
| "We investigated whether high levels of activated mitogen-activated protein kinase (p-MAPK) were associated with poor survival among patients with newly diagnosed glioblastoma during the temozolomide era." | 3.79 | High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. ( Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Fan, X; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Yu, JS, 2013) |
| " This study aimed to investigate the possible mechanism of mutant TP53 inducing temozolomide resistance in glioblastoma cells." | 3.79 | Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. ( Chen, JX; Liu, YH; Mao, Q; Wang, X; You, C, 2013) |
| " In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model." | 3.79 | Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. ( Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y, 2013) |
| "To compare survival and hematological toxicity rates between two postoperative therapy regimens in patients with primary glioblastoma (GBM), namely temozolomide (TMZ) concomitant to radiation, followed by adjuvant TMZ, versus adjuvant TMZ after radiation only." | 3.79 | Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. ( Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G, 2013) |
| " MRSI and CE abnormalities are now integrated for glioblastoma SIB-IMRT, concomitant with temozolomide, in an ongoing multi-institutional phase-III clinical trial." | 3.79 | Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. ( Berry, I; Cassol, E; Celsis, P; Cohen-Jonathan, EM; Delannes, M; Filleron, T; Franceries, X; Ken, S; Laprie, A; Lotterie, JA; Lubrano, V; Simon, L; Supper, C; Vieillevigne, L, 2013) |
| "We evaluated the predictive value of O6-methylguanine-DNA methyltransferase (MGMT) protein expression and MGMT promoter methylation status in glioblastomas (GBM) treated with temozolomide (TMZ) in a Taiwan medical center." | 3.79 | Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. ( Chang-Chien, YC; Chen, MH; Guo, WY; Ho, DM; Ho, HL; Hsu, CY; Hsu, SP; Lin, SC; Yen, YS, 2013) |
| " Temozolomide is an alkylating agent approved for treating malignant gliomas." | 3.79 | Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. ( Blackwood, R; Brown, M; Harmon, M; Lesser, G; Lovato, J; Strowd, RE; Yalcinkaya, T, 2013) |
| "We retrospectively reviewed nine cases of relapsed medulloblastoma treated with bevacizumab, irinotecan, ± temozolomide." | 3.79 | Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. ( Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY, 2013) |
| "Glioblastoma (GBM), one of the most malignant human neoplasias, responds poorly to current treatment modalities, with temozolomide (TMZ) being the drug most frequently used for its treatment." | 3.79 | Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. ( Borges, KS; Carlotti, CG; Castro-Gamero, AM; de Oliveira, HF; de Paula Gomes Queiroz, R; Fujinami, MM; Moreno, DA; Scrideli, CA; Suazo, VK; Tone, LG, 2013) |
| "For elderly patients with glioblastoma multiforme (GBM), radiotherapy plus concomitant and adjuvant temozolomide has resulted in longer survival." | 3.79 | Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. ( Jang, WY; Jeong, EH; Jung, S; Jung, TY; Kim, IY; Lee, JH; Moon, KS, 2013) |
| "The goal of this study was to investigate whether the amount of hypointense signal on susceptibility-weighted imaging within the contrast-enhancing lesion (%SWI-h) on the pretreatment scan could determine response in patients with newly diagnosed glioblastoma multiforme who received external beam radiation therapy with concomitant anti-angiogenic therapy (enzastaurin) and cytotoxic chemotherapy (temozolomide)." | 3.79 | Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. ( Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ, 2013) |
| "After previous treatment with standard radiotherapy (with or without temozolomide) patients with recurrent malignant glioma received bevacizumab (10 mg/kg intravenous) on Day 1 and Day 15 during radiotherapy." | 3.78 | Irradiation and bevacizumab in high-grade glioma retreatment settings. ( Belka, C; Ertl, L; Ganswindt, U; Geisler, J; Kreth, FW; la Fougère, C; Linn, J; Niyazi, M; Schwarz, SB; Siefert, A; Tonn, JC, 2012) |
| "To evaluate pathologically confirmed incidence of pseudoprogression and its impact on survival in glioblastoma multiforme (GBM) patients treated with radiotherapy and concurrent temozolomide (TMZ), followed by 6 months of TMZ maintenance therapy." | 3.78 | Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. ( Oymak, E; Parlak, C; Pehlivan, B; Topkan, E; Topuk, S, 2012) |
| "We report retrospective data on the feasibility and efficacy of prolonging adjuvant temozolomide (TMZ) more than 6 months after chemoradiotherapy completion in patients with glioblastoma (GBM)." | 3.78 | Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2012) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 3.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone." | 3.78 | Glioblastoma survival in the United States before and during the temozolomide era. ( Johnson, DR; O'Neill, BP, 2012) |
| "To determine the maximum-tolerated dose (MTD) of radiation (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma (GBM), to estimate their progression-free (PFS) and overall survival (OS), and to assess the role of (11)C methionine PET (MET-PET) imaging in predicting recurrence." | 3.78 | Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. ( Brown, D; Cao, Y; Chenevert, T; Gomez-Hassan, D; Heth, J; Junck, L; Lawrence, T; Normolle, D; Piert, M; Schipper, M; Ten Haken, RK; Tsien, CI, 2012) |
| "The alkylating agent temozolomide (TMZ) is the major chemotherapeutic drug used clinically in the treatment of malignant gliomas." | 3.78 | Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. ( Lee, CC; Lin, CJ; Lin, TY; Lin, YF; Shih, CM; Shih, YL; Wang, SH, 2012) |
| "Although both the alkylating agent temozolomide (TMZ) and oncolytic viruses hold promise for treating glioblastoma, which remains uniformly lethal, the effectiveness of combining the two treatments and the mechanism of their interaction on cancer stem cells are unknown." | 3.78 | Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. ( Hirose, Y; Kanai, R; Louis, DN; Martuza, RL; Rabkin, SD; Sgubin, D; Wakimoto, H; Yip, S; Zaupa, CM, 2012) |
| "We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy with concomitant adjuvant temozolomide." | 3.78 | Volumetric and MGMT parameters in glioblastoma patients: survival analysis. ( Chatzisotiriou, A; Eleftheraki, AG; Fountzilas, G; Iliadis, G; Kotoula, V; Lambaki, S; Misailidou, D; Selviaridis, P; Televantou, D, 2012) |
| "Standard treatment for glioblastoma multiforme (GBM) changed in 2005 when addition of temozolomide (TMZ) to maximal surgical resection followed by radiation therapy (RT) was shown to prolong survival in a clinical trial." | 3.78 | Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. ( Abrams, J; Harlan, L; Mann, B; Yabroff, KR; Zeruto, C, 2012) |
| "To illustrate this, we report the case of a 60-year-old male patient confronted with an inoperable glioblastoma multiforme on the splenium of the corpus callosum, of poor prognosis, treated by concomitant radiochemotherapy with temozolomide, who developed psychotic depression with Cotard's syndrome." | 3.78 | Cotard's syndrome with glioblastoma multiforme. ( Comet, B; Le Rhun, E; Ramirez, C; Reich, M, 2012) |
| "The standard of care for newly diagnosed glioblastoma multiforme (GBM) is temozolomide (TMZ) chemotherapy given concurrently with radiation for 6 weeks followed by 6 months of adjuvant TMZ." | 3.78 | Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. ( Easaw, JC; Roldán Urgoiti, GB; Singh, AD, 2012) |
| "Alkylating agents, such as temozolomide (TMZ) and fotemustine (FTM) are widely used in recurrent glioblastoma (GBM) regimes." | 3.78 | Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. ( Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M, 2012) |
| "Cox regressions for survival with 314,635 inherited autosomal single-nucleotide polymorphisms (SNP) among 315 San Francisco Adult Glioma Study patients for discovery and three independent validation data sets [87 Mayo Clinic, 232 glioma patients recruited from several medical centers in Southeastern United States (GliomaSE), and 115 The Cancer Genome Atlas patients] were used to identify SNPs associated with overall survival for Caucasian glioblastoma patients treated with the current standard of care, resection, radiation, and temozolomide (total n = 749)." | 3.78 | SSBP2 variants are associated with survival in glioblastoma patients. ( Berger, MS; Brem, S; Browning, JE; Buckner, JC; Chang, SM; Decker, PA; Egan, KM; Fridley, BL; Hansen, HM; Jenkins, RB; Kosel, ML; Lachance, DH; Madden, MH; McCoy, LS; Nabors, LB; O'Neill, BP; Olson, JJ; Patoka, JS; Prados, MD; Rice, T; Smirnov, I; Thompson, RC; Tihan, T; Wiemels, JL; Wiencke, JK; Wrensch, MR; Xiao, Y, 2012) |
| "Polysorbate 80 coated temozolomide-loaded PLGA-based superparamagnetic nanoparticles (P80-TMZ/SPIO-NPs) were successfully synthesized and characterized as drug carriers and diagnosis agent for malignant brain glioma." | 3.78 | Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. ( Ling, Y; Wei, K; Zhong, S; Zou, F, 2012) |
| "The DNA alkylating agent temozolomide (TMZ) is widely used in the treatment of human malignancies such as glioma and melanoma." | 3.78 | Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. ( Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y, 2012) |
| "Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT." | 3.78 | Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. ( Hara, K; Kageji, T; Kitazato, KT; Kuwayama, K; Matsuzaki, K; Mizobuchi, Y; Morigaki, R; Mure, H; Nagahiro, S; Okazaki, T, 2012) |
| "The effectiveness of temozolomide (TMZ) dosing schemes and the "rechallenge" of recurrent glioblastoma (GBM) with TMZ are controversial." | 3.78 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. ( Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J, 2012) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma." | 3.78 | Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. ( Florea, AM; Happold, C; Reifenberger, G; Roth, P; Schmidt, N; Silginer, M; Weller, M; Wick, W, 2012) |
| "Genome-wide microRNA (miRNA) profiling of 82 glioblastomas demonstrated that miR-181d was inversely associated with patient overall survival after correcting for age, Karnofsky performance status, extent of resection, and temozolomide (TMZ) treatment." | 3.78 | miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. ( Chen, CC; Hoadley, K; Jiang, C; Jiang, T; Kang, C; Kushwaha, D; Li, S; Ramakrishnan, V; Song, SW; You, Y; Zhang, J; Zhang, W, 2012) |
| "We analyzed the usefulness of initial or recurrent treatment of temozolomide (TMZ) in pediatric high-grade gliomas (HGGs)." | 3.78 | Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study. ( Baek, HJ; Choi, HS; Jung, TY; Kim, CY; Kim, DS; Kim, IA; Kim, SH; Ra, YS, 2012) |
| " In this study, we show that high expression of the α5 integrin subunit compromises temozolomide-induced tumor suppressor p53 activity in human glioblastoma cells." | 3.78 | Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. ( Bossert, C; Chastagner, P; Dontenwill, M; Entz-Werle, N; Godet, J; Guenot, D; Guerin, E; Janouskova, H; Leger, DY; Lehmann-Che, J; Maglott, A; Martin, S; Noulet, F; Pinel, S; Plenat, F; Teisinger, J, 2012) |
| "Radiotherapy plus concomitant and adjuvant temozolomide (RCAT) is now standard treatment for grade IV glioblastoma (GBM)." | 3.78 | Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. ( Hargreaves, S; Kooner, I; Liu, ZW; Menashy, R; Michalarea, V; Williams, M; Wilson, E; Woolf, D, 2012) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 3.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 3.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| "Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM)." | 3.78 | Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. ( Fung, CF; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Wong, ST, 2012) |
| "Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year." | 3.78 | Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment. ( Groves, MD; Plummer, AB, 2012) |
| "Currently, treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy." | 3.78 | Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. ( Chen, Y; Cui, B; Dai, X; Dong, J; Huang, Q; Lan, Q; Tang, D; Zhang, J; Zhou, G, 2012) |
| "The effect of temozolomide (TMZ) and radiotherapy (RT) in the treatment of glioblastoma multiforme (GBM) has been well documented in randomized controlled trials." | 3.78 | A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. ( Helseth, E; Johannesen, TB; Meling, TR; Rønning, PA, 2012) |
| "Few studies have assessed the presentation, management, and outcome of anaplastic astrocytoma (AA) in elderly patients in the temozolomide era." | 3.78 | Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. ( Buckner, JC; Meyer, FB; Parney, IF; Tanaka, S; Uhm, JH; Yan, ES, 2012) |
| "Temozolomide (TMZ) is an oral alkylating agent widely used in the treatment of refractory glioma." | 3.78 | The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels. ( Cao, K; Li, QY; Lu, PS; Lu, XY; Yuan, ZC, 2012) |
| " Recently, in a phase II trial in Brazil for the treatment of temozolomide (TMZ)-resistant malignant gliomas, POH was well tolerated when administered intranasally." | 3.78 | Perillyl alcohol for the treatment of temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012) |
| "We have investigated on the potentiation of etoposide (ETP) and temozolomide (TMZ) cytotoxicity in U-87MG glioblastoma and D283 medulloblastoma cell lines by curcumin (CUR) and turmeric force (TF), a nutraceutical formulation of turmeric, with the objective of assessing the potential for their adjuvant use in brain tumor chemotherapy." | 3.78 | Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines. ( Escalon, E; Melnick, SJ; Nair, SM; Ramachandran, C, 2012) |
| " Concurrent temozolomide (TMZ) improves survival in non-elderly patients with glioblastoma treated with standard schedule of 60 Gy in 30 fractions." | 3.78 | Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. ( Beal, K; Chan, TA; Gutin, PH; Lassman, AB; Reyngold, M; Yamada, Y, 2012) |
| "To test the effect of starvation on glioma cells in vitro, we treated primary mouse glia, murine GL26, rat C6 and human U251, LN229 and A172 glioma cells with Temozolomide in ad lib and STS mimicking conditions." | 3.78 | Fasting enhances the response of glioma to chemo- and radiotherapy. ( Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M, 2012) |
| "Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy." | 3.78 | A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. ( Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012) |
| "Implementation of chemotherapy with the drug temozolomide increased the overall survival of patients with glioblastoma multiforme (GBM; WHO grade IV), in particular when the O(6)-methylguanine DNA methyltransferase (MGMT) promoter is epigenetically silenced." | 3.78 | Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. ( Beier, CP; Bettstetter, M; Gempt, J; Hoepner, I; Koeritzer, J; Meyer, B; Rasper, M; Ringel, F; Schäfer, A; Schlegel, J; Schmidt-Graf, F; Teufel, J, 2012) |
| "Implantable and poly (d,l-lactide-co-glycolide) (PLGA) microparticles were developed to deliver temozolomide (TM) continuously in interstitial chemotherapy for glioma." | 3.77 | Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. ( Liu, JM; Yue, ZJ; Zhang, H; Zhang, YH, 2011) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 3.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors." | 3.77 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. ( Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH, 2011) |
| "To evaluate the safety and efficacy of hypofractionated radiotherapy (RT) with a standard temozolomide (TMZ) regimen for adults with newly diagnosed glioblastoma multiforme (GBM), twenty-six consecutive adults (range 39-79 years) who met our enrollment criteria received short courses of hypofractionated RT (45 Gy in 15 fractions over three weeks) with concomitant TMZ at 75 mg/m(2)/d." | 3.77 | A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. ( Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T, 2011) |
| " A 56-year-old man with a left parietal glioblastoma was treated with resection, radiation and concomitant and adjuvant temozolomide chemotherapy." | 3.77 | Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma. ( Grommes, C; Papanicolaou, G; Redelman-Sidi, G, 2011) |
| "Temozolomide in combination with radiation has been in use for more than 5 years for the therapy of glioblastoma." | 3.77 | Hepatic encephalopathy after treatment with temozolomide. ( Goldbecker, A; Herrmann, J; Raab, P; Tryc, AB; Weissenborn, K; Worthmann, H, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with proven antitumoral activity in preclinical and clinical studies in adults with high-grade glioma (HGG)." | 3.77 | Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. ( Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A, 2011) |
| " Whether MGMT promoter methylation correlates with tumor response to temozolomide in low-grade gliomas is less clear." | 3.77 | Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. ( Mariani, L; Ochsenbein, AF; Schubert, AD; Vassella, E, 2011) |
| "Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ→TMZ)." | 3.77 | Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. ( Belka, C; Eigenbrod, S; Grasbon-Frodl, EM; Kreth, FW; Kreth, S; Kretzschmar, HA; Lutz, J; Popperl, G; Thon, N; Tonn, JC, 2011) |
| "This prospective study was performed to determine the efficacy, safety, and tolerability of concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with WHO grade III gliomas." | 3.77 | Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. ( Bae, SH; Cha, SH; Cho, WH; Choe, G; Jung, HW; Kim, CY; Kim, DG; Kim, IA; Kim, IH; Kim, YH; Lee, MM; Moon, S; Park, CK; Park, SH, 2011) |
| "The aim of this paper is to evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) and concomitant temozolomide (TMZ) as a salvage treatment option in patients with recurrent glioblastoma (GBM)." | 3.77 | Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. ( Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M, 2011) |
| "Only a few studies examined the effect of temozolomide (TMZ) in recurrent low-grade astrocytoma (LGA) after surgery, none of which included a homogeneous and sufficiently sized group of patients with progression after radiotherapy (RT)." | 3.77 | First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. ( Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB, 2011) |
| "The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma." | 3.77 | Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. ( Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W, 2011) |
| " Induction of autophagy by temozolomide (TMZ) has been noted in glioma cell lines." | 3.77 | Induction of autophagy in temozolomide treated malignant gliomas. ( Aoki, H; Fujii, Y; Kakita, A; Miyahara, H; Natsumeda, M; Takahashi, H; Toyoshima, Y; Uzuka, T; Yajima, N, 2011) |
| "Concomitant radiation therapy (RT) and temozolomide (TMZ) therapy after surgery is the standard treatment for glioblastoma multiforme (GBM)." | 3.77 | Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. ( Côté, AL; Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH, 2011) |
| "We analyzed prospectively whether MGMT (O(6)-methylguanine-DNA methyltransferase) mRNA expression gains prognostic/predictive impact independent of MGMT promoter methylation in malignant glioma patients undergoing radiotherapy with concomitant and adjuvant temozolomide or temozolomide alone." | 3.77 | O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. ( Egensperger, R; Eigenbrod, S; Hinske, LC; Kreth, FW; Kreth, S; Kretzschmar, HA; Ledderose, C; Lutz, J; Thon, N; Tonn, JC, 2011) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic agent in the treatment of glioma following surgical resection and/or radiation." | 3.77 | N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. ( Banze, LA; Brown, AR; Goellner, EM; Hamilton, RL; Moore, B; Sobol, RW; Svilar, D; Tang, JB; Trivedi, RN; Wang, XH, 2011) |
| " Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide." | 3.77 | Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. ( Blasberg, RG; de Stanchina, E; Gamez, I; Huang, R; Kochetkov, T; Moroz, MA; Ryan, RP; Shi, W; Thaler, H, 2011) |
| "We investigated the molecular mechanisms underlying the cytotoxic effect of Temozolomide (TMZ) in both O(6)-methylguanine-DNA methyl transferase (MGMT) depleted as well as undepleted glioblastoma cell lines." | 3.77 | Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. ( Brunetti, E; Bucci, B; D'agnano, I; De Paula, U; De Salvo, M; Gagliassi, R; Marchese, R; Maresca, G; Raza, GH; Stigliano, A, 2011) |
| "To study the impact of two human glioma tissue resistance genes MGMT and ERCC(2) on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions." | 3.77 | [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship]. ( Hou, X; Sun, JH; Wang, JJ; Wu, ZC; Zhao, Y; Zheng, YR, 2011) |
| "Epigenetic silencing of the O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter is associated with prolonged survival in glioblastoma patients treated with temozolomide (TMZ)." | 3.77 | Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. ( Eigenbrod, S; Felsberg, J; Hentschel, B; Kreth, FW; Löffler, M; Pietsch, T; Reifenberger, G; Sabel, MC; Schackert, G; Thon, N; Tonn, JC; Weller, M; Westphal, M, 2011) |
| "Temozolomide has significantly improved the outcome of patients with glioblastoma." | 3.77 | [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2011) |
| "Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM." | 3.77 | Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - . ( Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T, 2011) |
| "5 years, ranging from 25-82 years, 19 female and 29 male) with histologically proven glioblastoma received surgery (16 biopsies, 18 partial and 14 complete resections) and postoperative chemo-irradiation with concomitant and adjuvant temozolomide." | 3.77 | Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study. ( Cejna, M; DeVries, A; Eiter, H; Maier, R; Muxel, B; Muxel, M; Roessler, K; Zachenhofer, I, 2011) |
| "To demonstrate the feasibility of using DNP hyperpolarized [1-(13)C]-pyruvate to measure early response to temozolomide (TMZ) therapy using an orthotopic human glioblastoma xenograft model." | 3.77 | Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. ( Bok, R; James, CD; Nelson, SJ; Ozawa, T; Park, I; Phillips, JJ; Ronen, SM; Vigneron, DB, 2011) |
| "This study was designed to evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for monitoring the WHO grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ)." | 3.77 | Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. ( Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN, 2011) |
| "It is controversial if distant recurrence of glioblastoma is more common after temozolomide (TMZ) concurrent with radiotherapy (RT)." | 3.77 | Glioblastoma: patterns of recurrence and efficacy of salvage treatments. ( Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2011) |
| " In vitro Southern Blot analysis and cytopathic effect assays demonstrate high anti-glioma potency, which was significantly increased in combination with temozolomide (TMZ), daunorubicin and cisplatin." | 3.77 | YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. ( Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W, 2011) |
| "We tested the use of the small-molecule Inhibitor of Apoptosis Protein (IAP) inhibitor LBW242 in combination with the standard-of-care therapies of irradiation and temozolomide for malignant gliomas." | 3.77 | A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. ( Barnes, J; Fast, EM; Keating, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, N; Veldhuijzen van Zanten, SE; Zawel, L; Ziegler, DS, 2011) |
| "Patients with high-grade gliomas (HGG) routinely receive radiation, temozolomide, and glucocorticoids." | 3.77 | Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. ( Carraway, H; Desideri, S; Grossman, SA; Lesser, G; Piantadosi, S; Sloan, A; Ye, X, 2011) |
| "Promoter methylation of the O⁶-methylguanine-DNA-methyltransferase (MGMT) gene is widely recognized as an important predictive factor in the treatment of glioblastoma (GBM) patients with temozolomide." | 3.77 | MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. ( Cho, BK; Kim, SK; Lee, JY; Park, CK; Park, SH; Wang, KC, 2011) |
| "Temozolomide (TMZ) is an alkylating agent that has yielded significant benefits and is a current standard agent in the treatment of malignant gliomas." | 3.77 | Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. ( Fukushima, T; Katayama, Y; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tashiro, S; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2011) |
| "The goal of this study was to evaluate accelerated radiotherapy with and without temozolomide (TMZ) for glioblastoma multiforme (GBM)." | 3.77 | Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. ( Buttmann, M; Flentje, M; Guckenberger, M; Mayer, M; Sweeney, RA; Vince, GH, 2011) |
| "A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status." | 3.77 | Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? ( Abdollahi, A; Combs, SE; Debus, J; Hartmann, C; Rieken, S; von Deimling, A; Wick, W, 2011) |
| " Treatment of glioblastoma multiforme (GBM) with temozolomide (TMZ), its current standard of care, is problematic because the tumor generally recurs and is then resistant to this drug." | 3.77 | Noscapine inhibits tumor growth in TMZ-resistant gliomas. ( Chen, TC; Cho, H; Hofman, FM; Jhaveri, N; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Wang, W, 2011) |
| "A 61-year-old man with glioblastoma and positive for hepatitis B surface antigen (HBsAg) developed acute hepatitis due to hepatitis B virus (HBV) reactivation after concomitant postoperative treatment with temozolomide (75 mg/m(2)/day) and radiation therapy (60 Gy in 30 fractions)." | 3.77 | Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report. ( Kayama, T; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Ueno, H, 2011) |
| "The objective of this retrospective analysis was to assess long-term outcome and prognostic factors of unselected patients treated for glioblastoma (GB) at a single center with surgery, standard radiotherapy (RT), and concomitant temozolomide (TMZ)." | 3.77 | Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. ( Franz, K; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 3.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "A 62-year female received radiotherapy over six weeks with daily 75 mg/m2 Temozolomide (TMZ) for Glioblastoma (GB)." | 3.77 | Temozolomide induced liver injury. ( Afzal, P; Campbell, AP; Dixit, S; Hingorani, M, 2011) |
| "To evaluate the incidence and impact of early post-chemoradiation (cRT) 'pseudoprogression' (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of care - 60 Gy conformal radiotherapy with concurrent low-dose temozolomide, followed by six cycles of high-dose temozolomide (the 'Stupp protocol')." | 3.77 | Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. ( Gunjur, A; Lau, E; Ryan, G; Taouk, Y, 2011) |
| "To study the efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide (TMZ) for gliomas." | 3.77 | [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. ( Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011) |
| " Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases." | 3.77 | Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| "The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ)." | 3.76 | Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. ( Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ, 2010) |
| "Concomitant daily temozolomide and radiation followed by adjuvant temozolomide is a tolerable and reasonable treatment option and has a good performance status for elderly patients diagnosed with glioblastoma." | 3.76 | Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? ( Collichio, F; Ewend, MG; Grabowski, S; Kimple, RJ; Morris, DE; Papez, M, 2010) |
| "In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model." | 3.76 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. ( Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD, 2010) |
| "This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma." | 3.76 | Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? ( Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE, 2010) |
| "We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively." | 3.76 | Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. ( Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT, 2010) |
| "O(6)-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of glioblastoma multiforme (GBM) patients." | 3.76 | O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. ( Berger, W; Buchroithner, J; Filipits, M; Fischer, J; Lötsch, D; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S; Weis, S, 2010) |
| "Epigenetic silencing of the MGMT gene by promoter methylation is associated with loss of MGMT expression, diminished DNA-repair activity and longer overall survival in patients with glioblastoma who, in addition to radiotherapy, received alkylating chemotherapy with carmustine or temozolomide." | 3.76 | Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. ( Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A, 2010) |
| "Pseudoprogression (psPD) is now recognised following radiotherapy with concurrent temozolomide (RT/TMZ) for glioblastoma multiforme (GBM)." | 3.76 | Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. ( Aviv, R; Davey, P; Lam, K; Morrison, M; Perry, J; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 3.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation." | 3.76 | Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. ( Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA, 2010) |
| "Novel agents are currently combined with radiation and temozolomide (RT + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end point." | 3.76 | Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. ( Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X, 2010) |
| " We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide." | 3.76 | Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010) |
| "A retrospective multicenter study was conducted in 26 French Departments of Neurosurgery to analyze practices of French neurosurgeons using Gliadel, compare the adverse effects and survival with those of previous phase III trials, and assess survival in patients with newly diagnosed malignant gliomas (MG) receiving Gliadel plus radiochemotherapy with temozolomide (TMZ)." | 3.76 | Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. ( Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E, 2010) |
| "Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades." | 3.76 | Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. ( Blank, A; Bobola, MS; Kolstoe, DD; Silber, JR, 2010) |
| "There is a growing evidence of using Temozolomide as upfront therapy for progressive low grade gliomas." | 3.76 | Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. ( Dehais, C; Delattre, JY; Ducray, F; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Omuro, A; Psimaras, D; Sanson, M; Sierra del Rio, M; Taillibert, S, 2010) |
| "The purpose of this study was to evaluate diffusion parameters at pre-, mid-, and post-radiation therapy (RT) in contrast-enhancing and nonenhancing lesions of postsurgical glioblastoma multiforme patients treated with the standard of care RT concurrently with temozolomide (TMZ) followed by adjuvant TMZ and an antiangiogenic drug." | 3.76 | Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. ( Butowski, NA; Cha, S; Chang, SM; Elkhaled, A; Jalbert, L; Khayal, IS; Nelson, SJ; Polley, MY, 2010) |
| "To evaluate perfusion parameter changes in patients with glioblastoma multiforme by comparing the perfusion magnetic resonance (MR) imaging measurements obtained before combined radiation and temozolomide therapy (RT-TMZ) with the follow-up MR imaging measurements obtained 1 month after completion of this treatment." | 3.76 | Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. ( Ekholm, SE; Korones, DN; Mangla, R; Milano, MT; Singh, G; Zhong, J; Ziegelitz, D, 2010) |
| "Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme." | 3.76 | Temozolomide (Temodar). ( Mukherji, SK; Rajdev, P; Wesolowski, JR, 2010) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 3.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "O(6)-methylguanine-DNA methyltransferase (MGMT) expression in glioblastoma correlates with temozolomide resistance." | 3.76 | Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. ( Donze, J; Liu, L; McGraw, M; Palomo, JM; Rahmathulla, G; Robinson, CG; Vogelbaum, MA, 2010) |
| "The aim of the present study was to investigate the effect of Temozolomide (an alkylating chemotherapeutic agent) and quercetin (natural flavonoid) on cell death in the human astrocytoma cell line MOGGCCM (WHO grade III)." | 3.76 | Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. ( Jakubowicz-Gil, J; Langner, E; Piersiak, T; Rzeski, W; Wertel, I, 2010) |
| "We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)." | 3.76 | Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010) |
| " We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy." | 3.76 | First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. ( Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M, 2010) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 3.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia." | 3.76 | Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. ( Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T, 2010) |
| "Temozolomide (TM) has anti-tumor activity in patients with malignant glioma." | 3.76 | Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010) |
| "The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GB) when compared to postoperative RT alone in patients up to 65 years of age." | 3.76 | Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. ( Franz, K; Fraunholz, I; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2010) |
| "To analyze the recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with conformal radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), and to compare the patterns of failure according to different target volume delineations." | 3.76 | Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. ( Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S, 2010) |
| "Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers." | 3.76 | Urticarial hypersensitivity reaction caused by temozolomide. ( Hsu, MY; Ibrahimi, OA; Kesari, S; Pothiawala, S; Yang, C, 2010) |
| " We assessed the ability of 17-AAG to inhibit the growth of glioma cell lines and glioma stem cells both in vitro and in vivo and assessed its ability to synergize with radiation and/or temozolomide, the standard therapies for GBM." | 3.75 | Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. ( Barnes, J; Dellagatta, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, NR; Sauvageot, CM; Stiles, CD; Weatherbee, JL; Wen, PY; Winters, SE, 2009) |
| "Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT)." | 3.75 | A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. ( Dill, C; Ehninger, G; Illmer, T; Kestel, L; Kramer, M; Krex, D; Pfirrmann, M; Robel, K; Schackert, G; Schaich, M, 2009) |
| " In this study, we used pharmacokinetic and pharmacodynamic approaches to investigate how sunitinib at different dose levels affects brain distribution of temozolomide (TMZ), and to ascertain the relationship between intratumoral TMZ concentrations and tumor vascularity in an orthotopic human glioma model." | 3.75 | Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ( Gallo, JM; Zhou, Q, 2009) |
| "CpG methylation within the O6-methylguanine-DNA-methyltransferase (MGMT) promoter is associated with enhanced survival of glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ)." | 3.75 | Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. ( Ballman, KV; Buckner, JC; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| " In this study, we investigated whether, intravenously administered, ATP-sensitive potassium channel (K(ATP)) activator (minoxidil sulfate; MS) increases temozolomide and Herceptin delivery to brain tumors to induce anti-tumor activity and increase survival in nude mice with Glioblastoma multiforme (GBM) cells." | 3.75 | Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. ( Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, T, 2009) |
| "We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT)." | 3.75 | Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ( Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A, 2009) |
| "Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients)." | 3.75 | Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. ( Chamberlain, MC; Raizer, J, 2009) |
| " The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment." | 3.75 | Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 3.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| " Moreover, enhanced growth delay with the addition of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug in the treatment of glioblastoma multiforme." | 3.75 | In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. ( Beam, K; Burgan, WE; Camphausen, K; Carter, D; Chakravarti, A; Kwon, HC; Russo, AL; Slusher, BS; Tofilon, PJ; Weizheng, X; Zhang, J, 2009) |
| "The aim of the present study was to evaluate factors predicting the recurrence pattern after the administration of temozolomide (TMZ), initially concurrent with radiotherapy (RT) and subsequently as maintenance therapy, which has become standard treatment for patients with newly diagnosed glioblastoma (GBM)." | 3.75 | Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. ( Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A, 2009) |
| "Recently, there has been greater awareness that combination radiation and temozolomide used to treat glioblastomas may cause increased contrast enhancement on the first post radiation MRI scan." | 3.75 | Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. ( Gerstner, ER; Lafrankie, D; McNamara, MB; Norden, AD; Wen, PY, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 3.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 3.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| "We have completed in vivo safety and efficacy studies of the use of a novel drug delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the post-resection cavity, as a candidate for glioma therapy." | 3.75 | Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. ( Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J, 2009) |
| "Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas." | 3.75 | Glioma-associated endothelial cells are chemoresistant to temozolomide. ( Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W, 2009) |
| "We evaluated the benefit of preradiation chemotherapy with ACNU (nimustine) and CDDP (cisplatin) in patients with newly diagnosed glioblastoma by retrospective analysis." | 3.75 | Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. ( Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IH; Lee, SH; Paek, SH; Park, CK, 2009) |
| "A 46-year-old man developed Stevens-Johnson syndrome and toxic epidermal necrolysis overlap, with severe localized denudation of the skin on the head and neck, following radiotherapy and oral temozolomide therapy for cranial glioblastoma multiforme." | 3.75 | Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. ( Sarma, N, 2009) |
| " On the other hand, temozolomide (TMZ), an oral bioavailable alkylating agent with excellent tolerability, has demonstrated efficacy and has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 3.75 | Effect of IFN-beta on human glioma cell lines with temozolomide resistance. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Watanabe, T; Yachi, K; Yoshino, A, 2009) |
| "A recent randomized study conducted on newly diagnosed glioblastoma (GBM) patients demonstrated that concomitant and adjuvant temozolomide added to standard radiotherapy had a survival advantage compared with radiotherapy alone." | 3.75 | Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. ( Agati, R; Bacci, A; Benevento, F; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Mazzocchi, V; Scopece, L; Tosoni, A, 2009) |
| "Previous studies have revealed that p38, a member of the family of stress-activated protein kinases (SAPKs), cooperates with the Chk1-pathway to bring about temozolomide (TMZ)-induced G2 arrest, and that the inhibition of either pathway alone is sufficient to sensitize U87MG glioma cells to TMZ-induced cytotoxicity." | 3.75 | Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Sano, H, 2009) |
| "Methionine depletion causes a demonstrable increase in glutathione levels for medulloblastoma (Daoy) and glioma (D54) cells, with a decrease in MGMT activity for Daoy cells." | 3.75 | Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. ( Estlin, EJ; McGown, A; Najim, N; Podmore, ID, 2009) |
| "Concurrent temozolomide (TMZ) and radiation therapy (RT) followed by adjuvant TMZ is standard treatment for patients with glioblastoma multiforme (GBM), although the relative contribution of concurrent versus adjuvant TMZ is unknown." | 3.75 | Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. ( Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| " For example, Temozolomide (TMZ) exhibits some antitumor activity against brain tumors, so does Trastuzumab (Herceptin, Her-2 inhibitor), which might be effective against Her2 neu overexpressing gliomas." | 3.75 | Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. ( Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, TS, 2009) |
| "Eighty-three patients with glioblastoma underwent surgery followed by radiotherapy and temozolomide chemotherapy between October 2000 and June 2008." | 3.75 | The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. ( Cao, VT; Chae, HJ; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Lee, KH; Moon, KS; Park, CS, 2009) |
| "Our data suggest that temozolomide is an active regimen for malignant gliomas." | 3.74 | Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Gunel, N; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2008) |
| "Although high AGT levels may mediate resistance in a portion of these samples, MMR deficiency does not seem to be responsible for mediating temozolomide resistance in adult malignant glioma." | 3.74 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. ( Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A, 2008) |
| " Convection-enhanced delivery (CED) of either the replication-defective, ICP0-producing HSV-1 mutant, d106, or the recombinant d109, devoid of all viral genome expression, was performed to determine the in vivo efficacy of ICP0 in combination with ionizing radiation (IR) or systemic temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 3.74 | Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. ( Deluca, NA; Fellows-Mayle, W; Hadjipanayis, CG, 2008) |
| "Use of antiangiogenic therapy with radiation and temozolomide in the primary management of high-grade glioma is feasible." | 3.74 | Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. ( Eagan, P; Fischer, I; Golfinos, JG; Gruber, ML; Kelly, P; Knopp, EA; Medabalmi, P; Narayana, A; Parker, E; Raza, S; Zagzag, D, 2008) |
| "Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy." | 3.74 | [Alveolo-interstitial pneumonia due to Temozolamide]. ( Autret-Leca, E; Beau Salinas, F; Carré, P; de Luca, K; Diot, P; Guilleminault, L; Narciso, B, 2008) |
| " In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide." | 3.74 | Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008) |
| "Human GBM-derived cell lines U87, G44, G112, and the gliosarcoma-derived line G28 were treated with EPO, with and without combinations of irradiation or temozolomide (TMZ)." | 3.74 | Erythropoietin augments survival of glioma cells after radiation and temozolomide. ( Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S, 2008) |
| "In the 4-year retrospective study, 31 patients with histologically confirmed malignant gliomas, in which 10 patients received radiotherapy followed by temozolomide (group A) and 21 patients received radiotherapy alone (group B)." | 3.74 | Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. ( Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM, 2008) |
| "In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches." | 3.74 | p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. ( Berger, MS; Dinca, EB; Haas-Kogan, DA; James, CD; Lu, KV; Pieper, RO; Prados, MD; Sarkaria, JN; Vandenberg, SR, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 3.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents." | 3.74 | MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. ( Addo-Yobo, SO; Donson, AM; Foreman, NK; Gore, L; Handler, MH, 2007) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas)." | 3.74 | Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. ( Batista, LF; Kaina, B; Menck, CF; Naumann, SC; Roos, WP; Weller, M; Wick, W, 2007) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| "Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model." | 3.74 | Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. ( Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "The aim of this study was to investigate the effect of temozolomide (TZM) in combination with X-rays on proliferation and migration in human glioma spheroids." | 3.74 | The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation. ( Fehlauer, F; Muench, M; Rades, D; Richter, E, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 3.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations." | 3.74 | Dynamic history of low-grade gliomas before and after temozolomide treatment. ( Amiel-Benouaich, A; Capelle, L; Carpentier, AF; Cornu, P; Delattre, JY; Duffau, H; Guillevin, R; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Laigle-Donadey, F; Lejeune, J; Mandonnet, E; Marie, Y; Mokhtari, K; Omuro, A; Ricard, D; Sanson, M; Taillibert, S, 2007) |
| "We report the case of a 30-year-old woman with glioblastoma multiforme (GBM) treated with surgery followed by concomitant Temozolomide (TMZ) and external beam radiation, which she tolerated well without any interruptions." | 3.74 | Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. ( Gujral, S; Jalali, R; Menon, H; Singh, P, 2007) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 3.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "The use of adjuvant temozolomide (TMZ) in patients managed with surgery and adjuvant radiation therapy (RT) for glioblastoma multiforme (GBM) has been demonstrated to improve median and 2-year survival in a recent large international multicentre study." | 3.74 | Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. ( Ang, EL; Back, MF; Chan, SP; Lim, CC; Ng, WH; See, SJ; Yeo, TT, 2007) |
| " In this study, as we determined p53 gene mutation occurring in multinucleated giant cell glioblastoma, we investigated the role of Aurora-B in formation of multinucleated cells in human neoplasm cells with various p53 statuses as well as cytotoxity of glioma cells to temozolomide (TMZ), a common oral alkylating agent used in the treatment of gliomas." | 3.74 | Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. ( Fujita, M; Inagaki, M; Katsumata, S; Mizuno, M; Nakahara, N; Natsume, A; Osawa, H; Satoh, Y; Tsuno, T; Wakabayashi, T; Yoshida, J, 2007) |
| " The potential therapeutic value of MGMT hypermethylation evaluation using MS-MLPA was shown in a group of 20 glioblastoma patients receiving temozolomide chemotherapy." | 3.74 | MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. ( Boots-Sprenger, SH; Cornelissen, SJ; Dekkers, MM; Errami, A; Jeuken, JW; Sijben, A; Vriezen, M; Wesseling, P, 2007) |
| "Treatment of malignant glioma involves concomitant temozolomide and ionizing radiation (IR)." | 3.74 | Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. ( Bickenbach, K; Galanopoulos, N; Pytel, P; Rawlani, V; Veerapong, J; Weichselbaum, RR; Yamini, B; Yu, X, 2007) |
| "To investigate the radiosensitizing potential of temozolomide (TMZ) for human glioblastoma multiforme (GBM) cell lines using single-dose and fractionated gamma-irradiation." | 3.74 | Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. ( Hulsebos, TJ; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; van den Berg, J; van Nifterik, KA, 2007) |
| "To evaluate efficacy and toxicity in elderly patients with glioblastoma multiforme (GBM) treated with postoperative radiochemotherapy with temozolomide (TMZ)." | 3.74 | Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. ( Bischof, M; Combs, SE; Debus, J; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T, 2008) |
| "Methylation of the promoter region of the O ( 6 ) -methylguanine-DNA methyltransferase (MGMT) gene is known to be predictive of response to temozolomide treatment in patients with glioblastoma." | 3.74 | Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. ( Biggs, MT; Clarkson, A; Cook, RJ; Little, NS; McDonald, KL; McKenzie, CA; Messina, M; Parkinson, JF; Robinson, BG; Wheeler, HR, 2008) |
| "Diffusion tensor imaging and multiple voxel magnetic resonance spectroscopy were performed in the MRI follow-up of a patient with a glioma treated with temozolomide chemotherapy." | 3.74 | Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. ( Enting, RH; Heesters, MA; Irwan, R; Meiners, LC; Oudkerk, M; Potze, JH; Sijens, PE; van der Graaf, WT, 2007) |
| "The purpose of this study was to report our experience with concomitant and adjuvant temozolomide (TMZ) with radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 3.74 | Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. ( Basu, A; Goel, A; Gupta, T; Jalali, R; Menon, H; Munshi, A; Sarin, R, 2007) |
| " Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia." | 3.74 | Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. ( Aldape, K; Archer, GE; Bigner, DD; Crutcher, L; Dey, M; Gilbert, M; Hassenbusch, SJ; Heimberger, AB; Hussain, SF; Mitchell, DA; Sampson, JH; Sawaya, R; Schmittling, B; Sun, W, 2008) |
| "Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM)." | 3.74 | The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. ( Avutu, B; Barker, FG; Batchelor, TT; Chakravarti, A; Henson, JW; Hochberg, FH; Loeffler, JS; Martuza, RL; Sher, DJ, 2008) |
| "32 patients 70 years of age or older with a newly diagnosed glioblastoma and a Karnofsky performance status (KPS) > or = 70 were treated with RT (daily fractions of 2 Gy for a total of 60 Gy) plus temozolomide at the dose of 75 mg/m(2) per day followed by six cycles of adjuvant temozolomide (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 3.74 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. ( Bozzao, A; De Paula, U; De Sanctis, V; Filippone, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Tombolini, V; Valeriani, M, 2008) |
| "The oral alkylating agent, temozolomide (Temodal: TMZ), is the only anticancer drug that has been shown in a phase III study to improve survival in glioblastoma (GBM) when administered with concomitant radiotherapy." | 3.74 | [Temozolomide: Temodal]. ( Nakamura, O; Saito, K; Shinoura, N; Tabei, Y; Takahashi, M; Yamada, R, 2008) |
| "Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
| "The in vitro cytotoxicity of TRA-8 and temozolomide (Tmz) or RT was examined using adenosine triphosphate-dependent viability and clonogenic survival assays with five glioma cell lines." | 3.74 | Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. ( Belenky, ML; Buchsbaum, DJ; Fiveash, JB; Gillespie, GY; Oliver, PG; Zhou, T, 2008) |
| "To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma." | 3.73 | Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. ( Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005) |
| "Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit." | 3.73 | MGMT gene silencing and benefit from temozolomide in glioblastoma. ( Bromberg, JE; Cairncross, JG; de Tribolet, N; Diserens, AC; Gorlia, T; Hainfellner, JA; Hamou, MF; Hau, P; Hegi, ME; Janzer, RC; Kros, JM; Mariani, L; Mason, W; Mirimanoff, RO; Stupp, R; Weller, M, 2005) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 3.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 3.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "Cimetidine added to temozolomide compared with temozolomide alone induced survival benefits in nude mice with U373 human glioblastoma multiforme (GBM) cells orthotopically xenografted in the brain." | 3.73 | Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. ( Brotchi, J; Camby, I; Darro, F; Gabius, J; Gaussin, JF; James, S; Kiss, R; Lefranc, F, 2005) |
| "There are new scientific data concerning the treatment of patients with glioblastoma multiforme with concomitant and adjuvant temozolomide following surgery and radiotherapy." | 3.73 | [Temozolomide in patients with a glioblastoma multiforme: new developments]. ( Bromberg, JE; Postma, TJ, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 3.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| "Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 3.73 | Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. ( Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P, 2005) |
| " Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 3.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 3.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 3.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma." | 3.73 | Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M, 2006) |
| "This is a report of a 53 year-old man with a glioblastoma multiforme (GBM) treated with an excessive dose of temozolomide (TMZ)." | 3.73 | Complications of a temozolomide overdose: a case report. ( Kiem, HP; Partap, S; Peterson, RA; Schuetze, S; Silber, JR; Spence, AM, 2006) |
| "Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma." | 3.73 | Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. ( Bally, F; Christen, G; de Ribaupierre, S; Ganière, V; Guillou, L; Pica, A; Stupp, R, 2006) |
| "Previously we defined a pathway of transforming growth factor beta (TGF-beta) and stromal cell-derived factor-1/CXC chemokine ligand 12 (SDF-1alpha/CXCL12) dependent migration of adult haematopoietic stem and progenitor cells (HPC) towards glioma cells in vitro and their homing to experimental gliomas in vivo." | 3.73 | Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. ( Frank, B; Möhle, R; Tabatabai, G; Weller, M; Wick, W, 2006) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 3.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma." | 3.73 | Potentiation of antiglioma effect with combined temozolomide and interferon-beta. ( Hong, YK; Joe, YA; Kim, TG; Park, JA, 2006) |
| "In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent." | 3.72 | Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. ( Barnett, G; Chahlavi, A; Elson, P; Kanner, A; Peereboom, D; Staugaitis, SM, 2003) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 3.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases." | 3.72 | Complete response of multiple melanoma brain metastases after treatment with temozolomide. ( Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J, 2004) |
| "The Chk1 and p38 mitogen-activated protein kinase (MAPK) pathways play key roles in the G2 arrest caused by exposing glioma cells to temozolomide (TMZ)." | 3.72 | Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. ( Berger, MS; Hirose, Y; Katayama, M; Pieper, RO, 2004) |
| "The phase III randomised European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trail Group (NCIC) Intergroup trial (EORTC 26981/22981; CE3) compares irradiation alone with irradiation plus temozolomide for patients with glioblastoma multiforme (GBM)." | 3.72 | Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. ( Ataman, F; Fisher, B; Mirimanoff, RO; Poortmans, P; Stupp, R, 2004) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 3.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| "Temozolomide is an oral alkylating agent shown to have modest efficacy in the treatment of glioblastoma multiforme." | 3.72 | Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. ( Gillespie, GY; Kufe, DW; Weichselbaum, RR; Yamini, B; Yu, X, 2004) |
| "Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence." | 3.71 | Temozolomide as second-line chemotherapy for relapsed gliomas. ( Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S, 2002) |
| "Temozolomide (TZM) is a novel methylating agent currently under investigation for treatment of recurrent high-grade gliomas." | 3.71 | Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. ( Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F, 2002) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 3.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "A case is reported in which temozolomide, a promising new DNA alkylating agent, was successfully used to treat radiation refractory metastatic brain tumors arising from primary breast cancer." | 3.71 | Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report. ( Isaacson, BJ; Islam, R; Ratanawong, C; Tipping, SJ; Zickerman, PM, 2002) |
| "Temozolomide has an evolving role in the treatment of high grade gliomas." | 3.71 | An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. ( Ashley, DL; Cher, L; Harris, MT; Rosenthal, MA, 2001) |
| "The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days." | 3.71 | Temozolomide chemotherapy in recurrent oligodendroglioma. ( Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ, 2001) |
| "Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy." | 3.71 | Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. ( Chou, TC; Droege, JW; Fels, C; Kramm, CM; Rainov, NG; Schäfer, C, 2001) |
| "To investigate the effect of temozolomide, a 3-methyl derivative of mitozolomide in combination with X-rays in human glioma-derived cell lines." | 3.70 | Survival of human glioma cells treated with various combination of temozolomide and X-rays. ( Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J, 2000) |
| "The activity of temozolomide combined with irinotecan (CPT-11) was evaluated against eight independent xenografts (four neuroblastomas, three rhabdomyosarcomas, and one glioblastoma)." | 3.70 | Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. ( Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M, 2000) |
| " Temozolomide is a novel methylating agent with proven efficacy against malignant gliomas (MGs) after systemic administration but with dose-limiting myelotoxicity." | 3.70 | Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. ( Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Heimberger, AB; Hulette, C; McLendon, RE; Sampson, JH, 2000) |
| "The in vitro cytotoxicity of 8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazine-4(3H)-one (temozolomide) with concurrent X-irradiation was examined in a human glioblastoma cell line (U373MG) as a potential radio-chemotherapeutic treatment for malignant glioma." | 3.69 | In vitro evaluation of temozolomide combined with X-irradiation. ( Glaser, MG; Marcus, K; Newlands, ES; Porteous, JK; Wedge, SR, 1997) |
| "Glioblastoma is the most common and most aggressive type of primary brain tumor." | 3.30 | Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023) |
| "Glioblastoma is the most lethal primary brain cancer." | 3.30 | Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. ( Abram, S; Aiken, RD; Ansstas, G; Ashkan, K; Avigan, DE; Baskin, DS; Battiste, JD; Bosch, ML; Bota, DA; Boynton, AL; Brem, S; Brenner, AJ; Campian, JL; Chaudhary, R; Cobbs, CS; D'Andre, S; Dunbar, EM; Elinzano, H; Etame, AB; Ewend, MG; Fink, KL; Geoffroy, FJ; Giglio, P; Gligich, O; Goldlust, SA; Grewal, J; Heth, JA; Iwamoto, FM; Kesari, S; Khagi, S; Kim, L; Krex, D; Lacroix, M; Lee, IY; Liau, LM; Lillehei, K; Lindhorst, SM; Loudon, WG; Lovick, DS; Lutzky, J; Martinez, NL; Mathieu, D; May, SA; Meisel, HJ; Mikkelsen, T; Moshel, YA; Mulholland, PJ; Nadji-Ohl, M; Nam, JY; New, PZ; Peak, S; Pearlman, ML; Petrecca, K; Piccioni, DE; Pillainayagam, CP; Pluard, TJ; Portnow, J; Prins, RM; Salacz, ME; Sanchin, L; Schulder, M; Sloan, A; Taylor, LP; Thompson, RC; Toms, SA; Tran, DD; Trusheim, JE; Tse, V; Villano, JL; Wagner, SA; Walbert, T; Walter, KA; Wu, JK, 2023) |
| "Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14." | 3.11 | Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. ( Burgess, C; FitzJohn, T; Kaye, AH; O'Rawe, M; Pandey, R; Sim, D; Tan, ST; Wickremesekera, AC; Young, D, 2022) |
| "The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade." | 3.11 | Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. ( Amatu, A; Barault, L; Bardelli, A; Bartolini, A; Battuello, P; Bonoldi, E; Cassingena, A; Crisafulli, G; Di Nicolantonio, F; Germano, G; Idotta, L; Lazzari, L; Luraghi, P; Macagno, M; Marsoni, S; Mauri, G; Morano, F; Personeni, N; Pessei, V; Pietrantonio, F; Sartore-Bianchi, A; Siena, S; Tosi, F; Valtorta, E; Vitiello, PP; Zampino, MG, 2022) |
| "Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22." | 3.11 | Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. ( Borger, V; Goldbrunner, R; Güresir, E; Hau, P; Herrlinger, U; Krex, D; Pietsch, T; Potthoff, AL; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Tzaridis, T; Vatter, H; Weller, J; Zeyen, T, 2022) |
| "The most frequently diagnosed primary brain tumor is glioblastoma (GBM)." | 3.11 | A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol. ( Dai, J; Gong, X; Guan, Y; Han, L; Li, J; Liu, X; Liu, Y; Lu, Q; Mei, G; Pan, L; Pan, M; Wang, E; Wang, X; Wang, Y; Yang, J; Zhu, H, 2022) |
| " Common nonocular treatment-emergent adverse events (TEAEs) with both second-line and first-line Depatux-M included lymphopenia (42%, 33%, respectively), thrombocytopenia (39%, 47%), alanine aminotransferase increase (29%, 47%), and aspartate aminotransferase increase (24%, 60%); incidence of grade ≥3 TEAEs was 66% and 53%, respectively." | 3.01 | Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. ( Asai, K; Beppu, T; Date, I; Kagawa, N; Kanamori, M; Kasai, S; Kobayashi, H; Kumabe, T; Kuroda, J; Matsuda, M; Mishima, K; Muragaki, Y; Nagane, M; Narita, Y; Nishimura, Y; Ocampo, C; Ueki, K; Xiong, H; Yamada, M, 2021) |
| " Only one possibly treatment-related treatment emergent adverse event (TEAE), Grade 1 gingival swelling, was observed." | 3.01 | Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study. ( Chen, KT; Hsu, PW; Huang, HL; Jung, SM; Ke, YX; Lin, YJ; Toh, CH; Tsai, HC; Tseng, CK; Wei, KC, 2021) |
| " Glioblastoma is the most aggressive and diffusely infiltrative primary brain tumor." | 3.01 | Updates in the Management of Recurrent Glioblastoma Multiforme. ( Ansari, A; Prajapati, HP, 2023) |
| "Gliomas are the most common primary central nervous system tumors; despite recent advances in diagnosis and treatment, glioma patients generally have a poor prognosis." | 3.01 | Current and promising treatment strategies in glioma. ( Bebyn, M; Furtak, J; Koper, A; Koper, K; Śledzińska, P, 2023) |
| "Glioma is a deadly form of brain cancer, and the difficulty of treating glioma is exacerbated by the chemotherapeutic resistance developed in the tumor cells over the time of treatment." | 3.01 | Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells. ( Chung, S; Huang, J; Sugimoto, Y; Zhang, M, 2023) |
| "Malignant primary brain tumors cause more than 15 000 deaths per year in the United States." | 3.01 | Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. ( Mellinghoff, IK; Schaff, LR, 2023) |
| "As the most malignant primary brain tumor in adults, a diagnosis of glioblastoma multiforme (GBM) continues to carry a poor prognosis." | 3.01 | Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme. ( Manea, AJ; Ray, SK, 2023) |
| "Temozolomide (TMZ) is a DNA alkylating agent that can cross the blood-brain barrier." | 3.01 | Expert opinion on translational research for advanced glioblastoma treatment. ( Cui, X; Kang, C; Wang, Q; Wang, Y; Zhou, J, 2023) |
| "Glioblastoma Multiforme (GBM) is the primary brain tumor and accounts for 200,000 deaths each year worldwide." | 3.01 | Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme. ( Adusumilli, K; Angirekula, HSR; Chamarthy, S; Mekala, JR, 2023) |
| "Glioblastoma is the most common and lethal brain tumor in adults." | 3.01 | Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. ( Iturrioz-Rodríguez, N; Matheu, A; Sampron, N, 2023) |
| "TMZ is utilized in brain cancer removal, but resistance is a drawback." | 3.01 | Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs. ( Ajdari, A; Aref, AR; Etemad, S; Eydivandi, S; Fan, X; Hushmandi, K; Karimi, AS; Khorrami, R; Nabavi, N; Rahmanian, P; Rajabi, R; Rashidi, M; Rezaee, A; Sanadgol, N; Tehrany, PM; Tirabadi, FJ; Zandieh, MA; Zou, R, 2023) |
| "Atorvastatin was not shown to improve PFS-6." | 3.01 | Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study. ( Aldanan, S; Alghareeb, WA; Alhussain, H; AlNajjar, FH; Alsaeed, E; Alsharm, AA; Altwairgi, AK; Balbaid, AAO; Orz, Y, 2021) |
| " Methods This is an open-label, 2-arm Phase 1b/2a study (N = 56) of galunisertib (intermittent dosing: 14 days on/14 days off per cycle of 28 days) in combination with TMZ/RTX (n = 40), versus a control arm (TMZ/RTX, n = 16)." | 2.94 | Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ( Burkholder, T; Capper, D; Cleverly, AL; Desjardins, A; Estrem, ST; Forsyth, P; Guba, SC; Gueorguieva, I; Lahn, MM; Rodon, J; Suarez, C; Wang, S; Wick, A, 2020) |
| "Primary end point is freedom from new brain metastases at 1 year." | 2.94 | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. ( Armstrong, TS; Biassou, N; Brastianos, PK; Burton, E; Carter, S; Gilbert, MR; Gril, B; Houston, N; Lipkowitz, S; Lyden, D; Smart, DD; Steeg, PS; Steinberg, SM; Zimmer, AS, 2020) |
| " In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide (TMZ) to treat these patients, although large-scale prospective studies are lacking." | 2.90 | Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial. ( Guan, H; He, L; He, Y; Mu, X; Peng, X; Wang, J; Wang, Y, 2019) |
| " Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%)." | 2.90 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ( Ansell, PJ; Bain, E; Butowski, N; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Maag, D; Merrell, R; Mikkelsen, T; Nabors, LB; Papadopoulos, KP; Penas-Prado, M; Reardon, DA; Roberts-Rapp, L; Scott, AM; Simes, J; van den Bent, MJ; Walbert, T; Wheeler, H; Xiong, H, 2019) |
| "Cerebral edema was assessed at 4, 12, 22 and 34 weeks post-surgery, together with steroids consumption and patients' psychological status." | 2.90 | A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience. ( Bertuccioli, A; Botta, L; Bruzzone, MG; Cuccarini, V; Di Pierro, F; Fariselli, L; Lamperti, E; Petruzzi, A; Simonetti, G, 2019) |
| " The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM." | 2.90 | Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. ( Chen, G; Chen, L; Li, G; Li, Q; Luo, W; Lv, S; Zhong, L; Zhou, P, 2019) |
| "Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 2.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
| " The observation index of both groups included the short- and long-term clinical efficacies, improvement of symptoms and signs, quality of life (QOL), and adverse responses." | 2.84 | Efficacy and safety of temozolomide plus whole-brain radiotherapy in the treatment of intracranial metastases. ( Liu, HP; Wang, JW; Zheng, KB, 2017) |
| "Cancer is one of the main causes of human mortality and brain tumors, including invasive pituitary adenomas, medulloblastomas and glioblastomas are common brain malignancies with poor prognosis." | 2.82 | Oxamate targeting aggressive cancers with special emphasis to brain tumors. ( Altinoz, MA; Ozpinar, A, 2022) |
| "Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit angiogenesis." | 2.82 | Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature. ( Sun, X; Xu, X; Xu, Y; Zhan, W; Zhao, L; Zhu, Y, 2022) |
| " There is insufficient data to make a recommendation about which alternative TMZ dosing provides the best benefits." | 2.82 | Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. ( Germano, IM; Olson, JJ; Ormond, DR; Wen, P; Ziu, M, 2022) |
| " Although these beneficial effects are promising, the efficacy of natural compounds in glioblastoma is limited due to their bioavailability and blood-brain barrier permeability." | 2.82 | Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas. ( Gigli, G; Leporatti, S; Persano, F, 2022) |
| " TMZ is an orally bioavailable prodrug, which is well absorbed from the gastrointestinal tract and is converted to its active alkylating metabolite 5-(3-methyl triazen-1-yl)imidazole-4-carbozamide (MTIC) spontaneously in physiological condition that does not require hepatic involvement." | 2.82 | Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems. ( Alyautdin, R; Chubarev, V; Grigorevskikh, E; Ismail, N; Merkulov, V; Petrenko, D; Smolyarchuk, E; Sologova, S; Syzrantsev, N, 2022) |
| " In addition, OS, PFS and adverse event (AE) data on ndGBM and recurrent GBM (rGBM) were assessed." | 2.82 | Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. ( Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B, 2022) |
| "Glioblastoma is the most aggressive form of brain tumor, accounting for the highest mortality and morbidity rates." | 2.82 | Nanomedicine for glioblastoma: Progress and future prospects. ( Baig, MH; Cho, JY; Dong, JJ; Hatiboglu, MA; Imran, MA; Khan, I; Khan, MI; Mahfooz, S, 2022) |
| "Glioblastoma is a fatal brain tumor with a bleak prognosis." | 2.82 | Glioblastoma and Methionine Addiction. ( Sowers, LC; Sowers, ML, 2022) |
| "(1) Background: Glioblastoma is the most frequent and lethal primary tumor of the central nervous system." | 2.82 | Glioblastoma Treatment: State-of-the-Art and Future Perspectives. ( Celis-López, MÁ; Cid-Sánchez, DR; Contreras-Palafox, GA; Flores-Vázquez, JG; Gutiérrez-Aceves, GA; Heredia-Gutiérrez, JC; Hernández-Sánchez, LC; Macías-González, MDS; Moreno-Jiménez, S; Moscardini-Martelli, J; Olmos-Guzmán, A; Ortiz-Arce, CS; Pérez, SR; Rodríguez-Camacho, A; Suárez-Campos, JJE; Torres-Ríos, JA, 2022) |
| "Gliomas are the deadliest of all primary brain tumors, and they constitute a serious global health problem." | 2.82 | MicroRNA delivery systems in glioma therapy and perspectives: A systematic review. ( Abrahantes-Pérez, MDC; Barajas-Olmos, F; García-Ortiz, H; Hernández-Cuenca, YE; Jiménez-Morales, JM; Orozco, L; Quiñones-Hinojosa, A; Reyes-Abrahantes, A; Reyes-González, J; Ruiz-García, H, 2022) |
| "Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options." | 2.82 | Immune-checkpoint inhibitors for glioblastoma: what have we learned? ( Omuro, A, 2022) |
| "Gliomas are tumors of the primary central nervous system associated with poor prognosis and high mortality." | 2.82 | MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine. ( Du, J; Fan, H; Kuang, X; Peng, F; Xie, X, 2022) |
| "Therefore, brain cancer research models need to aim to recapitulate glioblastoma stem cell function, whilst remaining amenable for analysis." | 2.82 | Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications. ( Gray, C; Paterson, E; Peng, L; Tan, ST; Weth, FR, 2022) |
| "Glioblastoma is the most frequently diagnosed type of primary brain tumour in adults." | 2.82 | DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. ( Collis, SJ; Rominiyi, O, 2022) |
| "Temozolomide was administered twice daily on days -10 to -6, followed by thiotepa 300 mg/m(2) per day and carboplatin dosed using the Calvert formula or body surface area on days -5 to -3, with AHCR day 0." | 2.82 | Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease. ( Belasco, JB; Cervone, KA; Egan, G; Finlay, JL; Gardner, SL; Philips, PC, 2016) |
| "Glioblastoma is the most common malignant brain tumor in adults." | 2.82 | Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. ( Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D, 2016) |
| "Treatment was bortezomib 1." | 2.82 | A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. ( Bredel, M; Chandler, JP; Ferrarese, R; Grimm, SA; Helenowski, I; Levy, RM; Muro, K; Paton, M; Rademaker, A; Raizer, JJ; Rosenow, J, 2016) |
| "Retreatment with temozolomide (TMZ) is one treatment option." | 2.80 | Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. ( Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015) |
| "Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression." | 2.80 | A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. ( Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH, 2015) |
| "Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles." | 2.80 | Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H, 2015) |
| "The rate of dying after disease progression is about 6." | 2.80 | Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. ( Curran, W; Dignam, JJ; Gilbert, MR; Mehta, M; Wang, M; Won, M, 2015) |
| "Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1-6), followed by TMZ maintenance therapy (TMZ/RT→TMZ)." | 2.80 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. ( Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015) |
| "Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase." | 2.79 | Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ( Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014) |
| " There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied." | 2.78 | A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. ( Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013) |
| "Cefixime prophylaxis was used to reduce irinotecan-associated diarrhea." | 2.78 | Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. ( Cripe, T; Geller, J; Nagarajan, R; Turpin, B; Wagner, L; Weiss, B, 2013) |
| "The upfront approach to treatment of glioblastoma in the unresectable population warrants further investigation in randomized controlled phase III trials." | 2.78 | Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ, 2013) |
| "Patients with multiple brain metastases from NSCLC aged ≥ 18 years, classified according to recursive partitioning analysis class I or II and with adequate organ functions were eligible." | 2.78 | Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. ( Altorjai, G; Dieckmann, K; Geissler, K; Hassler, MR; Knocke-Abulesz, TH; Marosi, C; Pfeifer, W, 2013) |
| "NSCLC patients with 1 to 3 brain metastases were randomized to receive WBRT (2." | 2.78 | A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. ( Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M, 2013) |
| "The results suggest that Cyberknife re-treatments are relatively safe using selected dose/fraction schemes." | 2.77 | Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. ( Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F, 2012) |
| "Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 2.77 | Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. ( Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012) |
| "Patients with brain metastases (BM) rarely survive longer than 6months and are commonly excluded from clinical trials." | 2.77 | Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca ( Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A, 2012) |
| "WBI alone in patients with Brain metastases (BM) from solid tumours." | 2.77 | Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial. ( Arrieta, Ó; Ferrari-Carballo, T; Gamboa-Vignolle, C; Mohar, A, 2012) |
| "The median number of brain metastases was 1." | 2.77 | Chemosensitized radiosurgery for recurrent brain metastases. ( Fortin, MA; Pouliot, JF; Roberge, D; Souhami, L, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 2.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases)." | 2.76 | Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. ( Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L, 2011) |
| " On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study." | 2.76 | North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. ( Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011) |
| "The primary objective of this augmental, prospective, uncontrolled phase II multicentre trial was to assess adverse events (AE) associated with malignant glioma resection using 5-aminolevulinic (5-ALA)." | 2.76 | Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. ( Kern, BC; Krex, D; Mehdorn, HM; Nestler, U; Pichlmeier, U; Stockhammer, F; Stummer, W; Vince, GH, 2011) |
| " The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation." | 2.76 | Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. ( Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y, 2011) |
| "Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70." | 2.76 | Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. ( Barrie, M; Beauchesne, P; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, O; Delattre, JY; Ducray, F; Gállego Pérez-Larraya, J; Guillamo, JS; Honnorat, J; Huchet, A; Matta, M; Mokhtari, K; Monjour, A; Taillandier, L; Tanguy, ML, 2011) |
| "Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles." | 2.76 | A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. ( Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ, 2011) |
| "Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR." | 2.75 | EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. ( Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ, 2010) |
| "The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q." | 2.74 | Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. ( Anderson, J; Avedissian, R; Croteau, D; Doyle, T; Gutierrez, J; Hasselbach, L; Margolis, J; Mikkelsen, T; Paleologos, N; Schultz, L, 2009) |
| "Patients with primary or metastatic brain tumors had a microdialysis catheter placed in peritumoral brain tissue at the time of surgical debulking." | 2.74 | The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. ( Badie, B; Blanchard, S; Chen, M; Liu, A; Portnow, J; Synold, TW, 2009) |
| "Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells." | 2.73 | Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. ( Cairncross, JG; de Tribolet, N; Delorenzi, M; Dietrich, PY; Domany, E; Gorlia, T; Hainfellner, JA; Hamou, MF; Hegi, ME; Heppner, FL; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Migliavacca, E; Murat, A; Regli, L; Shay, T; Stupp, R; Wick, W; Zimmer, Y, 2008) |
| "Temozolomide treatment did not affect TPM plasma concentrations in chronically treated patients." | 2.73 | Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Pace, A; Zarabla, A, 2008) |
| "We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors." | 2.73 | Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. ( Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD, 2008) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 2.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "33 patients with brain metastases were included in the study and treated with TMZ 60 mg/m2/day (days 1-16) concomitantly with WBI (36 Gy/12 fractions given in 16 days)." | 2.73 | Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. ( Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ, 2007) |
| " Single-dose temozolomide at five dosage levels (267, 355, 472, 628, and 835 mg/m(2)) was given at least 6 h after completion of O(6)-benzylguanine bolus." | 2.73 | Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. ( Boyett, JM; Broniscer, A; Danks, MK; Friedman, HS; Gajjar, A; Goldman, S; Gururangan, S; Kun, LE; MacDonald, TJ; Packer, RJ; Poussaint, TY; Stewart, CF; Wallace, D, 2007) |
| " CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion." | 2.73 | Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. ( Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 2.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| " The main advantages are its high oral bioavailability (almost 100% although the concentration found in the cerebrospinal fluid was approximately 20% of the plasma concentration of TMZ), its lipophilic properties, and small size that confer the ability to cross the blood-brain barrier." | 2.72 | Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. ( Cabeza, L; Jiménez-Luna, C; Luque, R; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J, 2021) |
| "GBM is the grade IV glioma brain cancer which is life-threatening to many individuals affected by this cancer." | 2.72 | Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. ( Shetty, K; Yadav, KS; Yasaswi, PS, 2021) |
| "Malignant tumors in young patients present a significant therapeutic challenge for physicians, partially due to their rarity and a relative lack of data, at least compared to adult tumors." | 2.72 | An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors. ( Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S, 2021) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 2.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard." | 2.72 | Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. ( Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ, 2006) |
| "Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM)." | 2.72 | Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. ( Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "To construct a population pharmacokinetic model for temozolomide (TMZ), a novel imidazo-tetrazine methylating agent and its metabolites MTIC and AIC in infants and children with primary central nervous system tumors." | 2.71 | Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. ( Fouladi, M; Gajjar, A; Heideman, RL; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF; Wilkinson, M, 2003) |
| "To characterize and compare pharmacokinetic parameters in children and adults treated with temozolomide (TMZ) administered for 5 days in three doses daily, and to evaluate the possible relationship between AUC values and hematologic toxicity." | 2.71 | Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. ( Barone, C; Caldarelli, M; Cefalo, G; Garrè, ML; Lazzareschi, I; Madon, E; Maira, G; Massimino, M; Mastrangelo, S; Mazzarella, G; Riccardi, A; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2003) |
| "Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration." | 2.71 | Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. ( Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K, 2004) |
| "Temozolomide is an oral chemotherapeutic agent with efficacy against malignant gliomas and a favorable safety profile." | 2.71 | Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Frauger, E; Grisoli, F; Hoang-Xuan, K; Martin, PM; Moktari, K; Palmari, J; Peragut, JC, 2004) |
| "Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS." | 2.71 | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. ( Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N, 2004) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| "The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known." | 2.71 | Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. ( Gomori, JM; Levin, N; Siegal, T, 2004) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%." | 2.71 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. ( Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D, 2004) |
| "Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)." | 2.71 | Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004) |
| "To evaluate the efficacy of temozolomide (TMZ) combined with cisplatin (CDDP) in terms of response rate, time to progression (TTP) and overall survival (OS), as well as the tolerability of the regimen in patients with brain metastases from solid tumors." | 2.71 | Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005) |
| "Temozolomide was administered orally each therapy day at a dose of 50 mg/m(2)." | 2.71 | Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. ( Combs, SE; Debus, J; Edler, L; Gutwein, S; Schulz-Ertner, D; Thilmann, C; van Kampen, M; Wannenmacher, MM, 2005) |
| "Temozolomide was administered orally at 150 mg/mq/day for five consecutive days for the first cycle, doses were increased to 200 mg/mq/day for 5 days every 28 days for subsequent cycles if no grade 3/4 haematological toxicity was observed." | 2.71 | Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. ( Blanco, G; Bordonaro, R; Castorina, S; Failla, G; Giorgio, CG; Giuffrida, D; Pappalardo, A; Russo, A; Salice, P; Santini, D, 2005) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 2.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| "Fifty-two patients with brain metastases from solid tumors were randomized to oral temozolomide (75 mg/m(2)/d) concurrent with 40-Gy fractionated conventional external-beam radiotherapy (2 Gy, 5 d/wk) for 4 weeks versus 40-Gy radiotherapy alone." | 2.70 | Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. ( Antonadou, D; Coliarakis, N; Economou, I; Karageorgis, P; Paraskevaidis, M; Sarris, G; Throuvalas, N, 2002) |
| "Temozolomide is a new cytotoxic alkylating agent that has recently been approved in Portugal for the treatment of recurrent high-grade glioma." | 2.70 | Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. ( Albano, J; Cernuda, M; Garcia, I; Lima, L; Oliveira, C; Portela, I; Teixeira, MM, 2002) |
| "Treatment with temozolomide was well tolerated." | 2.70 | Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. ( Bacoyiannis, C; Bafaloukos, D; Bamias, A; Christodoulou, C; Karabelis, A; Kosmidis, P; Papakostas, P; Samantas, E; Skarlos, DV, 2001) |
| "Eight children with poor prognosis brain tumors were eligible." | 2.70 | Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. ( Pavelka, Z; Slampa, P; Sterba, J, 2002) |
| " The absolute bioavailability of TMZ was 0." | 2.69 | Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ( Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F, 1998) |
| "Fotemustine 100 mg/m2 was given intravenously on day 2, 4 hours after TMZ." | 2.69 | Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. ( Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D, 1999) |
| " Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1." | 2.69 | Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ( Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P, 1999) |
| "Temozolomide was well tolerated with little subjective toxicity and usually predictable myelosuppression and is a promising new drug in the treatment of primary brain tumours." | 2.67 | Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. ( Brampton, M; Colquhoun, IR; Glaser, MG; Illingworth, RD; Kennard, C; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1993) |
| "Glioblastoma is the most common primary malignant brain tumor." | 2.66 | MGMT Status as a Clinical Biomarker in Glioblastoma. ( Aldape, K; Butler, M; Pommier, Y; Pongor, L; Quezado, M; Raffeld, M; Su, YT; Trepel, J; Wu, J; Xi, L, 2020) |
| "Glioblastoma is the most common malignant primary brain tumor." | 2.66 | Management of glioblastoma: State of the art and future directions. ( Ashley, DM; Friedman, HS; Khasraw, M; López, GY; Malinzak, M; Tan, AC, 2020) |
| "Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
| "Glioblastoma (GBM), the most common primary brain tumor, is the most aggressive human cancers, with a median survival rate of only 14." | 2.61 | Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide. ( Aoki, K; Hirano, M; Natsume, A; Ranjit, M; Wakabayashi, T, 2019) |
| "Temozolomide (TMZ) is an antiangiogenic agent." | 2.58 | Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. ( Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN, 2018) |
| "The approach to treat glioblastoma has not suffered major changes over the last decade and temozolomide (TMZ) remains the mainstay for chemotherapy." | 2.58 | Repurposing drugs for glioblastoma: From bench to bedside. ( Basso, J; Miranda, A; Pais, A; Sousa, J; Vitorino, C, 2018) |
| "Glioblastomas are rich in blood vessels (i." | 2.58 | Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018) |
| "Temozolomide may cause thrombocytopenia or neutropenia in 3-4% of glioblastoma patients, respectively." | 2.55 | MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case. ( Altinoz, MA; Bolukbasi, FH; Ekmekci, CG; Elmaci, I; Sari, R; Sav, A; Yenmis, G, 2017) |
| "The standard treatment for brain metastases is radiotherapy." | 2.55 | Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. ( Luo, Y; Tang, J; Tian, J; Xiang, J, 2017) |
| "Glioblastoma is the most common primary CNS malignancy and it is becoming more frequently diagnosed in the elderly population." | 2.55 | Glioblastoma in the elderly: initial management. ( de Moraes, FY; Laperriere, N, 2017) |
| " This review summarizes the mechanism of action, efficacy, and adverse events based on pre-clinical studies and clinical trials for TTF in GBM." | 2.55 | Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. ( Zhu, JJ; Zhu, P, 2017) |
| "The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered." | 2.55 | Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature. ( Abraham Koshy, A; Kumar A, A, 2017) |
| "Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity." | 2.55 | Treatment of Glioblastoma. ( de Groot, JF; Nam, JY, 2017) |
| "Fibrosarcoma is a rare brain tumour with 33 cases reported so far." | 2.53 | Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases. ( Giridhar, P; Gupta, S; Haresh, KP; Julka, PK; Mallick, S; Rath, GK, 2016) |
| "Glioblastoma is the most common and the most lethal primary brain tumor in adults." | 2.53 | Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party. ( , 2016) |
| "Glioblastoma is almost always incurable and most older patients survive less than 6 months." | 2.53 | How I treat glioblastoma in older patients. ( Mohile, NA, 2016) |
| "To enhance the benefit of TMZ in the treatment of glioblastomas, effective combination strategies are needed to sensitize glioblastoma cells to TMZ." | 2.53 | Targeting autophagy to sensitive glioma to temozolomide treatment. ( Dai, S; Gong, Z; Qian, L; Sun, L; Xu, Z; Yan, Y, 2016) |
| "Glioblastoma is a unique model of non-metastasising disease that kills the vast majority of patients through local growth, despite surgery and local irradiation." | 2.53 | Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. ( Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG, 2016) |
| "Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors." | 2.53 | Low-grade and anaplastic oligodendroglioma. ( Bromberg, JE; Buckner, J; Van Den Bent, MJ, 2016) |
| "889 with respect to OS, while BEV in combination with TMZ - with a probability of 0." | 2.53 | A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). ( Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y, 2016) |
| "Glioblastoma is a malignant tumor of astrocytic origin that is highly invasive, proliferative and angiogenic." | 2.53 | Microglia in Cancer: For Good or for Bad? ( Amaral, R; da Fonseca, AC; Garcia, C; Geraldo, LH; Lima, FR; Matias, D, 2016) |
| "Temozolomide (TMZ) is a DNA-methylating agent." | 2.53 | Current and Future Drug Treatments for Glioblastomas. ( Hirose, Y; Ohba, S, 2016) |
| " Patients aged over 70 years with favorable KPS, or patients aged 60-70 years with borderline KPS, should be considered for monotherapy utilizing standard TMZ dosing for patients with MGMT-methylated tumors, and hypofractionated RT (34 Gy in ten fractions or 40 Gy in 15 fractions) for patients with MGMT-unmethylated tumors." | 2.50 | Treatment options and outcomes for glioblastoma in the elderly patient. ( Arvold, ND; Reardon, DA, 2014) |
| "The incidence of brain metastases from breast cancer is increasing with diagnosis and therapeutics progress, especially with systemic therapies." | 2.50 | [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. ( Cao, KI; Kirova, YM, 2014) |
| "Glioblastoma is the most aggressive primary brain tumor in adults." | 2.50 | Predictive biomarkers investigated in glioblastoma. ( Chinot, O; Delattre, JY; Hoang-Xuan, K; Idbaih, A; Loundou, A; Sanson, M; Tabouret, E, 2014) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Brain metastases are associated with substantial morbidity and mortality." | 2.50 | Treatment of brain metastases. ( Chmura, SJ; Gabikian, P; Garza, M; Lukas, RV, 2014) |
| "Glioblastoma is the most common malignant brain tumor in adults and carries a particularly poor prognosis." | 2.50 | Glioblastoma survival: has it improved? Evidence from population-based studies. ( Barnholtz-Sloan, JS; Bauchet, L; Woehrer, A, 2014) |
| "Glioblastoma multiforme is the most common and most lethal pri- mary malignant tumor of the central nervous system." | 2.50 | Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review. ( Bochenek-Cibor, J; Krupa, M; Moskała, M; Trojanowski, T, 2014) |
| "Abstract: Anaplastic oligodendroglioma (AO) is a rare malignant tumor occurring in adults." | 2.49 | Treatment recommendations for anaplastic oligodendrogliomas that are codeleted. ( Anderson, MD; Gilbert, MR, 2013) |
| "Many physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies." | 2.49 | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. ( Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2013) |
| "Gliomas are the most frequent primary brain tumors in adults." | 2.49 | High-grade glioma in elderly patients: can the oncogeriatrician help? ( Chinot, O; Crétel, E; Retornaz, F; Rousseau, F; Tabouret, E; Tassy, L, 2013) |
| "Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma." | 2.49 | Temozolomide and unusual indications: review of literature. ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013) |
| "Brain metastases affect 37% of patients suffering from metastatic melanoma, and their prognosis remains poor, with an overall survival lower than six months." | 2.49 | [Therapeutic strategies and systemic treatment of brain melanoma metastases]. ( Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E, 2013) |
| " Hematotoxicity is listed as a frequent adverse drug reaction in the US prescribing information and hepatotoxicity has been reported infrequently in the postmarketing period." | 2.48 | Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. ( Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M, 2012) |
| "Ganglioneuroblastoma is a rare tumor variant of neuroblastoma." | 2.48 | Cerebral ganglioneuroblastoma of adult onset: two patients and a review of the literature. ( Kloet, A; Schipper, MH; Taphoorn, MJ; van Duinen, SG; Vecht, CJ; Walchenbach, R; Wiggenraad, RG, 2012) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 2.48 | Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. ( Caporello, P; Enrici, RM; Minniti, G; Scaringi, C, 2012) |
| "For the treatment of brain metastases from NSCLC, the combined therapy of WBRT plus TMZ improves OR, but without significant improvement in OS." | 2.48 | [Whole brain radiation therapy plus temozolomide in the treatment of brain metastases from non small cell lung cancer: a meta-analysis]. ( Bi, ZF; He, Y; Liao, K; Liu, YM, 2012) |
| "Angiocentric gliomas have recently been reclassified as a separate central nervous system tumor." | 2.48 | Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature. ( Aguilar, HN; Hung, RW; Kotylak, T; Mehta, V, 2012) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 2.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Medical treatment of brain metastases (BM) is still a controversial issue in cancer therapy being mainly limited by the existence of the BBB." | 2.47 | Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? ( Addeo, R; Caraglia, M, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with activity in high and LGG." | 2.47 | Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. ( Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S, 2011) |
| " These may include TMZ concentrations in the brain parenchyma, TMZ dosing schemes, hypoxic microenvironments, niche factors, and the re-acquisition of stem cell properties by non-stem cells." | 2.47 | Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. ( Beier, CP; Beier, D; Schulz, JB, 2011) |
| "Temozolomide is a second-generation alkylating chemotherapeutic agent, introduced to therapy of primary brain tumors in the 1990s." | 2.46 | Temozolomide: Expanding its role in brain cancer. ( Adair, J; Kiem, HP; Mrugala, MM, 2010) |
| "Temozolomide is a new drug which has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 2.45 | Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. ( Beli, I; Chaldeopoulos, D; Fotineas, A; Koukourakis, GV; Kouloulias, V; Kouvaris, J; Maravelis, G; Pantelakos, P; Papadimitriou, C; Zacharias, G, 2009) |
| "Temozolomide is an oral alkylating cytotoxic agent of second generation, used in the treatment of high-grade gliomas." | 2.45 | [Prescription guidebook for temozolomide usage in brain tumors]. ( Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P, 2009) |
| "Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug." | 2.45 | Temozolomide in malignant gliomas: current use and future targets. ( Bressler, LR; Seery, TE; Villano, JL, 2009) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| " Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O(6)-guanine mimetic agents as substrates for MGMT." | 2.44 | Mechanisms of disease: temozolomide and glioblastoma--look to the future. ( Chamberlain, MC; Mrugala, MM, 2008) |
| "Anaplastic astrocytoma is an uncommon disease in the adult population." | 2.44 | Anaplastic astrocytoma in adults. ( Gatta, G; Mazza, E; Reni, M; Stupp, R; Vecht, C, 2007) |
| "Temozolomide is an alkylating agent used frequently in the management of gliomas." | 2.44 | Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. ( Brown, MP; Selva-Nayagam, S; Singhal, N, 2007) |
| "Glioma is a highly invasive, rapidly spreading form of brain cancer that is resistant to surgical and medical treatment." | 2.44 | Potential biochemical therapy of glioma cancer. ( Fan, XJ; Fu, YJ; Liang, AH; Liu, ZL; Xu, CG; Xu, QL; Yang, J; Yin, LT, 2007) |
| "Temozolomide has proven benefit in grade II/III gliomas progressive following standard therapy and when added to radiation for glioblastoma." | 2.44 | Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. ( Schiff, D, 2007) |
| "Temozolomide (TMZ) has emerged as an active agent against malignant gliomas." | 2.44 | Management of glioblastoma. ( Aoki, T; Hashimoto, N; Matsutani, M, 2007) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "Leptomeningeal dissemination of juvenile pilocytic astrocytoma (JPA) is a rare event." | 2.43 | Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. ( Aryan, HE; Bruce, DA; Levy, ML; Lu, DC; Meltzer, HS; Ozgur, BM, 2005) |
| "Temozolomide (TMZ) is a promising new drug that seems to be effective in patients with recurrent disease." | 2.43 | Adjuvant chemotherapy in the treatment of high grade gliomas. ( Brandes, AA; Lonardi, S; Tosoni, A, 2005) |
| "Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma." | 2.43 | Optimal role of temozolomide in the treatment of malignant gliomas. ( Hegi, ME; Stupp, R; van den Bent, MJ, 2005) |
| "Astrocytomas are the most common primary brain tumors." | 2.43 | Treatment of astrocytomas. ( Gilbert, MR; Gonzalez, J, 2005) |
| "Glioblastomas are the most frequent and the most aggressive primary brain tumors in adults." | 2.43 | [Concomitant radiotherapy with chemotherapy in patients with glioblastoma]. ( Benouaich-Amiel, A; Delattre, JY; Simon, JM, 2005) |
| "The prognosis for patients with malignant primary brain tumors has been poor, and until recently, there was little evidence that chemotherapy was beneficial." | 2.43 | Advances in the treatment of primary brain tumors: dawn of a new era? ( Gilbert, MR, 2006) |
| "Temozolomide (TMZ) is an alkylating agent earlier approved for recurrent anaplastic astrocytoma and approved for the treatment of newly diagnosed glioblastoma in the USA and Europe in 2005." | 2.43 | Temozolomide: a milestone in the pharmacotherapy of brain tumors. ( Steinbach, JP; Weller, M; Wick, W, 2005) |
| " TMZ is able to cross the blood brain barrier and is stable at gastric acid pH so it has almost 100% oral bioavailability and is rapidly absorbed after it is taken orally." | 2.43 | Role of temozolomide in pediatric brain tumors. ( Barone, G; Maurizi, P; Riccardi, R; Tamburrini, G, 2006) |
| "Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality." | 2.43 | Radiation therapy in the management of brain metastases from renal cell carcinoma. ( Amato, R; Doh, LS; Paulino, AC; Teh, BS, 2006) |
| "Glioblastoma multiforme is the most common primary brain tumor in adults." | 2.43 | Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial. ( Cairncross, JG; Mason, WP, 2005) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 2.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "First-line chemotherapy for brain metastases or with only minor neurological signs and symptoms, and who have an indication for systematic chemotherapy for metastases elsewhere in the body." | 2.42 | The role of chemotherapy in brain metastases. ( van den Bent, MJ, 2003) |
| "The incidence of oligodendroglioma is increasing, most likely due to its improved recognition." | 2.42 | Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. ( Engelhard, HH; Mundt, A; Stelea, A, 2003) |
| "Temozolomide has activity and a favorable safety profile in all dosing schedules tested." | 2.42 | Temozolomide: realizing the promise and potential. ( Dolan, ME; Nagasubramanian, R, 2003) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | 2.42 | [Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004) |
| "Melanoma is the third most common metastatic brain tumor in the United States and is a major cause of morbidity and mortality." | 2.42 | Management of brain metastases in patients with melanoma. ( Agarwala, SS; Tarhini, AA, 2004) |
| "Brain metastases are a major clinical challenge and usually signify very poor prognosis for most patients." | 2.42 | Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide. ( Abrey, LE; Mehta, MP, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC)." | 2.41 | Temozolomide: a novel oral alkylating agent. ( Danson, SJ; Middleton, MR, 2001) |
| " The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules." | 2.41 | The use of temozolomide in recurrent malignant gliomas. ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "Metastatic brain tumors are the most common complication of systemic cancer and affect 20-40% of all adult cancer patients." | 2.41 | Chemotherapy for the treatment of metastatic brain tumors. ( Newton, HB, 2002) |
| "Temozolomide was effective in delaying disease progression and maintaining health-related quality of life." | 2.41 | Temozolomide in malignant gliomas. ( Yung, WK, 2000) |
| "Temozolomide is a novel, oral, second-generation alkylating agent." | 2.41 | Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. ( Friedman, HS, 2000) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 2.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| "Temozolomide appears to produce few serious adverse effects and may also have a positive impact on health-related quality of life." | 2.41 | A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. ( Cave, C; Dinnes, J; Huang, S; Milne, R, 2002) |
| "Moreover, the efficacy of the treatment of glioma cells with temozolomide (TMZ) and Gli1 inhibitor GANT61 was higher than that of TMZ alone." | 1.91 | Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance. ( Ahmed, SP; Ali, A; Arif, SH; Chosdol, K; Farheen, S; Hoda, MF; Kausar, T; Mariyath P M, M; Nayeem, SM; Shahi, MH, 2023) |
| "Glioblastoma (GBM) is a fast-growing primary brain tumor characterized by high invasiveness and resistance." | 1.91 | Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma. ( Cordes, N; Korovina, I; Temme, A; Vehlow, A, 2023) |
| " However, poor site-specific delivery and bioavailability significantly restrict the efficient permeability of regorafenib to brain lesions and compromise its treatment efficacy." | 1.91 | Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma. ( Ding, N; Huang, C; Jia, W; Jiang, J; Li, L; Luo, M; Nice, EC; Tian, H; Zhang, H; Zhou, L, 2023) |
| "Temozolomide was successfully up-titrated to the full dose." | 1.91 | Safe administration of temozolomide in end-stage renal disease patients. ( Hundal, J; Pereira, MK; Singh, A; Vredenburg, J, 2023) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system." | 1.91 | Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98). ( Ahmadi-Zeidabadi, M; Amirinejad, M; Jomehzadeh, A; Khoei, S; Kordestani, Z; Larizadeh, MH; Yahyapour, R, 2023) |
| "Glioblastoma (GBM) is the most lethal primary brain tumor in adults and harbors a subpopulation of glioma stem cells (GSCs)." | 1.91 | EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. ( Li, M; Tian, W; Wang, B; Wang, Y; Xu, R; Yu, T; Zeng, A; Zhang, J; Zhou, F; Zhou, Z, 2023) |
| "Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis." | 1.91 | Role of COL6A2 in malignant progression and temozolomide resistance of glioma. ( Hong, X; Ouyang, J; Peng, X; Wang, P; Xiao, B; Zhang, J; Zou, J, 2023) |
| "Glioblastoma is among the most lethal cancers, with no known cure." | 1.91 | A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance. ( Bhatt, H; Brown, JMC; Gray, WP; Ormonde, C; Sharouf, F; Siebzehnrubl, FA; Spencer, R; Zaben, M, 2023) |
| " The primary endpoints were skin, neurological and psychiatric adverse events." | 1.91 | Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. ( Arakawa, Y; Kanamori, M; Mukasa, A; Muragaki, Y; Narita, Y; Nishikawa, R; Tanaka, S; Yamaguchi, S; Yamasaki, F, 2023) |
| "Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components." | 1.91 | Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study. ( Shen, J; Song, K; Wei, L; Xu, H; Xu, M; Yu, Z; Zhou, Z; Zhu, W, 2023) |
| " Safety was determined by the number of treatment-related adverse events." | 1.91 | Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma. ( Belting, M; Bengzon, J; Cederberg, D; Darabi, A; Edvardsson, C; Ehinger, E; Kopecky, J; Siesjö, P; Tomasevic, G; Visse, E, 2023) |
| "Glioblastoma (GBM) is the most frequent brain cancer and more lethal than other cancers." | 1.91 | Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma. ( Agredano-Moreno, LT; Gallardo-Pérez, JC; Jimenez-García, LF; López-Marure, R; Robledo-Cadena, DX; Sánchez-Lozada, LG; Trejo-Solís, MC, 2023) |
| "High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need to develop tools to improve patient outcomes." | 1.91 | The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. ( Brochu-Gaudreau, K; Charbonneau, M; Dubois, CM; Fortin, D; Harper, K; Lucien, F; Perreault, A; Roy, LO; Tian, S, 2023) |
| " Based on the genetic testing results, almonertinib combined with anlotinib and temozolomide was administered and obtained 12 months of progression-free survival after the diagnosis of recurrence as the fourth-line treatment." | 1.91 | Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. ( Dong, S; Hou, Z; Li, S; Luo, N; Tao, R; Wu, H; Zhang, H; Zhang, X; Zhu, D, 2023) |
| "Temozolomide (TMZ) is a first line agent used in the clinic for glioblastoma and it has been useful in increasing patient survival rates." | 1.91 | Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. ( Ahmed-Cox, A; Akhter, DT; Cao, Y; Fletcher, NL; Janjua, TI; Kavallaris, M; Moniruzzaman, M; Popat, A; Raza, A; Thurecht, KJ, 2023) |
| "Glioblastoma is the most common malignant brain tumor in adults." | 1.91 | Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. ( Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C, 2023) |
| "Temozolomide (TMZ) is a chemotherapy agent used to treat primary central nervous system tumors." | 1.91 | Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis. ( Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F, 2023) |
| " In this paper, we present the effects of juglone alone and in combination with temozolomide on glioblastoma cells." | 1.91 | Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. ( Barciszewska, AM; Belter, A; Gawrońska, I; Giel-Pietraszuk, M; Naskręt-Barciszewska, MZ, 2023) |
| "Glioblastoma (GBM) is an incurable primary brain tumor with a poor prognosis." | 1.91 | Acetogenins-Rich Fractions of ( Alexandre, GP; Arantes, A; Junqueira, JGM; Kim, B; Oliveira, AGS; Reis, RM; Ribeiro, RIMA; Severino, VGP; Sousa, LR, 2023) |
| "Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM." | 1.91 | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. ( Fong, IH; Lin, CM; Liu, HW; Setiawan, SA; Su, IC; Su, YK; Yadav, VK; Yeh, CT, 2023) |
| "Temozolomide has been mainly used for the treatment of malignant gliomas over a decade." | 1.91 | [Medical Treatments for Malignant Brain Tumor]. ( Kitamura, Y; Toda, M, 2023) |
| "Temozolomide (TMZ) is a standard chemotherapeutic for GBM, but TMZ treatment benefits are compromised by chemoresistance." | 1.91 | Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. ( Cui, X; Kang, C; Liu, X; Tong, F; Wang, G; Wang, Q; Wang, Y; Zhao, J; Zhou, J, 2023) |
| "Glioblastoma is the most aggressive and fatal form of brain cancer." | 1.91 | The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. ( Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M, 2023) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | 1.91 | Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma. ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| " The most common adverse events were leukocytopenia (66." | 1.91 | Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. ( Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023) |
| "GBM (Glioblastoma) is the most lethal CNS (Central nervous system) tumor in adults, which inevitably develops resistance to standard treatments leading to recurrence and mortality." | 1.91 | TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways. ( Becker, AP; Becker, V; Bell, EH; Chakravarti, A; Cui, T; Fleming, JL; Grosu, AL; Han, C; Haque, SJ; Johnson, B; Kumar, A; Manring, HR; McElroy, J; Meng, X; Robe, PA; Schrock, MS; Sebastian, E; Showalter, CA; Singh, K; Summers, MK; Tong, ZY; Venere, M, 2023) |
| "Neuroblastoma is the most common tumour in children under 1 year old, accounting for 12-15% of childhood cancer deaths." | 1.91 | Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma. ( Balachandar, A; Bhagirath, E; Pandey, S; Vegh, C; Wear, D, 2023) |
| "Temozolomide (TMZ) was given to 24 patients and 11 patients received TMZ plus other chemotherapies." | 1.91 | The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma. ( Alkhayyat, S; Alkhotani, A; Almansouri, M; Alshanqiti, M; Alsinani, T; Baeesa, S; Bamaga, AK; Butt, N; Enani, M; Fadul, MM; Faizo, E; Hassan, A; Karami, MM; Kurdi, M, 2023) |
| "Mismatch repair-deficient (MMRD) brain tumors are rare among primary brain tumors and can be induced by germline or sporadic mutations." | 1.72 | Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. ( Choi, SH; Kang, J; Kim, H; Kim, SK; Kim, TM; Lee, K; Lim, KY; Park, CK; Park, JW; Park, SH; Shim, Y; Won, JK; Yun, H, 2022) |
| "Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders." | 1.72 | Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. ( Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022) |
| "Glioblastoma (GBM) is the most lethal primary brain tumor." | 1.72 | Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture. ( Berry, MR; Fan, TM; Hergenrother, PJ; Kelly, AM; McKee, SA; Svec, RL, 2022) |
| "The incidence of gliomas is increasing." | 1.72 | CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells. ( Ding, P; Lu, B; Nie, X; Qian, Y; Xu, J, 2022) |
| "Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing." | 1.72 | Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report. ( Dohmen, H; Gött, H; Kiez, S; Kolodziej, M; Stein, M, 2022) |
| "Glioblastoma multiforme (GBM) is a primary brain tumor with devastating prognosis." | 1.72 | Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. ( Huang, G; Lin, R; Liu, Y; Ni, B; Qi, ST; Song, H; Wang, H; Wang, Z; Xie, S; Xu, Y; Yi, GZ; Zhang, Y, 2022) |
| " Therefore, localised approaches that treat GB straight into the tumour site provide an alternative to enhance chemotherapy bioavailability and efficacy, reducing systemic toxicity." | 1.72 | Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. ( Arantes, PR; Borges, GR; Braganhol, E; Dalanhol, CS; de Barros Dias, MCH; de Oliveira Merib, J; de Souza, PO; Ferro, MB; Henn, JG; Morás, AM; Moura, DJ; Nugent, M; Reinhardt, LS, 2022) |
| "Glioblastomas are the most aggressive brain tumors for which therapeutic options are limited." | 1.72 | Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration. ( Carson, SC; Colley, SB; Faia, C; Ingraham Iv, CH; Jursic, BS; Lassak, A; Peruzzi, F; Plaisance-Bonstaff, K; Reiss, K; Stalinska, J; Vittori, C, 2022) |
| "Temozolomide (TMZ) is a DNA alkylating agent that appears to have a radiosensitizing effect when used in combination with RT and may be worthwhile in meningioma treatment." | 1.72 | Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. ( Belanger, K; Damek, D; Lillehei, KO; Ormond, DR; Ung, TH, 2022) |
| "Glioma is the most common and malignant brain tumor with poor prognosis." | 1.72 | LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis. ( Li, X; Luo, C; Nie, C; Qian, K; Wang, X; Zeng, Y, 2022) |
| "Temozolomide use was affected by age, performance and MGMT promoter (all P < 0." | 1.72 | Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05). ( In Yoon, H; Lee, SW; Lim, DH; Wee, CW, 2022) |
| "Glioma is one of the main causes of cancer-related mortality worldwide and is associated with high heterogeneity." | 1.72 | Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway. ( Gao, X; Guo, Z; Xie, Q; Yang, Q; Zhang, J; Zhong, C, 2022) |
| " Additionally, by lowering the effective dosage of TMZ, the combination liposomes reduced systemic TMZ-induced toxicity, highlighting the preclinical potential of this novel integrative strategy to deliver combination therapies to brain tumors." | 1.72 | Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. ( Chai, T; Du, Q; Hanif, S; Ismail, M; Li, Y; Muhammad, P; Shi, B; Yang, W; Zhang, D; Zheng, M, 2022) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic drug for glioma." | 1.72 | FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway. ( Guo, L; Wu, Z, 2022) |
| " Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies." | 1.72 | Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide. ( Astori, G; Belli, R; Bernardi, M; Bozza, A; Catanzaro, D; Celli, P; Chieregato, K; Menarin, M; Merlo, A; Milani, G; Peroni, D; Pozzato, A; Pozzato, G; Raneri, FA; Ruggeri, M; Volpin, L, 2022) |
| "Temozolomide (TMZ) is a chemotherapeutic drug for the treatment of GBM." | 1.72 | Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells. ( Adıgüzel, Z; Kıyga, E; Önay Uçar, E, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 1.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but the emergence of drug resistance limits its anti-tumor activity." | 1.72 | GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair. ( Chen, CC; Chen, Y; Grigore, FN; Jin, J; Lan, Q; Li, M; Li, S; Ma, J; Wang, J; Wang, Q; Wu, G; Xu, H; Zhu, H, 2022) |
| "Metformin is a biguanide drug utilized as the first-line medication in treating type 2 diabetes." | 1.72 | Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022) |
| "Gliomas are the most common type of primary brain tumors, with high recurrence rate and mortality." | 1.72 | ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12. ( Fu, J; Peng, J; Tu, G, 2022) |
| "Temozolomide-based treatment was administered to 64 of 68 (94." | 1.72 | Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. ( Aichholzer, M; Berghoff, AS; Dieckmann, K; Furtner, J; Goldberger, S; Hatziioannou, T; Heller, G; Leibetseder, A; Mair, MJ; Pichler, J; Preusser, M; Puhr, R; Tomasich, E; von Oertzen, T; Weis, S; Widhalm, G; Wöhrer, A, 2022) |
| "After surgical treatment, glioblastoma (GBM) patients require prompt therapy within 14 days in a patient-specific manner." | 1.72 | Tissue Niche Miniature of Glioblastoma Patient Treated with Nano-Awakeners to Induce Suicide of Cancer Stem Cells. ( Baek, S; Chang, JH; Choi, RJ; Jo, E; Kang, SG; Kim, EH; Lee, D; Lee, JB; Moon, JH; Park, J; Park, JS; Shim, JK; Sung, HJ; Yoon, SJ; Yu, SE, 2022) |
| "Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide." | 1.72 | Current therapeutic options for glioblastoma and future perspectives. ( Aquilanti, E; Wen, PY, 2022) |
| "Apatinib is a multitarget tyrosine kinase inhibitor, which has been reported to exhibit broad antitumor profiles." | 1.72 | Apatinib and temozolomide in children with recurrent ependymoma: A case report. ( Li, J; Shen, Z; Shi, L; Zhang, N; Zhao, S, 2022) |
| "Temozolomide (TMZ) is a first-line clinical chemotherapeutic drug." | 1.72 | Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment. ( Chen, KC; Chen, PH; Ho, KH; Kuo, YY; Liu, AJ; Shih, CM, 2022) |
| "Glioblastoma is the most common brain tumor." | 1.72 | ( Balkanov, AS; Belyaev, AY; Glazkov, AA; Kobyakov, GL; Rozanov, ID; Shmakov, PN; Strunina, YV; Telysheva, EN; Usachev, DY, 2022) |
| "Glioma is a fatal tumor originating from the brain, which accounts for most intracranial malignancies." | 1.72 | SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma. ( Fang, C; Liu, Y; Lou, M; Shao, A; Wang, W; Wang, X; Xu, H; Xu, Y; Yuan, L; Zhang, A; Zhang, Z; Zhu, Q, 2022) |
| "Glioma is a common type of malignant and aggressive tumor in the brain." | 1.72 | Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma. ( Chen, M; Feng, W; Li, J; Li, M; Li, T; Liu, Y; Xia, X; Yang, W; Yuan, Q; Zhang, S; Zhou, X; Zuo, M, 2022) |
| " The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts." | 1.72 | Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. ( Bachmann, F; Bakken, KK; Burgenske, DM; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Gampa, G; Giannini, C; He, L; Hu, Z; Kitange, GJ; Kosel, ML; Lane, HA; McSheehy, P; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schmitt-Hoffmann, A; Schroeder, MA; Talele, S; Vaubel, RA, 2022) |
| "Malignant gliomas are the most common brain tumors, with generally dismal prognosis, early clinical deterioration and high mortality." | 1.62 | Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides. ( Gu, X; Liu, J; Ni, X; Qi, Y; Qian, X; Shao, X; Xu, X; Yuan, P, 2021) |
| "Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis." | 1.62 | Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH ( Chen, H; Gu, J; Jiang, J; Li, C; Li, Y; Luo, C; Qian, J; Wan, Z; Wang, J; Zhu, J, 2021) |
| "The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible." | 1.62 | Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. ( Armando, AM; Bi, J; Cloughesy, TF; Cravatt, BF; Curtis, EJ; Furnari, FB; Gimple, RC; Gu, Y; Jing, H; Khan, A; Koga, T; Kornblum, HI; Miki, S; Mischel, PS; Prager, B; Quehenberger, O; Reed, A; Rich, JN; Rzhetsky, A; Tang, J; Wainwright, DA; Wong, IT; Wu, S; Yang, H; Zhang, W, 2021) |
| "Glioma is the most common primary intracranial tumor." | 1.62 | FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. ( Huang, L; Jiang, T; Li, G; Liu, Y; Zhao, Z; Zhou, K, 2021) |
| "Temozolomide is an alkylating agent most commonly used with a few other second line options." | 1.62 | Nanomedicine in the treatment of Glioblastoma. ( Bukhari, SS; Kishwar Jafri, SK; Shamim, MS, 2021) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic dosage of hydroxyurea and temozolomide had increased the DBM therapy outcome by strengthening anti-tumor capability." | 1.62 | A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G, 2021) |
| "Brain cancer is a devastating disease given its extreme invasiveness and intricate location." | 1.62 | Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D. ( Grant, GA; Li, J; Trinh, P; Yang, F; Zhu, D, 2021) |
| " The aim of this study was to introduce the Z-scan technique as a fast, accurate, inexpensive, and safe in vitro method to distinguish the cytotoxic effects of various treatments." | 1.62 | Z-scan method to measure the nonlinear optical behavior of cells for evaluating the cytotoxic effects of chemotherapy and hyperthermia treatments. ( Ara, MHM; Ardakani, AA; Asgari, H; Ghader, A; Khoei, S; Minaei, SE, 2021) |
| "Temozolomide (TMZ) has been used to treat glioma." | 1.62 | Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis. ( Jia, X; Li, W; Liu, Q; Ma, Q; Wang, X; Yan, P, 2021) |
| "Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis." | 1.62 | Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. ( Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA, 2021) |
| "Glioblastoma multiforme is one of the most common malignant types of tumor arising from the central nervous system known for its devastating intracranial progress and dismal prognosis." | 1.62 | FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis. ( Malik, D, 2021) |
| "Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times." | 1.62 | Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. ( Efferth, T; Giordano, FA; Greten, HJ; Kadioglu, O; Mayr, K; Saeed, MEM; Wenz, F; Yildirim, A, 2021) |
| "GBM (glioblastoma multiforme) is the most common and aggressive brain tumor." | 1.62 | Regorafenib in glioblastoma recurrence: A case report. ( Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA, 2021) |
| "Temozolomide (TMZ) has been widely used as a first-line treatment for GBM." | 1.62 | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. ( Li, N; Li, Y; Lv, Y; Sha, C; Sun, K; Tang, S; Wang, A; Wang, L; Yan, X; Yu, Y, 2021) |
| "In this work, we constructed LPHNs-cRGD for targeting delivery of the CRISPR/Cas9 system, in combination with FUS-MBs to open the BBB." | 1.62 | Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound. ( Chen, J; Cheng, Y; Huang, N; Wang, Z; Yang, Q; Zhou, Y, 2021) |
| "Canine glioma is a common brain tumor with poor prognosis despite surgery and/or radiation therapy." | 1.62 | The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma. ( Akiyoshi, H; Ichikawa, T; Inoue, M; Kamishina, H; Kurozumi, K; Matsumoto, Y; Nakamoto, Y; Noguchi, S, 2021) |
| " However, clinical trials show that treatment schedule and drug dosage significantly affect patient survival." | 1.62 | A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients. ( Ebrahimi Zade, A; Shahabi Haghighi, S; Soltani, M, 2021) |
| "Glioblastoma multiforme is the most aggressive and lethal form of brain tumour due to the high degree of cancer cells infiltration into surrounding brain tissue." | 1.62 | Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole. ( Janeczek, H; Karpeta-Jarząbek, P; Kasperczyk, J; Musiał-Kulik, M; Pastusiak, M; Stojko, M; Włodarczyk, J, 2021) |
| "Temozolomide (TMZ) is an effective chemotherapy drug for glioblastoma, but the resistance to TMZ has come to represent a major clinical problem, and its underlying mechanism has yet to be elucidated." | 1.62 | Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide. ( Bi, QC; Gan, LJ; Han, XJ; Hong, T; Jiang, LP; Lan, XM; Liu, LH; Tan, RJ; Wei, MJ; Yang, ZJ; Zhang, LL, 2021) |
| "Glioblastoma is the most malignant brain tumor and presents high resistance to chemotherapy and radiotherapy." | 1.62 | APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2021) |
| "Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics." | 1.62 | Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. ( Boockvar, J; Brahmbhatt, H; Gao, S; Gonzalez, C; Jamil, E; Khan, MB; MacDiarmid, J; Mugridge, N; Ruggieri, R; Sarkaria, JN; Symons, M; Tran, NL, 2021) |
| "Glioblastoma is a primary brain cancer with a near 100% recurrence rate." | 1.62 | De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. ( Ahmed, AU; Ali, ES; Atashi, F; Baisiwala, S; Ben-Sahra, I; Horbinski, CM; James, CD; Kumthekar, P; Lee, G; Lesniak, MS; Miska, J; Park, CH; Saathoff, MR; Savchuk, S; Shireman, JM; Stupp, R, 2021) |
| "Celecoxib and 2,5-DMC were the most cytotoxic." | 1.62 | COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. ( Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K, 2021) |
| "Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
| "Temozolomide (TMZ) is an alkylating agent widely used for glioma treatment." | 1.62 | miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma. ( Cui, B; Gao, K; Qiao, Y; Wang, T, 2021) |
| "Glioma is the most common malignant tumor of the brain in adult patients." | 1.62 | Molecular Characterization of AEBP1 at Transcriptional Level in Glioma. ( Huang, R; Sun, S; Tong, X; Wang, K; Wang, Z; Wu, C, 2021) |
| "Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact." | 1.62 | Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). ( Bachmann, F; Dietrich, PY; Espinoza, FI; Genoud, V; Lane, HA; Marinari, E; McSheehy, P; Rochemont, V; Walker, PR, 2021) |
| "Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide." | 1.56 | Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. ( Batchelor, T; Beers, AL; Catana, C; Chang, K; Dietrich, J; Duda, DG; Emblem, KE; Gerstner, ER; Hooker, JM; Jain, RK; Kalpathy-Cramer, J; Plotkin, SR; Rosen, B; Vakulenko-Lagun, B; Yen, YF, 2020) |
| "Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice." | 1.56 | Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020) |
| "Glioblastoma is the most frequent and lethal primary brain tumor." | 1.56 | Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. ( Berens, ME; Burns, TC; Califano, A; Carlson, BL; Caron, A; Decker, PA; Dhruv, HD; Eckel-Passow, JE; Evers, L; Giannini, C; Grove, R; Jenkins, RB; Kitange, GJ; Klee, EW; Kollmeyer, TM; LaChance, DH; Ma, DJ; Marin, BM; Meyer, FB; Mladek, AC; O'Neill, BP; Parney, IF; Peng, S; Remonde, D; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Tian, S; Tran, NL; Vaubel, RA; Verhaak, RG; Wang, Q; Yan, H, 2020) |
| " Because the free drug cannot pass the blood-brain barrier (BBB), we investigated the use of nanocarriers for transport of the drug through the BBB and its efficacy when combined with radiotherapy and temozolomide (TMZ) in glioma spheroids." | 1.56 | Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. ( Becerril Aragon, G; Bikhezar, F; de Kruijff, RM; de Vries, HE; Denkova, AG; Gasol Garcia, A; Narayan, RS; Slotman, BJ; Sminia, P; Torrelo Villa, G; van der Meer, AJGM; van der Pol, SMA, 2020) |
| "We identified the preoperative seizure frequency threshold by plotting a receiver operating characteristic curve." | 1.56 | Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas. ( Chen, Q; Deng, G; Gao, L; Jiang, H; Liu, B; Tan, Y; Wang, J; Yang, K; Yuan, F, 2020) |
| "Glioblastoma is the most common primary tumor of the central nervous system that develops chemotherapy resistance." | 1.56 | Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT. ( Chen, J; Chen, L; Hao, B; He, M; Li, X; Wang, C; Wu, H; Zhang, G; Zhang, T, 2020) |
| "Calpeptin could inhibit the effect." | 1.56 | Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. ( Cai, L; Li, Q; Li, W; Lu, X; Su, Z; Tu, M; Wang, C; Zhu, Z, 2020) |
| "Temozolomide (TMZ) is an effective drug for prolonging the overall survival time of patients, while drug-resistance is an important clinical problem at present." | 1.56 | A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway. ( Fang, F; Ji, Y; Li, H; Lu, Y; Qiu, P; Tang, H; Zhang, S, 2020) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | 1.56 | MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Niacin treatment of mice bearing intracranial BTICs increased macrophage/microglia representation within the tumor, reduced tumor size, and prolonged survival." | 1.56 | Control of brain tumor growth by reactivating myeloid cells with niacin. ( Bose, P; Dunn, JF; Kelly, J; Mirzaei, R; Mishra, MK; Poon, C; Rawji, K; Sarkar, S; Yang, R; Yong, VW; Zemp, FJ, 2020) |
| "Glioma is a common cancer that affects people worldwide with high morbidity and mortality." | 1.56 | miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells. ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B, 2020) |
| "In adults, glioma is the most commonly occurring and invasive brain tumour." | 1.56 | CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. ( Cao, Y; Kong, S; Li, X; Qi, Y; Shang, S, 2020) |
| "Trametinib has a strong anti-proliferative effect on established GB cell lines, stem cell-like cells and their differentiated progeny and while it does not enhance anti-proliferative and cell death-inducing properties of the standard treatment, i." | 1.56 | The limitations of targeting MEK signalling in Glioblastoma therapy. ( Debatin, KM; Hadzalic, A; Halatsch, ME; Karpel-Massler, G; Payer, C; Schuster, A; Selvasaravanan, KD; Siegelin, MD; Strobel, H; Westhoff, MA; Wiederspohn, N, 2020) |
| "Glioblastoma is the most devastating primary brain tumor and effective therapies are not available." | 1.56 | CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Gelsleichter, NE; Lenz, GS; Michels, LR; Schuh, RS; Stefani, MA; Teixeira, HF; Wink, MR, 2020) |
| "Osthole was the most effective." | 1.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
| "The studies on the treatment of brain metastases from esophageal cancer by radiotherapy combined with temozolomide (TMZ) are even rarer." | 1.56 | Brain metastases from esophageal cancer: A case report. ( Cui, G; Li, N; Liu, C; Liu, M; Qie, S; Ran, Y; Sun, W; Sun, X; Tian, Y; Yang, H, 2020) |
| "Gliomas are intrinsic brain tumours, which are classified by the World Health Organization (WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malignant subtype (WHO grade IV)." | 1.56 | A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. ( Hofer, S; Hottinger, AF; Hundsberger, T; Läubli, H; Mamot, C; Pesce, G; Reinert, M; Roelcke, U; Roth, P; Schucht, P; Weller, M, 2020) |
| "Glioblastoma is devastating cancer with a high frequency of occurrence and poor survival rate and it is urgent to discover novel glioblastoma-specific antigens for the therapy." | 1.56 | Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells. ( Liu, C; Liu, R; Lu, Y; Zhang, F; Zhang, H, 2020) |
| "The major difficulty in treating glioblastoma stems from the intrinsic privileged nature of the brain." | 1.56 | Vascularized Temporoparietal Fascial Flap: A Novel Surgical Technique to Bypass the Blood-Brain Barrier in Glioblastoma. ( Abrams, M; Anderson, T; Boockvar, JA; D'Amico, R; Faltings, L; Filippi, CG; Fralin, S; Khatri, D; Langer, DJ; Li, M; Patel, NV; Ratzon, F; Reichman, N; Wong, T, 2020) |
| "Temozolomide chemotherapy was an independent index to prolong overall survival in high ABCC8 mRNA expression glioma patients, whereas in patients with low expression, there was no significant difference." | 1.56 | ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. ( Chai, R; Huang, L; Jiang, T; Li, G; Liu, Y; Wang, Y; Zhao, Z; Zhou, K, 2020) |
| "Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion." | 1.56 | Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. ( Kamataki, A; Nanjo, H; Ono, T; Reinhardt, A; Shimizu, H; Takahashi, M; von Deimling, A, 2020) |
| "Glioma is one of the most aggressive forms of brain tumor and is hallmarked by high rate of mortality, metastasis and drug resistance." | 1.56 | Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294. ( Feng, H; Hua, L; Huang, L; Zhang, X, 2020) |
| "Temozolomide (TMZ) is an oral chemotherapy drug constituting the backbone of chemotherapy regimens utilized as first-line treatment of GBM." | 1.56 | LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis. ( Bi, CL; Fang, JS; Lan, S; Liu, JF; Yang, ZY; Zhang, MY, 2020) |
| "Glioma is the most malignant tumour of the human brain still lacking effective treatment modalities." | 1.56 | Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells ( Bębenek, E; Boryczka, S; Dmoszyńska-Graniczka, M; Król, SK; Stepulak, A; Sławińska-Brych, A, 2020) |
| "Glioblastoma (GBM) is a lethal type of primary brain tumor with a median survival less than 15 months." | 1.56 | Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. ( Alafate, W; Bai, X; Ma, X; Wang, J; Wang, M; Wu, W; Xiang, J; Xie, W; Xu, D, 2020) |
| "Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults." | 1.56 | Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. ( Arús, C; Candiota, AP; Julià-Sapé, M; Ledesma-Carbayo, MJ; Núñez, LM; Romero, E; Santos, A; Vellido, A, 2020) |
| "Glioblastoma multiforme (GBM) is a primary brain tumor with a very high degree of malignancy and is classified by WHO as a glioma IV." | 1.56 | Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study. ( Chwiej, J; Drozdz, A; Janeczko, K; Janik-Olchawa, N; Matusiak, K; Ostachowicz, B; Planeta, K; Ryszawy, D; Setkowicz, Z, 2020) |
| "Glioblastoma is a severe type of brain tumor with a poor prognosis and few therapy options." | 1.56 | Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries. ( Andrade Tomaz, M; de Souza, I; Karolynne Seregni Monteiro, L; Menck, CFM; Molina Silva, M; Reily Rocha, A; Rocha, CRR; Rodrigues Gomes, L; Teatin Latancia, M, 2020) |
| "Metformin has been linked to improve survival of patients with various cancers." | 1.56 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. ( Chinot, O; Genbrugge, E; Gorlia, T; Hau, P; Nabors, B; Seliger, C; Stupp, R; Weller, M, 2020) |
| "Palbociclib treatment significantly reduced tumorigenesis in TMZ-R/HMC3 bearing mice and SNHG15 and CDK6 expression was significantly reduced while miR-627-5p level was increased." | 1.51 | Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. ( Bao, H; Jin, H; Li, C; Li, Z; Liang, P; Wang, W; Xiong, J; Zhang, J; Zheng, H, 2019) |
| "Glioma is one of the most lethal malignancies and molecular regulators driving gliomagenesis are incompletely understood." | 1.51 | DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. ( Dai, X; He, Q; Shao, Y; Tan, B; Wang, J; Weng, Q; Yang, B; Zhao, M, 2019) |
| "Glioma is the most common malignant tumor of the central nervous system (CNS)." | 1.51 | Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases. ( Chen, L; Chen, PR; Gao, Y; Li, C; Lin, J; Xu, N; Zeng, D; Zhang, W; Zhu, X, 2019) |
| "Controlling seizures is essential during GBM treatment because they are often present and closely associated with the quality of life of GBM patients." | 1.51 | Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. ( Chang, MJ; Min, KL; Ryu, JY, 2019) |
| "Papaverine is a potential anticancer drug in GBM treatment." | 1.51 | Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth. ( Akasaki, Y; Ichimura, K; Inada, M; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019) |
| "Euphol is a tetracyclic triterpene alcohol, and it is the main constituent of the sap of the medicinal plant Euphorbia tirucalli." | 1.51 | Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. ( Carloni, AC; Costa, AM; Evangelista, AF; Jones, C; Lima, JP; Martinho, O; Miranda-Gonçalves, V; Pianowski, LF; Reis, RM; Rosa, MN; Silva, VAO; Tansini, A, 2019) |
| "Diffuse low-grade gliomas (DLGG) are brain tumors of young adults." | 1.51 | Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy. ( Abdallah, MB; Blonski, M; Darlix, A; de Champfleur, NM; Duffau, H; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S, 2019) |
| "Glioblastoma is the worst and most common primary brain tumor." | 1.51 | CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Fernandes, MC; Figueiró, F; Gelsleichter, NE; Iser, IC; Scholl, JN; Sévigny, J; Spanevello, RM; Stefani, MA; Teixeira, HF; Wink, MR, 2019) |
| "Glioblastoma is the most common and lethal adult brain tumor." | 1.51 | SOX3 can promote the malignant behavior of glioblastoma cells. ( Aldaz, P; Anastasov, N; Atkinson, MJ; Drakulic, D; Garcia, I; Garros-Regulez, L; Marjanovic Vicentic, J; Matheu, A; Nikolic, I; Puskas, N; Raicevic, S; Sampron, N; Stevanovic, M; Tasic, G; Vukovic, V, 2019) |
| "Malignant gliomas are aggressive primary neoplasms that originate in the glial cells of the brain or the spine with notable resistance to standard treatment options." | 1.51 | Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway. ( Bu, XY; Gao, YS; Han, SY; Hu, S; Qu, MQ; Wang, BQ; Wang, JY; Yan, ZY; Yang, B; Yang, HC, 2019) |
| "Pathology was anaplastic oligodendroglioma (AOD) and anaplastic astrocytoma IDH-mutated (AAmut) in 32 and 21 patients respectively." | 1.51 | Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. ( Back, M; Bailey, D; Brazier, D; Guo, L; Hsiao, E; Jayamanne, D; Wheeler, H, 2019) |
| "Malignant glioma is a lethal brain tumor with a low survival rate and poor prognosis." | 1.51 | Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. ( Lan, Q; Mao, J; Shao, N; Wang, R; Xue, L; Zhi, F, 2019) |
| "our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients." | 1.51 | Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). ( Alongi, F; Amelio, D; Borzillo, V; Ciammella, P; Clerici, E; di Monale, MB; Draghini, L; Fariselli, L; Ferrarese, F; Fiorentino, A; Galaverni, M; Krengli, M; Livi, L; Magrini, S; Maranzano, E; Masini, L; Minniti, G; Muto, P; Navarria, P; Pasqualetti, F; Pinzi, V; Scartoni, D; Scoccianti, S; Scorsetti, M; Tomatis, S, 2019) |
| "Human glioblastoma is a malignant and aggressive primary human brain solid tumor characterized by severe hypoxia." | 1.51 | The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma. ( He, X; Huang, S; Li, F; Qi, P; Zhang, T, 2019) |
| "Glioma is the most common brain malignancy." | 1.51 | Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. ( Fedulov, A; Karlsson, I; Lokot, I; Pejler, G; Veevnik, D; Yurkshtovich, N; Yurkshtovich, T, 2019) |
| " Delivery outcomes are evaluated by the bioavailability of free temozolomide across time." | 1.51 | Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation. ( Zhan, W, 2019) |
| "Isofuranodiene (IFD) is a bioactive sesquiterpene occurring in the essential oils obtained from Alexanders (Smyrnium olusatrum L." | 1.51 | Isofuranodiene synergizes with temozolomide in inducing glioma cells death. ( Amantini, C; Brunetti, A; Iannarelli, R; Maggi, F; Marinelli, O; Morelli, MB; Nabissi, M; Russotti, D; Santoni, G, 2019) |
| " The procedure was well-tolerated, with no adverse clinical or radiologic events related to the procedure." | 1.51 | Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. ( Alkins, R; Bethune, A; Heyn, C; Huang, Y; Hynynen, K; Ironside, S; Lipsman, N; Mainprize, T; Meng, Y; Perry, J; Sahgal, A; Trudeau, M, 2019) |
| "Glioma is a primary intracranial malignant tumor with poor prognosis." | 1.51 | Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy. ( Liu, G; Mao, J; Meng, X; Yang, Y; Zhao, C, 2019) |
| "The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to determine if the malignant phenotype may be reverted." | 1.51 | Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells. ( Castresana, JS; Erausquin, E; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A, 2019) |
| " Combinatorial therapy of diosgenin and TMZ significantly reduced the dosage regimen of TMZ and also showed affectivity in hitherto TMZ resistant GBM cells." | 1.51 | Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. ( Banerjee, I; Banik, P; Bharti, R; Biswas, A; Das, S; Ghosh, SK; Kumar, U; Mandal, M; Nayak, S; Rajesh, Y, 2019) |
| "Glioma is a common brain tumor with a high mortality rate." | 1.51 | Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma. ( Bai, X; Hu, M; Jia, L; Li, Y; Tan, X; Wang, Q; Yang, X; Zeng, X; Zhang, Z; Zhu, Y, 2019) |
| "Temozolomide treatment inhibited p50 recruitment to its cognate element as a function of Ser329 phosphorylation while concomitantly increasing p53 recruitment." | 1.51 | Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. ( Bernal, GM; Cahill, KE; Crawley, CD; Khodarev, NN; Larsen, G; Mansour, NM; Nunez, L; Raleigh, DR; Spretz, R; Szymura, SJ; Uppal, A; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W, 2019) |
| "Temozolomide (TMZ) is an important agent against GBM." | 1.51 | Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. ( Chen, Z; Liang, H; Sun, L, 2019) |
| "Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect." | 1.51 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. ( Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T, 2019) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | 1.51 | Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 1.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Glioblastoma is the most common primary brain tumor in adults." | 1.51 | ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. ( Al-Omaishi, S; Celebre, A; Chan, J; Das, S; Dirks, PB; Ghannad-Zadeh, K; Guan, J; Isaev, K; Kaskun, O; Moran, MF; Morrissy, AS; Munoz, DG; Reimand, J; Sachdeva, R; Smiljanic, S; Taylor, MD; Tong, J; Wilson, TM; Wu, M, 2019) |
| "Glioma is the most common type of primary brain tumor and has an undesirable prognosis." | 1.48 | β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells. ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2018) |
| " Proliferation, cell cycle, and apoptotic assays were performed with ML00253764, whereas the synergism of the simultaneous combination with temozolomide was evaluated by the combination index method." | 1.48 | Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. ( Bocci, G; Di Desidero, T; Giuliani, D; Guarini, S; Orlandi, P; Ottani, A; Pacini, S; Pardini, C; Pasqualetti, F; Vaglini, F, 2018) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 1.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "OBJECTIVE Glioblastoma is the most common primary central nervous system tumor in adults." | 1.48 | Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide. ( Kaye, AH; Luwor, RB; Mao, L; Morokoff, AP; Paradiso, L; Stylli, SS; Whitehead, CA, 2018) |
| "Temozolomide (TMZ) has been considered to be one of the most effective chemotherapeutic agents to prolong the survival of patients with glioblastoma." | 1.48 | Differential Characterization of Temozolomide-Resistant Human Glioma Cells. ( Chen, CC; Huang, BR; Lai, SW; Lin, C; Lin, HY; Liu, YS; Lu, DY; Tsai, CF, 2018) |
| "Glioblastoma (GBM) is the most malignant primary brain tumor and contains tumorigenic cancer stem cells (CSCs), which support the progression of tumor growth." | 1.48 | Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype. ( Chen, PY; Lee, IC; Liu, YC, 2018) |
| "Oligodendrogliomas are therapy-responsive tumors, which have better prognosis compared to their astrocytic counterparts." | 1.48 | Chemotherapy of Oligodendrogliomas. ( Drappatz, J; Lieberman, F, 2018) |
| "Central nervous system primitive neuroectodermal tumors (CNS PNETs) mostly occur in children and present as cerebellar medulloblastoma." | 1.48 | A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics. ( Chen, Z; Dong, Y; He, X; Tong, D, 2018) |
| "Glioma is the most common intracranial malignant tumors, accounting for about 40% of intracranial tumors." | 1.48 | MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. ( Jiang, Y; Tan, Z; Zhao, J, 2018) |
| "Glioblastoma is the most frequent and aggressive form of high-grade malignant glioma." | 1.48 | XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. ( Frohnapfel, L; Kaina, B; Quiros, S; Ringel, F; Roos, WP, 2018) |
| "Glioblastoma multiforme is the most lethal type of brain tumor and the established therapy only extends patients survival to approximately one year." | 1.48 | Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. ( Coelho, MAN; Gosselet, F; Lima, J; Loureiro, JA; Pereira, MC; Ramalho, MJ; Sevin, E, 2018) |
| " In addition, TMZ could increase the levels of miR-505 and combination with pri-miR-505 and TMZ promoted the suppressive role mediated by miR-505 in GBM cells." | 1.48 | Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway. ( Fu, C; Liu, X; Yang, X; Zhang, C, 2018) |
| "We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM)." | 1.48 | Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases. ( Fu, L; Guo, D; Jing, W; Kong, L; Yu, J; Zhu, Y, 2018) |
| "Peripheral primitive neuroectodermal tumors of the lumbar paraspinal region with diffuse and strong glial differentiation have never been reported before." | 1.48 | Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide. ( Botros, J; El Ahmadieh, TY; Gluf, W; Kabangu, JL; Pan, E; Raisanen, JM, 2018) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | 1.48 | Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| " Our results demonstrate benefit of ddTMZ after previous treatment with standard TMZ dosing with no apparent increase in treatment-related toxicities." | 1.48 | Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ( Garcia, CR; Gruber, L; Kumar, SS; Lightner, DD; Morgan, RM; Slone, SA; Villano, JL, 2018) |
| "Glioblastoma is the most common malignant brain tumor." | 1.48 | Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. ( Chu, L; Liu, S; Mu, H; Ni, L; Song, Y; Sun, K; Wang, A; Wu, Z; Yan, X; Zhang, C; Zhao, M, 2018) |
| "Glioma is the most common and lethal primary brain tumor." | 1.48 | Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line. ( Chen, MF; Cheng, CY; Wang, TC; Yang, WH, 2018) |
| "GBM is a deadly brain cancer that doesn't discriminate between sexes and knows no age limit." | 1.48 | A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice. ( Chen, TC; Markland, FS; Minea, RO; Swenson, S; Thein, TZ; Tuan, CD, 2018) |
| "Temozolomide (TMZ) is a drug used to treat GBM, while the survival period of GBM patients with positive treatment remains less than 15 months." | 1.48 | Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma. ( Cao, Z; Li, L; Wu, Q; Xiao, W; Xie, Q; Zhang, B; Zhao, W; Zhu, L, 2018) |
| "Human glioma is the most common type of primary brain tumor." | 1.48 | Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy. ( Liu, J; Lv, H; Ma, R; Shao, C; Zhang, G; Zheng, G, 2018) |
| " ATOR showed similar cytotoxic effect as TMZ to glioma cells, and it may be a safer drug, regarding side effect induction, than chemotherapic agents." | 1.48 | Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. ( Dal-Cim, T; Lopes, FG; Ludka, FK; Nedel, CB; Oliveira, KA; Tasca, CI, 2018) |
| "Glioblastoma (GBM) is one of the lethal central nervous system tumors." | 1.48 | The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. ( Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM, 2018) |
| "Glioma is the most common primary brain tumor and has an undesirable prognosis due to the blood-brain barrier (BBB) and drug resistance." | 1.46 | β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1. ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2017) |
| "Glioblastomas (GBM) comprise 17% of all primary brain tumors." | 1.46 | Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. ( Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB, 2017) |
| "Glioblastoma is one of the most frequent and aggressive brain tumors." | 1.46 | MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. ( Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X, 2017) |
| "Chlorpromazine is a United States Food and Drug Administration-approved phenothiazine widely used as a psychotropic in clinical practice." | 1.46 | Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. ( Griguer, CE; Langford, C; Oliva, CR; Suto, MJ; Zhang, W, 2017) |
| "Neuroendocrine tumors are rare, and little is known about the existence of cancer stem cells in this disease." | 1.46 | Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor. ( Asai, A; Ito, T; Iwata, R; Kanemura, Y; Koike, T; Maruyama, M; Nakano, Y; Nomura, S; Nonaka, M; Oe, S; Sugimoto, T; Yamada, H; Yoshimura, K, 2017) |
| "Guanosine (GUO) is an endogenous nucleoside involved in extracellular signaling that presents neuroprotective effects and also shows the effect of inducing differentiation in cancer cells." | 1.46 | Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells. ( Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI, 2017) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent widely used in anti-glioma treatment." | 1.46 | Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells. ( Fu, Z; Guo, H; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H, 2017) |
| "The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB)." | 1.46 | The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts. ( Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J, 2017) |
| "Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity." | 1.46 | Zika virus has oncolytic activity against glioblastoma stem cells. ( Chai, JN; Chheda, MG; Diamond, MS; Fernandez, E; Gorman, MJ; Hubert, CG; McKenzie, LD; Prager, BC; Rich, JN; Richner, JM; Shan, C; Shi, PY; Tycksen, E; Wang, X; Zhang, R; Zhu, Z, 2017) |
| "Glioblastoma is the most common and aggressive primary brain tumor and has a high mortality in humans." | 1.46 | Identification of WISP1 as a novel oncogene in glioblastoma. ( Jing, D; Shen, L; Yu, H; Zhang, Q; Zhao, Y, 2017) |
| "Malignant gliomas are a group of aggressive neoplasms among human cancers." | 1.46 | Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells. ( An, TT; Chen, YD; Dong, TX; Liu, PF; Xu, YT; Yang, XH; Zhang, W; Zhang, Y, 2017) |
| "Among 350 glioma and ganglioglioma cases, the MGMT promoter tested positive for methylation in 53." | 1.46 | Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. ( Chen, L; Hu, Z; Li, Z; Liu, C; Liu, L; Lu, D; Teng, L; Wang, L; Zhao, L, 2017) |
| " In vivo, systemic treatment with pacritinib demonstrated blood-brain barrier penetration and led to improved overall median survival in combination with TMZ, in mice orthotopically xenografted with an aggressive recurrent GBM BTIC culture." | 1.46 | The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. ( Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S, 2017) |
| " In vivo, we implanted the cells orthotopically in nude mice and administered CBL0137 in various dosing regimens to assess brain and tumor accumulation of CBL0137, its effect on tumor cell proliferation and apoptosis, and on survival of mice with and without temozolomide (TMZ)." | 1.46 | Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. ( Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A, 2017) |
| "Temozolomide is a commonly used chemotherapy drug and frequently causes lymphocytopenia." | 1.46 | Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy. ( Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H, 2017) |
| "Temozolomide (TMZ) is a novel cytotoxic agent used as first-line chemotherapy for GBM, however, some individual cells can't be isolated for surgical resection and show treatment-resistance, thus inducing poor prognosis." | 1.46 | MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. ( Chen, C; Chen, W; Ge, XS; He, J; Kong, KK; Li, FC; Li, H; Li, JL; Li, P; Wang, F; Xu, XK, 2017) |
| "6 μg/day) with negligible leakage into the peripheral blood (<100 ng) rendering ~1000 fold differential drug dosage in tumor versus peripheral blood." | 1.46 | Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. ( Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK, 2017) |
| "A 43-year-old man with an anaplastic astrocytoma received radiation therapy synchronized with ranimustine and adjuvant TMZ chemotherapy for 15 cycles." | 1.46 | A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( Kosugi, K; Saito, K; Takahashi, W; Tokuda, Y; Tomita, H, 2017) |
| "Orthotopic xenograft model of human brain cancer cells is a good preclinical model for evaluation of antitumor compounds." | 1.43 | [Establishment of a glioma orthotopic xenograft model based on imaging technology]. ( Chen, XG; Ji, M; Lai, FF; Lü, YH; Wang, LY, 2016) |
| "Glioblastoma is the deadliest brain tumor in humans." | 1.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "Primary brain tumors are hallmarked for their destructive activity on the microenvironment and vasculature." | 1.43 | A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain. ( Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hock, S; Savaskan, NE; Sehm, T; Yakubov, E, 2016) |
| "The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years." | 1.43 | High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016) |
| "BBBD temozolomide was toxic in the efficacy study, but there was no evidence of symptomatic neurotoxicity in rats given IA temozolomide." | 1.43 | Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. ( Muldoon, LL; Netto, JP; Neuwelt, EA; Pagel, MA, 2016) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 1.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 1.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "Glioblastoma is the most common and deadly primary brain tumor in adults." | 1.43 | Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro. ( Feng, F; Ling, Z; Sun, C; Wang, L; Wang, S; Wu, B; Xia, L; Yu, Y, 2016) |
| "Glioblastoma multiforme is a devastating disease with no curative options due to the difficulty in achieving sufficient quantities of effective chemotherapies into the tumor past the blood-brain barrier." | 1.43 | Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. ( Bredlau, AL; Broome, AM; Dixit, S; McKinnon, E; Miller, K; Moore, A, 2016) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | 1.43 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| "Glioblastomas (GBM), deadly brain tumors, have greater incidence in males than females." | 1.43 | Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. ( Brenner, A; Cavazos, D; Garcia, L; Garcia, M; Gruslova, A; Gustafsson, JA; Li, X; Liu, J; Sareddy, GR; Strom, AM; Tekmal, RR; Vadlamudi, RK; Viswanadhapalli, S, 2016) |
| "Fotemustine (FTM) is a third-generation nitrosourea showing efficacy in gliomas and it has been used with different schedules in adult patients." | 1.43 | Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. ( Bellu, L; D'Avella, D; Della Puppa, A; Farina, M; Fiduccia, P; Lombardi, G; Pambuku, A; Zagonel, V, 2016) |
| "The analysis included all patients treated for gliosarcoma between 1998 and 2014 in seven French academic centres." | 1.43 | Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( Antoni, D; Berger, A; Biau, J; Castelli, J; Crehange, G; de Crevoisier, R; Feuvret, L; Gutierrez, FL; Haoming, QC; Jouglar, E; Le Reste, PJ; Loussouarn, D; Morandi, X; Noel, G; Nouhaud, E; Thillays, F; Truc, G; Vauleon, E, 2016) |
| "Dysembryoplastic neuroepithelial tumors (DNETs) are low-grade neuroglial tumors that are traditionally considered to be benign hamartoma-like mass lesions." | 1.43 | Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor. ( Fenstermaker, RA; Mechtler, LL; Morr, S; Prasad, D; Qiu, J, 2016) |
| " We show that GSI in combination with RT and TMZ attenuates proliferation, decreases 3D spheroid growth and results into a marked reduction in clonogenic survival in primary and established glioma cell lines." | 1.43 | NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. ( Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2016) |
| " We investigated the pharmacologic characteristics of OTX015 as a single agent and combined with targeted therapy or conventional chemotherapies in glioblastoma cell lines." | 1.43 | OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. ( Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME, 2016) |
| " As a comparison group 33 patients with bevacizumab for at least 6 months continuously dosed at 10 mg/kg every 2 weeks were selected." | 1.43 | Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. ( Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F, 2016) |
| "Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0." | 1.43 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. ( Arnal, AV; Donovan, LE; Odia, Y; Wang, SH, 2016) |
| "Glioblastoma multiforme is the most aggressive malignant primary brain tumor in adults." | 1.43 | Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. ( Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF, 2016) |
| "Gliomas are the most common primary intracranial malignant tumors in adults." | 1.43 | Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. ( Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G, 2016) |
| "Glioma is still difficult to treat because of its high malignancy, high recurrence rate, and high resistance to anticancer drugs." | 1.43 | 3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility. ( Dai, X; Lan, Q; Ma, C; Xu, T, 2016) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of aggressive forms of brain tumor based on its antitumor actions." | 1.43 | Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells. ( Gao, S; Liang, J; Wang, W; Wang, Y, 2016) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 1.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Diffuse low-grade gliomas are rare primitive cerebral tumours of adults." | 1.43 | Predictive models for diffuse low-grade glioma patients under chemotherapy. ( Ben Abdallah, M; Blonski, M; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S, 2016) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 1.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Glioblastoma is a highly aggressive, common brain tumor with poor prognosis." | 1.42 | RIST: a potent new combination therapy for glioblastoma. ( Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA, 2015) |
| "Malignant glioma is a common and lethal primary brain tumor in adults." | 1.42 | VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. ( Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y, 2015) |
| "These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway." | 1.42 | Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway. ( Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S, 2015) |
| "Glioblastoma is the most aggressive primary brain tumor, and is associated with a very poor prognosis." | 1.42 | Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. ( Alder, JE; Boissinot, M; Droop, A; Hayes, J; Hughes, TA; Lawler, SE; Shaw, L; Short, SC; Thygesen, H; Tumilson, C; Westhead, D, 2015) |
| "Glioblastoma is a devastating primary brain tumor resistant to conventional therapies." | 1.42 | Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. ( Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 1.42 | Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. ( Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 1.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Glioblastoma is the most malignant brain tumor, exhibiting remarkable resistance to treatment." | 1.42 | A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. ( Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A, 2015) |
| "Irinotecan has shown some efficacy in recurrent malignant gliomas." | 1.42 | Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. ( Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C, 2015) |
| "Temozolomide treatment significantly induced mRNA expression of nearly all investigated EMT markers in T98G glioma cells." | 1.42 | Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas. ( Hattermann, K; Held-Feindt, J; Kubelt, C; Mehdorn, HM; Sebens, S, 2015) |
| "Thromboembolic events, seizures, neurologic symptoms and adverse effects from corticosteroids and chemotherapies are frequent clinical complications seen in Glioblastoma (GB) patients." | 1.42 | Risk factors for glioblastoma therapy associated complications. ( Brenke, C; Capper, D; Ening, G; Osterheld, F; Schmieder, K, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 1.42 | Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. ( Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K, 2015) |
| "Evidence suggests hyperglycemia is associated with worse outcomes in glioblastoma (GB)." | 1.42 | Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. ( Chung, C; Kiehl, TR; Laperriere, N; Lovblom, LE; Mason, W; McNamara, MG; Ménard, C; Millar, BA; Perkins, BA; Tieu, MT, 2015) |
| "Patients diagnosed with primary brain tumors were treated with PDT." | 1.42 | Photodynamic therapy in the treatment of brain tumours. A feasibility study. ( Azinovic, I; Brugarolas, A; Cañón, R; Cases, FG; Rebollo, J; Sapena, NS; Sureda, M; Vanaclocha, V, 2015) |
| " Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ)." | 1.42 | Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. ( Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN, 2015) |
| "Glioblastoma multiforme is the most common malignant brain tumor." | 1.42 | An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response. ( Barbeau, LM; Granton, PV; Paesmans, K; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2015) |
| "Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM)." | 1.42 | A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. ( Barciszewska, AM; Gurda, D; Głodowicz, P; Naskręt-Barciszewska, MZ; Nowak, S, 2015) |
| "Glioma is one of the most common primary tumors of the central nervous system in adults." | 1.42 | Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. ( Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY, 2015) |
| "Gliomas are the most common primary brain tumors." | 1.42 | Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. ( Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L, 2015) |
| " This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells." | 1.40 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. ( Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014) |
| " We report five patients who received long-term treatment with TMZ chemotherapy at normal dosing levels." | 1.40 | Long-term treatment with temozolomide in malignant glioma. ( Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL, 2014) |
| "Our case exhibited atypical central neurocytoma with an initially elevated MIB-1 labeling index (25-30 %)." | 1.40 | Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation. ( Barzo, P; Cserhati, A; Fodor, E; Hideghety, K; Mozes, P; Szanto, E; Tiszlavicz, L, 2014) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 1.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| " More generally, these results suggest that traditional therapy in combination with local, as opposed to systemic, delivery of angiogenesis inhibitors may be able to increase median survival for patients with glioblastoma." | 1.40 | Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. ( Bow, H; Brem, H; Hwang, LS; Murray, L; Salditch, Q; Schildhaus, N; Tyler, B; Weingart, J; Xing, J; Ye, X; Zhang, Y, 2014) |
| "One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start of treatment." | 1.40 | Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. ( Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P, 2014) |
| "Glioblastoma is the most common malignant primary brain tumor." | 1.40 | EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. ( Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "In a cohort of HER2+ breast cancer brain metastases, we identified a gene expression signature that anti-correlates with overexpression of BRCA1." | 1.40 | A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. ( Akbari, MR; Aldape, KD; Denton-Schneider, BR; Hicks, D; Lee, J; McMullin, RP; Moulis, S; Narod, SA; Ramaswamy, S; Sgroi, DC; Singavarapu, R; Steeg, PS; Wittner, BS; Yang, C, 2014) |
| "Most patients with brain metastases have active extracranial disease, which limits survival unless effective systemic therapy can be administered." | 1.40 | Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases. ( Aandahl, G; Dalhaug, A; Haukland, E; Marienhagen, K; Nieder, C; Pawinski, A, 2014) |
| "optimal treatment of glioblastoma (gBM) in the elderly remains unclear." | 1.40 | Glioblastoma treatment in the elderly in the temozolomide therapy era. ( Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A, 2014) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma multiforme (GBM), the main form of human brain tumours in adults." | 1.40 | Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. ( Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM, 2014) |
| "Glioma is one of the most aggressive and lethal human brain tumors." | 1.40 | MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. ( Chen, Q; Jiang, BH; Jiang, C; Jiang, T; Kang, C; Li, C; Li, H; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, Z; Wang, L; Wang, X; You, Y, 2014) |
| "WBRT followed by IMBRT combined with concomitant TMZ is well tolerated, yielding an encouraging objective response rate; however, overall survival improves slightly comparing with RTOG 9508 randomized trial." | 1.40 | Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer. ( Jiang, Z; Leng, C; Liang, S; Liu, H; Lu, F; Lu, S; Qi, X; Shi, J; Wang, Q; Wang, S, 2014) |
| "Three scales, i." | 1.40 | Longitudinal quality of life data: a comparison of continuous and ordinal approaches. ( Albert, A; Bottomley, A; Coens, C; Donneau, AF; Mauer, M, 2014) |
| "Glioblastoma is the most prevalent primary brain tumor and is essentially universally fatal within 2 years of diagnosis." | 1.40 | Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. ( Bai, Y; Flavahan, W; Lathia, JD; Mattson, MP; Rich, JN; Zhang, P, 2014) |
| "Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of GBM following surgery." | 1.40 | miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. ( Cui, Y; Lei, Q; Li, G; She, X; Wang, Z; Wu, M; Xiang, J; Xu, G; Yu, Z, 2014) |
| "Non-invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI." | 1.40 | Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. ( Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M, 2014) |
| "GBM is a primary brain tumor known to frequently demonstrate resistance to apoptosis-inducing therapeutics." | 1.40 | SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. ( Chakravarti, A; Chu, Z; Denton, N; Dmitrieva, N; Hardcastle, J; Jacob, NK; Kaur, B; Kwon, CH; Marsh, R; Meisen, WH; Qi, X; Thorne, AH; Van Meir, EG; Wojton, J, 2014) |
| " In the present work, TMZ was combined with a specific SKI, and the cytotoxic effect of each drug alone or in combination was tested on GBM cell lines." | 1.40 | A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. ( Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K, 2014) |
| "Metastases represent the most common brain tumors in adults." | 1.40 | Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. ( Brem, H; Cima, M; Grossman, R; Hwang, L; Langer, R; Masi, B; Patta, Y; Scott, A; Spencer, K; Tyler, B; Upadhyay, UM; Wicks, R, 2014) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | 1.40 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Glioblastoma are highly aggressive brain tumors with poor prognosis." | 1.40 | Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. ( Cai, J; Chang, L; Chen, L; Cui, Y; Dou, Z; Du, W; Jiang, C; Liu, X; Liu, Y; Wang, G; Wang, H; Wang, X; Yi, L; Zhang, P, 2014) |
| "Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf)." | 1.40 | Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. ( Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S, 2014) |
| " In a human GBM xenograft model, a single daily dosage of MB does not activate AMP-activated protein kinase signaling, and no tumor regression was observed." | 1.39 | Reversing the Warburg effect as a treatment for glioblastoma. ( Bigner, DD; Choudhury, GR; Ghorpade, A; Keir, ST; Li, W; Liu, R; Poteet, E; Ryou, MG; Simpkins, JW; Tang, L; Wen, Y; Winters, A; Yan, H; Yang, SH; Yuan, F, 2013) |
| "Clinical presentation of gliomatosis cerebri is variable and depends on the degree, extent, and location of cortical involvement." | 1.39 | Bilateral ptosis as initial presentation of gliomatosis cerebri: case report. ( Braca, J; Kovanda, T; Prabhu, V, 2013) |
| " Sufficient information on steroid dosing was available in 72 patients included in the final analysis." | 1.39 | Steroid management in newly diagnosed glioblastoma. ( Deangelis, LM; Deutsch, MB; Lassman, AB; Panageas, KS, 2013) |
| "Temozolomide was used almost exclusively during CRT (94." | 1.39 | Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. ( Cahill, D; Gilbert, MR; Lei, X; Shonka, NA; Smith, L; Theeler, B; Yung, A, 2013) |
| "Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases." | 1.39 | Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. ( Archer, GE; Bigner, DD; Choi, BD; Cui, X; Flores, C; Herndon, JE; Johnson, LA; Mitchell, DA; Sampson, JH; Sanchez-Perez, LA; Schmittling, RJ; Snyder, D, 2013) |
| "Glioblastoma multiforme is the most common lethal brain tumor in human adults, with no major therapeutic breakthroughs in recent decades." | 1.39 | Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. ( Bauer, M; Bechmann, I; Dehghani, F; Durante, M; Gaunitz, F; Giese, A; Gutenberg, A; Hellwig, C; Meixensberger, J; Merz, F; Renner, C; Schäfer, M; Schopow, K; Stöcker, H; Taucher-Scholz, G, 2013) |
| "Glioblastoma multiforme is the most aggressive primary brain tumour." | 1.39 | Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2013) |
| "C6 rat gliomas were incubated with low-dose TMZ to induce chemoresistance." | 1.39 | Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, T; Sasajima, T; Shimada, N, 2013) |
| "The presence of subcutaneous metastases raised the suspicion for metastatic melanoma; however, pathological confirmation remained the ultimate tool to reach the final diagnosis." | 1.39 | Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. ( Ejaz, S; Habra, MA; Henderson, SA; Shawa, H, 2013) |
| "Glioblastoma is the most lethal brain cancer." | 1.39 | Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model. ( Li, C; Li, X; Liu, X; Yan, B; Zhang, Q; Zhou, H, 2013) |
| "Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system." | 1.39 | Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013) |
| "Glioblastoma is a highly aggressive malignant disease with notable resistance to chemotherapy." | 1.39 | High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma. ( Han, G; Hu, X; Li, Y; Liu, J; Wang, L; Yue, Z; Zhao, R; Zhao, W; Zhou, X, 2013) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | 1.39 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "Anaplastic ependymomas are rare tumors in adult patients." | 1.39 | Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( Bellu, L; Della Puppa, A; Gardiman, MP; Lombardi, G; Pambuku, A; Pomerri, F; Rumanò, L; Zagonel, V, 2013) |
| "Pseudoprogression (PP) during adjuvant treatment of glioblastoma (GBM) is frequent and is a clinically and radiologically challenging problem." | 1.39 | Is there pseudoprogression in secondary glioblastomas? ( Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R, 2013) |
| "We analyzed the data of 210 patients treated for glioblastoma between 2005 and 2013." | 1.39 | [Results of postoperative radiochemotherapy of glioblastoma multiforme]. ( Bagó, A; Bajcsay, A; Fedorcsák, I; Kásler, M; Lövey, J; Mangel, L; Sipos, L, 2013) |
| "Temozolomide is an attractive candidate treatment in neuroblastoma with methylated MGMT, especially in central nervous system relapsed cases." | 1.39 | Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation. ( Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K, 2013) |
| "Glioblastoma multiforme is the most common malignant central nervous system tumor, and also among the most difficult to treat due to a lack of response to chemotherapeutics." | 1.39 | Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. ( Payne, CA; Safdar, S; Taite, LJ; Tu, NH, 2013) |
| " This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs." | 1.39 | Effective elimination of cancer stem cells by a novel drug combination strategy. ( Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H, 2013) |
| "Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | 1.39 | Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
| "Gliosarcoma was more common in males (n = 31, 67." | 1.39 | Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. ( Brown, PD; Gilbert, MR; McAleer, MF; Prabhu, SS; Walker, GV, 2013) |
| "More effective drugs for brain cancer and brain metastasis can be screened and can be identified with this technology." | 1.39 | Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice. ( Bouvet, M; Chishima, T; Endo, I; Hoffman, RM; Momiyama, M; Suetsugu, A, 2013) |
| "We here show that glioblastomas are capable to downregulate MGMT expression independently of promoter methylation by elongation of the 3'-UTR of the mRNA, rendering the alternatively polyadenylated transcript susceptible to miRNA-mediated suppression." | 1.39 | In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. ( Egensperger, R; Hinske, LC; Hoefig, K; Kreth, FW; Kreth, S; Limbeck, E; Schütz, SV; Thon, N, 2013) |
| "The tumor was partially resected and anaplastic astrocytoma was diagnosed." | 1.38 | Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. ( Fujimoto, Y; Hashimoto, N; Kagawa, N; Kinoshita, M; Miyazaki, Y; Takehara, T; Tanaka, S; Yakushijin, T; Yoshimine, T, 2012) |
| "Temozolomide is an active drug against gliomas in adults." | 1.38 | Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center. ( Akyüz, C; Büyükpamukçu, M; Demir, HA; Kutluk, T; Varan, A; Yalçin, B, 2012) |
| "Glioblastoma is the most common and most malignant primary brain tumor in adults." | 1.38 | Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. ( Hedderich, J; Mehdorn, HM; Nabavi, A; Stark, AM; van de Bergh, J, 2012) |
| "Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100." | 1.38 | Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. ( Blasco, J; Bruna, J; Gil, M; Graus, F; Pineda, E; Simó, M; Velasco, R; Verger, E, 2012) |
| " These results suggest that GBMs with EGFR amplification are a heterogenous group of tumors and that behavior might differ according to the degree of amplification, although not in a straightforward dose-response manner." | 1.38 | Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. ( Bortoluzzi, S; Cieply, K; Fardo, DW; Hamilton, RL; Hobbs, J; Horbinski, C; Nikiforova, MN, 2012) |
| "Primary malignant brain tumors (BT) are the most common and aggressive malignant brain tumor." | 1.38 | Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. ( Bow, H; Brem, H; Cima, MJ; Langer, R; Masi, BC; Tyler, BM; Wicks, RT; Xue, Y, 2012) |
| " These data reassuringly suggest that BEV does not significantly change the ECF tumor concentrations of TMZ in either tumor-bearing or normal brain when dosed 36 h prior to TMZ." | 1.38 | The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ( Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P, 2012) |
| "Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)." | 1.38 | Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. ( Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012) |
| "Glioblastoma multiforme is the most common primary malignant brain tumour, with a median survival of about one year." | 1.38 | A restricted cell population propagates glioblastoma growth after chemotherapy. ( Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS, 2012) |
| "The management of brain metastases (BM) from breast cancer (BC) needs to be improved, and new therapeutic strategies are urgently requested." | 1.38 | Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. ( Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; Iodice, P; Lombardi, A; Montella, L; Parlato, C; Prete, SD; Russo, P; Salzano, A; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2012) |
| "These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 1.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
| "To report the serial development of oral mucositis following infusion of bevacizumab in a young woman with a malignant brain tumor and history of cutaneous psoriasis." | 1.38 | Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis. ( Cuellar, S; Popa, AM; Radhakrishnan, L; Valla, K; Villano, JL, 2012) |
| "Temozolomide (TMZ) is a prodrug for an alkylating agent used for the treatment of malignant brain tumors." | 1.38 | An efficient and practical radiosynthesis of [11C]temozolomide. ( Carlin, SM; Hooker, JM; Moseley, CK; Neelamegam, R, 2012) |
| "Extracranial metastasis of primary brain tumors is rarely observed." | 1.38 | Breast metastasis of anaplastic oligodendroglioma: a case report. ( Alacacioglu, A; Canpolat, S; Coskun, A; Karatas, A; Oztekin, O; Postaci, H; Sop, G; Unal, S; Yurt, A, 2012) |
| "Temozolomide was prescribed, and a disease-free period of 2 years followed." | 1.37 | Case of atypical teratoid/rhabdoid tumor in an adult, with long survival. ( Ikeda, J; Kanno, H; Katoh, M; Kimura, T; Mahabir, R; Nagashima, K; Nishihara, H; Sawamura, Y; Takahashi, K; Tanaka, S; Tanino, M; Yoshinaga, T, 2011) |
| "All patients had seizure disorders that were treated with anticonvulsants." | 1.37 | Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | 1.37 | Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| " We evaluated the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor (XL765) in in vitro and in vivo studies." | 1.37 | Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. ( Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X, 2011) |
| "The long-term TMZ-treated astroglioma cells, but not the Hs683 oligodendroglioma cells, developed in vivo a certain level of resistance to TMZ, which correlated with the up- regulation of CXCL2, CXCL3 and CXCL8 expression in the U373 and T98G astroglioma cells." | 1.37 | Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. ( Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S, 2011) |
| "Metformin or olanzapine have been shown independently to enhance AMPK activation." | 1.37 | Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? ( Halatsch, ME; Karpel-Massler, G; Kast, RE, 2011) |
| "The prognostic value of postoperative residual tumor volume in FET PET, TBR(mean,) TBR(max) and Gd-volume was evaluated using Kaplan-Maier estimates for disease-free survival (DFS) and overall survival (OS)." | 1.37 | Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. ( Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G, 2011) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 1.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| "Cediranib is a highly potent receptor tyrosine kinase inhibitor that inhibits all three VEGF receptors." | 1.37 | Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. ( Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X, 2011) |
| "Temozolomide is an effective treatment for seizure control in patients with brain tumors." | 1.37 | Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. ( Hu, A; Kesari, S; Kim, RY; Lee, JW; Nguyen, A; Xu, Z, 2011) |
| "Communicating hydrocephalus is an uncommon complication in patients treated for glioblastoma multiforme (GBM)." | 1.37 | Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma. ( Bianchi, F; D'Alessandris, QG; Doglietto, F; Fernandez, E; Lauretti, L; Maira, G; Montano, N; Pallini, R, 2011) |
| "Oral temozolomide (TMZ) was administered in combination with mFc-endostatin to determine if there was a beneficial synergistic effect." | 1.37 | Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. ( Brem, H; Grossman, R; Hwang, L; Javaherian, K; Lal, B; Tyler, B; Zadnik, P, 2011) |
| " The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment." | 1.37 | Rechallenge with temozolomide in recurrent glioma. ( Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011) |
| "Our results of combined treatment of brain metastases are presented and available approaches to brain irradiation and chemotherapy are discussed." | 1.37 | [Brain metastasis in breast cancer]. ( Ivanov, VG; Korytova, LI; Masliukova, EA; Meshechkin, AV; Zhabuna, RM, 2011) |
| "Sixty-eight patients with brain tumors were studied (60% high-grade glioma)." | 1.36 | Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials. ( Anderson, SK; Brown, PD; Cerhan, JH; Lageman, SK; Locke, DE; Wu, W, 2010) |
| "MGMT expression in brain metastases was significantly correlated with better survival." | 1.36 | O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. ( Cheng, AL; Kuo, KT; Kuo, LT; Lee, WC; Lin, CH; Lin, YT; Lu, YS; Tasi, JC; Tseng, HM; Tseng, SH; Tu, YK; Wu, PF; Wu, RM; Yang, CH, 2010) |
| "Gliomas account for more than 50% of all primary brain tumors." | 1.36 | Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. ( Bontempi, G; Bruyère, C; Decaestecker, C; Dubois, J; Haibe-Kains, B; Kiss, R; Lamoral-Theys, D; Le Calvé, B; Le Mercier, M; Lefranc, F; Rynkowski, MA, 2010) |
| "Poor drug delivery to brain tumors caused by aberrant tumor vasculature and a partly intact blood-brain barrier (BBB) and blood-brain tumor barrier (BTB) can significantly impair the efficacy of chemotherapy." | 1.36 | Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy. ( Artemov, D; Holm, DA; Kato, Y; Okollie, B, 2010) |
| "Concurrent treatment of the glioma cell line U87-MG with siRNA 1 and temozolomide (TMZ) resulted in a 13-fold reduction in the dose of TMZ required to achieve a similar effect if TMZ was used alone." | 1.36 | Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma? ( Cruickshanks, N; Munje, C; Patel, R; Shervington, A; Shervington, L; Thakkar, D, 2010) |
| "Glioblastoma multiforme is the most common and most malignant primary brain tumour." | 1.36 | Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. ( Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P, 2010) |
| "Glioblastoma multiforme is the most commonly diagnosed malignant primary brain tumour in adults." | 1.36 | Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. ( Bendinelli, S; Casalini, F; Costa, B; Da Pozzo, E; Da Settimo, F; Gabelloni, P; Martini, C; Nuti, E; Orlandini, E; Rossello, A, 2010) |
| "Temozolomide (TMZ) is a recently introduced alkylating agent that has yielded significant benefits and become a key agent in the treatment of high-grade gliomas." | 1.36 | Gene expression profiling predicts response to temozolomide in malignant gliomas. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2010) |
| "High-grade gliomas are among the most lethal of all cancers." | 1.36 | Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. ( Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M, 2010) |
| "Glioblastomas (GBM) are lethal brain tumors that are highly resistant to therapy." | 1.36 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. ( Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N, 2010) |
| "A major barrier to progress in treatment of glioblastoma is the relative inaccessibility of tumors to chemotherapeutic agents." | 1.36 | Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. ( Kumabe, T; Nishihara, M; Saito, R; Satoh, T; Sonoda, Y; Sugiyama, S; Tominaga, T; Yamashita, Y; Yokosawa, M; Yokoyama, M, 2010) |
| "Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children." | 1.36 | Long-term outcomes in children with glioblastoma. ( Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC, 2010) |
| "A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting." | 1.36 | Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. ( Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H, 2010) |
| "Malignant astrocytic brain tumors are among the most lethal cancers." | 1.36 | Non-stem cell origin for oligodendroglioma. ( Auvergne, R; Ayers-Ringler, J; Berger, MS; Bergers, G; Goldenberg, DD; Goldman, SA; Itsara, M; McKnight, TR; Nguyen, KN; Nishiyama, A; Persson, AI; Petritsch, C; Sim, FJ; Stallcup, WB; Swartling, FJ; Vandenberg, SR; Weiss, WA; Yakovenko, S, 2010) |
| "6% and 1/6 rat survived more than 1 year in case of MRT combined with gadolinium injection." | 1.35 | Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. ( Bräuer-Krisch, E; Bravin, A; Keyriläinen, J; Le Duc, G; Régnard, P; Troprès, I, 2008) |
| "Temozolomide is a relatively new chemotherapeutic agent frequently associated with selective CD4+ T-lymphocytopenia." | 1.35 | Disseminated salmonellosis in a patient treated with temozolomide. ( Adachi, J; Georgescu, G; Isola, IM; Rolston, K; Youssef, S, 2008) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 1.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "Temozolomide (TMZ) is a cytotoxic agent of the imidazotetrazine class, chemically related to dacarbazine." | 1.35 | Tuberculosis in a patient on temozolomide: a case report. ( de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA, 2009) |
| "Temozolomide is an effective alkylating agent that is increasingly used for the treatment of pediatric brain tumors." | 1.35 | Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. ( Auger, N; Bhangoo, R; Da Costa, L; Dufour, C; Grill, J; Jullien, M, 2008) |
| "As favorable outcomes from malignant brain tumors remain limited by poor survival and treatment-related toxicity, novel approaches to cure are essential." | 1.35 | Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. ( Goldhoff, P; Hope, A; Jackson, E; Limbrick, DD; Perry, A; Piwnica-Worms, D; Rubin, JB; Warrington, NM; Woerner, BM, 2008) |
| "We report a case of pituitary carcinoma with multiple craniospinal metastases in a child." | 1.35 | Pituitary carcinoma presenting with multiple metastases: case report. ( Cayli, SR; Guzel, A; Guzel, E; Sav, A; Senturk, S; Tatli, M, 2008) |
| " The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d)." | 1.35 | A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. ( Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE, 2009) |
| "Glioblastoma multiforme is a primary malignant brain tumor with a prognosis of typically less than 2 years." | 1.35 | Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? ( Binello, E; Germano, IM, 2009) |
| "Cilengitide is a cyclic peptide antagonist of integrins alphavbeta3 and alphavbeta5 that is currently being evaluated as a novel therapeutic agent for recurrent and newly diagnosed glioblastoma." | 1.35 | Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. ( Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W, 2009) |
| "First clinical reports on treating brain metastases with temozolomide describe varying effects." | 1.35 | Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. ( Heppner, FL; Ingold, B; Moch, H; Schraml, P, 2009) |
| "We report the case of a patient with primary brain tumor who developed cytomegalovirus associated colonic pseudotumor as an opportunistic infection while receiving chemotherapy with Temozolomide and radiation." | 1.35 | Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. ( De Jesus, A; Grossman, SA; Paun, O, 2009) |
| "Carmustine wafer was not an independent predictor (P=." | 1.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| " After irradiation of the symptomatic sites, intrathecal liposomal Ara-C every 2-4 weeks was combined with temozolomide 100 mg/m(2) day 1-5/7." | 1.35 | Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ( Buhk, JH; Hoffmann, AL; Strik, H, 2009) |
| "Glioblastomas are highly aggressive primary brain tumors." | 1.35 | Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. ( Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P, 2008) |
| " The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide." | 1.35 | Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. ( Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008) |
| "Temozolomide has become the standard of care in newly diagnosed glioblastoma." | 1.35 | [Chemotherapy for brain tumors in adult patients]. ( Weller, M, 2008) |
| "Astroblastoma is a historically traded microscopic diagnosis to denote a rare neuroepithelial tumor of uncertain nosology, involving a distinctive pattern of pseudorosette arrangement of neoplastic cells." | 1.35 | Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up. ( El-Koussy, M; Fathi, AR; Kappeler, A; Mariani, L; Novoa, E; Vajtai, I, 2008) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 1.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Temozolomide is a proautophagic (type II programmed cell death) drug and can thus circumvent part of the glioblastoma resistance to apoptosis." | 1.35 | [The sodium pump could constitute a new target to combat glioblastomas]. ( Kiss, R; Lefranc, F; Mijatovic, T, 2008) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | 1.35 | Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. ( Banik, NL; Das, A; Ray, SK, 2008) |
| "We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years)." | 1.35 | Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. ( Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC, 2009) |
| "The anterior temporal lesion was a ganglioglioma and did not recur." | 1.34 | Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion? ( Dickerman, RD; Howes, G; Lee, JM; Nardone, EM; Stevens, QE, 2007) |
| " Three patients (12%) were changed to standard temozolomide dosing due to side effects, including intractable nausea (n = 2) and multiple cytopenias (n = 1)." | 1.34 | Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. ( Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH, 2007) |
| "Glioblastoma multiforme is a malignant astrocytic tumor characterized by rapid growth, extensive invasiveness and high vascularity." | 1.34 | Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells. ( Cambar, J; L'Azou, B; Liguoro, D; Pédeboscq, S; Pometan, JP, 2007) |
| " Although this approach is promising, there has not been any attempt to define optimal metronomic dosing regimens by integrating pharmacokinetic (PK) with pharmacodynamic (PD) measurements." | 1.34 | Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. ( Gallo, JM; Guo, P; Nuthalapati, S; Wang, X; Zhou, Q, 2007) |
| "Glioblastoma multiforme is characterised by invasive growth and frequent recurrence." | 1.34 | Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. ( Berger, W; Buchroithner, J; Fischer, J; Marosi, C; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S, 2007) |
| "Glioblastomas are malignant brain tumors that are very difficult to cure, even with aggressive therapy consisting of surgery, chemotherapy, and radiation." | 1.34 | Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. ( Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N, 2007) |
| "Temozolomide treatment of high-grade tv-a gliomas provided a 14-day growth delay compared with vehicle controls." | 1.34 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. ( Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ, 2007) |
| "Gliomas, the most common primary brain tumors, are diffusive and highly invasive." | 1.34 | Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy. ( Kohandel, M; Milosevic, M; Oza, A; Powathil, G; Sivaloganathan, S, 2007) |
| "For patients with anaplastic astrocytoma, the 12-month survival rate was 73%." | 1.34 | Salvage chemotherapy in progressive high-grade astrocytoma. ( See, SJ; Ty, A; Wong, MC, 2007) |
| "Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle." | 1.34 | Temozolomide in pediatric low-grade glioma. ( Ashley, DM; Coleman, LT; Downie, PA; Heath, JA; Khaw, SL, 2007) |
| "Brain metastases are an alarming complication of advanced melanoma, frequently contributing to patient demise." | 1.34 | Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. ( Boucher, KM; Jensen, RL; Leachman, SA; Majer, M; Samlowski, WE; Shrieve, DC; Wang, M; Watson, GA, 2007) |
| " Because significant obstacles prevent making these measurements in humans, development of a predictive pharmacokinetic model would be of great value to the translation of preclinical data to the clinic." | 1.34 | Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. ( Gallo, JM; Guo, P; Kruh, GD; Vicini, P; Wang, X; Zhou, Q, 2007) |
| "The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h." | 1.34 | Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ( Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007) |
| "Sixty four patients with melanoma brain metastases were treated in our department within a 15-year period." | 1.33 | Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. ( Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA, 2005) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 1.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 1.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "At the time of the initial disease recurrence, 13 patients were readministered TMZ." | 1.33 | Salvage temozolomide for prior temozolomide responders. ( Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM, 2005) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 1.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| "Grosstotal resection of an anaplastic astrocytoma was followed by chemotherapy with temozolomide and vincristine." | 1.33 | A congenital brain tumor associated with assisted in vitro fertilization. Case report. ( Danielpour, M; Das, A; Simmons, C, 2005) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 1.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Malignant gliomas have a very poor prognosis." | 1.33 | A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. ( Avis, T; Barthorpe, S; Batchelor, TT; Bignell, G; Brackenbury, L; Buck, G; Butler, A; Cahill, DP; Clements, J; Cole, J; Davies, H; Dicks, E; Easton, DF; Edkins, S; Forbes, S; Futreal, PA; Gorton, M; Gray, K; Greenman, C; Halliday, K; Harrison, R; Hills, K; Hinton, J; Hunter, C; Jenkinson, A; Jones, D; Kosmidou, V; Laman, R; Levine, KK; Louis, DN; Lugg, R; Menzies, A; Mueller, W; O'Meara, S; Parker, A; Perry, J; Petty, R; Raine, K; Richardson, D; Riggins, G; Roy, JE; Shepherd, R; Small, A; Smith, R; Solomon, H; Stephens, P; Stevens, C; Stratton, MR; Teague, J; Tofts, C; Varian, J; West, S; Widaa, S; Wooster, R; Yates, A, 2006) |
| "Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma." | 1.33 | Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. ( Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R, 2006) |
| "Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components." | 1.33 | Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. ( Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W, 2006) |
| "We report a case of multiple gangliogliomas of the optic pathway in an 18-year-old boy." | 1.33 | Multiple gangliogliomas of the optic pathway. ( Dambatta, S; Grundy, PL; Vajramani, GV; Walker, M, 2006) |
| " Temozolomide, an orally bioavailable alkylating agent that crosses the blood-brain barrier, has activity against brain metastases from both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) when used as a single agent, but response rates are low." | 1.32 | Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. ( Ebert, BL; Niemierko, E; Salgia, R; Shaffer, K, 2003) |
| "Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors." | 1.32 | Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors. ( Berger, MS; Bodell, WJ; Gaikwad, NW; Miller, D, 2003) |
| "Temozolomide has shown antineoplastic activity against malignant gliomas and more recently was beneficial in one patient with gliomatosis cerebri." | 1.32 | Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration. ( Ambrosetto, P; Barbiroli, B; Cortelli, P; Crinò, L; Franceschi, E; Lodi, R; Setola, E; Tonon, C, 2003) |
| "Temozolomide (TMZ) displays efficacy for the treatment of metastatic melanoma." | 1.32 | [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation]. ( Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M, 2004) |
| "Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas." | 1.32 | Long-term outcome of oligodendrogliomas. ( Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F, 2004) |
| " The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software." | 1.32 | Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ( Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R, 2004) |
| " In this work we investigated the effect of association of temozolomide (TMZ), an orally bioavailable alkylating agent, with three chemotherapeutic drugs, liposomal doxorubicin (DOXO), cis-platinum (CDDP)." | 1.32 | Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A, 2004) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent high-grade gliomas in prospective phase II studies." | 1.32 | Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. ( Branle, F; Everaert, E; Joosens, E; Menten, J; Neyns, B; Strauven, T, 2004) |
| "Temozolomide (TMZ) is a methylating agent with promising antitumor efficacy for the treatment of melanomas and intermediate-grade gliomas." | 1.32 | The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. ( Cereda, E; Gariboldi, MB; Monti, E; Ravizza, R, 2004) |
| " To that end, a novel method, based on physiologically based hybrid pharmacokinetic models, is presented to predict human tumor drug concentrations." | 1.32 | Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. ( Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F, 2004) |
| "Glioblastoma is the deadliest and most prevalent brain tumor." | 1.32 | Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. ( Banik, NL; Das, A; Patel, SJ; Ray, SK, 2004) |
| "Temozolomide was administered p." | 1.31 | Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. ( Brent, TP; Friedman, HS; Houghton, PJ; Kirstein, MN; Middlemas, DS; Poquette, C; Stewart, CF, 2000) |
| "Temozolomide has recently been introduced by Schering-Plough Ltd (Welwyn Garden City, UK) as a new treatment which merits further investigation in this situation." | 1.31 | Temozolomide (Temodal) for treatment of primary brain tumours. ( MacConnachie, AM, 2000) |
| "Temozolomide was studied using a continuous exposure at final concentrations from 0." | 1.30 | Activity of temozolomide against human tumor colony-forming units. ( Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD, 1997) |
| "Thirty-three patients with newly diagnosed glioblastoma multiforme (GBM) and five patients with newly diagnosed anaplastic astrocytoma (AA) were treated with Temodal at a starting dose of 200 mg/m2 daily for 5 consecutive days with repeat dosing every 28 days after the first daily dose." | 1.30 | DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. ( Ashley, DM; Bigner, DD; Bigner, SH; Cokgor, I; Colvin, OM; Dugan, M; Friedman, AH; Friedman, HS; Haglund, MM; Henry, AJ; Kerby, T; Krischer, J; Lovell, S; Marchev, F; McLendon, RE; Modrich, PL; Provenzale, JM; Rasheed, K; Rich, J; Seman, AJ; Stewart, E, 1998) |
| "Temozolomide was also highly effective against intracerebral implants of the U251 and SF-295 glioblastomas." | 1.29 | Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Grever, MR; Koutsoukos, AD; Moore, TD; Plowman, J; Rubinstein, LV; Waud, WR, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (0.64) | 18.2507 |
| 2000's | 606 (18.53) | 29.6817 |
| 2010's | 1793 (54.83) | 24.3611 |
| 2020's | 850 (25.99) | 2.80 |
| Authors | Studies |
|---|---|
| Clarion, L | 1 |
| Jacquard, C | 1 |
| Sainte-Catherine, O | 1 |
| Loiseau, S | 1 |
| Filippini, D | 1 |
| Hirlemann, MH | 1 |
| Volle, JN | 1 |
| Virieux, D | 1 |
| Lecouvey, M | 1 |
| Pirat, JL | 1 |
| Bakalara, N | 1 |
| Liu, Z | 19 |
| Yao, Y | 4 |
| Kogiso, M | 1 |
| Zheng, B | 1 |
| Deng, L | 4 |
| Qiu, JJ | 1 |
| Dong, S | 4 |
| Lv, H | 2 |
| Gallo, JM | 9 |
| Li, XN | 3 |
| Song, Y | 8 |
| de Moura Sperotto, ND | 1 |
| Deves Roth, C | 1 |
| Rodrigues-Junior, VS | 1 |
| Ev Neves, C | 1 |
| Reisdorfer Paula, F | 1 |
| da Silva Dadda, A | 1 |
| Bergo, P | 1 |
| Freitas de Freitas, T | 1 |
| Souza Macchi, F | 1 |
| Moura, S | 1 |
| Duarte de Souza, AP | 1 |
| Campos, MM | 1 |
| Valim Bizarro, C | 1 |
| Santos, DS | 1 |
| Basso, LA | 1 |
| Machado, P | 1 |
| Mujumdar, P | 2 |
| Kopecka, J | 3 |
| Bua, S | 1 |
| Supuran, CT | 1 |
| Riganti, C | 4 |
| Poulsen, SA | 2 |
| Braga, C | 2 |
| Vaz, AR | 1 |
| Oliveira, MC | 1 |
| Matilde Marques, M | 1 |
| Moreira, R | 2 |
| Brites, D | 2 |
| Perry, MJ | 2 |
| Choi, PJ | 3 |
| Cooper, E | 3 |
| Schweder, P | 3 |
| Mee, E | 3 |
| Faull, R | 3 |
| Denny, WA | 3 |
| Dragunow, M | 3 |
| Park, TI | 2 |
| Jose, J | 3 |
| Turner, C | 2 |
| Dai, Z | 2 |
| Liu, H | 15 |
| Wang, B | 10 |
| Yang, D | 3 |
| Zhu, YY | 1 |
| Yan, H | 8 |
| Zhu, PF | 1 |
| Liu, YP | 1 |
| Chen, HC | 1 |
| Zhao, YL | 1 |
| Zhao, LX | 1 |
| Zhao, XD | 1 |
| Liu, HY | 1 |
| Luo, XD | 1 |
| Xiang, W | 5 |
| Quadery, TM | 1 |
| Hamel, E | 1 |
| Luckett-Chastain, LR | 1 |
| Ihnat, MA | 1 |
| Mooberry, SL | 1 |
| Gangjee, A | 2 |
| Nguyen, P | 3 |
| Doan, P | 3 |
| Rimpilainen, T | 2 |
| Konda Mani, S | 1 |
| Murugesan, A | 3 |
| Yli-Harja, O | 5 |
| Candeias, NR | 3 |
| Kandhavelu, M | 3 |
| Yuan, P | 1 |
| Gu, X | 3 |
| Ni, X | 2 |
| Qi, Y | 4 |
| Shao, X | 1 |
| Xu, X | 7 |
| Liu, J | 22 |
| Qian, X | 5 |
| Gerlach, SL | 1 |
| Dunlop, RA | 1 |
| Metcalf, JS | 1 |
| Banack, SA | 1 |
| Cox, PA | 1 |
| Delello Di Filippo, L | 1 |
| Hofstätter Azambuja, J | 1 |
| Paes Dutra, JA | 1 |
| Tavares Luiz, M | 1 |
| Lobato Duarte, J | 1 |
| Nicoleti, LR | 1 |
| Olalla Saad, ST | 1 |
| Chorilli, M | 2 |
| Li, J | 42 |
| Sun, Y | 16 |
| Sun, X | 8 |
| Zhao, X | 3 |
| Ma, Y | 5 |
| Wang, Y | 66 |
| Zhang, X | 35 |
| Brandner, S | 4 |
| McAleenan, A | 2 |
| Kelly, C | 2 |
| Spiga, F | 2 |
| Cheng, HY | 2 |
| Dawson, S | 2 |
| Schmidt, L | 2 |
| Faulkner, CL | 2 |
| Wragg, C | 2 |
| Jefferies, S | 3 |
| Higgins, JPT | 2 |
| Kurian, KM | 3 |
| Tresch, NS | 1 |
| Fuchs, D | 2 |
| Morandi, L | 3 |
| Tonon, C | 2 |
| Rohrer Bley, C | 1 |
| Nytko, KJ | 1 |
| Lukas, RV | 6 |
| Razis, ED | 1 |
| Huse, JT | 5 |
| Gondi, V | 5 |
| Yamamuro, S | 2 |
| Takahashi, M | 9 |
| Satomi, K | 4 |
| Sasaki, N | 2 |
| Kobayashi, T | 2 |
| Uchida, E | 2 |
| Kawauchi, D | 3 |
| Nakano, T | 2 |
| Fujii, T | 2 |
| Narita, Y | 21 |
| Kondo, A | 1 |
| Wada, K | 3 |
| Yoshino, A | 6 |
| Ichimura, K | 13 |
| Tomiyama, A | 3 |
| Li, C | 19 |
| Li, W | 17 |
| Dai, S | 2 |
| Sharma, A | 4 |
| Sharma, HS | 2 |
| Wu, Y | 12 |
| Brault, C | 1 |
| Zerbib, Y | 1 |
| Chouaki, T | 1 |
| Maizel, J | 1 |
| Nyga, R | 1 |
| Li, F | 7 |
| Chen, S | 12 |
| Yu, J | 7 |
| Gao, Z | 7 |
| Sun, Z | 4 |
| Yi, Y | 1 |
| Long, T | 1 |
| Zhang, C | 13 |
| Li, Y | 50 |
| Pan, Y | 5 |
| Qin, C | 2 |
| Long, W | 2 |
| Liu, Q | 15 |
| Zhao, W | 8 |
| Muragaki, Y | 9 |
| Kagawa, N | 5 |
| Asai, K | 1 |
| Nagane, M | 7 |
| Matsuda, M | 4 |
| Ueki, K | 2 |
| Kuroda, J | 2 |
| Date, I | 2 |
| Kobayashi, H | 5 |
| Kumabe, T | 7 |
| Beppu, T | 4 |
| Kanamori, M | 7 |
| Kasai, S | 1 |
| Nishimura, Y | 1 |
| Xiong, H | 4 |
| Ocampo, C | 1 |
| Yamada, M | 1 |
| Mishima, K | 3 |
| Stockslager, MA | 1 |
| Malinowski, S | 2 |
| Touat, M | 4 |
| Yoon, JC | 1 |
| Geduldig, J | 1 |
| Mirza, M | 1 |
| Kim, AS | 1 |
| Wen, PY | 37 |
| Chow, KH | 3 |
| Ligon, KL | 17 |
| Manalis, SR | 1 |
| Wang, Z | 30 |
| Yang, Z | 7 |
| Jiang, J | 9 |
| Shi, Z | 9 |
| Mao, Y | 2 |
| Qin, N | 1 |
| Tao, TH | 1 |
| Jin, L | 3 |
| Kiang, KM | 4 |
| Cheng, SY | 3 |
| Leung, GK | 10 |
| Chuang, HY | 2 |
| Hsu, LY | 1 |
| Pan, CM | 1 |
| Pikatan, NW | 1 |
| Yadav, VK | 2 |
| Fong, IH | 3 |
| Chen, CH | 2 |
| Yeh, CT | 4 |
| Chiu, SC | 2 |
| Larrouquère, L | 1 |
| Berthier, S | 1 |
| Chovelon, B | 1 |
| Garrel, C | 1 |
| Vacchina, V | 1 |
| Paucot, H | 1 |
| Boutonnat, J | 1 |
| Faure, P | 1 |
| Hazane-Puch, F | 1 |
| Lavogina, D | 1 |
| Laasfeld, T | 1 |
| Vardja, M | 1 |
| Lust, H | 1 |
| Jaal, J | 1 |
| Wan, Z | 1 |
| Gu, J | 6 |
| Qian, J | 5 |
| Zhu, J | 8 |
| Wang, J | 54 |
| Chen, H | 13 |
| Luo, C | 4 |
| Tong, S | 2 |
| Wu, J | 19 |
| Long, J | 1 |
| Zhong, P | 1 |
| Rotondo, R | 1 |
| Ragucci, S | 1 |
| Castaldo, S | 1 |
| Oliva, MA | 4 |
| Landi, N | 1 |
| Pedone, PV | 1 |
| Arcella, A | 11 |
| Di Maro, A | 1 |
| Urbantat, RM | 1 |
| Jelgersma, C | 1 |
| Brandenburg, S | 1 |
| Nieminen-Kelhä, M | 1 |
| Kremenetskaia, I | 3 |
| Zollfrank, J | 1 |
| Mueller, S | 3 |
| Rubarth, K | 1 |
| Koch, A | 4 |
| Vajkoczy, P | 11 |
| Acker, G | 1 |
| Lamb, LS | 2 |
| Pereboeva, L | 1 |
| Youngblood, S | 1 |
| Gillespie, GY | 7 |
| Nabors, LB | 16 |
| Markert, JM | 6 |
| Dasgupta, A | 3 |
| Langford, C | 2 |
| Spencer, HT | 2 |
| Han, J | 6 |
| Qiu, M | 1 |
| Su, L | 3 |
| Wu, C | 6 |
| Cheng, S | 2 |
| Zhao, Z | 11 |
| Li, D | 10 |
| Wang, M | 20 |
| Tao, W | 1 |
| Du, S | 3 |
| Chernov, AN | 2 |
| Alaverdian, DA | 2 |
| Glotov, OS | 1 |
| Talabaev, MV | 1 |
| Urazov, SP | 1 |
| Shcherbak, SG | 1 |
| Renieri, A | 1 |
| Frullanti, E | 1 |
| Shamova, O | 1 |
| Awah, CU | 1 |
| Winter, J | 1 |
| Mazdoom, CM | 1 |
| Ogunwobi, OO | 1 |
| Liu, Y | 53 |
| Bao, Q | 1 |
| Chen, Z | 19 |
| Yao, L | 4 |
| Ci, Z | 1 |
| Wei, X | 6 |
| Sun, K | 5 |
| Zhou, G | 5 |
| Li, S | 32 |
| Ma, W | 8 |
| Tao, K | 1 |
| Huang, B | 3 |
| Yu, Z | 13 |
| Liang, R | 1 |
| Bi, J | 1 |
| Khan, A | 1 |
| Tang, J | 7 |
| Armando, AM | 1 |
| Wu, S | 7 |
| Zhang, W | 26 |
| Gimple, RC | 1 |
| Reed, A | 1 |
| Jing, H | 1 |
| Koga, T | 2 |
| Wong, IT | 1 |
| Gu, Y | 1 |
| Miki, S | 1 |
| Yang, H | 9 |
| Prager, B | 1 |
| Curtis, EJ | 1 |
| Wainwright, DA | 2 |
| Furnari, FB | 2 |
| Rich, JN | 12 |
| Cloughesy, TF | 21 |
| Kornblum, HI | 3 |
| Quehenberger, O | 1 |
| Rzhetsky, A | 1 |
| Cravatt, BF | 1 |
| Mischel, PS | 4 |
| Ding, Y | 3 |
| He, L | 7 |
| Song, X | 6 |
| Zheng, C | 1 |
| Yu, S | 4 |
| Zhou, K | 2 |
| Jiang, T | 22 |
| Huang, L | 5 |
| Li, G | 19 |
| Lan, Q | 6 |
| Vaugier, L | 1 |
| Ah-Thiane, L | 1 |
| Aumont, M | 2 |
| Jouglar, E | 2 |
| Campone, M | 3 |
| Colliard, C | 1 |
| Doucet, L | 1 |
| Frenel, JS | 4 |
| Gourmelon, C | 1 |
| Robert, M | 1 |
| Martin, SA | 1 |
| Riem, T | 1 |
| Roualdes, V | 2 |
| Campion, L | 1 |
| Mervoyer, A | 1 |
| Zampieri, LX | 1 |
| Sboarina, M | 1 |
| Cacace, A | 1 |
| Grasso, D | 1 |
| Thabault, L | 1 |
| Hamelin, L | 1 |
| Vazeille, T | 1 |
| Dumon, E | 1 |
| Rossignol, R | 1 |
| Frédérick, R | 1 |
| Sonveaux, E | 1 |
| Lefranc, F | 12 |
| Sonveaux, P | 1 |
| Tabouret, E | 6 |
| Kishwar Jafri, SK | 1 |
| Bukhari, SS | 1 |
| Shamim, MS | 1 |
| Saran, F | 11 |
| Welsh, L | 1 |
| James, A | 1 |
| McBain, C | 3 |
| Gattamaneni, R | 1 |
| Harris, F | 1 |
| Pemberton, K | 1 |
| Schaible, J | 1 |
| Bender, S | 1 |
| Cseh, A | 3 |
| Brada, M | 15 |
| Poon, MTC | 2 |
| Bruce, M | 1 |
| Simpson, JE | 1 |
| Hannan, CJ | 1 |
| Brennan, PM | 2 |
| Fazzari, FGT | 1 |
| Rose, F | 1 |
| Pauls, M | 1 |
| Guay, E | 1 |
| Ibrahim, MFK | 1 |
| Basulaiman, B | 1 |
| Tu, M | 3 |
| Hutton, B | 1 |
| Nicholas, G | 2 |
| Ng, TL | 2 |
| Garcia, CR | 2 |
| Myint, ZW | 1 |
| Jayswal, R | 1 |
| Wang, C | 15 |
| Morgan, RM | 2 |
| Butts, AR | 1 |
| Weiss, HL | 1 |
| Villano, JL | 14 |
| Kim, H | 7 |
| Lim, KY | 1 |
| Park, JW | 1 |
| Kang, J | 2 |
| Won, JK | 2 |
| Lee, K | 3 |
| Shim, Y | 1 |
| Park, CK | 28 |
| Kim, SK | 5 |
| Choi, SH | 19 |
| Kim, TM | 17 |
| Yun, H | 1 |
| Park, SH | 16 |
| Neth, BJ | 2 |
| Carabenciov, ID | 1 |
| Ruff, MW | 2 |
| Johnson, DR | 4 |
| Qiu, X | 8 |
| Chen, Y | 33 |
| Bao, Z | 5 |
| Chen, L | 30 |
| Wei, KC | 6 |
| Hsu, PW | 3 |
| Tsai, HC | 3 |
| Lin, YJ | 6 |
| Chen, KT | 3 |
| Toh, CH | 1 |
| Huang, HL | 1 |
| Jung, SM | 1 |
| Tseng, CK | 1 |
| Ke, YX | 1 |
| Haehnel, S | 1 |
| Rade, M | 1 |
| Kaiser, N | 1 |
| Reiche, K | 1 |
| Horn, A | 1 |
| Loeffler, D | 1 |
| Blumert, C | 1 |
| Rapp, F | 1 |
| Horn, F | 1 |
| Meixensberger, J | 7 |
| Renner, C | 2 |
| Mueller, W | 3 |
| Gaunitz, F | 4 |
| Bechmann, I | 2 |
| Winter, K | 1 |
| O'Rawe, M | 1 |
| Wickremesekera, AC | 1 |
| Pandey, R | 1 |
| Young, D | 1 |
| Sim, D | 1 |
| FitzJohn, T | 1 |
| Burgess, C | 1 |
| Kaye, AH | 5 |
| Tan, ST | 2 |
| Klement, RJ | 2 |
| Popp, I | 1 |
| Kaul, D | 3 |
| Ehret, F | 2 |
| Grosu, AL | 4 |
| Polat, B | 2 |
| Sweeney, RA | 2 |
| Lewitzki, V | 2 |
| Schmitt, RR | 1 |
| Mahajan, SD | 1 |
| Pliss, A | 1 |
| Prasad, PN | 1 |
| Wang, N | 8 |
| Huang, R | 3 |
| Yang, K | 6 |
| He, Y | 10 |
| Gao, Y | 12 |
| Dong, D | 2 |
| Serra, R | 2 |
| Mangraviti, A | 5 |
| Gorelick, NL | 1 |
| Shapira-Furman, T | 2 |
| Alomari, S | 1 |
| Cecia, A | 2 |
| Darjee, N | 1 |
| Brem, H | 19 |
| Rottenberg, Y | 2 |
| Domb, AJ | 2 |
| Tyler, B | 11 |
| Dong, Q | 1 |
| Wang, D | 10 |
| Li, L | 17 |
| Li, Q | 10 |
| Duan, L | 1 |
| Yin, H | 2 |
| Wang, X | 44 |
| Yuan, G | 2 |
| Zhao, K | 3 |
| Schäfer, A | 3 |
| Zhang, Z | 25 |
| Elsässer, K | 1 |
| Culmsee, C | 2 |
| Zhong, L | 2 |
| Pagenstecher, A | 2 |
| Nimsky, C | 2 |
| Bartsch, JW | 2 |
| Perlow, HK | 3 |
| Yaney, A | 1 |
| Yang, M | 5 |
| Klamer, B | 2 |
| Matsui, J | 2 |
| Raval, RR | 3 |
| Blakaj, DM | 1 |
| Arnett, A | 2 |
| Beyer, S | 2 |
| Elder, JB | 2 |
| Ammirati, M | 3 |
| Lonser, R | 2 |
| Hardesty, D | 1 |
| Ong, S | 1 |
| Giglio, P | 7 |
| Pillainayagam, C | 1 |
| Goranovich, J | 1 |
| Grecula, J | 3 |
| Chakravarti, A | 20 |
| Brown, PD | 19 |
| Palmer, JD | 5 |
| Ramesh, T | 1 |
| Campian, JL | 8 |
| Ghosh, S | 4 |
| Kapoor, V | 2 |
| Yan, R | 1 |
| Thotala, S | 1 |
| Jash, A | 1 |
| Hu, T | 1 |
| Mahadevan, A | 1 |
| Rifai, K | 1 |
| Page, L | 1 |
| Lee, BH | 1 |
| Ferrando-Martinez, S | 1 |
| Wolfarth, AA | 1 |
| Yang, SH | 6 |
| Hallahan, D | 1 |
| Chheda, MG | 4 |
| Thotala, D | 2 |
| Ma, Z | 2 |
| Cai, S | 4 |
| Xiong, Q | 1 |
| Liu, W | 11 |
| Xia, H | 1 |
| Zhu, Z | 9 |
| Huang, Z | 3 |
| Yan, X | 5 |
| Wang, Q | 22 |
| Moitra, P | 1 |
| Chatterjee, A | 2 |
| Kota, PK | 1 |
| Epari, S | 3 |
| Patil, V | 3 |
| Kowtal, P | 1 |
| Sarin, R | 3 |
| Gupta, T | 8 |
| Picca, A | 1 |
| Desjardins, C | 1 |
| Bihan, K | 1 |
| Weiss, N | 1 |
| Guihot, A | 1 |
| Nichelli, L | 1 |
| Feuvret, L | 9 |
| Pourcher, V | 1 |
| Dehais, C | 7 |
| Scherschinski, L | 1 |
| Prem, M | 1 |
| Tinhofer, I | 1 |
| Karbe, AG | 1 |
| Onken, JS | 1 |
| Park, DY | 2 |
| Tom, MC | 4 |
| Wei, W | 4 |
| Tewari, S | 2 |
| Ahluwalia, MS | 13 |
| Yu, JS | 6 |
| Chao, ST | 4 |
| Suh, JH | 8 |
| Peereboom, D | 6 |
| Stevens, GHJ | 3 |
| Barnett, GH | 5 |
| Angelov, L | 2 |
| Mohammadi, AM | 1 |
| Hogan, T | 2 |
| Kissel, C | 2 |
| Lapin, B | 2 |
| Schuermeyer, I | 2 |
| Parsons, MW | 2 |
| Naugle, R | 2 |
| Murphy, ES | 3 |
| Tesileanu, CMS | 2 |
| Gorlia, T | 32 |
| Golfinopoulos, V | 10 |
| French, PJ | 6 |
| van den Bent, MJ | 46 |
| Feng, YH | 1 |
| Lim, SW | 1 |
| Lin, HY | 3 |
| Wang, SA | 1 |
| Hsu, SP | 3 |
| Kao, TJ | 4 |
| Ko, CY | 5 |
| Hsu, TI | 8 |
| Svec, RL | 1 |
| McKee, SA | 1 |
| Berry, MR | 1 |
| Kelly, AM | 1 |
| Fan, TM | 1 |
| Hergenrother, PJ | 1 |
| Yuen, CA | 1 |
| Barbaro, M | 1 |
| Haggiagi, A | 2 |
| Altinoz, MA | 5 |
| Ozpinar, A | 6 |
| Xu, J | 9 |
| Wu, PJ | 1 |
| Lai, TH | 1 |
| Sharma, P | 2 |
| Canella, A | 1 |
| Welker, AM | 2 |
| Beattie, CE | 2 |
| Easley, M | 1 |
| Jacob, NK | 2 |
| Pietrzak, M | 1 |
| Timmers, CM | 1 |
| Lang, F | 2 |
| Sampath, D | 1 |
| Puduvalli, VK | 11 |
| Barresi, V | 1 |
| Mafficini, A | 1 |
| Calicchia, M | 1 |
| Piredda, ML | 1 |
| Musumeci, A | 1 |
| Ghimenton, C | 3 |
| Scarpa, A | 1 |
| Zhu, Y | 8 |
| Zhao, L | 12 |
| Xu, Y | 18 |
| Zhan, W | 4 |
| Li, T | 5 |
| Du, Q | 2 |
| Wang, R | 11 |
| Fu, B | 1 |
| Tan, Y | 6 |
| Cao, M | 1 |
| Hu, R | 2 |
| Maciaczyk, J | 4 |
| Schmidt-Wolf, IGH | 1 |
| Lombardi, F | 1 |
| Augello, FR | 1 |
| Artone, S | 1 |
| Gugu, MK | 1 |
| Cifone, MG | 2 |
| Cinque, B | 2 |
| Palumbo, P | 1 |
| Van Gool, SW | 3 |
| Makalowski, J | 1 |
| Bitar, M | 1 |
| Van de Vliet, P | 1 |
| Schirrmacher, V | 1 |
| Stuecker, W | 1 |
| Qian, Y | 4 |
| Ding, P | 2 |
| Nie, X | 1 |
| Lu, B | 3 |
| Dono, A | 2 |
| Alfaro-Munoz, K | 1 |
| Yan, Y | 3 |
| Lopez-Garcia, CA | 1 |
| Soomro, Z | 1 |
| Williford, G | 1 |
| Takayasu, T | 6 |
| Robell, L | 1 |
| Majd, NK | 1 |
| de Groot, J | 3 |
| Esquenazi, Y | 3 |
| Kamiya-Matsuoka, C | 1 |
| Ballester, LY | 3 |
| Gött, H | 1 |
| Kiez, S | 1 |
| Dohmen, H | 1 |
| Kolodziej, M | 1 |
| Stein, M | 2 |
| Lin, R | 1 |
| Xie, S | 2 |
| Zhang, Y | 44 |
| Wang, H | 34 |
| Yi, GZ | 6 |
| Huang, G | 9 |
| Ni, B | 1 |
| Song, H | 7 |
| Qi, ST | 3 |
| Germano, IM | 3 |
| Ziu, M | 1 |
| Wen, P | 4 |
| Ormond, DR | 4 |
| Olson, JJ | 3 |
| Reinhardt, LS | 1 |
| Morás, AM | 2 |
| Henn, JG | 2 |
| Arantes, PR | 1 |
| Ferro, MB | 1 |
| Braganhol, E | 7 |
| de Souza, PO | 3 |
| de Oliveira Merib, J | 1 |
| Borges, GR | 1 |
| Dalanhol, CS | 1 |
| de Barros Dias, MCH | 1 |
| Nugent, M | 2 |
| Moura, DJ | 2 |
| Yuan, F | 4 |
| Zhang, S | 20 |
| Sun, Q | 3 |
| Ye, L | 4 |
| Xu, Z | 7 |
| Deng, G | 2 |
| Liu, B | 10 |
| Chen, Q | 9 |
| Damanskienė, E | 1 |
| Balnytė, I | 1 |
| Valančiūtė, A | 1 |
| Alonso, MM | 3 |
| Preikšaitis, A | 1 |
| Stakišaitis, D | 1 |
| Bao, G | 1 |
| Zhang, M | 23 |
| Xiang, J | 5 |
| Zhou, H | 5 |
| Wahafu, A | 3 |
| Wu, W | 15 |
| Ma, X | 5 |
| Huo, L | 1 |
| Bai, X | 3 |
| Xie, W | 4 |
| Liu, P | 8 |
| Scheffel, TB | 1 |
| Rockenbach, L | 1 |
| Cruz, FF | 1 |
| Kist, LW | 1 |
| Bogo, MR | 1 |
| Scholl, JN | 2 |
| Figueiró, F | 3 |
| Lenz, G | 3 |
| Morrone, FB | 1 |
| Mladek, AC | 10 |
| Tian, S | 3 |
| Decker, PA | 10 |
| Burgenske, DM | 3 |
| Bakken, K | 1 |
| Hu, Z | 6 |
| Connors, MA | 1 |
| Carlson, BL | 10 |
| Wilson, J | 1 |
| Bommi-Reddy, A | 1 |
| Conery, A | 1 |
| Eckel-Passow, JE | 4 |
| Sarkaria, JN | 24 |
| Kitange, GJ | 10 |
| Stalinska, J | 1 |
| Vittori, C | 1 |
| Ingraham Iv, CH | 1 |
| Carson, SC | 1 |
| Plaisance-Bonstaff, K | 1 |
| Lassak, A | 1 |
| Faia, C | 1 |
| Colley, SB | 1 |
| Peruzzi, F | 1 |
| Reiss, K | 1 |
| Jursic, BS | 1 |
| Wei, S | 2 |
| Yin, D | 1 |
| Lin, X | 2 |
| Savani, MR | 1 |
| Du, K | 3 |
| Ku, Y | 1 |
| Wu, D | 4 |
| Tian, M | 2 |
| Bowie, M | 1 |
| Hariharan, S | 1 |
| Waitkus, M | 1 |
| Keir, ST | 5 |
| Sugarman, ET | 1 |
| Deek, RA | 1 |
| Labrie, M | 1 |
| Khasraw, M | 14 |
| Lu, Y | 14 |
| Mills, GB | 2 |
| Herlyn, M | 1 |
| Wu, K | 2 |
| Liu, L | 10 |
| Wei, Z | 5 |
| Flaherty, KT | 1 |
| Abdullah, K | 1 |
| Zhang, G | 13 |
| Ashley, DM | 6 |
| Yu, Y | 10 |
| Wang, A | 5 |
| Wang, S | 23 |
| Chu, L | 3 |
| Zhou, L | 12 |
| Yang, X | 12 |
| Liu, X | 32 |
| Sha, C | 3 |
| Xu, L | 7 |
| Chiang, IT | 1 |
| Liu, YC | 3 |
| Liu, HS | 1 |
| Ali, AAA | 1 |
| Chou, SY | 1 |
| Hsu, FT | 1 |
| Sanson, M | 22 |
| Wick, W | 57 |
| Brandes, AA | 39 |
| Clement, PM | 8 |
| Erridge, SC | 4 |
| Vogelbaum, MA | 15 |
| Nowak, AK | 5 |
| Baurain, JF | 2 |
| Mason, WP | 24 |
| Wheeler, H | 14 |
| Chinot, OL | 15 |
| Gill, S | 2 |
| Griffin, M | 1 |
| Rogers, L | 3 |
| Taal, W | 8 |
| Rudà, R | 13 |
| Weller, M | 69 |
| van Linde, ME | 4 |
| Aldape, K | 9 |
| Jenkins, RB | 6 |
| Kros, JM | 18 |
| Wesseling, P | 11 |
| von Deimling, A | 18 |
| Hoogstrate, Y | 1 |
| de Heer, I | 2 |
| Atmodimedjo, PN | 1 |
| Dubbink, HJ | 4 |
| Brouwer, RWW | 1 |
| van IJcken, WFJ | 1 |
| Cheung, KJ | 1 |
| Baumert, BG | 14 |
| Moon, HH | 1 |
| Park, JE | 4 |
| Kim, YH | 7 |
| Kim, JH | 31 |
| Kim, HS | 6 |
| Alanazi, R | 1 |
| Nakatogawa, H | 1 |
| Ji, D | 1 |
| Luo, Z | 3 |
| Golbourn, B | 2 |
| Feng, ZP | 1 |
| Rutka, JT | 1 |
| Sun, HS | 1 |
| Wei, Y | 5 |
| Duan, S | 1 |
| Gong, F | 2 |
| Basu Achari, R | 1 |
| Chakraborty, S | 6 |
| Goyal, L | 1 |
| Saha, S | 1 |
| Roy, P | 1 |
| Zameer, L | 1 |
| Mishra, D | 1 |
| Parihar, M | 1 |
| Das, A | 8 |
| Chandra, A | 1 |
| Biswas, B | 1 |
| Mallick, I | 2 |
| Arunsingh, MA | 1 |
| Chatterjee, S | 2 |
| Bhattacharyya, T | 1 |
| Le Rhun, E | 6 |
| Oppong, FB | 1 |
| Vanlancker, M | 1 |
| Stupp, R | 69 |
| Nabors, B | 3 |
| Chinot, O | 29 |
| Preusser, M | 4 |
| Márquez, M | 1 |
| Olausson, KH | 1 |
| Alaiya, A | 1 |
| Nilsson, S | 1 |
| Meurling, L | 1 |
| Holmberg, AR | 1 |
| Prasad, RN | 1 |
| Marrazzo, L | 2 |
| Detti, B | 7 |
| Scorsetti, M | 4 |
| Clerici, E | 3 |
| Navarria, P | 5 |
| Scoccianti, S | 10 |
| Grecula, JC | 1 |
| Maimó-Barceló, A | 1 |
| Martín-Saiz, L | 1 |
| Fernández, JA | 1 |
| Pérez-Romero, K | 1 |
| Garfias-Arjona, S | 1 |
| Lara-Almúnia, M | 1 |
| Piérola-Lopetegui, J | 1 |
| Bestard-Escalas, J | 1 |
| Barceló-Coblijn, G | 1 |
| Persano, F | 1 |
| Gigli, G | 1 |
| Leporatti, S | 1 |
| Bady, P | 4 |
| Marosi, C | 16 |
| Grønberg, BH | 2 |
| Schultz, H | 2 |
| Taphoorn, MJB | 8 |
| Gijtenbeek, JMM | 3 |
| Malmström, A | 4 |
| Hegi, ME | 27 |
| Rehman, FU | 1 |
| Yang, Q | 6 |
| Liu, R | 8 |
| Zhang, D | 6 |
| Muhammad, P | 2 |
| Hanif, S | 2 |
| Ismail, M | 2 |
| Zheng, M | 3 |
| Shi, B | 3 |
| Sun, M | 1 |
| Huang, N | 3 |
| Tao, Y | 1 |
| Wen, R | 1 |
| Zhao, G | 6 |
| Xie, Z | 5 |
| Cheng, Y | 10 |
| Mao, J | 4 |
| Liu, G | 4 |
| Zeiner, PS | 4 |
| Filipski, K | 2 |
| Filmann, N | 1 |
| Forster, MT | 2 |
| Voss, M | 1 |
| Fokas, E | 2 |
| Herrlinger, U | 20 |
| Harter, PN | 4 |
| Steinbach, JP | 21 |
| Ronellenfitsch, MW | 4 |
| Yang, FC | 1 |
| Gai, QJ | 1 |
| Mao, M | 1 |
| He, J | 4 |
| Qin, Y | 1 |
| Yao, XX | 1 |
| Wang, YX | 1 |
| Lu, HM | 1 |
| Cao, MF | 1 |
| He, MM | 1 |
| Wen, XM | 1 |
| Leng, P | 1 |
| Cai, XW | 1 |
| Yao, XH | 1 |
| Bian, XW | 2 |
| Yao, J | 3 |
| Feng, X | 2 |
| Dai, X | 5 |
| Peng, G | 1 |
| Guo, Z | 4 |
| Guo, W | 2 |
| Zhang, P | 16 |
| Hanisch, D | 1 |
| Krumm, A | 1 |
| Diehl, T | 1 |
| Stork, CM | 1 |
| Dejung, M | 1 |
| Butter, F | 1 |
| Kim, E | 9 |
| Brenner, W | 1 |
| Fritz, G | 1 |
| Hofmann, TG | 1 |
| Roos, WP | 3 |
| Milano, MT | 4 |
| Soltys, SG | 3 |
| Knisely, JPS | 1 |
| Sahgal, A | 9 |
| Nagpal, S | 3 |
| Lo, SS | 2 |
| Jabbari, S | 1 |
| Wang, TJC | 3 |
| Simonson, M | 1 |
| Gephart, MH | 1 |
| Halasz, LM | 1 |
| Garg, AK | 1 |
| Chiang, VLS | 1 |
| Chang, EL | 3 |
| Rao, V | 1 |
| Kumar, G | 1 |
| Vibhavari, RJA | 1 |
| Nandakumar, K | 1 |
| Thorat, ND | 1 |
| Chamallamudi, MR | 1 |
| Kumar, N | 4 |
| Huang, X | 7 |
| Li, H | 24 |
| Huang, H | 8 |
| Belanger, K | 6 |
| Ung, TH | 2 |
| Damek, D | 7 |
| Lillehei, KO | 3 |
| Aldoghachi, AF | 2 |
| Breyne, K | 1 |
| Ling, KH | 1 |
| Cheah, PS | 1 |
| Liang, L | 1 |
| Yan, B | 2 |
| Jiang, S | 3 |
| He, H | 6 |
| Huang, J | 14 |
| Xie, L | 1 |
| Yu, X | 5 |
| Xu, H | 6 |
| Wei, K | 2 |
| Omuro, A | 15 |
| Carpentier, AF | 8 |
| Idbaih, A | 18 |
| Reardon, DA | 51 |
| Cloughesy, T | 17 |
| Sumrall, A | 3 |
| Baehring, J | 3 |
| van den Bent, M | 8 |
| Bähr, O | 6 |
| Lombardi, G | 13 |
| Mulholland, P | 3 |
| Tabatabai, G | 12 |
| Lassen, U | 3 |
| Sepulveda, JM | 9 |
| Vauleon, E | 7 |
| Di Giacomo, AM | 2 |
| Butowski, N | 17 |
| Roth, P | 16 |
| Fu, AZ | 1 |
| Potter, V | 1 |
| Chalamandaris, AG | 1 |
| Tatsuoka, K | 2 |
| Lim, M | 5 |
| Nie, C | 1 |
| Zeng, Y | 1 |
| Qian, K | 2 |
| Li, X | 40 |
| Rosen, J | 2 |
| Ceccon, G | 3 |
| Bauer, EK | 2 |
| Werner, JM | 3 |
| Tscherpel, C | 3 |
| Dunkl, V | 3 |
| Rapp, M | 7 |
| Sabel, M | 18 |
| Heinzel, A | 1 |
| Schäfer, N | 12 |
| Ruge, M | 1 |
| Goldbrunner, R | 10 |
| Stoffels, G | 5 |
| Kabbasch, C | 2 |
| Fink, GR | 4 |
| Langen, KJ | 6 |
| Galldiks, N | 11 |
| Schnöller, LE | 2 |
| Albrecht, V | 1 |
| Brix, N | 2 |
| Nieto, AE | 2 |
| Fleischmann, DF | 4 |
| Niyazi, M | 9 |
| Hess, J | 2 |
| Belka, C | 11 |
| Unger, K | 2 |
| Lauber, K | 2 |
| Orth, M | 2 |
| Iwaya, T | 1 |
| Sato, Y | 3 |
| Nomura, JI | 1 |
| Terasaki, K | 2 |
| Sasaki, T | 3 |
| Yamada, N | 1 |
| Fujiwara, S | 1 |
| Sugai, T | 1 |
| Ogasawara, K | 2 |
| Wee, CW | 7 |
| In Yoon, H | 1 |
| Lee, SW | 2 |
| Lim, DH | 10 |
| Zhang, J | 35 |
| Xie, Q | 4 |
| Zhong, C | 2 |
| Gao, X | 1 |
| Kavouridis, VK | 1 |
| Iorgulescu, JB | 2 |
| Peereboom, DM | 8 |
| Mohammadi, A | 1 |
| Liang, Q | 2 |
| Di, Z | 1 |
| Di, L | 1 |
| Di Bella, G | 1 |
| Borghetto, V | 1 |
| Costanzo, E | 1 |
| Fei, YQ | 1 |
| Shi, RT | 1 |
| Zhou, YF | 1 |
| Wu, JZ | 1 |
| Song, Z | 2 |
| Ye, T | 1 |
| Chen, R | 6 |
| Zhou, Y | 15 |
| Wei, H | 2 |
| Steinbach, J | 2 |
| Finocchiaro, G | 4 |
| Ansstas, G | 5 |
| Taylor, JW | 4 |
| Honnorat, J | 11 |
| Petrecca, K | 12 |
| De Vos, F | 2 |
| Wick, A | 18 |
| Sahebjam, S | 2 |
| Mellinghoff, IK | 2 |
| Kinoshita, M | 8 |
| Roberts, M | 1 |
| Slepetis, R | 1 |
| Warad, D | 1 |
| Leung, D | 4 |
| Lee, M | 3 |
| Crisafulli, G | 1 |
| Sartore-Bianchi, A | 2 |
| Lazzari, L | 1 |
| Pietrantonio, F | 2 |
| Amatu, A | 2 |
| Macagno, M | 1 |
| Barault, L | 2 |
| Cassingena, A | 2 |
| Bartolini, A | 1 |
| Luraghi, P | 1 |
| Mauri, G | 1 |
| Battuello, P | 1 |
| Personeni, N | 1 |
| Zampino, MG | 1 |
| Pessei, V | 1 |
| Vitiello, PP | 1 |
| Tosi, F | 1 |
| Idotta, L | 1 |
| Morano, F | 1 |
| Valtorta, E | 1 |
| Bonoldi, E | 1 |
| Germano, G | 1 |
| Di Nicolantonio, F | 2 |
| Marsoni, S | 1 |
| Siena, S | 3 |
| Bardelli, A | 2 |
| Garnier, L | 1 |
| Vidal, C | 2 |
| Cohen-Jonathan Moyal, E | 3 |
| Djelad, A | 1 |
| Bronnimann, C | 1 |
| Bekaert, L | 1 |
| Taillandier, L | 16 |
| Langlois, O | 5 |
| Colin, P | 2 |
| Menei, P | 4 |
| Dhermain, F | 6 |
| Carpentier, C | 4 |
| Gerazime, A | 1 |
| Curtit, E | 1 |
| Figarella-Branger, D | 16 |
| Ducray, F | 14 |
| Daisy Precilla, S | 1 |
| Kuduvalli, SS | 1 |
| Angeline Praveena, E | 1 |
| Thangavel, S | 1 |
| Anitha, TS | 1 |
| Ding, D | 2 |
| Li, Z | 19 |
| Cheng, L | 1 |
| You, Q | 1 |
| Arakawa, Y | 5 |
| Mineharu, Y | 2 |
| Uto, M | 1 |
| Mizowaki, T | 3 |
| Feldheim, J | 1 |
| Kessler, AF | 1 |
| Feldheim, JJ | 1 |
| Schulz, E | 1 |
| Wend, D | 1 |
| Lazaridis, L | 2 |
| Kleinschnitz, C | 2 |
| Glas, M | 10 |
| Ernestus, RI | 1 |
| Monoranu, CM | 1 |
| Löhr, M | 1 |
| Hagemann, C | 1 |
| Shervington, LA | 1 |
| Ingham, O | 1 |
| Imai, R | 1 |
| Sasaki, H | 7 |
| McAleavey, PG | 1 |
| Walls, GM | 1 |
| Chalmers, AJ | 3 |
| Min, X | 1 |
| Dingchao, X | 1 |
| Xun, Z | 1 |
| Cunzu, W | 1 |
| Smiley, SB | 2 |
| Zarrinmayeh, H | 1 |
| Das, SK | 3 |
| Pollok, KE | 3 |
| Vannier, MW | 2 |
| Veronesi, MC | 2 |
| Baro, V | 1 |
| Cerretti, G | 2 |
| Todoverto, M | 1 |
| Della Puppa, A | 8 |
| Chioffi, F | 2 |
| Volpin, F | 3 |
| Causin, F | 1 |
| Busato, F | 1 |
| Fiduccia, P | 2 |
| Landi, A | 2 |
| d'Avella, D | 4 |
| Zagonel, V | 9 |
| Denaro, L | 3 |
| Yeo, AT | 1 |
| Rawal, S | 1 |
| Delcuze, B | 1 |
| Christofides, A | 1 |
| Atayde, A | 1 |
| Strauss, L | 1 |
| Balaj, L | 2 |
| Rogers, VA | 1 |
| Uhlmann, EJ | 1 |
| Varma, H | 1 |
| Carter, BS | 6 |
| Boussiotis, VA | 1 |
| Charest, A | 1 |
| Zhou, J | 9 |
| Xu, N | 6 |
| He, Z | 4 |
| Lenahan, C | 1 |
| Tang, W | 3 |
| Zeng, H | 6 |
| Guo, H | 7 |
| Dutra, JAP | 1 |
| Luiz, MT | 1 |
| Tavares Junior, AG | 1 |
| Di Filippo, LD | 1 |
| Carvalho, SG | 1 |
| Bruns, J | 1 |
| Egan, T | 1 |
| Mercier, P | 1 |
| Zustiak, SP | 1 |
| Elmaci, İ | 4 |
| Kahraman Ozlu, EB | 1 |
| Sari, R | 2 |
| Er, O | 1 |
| Gokhan Ekmekci, C | 1 |
| Turkgenc, B | 1 |
| Hacker, E | 1 |
| Yang, E | 1 |
| Wang, L | 32 |
| Jin, W | 1 |
| Cui, X | 5 |
| Zhao, J | 10 |
| Tong, F | 5 |
| Hong, B | 2 |
| Xiao, M | 2 |
| Fang, C | 3 |
| Kang, C | 10 |
| Wei, L | 5 |
| Cai, H | 1 |
| Peng, SP | 1 |
| Tian, HB | 1 |
| Wang, JF | 1 |
| Gao, L | 6 |
| He, JP | 1 |
| Cucchiara, F | 1 |
| Luci, G | 1 |
| Giannini, N | 1 |
| Giorgi, FS | 1 |
| Orlandi, P | 2 |
| Banchi, M | 1 |
| Di Paolo, A | 1 |
| Pasqualetti, F | 7 |
| Danesi, R | 1 |
| Bocci, G | 3 |
| Petrenko, D | 1 |
| Chubarev, V | 1 |
| Syzrantsev, N | 1 |
| Ismail, N | 1 |
| Merkulov, V | 1 |
| Sologova, S | 1 |
| Grigorevskikh, E | 1 |
| Smolyarchuk, E | 1 |
| Alyautdin, R | 1 |
| Yang, W | 6 |
| Chai, T | 1 |
| Guo, L | 8 |
| Wu, Z | 7 |
| Drljača, J | 1 |
| Popović, A | 1 |
| Bulajić, D | 1 |
| Stilinović, N | 1 |
| Vidičević Novaković, S | 1 |
| Sekulić, S | 1 |
| Milenković, I | 1 |
| Ninković, S | 1 |
| Ljubković, M | 1 |
| Čapo, I | 1 |
| Weller, J | 9 |
| Schaub, C | 7 |
| Potthoff, AL | 3 |
| Schlegel, U | 10 |
| Hau, P | 24 |
| Seidel, C | 7 |
| Krex, D | 17 |
| Pietsch, T | 17 |
| Tzaridis, T | 7 |
| Zeyen, T | 3 |
| Borger, V | 1 |
| Güresir, E | 2 |
| Vatter, H | 5 |
| Schneider, M | 5 |
| Catanzaro, D | 1 |
| Milani, G | 1 |
| Bozza, A | 1 |
| Bernardi, M | 1 |
| Chieregato, K | 1 |
| Menarin, M | 1 |
| Merlo, A | 2 |
| Celli, P | 1 |
| Belli, R | 1 |
| Peroni, D | 1 |
| Pozzato, A | 1 |
| Pozzato, G | 1 |
| Raneri, FA | 1 |
| Volpin, L | 1 |
| Ruggeri, M | 1 |
| Astori, G | 1 |
| McMahon, DJ | 1 |
| Gleeson, JP | 1 |
| O'Reilly, S | 1 |
| Bambury, RM | 1 |
| Tian, F | 1 |
| Chen, X | 18 |
| Zhao, B | 3 |
| Xia, Y | 1 |
| Qu, T | 1 |
| Xing, H | 2 |
| Han, L | 7 |
| Yang, F | 5 |
| Zhao, M | 7 |
| Hu, L | 5 |
| Hu, Y | 6 |
| Tang, L | 2 |
| Yin, S | 1 |
| Lv, L | 1 |
| Zhou, P | 7 |
| Tiek, DM | 2 |
| Erdogdu, B | 1 |
| Razaghi, R | 1 |
| Sadowski, N | 1 |
| Alamillo-Ferrer, C | 1 |
| Hogg, JR | 1 |
| Haddad, BR | 2 |
| Drewry, DH | 1 |
| Wells, CI | 1 |
| Pickett, JE | 1 |
| Goenka, A | 1 |
| Hu, B | 1 |
| Goldlust, SA | 5 |
| Zuercher, WJ | 1 |
| Pertea, M | 1 |
| Timp, W | 1 |
| Riggins, RB | 2 |
| Zou, Y | 5 |
| Xu, S | 4 |
| Yin, J | 5 |
| Lovejoy, DB | 1 |
| Liang, XJ | 1 |
| Park, JB | 1 |
| Efremov, YM | 1 |
| Ulasov, I | 2 |
| Kıyga, E | 1 |
| Adıgüzel, Z | 1 |
| Önay Uçar, E | 1 |
| Khan, I | 2 |
| Baig, MH | 1 |
| Mahfooz, S | 1 |
| Imran, MA | 1 |
| Khan, MI | 1 |
| Dong, JJ | 1 |
| Cho, JY | 1 |
| Hatiboglu, MA | 1 |
| Werner, M | 1 |
| Lyu, C | 1 |
| Stadlbauer, B | 1 |
| Schrader, I | 1 |
| Buchner, A | 1 |
| Stepp, H | 1 |
| Sroka, R | 1 |
| Pohla, H | 1 |
| Prajapati, HP | 1 |
| Ansari, A | 1 |
| Jin, J | 3 |
| Wu, G | 3 |
| Zhu, H | 7 |
| Grigore, FN | 1 |
| Ma, J | 7 |
| Chen, CC | 16 |
| Li, M | 18 |
| Sowers, ML | 1 |
| Sowers, LC | 1 |
| Rodríguez-Camacho, A | 1 |
| Flores-Vázquez, JG | 1 |
| Moscardini-Martelli, J | 1 |
| Torres-Ríos, JA | 1 |
| Olmos-Guzmán, A | 1 |
| Ortiz-Arce, CS | 1 |
| Cid-Sánchez, DR | 1 |
| Pérez, SR | 1 |
| Macías-González, MDS | 1 |
| Hernández-Sánchez, LC | 1 |
| Heredia-Gutiérrez, JC | 1 |
| Contreras-Palafox, GA | 1 |
| Suárez-Campos, JJE | 1 |
| Celis-López, MÁ | 1 |
| Gutiérrez-Aceves, GA | 1 |
| Moreno-Jiménez, S | 1 |
| Yun, K | 2 |
| Geng, X | 1 |
| Zeng, Z | 3 |
| Hu, J | 13 |
| Hao, L | 1 |
| Chien, CH | 2 |
| Yang, WB | 5 |
| Chuang, JY | 6 |
| Lee, JS | 2 |
| Liao, WA | 1 |
| Huang, CY | 6 |
| Chen, PY | 5 |
| Wu, AC | 2 |
| Yang, ST | 2 |
| Lai, CC | 2 |
| Chi, PI | 1 |
| Chu, JM | 2 |
| Cheng, SM | 1 |
| Liu, CC | 2 |
| Hwang, DY | 2 |
| Chen, SH | 2 |
| Chang, KY | 3 |
| Qiu, Q | 1 |
| She, D | 1 |
| Yin, B | 1 |
| Gu, G | 1 |
| Chai, M | 1 |
| Heo, DN | 1 |
| Sadeghipour, N | 1 |
| Kumar, SU | 1 |
| Massoud, TF | 2 |
| Paulmurugan, R | 2 |
| Fan, Y | 7 |
| Zhao, S | 8 |
| Guo, X | 3 |
| Xue, H | 2 |
| Zhao, R | 3 |
| Sun, C | 2 |
| Melnick, KF | 1 |
| Miller, P | 2 |
| Carmichael, E | 1 |
| McGrath, K | 1 |
| Ghiaseddin, A | 1 |
| Tran, DD | 10 |
| Rahman, M | 3 |
| Lassman, AB | 22 |
| Pugh, SL | 5 |
| Gan, HK | 7 |
| Sulman, EP | 7 |
| Won, M | 11 |
| Moazami, G | 1 |
| Macsai, MS | 1 |
| Gilbert, MR | 42 |
| Bain, EE | 1 |
| Blot, V | 1 |
| Ansell, PJ | 3 |
| Samanta, S | 1 |
| Kundu, MG | 1 |
| Armstrong, TS | 11 |
| Wefel, JS | 6 |
| de Vos, FY | 1 |
| Hsu, S | 1 |
| Cardona, AF | 1 |
| Bentsion, D | 1 |
| Peterson, RA | 3 |
| Gedye, C | 2 |
| Bourg, V | 2 |
| Curran, WJ | 5 |
| Mehta, MP | 27 |
| Gao, G | 4 |
| Zhang, K | 4 |
| Yang, Y | 11 |
| Zhuang, J | 2 |
| Guo, G | 4 |
| Chao, X | 1 |
| Ohno, M | 7 |
| Miyakita, Y | 8 |
| Yanagisawa, S | 2 |
| Tamura, Y | 1 |
| Jiao, W | 1 |
| Zhu, S | 2 |
| Shao, J | 1 |
| Zhong, Y | 2 |
| Kong, D | 4 |
| Wang, T | 9 |
| Wan, Q | 1 |
| Ye, Y | 1 |
| Lin, J | 4 |
| Yang, J | 11 |
| Lu, N | 1 |
| Feng, SW | 2 |
| Chang, PC | 1 |
| Chen, HY | 1 |
| Hueng, DY | 1 |
| Li, YF | 2 |
| Huang, SM | 2 |
| Lin, K | 1 |
| Gueble, SE | 1 |
| Sundaram, RK | 1 |
| Huseman, ED | 1 |
| Bindra, RS | 4 |
| Herzon, SB | 1 |
| Thakur, S | 1 |
| Salunke, P | 1 |
| Ahuja, C | 1 |
| Madan, R | 2 |
| Jiménez-Morales, JM | 1 |
| Hernández-Cuenca, YE | 1 |
| Reyes-Abrahantes, A | 1 |
| Ruiz-García, H | 1 |
| Barajas-Olmos, F | 1 |
| García-Ortiz, H | 1 |
| Orozco, L | 1 |
| Quiñones-Hinojosa, A | 10 |
| Reyes-González, J | 1 |
| Abrahantes-Pérez, MDC | 1 |
| Guan, Y | 1 |
| Pan, M | 2 |
| Lu, Q | 1 |
| Gong, X | 3 |
| Mei, G | 1 |
| Pan, L | 2 |
| Dai, J | 3 |
| Wang, E | 2 |
| Jo, J | 2 |
| Schiff, D | 21 |
| Raghava Kurup, R | 1 |
| Oakes, EK | 1 |
| Vadlamani, P | 1 |
| Nwosu, O | 1 |
| Danthi, P | 1 |
| Hundley, HA | 1 |
| Schulz, JA | 1 |
| Rodgers, LT | 1 |
| Kryscio, RJ | 1 |
| Hartz, AMS | 1 |
| Bauer, B | 2 |
| Cieśluk, M | 1 |
| Piktel, E | 1 |
| Wnorowska, U | 1 |
| Skłodowski, K | 1 |
| Kochanowicz, J | 1 |
| Kułakowska, A | 1 |
| Bucki, R | 1 |
| Pogoda, K | 1 |
| Fu, J | 2 |
| Peng, J | 3 |
| Tu, G | 1 |
| Tseng, AJ | 1 |
| Tu, TH | 1 |
| Hua, WJ | 1 |
| Yeh, H | 1 |
| Chen, CJ | 1 |
| Lin, ZH | 1 |
| Hsu, WH | 1 |
| Chen, YL | 1 |
| Hsu, CC | 2 |
| Lin, TY | 3 |
| Filatenkova, TA | 1 |
| Glushakov, RI | 1 |
| Buntovskaya, AS | 1 |
| Tsapieva, AN | 1 |
| Kim, AV | 1 |
| Fedorov, EV | 1 |
| Skliar, SS | 1 |
| Matsko, MV | 2 |
| Galimova, ES | 1 |
| Shamova, OV | 1 |
| Hu, K | 3 |
| Hesse, F | 1 |
| Wright, AJ | 1 |
| Somai, V | 1 |
| Bulat, F | 1 |
| Kreis, F | 1 |
| Brindle, KM | 1 |
| Shi, DD | 1 |
| Youssef, GC | 1 |
| Nassar, AH | 1 |
| Lim-Fat, MJ | 2 |
| Rahman, R | 2 |
| Chen, J | 18 |
| Tao, S | 1 |
| Zou, Q | 1 |
| He, C | 1 |
| Jatyan, R | 2 |
| Singh, P | 5 |
| Sahel, DK | 2 |
| Karthik, YG | 1 |
| Mittal, A | 3 |
| Chitkara, D | 3 |
| Mair, MJ | 1 |
| Leibetseder, A | 1 |
| Heller, G | 1 |
| Puhr, R | 1 |
| Tomasich, E | 1 |
| Goldberger, S | 1 |
| Hatziioannou, T | 1 |
| Wöhrer, A | 1 |
| Widhalm, G | 1 |
| Dieckmann, K | 2 |
| Aichholzer, M | 1 |
| Weis, S | 3 |
| von Oertzen, T | 1 |
| Furtner, J | 1 |
| Pichler, J | 6 |
| Berghoff, AS | 2 |
| Garzio, K | 1 |
| McElroy, K | 1 |
| Grossman, S | 2 |
| Holdhoff, M | 3 |
| Ozer, B | 1 |
| Yankulina, O | 1 |
| Sandbhor, P | 1 |
| Goda, JS | 5 |
| Mohanty, B | 1 |
| Chaudhari, P | 2 |
| Dutt, S | 1 |
| Banerjee, R | 1 |
| Drakulic, D | 2 |
| Schwirtlich, M | 1 |
| Petrovic, I | 1 |
| Mojsin, M | 1 |
| Milivojevic, M | 1 |
| Kovacevic-Grujicic, N | 1 |
| Stevanovic, M | 2 |
| Luo, K | 1 |
| Liu, A | 3 |
| Wu, H | 8 |
| Shuai, SY | 1 |
| Liu, SS | 1 |
| Liu, XJ | 1 |
| Zhang, GS | 1 |
| Zheng, Q | 1 |
| Yue, PF | 1 |
| Hu, PY | 1 |
| Fu, Z | 5 |
| Fan, W | 1 |
| Wu, X | 8 |
| Tao, X | 1 |
| Ji, B | 1 |
| Gong, J | 1 |
| Yoon, SJ | 1 |
| Baek, S | 1 |
| Yu, SE | 1 |
| Jo, E | 1 |
| Lee, D | 5 |
| Shim, JK | 4 |
| Choi, RJ | 2 |
| Park, J | 4 |
| Moon, JH | 4 |
| Kim, EH | 7 |
| Chang, JH | 16 |
| Lee, JB | 1 |
| Park, JS | 2 |
| Sung, HJ | 1 |
| Kang, SG | 9 |
| Karve, AS | 1 |
| Desai, JM | 1 |
| Dave, N | 1 |
| Wise-Draper, TM | 1 |
| Gudelsky, GA | 1 |
| Phoenix, TN | 1 |
| DasGupta, B | 2 |
| Sengupta, S | 2 |
| Plas, DR | 1 |
| Desai, PB | 2 |
| Shidoh, S | 1 |
| Savjani, RR | 1 |
| Cho, NS | 1 |
| Ullman, HE | 1 |
| Hagiwara, A | 1 |
| Raymond, C | 2 |
| Lai, A | 10 |
| Nghiemphu, PL | 9 |
| Liau, LM | 10 |
| Pope, WB | 6 |
| Kaprealian, TB | 1 |
| Salamon, N | 1 |
| Ellingson, BM | 7 |
| Śledzińska, P | 1 |
| Bebyn, M | 1 |
| Furtak, J | 1 |
| Koper, A | 1 |
| Koper, K | 1 |
| Huang, T | 2 |
| Fan, H | 4 |
| Zhang, Q | 13 |
| Qiu, R | 1 |
| Wang, K | 12 |
| Chen, W | 11 |
| Jiang, X | 9 |
| Feng, M | 3 |
| Tu, Z | 1 |
| Ji, Q | 1 |
| Han, Q | 3 |
| Long, X | 1 |
| Wu, L | 6 |
| Huang, K | 3 |
| Zhu, X | 9 |
| Choo, M | 1 |
| Mai, VH | 1 |
| Kim, DH | 2 |
| Ku, JL | 1 |
| Lee, SK | 2 |
| An, YJ | 1 |
| Park, S | 2 |
| Aquilanti, E | 1 |
| Gan, T | 1 |
| Xie, M | 1 |
| Wang, P | 6 |
| Shi, Q | 1 |
| Miao, F | 1 |
| Shen, Z | 3 |
| Nie, E | 3 |
| Katzendobler, S | 2 |
| Blobner, J | 1 |
| Thiele, F | 1 |
| Becker, H | 1 |
| Quach, S | 2 |
| Egensperger, R | 4 |
| Suchorska, B | 5 |
| Thon, N | 8 |
| Tonn, JC | 16 |
| Lan, B | 1 |
| Zhao, H | 11 |
| Xie, X | 2 |
| Kuang, X | 1 |
| Du, J | 4 |
| Peng, F | 1 |
| Shi, L | 7 |
| Zhang, N | 1 |
| Kadhim, ZA | 1 |
| Sulaiman, GM | 1 |
| Al-Shammari, AM | 1 |
| Khan, RA | 1 |
| Al Rugaie, O | 1 |
| Mohammed, HA | 1 |
| Fu, G | 1 |
| Zhao, Q | 7 |
| Ke, Z | 1 |
| Zhang, R | 6 |
| Cheng, F | 1 |
| Wan, X | 2 |
| Peng, P | 2 |
| Han, C | 4 |
| Mao, F | 1 |
| Guo, D | 5 |
| Mai, A | 2 |
| Ye, SW | 1 |
| Tu, JY | 1 |
| Gao, J | 8 |
| Kang, ZF | 1 |
| Yao, QM | 1 |
| Ting, WJ | 1 |
| She, L | 1 |
| Liu, C | 12 |
| Cheng, M | 1 |
| Cao, D | 1 |
| Wang, XL | 1 |
| Jiao, BH | 3 |
| Wu, JL | 2 |
| Yang, JK | 2 |
| Hu, YH | 2 |
| Cui, K | 1 |
| Yadav, A | 1 |
| Alnakhli, A | 1 |
| Vemana, HP | 1 |
| Bhutkar, S | 1 |
| Muth, A | 1 |
| Dukhande, VV | 1 |
| Kuo, YY | 1 |
| Ho, KH | 5 |
| Shih, CM | 6 |
| Chen, PH | 5 |
| Liu, AJ | 3 |
| Chen, KC | 5 |
| Lu, G | 3 |
| Zhu, P | 3 |
| Rao, M | 1 |
| Linendoll, N | 1 |
| Buja, LM | 1 |
| Bhattacharjee, MB | 1 |
| Brown, RE | 1 |
| Tian, X | 1 |
| Pilichowska, M | 1 |
| Wu, JK | 4 |
| Hergenroeder, GW | 1 |
| Glass, WF | 1 |
| Pillai, AK | 1 |
| Hunter, RL | 1 |
| Zhu, JJ | 8 |
| Farheen, S | 1 |
| Ahmed, SP | 1 |
| Mariyath P M, M | 1 |
| Kausar, T | 1 |
| Hoda, MF | 1 |
| Arif, SH | 1 |
| Nayeem, SM | 1 |
| Ali, A | 3 |
| Chosdol, K | 2 |
| Shahi, MH | 1 |
| Kaulen, LD | 1 |
| Baehring, JM | 2 |
| Korovina, I | 1 |
| Vehlow, A | 1 |
| Temme, A | 1 |
| Cordes, N | 1 |
| Chang, CY | 1 |
| Chen, JT | 1 |
| Chen, TH | 1 |
| Chen, RM | 1 |
| Kebir, S | 5 |
| Ullrich, V | 1 |
| Berger, P | 1 |
| Dobersalske, C | 1 |
| Langer, S | 1 |
| Rauschenbach, L | 1 |
| Trageser, D | 1 |
| Till, A | 1 |
| Lorbeer, FK | 1 |
| Wieland, A | 1 |
| Wilhelm-Buchstab, T | 1 |
| Ahmad, A | 1 |
| Fröhlich, H | 1 |
| Cima, I | 1 |
| Prasad, S | 1 |
| Matschke, J | 2 |
| Jendrossek, V | 2 |
| Remke, M | 3 |
| Grüner, BM | 1 |
| Roesch, A | 1 |
| Siveke, JT | 1 |
| Herold-Mende, C | 6 |
| Blau, T | 3 |
| Keyvani, K | 3 |
| van Landeghem, FKH | 1 |
| Felsberg, J | 16 |
| Reifenberger, G | 21 |
| Sure, U | 3 |
| Brüstle, O | 1 |
| Simon, M | 8 |
| Scheffler, B | 3 |
| Balkanov, AS | 1 |
| Rozanov, ID | 1 |
| Glazkov, AA | 1 |
| Belyaev, AY | 1 |
| Kobyakov, GL | 3 |
| Shmakov, PN | 1 |
| Telysheva, EN | 1 |
| Strunina, YV | 1 |
| Usachev, DY | 1 |
| Zhu, TC | 1 |
| Que, TS | 1 |
| Li, ZY | 3 |
| Huang, GL | 1 |
| Gallitto, M | 2 |
| Savacool, M | 1 |
| Lee, A | 3 |
| Sisti, MB | 2 |
| Hosoya, T | 1 |
| Davey, C | 1 |
| Sese, J | 1 |
| Honda-Kitahara, M | 2 |
| Omura, T | 1 |
| Ozeki, Y | 1 |
| Kikuchi, M | 1 |
| Yoshida, A | 3 |
| Igaki, H | 3 |
| Matsushita, Y | 4 |
| Leng, H | 1 |
| Yuan, H | 1 |
| Jones, D | 2 |
| Whitehead, CA | 2 |
| Dinevska, M | 1 |
| Widodo, SS | 1 |
| Furst, LM | 1 |
| Morokoff, AP | 4 |
| Drummond, KJ | 1 |
| Mantamadiotis, T | 3 |
| Stylli, SS | 3 |
| Yang, DY | 1 |
| Cheng, X | 3 |
| Bu, XY | 2 |
| Yan, ZY | 2 |
| Qu, MQ | 2 |
| Zhao, YW | 1 |
| Kong, LF | 1 |
| Wang, YW | 1 |
| Luo, JC | 1 |
| Hansch, A | 1 |
| Meinhardt, J | 1 |
| Hain, EG | 1 |
| Misch, M | 2 |
| Onken, J | 1 |
| Roohani, S | 1 |
| Schweizer, L | 1 |
| Radke, J | 1 |
| Miller, R | 3 |
| Niazi, M | 2 |
| Russial, O | 1 |
| Poiset, S | 2 |
| Shi, W | 10 |
| Wu, M | 13 |
| Xu, C | 4 |
| Shi, Y | 5 |
| Ali, AS | 1 |
| Lombardo, J | 1 |
| Niazi, MZ | 1 |
| Miller, RC | 1 |
| Alnahhas, I | 2 |
| Martinez, NL | 5 |
| Andrews, DW | 4 |
| Judy, KD | 1 |
| Chidley, P | 1 |
| Shanker, M | 1 |
| Phillips, C | 2 |
| Haghighi, N | 1 |
| Pinkham, MB | 1 |
| Whittle, JR | 1 |
| Sia, J | 1 |
| Huang, Y | 7 |
| Zhao, F | 1 |
| Pei, Y | 1 |
| Li, R | 10 |
| Ai, P | 2 |
| Peng, X | 11 |
| Jovanović, N | 2 |
| Lazarević, M | 1 |
| Cvetković, VJ | 2 |
| Nikolov, V | 2 |
| Kostić Perić, J | 1 |
| Ugrin, M | 1 |
| Pavlović, S | 1 |
| Mitrović, T | 2 |
| Anwer, F | 1 |
| Waseem, M | 1 |
| Fatima, A | 1 |
| Malik, N | 1 |
| Zahid, S | 1 |
| Oh, CR | 1 |
| Kim, JE | 1 |
| Kim, SY | 3 |
| Kim, TW | 1 |
| Choi, J | 4 |
| Kim, J | 4 |
| Park, IJ | 1 |
| Lim, SB | 1 |
| Park, JH | 1 |
| Choi, MK | 1 |
| Cha, Y | 1 |
| Baek, JY | 1 |
| Beom, SH | 1 |
| Hong, YS | 1 |
| Ashkan, K | 3 |
| Brem, S | 11 |
| Trusheim, JE | 3 |
| Iwamoto, FM | 8 |
| Cobbs, CS | 3 |
| Heth, JA | 4 |
| Salacz, ME | 4 |
| D'Andre, S | 3 |
| Aiken, RD | 6 |
| Moshel, YA | 3 |
| Nam, JY | 4 |
| Pillainayagam, CP | 3 |
| Wagner, SA | 3 |
| Walter, KA | 5 |
| Chaudhary, R | 4 |
| Lee, IY | 4 |
| Bota, DA | 9 |
| Elinzano, H | 5 |
| Grewal, J | 4 |
| Lillehei, K | 8 |
| Mikkelsen, T | 17 |
| Walbert, T | 8 |
| Abram, S | 3 |
| Brenner, AJ | 4 |
| Ewend, MG | 6 |
| Khagi, S | 3 |
| Lovick, DS | 3 |
| Portnow, J | 4 |
| Kim, L | 5 |
| Loudon, WG | 3 |
| Thompson, RC | 4 |
| Avigan, DE | 3 |
| Fink, KL | 9 |
| Geoffroy, FJ | 3 |
| Gligich, O | 3 |
| Lindhorst, SM | 5 |
| Lutzky, J | 3 |
| Meisel, HJ | 3 |
| Nadji-Ohl, M | 3 |
| Sanchin, L | 3 |
| Sloan, A | 6 |
| Taylor, LP | 4 |
| Dunbar, EM | 4 |
| Etame, AB | 5 |
| Kesari, S | 23 |
| Mathieu, D | 5 |
| Piccioni, DE | 7 |
| Baskin, DS | 4 |
| Lacroix, M | 4 |
| May, SA | 3 |
| New, PZ | 4 |
| Pluard, TJ | 3 |
| Toms, SA | 8 |
| Tse, V | 3 |
| Peak, S | 4 |
| Battiste, JD | 3 |
| Mulholland, PJ | 5 |
| Pearlman, ML | 3 |
| Schulder, M | 3 |
| Prins, RM | 3 |
| Boynton, AL | 3 |
| Bosch, ML | 3 |
| Jia, W | 3 |
| Tian, H | 5 |
| Luo, M | 4 |
| Ding, N | 3 |
| Nice, EC | 3 |
| Huang, C | 6 |
| Zhang, H | 20 |
| Guo, Y | 4 |
| Ning, W | 3 |
| Zhao, C | 7 |
| Qu, Y | 7 |
| Zhou, W | 8 |
| Cui, Q | 3 |
| Khristov, V | 3 |
| Nesterova, D | 3 |
| Trifoi, M | 3 |
| Clegg, T | 3 |
| Daya, A | 3 |
| Barrett, T | 3 |
| Tufano, E | 3 |
| Shenoy, G | 3 |
| Pandya, B | 3 |
| Beselia, G | 3 |
| Smith, N | 4 |
| Mrowczynski, O | 3 |
| Zacharia, B | 3 |
| Waite, K | 3 |
| Lathia, J | 3 |
| Barnholtz-Sloan, J | 4 |
| Connor, J | 4 |
| Yavuz, M | 3 |
| Demircan, T | 3 |
| Urquhart, C | 3 |
| Fleming, B | 3 |
| Harper, I | 3 |
| Aloj, L | 3 |
| Armstrong, R | 3 |
| Hook, L | 3 |
| Long, AM | 3 |
| Jackson, C | 3 |
| Gallagher, FA | 3 |
| McLean, MA | 3 |
| Tarpey, P | 3 |
| Kosmoliaptsis, V | 3 |
| Nicholson, J | 3 |
| Hendriks, AEJ | 3 |
| Casey, RT | 3 |
| Chung, S | 3 |
| Sugimoto, Y | 3 |
| Frosina, G | 3 |
| Zhou, Z | 8 |
| Zhong, Z | 3 |
| Zhang, L | 28 |
| Chen, ZS | 3 |
| Claret, FX | 3 |
| Elkabets, M | 3 |
| Wang, F | 15 |
| Sun, F | 3 |
| Liang, H | 8 |
| Lin, HW | 3 |
| Moreno, V | 3 |
| Manuel Sepúlveda, J | 4 |
| Pérez-Núñez, Á | 4 |
| González León, P | 3 |
| Hanna, B | 3 |
| Filvaroff, E | 3 |
| Aronchik, I | 3 |
| Chang, H | 3 |
| Amoroso, B | 3 |
| Zuraek, M | 3 |
| Sanchez-Perez, T | 3 |
| Mendez, C | 3 |
| Stephens, D | 3 |
| Nikolova, Z | 4 |
| Hundal, J | 3 |
| Singh, A | 4 |
| Pereira, MK | 3 |
| Vredenburg, J | 3 |
| Goker Bagca, B | 4 |
| Ozates, NP | 4 |
| Biray Avci, C | 4 |
| Dong, J | 8 |
| Peng, Y | 6 |
| Zhong, M | 3 |
| Jiang, Z | 7 |
| Ge, R | 2 |
| Jiang, H | 10 |
| Schatz, J | 2 |
| Ladinig, A | 2 |
| Fietkau, R | 4 |
| Putz, F | 3 |
| Gaipl, US | 3 |
| Frey, B | 3 |
| Derer, A | 3 |
| Wen, B | 3 |
| Song, S | 4 |
| Wu, Q | 9 |
| Tong, X | 4 |
| Luo, GQ | 2 |
| Bai, S | 2 |
| Yan, ZJ | 2 |
| Fan, LL | 2 |
| Morelli, MB | 4 |
| Nabissi, M | 4 |
| Amantini, C | 3 |
| Maggi, F | 3 |
| Ricci-Vitiani, L | 6 |
| Pallini, R | 9 |
| Santoni, G | 4 |
| Staffieri, S | 2 |
| Sanchez, M | 6 |
| Devalckeneer, A | 2 |
| Aboukaïs, R | 3 |
| Bourgeois, P | 2 |
| Reyns, N | 3 |
| Lejeune, JP | 2 |
| Yahyapour, R | 2 |
| Khoei, S | 3 |
| Kordestani, Z | 2 |
| Larizadeh, MH | 2 |
| Jomehzadeh, A | 2 |
| Amirinejad, M | 2 |
| Ahmadi-Zeidabadi, M | 2 |
| Zhao, JX | 2 |
| Fang, ZY | 2 |
| Cui, XT | 2 |
| Su, DY | 2 |
| Zhou, JH | 2 |
| Wang, GX | 2 |
| Qiu, ZJ | 2 |
| Liu, SZ | 2 |
| Fu, JQ | 2 |
| Kang, CS | 3 |
| Wang, JC | 3 |
| Wang, QX | 2 |
| Yu, T | 4 |
| Zhou, F | 4 |
| Tian, W | 2 |
| Xu, R | 3 |
| Zeng, A | 6 |
| Taylor, TH | 2 |
| Duma, CM | 2 |
| LaRocca, RV | 2 |
| Carrillo, JA | 3 |
| Abedi, M | 2 |
| Hsu, FPK | 2 |
| Kong, XT | 2 |
| Hsieh, C | 2 |
| Bota, PG | 2 |
| Nistor, GI | 2 |
| Keirstead, HS | 2 |
| Dillman, RO | 2 |
| Abad, AP | 2 |
| Curry, WT | 5 |
| Wong, ET | 8 |
| Figel, SA | 2 |
| Mechtler, LL | 3 |
| Hutson, AD | 2 |
| Withers, HG | 2 |
| Liu, S | 9 |
| Belal, AN | 2 |
| Qiu, J | 4 |
| Mogensen, KM | 2 |
| Dharma, SS | 2 |
| Dhawan, A | 2 |
| Birkemeier, MT | 2 |
| Casucci, DM | 2 |
| Ciesielski, MJ | 2 |
| Fenstermaker, RA | 3 |
| Hong, X | 4 |
| Zou, J | 2 |
| Ouyang, J | 2 |
| Xiao, B | 4 |
| Zhang, A | 4 |
| Zhu, Q | 1 |
| Wang, W | 21 |
| Yuan, L | 2 |
| Shao, A | 1 |
| Lou, M | 3 |
| Nie, XH | 1 |
| Yin, R | 1 |
| Su, ZZ | 1 |
| Qiu, S | 1 |
| Qian, YF | 1 |
| Ren, Y | 2 |
| Qian, F | 1 |
| Ma, H | 3 |
| Quan, A | 1 |
| Yu, R | 5 |
| Xie, Y | 4 |
| Chao, M | 2 |
| Cao, H | 4 |
| Xin, L | 1 |
| Shi, X | 2 |
| Uhrbom, L | 2 |
| Dimberg, A | 1 |
| Patel, P | 1 |
| Alghamdi, A | 1 |
| Shaw, G | 1 |
| Legge, C | 1 |
| Glover, M | 1 |
| Freeman, D | 1 |
| Hodgetts, H | 1 |
| Wilson, E | 2 |
| Howard, F | 1 |
| Staniland, S | 1 |
| Kennerley, AJ | 1 |
| Wood, D | 1 |
| Moorehead, R | 1 |
| Hadfield, C | 1 |
| Rominiyi, O | 2 |
| Griffin, J | 1 |
| Collis, SJ | 3 |
| Hyde, S | 1 |
| Crossley, M | 1 |
| Paley, M | 1 |
| Muthana, M | 1 |
| Faghani, S | 1 |
| Khosravi, B | 1 |
| Moassefi, M | 1 |
| Conte, GM | 1 |
| Erickson, BJ | 3 |
| Giordano, FA | 4 |
| Kowalski, T | 1 |
| Grauer, O | 5 |
| Schnell, O | 7 |
| Ringel, F | 4 |
| Schmidt-Graf, F | 5 |
| Brehmer, S | 2 |
| Bullinger, L | 1 |
| Weth, FR | 1 |
| Peng, L | 2 |
| Paterson, E | 1 |
| Gray, C | 1 |
| Chang, SM | 39 |
| Youssef, G | 1 |
| de Groot, JF | 8 |
| Galanis, E | 6 |
| Al-Holou, WN | 1 |
| Ravikumar, V | 1 |
| Shankar, S | 1 |
| Oneka, M | 1 |
| Fehmi, Z | 1 |
| Verhaak, RG | 2 |
| Pratt, D | 1 |
| Camelo-Piragua, S | 1 |
| Speers, C | 2 |
| Wahl, DR | 5 |
| Hollon, T | 1 |
| Sagher, O | 1 |
| Muraszko, KM | 1 |
| Lawrence, TS | 8 |
| de Carvalho, AC | 1 |
| Rao, A | 1 |
| Rehemtulla, A | 3 |
| Cheng, P | 1 |
| Zhao, Y | 9 |
| Brown, JMC | 1 |
| Zaben, M | 1 |
| Ormonde, C | 1 |
| Sharouf, F | 1 |
| Spencer, R | 1 |
| Bhatt, H | 1 |
| Siebzehnrubl, FA | 2 |
| Gray, WP | 1 |
| Nishikawa, R | 19 |
| Yamasaki, F | 6 |
| Tanaka, S | 15 |
| Yamaguchi, S | 3 |
| Mukasa, A | 6 |
| Chou, FJ | 1 |
| Davis, DL | 1 |
| Briceno, NJ | 1 |
| Cimino, PJ | 2 |
| Zaghloul, KA | 1 |
| Yang, C | 8 |
| Mizuhata, M | 1 |
| Takamatsu, S | 1 |
| Shibata, S | 1 |
| Sakurai, T | 1 |
| Minamikawa, R | 1 |
| Yamazaki, M | 1 |
| Miyashita, K | 2 |
| Kumano, T | 1 |
| Nakada, M | 7 |
| Gabata, T | 1 |
| Alejo, S | 1 |
| Palacios, BE | 1 |
| Venkata, PP | 2 |
| Johnson, JD | 1 |
| Jayamohan, S | 1 |
| Pratap, UP | 1 |
| Clarke, K | 1 |
| Lv, Y | 3 |
| Weldon, K | 1 |
| Viswanadhapalli, S | 3 |
| Lai, Z | 1 |
| Ye, Z | 2 |
| Gilbert, AR | 1 |
| Suzuki, T | 1 |
| Tekmal, RR | 3 |
| Zheng, S | 2 |
| Vadlamudi, RK | 3 |
| Sareddy, GR | 3 |
| Bastiancich, C | 1 |
| Newland, B | 1 |
| Marsland, M | 1 |
| Dowdell, A | 1 |
| Faulkner, S | 1 |
| Jobling, P | 1 |
| Rush, RA | 1 |
| Lynam, J | 2 |
| Griffin, CP | 1 |
| Baker, M | 1 |
| Marsland, J | 1 |
| Jiang, CC | 1 |
| Hondermarck, H | 1 |
| Amelot, A | 2 |
| Terrier, LM | 1 |
| Mathon, B | 2 |
| Joubert, C | 2 |
| Picart, T | 1 |
| Jecko, V | 1 |
| Bauchet, L | 8 |
| Bernard, F | 1 |
| Castel, X | 1 |
| Chenin, L | 1 |
| Cook, AR | 1 |
| Emery, E | 3 |
| Gauchotte, G | 1 |
| Graillon, T | 4 |
| Jouvet, A | 3 |
| Kalamarides, M | 1 |
| Knafo, S | 1 |
| Lazard, A | 1 |
| Lubrano, V | 4 |
| Mokhtari, K | 13 |
| Rigau, V | 5 |
| Rousseau, A | 2 |
| Seizeur, R | 1 |
| Uro-Coste, E | 3 |
| Voirin, J | 1 |
| Metellus, P | 7 |
| Pallud, J | 5 |
| Zemmoura, I | 1 |
| Jiang, Y | 7 |
| Lu, H | 4 |
| Jenkins, S | 1 |
| Steinberg, SM | 3 |
| Nousome, D | 1 |
| Houston, N | 2 |
| Burton, E | 5 |
| Smart, DD | 2 |
| Shah, R | 1 |
| Peer, CJ | 2 |
| Mozarsky, B | 1 |
| Arisa, O | 1 |
| Figg, WD | 3 |
| Mendoza, TR | 3 |
| Vera, E | 3 |
| Brastianos, P | 1 |
| Carter, S | 2 |
| Anders, CK | 1 |
| Connolly, RM | 1 |
| Tweed, C | 1 |
| Smith, KL | 1 |
| Lipkowitz, S | 2 |
| Steeg, PS | 5 |
| Zimmer, AS | 2 |
| Guo, C | 2 |
| Xu, P | 2 |
| Deng, M | 1 |
| Cai, L | 3 |
| Sai, K | 4 |
| Xi, S | 1 |
| Ouyang, H | 1 |
| Liu, M | 3 |
| Cao, X | 2 |
| Du, X | 3 |
| Su, J | 5 |
| Xue, X | 1 |
| Qin, Z | 1 |
| Zhou, T | 7 |
| Hu, X | 5 |
| Lin, F | 1 |
| Ke, C | 2 |
| Lv, X | 1 |
| Hu, W | 4 |
| Zeng, J | 1 |
| Zhong, S | 3 |
| Mou, Y | 2 |
| Kim, N | 6 |
| Choi, JW | 2 |
| Lee, JI | 11 |
| Kong, DS | 11 |
| Seol, HJ | 6 |
| Nam, DH | 26 |
| Perwein, T | 1 |
| Giese, B | 1 |
| Nussbaumer, G | 1 |
| von Bueren, AO | 2 |
| van Buiren, M | 1 |
| Benesch, M | 2 |
| Kramm, CM | 3 |
| Blakstad, H | 1 |
| Brekke, J | 2 |
| Rahman, MA | 2 |
| Arnesen, VS | 1 |
| Miletic, H | 2 |
| Brandal, P | 2 |
| Lie, SA | 2 |
| Chekenya, M | 2 |
| Goplen, D | 2 |
| Michels, LR | 3 |
| Fachel, FNS | 2 |
| Schuh, RS | 2 |
| Azambuja, JH | 4 |
| Gelsleichter, NE | 4 |
| Lenz, GS | 3 |
| Visioli, F | 2 |
| Teixeira, HF | 4 |
| Elsaka, R | 1 |
| Kitagwa, JM | 1 |
| Refaat, T | 1 |
| Mahmoud, AA | 1 |
| Shaikh, H | 1 |
| Meheissen, MAM | 1 |
| Elsaid, AA | 1 |
| Malik, S | 1 |
| Suh, HW | 1 |
| Xiao, Y | 3 |
| Deng, Y | 5 |
| Fan, R | 2 |
| Huttner, A | 2 |
| Singh, V | 1 |
| Saltzman, WM | 1 |
| Bahal, R | 1 |
| Guo, Q | 5 |
| Cao, Z | 2 |
| Guan, Z | 1 |
| Jia, B | 2 |
| Hao, Q | 1 |
| Xu, M | 3 |
| Song, K | 1 |
| Shen, J | 5 |
| Zhu, W | 3 |
| Liang, Z | 1 |
| Liu, F | 2 |
| Ortiz-Rivera, J | 1 |
| Nuñez, R | 1 |
| Kucheryavykh, Y | 1 |
| Kucheryavykh, L | 1 |
| Ehinger, E | 1 |
| Kopecky, J | 2 |
| Darabi, A | 2 |
| Visse, E | 1 |
| Edvardsson, C | 1 |
| Tomasevic, G | 1 |
| Cederberg, D | 1 |
| Belting, M | 1 |
| Bengzon, J | 1 |
| Siesjö, P | 2 |
| Pawlowski, KD | 1 |
| Duffy, JT | 1 |
| Babak, MV | 1 |
| Balyasnikova, IV | 3 |
| Schaff, LR | 2 |
| Glavatskyi, OY | 1 |
| Griazov, AB | 1 |
| Chuvashova, OY | 1 |
| Kruchok, IV | 1 |
| Griazov, AA | 1 |
| Khmelnytskyi, HV | 1 |
| Shuba, IM | 1 |
| Stuley, VA | 1 |
| Zemskova, OV | 1 |
| Gallardo-Pérez, JC | 1 |
| Trejo-Solís, MC | 1 |
| Robledo-Cadena, DX | 1 |
| López-Marure, R | 1 |
| Agredano-Moreno, LT | 1 |
| Jimenez-García, LF | 1 |
| Sánchez-Lozada, LG | 1 |
| Charbonneau, M | 1 |
| Harper, K | 1 |
| Brochu-Gaudreau, K | 1 |
| Perreault, A | 1 |
| Roy, LO | 1 |
| Lucien, F | 1 |
| Fortin, D | 2 |
| Dubois, CM | 1 |
| Jia, JL | 1 |
| Alshamsan, B | 1 |
| Elshazly, AM | 1 |
| Gewirtz, DA | 1 |
| Szymczak, B | 1 |
| Czarnecka, J | 1 |
| Czach, S | 1 |
| Nowak, W | 1 |
| Roszek, K | 1 |
| Bosio, A | 1 |
| Padovan, M | 1 |
| Caccese, M | 2 |
| Aldegheri, V | 1 |
| Guarneri, V | 1 |
| Yang, L | 6 |
| Huang, Q | 6 |
| Villa, GR | 1 |
| Chiocca, EA | 6 |
| Tang, S | 4 |
| Tan, Z | 3 |
| Shen, L | 5 |
| Piehlmaier, D | 1 |
| Weber, P | 2 |
| Selmansberger, M | 1 |
| Heider, T | 1 |
| Hou, Z | 1 |
| Luo, N | 1 |
| Zhu, D | 3 |
| Tao, R | 1 |
| Nam, Y | 1 |
| Koo, H | 1 |
| Shin, S | 1 |
| Kim, D | 1 |
| Cho, HJ | 4 |
| Mu, Q | 6 |
| Choi, SW | 1 |
| Sa, JK | 5 |
| Seo, YJ | 1 |
| Kim, Y | 8 |
| Oh, JW | 1 |
| Kwon, YJ | 2 |
| Park, WY | 3 |
| Lee, HW | 2 |
| Yoon, Y | 2 |
| Kut, C | 1 |
| Kleinberg, L | 3 |
| Waghule, T | 1 |
| Laxmi Swetha, K | 1 |
| Roy, A | 1 |
| Narayan Saha, R | 1 |
| Singhvi, G | 1 |
| Hou, X | 2 |
| Du, H | 2 |
| Qiao, J | 2 |
| Shu, X | 2 |
| Sun, B | 6 |
| Song, Q | 1 |
| Li, N | 10 |
| Lam, TL | 1 |
| Shum, HC | 1 |
| Gherardini, L | 1 |
| Vetri Buratti, V | 1 |
| Maturi, M | 1 |
| Inzalaco, G | 1 |
| Locatelli, E | 1 |
| Sambri, L | 1 |
| Gargiulo, S | 1 |
| Barone, V | 1 |
| Bonente, D | 1 |
| Bertelli, E | 1 |
| Tortorella, S | 1 |
| Franci, L | 1 |
| Fioravanti, A | 1 |
| Comes Franchini, M | 1 |
| Chiariello, M | 1 |
| Liao, X | 1 |
| Zheng, H | 2 |
| Qian, W | 1 |
| Tang, M | 1 |
| Song, L | 2 |
| Janjua, TI | 1 |
| Cao, Y | 11 |
| Ahmed-Cox, A | 1 |
| Raza, A | 1 |
| Moniruzzaman, M | 1 |
| Akhter, DT | 1 |
| Fletcher, NL | 2 |
| Kavallaris, M | 1 |
| Thurecht, KJ | 2 |
| Popat, A | 1 |
| You, F | 1 |
| Zhang, T | 5 |
| Meng, Q | 1 |
| Gao, S | 4 |
| Manea, AJ | 1 |
| Ray, SK | 6 |
| Salerno, S | 1 |
| Barresi, E | 1 |
| Baglini, E | 1 |
| Poggetti, V | 1 |
| Da Settimo, F | 2 |
| Taliani, S | 1 |
| Zha, B | 1 |
| Dang, Q | 1 |
| Li, P | 9 |
| Shi, S | 1 |
| Cui, H | 3 |
| Huangfu, L | 1 |
| Zheng, Y | 4 |
| Gong, Z | 3 |
| Law, J | 1 |
| Wanggou, S | 1 |
| Ying, B | 1 |
| Francisco, M | 1 |
| Dong, W | 3 |
| Xiong, Y | 3 |
| Fan, JJ | 1 |
| MacLeod, G | 2 |
| Angers, S | 2 |
| Dirks, PB | 5 |
| Erthal, LCS | 1 |
| Sweeney, KJ | 1 |
| Gobbo, OL | 1 |
| Ruiz-Hernandez, E | 1 |
| Yan, W | 11 |
| You, Y | 14 |
| Mousavi, SM | 1 |
| Hosseindoost, S | 1 |
| Mahdian, SMA | 1 |
| Vousooghi, N | 1 |
| Rajabi, A | 1 |
| Jafari, A | 1 |
| Ostadian, A | 1 |
| Hamblin, MR | 2 |
| Hadjighassem, M | 1 |
| Mirzaei, H | 2 |
| Brawanski, KR | 1 |
| Sprung, S | 1 |
| Freyschlag, CF | 5 |
| Hoeftberger, R | 1 |
| Ströbel, T | 1 |
| Haybaeck, J | 2 |
| Thomé, C | 5 |
| Manzl, C | 1 |
| Birkl-Toeglhofer, AM | 2 |
| Teixeira, FC | 1 |
| Debom, GN | 1 |
| Roliano, GG | 1 |
| de Cássia Sant'ana, R | 1 |
| Kong, YS | 1 |
| Vincent, KM | 1 |
| Dieters-Castator, D | 1 |
| Bukhari, AB | 1 |
| Glubrecht, D | 1 |
| Liu, RZ | 1 |
| Quilty, D | 1 |
| Findlay, SD | 1 |
| Yang, RZ | 1 |
| Tang, E | 1 |
| Lajoie, G | 1 |
| Eisenstat, DD | 3 |
| Gamper, AM | 1 |
| Fahlman, R | 1 |
| Godbout, R | 1 |
| Postovit, LM | 1 |
| Fu, Y | 3 |
| Thivat, E | 3 |
| Casile, M | 1 |
| Moreau, J | 1 |
| Molnar, I | 1 |
| Dufort, S | 2 |
| Seddik, K | 1 |
| Le Duc, G | 3 |
| De Beaumont, O | 1 |
| Loeffler, M | 3 |
| Durando, X | 8 |
| Biau, J | 4 |
| Alalami, H | 1 |
| Bannykh, S | 1 |
| Fan, X | 5 |
| Barciszewska, AM | 3 |
| Belter, A | 2 |
| Gawrońska, I | 1 |
| Giel-Pietraszuk, M | 1 |
| Naskręt-Barciszewska, MZ | 2 |
| Fishman, H | 1 |
| Monin, R | 1 |
| Dor-On, E | 1 |
| Kinzel, A | 2 |
| Haber, A | 1 |
| Giladi, M | 1 |
| Weinberg, U | 3 |
| Palti, Y | 2 |
| Chu, W | 1 |
| Houston, ZH | 1 |
| Huda, P | 1 |
| Ahamed, M | 1 |
| Lim, TX | 1 |
| Day, BW | 2 |
| Pinkham, M | 1 |
| Sim, HW | 2 |
| Lorrey, S | 1 |
| Schilling, M | 1 |
| Reischl, M | 1 |
| Levkin, PA | 1 |
| Popova, AA | 1 |
| Turcan, Ş | 2 |
| Regli, LKP | 1 |
| Huijs, SMH | 1 |
| Pasmans, RCOS | 1 |
| Leue, C | 1 |
| Dijkstra, JB | 1 |
| Eekers, DBP | 3 |
| Hovinga, KE | 1 |
| Anten, MHME | 1 |
| Hoeben, A | 3 |
| Broen, MPG | 1 |
| Sousa, LR | 1 |
| Oliveira, AGS | 1 |
| Arantes, A | 1 |
| Junqueira, JGM | 1 |
| Alexandre, GP | 1 |
| Severino, VGP | 1 |
| Reis, RM | 6 |
| Kim, B | 1 |
| Ribeiro, RIMA | 1 |
| Yang, JT | 3 |
| Lee, IN | 2 |
| Huang, HC | 1 |
| Wu, YP | 2 |
| Chong, ZY | 1 |
| Chen, JC | 3 |
| Su, IC | 1 |
| Su, YK | 2 |
| Setiawan, SA | 1 |
| Lin, CM | 2 |
| Liu, HW | 1 |
| Brandt, B | 1 |
| Németh, M | 1 |
| Berta, G | 1 |
| Szünstein, M | 1 |
| Heffer, M | 1 |
| Rauch, TA | 1 |
| Pap, M | 1 |
| Sakhuja, R | 1 |
| Kitamura, Y | 2 |
| Toda, M | 3 |
| Perrault, EN | 1 |
| Shireman, JM | 3 |
| Ali, ES | 2 |
| Lin, P | 1 |
| Preddy, I | 1 |
| Park, C | 1 |
| Budhiraja, S | 1 |
| Baisiwala, S | 3 |
| Dixit, K | 1 |
| James, CD | 15 |
| Heiland, DH | 3 |
| Ben-Sahra, I | 2 |
| Pott, S | 1 |
| Basu, A | 2 |
| Miska, J | 2 |
| Ahmed, AU | 6 |
| Wan, S | 1 |
| Abbas, MN | 1 |
| Tan, N | 1 |
| Pan, J | 3 |
| Bian, Y | 1 |
| Hellmold, D | 3 |
| Kubelt, C | 5 |
| Daunke, T | 1 |
| Beckinger, S | 1 |
| Janssen, O | 1 |
| Hauck, M | 1 |
| Schütt, F | 1 |
| Adelung, R | 1 |
| Lucius, R | 3 |
| Haag, J | 1 |
| Sebens, S | 3 |
| Synowitz, M | 6 |
| Held-Feindt, J | 8 |
| Shahmir, S | 1 |
| Zahmatkesh, N | 1 |
| Mirzaahmadi, S | 1 |
| Asaadi Tehrani, G | 1 |
| Allahyarzadeh Khiabani, N | 1 |
| Amin Doustvandi, M | 1 |
| Mohammadnejad, F | 1 |
| Salmani Hassan Kohal, E | 1 |
| Boushehri, N | 1 |
| Jafarlou, M | 1 |
| Baradaran, B | 2 |
| Zemskova, O | 1 |
| Yu, NY | 1 |
| Trillenberg, P | 1 |
| Bonsanto, MM | 1 |
| Leppert, J | 1 |
| Rades, D | 2 |
| Chen, K | 4 |
| Song, C | 6 |
| Huang, A | 2 |
| Qi, S | 9 |
| Mekala, JR | 1 |
| Adusumilli, K | 1 |
| Chamarthy, S | 1 |
| Angirekula, HSR | 1 |
| Summers, HS | 1 |
| Lewis, W | 1 |
| Williams, HEL | 1 |
| Bradshaw, TD | 1 |
| Moody, CJ | 1 |
| Stevens, MFG | 1 |
| Patrick, S | 1 |
| Lathoria, K | 1 |
| Suri, V | 3 |
| Sen, E | 1 |
| Helal, DO | 1 |
| Abdel-Mottaleb, MMA | 1 |
| Kamel, AO | 1 |
| Rouatbi, N | 1 |
| Han, S | 6 |
| Geneidi, AS | 1 |
| Al-Jamal, KT | 1 |
| Awad, GAS | 1 |
| Merenzon, MA | 1 |
| Hincapie Arias, E | 1 |
| Bhatia, S | 1 |
| Shah, AH | 2 |
| Higgins, DMO | 1 |
| Villaverde, M | 1 |
| Belgorosky, D | 1 |
| Eijan, AM | 1 |
| Wang, G | 7 |
| Iturrioz-Rodríguez, N | 1 |
| Sampron, N | 3 |
| Matheu, A | 3 |
| Pibuel, MA | 1 |
| Poodts, D | 1 |
| Sias, SA | 1 |
| Byrne, A | 1 |
| Hajos, SE | 1 |
| Franco, PG | 1 |
| Lompardía, SL | 1 |
| Esser, D | 1 |
| Ahmeti, H | 1 |
| Wu, ZS | 1 |
| Chiu, YL | 1 |
| Song, D | 2 |
| Ahmad, N | 1 |
| Deng, S | 3 |
| Zhang, ZX | 2 |
| Ren, P | 1 |
| Cao, YY | 1 |
| Wang, TT | 1 |
| Huang, GH | 3 |
| Zhou, S | 3 |
| Liu, GL | 1 |
| Xiang, Y | 5 |
| Pei, YC | 1 |
| Chen, QZ | 1 |
| Chen, JX | 5 |
| Lv, SQ | 3 |
| Makino, K | 4 |
| Otani, Y | 2 |
| Fujii, K | 1 |
| Ishida, J | 1 |
| Hirano, S | 1 |
| Suruga, Y | 1 |
| Washio, K | 1 |
| Nishida, K | 1 |
| Yanai, H | 1 |
| Tomida, S | 1 |
| Ennishi, D | 1 |
| Kang, Z | 1 |
| Kang, X | 1 |
| Deng, J | 2 |
| Chen, F | 2 |
| Cannella, L | 1 |
| Della Monica, R | 1 |
| Marretta, AL | 1 |
| Iervolino, D | 1 |
| Vincenzi, B | 5 |
| De Chiara, AR | 1 |
| Clemente, O | 1 |
| Buonaiuto, M | 1 |
| Barretta, ML | 1 |
| Di Mauro, A | 1 |
| Di Marzo, M | 1 |
| Guida, M | 2 |
| Badalamenti, G | 1 |
| Chiariotti, L | 1 |
| Tafuto, S | 2 |
| Smith, J | 1 |
| Field, M | 1 |
| Sugaya, K | 1 |
| Nakhle, J | 1 |
| Khattar, K | 1 |
| Özkan, T | 2 |
| Boughlita, A | 1 |
| Abba Moussa, D | 1 |
| Darlix, A | 5 |
| Lorcy, F | 1 |
| Gerbal-Chaloin, S | 1 |
| Daujat-Chavanieu, M | 1 |
| Bellvert, F | 1 |
| Turchi, L | 1 |
| Virolle, T | 1 |
| Hugnot, JP | 1 |
| Buisine, N | 1 |
| Galloni, M | 1 |
| Dardalhon, V | 1 |
| Rodriguez, AM | 1 |
| Vignais, ML | 1 |
| Barberis, A | 1 |
| Zanotti, S | 1 |
| Montemurro, N | 1 |
| De Salvo, GL | 2 |
| Soffietti, R | 11 |
| Mazzanti, CM | 1 |
| Ius, T | 1 |
| Caffo, M | 1 |
| Paiar, F | 1 |
| Harris, AL | 1 |
| Buffa, FM | 1 |
| Kinhult, S | 1 |
| Tavelin, B | 2 |
| Löfgren, D | 1 |
| Rosenlund, L | 1 |
| Sandström, M | 2 |
| Strandeus, M | 3 |
| Henriksson, R | 13 |
| Güven, M | 1 |
| Taşpınar, F | 1 |
| Denizler-Ebiri, FN | 1 |
| Castresana, JS | 4 |
| Taşpınar, M | 2 |
| Cappelli, L | 1 |
| Khan, MM | 1 |
| Kayne, A | 1 |
| Ji, N | 2 |
| Yue, S | 2 |
| Qi, J | 3 |
| Gu, L | 2 |
| Zhou, X | 10 |
| Onyiah, C | 1 |
| Shepard, MJ | 1 |
| Surendran, A | 1 |
| Jenner, AL | 1 |
| Karimi, E | 1 |
| Fiset, B | 1 |
| Quail, DF | 1 |
| Walsh, LA | 1 |
| Craig, M | 1 |
| Yuan, X | 2 |
| Mu, J | 2 |
| Li, B | 9 |
| Yin, Z | 1 |
| Mallick, S | 5 |
| Gupta, S | 5 |
| Amariyil, A | 1 |
| Kunhiparambath, H | 2 |
| Laviraj, MA | 2 |
| Sharma, S | 5 |
| Sagiraju, HKR | 1 |
| Julka, PK | 4 |
| Sharma, D | 2 |
| Rath, GK | 4 |
| Reijneveld, JC | 16 |
| Machingura, A | 1 |
| Coens, C | 7 |
| de Vos, FYF | 2 |
| Klein, M | 10 |
| Lewis, J | 2 |
| Ghislain, I | 1 |
| Bottomley, A | 7 |
| Krajcer, A | 1 |
| Grzywna, E | 1 |
| Lewandowska-Łańcucka, J | 1 |
| Czarnywojtek, A | 1 |
| Borowska, M | 1 |
| Dyrka, K | 1 |
| Van Gool, S | 2 |
| Sawicka-Gutaj, N | 1 |
| Moskal, J | 1 |
| Kościński, J | 1 |
| Graczyk, P | 1 |
| Hałas, T | 1 |
| Lewandowska, AM | 1 |
| Czepczyński, R | 1 |
| Ruchała, M | 1 |
| Xu, Q | 4 |
| Meng, X | 10 |
| Weng, Y | 2 |
| Bu, L | 1 |
| Zheng, X | 4 |
| Cai, J | 9 |
| Zhan, R | 1 |
| Ballo, MT | 1 |
| Conlon, P | 1 |
| Lavy-Shahaf, G | 2 |
| Vymazal, J | 2 |
| Rulseh, AM | 2 |
| Rezaee, A | 1 |
| Tehrany, PM | 1 |
| Tirabadi, FJ | 1 |
| Sanadgol, N | 1 |
| Karimi, AS | 1 |
| Ajdari, A | 1 |
| Eydivandi, S | 1 |
| Etemad, S | 1 |
| Rajabi, R | 1 |
| Rahmanian, P | 1 |
| Khorrami, R | 1 |
| Nabavi, N | 1 |
| Aref, AR | 1 |
| Zou, R | 2 |
| Rashidi, M | 1 |
| Zandieh, MA | 1 |
| Hushmandi, K | 1 |
| Salvatori, L | 1 |
| Malatesta, S | 1 |
| Illi, B | 1 |
| Somma, MP | 1 |
| Fionda, C | 1 |
| Stabile, H | 1 |
| Fontanella, RA | 1 |
| Gaetano, C | 1 |
| Singh, K | 1 |
| Fleming, JL | 1 |
| Becker, AP | 3 |
| McElroy, J | 1 |
| Cui, T | 1 |
| Johnson, B | 1 |
| Kumar, A | 2 |
| Sebastian, E | 1 |
| Showalter, CA | 1 |
| Schrock, MS | 1 |
| Summers, MK | 1 |
| Becker, V | 1 |
| Tong, ZY | 1 |
| Manring, HR | 1 |
| Venere, M | 1 |
| Bell, EH | 4 |
| Robe, PA | 2 |
| Haque, SJ | 1 |
| Demircan, NV | 1 |
| Erpolat, OP | 1 |
| Guzel, C | 1 |
| Senturk, E | 1 |
| Bora, H | 1 |
| Karahacioglu, E | 1 |
| Albert, NL | 2 |
| Nelwan, DV | 1 |
| von Rohr, K | 1 |
| Kaiser, L | 1 |
| Teske, N | 1 |
| Unterrainer, LM | 1 |
| Bartos, LM | 1 |
| Ruf, VC | 1 |
| Brendel, M | 1 |
| Riemenschneider, MJ | 3 |
| Wetzel, C | 1 |
| Herms, J | 1 |
| Rupprecht, R | 1 |
| Bartenstein, P | 2 |
| von Baumgarten, L | 1 |
| Unterrainer, M | 2 |
| Holzgreve, A | 1 |
| Lin, CL | 2 |
| Li, HY | 1 |
| Chen, C | 15 |
| Maeoka, R | 1 |
| Ouji, Y | 1 |
| Nakazawa, T | 1 |
| Matsuda, R | 1 |
| Morimoto, T | 1 |
| Yokoyama, S | 1 |
| Yamada, S | 1 |
| Nishimura, F | 1 |
| Nakagawa, I | 1 |
| Park, YS | 1 |
| Yoshikawa, M | 1 |
| Nakase, H | 2 |
| Nizar, R | 1 |
| Cazacu, S | 1 |
| Xiang, C | 1 |
| Krasner, M | 1 |
| Barbiro-Michaely, E | 1 |
| Gerber, D | 1 |
| Schwartz, J | 1 |
| Fried, I | 1 |
| Yuval, S | 1 |
| Brodie, A | 1 |
| Kazimirsky, G | 1 |
| Amos, N | 1 |
| Unger, R | 1 |
| Brown, S | 1 |
| Penning, DH | 1 |
| Brodie, C | 1 |
| Wear, D | 1 |
| Bhagirath, E | 1 |
| Balachandar, A | 1 |
| Vegh, C | 1 |
| Pandey, S | 1 |
| Ntafoulis, I | 2 |
| Kleijn, A | 2 |
| Ju, J | 1 |
| Jimenez-Cowell, K | 1 |
| Fabro, F | 2 |
| Chi Yen, RT | 1 |
| Balvers, RK | 2 |
| Stubbs, AP | 1 |
| Kers, TV | 2 |
| Lawler, SE | 5 |
| Beerepoot, LV | 1 |
| Kremer, A | 2 |
| Verreault, M | 5 |
| Byrne, AT | 3 |
| O'Farrell, AC | 2 |
| Connor, K | 2 |
| Biswas, A | 6 |
| Salvucci, M | 3 |
| Prehn, JHM | 3 |
| Lambrechts, D | 2 |
| Dilcan, G | 2 |
| Lodi, F | 2 |
| Arijs, I | 2 |
| Dirven, CMF | 1 |
| Leenstra, S | 6 |
| Lamfers, MLM | 3 |
| Minniti, G | 16 |
| Paolini, S | 1 |
| Antonelli, M | 1 |
| Gianno, F | 1 |
| Tini, P | 5 |
| Lanzetta, G | 12 |
| De Pietro, R | 1 |
| Giraffa, M | 1 |
| Capone, L | 1 |
| Romano, A | 2 |
| Bozzao, A | 7 |
| Esposito, V | 8 |
| Tang, D | 3 |
| Gao, W | 4 |
| Jiao, J | 1 |
| Yang, R | 4 |
| Paech, D | 1 |
| Duffy, C | 1 |
| Nitsch, L | 1 |
| Stummer, W | 5 |
| Hattingen, E | 2 |
| Radbruch, A | 2 |
| Chai, R | 3 |
| Pang, B | 2 |
| Yan, M | 2 |
| Jiang, B | 3 |
| Mo, Z | 1 |
| Chang, Y | 5 |
| Chan, KHY | 1 |
| Loi, DSC | 1 |
| Tam, SST | 1 |
| Chan, AKY | 1 |
| Wu, AR | 1 |
| Poon, WS | 5 |
| Ng, HK | 2 |
| Chan, DTM | 2 |
| Iavarone, A | 2 |
| Yuan, J | 2 |
| Vincent, CA | 1 |
| Nissen, I | 1 |
| Dakhel, S | 1 |
| Hörnblad, A | 1 |
| Remeseiro, S | 1 |
| Butt, N | 1 |
| Enani, M | 1 |
| Alshanqiti, M | 1 |
| Alkhotani, A | 1 |
| Alsinani, T | 1 |
| Karami, MM | 1 |
| Fadul, MM | 1 |
| Almansouri, M | 1 |
| Hassan, A | 2 |
| Baeesa, S | 2 |
| Bamaga, AK | 1 |
| Alkhayyat, S | 2 |
| Faizo, E | 1 |
| Kurdi, M | 2 |
| Bernardes Ferro, M | 1 |
| Lopes Alves, GA | 1 |
| Pires Peña, F | 1 |
| de Oliveira, JVR | 1 |
| de Souza, BM | 1 |
| da Silva, LF | 1 |
| Rapack Jacinto Silva, V | 1 |
| Silva Pinheiro, AC | 1 |
| Steffens Reinhardt, L | 1 |
| da Rosa, RG | 1 |
| Silveira Aguirre, TA | 1 |
| Habiboglu, R | 1 |
| Kayali, I | 1 |
| Saricanbaz, I | 1 |
| Tezcan, Y | 1 |
| Umlauf, BJ | 1 |
| Frampton, G | 1 |
| Cooper, A | 2 |
| Greene, HF | 1 |
| Stringer, BW | 2 |
| De Silva, MI | 1 |
| Greenberg, Z | 1 |
| Noreña Puerta, A | 1 |
| Adams, R | 1 |
| Milky, B | 1 |
| Zabolocki, M | 1 |
| van den Hurk, M | 1 |
| Ebert, LM | 1 |
| Fairly Bishop, C | 1 |
| Conn, SJ | 1 |
| Kichenadasse, G | 1 |
| Michael, MZ | 1 |
| Ormsby, RJ | 1 |
| Poonoose, S | 1 |
| Bardy, C | 1 |
| Dumitru, CA | 1 |
| Schröder, H | 1 |
| Schäfer, FTA | 1 |
| Aust, JF | 1 |
| Kreße, N | 1 |
| Siebert, CLR | 1 |
| Stein, KP | 1 |
| Haghikia, A | 1 |
| Wilkens, L | 1 |
| Mawrin, C | 2 |
| Sandalcioglu, IE | 1 |
| Qu, S | 1 |
| Zhu, T | 2 |
| Ye, R | 1 |
| Berglund, AE | 1 |
| Macaulay, RJ | 1 |
| Bassi, R | 1 |
| Dei Cas, M | 1 |
| Tringali, C | 2 |
| Compostella, F | 1 |
| Paroni, R | 1 |
| Giussani, P | 2 |
| Krassnig, S | 1 |
| Leber, SL | 1 |
| Orthmann, A | 1 |
| Golob-Schwarzl, N | 1 |
| Huber, HJ | 2 |
| Wohlrab, C | 1 |
| Skofler, C | 1 |
| Pennauer, M | 1 |
| Raicht, A | 1 |
| Naumann, M | 1 |
| Mahdy-Ali, K | 1 |
| von Campe, G | 1 |
| Leoni, M | 1 |
| Alcaniz, J | 1 |
| Hoffmann, J | 2 |
| Wälchli, T | 1 |
| Tan, IL | 1 |
| Perez, AR | 1 |
| Lew, RJ | 2 |
| Baldwin, A | 1 |
| Zhu, YK | 1 |
| Shah, MM | 1 |
| Berger, MS | 23 |
| Doudna, JA | 2 |
| Fellmann, C | 2 |
| Rautajoki, KJ | 1 |
| Jaatinen, S | 1 |
| Hartewig, A | 1 |
| Tiihonen, AM | 1 |
| Annala, M | 1 |
| Salonen, I | 1 |
| Valkonen, M | 1 |
| Simola, V | 1 |
| Vuorinen, EM | 1 |
| Kivinen, A | 1 |
| Rauhala, MJ | 1 |
| Nurminen, R | 1 |
| Maass, KK | 1 |
| Lahtela, SL | 1 |
| Jukkola, A | 1 |
| Helén, P | 1 |
| Pajtler, KW | 2 |
| Ruusuvuori, P | 1 |
| Haapasalo, J | 1 |
| Haapasalo, H | 2 |
| Nykter, M | 3 |
| Sun, J | 8 |
| Xing, J | 2 |
| Tan, R | 2 |
| Tian, N | 1 |
| Fischer, A | 1 |
| Kloos, S | 1 |
| Remde, H | 1 |
| Dischinger, U | 1 |
| Pamporaki, C | 1 |
| Timmers, HJLM | 1 |
| Robledo, M | 1 |
| Fliedner, SMJ | 1 |
| Maurer, J | 1 |
| Reul, A | 1 |
| Bechmann, N | 1 |
| Hantel, C | 1 |
| Mohr, H | 1 |
| Pellegata, NS | 1 |
| Bornstein, SR | 1 |
| Kroiss, M | 1 |
| Auernhammer, CJ | 1 |
| Reincke, M | 1 |
| Pacak, K | 1 |
| Grossman, AB | 1 |
| Beuschlein, F | 1 |
| Nölting, S | 1 |
| Feller, KJ | 1 |
| Beerens, C | 1 |
| Tching Chi Yen, R | 1 |
| Chien, MP | 1 |
| Jiang, LY | 1 |
| Wang, GH | 2 |
| Xu, JJ | 1 |
| Li, XL | 1 |
| Lin, XY | 1 |
| Fang, X | 2 |
| Zhang, HX | 1 |
| Jiang, CM | 1 |
| Delobel, T | 1 |
| Ayala-Hernández, LE | 1 |
| Bosque, JJ | 1 |
| Pérez-Beteta, J | 1 |
| Chulián, S | 1 |
| García-Ferrer, M | 1 |
| Piñero, P | 1 |
| Schucht, P | 3 |
| Murek, M | 2 |
| Pérez-García, VM | 4 |
| Mu, Y | 1 |
| Guan, Q | 1 |
| Zhou, C | 2 |
| Ji, G | 1 |
| Sun, D | 2 |
| Sun, H | 4 |
| Wu, N | 2 |
| Jin, Y | 2 |
| Frandsen, S | 1 |
| Pedersen, AJ | 1 |
| Gredal, O | 1 |
| Møller, S | 1 |
| Geissler, UW | 1 |
| Nørøxe, DS | 1 |
| Chinyama, HA | 1 |
| Mokgautsi, N | 1 |
| Lawal, B | 1 |
| Wu, ATH | 1 |
| Huang, HS | 1 |
| Olatunji, G | 1 |
| Aderinto, N | 1 |
| Adefusi, T | 1 |
| Kokori, E | 1 |
| Akinmoju, O | 1 |
| Yusuf, I | 1 |
| Olusakin, T | 1 |
| Muzammil, MA | 1 |
| Yan, J | 2 |
| Li, K | 7 |
| Bian, L | 1 |
| Lin, B | 2 |
| Xi, Z | 1 |
| Cheng, CH | 4 |
| Chou, CM | 2 |
| Lin, CW | 2 |
| Nitta, RT | 1 |
| Bolin, S | 2 |
| Luo, E | 1 |
| Solow-Codero, DE | 1 |
| Samghabadi, P | 1 |
| Purzner, T | 1 |
| Aujla, PS | 1 |
| Nwagbo, G | 1 |
| Cho, YJ | 2 |
| Yun, Y | 3 |
| Zhu, R | 2 |
| Gras Navarro, A | 1 |
| Engelsen, A | 1 |
| Bindesbøll, C | 1 |
| Sarowar, S | 1 |
| Bahador, M | 1 |
| Bifulco, E | 1 |
| Waha, A | 2 |
| Gjertsen, BT | 1 |
| Selheim, F | 1 |
| Enger, PØ | 3 |
| Simonsen, A | 2 |
| Varlet, P | 2 |
| Le Teuff, G | 1 |
| Le Deley, MC | 1 |
| Giangaspero, F | 5 |
| Haberler, C | 1 |
| Jacques, TS | 1 |
| Andreiuolo, F | 1 |
| Deroulers, C | 1 |
| Jaspan, T | 2 |
| Jones, C | 5 |
| Grill, J | 5 |
| von Rosenstiel, C | 1 |
| Wiestler, B | 3 |
| Haller, B | 1 |
| Gempt, J | 3 |
| Bettstetter, M | 2 |
| Rihani, L | 1 |
| Meyer, B | 3 |
| Schlegel, J | 6 |
| Liesche-Starnecker, F | 1 |
| Kovaleva, K | 1 |
| Oleshko, O | 1 |
| Mamontova, E | 1 |
| Yarovaya, O | 1 |
| Zakharova, O | 1 |
| Zakharenko, A | 1 |
| Kononova, A | 1 |
| Dyrkheeva, N | 1 |
| Cheresiz, S | 1 |
| Pokrovsky, A | 1 |
| Lavrik, O | 1 |
| Salakhutdinov, N | 1 |
| Zhu, ZQ | 2 |
| Li, YX | 1 |
| Zhuang, QF | 1 |
| Lai, Y | 1 |
| Li, SF | 1 |
| Xu, XB | 1 |
| Liu, JM | 3 |
| Kwon, YM | 1 |
| Je, JY | 1 |
| Cha, SH | 2 |
| Oh, Y | 1 |
| Cho, WH | 2 |
| Schwendeman, SP | 1 |
| Patel, MP | 1 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 38 |
| Desjardins, A | 26 |
| Healy, P | 1 |
| Herndon, JE | 23 |
| McSherry, F | 3 |
| Lipp, ES | 5 |
| Miller, E | 3 |
| Peters, KB | 13 |
| Affronti, ML | 2 |
| Tsuji, S | 2 |
| Ohno, Y | 1 |
| Nakamura, S | 2 |
| Yamada, T | 2 |
| Noda, Y | 1 |
| Saio, M | 1 |
| Iwama, T | 3 |
| Shimazawa, M | 2 |
| Hara, H | 2 |
| Ulasov, IV | 2 |
| Mijanovic, O | 1 |
| Savchuk, S | 2 |
| Gonzalez-Buendia, E | 1 |
| Sonabend, A | 1 |
| Xiao, T | 1 |
| Timashev, P | 1 |
| Lesniak, MS | 9 |
| Xiong, J | 3 |
| Bao, H | 1 |
| Jin, H | 1 |
| Liang, P | 6 |
| Yoo, RE | 5 |
| Yun, TJ | 6 |
| Hwang, I | 1 |
| Hong, EK | 1 |
| Kang, KM | 2 |
| Sohn, CH | 8 |
| Chen, WL | 1 |
| Chen, HJ | 2 |
| Hou, GQ | 1 |
| Zhang, XH | 2 |
| Ge, JW | 1 |
| Petrova, L | 1 |
| Korfiatis, P | 2 |
| Petr, O | 1 |
| LaChance, DH | 3 |
| Parney, I | 1 |
| Buckner, JC | 9 |
| Chang, JS | 2 |
| Kim, IA | 12 |
| Lee, HS | 1 |
| Kim, SH | 19 |
| Yoon, HI | 1 |
| Kim, JW | 8 |
| Hong, CK | 3 |
| Cho, J | 5 |
| Kim, YJ | 8 |
| Kim, CY | 19 |
| Choe, G | 4 |
| Lee, ST | 6 |
| Kim, IH | 18 |
| Suh, CO | 8 |
| Yang, CH | 3 |
| Sims, M | 2 |
| Cai, C | 2 |
| Pfeffer, LM | 2 |
| Skarkova, V | 1 |
| Krupova, M | 1 |
| Vitovcova, B | 1 |
| Skarka, A | 1 |
| Kasparova, P | 1 |
| Krupa, P | 1 |
| Kralova, V | 1 |
| Rudolf, E | 1 |
| Sharifi, Z | 1 |
| Abdulkarim, B | 7 |
| Meehan, B | 2 |
| Rak, J | 2 |
| Daniel, P | 2 |
| Schmitt, J | 1 |
| Lauzon, N | 1 |
| Eppert, K | 1 |
| Duncan, HM | 1 |
| Guiot, MC | 10 |
| Jean-Claude, B | 1 |
| Sabri, S | 3 |
| Tan, B | 1 |
| Shao, Y | 2 |
| He, Q | 1 |
| Yang, B | 8 |
| Weng, Q | 1 |
| Gholamin, S | 1 |
| Youssef, OA | 1 |
| Rafat, M | 1 |
| Esparza, R | 1 |
| Kahn, S | 1 |
| Shahin, M | 1 |
| Giaccia, AJ | 1 |
| Graves, EE | 1 |
| Weissman, I | 1 |
| Mitra, S | 3 |
| Cheshier, SH | 1 |
| Pellerino, A | 3 |
| Pace, A | 7 |
| Carapella, CM | 2 |
| Dealis, C | 1 |
| Caroli, M | 6 |
| Faedi, M | 5 |
| Bello, L | 3 |
| Migliore, E | 1 |
| Marchese, G | 1 |
| Bertero, L | 2 |
| Cassoni, P | 6 |
| Gerstner, ER | 9 |
| Emblem, KE | 4 |
| Chang, K | 1 |
| Vakulenko-Lagun, B | 1 |
| Yen, YF | 1 |
| Beers, AL | 1 |
| Dietrich, J | 8 |
| Plotkin, SR | 4 |
| Catana, C | 1 |
| Hooker, JM | 2 |
| Duda, DG | 3 |
| Rosen, B | 1 |
| Kalpathy-Cramer, J | 4 |
| Jain, RK | 4 |
| Batchelor, T | 4 |
| Alafate, W | 2 |
| Zuo, J | 4 |
| Sun, L | 5 |
| Bouchart, C | 1 |
| Trépant, AL | 1 |
| Hein, M | 1 |
| Van Gestel, D | 1 |
| Demetter, P | 1 |
| Mei, S | 1 |
| Devos, P | 1 |
| Houillier, C | 4 |
| Cartalat, S | 1 |
| Di Stefano, AL | 1 |
| Lepage, C | 1 |
| Dubois, F | 2 |
| Yang, P | 6 |
| Yang, S | 11 |
| Zhai, Z | 1 |
| Hua, L | 3 |
| Feng, H | 4 |
| Shen, B | 1 |
| Sachdeva, R | 2 |
| Johnson, K | 1 |
| Celebre, A | 2 |
| Shahzad, U | 1 |
| Graham, MS | 1 |
| Kessler, JA | 1 |
| Chuang, JH | 1 |
| Karamchandani, J | 1 |
| Bredel, M | 4 |
| Verhaak, R | 1 |
| Das, S | 6 |
| Houy, N | 1 |
| Le Grand, F | 1 |
| Mao, P | 3 |
| Zeng, D | 1 |
| Chen, PR | 1 |
| Łysiak, M | 1 |
| Åkesson, L | 1 |
| Jakobsen, I | 1 |
| Mudaisi, M | 1 |
| Milos, P | 2 |
| Hallbeck, M | 3 |
| Fomichov, V | 1 |
| Broholm, H | 4 |
| Grunnet, K | 4 |
| Poulsen, HS | 5 |
| Bratthäll, C | 1 |
| Papagiannopoulou, A | 1 |
| Stenmark-Askmalm, M | 2 |
| Green, H | 1 |
| Söderkvist, P | 2 |
| Johannessen, TA | 1 |
| Bjerkvig, R | 6 |
| Youssef, M | 1 |
| Ludmir, EB | 1 |
| Mandel, JJ | 1 |
| Patel, AJ | 1 |
| Jalali, A | 1 |
| Treiber, J | 1 |
| McAleer, MF | 3 |
| Shao, F | 1 |
| Feng, F | 4 |
| Lo Dico, A | 2 |
| Salvatore, D | 1 |
| Martelli, C | 2 |
| Ronchi, D | 1 |
| Diceglie, C | 2 |
| Lucignani, G | 2 |
| Ottobrini, L | 2 |
| Kiang, KMY | 2 |
| Wong, VK | 1 |
| Dietterle, J | 2 |
| Oppermann, H | 2 |
| Glasow, A | 2 |
| Neumann, K | 2 |
| Ross, JA | 1 |
| Ahn, BY | 1 |
| King, J | 1 |
| Bressler, KR | 1 |
| Senger, DL | 2 |
| Thakor, N | 1 |
| Ren, T | 1 |
| Lin, M | 1 |
| Lee, SF | 1 |
| Yip, PL | 1 |
| Wong, FCS | 1 |
| Pinson, H | 2 |
| Hallaert, G | 2 |
| Van der Meulen, J | 1 |
| Dedeurwaerdere, F | 1 |
| Vanhauwaert, D | 1 |
| Van den Broecke, C | 2 |
| Van Dorpe, J | 1 |
| Van Roost, D | 2 |
| Kalala, JP | 2 |
| Boterberg, T | 2 |
| McDuff, SGR | 1 |
| Atkins, KM | 1 |
| Oh, KS | 2 |
| Loeffler, JS | 4 |
| Shih, HA | 3 |
| Wang, WL | 1 |
| Aru, N | 1 |
| Shen, X | 2 |
| Ding, YM | 1 |
| Wu, SJ | 1 |
| Qin, HH | 1 |
| Jin, WY | 1 |
| Drumm, MR | 1 |
| Dixit, KS | 1 |
| Grimm, S | 4 |
| Kumthekar, P | 6 |
| Raizer, JJ | 11 |
| Kam, KL | 1 |
| McCord, M | 1 |
| Sachdev, S | 1 |
| Kruser, T | 1 |
| Steffens, A | 1 |
| Javier, R | 1 |
| McCortney, K | 1 |
| Horbinski, C | 2 |
| Song, J | 5 |
| Chen, M | 4 |
| Tsai, YT | 1 |
| Chang, WC | 4 |
| Jana, A | 1 |
| Narula, P | 1 |
| Chugh, A | 1 |
| Kulshreshtha, R | 2 |
| Harder, BG | 2 |
| Peng, S | 3 |
| Sereduk, CP | 1 |
| Sodoma, AM | 1 |
| Loftus, JC | 4 |
| Tran, NL | 7 |
| Mukherjee, S | 2 |
| Wood, J | 1 |
| Liaquat, I | 1 |
| Stapleton, SR | 1 |
| Martin, AJ | 1 |
| Draaisma, K | 1 |
| Chatzipli, A | 1 |
| Taphoorn, M | 1 |
| Kerkhof, M | 2 |
| Weyerbrock, A | 7 |
| Lukacova, S | 1 |
| Hanse, M | 1 |
| Fleischeuer, R | 1 |
| Watts, C | 1 |
| McAbee, J | 1 |
| Angelopoulos, N | 1 |
| Verhaak, RGW | 2 |
| Bours, V | 1 |
| McDermott, U | 1 |
| Bernardo, PS | 1 |
| Guimarães, GHC | 1 |
| De Faria, FCC | 1 |
| Longo, GMDC | 1 |
| Lopes, GPF | 1 |
| Netto, CD | 1 |
| Costa, PRR | 1 |
| Maia, RC | 1 |
| Eoli, M | 7 |
| Smits, M | 2 |
| Walenkamp, A | 1 |
| Franceschi, E | 17 |
| Whenham, N | 2 |
| Sanghera, P | 5 |
| French, P | 2 |
| Looman, J | 1 |
| Dey, J | 1 |
| Krause, S | 1 |
| Ansell, P | 4 |
| Nuyens, S | 1 |
| Spruyt, M | 1 |
| Brilhante, J | 1 |
| Chonan, M | 3 |
| Saito, R | 7 |
| Osawa, SI | 1 |
| Watanabe, M | 3 |
| Suzuki, H | 3 |
| Nakasato, N | 1 |
| Tominaga, T | 7 |
| Ru, Y | 1 |
| Lyu, W | 3 |
| Fei, Z | 2 |
| Lin, W | 2 |
| Guan, H | 3 |
| Mu, X | 2 |
| Čančer, M | 1 |
| Drews, LF | 1 |
| Bengtsson, J | 1 |
| Rosén, G | 1 |
| Westermark, B | 1 |
| Nelander, S | 1 |
| Forsberg-Nilsson, K | 1 |
| Weishaupt, H | 1 |
| Swartling, FJ | 2 |
| Pötschke, R | 1 |
| Gielen, G | 1 |
| Kramm, C | 1 |
| Klusmann, JH | 1 |
| Hüttelmaier, S | 1 |
| Kühnöl, CD | 1 |
| Tomar, VS | 1 |
| Somasundaram, K | 2 |
| Hirono, S | 2 |
| Hasegawa, Y | 2 |
| Sakaida, T | 2 |
| Uchino, Y | 1 |
| Hatano, K | 2 |
| Iuchi, T | 2 |
| Ryu, JY | 1 |
| Min, KL | 1 |
| Chang, MJ | 1 |
| Stazi, G | 1 |
| Taglieri, L | 1 |
| Nicolai, A | 1 |
| Romanelli, A | 1 |
| Fioravanti, R | 1 |
| Morrone, S | 1 |
| Sabatino, M | 1 |
| Ragno, R | 1 |
| Taurone, S | 1 |
| Nebbioso, M | 1 |
| Carletti, R | 1 |
| Artico, M | 1 |
| Valente, S | 1 |
| Scarpa, S | 1 |
| Tang, JH | 2 |
| Li, QR | 1 |
| Zhu, LR | 1 |
| Xu, QF | 2 |
| Du, L | 2 |
| Kadota, T | 1 |
| Mizusawa, J | 1 |
| Katayama, H | 1 |
| Sumi, M | 2 |
| Komori, T | 2 |
| Kim, GW | 1 |
| Lee, DH | 2 |
| Yeon, SK | 1 |
| Jeon, YH | 1 |
| Yoo, J | 2 |
| Kwon, SH | 1 |
| Inada, M | 1 |
| Sato, A | 1 |
| Shindo, M | 1 |
| Yamamoto, Y | 2 |
| Akasaki, Y | 2 |
| Tanuma, SI | 1 |
| Pang, D | 2 |
| Feng, B | 2 |
| Geng, Y | 1 |
| Luo, Q | 1 |
| Guo, R | 2 |
| Yan, D | 3 |
| Thyparambil, S | 1 |
| Tian, Y | 4 |
| Cecchi, F | 1 |
| Rosenblum, M | 1 |
| Reiner, AS | 3 |
| Panageas, KS | 10 |
| Hembrough, T | 1 |
| Lin, AL | 1 |
| Teuber-Hanselmann, S | 1 |
| Schmidt, T | 1 |
| Oster, C | 1 |
| Pierscianek, D | 1 |
| Stuschke, M | 2 |
| Deuschl, C | 1 |
| Kosmala, R | 1 |
| Lisowski, D | 1 |
| Flentje, M | 2 |
| Guo, J | 4 |
| Guo, M | 4 |
| Oliveira, M | 1 |
| de Santana, LLB | 1 |
| Serafim, JC | 1 |
| Santos, AO | 1 |
| Quintino, MP | 1 |
| Correia, JTM | 1 |
| Damasceno, F | 1 |
| Sabino, JR | 1 |
| Pires, TRC | 1 |
| Coelho, PLC | 1 |
| de Faria Lopes, GP | 1 |
| Ulrich, H | 1 |
| Costa, SL | 1 |
| Cunha, S | 1 |
| Vaubel, RA | 2 |
| Remonde, D | 1 |
| Schroeder, MA | 8 |
| Caron, A | 1 |
| Kollmeyer, TM | 1 |
| Grove, R | 1 |
| Ma, DJ | 2 |
| Sarkar, G | 1 |
| Evers, L | 1 |
| Dhruv, HD | 3 |
| Berens, ME | 3 |
| Marin, BM | 1 |
| Klee, EW | 1 |
| Califano, A | 1 |
| Burns, TC | 3 |
| Meyer, FB | 2 |
| O'Neill, BP | 3 |
| Giannini, C | 13 |
| Parney, IF | 5 |
| Bunevicius, A | 1 |
| McDannold, NJ | 1 |
| Golby, AJ | 2 |
| Vaz Salgado, MA | 1 |
| Torres, J | 1 |
| Esteban, J | 1 |
| Gutiérrez, JA | 1 |
| Ley, L | 1 |
| Carrato, A | 1 |
| Hong, R | 1 |
| Lu, J | 4 |
| Nan, Y | 1 |
| Bikhezar, F | 1 |
| de Kruijff, RM | 1 |
| van der Meer, AJGM | 1 |
| Torrelo Villa, G | 1 |
| van der Pol, SMA | 1 |
| Becerril Aragon, G | 1 |
| Gasol Garcia, A | 1 |
| Narayan, RS | 2 |
| de Vries, HE | 1 |
| Slotman, BJ | 6 |
| Denkova, AG | 1 |
| Sminia, P | 6 |
| Quan, R | 1 |
| Lee, YT | 2 |
| Hu, C | 5 |
| Lal, B | 3 |
| Xia, S | 1 |
| Lv, S | 2 |
| Laterra, J | 1 |
| Umphlett, M | 1 |
| Shea, S | 1 |
| Tome-Garcia, J | 1 |
| Hormigo, A | 5 |
| Fowkes, M | 2 |
| Tsankova, NM | 1 |
| Yong, RL | 2 |
| Sorribes, IC | 1 |
| Handelman, SK | 1 |
| Jain, HV | 1 |
| Carvalho, B | 1 |
| Lopes, RG | 1 |
| Linhares, P | 2 |
| Costa, A | 1 |
| Caeiro, C | 2 |
| Fernandes, AC | 1 |
| Tavares, N | 1 |
| Osório, L | 2 |
| Vaz, R | 1 |
| Miyazaki, T | 2 |
| Ishikawa, E | 6 |
| Sugii, N | 1 |
| Kohzuki, H | 1 |
| Akutsu, H | 3 |
| Sakamoto, N | 3 |
| Takano, S | 4 |
| Matsumura, A | 6 |
| Diao, X | 1 |
| Rezaei, V | 1 |
| Rabiee, A | 1 |
| Khademi, F | 1 |
| Fontanilles, M | 5 |
| Fontanilles, A | 1 |
| Massy, N | 1 |
| Rouvet, J | 1 |
| Pereira, T | 1 |
| Alexandru, C | 4 |
| Hanzen, C | 3 |
| Basuyau, F | 1 |
| Clatot, F | 4 |
| Tennevet, I | 6 |
| Di Fiore, F | 4 |
| Joannidès, R | 1 |
| Lamoureux, F | 1 |
| Duan, H | 1 |
| Zheng, SY | 1 |
| Cui, HJ | 1 |
| Hu, KW | 1 |
| Pham, A | 1 |
| Yoo, S | 1 |
| Attenello, FJ | 3 |
| Jennelle, R | 1 |
| Wagle, N | 1 |
| Zada, G | 1 |
| Azoulay, M | 3 |
| Chang, SD | 3 |
| Gibbs, IC | 2 |
| Hancock, SL | 2 |
| Pollom, EL | 3 |
| Harsh, GR | 2 |
| Adler, JR | 2 |
| Harraher, C | 2 |
| Hayden Gephart, M | 1 |
| Thomas, RP | 2 |
| Recht, LD | 5 |
| Jacobs, LR | 2 |
| Modlin, LA | 2 |
| Wynne, J | 2 |
| Seiger, K | 2 |
| Fujimoto, D | 2 |
| Usoz, M | 1 |
| von Eyben, R | 2 |
| Choi, CYH | 2 |
| Petrelli, F | 1 |
| De Stefani, A | 1 |
| Ghidini, A | 1 |
| Bruschieri, L | 1 |
| Riboldi, V | 1 |
| Dottorini, L | 1 |
| Iaculli, A | 1 |
| Zaniboni, A | 1 |
| Trevisan, F | 1 |
| Baxter, PA | 1 |
| Su, JM | 2 |
| Onar-Thomas, A | 2 |
| Billups, CA | 1 |
| Poussaint, TY | 2 |
| Smith, ER | 1 |
| Thompson, P | 2 |
| Adesina, A | 2 |
| Giranda, V | 2 |
| Paulino, A | 1 |
| Kilburn, L | 2 |
| Quaddoumi, I | 1 |
| Broniscer, A | 3 |
| Blaney, SM | 5 |
| Dunkel, IJ | 1 |
| Fouladi, M | 5 |
| Paek, SH | 4 |
| Hong, YK | 9 |
| Kim, OL | 1 |
| Hata, N | 3 |
| Mizoguchi, M | 4 |
| Kuga, D | 2 |
| Hatae, R | 3 |
| Akagi, Y | 1 |
| Sangatsuda, Y | 2 |
| Amemiya, T | 1 |
| Michiwaki, Y | 2 |
| Fujioka, Y | 4 |
| Takigawa, K | 2 |
| Suzuki, SO | 2 |
| Yoshitake, T | 1 |
| Togao, O | 3 |
| Hiwatashi, A | 2 |
| Yoshimoto, K | 5 |
| Iihara, K | 1 |
| Choi, BD | 2 |
| Tunthanathip, T | 2 |
| Sangkhathat, S | 2 |
| Ning, J | 3 |
| Wakimoto, H | 4 |
| Kessler, T | 4 |
| Platten, M | 15 |
| Meisner, C | 4 |
| Bamberg, M | 5 |
| Papsdorf, K | 2 |
| Vesper, J | 2 |
| Debus, J | 17 |
| Ketter, R | 7 |
| Hertler, C | 1 |
| Mayer-Steinacker, R | 4 |
| Weisang, S | 1 |
| Bölting, H | 1 |
| Reuss, D | 1 |
| Sahm, F | 5 |
| Struve, N | 1 |
| Binder, ZA | 2 |
| Stead, LF | 2 |
| Brend, T | 1 |
| Bagley, SJ | 1 |
| Faulkner, C | 1 |
| Ott, L | 1 |
| Müller-Goebel, J | 1 |
| Weik, AS | 1 |
| Hoffer, K | 1 |
| Krug, L | 1 |
| Rieckmann, T | 1 |
| Bußmann, L | 1 |
| Henze, M | 1 |
| Morrissette, JJD | 1 |
| Schüller, U | 3 |
| Petersen, C | 1 |
| Rothkamm, K | 1 |
| O Rourke, DM | 1 |
| Short, SC | 6 |
| Kriegs, M | 1 |
| He, M | 2 |
| Hao, B | 2 |
| Barciszewski, J | 1 |
| Huang, M | 2 |
| Wu, JY | 1 |
| Xing, K | 1 |
| Yeo, E | 1 |
| Holland, E | 1 |
| Qin, L | 1 |
| O'Rourke, DM | 2 |
| Koumenis, C | 1 |
| Gong, Y | 3 |
| Su, Z | 3 |
| Lu, X | 2 |
| Dey, D | 1 |
| Parihar, VK | 1 |
| Szabo, GG | 1 |
| Klein, PM | 1 |
| Tran, J | 2 |
| Moayyad, J | 1 |
| Ahmed, F | 1 |
| Nguyen, QA | 1 |
| Murry, A | 1 |
| Merriott, D | 1 |
| Nguyen, B | 1 |
| Goldman, J | 1 |
| Angulo, MC | 1 |
| Piomelli, D | 1 |
| Soltesz, I | 1 |
| Baulch, JE | 1 |
| Limoli, CL | 1 |
| El Husseini, K | 1 |
| Marguet, F | 4 |
| Lamy, A | 1 |
| Magne, N | 8 |
| Suarez, C | 1 |
| Forsyth, P | 5 |
| Gueorguieva, I | 1 |
| Burkholder, T | 1 |
| Cleverly, AL | 1 |
| Estrem, ST | 1 |
| Lahn, MM | 1 |
| Guba, SC | 1 |
| Capper, D | 3 |
| Rodon, J | 1 |
| Lobbous, M | 1 |
| Tamura, R | 2 |
| Morimoto, Y | 1 |
| Kosugi, K | 2 |
| Sato, M | 2 |
| Oishi, Y | 1 |
| Ueda, R | 1 |
| Kikuchi, R | 1 |
| Nagashima, H | 1 |
| Hikichi, T | 1 |
| Noji, S | 1 |
| Kawakami, Y | 1 |
| Yoshida, K | 5 |
| Brown, NF | 1 |
| Ng, SM | 1 |
| Brooks, C | 1 |
| Coutts, T | 1 |
| Holmes, J | 1 |
| Roberts, C | 1 |
| Elhussein, L | 1 |
| Hoskin, P | 1 |
| Maughan, T | 1 |
| Blagden, S | 1 |
| Cui, P | 1 |
| Wei, F | 2 |
| Hou, J | 2 |
| Su, Y | 2 |
| Mathur, R | 1 |
| Grimmer, MR | 3 |
| Hong, C | 4 |
| Bollam, S | 1 |
| Clarke, J | 5 |
| Phillips, JJ | 8 |
| Oberheim-Bush, NA | 1 |
| Molinaro, AM | 10 |
| Costello, JF | 10 |
| Egashira, Y | 1 |
| Nakayama, N | 1 |
| Yano, H | 3 |
| Ji, Y | 1 |
| Fang, F | 1 |
| Tang, H | 3 |
| Qiu, P | 1 |
| Ma, JP | 1 |
| Weng, JC | 1 |
| Zhang, JT | 1 |
| Yin, P | 1 |
| Cao, G | 1 |
| Xin, X | 1 |
| Cai, X | 2 |
| Du, B | 2 |
| Cheng He, R | 1 |
| Inocencio, JF | 1 |
| Deikus, G | 1 |
| Wasserman, I | 1 |
| Strahl, M | 1 |
| Smith, M | 1 |
| Sebra, R | 1 |
| Ding, C | 2 |
| Yi, X | 2 |
| Bu, X | 3 |
| Kang, D | 2 |
| Song, A | 1 |
| Bar-Ad, V | 1 |
| Martinez, N | 2 |
| Glass, J | 4 |
| Judy, K | 2 |
| Evans, JJ | 1 |
| Farrell, CJ | 1 |
| Werner-Wasik, M | 12 |
| Chervoneva, I | 1 |
| Ly, M | 1 |
| Massey, SC | 1 |
| White, H | 1 |
| Whitmire, P | 1 |
| Doyle, T | 3 |
| Johnston, SK | 2 |
| Singleton, KW | 1 |
| Jackson, PR | 1 |
| Hawkins-Daarud, A | 3 |
| Bendok, BR | 1 |
| Porter, AB | 2 |
| Vora, S | 1 |
| Hu, LS | 1 |
| Mrugala, MM | 5 |
| Swanson, KR | 2 |
| Chen, G | 6 |
| Ran, D | 1 |
| Chai, Z | 1 |
| Xie, C | 6 |
| Lu, L | 3 |
| Zhan, C | 2 |
| Lu, W | 5 |
| Sarkar, S | 1 |
| Mirzaei, R | 1 |
| Rawji, K | 1 |
| Poon, C | 1 |
| Mishra, MK | 1 |
| Zemp, FJ | 1 |
| Bose, P | 1 |
| Kelly, J | 1 |
| Dunn, JF | 1 |
| Yong, VW | 1 |
| Hermann, RM | 1 |
| Merten, R | 1 |
| Xu, B | 4 |
| Luo, X | 2 |
| Ning, X | 1 |
| Luo, J | 1 |
| Ling, G | 1 |
| Fisher, BJ | 6 |
| Macdonald, DR | 8 |
| Chakravatri, A | 1 |
| Lesser, GJ | 9 |
| Fox, S | 1 |
| Rogers, CL | 1 |
| Bahary, JP | 5 |
| Fiveash, JB | 8 |
| Bovi, JA | 2 |
| Howard, SP | 3 |
| Michael Yu, HH | 2 |
| D'Souza, D | 1 |
| Laack, NN | 5 |
| Barani, IJ | 1 |
| Kwok, Y | 2 |
| Strasser, JF | 1 |
| Biassou, N | 1 |
| Gril, B | 2 |
| Brastianos, PK | 1 |
| Lyden, D | 1 |
| Xu, JX | 1 |
| Luan, XP | 1 |
| Kong, S | 1 |
| Shang, S | 1 |
| Lan, Y | 1 |
| Lou, J | 1 |
| Zhang, B | 5 |
| Ruminy, P | 1 |
| Basset, C | 1 |
| Noel, A | 1 |
| Beaussire, L | 2 |
| Viennot, M | 1 |
| Viailly, PJ | 1 |
| Cassinari, K | 1 |
| Chambon, P | 1 |
| Richard, D | 1 |
| Laquerrière, A | 3 |
| Sarafan-Vasseur, N | 2 |
| Laigle-Donadey, F | 12 |
| Greffard, S | 1 |
| Ebrahimi Zade, A | 2 |
| Shahabi Haghighi, S | 2 |
| Soltani, M | 2 |
| Lee, CAA | 1 |
| Banerjee, P | 1 |
| Wilson, BJ | 1 |
| Berg, G | 1 |
| Karpova, S | 1 |
| Mishra, A | 1 |
| Lian, JW | 1 |
| Emmerich, M | 1 |
| Murphy, GF | 1 |
| Frank, MH | 1 |
| Frank, NY | 1 |
| Li, YY | 1 |
| Boynton, AN | 1 |
| Spurr, LF | 1 |
| Bohrson, CL | 1 |
| Cortes-Ciriano, I | 1 |
| Birzu, C | 1 |
| Geduldig, JE | 1 |
| Pelton, K | 1 |
| Pal, S | 1 |
| Ferrer-Luna, R | 1 |
| Ramkissoon, SH | 3 |
| Bellamy, C | 1 |
| Currimjee, N | 1 |
| Bonardi, J | 1 |
| Ho, P | 1 |
| Taquet, L | 1 |
| Jones, RE | 1 |
| Shetty, A | 1 |
| Sharaf, R | 1 |
| Pavlick, D | 1 |
| Albacker, LA | 1 |
| Younan, N | 1 |
| Baldini, C | 1 |
| Giry, M | 1 |
| Guillerm, E | 1 |
| Ammari, S | 1 |
| Beuvon, F | 2 |
| Alentorn, A | 2 |
| Psimaras, D | 4 |
| Lee, EQ | 5 |
| Nayak, L | 4 |
| McFaline-Figueroa, JR | 1 |
| Carpentier, A | 5 |
| Cornu, P | 4 |
| Capelle, L | 8 |
| Barnholtz-Sloan, JS | 4 |
| Bi, WL | 1 |
| Fehnel, KP | 1 |
| Alexandrescu, S | 1 |
| Chi, SN | 1 |
| Haas-Kogan, D | 3 |
| Batchelor, TT | 21 |
| Frampton, GM | 1 |
| Alexander, BM | 3 |
| Huang, RY | 1 |
| Ligon, AH | 1 |
| Coulet, F | 1 |
| Delattre, JY | 22 |
| Hoang-Xuan, K | 23 |
| Meredith, DM | 1 |
| Santagata, S | 2 |
| Duval, A | 1 |
| Cherniack, AD | 1 |
| Marabelle, A | 1 |
| Park, PJ | 2 |
| Beroukhim, R | 2 |
| Bandopadhayay, P | 1 |
| Bielle, F | 2 |
| Balana, C | 14 |
| Vaz, MA | 3 |
| Mesia, C | 1 |
| Del Barco, S | 1 |
| Pineda, E | 2 |
| Muñoz-Langa, J | 1 |
| Estival, A | 2 |
| de Las Peñas, R | 2 |
| Fuster, J | 1 |
| Gironés, R | 1 |
| Navarro, LM | 1 |
| Gil-Gil, M | 3 |
| Alonso, M | 1 |
| Herrero, A | 3 |
| Peralta, S | 2 |
| Olier, C | 1 |
| Perez-Segura, P | 5 |
| Covela, M | 1 |
| Martinez-García, M | 2 |
| Berrocal, A | 5 |
| Gallego, O | 5 |
| Luque, R | 3 |
| Perez-Martín, FJ | 1 |
| Esteve, A | 1 |
| Munne, N | 1 |
| Domenech, M | 2 |
| Villa, S | 9 |
| Sanz, C | 3 |
| Carrato, C | 4 |
| Adamski, V | 2 |
| Hattermann, K | 5 |
| Cohrs, G | 1 |
| Butler, M | 1 |
| Pongor, L | 1 |
| Su, YT | 4 |
| Xi, L | 1 |
| Raffeld, M | 1 |
| Quezado, M | 1 |
| Trepel, J | 1 |
| Pommier, Y | 1 |
| Oh, YT | 2 |
| Chung, WK | 2 |
| Selvasaravanan, KD | 1 |
| Wiederspohn, N | 1 |
| Hadzalic, A | 1 |
| Strobel, H | 1 |
| Payer, C | 1 |
| Schuster, A | 1 |
| Karpel-Massler, G | 7 |
| Siegelin, MD | 3 |
| Halatsch, ME | 7 |
| Debatin, KM | 5 |
| Westhoff, MA | 4 |
| Natsume, A | 14 |
| Aoki, K | 4 |
| Ohka, F | 4 |
| Maeda, S | 1 |
| Hirano, M | 2 |
| Adilijiang, A | 1 |
| Motomura, K | 6 |
| Maruyama, T | 2 |
| Ito, T | 2 |
| Nakamura, H | 6 |
| Kayama, T | 6 |
| Sato, S | 2 |
| Nakasu, Y | 3 |
| Kurisu, K | 6 |
| Sugiyama, K | 8 |
| Onishi, T | 2 |
| Iwadate, Y | 3 |
| Terasaki, M | 3 |
| Matsuo, T | 1 |
| Hirano, H | 2 |
| Shinoura, N | 3 |
| Hashimoto, N | 9 |
| Aoki, T | 8 |
| Asai, A | 2 |
| Abe, T | 3 |
| Asano, K | 1 |
| Shibui, S | 7 |
| Okuno, Y | 1 |
| Wakabayashi, T | 16 |
| Feng, J | 3 |
| Ren, X | 7 |
| Fu, H | 1 |
| Kim, KS | 1 |
| Han, JH | 6 |
| Candido, MF | 1 |
| Baldissera, GC | 1 |
| Medeiros, M | 1 |
| Umezawa, K | 1 |
| Brassesco, MS | 3 |
| Hsu, BH | 1 |
| Lee, WH | 1 |
| Han, CT | 1 |
| Tseng, YY | 2 |
| Gawley, M | 1 |
| Almond, L | 1 |
| Daniel, S | 1 |
| Lastakchi, S | 1 |
| Kaur, S | 1 |
| Detta, A | 1 |
| Cruickshank, G | 2 |
| Hingtgen, S | 1 |
| Sheets, K | 1 |
| McConville, C | 1 |
| Rajesh, Y | 2 |
| Kumar, U | 2 |
| Banerjee, I | 2 |
| Maji, S | 1 |
| Emdad, L | 2 |
| Cavenee, WK | 3 |
| Mandal, M | 2 |
| Fisher, PB | 1 |
| Trippa, L | 1 |
| Alden, S | 1 |
| Fell, G | 1 |
| Abbasi, T | 1 |
| Mundkur, Y | 1 |
| Singh, NK | 1 |
| Talawdekar, A | 1 |
| Husain, Z | 1 |
| Vali, S | 1 |
| Beckenkamp, LR | 2 |
| de Oliveira, FH | 2 |
| Wink, MR | 2 |
| Stefani, MA | 2 |
| Battastini, AMO | 2 |
| Phuphanich, S | 4 |
| De Souza, P | 1 |
| Carleton, M | 1 |
| Taitt, C | 1 |
| Zwirtes, R | 1 |
| Sampson, J | 3 |
| Chi, Y | 1 |
| Wei, Q | 2 |
| Lian, C | 3 |
| Liao, C | 1 |
| Sumorek-Wiadro, J | 1 |
| Zając, A | 1 |
| Bądziul, D | 2 |
| Langner, E | 3 |
| Skalicka-Woźniak, K | 1 |
| Maciejczyk, A | 1 |
| Wertel, I | 3 |
| Rzeski, W | 3 |
| Jakubowicz-Gil, J | 3 |
| Tan, Q | 3 |
| Wu, B | 3 |
| Lyu, J | 1 |
| Tang, C | 3 |
| Hua, W | 2 |
| Hu, S | 3 |
| Saha, D | 2 |
| Rabkin, SD | 2 |
| Martuza, RL | 4 |
| Tan, AC | 1 |
| López, GY | 1 |
| Malinzak, M | 1 |
| Kotecha, R | 3 |
| Tanvejsilp, P | 1 |
| Kanjanapradit, K | 1 |
| Deligne, C | 1 |
| Hachani, J | 1 |
| Duban-Deweer, S | 1 |
| Meignan, S | 1 |
| Leblond, P | 2 |
| Carcaboso, AM | 1 |
| Sano, Y | 1 |
| Shimizu, F | 1 |
| Kanda, T | 1 |
| Gosselet, F | 2 |
| Dehouck, MP | 1 |
| Mysiorek, C | 1 |
| Gui, C | 1 |
| Vannorsdall, TD | 1 |
| Kleinberg, LR | 2 |
| Assadi, R | 1 |
| Moore, JA | 1 |
| Redmond, KJ | 1 |
| Ngo, MT | 2 |
| Karvelis, E | 1 |
| Harley, BAC | 2 |
| Roberts, TA | 1 |
| Hyare, H | 1 |
| Agliardi, G | 1 |
| Hipwell, B | 1 |
| d'Esposito, A | 1 |
| Ianus, A | 1 |
| Breen-Norris, JO | 1 |
| Ramasawmy, R | 1 |
| Taylor, V | 1 |
| Atkinson, D | 1 |
| Punwani, S | 1 |
| Lythgoe, MF | 1 |
| Siow, B | 1 |
| Rees, J | 4 |
| Panagiotaki, E | 1 |
| Alexander, DC | 1 |
| Walker-Samuel, S | 1 |
| Guan, F | 2 |
| Ma, S | 2 |
| Yan, L | 1 |
| He, X | 6 |
| Sheng, J | 1 |
| Yu, W | 1 |
| Qie, S | 2 |
| Ran, Y | 1 |
| Cui, G | 1 |
| Sun, W | 4 |
| Hottinger, AF | 10 |
| Hundsberger, T | 5 |
| Läubli, H | 1 |
| Reinert, M | 1 |
| Mamot, C | 1 |
| Roelcke, U | 4 |
| Pesce, G | 2 |
| Hofer, S | 4 |
| Kinashi, Y | 1 |
| Ikawa, T | 1 |
| Takahashi, S | 1 |
| Topkan, E | 4 |
| Besen, AA | 1 |
| Ozdemir, Y | 2 |
| Kucuk, A | 1 |
| Mertsoylu, H | 3 |
| Pehlivan, B | 3 |
| Selek, U | 2 |
| Kuo, C | 1 |
| Foon, D | 1 |
| Waters, K | 1 |
| Cheung, C | 1 |
| Margol, AS | 1 |
| Ortiz, R | 4 |
| Perazzoli, G | 2 |
| Cabeza, L | 1 |
| Jiménez-Luna, C | 1 |
| Prados, J | 3 |
| Melguizo, C | 3 |
| Bhawe, K | 1 |
| Felty, Q | 1 |
| Yoo, C | 1 |
| Ehtesham, NZ | 1 |
| Hasnain, SE | 1 |
| Singh, VP | 1 |
| Mohapatra, I | 1 |
| Roy, D | 1 |
| Zhu, SH | 1 |
| Xu, HB | 1 |
| Xu, YQ | 1 |
| Kong, PS | 1 |
| Vázquez-Blomquist, D | 1 |
| van der Kaaij, M | 1 |
| Villarreal, A | 1 |
| Bello-Rivero, I | 1 |
| Uram, Ł | 1 |
| Markowicz, J | 1 |
| Misiorek, M | 1 |
| Filipowicz-Rachwał, A | 1 |
| Wołowiec, S | 1 |
| Wałajtys-Rode, E | 1 |
| Feng, Y | 2 |
| Gudbergsson, JM | 1 |
| Christensen, E | 1 |
| Kostrikov, S | 1 |
| Moos, T | 1 |
| Duroux, M | 1 |
| Kjær, A | 1 |
| Johnsen, KB | 1 |
| Andresen, TL | 1 |
| Climans, SA | 1 |
| Cairncross, JG | 18 |
| Ding, K | 1 |
| Fay, M | 3 |
| Laperriere, N | 7 |
| Menten, J | 6 |
| O'Callaghan, CJ | 1 |
| Perry, JR | 11 |
| Roa, W | 3 |
| Winch, C | 1 |
| Wang, LH | 1 |
| Sui, L | 1 |
| Zhao, PH | 1 |
| Ma, HD | 1 |
| Liu, JY | 1 |
| Zhan, ZJ | 1 |
| Wang, YL | 1 |
| Couturier, CP | 1 |
| Ayyadhury, S | 1 |
| Le, PU | 2 |
| Nadaf, J | 1 |
| Monlong, J | 1 |
| Riva, G | 1 |
| Allache, R | 1 |
| Baig, S | 1 |
| Bourgey, M | 1 |
| Lee, C | 4 |
| Wang, YCD | 1 |
| Wee Yong, V | 1 |
| Najafabadi, H | 1 |
| Misic, B | 1 |
| Antel, J | 1 |
| Bourque, G | 1 |
| Ragoussis, J | 1 |
| Xia, Q | 2 |
| Heng, H | 1 |
| Barrascout, E | 1 |
| Lamuraglia, M | 1 |
| Kuo, YJ | 1 |
| Yang, YH | 1 |
| Chen, PC | 1 |
| Wang, TC | 2 |
| Lin, MH | 2 |
| Yang, WH | 2 |
| Cheng, CY | 2 |
| Huang, WC | 2 |
| Lee, MH | 2 |
| Ferri, A | 1 |
| Stagni, V | 1 |
| Barilà, D | 1 |
| Bagherian, A | 1 |
| Mardani, R | 1 |
| Roudi, B | 1 |
| Taghizadeh, M | 1 |
| Banfshe, HR | 1 |
| Ghaderi, A | 1 |
| Davoodvandi, A | 1 |
| Shamollaghamsari, S | 1 |
| Sudlow, CLM | 1 |
| Figueroa, JD | 1 |
| Jaeckle, KA | 8 |
| Ballman, KV | 5 |
| Aldape, KD | 17 |
| Dixon, JG | 1 |
| Anderson, SK | 6 |
| Cerhan, JH | 2 |
| Grossman, SA | 17 |
| Nordstrom, DG | 1 |
| Flynn, PJ | 2 |
| Xiao, L | 4 |
| Mu, Z | 2 |
| Zhang, F | 3 |
| Shukla, A | 2 |
| Srivastava, S | 1 |
| Darokar, J | 1 |
| Henderson, FC | 1 |
| Alshareef, M | 2 |
| Porto, GBF | 2 |
| Kanginakudru, I | 1 |
| Infinger, LK | 2 |
| Vandergrift, WA | 2 |
| Varma, AK | 2 |
| Patel, SJ | 3 |
| Cachia, D | 3 |
| Patel, NV | 1 |
| Khatri, D | 1 |
| D'Amico, R | 1 |
| Abrams, M | 1 |
| Reichman, N | 1 |
| Filippi, CG | 3 |
| Anderson, T | 1 |
| Ratzon, F | 1 |
| Wong, T | 2 |
| Fralin, S | 2 |
| Faltings, L | 1 |
| Langer, DJ | 2 |
| Boockvar, JA | 6 |
| Oh, HC | 1 |
| Lee, JH | 3 |
| Kim, NH | 1 |
| Yook, JI | 2 |
| Kang, DW | 1 |
| Hwang, WC | 1 |
| Noh, YN | 1 |
| Park, KS | 1 |
| Min, DS | 1 |
| Comas, S | 2 |
| Luguera, E | 1 |
| Molero, J | 1 |
| Castañer, S | 1 |
| Hostalot, C | 2 |
| Teixidor, P | 1 |
| Berger, K | 1 |
| Turowski, B | 2 |
| Malzkorn, B | 1 |
| Steiger, HJ | 6 |
| Budach, W | 3 |
| Haussmann, J | 1 |
| Knipps, J | 1 |
| Hänggi, D | 3 |
| Mijderwijk, HJ | 1 |
| Kamp, MA | 3 |
| Oldrini, B | 1 |
| Vaquero-Siguero, N | 1 |
| Kroon, P | 1 |
| Galán-Ganga, M | 1 |
| Rodriguez-Perales, S | 1 |
| Rabadan, R | 2 |
| Squatrito, M | 1 |
| Avci, NG | 1 |
| Ebrahimzadeh-Pustchi, S | 1 |
| Akay, YM | 1 |
| Tandon, N | 2 |
| Akay, M | 1 |
| Uhm, JH | 5 |
| Divekar, RD | 1 |
| Maddox, DE | 1 |
| Lin, JW | 1 |
| Shih, JW | 1 |
| Ono, T | 3 |
| Reinhardt, A | 1 |
| Nanjo, H | 1 |
| Kamataki, A | 1 |
| Shimizu, H | 2 |
| Pinto, F | 1 |
| Costa, ÂM | 2 |
| Andrade, RP | 1 |
| Li, PC | 1 |
| Chen, SY | 2 |
| Xiangfei, D | 1 |
| Mao, C | 1 |
| Wu, CH | 1 |
| Shih, JC | 2 |
| Hotchkiss, KM | 1 |
| Sampson, JH | 21 |
| de Melo, SM | 1 |
| Marta, GN | 1 |
| Cruz, C | 1 |
| Moraes, FY | 1 |
| Riera, R | 1 |
| Chen, WJ | 1 |
| Han, H | 1 |
| Lv, JN | 1 |
| Kang, EM | 1 |
| Zhang, YL | 1 |
| Liu, WP | 1 |
| He, XS | 1 |
| Yu, YB | 1 |
| Tsiailanis, AD | 2 |
| Renziehausen, A | 4 |
| Kiriakidi, S | 1 |
| Vrettos, EI | 1 |
| Markopoulos, GS | 1 |
| Sayyad, N | 1 |
| Hirmiz, B | 1 |
| Aguilar, MI | 1 |
| Del Borgo, MP | 1 |
| Kolettas, E | 1 |
| Widdop, RE | 1 |
| Mavromoustakos, T | 1 |
| Crook, T | 4 |
| Syed, N | 4 |
| Tzakos, AG | 3 |
| Altwairgi, AK | 1 |
| Alghareeb, WA | 1 |
| AlNajjar, FH | 1 |
| Alhussain, H | 1 |
| Alsaeed, E | 1 |
| Balbaid, AAO | 1 |
| Aldanan, S | 1 |
| Orz, Y | 1 |
| Alsharm, AA | 1 |
| Trinh, P | 1 |
| Grant, GA | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 2 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 2 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Bascuñán, J | 2 |
| Chu, Y | 2 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Huang, W | 1 |
| Cui, Y | 8 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 3 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Dong, X | 4 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| Dong, JH | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Tao, H | 1 |
| Lei, Y | 2 |
| Gan, H | 1 |
| Shan, A | 1 |
| Ma, Q | 2 |
| Zhang, E | 1 |
| Xue, F | 1 |
| Yan, Z | 3 |
| Meng, J | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, YS | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Lu, K | 2 |
| Ahmad, NH | 1 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Yao, H | 2 |
| Lee, DF | 1 |
| Wen, L | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Wan, L | 2 |
| Wen, Q | 2 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 2 |
| Su, X | 2 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Lee, HJ | 4 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 2 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 3 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 4 |
| Cheng, J | 2 |
| Kong, X | 2 |
| Yang, T | 3 |
| Dong, Y | 9 |
| Yuan, Z | 2 |
| Cao, J | 2 |
| Mei, Z | 1 |
| Liang, C | 1 |
| Yu, K | 2 |
| Zhu, C | 1 |
| Ge, J | 1 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Rathore, MG | 1 |
| Reddy, K | 6 |
| Shin, SH | 2 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 2 |
| Mu, W | 1 |
| Gao, F | 5 |
| Ji, RY | 1 |
| Hou, Y | 4 |
| Tian, J | 5 |
| Ying, S | 1 |
| Tan, M | 3 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 3 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 2 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 2 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 2 |
| Gupta, A | 2 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 2 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 3 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 2 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 5 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 3 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 3 |
| Luo, T | 2 |
| Su, H | 2 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Karmakar, D | 1 |
| Wu, T | 1 |
| Ye, C | 2 |
| Jiang, F | 2 |
| Yuan, D | 1 |
| Hong, M | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 2 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 2 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Mukhtar, A | 1 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 2 |
| Yu, PL | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Chen, B | 6 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Fei, P | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Gao, R | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 2 |
| Meng, Y | 2 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Cao, T | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 3 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 2 |
| Cao, P | 1 |
| Gu, S | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 2 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 3 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Hou, G | 2 |
| Cui, J | 1 |
| Xie, H | 2 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Cheng, Q | 3 |
| Pan, W | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 2 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Nabi, M | 1 |
| Cai, Y | 2 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Woo, YC | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Minea, RO | 2 |
| Duc, TC | 1 |
| Swenson, SD | 1 |
| Cho, HY | 3 |
| Hartman, H | 1 |
| Hofman, FM | 10 |
| Schönthal, AH | 9 |
| Chen, TC | 15 |
| Zuo, W | 1 |
| Ratner, B | 1 |
| Montaldi, AP | 1 |
| Lima, SCG | 1 |
| Godoy, PRDV | 1 |
| Xavier, DJ | 1 |
| Sakamoto-Hojo, ET | 1 |
| Xiao, K | 1 |
| Xiao, Q | 1 |
| Tu, GXE | 1 |
| Ho, YK | 2 |
| Ng, ZX | 1 |
| Teo, KJ | 1 |
| Yeo, TT | 2 |
| Too, HP | 2 |
| Lu, C | 3 |
| Lyu, X | 1 |
| Athavale, A | 1 |
| Morris, J | 1 |
| Jardine, M | 1 |
| Gallagher, M | 1 |
| Sen, S | 1 |
| Ritchie, A | 1 |
| Wang, AY | 1 |
| Faustino, AC | 1 |
| Viani, GA | 1 |
| Hamamura, AC | 1 |
| Gy, S | 1 |
| Dracham, CB | 1 |
| Dey, T | 1 |
| Khosla, D | 1 |
| Oinum, A | 1 |
| Kapoor, R | 1 |
| Kolodziej, MA | 1 |
| Al Barim, B | 1 |
| Nagl, J | 1 |
| Weigand, MA | 1 |
| Uhl, E | 1 |
| Uhle, F | 1 |
| Di Fazio, P | 1 |
| Schwarm, FP | 1 |
| Nakano, Y | 2 |
| Yamasaki, K | 2 |
| Fukushima, H | 1 |
| Okuhiro, Y | 1 |
| Okada, K | 1 |
| Osugi, Y | 1 |
| Sakamoto, H | 1 |
| Hara, J | 1 |
| Minaei, SE | 1 |
| Ghader, A | 1 |
| Ardakani, AA | 1 |
| Asgari, H | 1 |
| Ara, MHM | 1 |
| Jusue-Torres, I | 2 |
| Hulbert, A | 1 |
| Barton, K | 1 |
| Melian, E | 1 |
| Anderson, DE | 1 |
| Prabhu, VC | 1 |
| Strawderman, MS | 1 |
| Warren, KT | 1 |
| Richardson, M | 1 |
| Serventi, JN | 1 |
| Mohile, NA | 5 |
| Mahiat, C | 1 |
| Capes, A | 1 |
| Duprez, T | 1 |
| Duck, L | 1 |
| Labriola, L | 1 |
| Fuster-Garcia, E | 1 |
| Lorente Estellés, D | 1 |
| Álvarez-Torres, MDM | 1 |
| Juan-Albarracín, J | 1 |
| Chelebian, E | 1 |
| Rovira, A | 1 |
| Acosta, CA | 1 |
| Pineda, J | 1 |
| Oleaga, L | 1 |
| Mollá-Olmos, E | 1 |
| Filice, S | 1 |
| Due-Tønnessen, P | 1 |
| Meling, TR | 2 |
| García-Gómez, JM | 1 |
| Golebiewska, A | 2 |
| Hau, AC | 1 |
| Oudin, A | 1 |
| Stieber, D | 2 |
| Yabo, YA | 1 |
| Baus, V | 1 |
| Barthelemy, V | 1 |
| Klein, E | 1 |
| Bougnaud, S | 1 |
| Keunen, O | 1 |
| Wantz, M | 1 |
| Michelucci, A | 2 |
| Neirinckx, V | 1 |
| Muller, A | 2 |
| Kaoma, T | 1 |
| Nazarov, PV | 2 |
| Azuaje, F | 2 |
| De Falco, A | 1 |
| Flies, B | 1 |
| Richart, L | 1 |
| Poovathingal, S | 2 |
| Arns, T | 1 |
| Grzyb, K | 1 |
| Mock, A | 1 |
| Steino, A | 1 |
| May, P | 1 |
| Malta, TM | 1 |
| Noushmehr, H | 1 |
| Jahn, W | 1 |
| Klink, B | 1 |
| Tanner, G | 1 |
| Mittelbronn, M | 5 |
| Skupin, A | 2 |
| Hertel, F | 2 |
| Niclou, SP | 2 |
| Moon, BS | 1 |
| Cai, M | 1 |
| Lee, G | 4 |
| Giannotta, SL | 1 |
| Yu, M | 5 |
| Gjika, E | 1 |
| Pal-Ghosh, S | 1 |
| Kirschner, ME | 1 |
| Lin, L | 6 |
| Sherman, JH | 3 |
| Stepp, MA | 1 |
| Keidar, M | 1 |
| Jing, J | 1 |
| Saeed, H | 1 |
| Tseng, YD | 1 |
| Bi, CL | 1 |
| Liu, JF | 1 |
| Zhang, MY | 1 |
| Lan, S | 1 |
| Yang, ZY | 1 |
| Fang, JS | 1 |
| Jiang, C | 14 |
| Ni, XR | 1 |
| Guo, CC | 2 |
| Yu, YJ | 1 |
| Yu, ZH | 1 |
| Cai, HP | 1 |
| Wu, WC | 1 |
| Ma, JX | 1 |
| Chen, FR | 2 |
| Chen, ZP | 3 |
| Anselmo, P | 1 |
| Maranzano, E | 2 |
| Selimi, A | 1 |
| Lupattelli, M | 2 |
| Palumbo, I | 1 |
| Bini, V | 1 |
| Casale, M | 1 |
| Trippa, F | 1 |
| Bufi, A | 1 |
| Arcidiacono, F | 1 |
| Aristei, C | 1 |
| Banstola, A | 1 |
| Duwa, R | 1 |
| Emami, F | 1 |
| Jeong, JH | 1 |
| Yook, S | 1 |
| Areeb, Z | 1 |
| Stuart, SF | 1 |
| West, AJ | 1 |
| Gomez, J | 1 |
| Nguyen, HPT | 1 |
| Paradiso, L | 2 |
| Zulkifli, A | 1 |
| Jones, J | 1 |
| Luwor, RB | 3 |
| Yuan, Y | 5 |
| Mendoza, T | 1 |
| Lieberman, F | 6 |
| Robins, HI | 18 |
| Gilbar, PJ | 1 |
| Pokharel, K | 1 |
| Mangos, HM | 1 |
| Lu, VM | 3 |
| Jue, TR | 1 |
| McDonald, KL | 6 |
| Dastghaib, S | 1 |
| Shojaei, S | 2 |
| Mostafavi-Pour, Z | 1 |
| Patterson, JB | 1 |
| Samali, A | 2 |
| Mokarram, P | 1 |
| Ghavami, S | 2 |
| Asik, A | 1 |
| Caglar, HO | 1 |
| Gunduz, C | 1 |
| Król, SK | 1 |
| Bębenek, E | 1 |
| Sławińska-Brych, A | 1 |
| Dmoszyńska-Graniczka, M | 1 |
| Boryczka, S | 1 |
| Stepulak, A | 1 |
| Karakurt, S | 1 |
| Seidel, S | 1 |
| Coch, C | 1 |
| Fimmers, R | 1 |
| Shoji, T | 1 |
| Inoue, J | 1 |
| Osada, Y | 1 |
| Shimoda, Y | 1 |
| Uenohara, H | 1 |
| Masamune, A | 1 |
| Salacz, M | 2 |
| Perry, J | 7 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Iwamoto, F | 4 |
| Placantonakis, D | 1 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Moshel, Y | 1 |
| Piccioni, D | 2 |
| Landolfi, J | 2 |
| Gruber, H | 1 |
| Rao, AR | 1 |
| Hogan, D | 1 |
| Accomando, W | 1 |
| Ostertag, D | 2 |
| Montellano, TT | 1 |
| Kheoh, T | 1 |
| Kabbinavar, F | 1 |
| Hsu, PYH | 1 |
| Folkman, F | 1 |
| de Robles, P | 1 |
| Leckie, C | 1 |
| Dersch-Mills, D | 1 |
| Coppens, R | 1 |
| Chambers, C | 1 |
| Drijver, AJ | 1 |
| Bromberg, JC | 1 |
| Ben Hassel, M | 2 |
| Tzuk-Shina, T | 4 |
| Lucas, A | 1 |
| Freixa, SV | 1 |
| Pépin, LF | 1 |
| Jardin, F | 1 |
| Cheng, H | 1 |
| You, C | 4 |
| Lohmann, P | 2 |
| Shah, NJ | 1 |
| Zimmerman, MA | 1 |
| Wilkison, S | 1 |
| Qi, Q | 1 |
| Li, PA | 1 |
| Xu, D | 1 |
| Núñez, LM | 1 |
| Romero, E | 1 |
| Julià-Sapé, M | 3 |
| Ledesma-Carbayo, MJ | 1 |
| Santos, A | 1 |
| Arús, C | 5 |
| Candiota, AP | 5 |
| Vellido, A | 1 |
| Yan, P | 1 |
| Jia, X | 2 |
| Fei, M | 1 |
| Tang, T | 1 |
| Niu, W | 1 |
| Hanihara, M | 1 |
| Miyake, K | 2 |
| Watanabe, A | 1 |
| Yamada, Y | 3 |
| Oishi, N | 1 |
| Kawataki, T | 1 |
| Inukai, T | 1 |
| Kondo, T | 2 |
| Kinouchi, H | 1 |
| Planeta, K | 1 |
| Setkowicz, Z | 1 |
| Janik-Olchawa, N | 1 |
| Matusiak, K | 1 |
| Ryszawy, D | 1 |
| Drozdz, A | 1 |
| Janeczko, K | 1 |
| Ostachowicz, B | 1 |
| Chwiej, J | 1 |
| Ironside, SA | 1 |
| Detsky, J | 1 |
| Bale, TA | 1 |
| Sait, SF | 1 |
| Benhamida, J | 1 |
| Ptashkin, R | 1 |
| Haque, S | 1 |
| Villafania, L | 1 |
| Sill, M | 1 |
| Sadowska, J | 1 |
| Akhtar, RB | 1 |
| Liechty, B | 1 |
| Juthani, R | 1 |
| Ladanyi, M | 1 |
| Karajannis, MA | 1 |
| Rosenblum, MK | 6 |
| Papageorgiou, GI | 1 |
| Tsakatikas, SA | 1 |
| Fioretzaki, RG | 1 |
| Kosmas, C | 2 |
| Calero-Pérez, P | 1 |
| Malik, D | 1 |
| Akimoto, J | 4 |
| Chao, CN | 1 |
| Lin, HP | 1 |
| Huang, HY | 1 |
| Fang, CY | 1 |
| Kashyap, L | 1 |
| Bakhshi, S | 1 |
| Rocha, CRR | 1 |
| Reily Rocha, A | 1 |
| Molina Silva, M | 1 |
| Rodrigues Gomes, L | 1 |
| Teatin Latancia, M | 1 |
| Andrade Tomaz, M | 1 |
| de Souza, I | 1 |
| Karolynne Seregni Monteiro, L | 1 |
| Menck, CFM | 1 |
| Patrizz, A | 1 |
| Zorofchian, S | 1 |
| Hines, G | 1 |
| Husein, N | 1 |
| Arevalo, O | 1 |
| Choi, HA | 1 |
| Savarraj, J | 1 |
| Ganesh, BP | 1 |
| Kaur, B | 4 |
| McCullough, LD | 1 |
| Kim, HM | 1 |
| Lee, SH | 15 |
| Lim, J | 2 |
| Toms, S | 1 |
| Robison, J | 1 |
| Mohler, A | 1 |
| Carcieri, A | 1 |
| Cielo, D | 2 |
| Donnelly, J | 1 |
| Disano, D | 1 |
| Vatketich, J | 1 |
| Baekey, J | 1 |
| Sturtevant, A | 1 |
| MacKinnon, K | 1 |
| Wood, R | 1 |
| Safran, H | 2 |
| Riva, M | 1 |
| Wouters, R | 1 |
| Sterpin, E | 1 |
| Giovannoni, R | 1 |
| Boon, L | 1 |
| Himmelreich, U | 1 |
| Gsell, W | 1 |
| Van Ranst, M | 1 |
| Coosemans, A | 1 |
| Wood, MD | 1 |
| Neff, T | 1 |
| Nickerson, JP | 1 |
| Sayama, C | 1 |
| Raslan, AM | 1 |
| Ambady, P | 1 |
| Corless, CL | 1 |
| Nazemi, KJ | 1 |
| Saeed, MEM | 1 |
| Kadioglu, O | 1 |
| Greten, HJ | 1 |
| Yildirim, A | 1 |
| Mayr, K | 1 |
| Wenz, F | 5 |
| Efferth, T | 3 |
| Amini, A | 2 |
| Dandapani, S | 1 |
| Adolph, JE | 1 |
| Fleischhack, G | 1 |
| Mikasch, R | 1 |
| Zeller, J | 1 |
| Warmuth-Metz, M | 2 |
| Bison, B | 2 |
| Mynarek, M | 1 |
| Rutkowski, S | 2 |
| von Hoff, K | 1 |
| Obrecht, D | 1 |
| Pfister, SM | 3 |
| Witt, O | 1 |
| Witt, H | 1 |
| Kortmann, RD | 6 |
| Timmermann, B | 1 |
| Krauß, J | 1 |
| Frühwald, MC | 1 |
| Faldum, A | 1 |
| Kwiecien, R | 1 |
| Bode, U | 1 |
| Tippelt, S | 1 |
| Lucidi, S | 1 |
| Maragna, V | 1 |
| Teriaca, MA | 1 |
| Ganovelli, M | 1 |
| Desideri, I | 1 |
| Lorenzetti, V | 1 |
| Scoccimarro, E | 1 |
| Greto, D | 2 |
| Livi, L | 3 |
| Pu, Y | 2 |
| Dai, N | 1 |
| Seidlitz, A | 2 |
| Beuthien-Baumann, B | 2 |
| Löck, S | 1 |
| Jentsch, C | 2 |
| Platzek, I | 2 |
| Zöphel, K | 1 |
| Linge, A | 1 |
| Kotzerke, J | 1 |
| Petr, J | 2 |
| van den Hoff, J | 2 |
| Schmitz-Schackert, G | 1 |
| Falk, M | 1 |
| Baumann, M | 2 |
| Krause, M | 2 |
| White, ML | 1 |
| Kazmi, SAJ | 1 |
| Aizenberg, M | 1 |
| Shonka, N | 2 |
| Yu, F | 3 |
| Appiah, AK | 1 |
| Ge, X | 3 |
| Yu, C | 3 |
| Farshchian, M | 1 |
| Bardhi, R | 1 |
| Daveluy, S | 1 |
| Park, HH | 2 |
| Oprita, A | 1 |
| Baloi, SC | 1 |
| Staicu, GA | 1 |
| Alexandru, O | 1 |
| Tache, DE | 1 |
| Danoiu, S | 1 |
| Micu, ES | 1 |
| Sevastre, AS | 1 |
| Ren, C | 1 |
| Wang, CY | 2 |
| Kamson, DO | 1 |
| Toor, H | 1 |
| Savla, P | 1 |
| Podkovik, S | 1 |
| Patchana, T | 1 |
| Ghanchi, H | 1 |
| Kashyap, S | 1 |
| Tashjian, V | 1 |
| Miulli, D | 1 |
| Abbaszade, Z | 1 |
| Bagca, BG | 1 |
| Avci, CB | 1 |
| Okamura, R | 1 |
| Boichard, A | 1 |
| Lee, S | 1 |
| Jimenez, RE | 1 |
| Sicklick, JK | 1 |
| Kato, S | 2 |
| Kurzrock, R | 1 |
| Cheng, CL | 1 |
| Chan, MH | 1 |
| Feng, SJ | 1 |
| Hsiao, M | 1 |
| Liu, RS | 2 |
| Inoue, M | 1 |
| Ichikawa, T | 1 |
| Kurozumi, K | 1 |
| Matsumoto, Y | 1 |
| Nakamoto, Y | 1 |
| Akiyoshi, H | 1 |
| Kamishina, H | 1 |
| Yuan, Q | 2 |
| Zuo, M | 3 |
| Xia, X | 4 |
| Zhou, Q | 6 |
| Vaidya, KS | 1 |
| Mitten, MJ | 1 |
| Zelaya-Lazo, AL | 1 |
| Oleksijew, A | 1 |
| Alvey, C | 1 |
| Falls, HD | 1 |
| Mishra, S | 1 |
| Palma, J | 1 |
| Phillips, AC | 1 |
| Reilly, EB | 1 |
| Anderson, M | 1 |
| Boghaert, ER | 1 |
| Esteyrie, V | 1 |
| Martin, E | 1 |
| Bronniman, C | 1 |
| Pouessel, D | 1 |
| Ciron, DL | 1 |
| Moyal, EC | 1 |
| Network, P | 1 |
| Steidl, E | 1 |
| Wagner, M | 1 |
| Divé, I | 1 |
| Musiał-Kulik, M | 1 |
| Włodarczyk, J | 1 |
| Stojko, M | 1 |
| Karpeta-Jarząbek, P | 1 |
| Pastusiak, M | 1 |
| Janeczek, H | 1 |
| Kasperczyk, J | 1 |
| Day, EK | 1 |
| Zhong, Q | 1 |
| Purow, B | 1 |
| Lazzara, MJ | 1 |
| Benouaich-Amiel, A | 7 |
| Khasminsky, V | 1 |
| Gal, O | 1 |
| Weiss, T | 3 |
| Fichman, S | 1 |
| Kanner, AA | 4 |
| Berkowitz, S | 1 |
| Laviv, Y | 1 |
| Mandel, J | 1 |
| Dudnik, E | 1 |
| Siegal, T | 4 |
| Yust-Katz, S | 1 |
| Munisamy, M | 1 |
| Munisamy, S | 1 |
| Kumar, JP | 1 |
| Jose, A | 1 |
| Thomas, L | 1 |
| Baburaj, G | 1 |
| Subbiah, V | 1 |
| Fu, X | 1 |
| Xiang, P | 2 |
| Fan, T | 1 |
| Shi, J | 3 |
| Jiang, Q | 2 |
| Doherty, GJ | 1 |
| de Paula, BHR | 1 |
| Twelves, C | 1 |
| Checketts, D | 1 |
| Miller, S | 1 |
| Tayo, B | 1 |
| Jove, M | 1 |
| Brazil, L | 1 |
| Wu, F | 3 |
| Gramatzki, D | 5 |
| Hentschel, B | 4 |
| Wolter, M | 1 |
| Schackert, G | 6 |
| Westphal, M | 8 |
| Regli, L | 5 |
| Tatagiba, M | 2 |
| Suresh, MP | 1 |
| Rushing, EJ | 2 |
| Yang, ZJ | 1 |
| Zhang, LL | 1 |
| Bi, QC | 1 |
| Gan, LJ | 1 |
| Wei, MJ | 1 |
| Hong, T | 1 |
| Tan, RJ | 1 |
| Lan, XM | 1 |
| Liu, LH | 1 |
| Han, XJ | 1 |
| Jiang, LP | 1 |
| De La Rosa, J | 1 |
| Urdiciain, A | 2 |
| Zelaya, MV | 1 |
| Zazpe, I | 1 |
| Meléndez, B | 2 |
| Rey, JA | 3 |
| Idoate, MA | 4 |
| Butt, NS | 1 |
| Alghamdi, B | 1 |
| Maghrabi, Y | 1 |
| Bardeesi, A | 1 |
| Saeedi, R | 1 |
| Dallol, A | 1 |
| Mohamed, F | 1 |
| Bari, MO | 1 |
| Samkari, A | 1 |
| Lary, AI | 1 |
| Siller, S | 1 |
| Lauseker, M | 1 |
| Karschnia, P | 2 |
| Eigenbrod, S | 5 |
| Giese, A | 8 |
| Wielgat, P | 1 |
| Wawrusiewicz-Kurylonek, N | 1 |
| Czarnomysy, R | 1 |
| Rogowski, K | 1 |
| Bielawski, K | 1 |
| Car, H | 1 |
| Sweldens, C | 1 |
| Qu, C | 1 |
| Wei, J | 4 |
| Meng, L | 4 |
| Xin, Y | 5 |
| Dong, L | 3 |
| Trifiletti, DM | 2 |
| Chan, AA | 1 |
| Voce, DJ | 3 |
| Bernal, GM | 4 |
| Cahill, KE | 4 |
| Mansour, N | 2 |
| Crawley, CD | 2 |
| Campbell, PS | 1 |
| Arina, A | 1 |
| Weichselbaum, RR | 6 |
| Yamini, B | 6 |
| Kernohan, A | 1 |
| Robinson, T | 1 |
| Howell, A | 1 |
| Vale, L | 1 |
| Pellecchia, S | 1 |
| De Martino, M | 1 |
| Esposito, F | 1 |
| Quintavalle, C | 1 |
| Fusco, A | 2 |
| Pallante, P | 1 |
| Gao, Q | 1 |
| Ye, F | 1 |
| Fulbert, C | 1 |
| Chabardès, S | 1 |
| Ratel, D | 1 |
| Efremov, L | 1 |
| Abera, SF | 1 |
| Bedir, A | 1 |
| Vordermark, D | 1 |
| Medenwald, D | 1 |
| Rosas-Alonso, R | 1 |
| Colmenarejo-Fernandez, J | 1 |
| Pernia, O | 1 |
| Rodriguez-Antolín, C | 1 |
| Esteban, I | 1 |
| Ghanem, I | 1 |
| Sanchez-Cabrero, D | 1 |
| Losantos-Garcia, I | 1 |
| Palacios-Zambrano, S | 1 |
| Moreno-Bueno, G | 1 |
| de Castro, J | 1 |
| Martinez-Marin, V | 1 |
| Ibanez-de-Caceres, I | 1 |
| Menyhárt, O | 1 |
| Fekete, JT | 1 |
| Győrffy, B | 1 |
| Amen, AM | 1 |
| Soczek, KM | 1 |
| Ren, SM | 1 |
| Knott, GJ | 1 |
| McKinney, AM | 1 |
| Mancini, A | 1 |
| Khan, MB | 1 |
| Ruggieri, R | 2 |
| Jamil, E | 1 |
| Gonzalez, C | 1 |
| Mugridge, N | 1 |
| MacDiarmid, J | 1 |
| Brahmbhatt, H | 1 |
| Boockvar, J | 2 |
| Symons, M | 2 |
| Pafundi, D | 1 |
| Kaufmann, T | 1 |
| Lowe, V | 1 |
| Hunt, C | 1 |
| Vogen, D | 1 |
| Yan, E | 1 |
| Sarkaria, J | 1 |
| Brown, P | 3 |
| Kizilbash, S | 1 |
| Uhm, J | 1 |
| Ruff, M | 1 |
| Zakhary, M | 1 |
| Seaberg, M | 1 |
| Wan Chan Tseung, HS | 1 |
| Kabat, B | 1 |
| Kemp, B | 1 |
| Brinkmann, D | 1 |
| Long Priel, DA | 1 |
| Fink, D | 1 |
| Sissung, TM | 1 |
| Pang, Y | 1 |
| Yu, G | 2 |
| Butler, MK | 1 |
| Ahmad, S | 1 |
| Bryla, C | 1 |
| Lindsley, M | 1 |
| Grajkowska, E | 1 |
| Mentges, K | 1 |
| Boris, L | 1 |
| Antony, R | 1 |
| Garren, N | 1 |
| Siegel, C | 1 |
| Lollo, N | 1 |
| Cordova, C | 1 |
| Aboud, O | 1 |
| Theeler, BJ | 1 |
| Burton, EM | 1 |
| Penas-Prado, M | 5 |
| Leeper, H | 1 |
| Gonzales, J | 1 |
| Calvo, KR | 1 |
| Kuhns, DB | 1 |
| Gallin, JI | 1 |
| Yuan, SW | 1 |
| Song, YY | 1 |
| Hameed, NUF | 1 |
| Zhuang, DX | 1 |
| Lu, JF | 1 |
| Gong, FY | 1 |
| Aibaidula, A | 1 |
| Shi, ZF | 1 |
| Guo, QH | 1 |
| Wu, JS | 1 |
| Mahinfar, P | 1 |
| Davoudian, S | 1 |
| Vahidian, F | 1 |
| Cho, WC | 1 |
| Mansoori, B | 1 |
| Caylioglu, D | 1 |
| Meyer, RJ | 1 |
| Villamañan, L | 1 |
| Martínez-Escardó, L | 1 |
| Yuste, VJ | 1 |
| Villanueva-Meyer, J | 1 |
| Hilz, S | 1 |
| Solomon, DA | 2 |
| Choi, S | 3 |
| Wahl, M | 3 |
| Mazor, T | 3 |
| Shai, A | 1 |
| Wainer, BH | 1 |
| McDermott, M | 1 |
| Clarke, JL | 8 |
| Oberheim Bush, NA | 1 |
| Xing, B | 2 |
| Kaneda, MM | 1 |
| Shepard, RM | 1 |
| Patel, K | 1 |
| Sarver, A | 1 |
| Furnari, F | 2 |
| Dhawan, S | 1 |
| Wu, A | 5 |
| You, G | 3 |
| Venteicher, AS | 1 |
| Glass, CK | 1 |
| Varner, JA | 1 |
| Atashi, F | 2 |
| Saathoff, MR | 1 |
| Park, CH | 2 |
| Horbinski, CM | 3 |
| Cheng, HS | 1 |
| Marvalim, C | 1 |
| Law, CLD | 1 |
| Low, ZYJ | 1 |
| Chong, YK | 1 |
| Ang, BT | 2 |
| Tan, NS | 1 |
| Randles, A | 1 |
| Wirsching, HG | 2 |
| Dean, JA | 1 |
| Cheng, YK | 1 |
| Emerson, S | 1 |
| Pattwell, SS | 1 |
| Holland, EC | 5 |
| Michor, F | 1 |
| Geng, W | 1 |
| Zou, H | 1 |
| Dai, Y | 1 |
| Ding, X | 1 |
| Li, XC | 1 |
| Wu, BS | 1 |
| Wang, ZF | 2 |
| Ma, C | 3 |
| Li, YR | 1 |
| Jin, XQ | 1 |
| Li, ZQ | 2 |
| Lietke, S | 1 |
| Majchrzak-Celińska, A | 1 |
| Misiorek, JO | 1 |
| Kruhlenia, N | 1 |
| Przybyl, L | 1 |
| Kleszcz, R | 1 |
| Rolle, K | 1 |
| Krajka-Kuźniak, V | 1 |
| Baues, C | 1 |
| Celik, E | 1 |
| Marnitz, S | 1 |
| Gielen, GH | 2 |
| Babu, D | 1 |
| Mudiraj, A | 1 |
| Yadav, N | 1 |
| Y B V K, C | 1 |
| Panigrahi, M | 1 |
| Prakash Babu, P | 1 |
| Lin, S | 3 |
| Zang, L | 1 |
| Che, F | 1 |
| You, H | 1 |
| Lin, Z | 2 |
| Lin, Y | 5 |
| Lwin, Z | 8 |
| Barnes, EH | 1 |
| Rosenthal, M | 1 |
| Foote, MC | 1 |
| Koh, ES | 1 |
| Back, M | 8 |
| Buckland, ME | 1 |
| Fisher, L | 1 |
| Leonard, R | 1 |
| Hall, M | 1 |
| Yip, S | 3 |
| Simes, J | 4 |
| Filppu, P | 1 |
| Tanjore Ramanathan, J | 1 |
| Granberg, KJ | 2 |
| Gucciardo, E | 1 |
| Lehti, K | 1 |
| Le Joncour, V | 1 |
| Laakkonen, P | 1 |
| Singh, R | 2 |
| Lehrer, EJ | 1 |
| Zaorsky, NG | 1 |
| Bovi, J | 1 |
| Zhai, X | 5 |
| Li, LS | 1 |
| Zhou, YD | 1 |
| Ji, WY | 1 |
| Xiao, H | 3 |
| Oronsky, B | 1 |
| Reid, T | 1 |
| Cabrales, P | 1 |
| Romero, D | 1 |
| Si, J | 1 |
| Cao, L | 1 |
| Wei, D | 1 |
| Lee, T | 1 |
| Mandl, HK | 1 |
| Piotrowski-Daspit, AS | 1 |
| Josowitz, A | 1 |
| Mark Saltzman, W | 1 |
| Lozinski, M | 1 |
| Bowden, NA | 1 |
| Graves, MC | 1 |
| Tooney, PA | 1 |
| Feng, W | 2 |
| Hwang, JH | 1 |
| Juric, V | 1 |
| Düssmann, H | 1 |
| Rehm, M | 4 |
| Murphy, BM | 3 |
| Kong, Z | 1 |
| Yang, TC | 1 |
| Liu, SJ | 1 |
| Lo, WL | 1 |
| Chen, SM | 1 |
| Tang, YL | 1 |
| Cheng, HW | 1 |
| Huang, CH | 1 |
| Wang, HT | 1 |
| Xing, R | 1 |
| Guan, J | 3 |
| Ayyagari, P | 1 |
| Shannon, HE | 3 |
| Reich, TR | 1 |
| Schwarzenbach, C | 1 |
| Vilar, JB | 1 |
| Unger, S | 1 |
| Mühlhäusler, F | 1 |
| Nikolova, T | 2 |
| Poplawski, A | 1 |
| Baymaz, HI | 1 |
| Beli, P | 1 |
| Christmann, M | 4 |
| Tomicic, MT | 2 |
| Castro, M | 1 |
| Pampana, A | 1 |
| Alam, A | 1 |
| Parashar, R | 1 |
| Rajagopalan, S | 1 |
| Lala, DA | 1 |
| Roy, KGG | 1 |
| Basu, S | 1 |
| Prakash, A | 1 |
| Nair, P | 1 |
| Joseph, V | 1 |
| Agarwal, A | 3 |
| G, P | 1 |
| Behura, L | 1 |
| Kulkarni, S | 1 |
| Choudhary, NR | 1 |
| Kapoor, S | 1 |
| Kosel, ML | 3 |
| Oberg, AL | 1 |
| Gao, K | 1 |
| Qiao, Y | 1 |
| Cui, B | 2 |
| Jiao, Y | 2 |
| Luo, W | 3 |
| Inoue, A | 1 |
| Nishikawa, M | 1 |
| Ohnishi, T | 1 |
| Kanemura, Y | 4 |
| Ohtsuka, Y | 1 |
| Ozaki, S | 1 |
| Nakamura, Y | 1 |
| Matsumoto, S | 1 |
| Suehiro, S | 2 |
| Yamashita, D | 2 |
| Shigekawa, S | 1 |
| Watanabe, H | 1 |
| Kitazawa, R | 1 |
| Tanaka, J | 1 |
| Kunieda, T | 2 |
| Xi, X | 1 |
| Kan, R | 1 |
| Liao, KH | 1 |
| Chen, GY | 1 |
| Hung, CY | 1 |
| Pinheiro, L | 1 |
| Perdomo-Pantoja, A | 1 |
| Casaos, J | 2 |
| Huq, S | 1 |
| Paldor, I | 1 |
| Vigilar, V | 1 |
| Witham, TF | 1 |
| Mir, T | 1 |
| Pond, G | 1 |
| Greenspoon, JN | 1 |
| Zheng, Z | 2 |
| Yasaswi, PS | 1 |
| Shetty, K | 1 |
| Yadav, KS | 1 |
| Talele, S | 1 |
| Pokorny, JL | 2 |
| Bakken, KK | 2 |
| Gampa, G | 1 |
| Schmitt-Hoffmann, A | 1 |
| Bachmann, F | 2 |
| McSheehy, P | 2 |
| Lane, HA | 2 |
| Elmquist, WF | 1 |
| Ahn, GS | 1 |
| Hwang, K | 1 |
| Jung, TY | 6 |
| Yoo, H | 3 |
| Kim, EY | 2 |
| Lee, DE | 1 |
| Joo, J | 1 |
| Choi, BS | 1 |
| Anand, S | 1 |
| Panda, P | 1 |
| Moiyadi, A | 3 |
| Krishnatry, R | 2 |
| Jalali, R | 8 |
| Kuang, W | 1 |
| Jiang, W | 1 |
| Xue, BZ | 1 |
| Wang, HF | 1 |
| Zhou, YJ | 1 |
| Abdelmaksou, A | 1 |
| Xue, J | 1 |
| Sun, MX | 1 |
| Yi, DY | 1 |
| Xiong, NX | 1 |
| Jiang, XB | 2 |
| Zhao, HY | 1 |
| Fu, P | 1 |
| Ozaki, K | 1 |
| Hara, A | 1 |
| Yamaki, T | 1 |
| Matsutani, T | 1 |
| Miao, YB | 1 |
| Chen, KH | 1 |
| Chen, CT | 1 |
| Mi, FL | 1 |
| Chiang, CS | 2 |
| Wang, JT | 1 |
| Lin, KJ | 1 |
| Sung, HW | 1 |
| Campos-Sandoval, JA | 1 |
| Gómez-García, MC | 1 |
| Santos-Jiménez, JL | 1 |
| Matés, JM | 1 |
| Alonso, FJ | 1 |
| Márquez, J | 1 |
| Gan, W | 1 |
| Karami, A | 1 |
| Hossienpour, M | 1 |
| Mohammadi Noori, E | 1 |
| Rahpyma, M | 1 |
| Najafi, K | 1 |
| Kiani, A | 1 |
| Hernandez, A | 1 |
| Kresbach, C | 1 |
| Bronsema, A | 1 |
| Guerreiro, H | 1 |
| Winkler, B | 1 |
| Besiroglu, M | 1 |
| Demir, T | 1 |
| Shbair, ATM | 1 |
| Yasin, AI | 1 |
| Topcu, A | 1 |
| Turk, HM | 1 |
| Yonezawa, H | 2 |
| Funakoshi, Y | 1 |
| Otsuji, R | 1 |
| Sako, A | 1 |
| Yoshiura, T | 1 |
| Caja, L | 1 |
| Dadras, MS | 1 |
| Mezheyeuski, A | 1 |
| Rodrigues-Junior, DM | 1 |
| Webb, AT | 1 |
| Gomez-Puerto, MC | 1 |
| Ten Dijke, P | 1 |
| Heldin, CH | 1 |
| Moustakas, A | 1 |
| Verma, V | 2 |
| Mohania, D | 1 |
| Babbar, AK | 1 |
| Rathi, B | 1 |
| Dhanda, RS | 1 |
| Yadav, M | 1 |
| Sun, S | 9 |
| Li, XD | 1 |
| Wang, MJ | 1 |
| Zheng, JL | 1 |
| Wu, YH | 1 |
| Genoud, V | 1 |
| Espinoza, FI | 1 |
| Marinari, E | 1 |
| Rochemont, V | 1 |
| Dietrich, PY | 10 |
| Walker, PR | 1 |
| Behrooz, AB | 1 |
| Vazifehmand, R | 1 |
| Tajudin, AA | 1 |
| Masarudin, MJ | 1 |
| Sekawi, Z | 1 |
| Masomian, M | 1 |
| Syahir, A | 1 |
| Han, W | 1 |
| Qian, Z | 2 |
| Salama, S | 1 |
| Sharaf, M | 1 |
| Salem, SM | 1 |
| Rasheed, MA | 1 |
| Salama, E | 1 |
| Elnahas, T | 1 |
| Lotfy, R | 1 |
| Zhong, X | 1 |
| Dai, L | 1 |
| Madhusudhan, T | 1 |
| Qu, X | 3 |
| Guo, K | 1 |
| Dou, W | 1 |
| Feng, L | 2 |
| Martins, ICA | 1 |
| Contieri, LS | 1 |
| Amaral, CL | 1 |
| Costa, SO | 1 |
| Souza, ACP | 1 |
| Ignacio-Souza, LM | 1 |
| Milanski, M | 1 |
| Torsoni, AS | 1 |
| Torsoni, MA | 1 |
| Braverman, V | 1 |
| Drineas, P | 1 |
| Musco, C | 2 |
| Upadhyay, J | 1 |
| Woodruff, DP | 1 |
| Thurnherr, E | 1 |
| Meaney, CJ | 1 |
| Fusco, NM | 1 |
| Schultz, K | 1 |
| Enterline, L | 1 |
| Igboechi, O | 1 |
| Brahmbhatt, P | 1 |
| Hinkley, J | 1 |
| Clement, C | 1 |
| Harris, SN | 1 |
| Ortolan, SC | 1 |
| Edmonds, CR | 1 |
| Fields, KG | 1 |
| Liguori, GA | 1 |
| Galal, S | 2 |
| Shin, J | 1 |
| Principe, P | 1 |
| Mehta, R | 1 |
| Khabyeh-Hasbani, N | 1 |
| Hamilton, A | 1 |
| Fragomen, A | 1 |
| Rozbruch, SR | 1 |
| Ashouri-Sanjani, M | 1 |
| Mohammadi-Moghadam, S | 1 |
| Azimi, P | 1 |
| Arjmand, N | 1 |
| Lamplot, JD | 1 |
| Premkumar, A | 1 |
| James, EW | 1 |
| Lawton, CD | 1 |
| Pearle, AD | 1 |
| Tsakatikas, S | 1 |
| Papageorgiou, G | 1 |
| Fioretzaki, R | 1 |
| Gautam, M | 1 |
| Gabrani, R | 1 |
| Fu, T | 1 |
| Sun, R | 2 |
| I-H Park, T | 1 |
| Guerriero, C | 1 |
| Matera, C | 1 |
| Del Bufalo, D | 1 |
| De Amici, M | 1 |
| Conti, L | 1 |
| Dallanoce, C | 1 |
| Tata, AM | 1 |
| Press, RH | 1 |
| Chhabra, AM | 1 |
| Choi, JI | 1 |
| Hasan, S | 1 |
| Garg, M | 1 |
| Lazarev, S | 1 |
| Yang, TJ | 1 |
| Yamada, J | 1 |
| Simone, CB | 1 |
| Schöttler, U | 1 |
| Krishna, S | 1 |
| Schmiedek, P | 2 |
| Fedrigo, CA | 1 |
| Brands, E | 1 |
| Dik, R | 1 |
| Stalpers, LJ | 4 |
| Westerman, BA | 1 |
| Peters, GJ | 1 |
| Huang, BS | 1 |
| Luo, QZ | 1 |
| Han, Y | 6 |
| Huang, D | 2 |
| Tang, QP | 1 |
| Wu, LX | 1 |
| Lu, IL | 1 |
| Chiang, WH | 1 |
| Lin, YW | 1 |
| Tsai, YC | 1 |
| Chen, HH | 2 |
| Chang, CW | 1 |
| Chiu, HC | 1 |
| Cheng, W | 2 |
| Khazaei, M | 1 |
| Pazhouhi, M | 1 |
| Tie, X | 1 |
| Xia, J | 1 |
| Carroll, KT | 1 |
| Hirshman, B | 1 |
| Ali, MA | 1 |
| Alattar, AA | 1 |
| Brandel, MG | 2 |
| Lochte, B | 1 |
| Lanman, T | 1 |
| Carter, B | 2 |
| Ye, X | 17 |
| Supko, JG | 3 |
| Desai, AS | 1 |
| Read, WL | 1 |
| Lieberman, FS | 6 |
| Lodge, MA | 1 |
| Leal, J | 1 |
| Fisher, JD | 2 |
| Desideri, S | 9 |
| Wahl, RL | 1 |
| Blumenthal, DT | 8 |
| Kim, MM | 5 |
| Burt Nabors, L | 1 |
| Hyun Nam, D | 1 |
| Corn, BW | 3 |
| Mirimanoff, RO | 13 |
| Sita, TL | 1 |
| Kouri, FM | 2 |
| Hurley, LA | 1 |
| Merkel, TJ | 1 |
| Chalastanis, A | 1 |
| May, JL | 1 |
| Ghelfi, ST | 1 |
| Cole, LE | 1 |
| Cayton, TC | 1 |
| Barnaby, SN | 1 |
| Sprangers, AJ | 1 |
| Savalia, N | 1 |
| Mirkin, CA | 1 |
| Stegh, AH | 2 |
| Sun, P | 1 |
| Lv, M | 1 |
| Tong, G | 1 |
| Jin, X | 3 |
| Russell, L | 1 |
| Bolyard, C | 1 |
| Banasavadi-Siddegowda, Y | 2 |
| Weiss, A | 1 |
| Shakya, R | 1 |
| Powell, K | 1 |
| Ning, B | 2 |
| Fang, Y | 2 |
| Foro Arnalot, P | 1 |
| Pera, O | 1 |
| Rodriguez, N | 1 |
| Sanz, X | 1 |
| Reig, A | 1 |
| Membrive, I | 1 |
| Ortiz, A | 1 |
| Granados, R | 1 |
| Algara, M | 1 |
| Ram, Z | 4 |
| Matias, D | 3 |
| Balça-Silva, J | 2 |
| Dubois, LG | 1 |
| Pontes, B | 2 |
| Ferrer, VP | 1 |
| Rosário, L | 1 |
| do Carmo, A | 2 |
| Echevarria-Lima, J | 1 |
| Sarmento-Ribeiro, AB | 2 |
| Lopes, MC | 2 |
| Moura-Neto, V | 3 |
| Коbylinska, LI | 1 |
| Klyuchivska, OY | 1 |
| Grytsyna, II | 1 |
| Finiuk, N | 2 |
| Panchuk, RR | 1 |
| Starykovych, MO | 1 |
| Lehka, L | 1 |
| Lesyk, RB | 1 |
| Zіmenkovsky, BS | 1 |
| Stoika, RS | 1 |
| Wang, HW | 3 |
| Xu, ZK | 1 |
| Liu, YG | 1 |
| Shen, HY | 1 |
| Weil, S | 1 |
| Osswald, M | 2 |
| Solecki, G | 1 |
| Grosch, J | 1 |
| Jung, E | 1 |
| Lemke, D | 2 |
| Ratliff, M | 1 |
| Winkler, F | 8 |
| Furuta, T | 4 |
| Sabit, H | 2 |
| Uchiyama, N | 1 |
| Hayashi, Y | 6 |
| Minamoto, T | 2 |
| Sullivan, KE | 1 |
| Rojas, K | 1 |
| Cerione, RA | 1 |
| Nakano, I | 4 |
| Wilson, KF | 1 |
| Liu, N | 6 |
| Silginer, M | 4 |
| Ouyang, L | 1 |
| Cai, W | 2 |
| Tu, Y | 2 |
| Pi, R | 1 |
| Tokuda, Y | 2 |
| Ohara, K | 2 |
| Saito, T | 4 |
| Takeshima, Y | 1 |
| Amatya, VJ | 1 |
| Nosaka, R | 4 |
| Kawamata, T | 4 |
| Banelli, B | 2 |
| Daga, A | 2 |
| Forlani, A | 2 |
| Allemanni, G | 2 |
| Marubbi, D | 2 |
| Pistillo, MP | 1 |
| Profumo, A | 1 |
| Romani, M | 2 |
| Emery, IF | 1 |
| Gopalan, A | 1 |
| Wood, S | 1 |
| Battelli, C | 1 |
| George, J | 1 |
| Blaszyk, H | 1 |
| Florman, J | 1 |
| Baernreuther, J | 1 |
| Bolukbasi, FH | 1 |
| Ekmekci, CG | 1 |
| Yenmis, G | 1 |
| Sav, A | 2 |
| Yu, Q | 2 |
| Xue, Y | 4 |
| Egeland, M | 1 |
| Guinaudie, C | 1 |
| Du Preez, A | 1 |
| Musaelyan, K | 1 |
| Zunszain, PA | 1 |
| Fernandes, C | 1 |
| Pariante, CM | 1 |
| Thuret, S | 1 |
| Lan, T | 2 |
| Zhan, Q | 3 |
| Ming, J | 2 |
| Han, B | 4 |
| Wu, P | 3 |
| Oliva, CR | 1 |
| Suto, MJ | 1 |
| Griguer, CE | 2 |
| Thomas, AA | 4 |
| Abrey, LE | 20 |
| Terziev, R | 1 |
| Raizer, J | 5 |
| Paleologos, N | 3 |
| Matasar, M | 1 |
| Sauter, CS | 1 |
| Moskowitz, C | 1 |
| Nimer, SD | 1 |
| DeAngelis, LM | 17 |
| Kaley, T | 2 |
| Louis, DN | 10 |
| Briggs, S | 1 |
| Faivre, G | 2 |
| Mehta, J | 1 |
| Jonsson, P | 1 |
| Chakravarty, D | 1 |
| Schultz, N | 1 |
| Brennan, CW | 3 |
| Alter, RA | 2 |
| White, TG | 1 |
| Fanous, AA | 1 |
| Pisapia, DJ | 1 |
| Tsiouris, AJ | 1 |
| Flanigan, PM | 1 |
| Jahangiri, A | 1 |
| Kuang, R | 1 |
| Truong, A | 1 |
| Chou, A | 1 |
| McDermott, MW | 4 |
| Aghi, MK | 1 |
| Liu, YJ | 1 |
| Ma, YC | 1 |
| Zhang, WJ | 1 |
| Yang, ZZ | 1 |
| Liang, DS | 1 |
| Wu, ZF | 1 |
| Qi, XR | 1 |
| Lin, CH | 2 |
| Trogrlić, I | 1 |
| Trogrlić, D | 1 |
| Trogrlić, Z | 1 |
| Oancea-Castillo, LR | 1 |
| Klein, C | 1 |
| Abdollahi, A | 3 |
| Weber, KJ | 1 |
| Régnier-Vigouroux, A | 2 |
| Dokic, I | 1 |
| Bielecka-Wajdman, AM | 1 |
| Lesiak, M | 1 |
| Ludyga, T | 1 |
| Sieroń, A | 1 |
| Obuchowicz, E | 2 |
| Pejin, B | 1 |
| Tommonaro, G | 1 |
| Glumac, M | 1 |
| Jakimov, D | 1 |
| Kojic, V | 1 |
| Chandler, J | 1 |
| Mehta, M | 13 |
| Marymont, M | 2 |
| Levy, R | 1 |
| Muro, K | 3 |
| Helenowski, I | 2 |
| McCarthy, K | 2 |
| Fountas, L | 1 |
| Fu, A | 1 |
| Chen, T | 1 |
| Iwata, R | 1 |
| Maruyama, M | 1 |
| Koike, T | 1 |
| Oe, S | 1 |
| Yoshimura, K | 1 |
| Nonaka, M | 3 |
| Nomura, S | 1 |
| Sugimoto, T | 1 |
| Niu, L | 1 |
| Ma, K | 1 |
| Illic, R | 1 |
| Somma, T | 1 |
| Savic, D | 1 |
| Frio, F | 1 |
| Milicevic, M | 1 |
| Solari, D | 1 |
| Nikitovic, M | 1 |
| Lavrnic, S | 1 |
| Raicevic, S | 2 |
| Milosevic, S | 1 |
| Cavallo, LM | 1 |
| Cappabianca, P | 1 |
| Grujicic, D | 3 |
| Jaros, BD | 1 |
| An, M | 1 |
| Oliveira, KA | 2 |
| Dal-Cim, TA | 1 |
| Lopes, FG | 2 |
| Nedel, CB | 2 |
| Tasca, CI | 2 |
| Steverding, D | 1 |
| Rushworth, SA | 1 |
| Long, C | 1 |
| Jahan, N | 1 |
| Lee, JM | 2 |
| Shah, K | 1 |
| Maciaczyk, D | 2 |
| Picard, D | 2 |
| Koch, K | 2 |
| Herrera-Rios, D | 1 |
| Marquardt, V | 1 |
| Pauck, D | 1 |
| Hoerbelt, T | 1 |
| Ouwens, DM | 1 |
| Kahlert, UD | 2 |
| Chen, CY | 1 |
| Feng, LY | 2 |
| Huang, WT | 1 |
| Hood, LE | 1 |
| Chen, LY | 2 |
| Tupper, L | 1 |
| Harris, G | 1 |
| Jayamanne, D | 4 |
| Gzell, C | 3 |
| Kastelan, M | 6 |
| Schembri, G | 3 |
| Brazier, D | 5 |
| Cook, R | 2 |
| Parkinson, J | 1 |
| Louw, S | 1 |
| Hama, S | 2 |
| Onishi, S | 1 |
| Villodre, ES | 1 |
| Kipper, FC | 1 |
| Silva, AO | 1 |
| Lopez, PLDC | 1 |
| Lue, S | 1 |
| Snyder, J | 1 |
| Italiya, K | 1 |
| Dolera, M | 1 |
| Malfassi, L | 1 |
| Bianchi, C | 1 |
| Carrara, N | 1 |
| Finesso, S | 1 |
| Marcarini, S | 1 |
| Mazza, G | 1 |
| Pavesi, S | 1 |
| Sala, M | 1 |
| Urso, G | 1 |
| Mohanty, S | 2 |
| Morais, GR | 1 |
| Klockow, J | 1 |
| Yerneni, K | 1 |
| Pisani, L | 1 |
| Chin, FT | 1 |
| Cheshier, S | 1 |
| Chang, E | 1 |
| Gambhir, SS | 1 |
| Rao, J | 1 |
| Loadman, PM | 1 |
| Falconer, RA | 1 |
| Daldrup-Link, HE | 1 |
| Nordling-David, MM | 1 |
| Yaffe, R | 1 |
| Guez, D | 2 |
| Meirow, H | 1 |
| Last, D | 2 |
| Grad, E | 1 |
| Salomon, S | 1 |
| Sharabi, S | 1 |
| Levi-Kalisman, Y | 1 |
| Golomb, G | 1 |
| Mardor, Y | 2 |
| Sumida, M | 1 |
| Okita, Y | 2 |
| Yoshioka, E | 1 |
| Yamamoto, A | 1 |
| Kanematsu, D | 1 |
| Handa, Y | 1 |
| Fukusumi, H | 1 |
| Inazawa, Y | 1 |
| Takada, AI | 1 |
| Nakajima, S | 1 |
| Mori, K | 3 |
| Goto, S | 1 |
| Kamigaki, T | 1 |
| Shofuda, T | 2 |
| Moriuchi, S | 2 |
| Yamasaki, M | 1 |
| Yu, A | 1 |
| Faiq, N | 1 |
| Green, S | 1 |
| Green, R | 2 |
| Mellinghoff, I | 3 |
| Roh, TH | 1 |
| Ahn, SS | 1 |
| Choi, HJ | 1 |
| Kim, DS | 3 |
| Lee, KS | 3 |
| Sorge, C | 1 |
| Singh, S | 1 |
| Reddy, AT | 2 |
| Perry, A | 6 |
| Friedman, GK | 2 |
| Al-Saffar, NMS | 1 |
| Agliano, A | 1 |
| Marshall, LV | 2 |
| Jackson, LE | 1 |
| Balarajah, G | 1 |
| Sidhu, J | 1 |
| Clarke, PA | 1 |
| Workman, P | 1 |
| Pearson, ADJ | 1 |
| Leach, MO | 3 |
| Desai, VCA | 1 |
| Quinlan, SC | 1 |
| Deitz, AC | 1 |
| Holick, CN | 1 |
| Lanes, S | 1 |
| Luo, Y | 3 |
| Prabhu, S | 1 |
| Mutalik, S | 1 |
| Mohanty, BS | 1 |
| Rai, S | 1 |
| Udupa, N | 1 |
| Rao, BSS | 1 |
| Ryu, KH | 1 |
| Kim, HW | 1 |
| Shim, WH | 3 |
| Jung, SC | 2 |
| Choi, CG | 2 |
| Kim, SJ | 3 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 3 |
| Cui, C | 1 |
| Zou, S | 1 |
| Vaglini, F | 1 |
| Pardini, C | 1 |
| Di Desidero, T | 1 |
| Ottani, A | 1 |
| Pacini, S | 1 |
| Giuliani, D | 1 |
| Guarini, S | 1 |
| Tay, RY | 1 |
| Blackley, E | 1 |
| McLean, C | 1 |
| Moore, M | 1 |
| Bergin, P | 1 |
| Haydon, A | 1 |
| Hsieh, SY | 1 |
| Chan, DT | 2 |
| Kam, MK | 1 |
| Loong, HH | 1 |
| Tsang, WK | 1 |
| Poon, DM | 1 |
| Ng, SC | 1 |
| Chow, RD | 1 |
| Guzman, CD | 1 |
| Schmidt, F | 1 |
| Youngblood, MW | 1 |
| Errami, Y | 1 |
| Dong, MB | 1 |
| Martinez, MA | 1 |
| Renauer, P | 1 |
| Bilguvar, K | 1 |
| Gunel, M | 1 |
| Sharp, PA | 1 |
| Platt, RJ | 1 |
| Jbeli, AH | 1 |
| Badruddoja, MA | 1 |
| Pazzi, M | 1 |
| Sanan, A | 1 |
| Schroeder, K | 1 |
| Kuzma, K | 1 |
| Norton, T | 1 |
| Scully, T | 1 |
| Mahadevan, D | 1 |
| Ahmadi, MM | 1 |
| Tsai, SY | 2 |
| Chou, SW | 1 |
| Liu, MS | 1 |
| Liou, JP | 1 |
| Chen, KY | 1 |
| Hung, JJ | 1 |
| Chuang, CK | 1 |
| Burri, SH | 2 |
| Herting, CJ | 1 |
| Pitter, KL | 1 |
| Szulzewsky, F | 1 |
| Kaffes, I | 1 |
| Kaluzova, M | 1 |
| Park, JC | 1 |
| Brennan, C | 1 |
| Hambardzumyan, D | 2 |
| de Moraes, FY | 1 |
| Yi, H | 1 |
| Sun, G | 4 |
| Hirte, H | 1 |
| Ashby, L | 4 |
| Mechtler, L | 2 |
| Drappatz, J | 13 |
| Wong, M | 3 |
| Hamilton, MG | 2 |
| Green, J | 1 |
| Turner, CD | 1 |
| Yellin, MJ | 1 |
| Keler, T | 2 |
| Davis, TA | 2 |
| Demireva, P | 1 |
| Pannullo, S | 3 |
| Mehdorn, M | 2 |
| Avgeropoulos, N | 1 |
| Salmaggi, A | 9 |
| Silvani, A | 9 |
| Goldlust, S | 2 |
| David, C | 2 |
| Kumar A, A | 1 |
| Abraham Koshy, A | 1 |
| Adhikari, B | 1 |
| Futalan, D | 3 |
| Akers, J | 3 |
| Deming, T | 1 |
| Kim, WJ | 1 |
| Newman, WC | 1 |
| Amankulor, NM | 1 |
| Gorman, MJ | 1 |
| McKenzie, LD | 1 |
| Chai, JN | 1 |
| Hubert, CG | 1 |
| Prager, BC | 1 |
| Fernandez, E | 2 |
| Richner, JM | 1 |
| Shan, C | 1 |
| Tycksen, E | 1 |
| Shi, PY | 1 |
| Diamond, MS | 1 |
| Krengli, M | 5 |
| Magrini, SM | 5 |
| Fusco, V | 7 |
| Pirtoli, L | 8 |
| Doino, D | 1 |
| Fiorentino, A | 10 |
| Masini, L | 4 |
| Buglione, M | 6 |
| Rubino, G | 5 |
| Lonardi, F | 1 |
| Migliaccio, F | 1 |
| Marzano, S | 1 |
| Santoni, R | 4 |
| Ricardi, U | 4 |
| Shiraki, Y | 1 |
| Mii, S | 1 |
| Enomoto, A | 1 |
| Momota, H | 4 |
| Han, YP | 1 |
| Kato, T | 3 |
| Ushida, K | 1 |
| Kato, A | 1 |
| Asai, N | 1 |
| Murakumo, Y | 1 |
| Todo, T | 2 |
| Ogawa, S | 1 |
| Cheng, ZX | 1 |
| Yin, WB | 1 |
| Wang, ZY | 1 |
| Jing, D | 1 |
| Yu, H | 7 |
| Lin, CY | 1 |
| Li, RJ | 2 |
| Teo, C | 1 |
| Back, MF | 2 |
| Lun, X | 1 |
| Hao, X | 3 |
| Yin, X | 1 |
| He, W | 2 |
| Vieira de Castro, J | 1 |
| Gomes, ED | 1 |
| Granja, S | 1 |
| Anjo, SI | 1 |
| Baltazar, F | 1 |
| Manadas, B | 1 |
| Salgado, AJ | 1 |
| Costa, BM | 4 |
| Séry, Q | 2 |
| Rabé, M | 2 |
| Oliver, L | 2 |
| Vallette, FM | 2 |
| Gratas, C | 2 |
| Elia, AEH | 1 |
| Miller, CR | 3 |
| Jaeckle, K | 3 |
| Moore, DF | 1 |
| Nebozhyn, M | 1 |
| Loboda, A | 1 |
| Prados, M | 12 |
| Cerhan, J | 1 |
| Garnier, D | 1 |
| Kislinger, T | 1 |
| Sinha, A | 1 |
| Nowosielski, M | 2 |
| Garcia, J | 4 |
| Revil, C | 2 |
| Kickingereder, P | 3 |
| Sandmann, T | 2 |
| Bendszus, M | 5 |
| Bojko, S | 1 |
| Hoffmann, M | 1 |
| Mathivet, T | 1 |
| Bouleti, C | 1 |
| Van Woensel, M | 2 |
| Stanchi, F | 1 |
| Verschuere, T | 2 |
| Phng, LK | 1 |
| Dejaegher, J | 2 |
| Balcer, M | 1 |
| Matsumoto, K | 1 |
| Georgieva, PB | 1 |
| Belmans, J | 2 |
| Sciot, R | 3 |
| Stockmann, C | 1 |
| Mazzone, M | 1 |
| De Vleeschouwer, S | 2 |
| Gerhardt, H | 1 |
| Chen, YD | 2 |
| Dong, TX | 1 |
| Xu, YT | 1 |
| An, TT | 1 |
| Liu, PF | 1 |
| Yang, XH | 1 |
| Adeberg, S | 4 |
| Bernhardt, D | 3 |
| Harrabi, SB | 2 |
| Uhl, M | 3 |
| Paul, A | 1 |
| Bougatf, N | 1 |
| Unterberg, A | 4 |
| Haberer, T | 3 |
| Combs, SE | 13 |
| Herfarth, K | 2 |
| Rieken, S | 6 |
| Nardone, V | 1 |
| Pastina, P | 1 |
| Battaglia, G | 1 |
| Miracco, C | 4 |
| Carbone, SF | 1 |
| Sebaste, L | 1 |
| Cerase, A | 1 |
| Creyns, B | 1 |
| Bullens, DM | 1 |
| Nam, JG | 1 |
| Lim, WH | 1 |
| Merrell, R | 4 |
| Fichtel, L | 2 |
| Scott, AM | 3 |
| Gomez, EJ | 1 |
| Fischer, J | 5 |
| Mandich, H | 2 |
| Munasinghe, WP | 1 |
| Roberts-Rapp, LA | 1 |
| Holen, KD | 3 |
| Hombach-Klonisch, S | 2 |
| Mehrpour, M | 1 |
| Harlos, C | 1 |
| Pitz, M | 2 |
| Hamai, A | 1 |
| Siemianowicz, K | 1 |
| Likus, W | 1 |
| Wiechec, E | 1 |
| Toyota, BD | 1 |
| Hoshyar, R | 1 |
| Seyfoori, A | 1 |
| Sepehri, Z | 1 |
| Ande, SR | 1 |
| Khadem, F | 1 |
| Akbari, M | 1 |
| Gorman, AM | 1 |
| Klonisch, T | 2 |
| Teng, J | 3 |
| Hejazi, S | 1 |
| Hiddingh, L | 2 |
| Carvalho, L | 1 |
| de Gooijer, MC | 1 |
| Barazas, M | 1 |
| Tannous, M | 1 |
| Chi, AS | 5 |
| Noske, DP | 3 |
| Wurdinger, T | 2 |
| Tannous, BA | 2 |
| Scannell Bryan, M | 1 |
| Valeinis, E | 2 |
| Hopkins, K | 3 |
| Souhami, L | 10 |
| Youssef, EF | 1 |
| Lessard, N | 1 |
| Dignam, JJ | 3 |
| Roussakow, SV | 1 |
| Perry, LA | 1 |
| Agrawal, JP | 1 |
| Lu, D | 3 |
| Teng, L | 1 |
| Du, Y | 1 |
| Ren, J | 2 |
| Ying, G | 1 |
| Shao, M | 1 |
| Ma, L | 3 |
| Zhong, G | 1 |
| Xia, Z | 1 |
| Proescholdt, M | 5 |
| Friedrich, F | 1 |
| Rohde, V | 4 |
| Grau, S | 1 |
| Hänel, M | 2 |
| Mack, F | 4 |
| Nießen, M | 1 |
| Leutgeb, B | 1 |
| Urbach, H | 2 |
| Roux, A | 1 |
| Caire, F | 1 |
| Guyotat, J | 5 |
| Chinnaiyan, P | 5 |
| Rojiani, AM | 3 |
| Ashby, LS | 6 |
| Stieber, VW | 2 |
| Malone, SC | 1 |
| Wendland, MM | 2 |
| Stella, PJ | 1 |
| Kee, AY | 2 |
| Shen, F | 4 |
| Izquierdo, C | 1 |
| Simó, M | 2 |
| Kaloshi, G | 8 |
| Ricard, D | 4 |
| Barritault, M | 1 |
| Meyronet, D | 2 |
| Bruna, J | 4 |
| Mao, L | 1 |
| Puente, P | 1 |
| Fettig, N | 1 |
| Luderer, MJ | 1 |
| Jin, A | 1 |
| Shah, S | 2 |
| Muz, B | 1 |
| Goddu, SM | 1 |
| Salama, NN | 1 |
| Tsien, C | 4 |
| Shoghi, K | 1 |
| Rogers, B | 1 |
| Azab, AK | 1 |
| Schneider, H | 1 |
| Steinle, A | 1 |
| Pruschy, M | 1 |
| Polić, B | 1 |
| Puri, RK | 2 |
| Marques-Torrejon, MA | 1 |
| Gangoso, E | 1 |
| Pollard, SM | 1 |
| Kim, SS | 4 |
| Harford, JB | 1 |
| Moghe, M | 1 |
| Rait, A | 3 |
| Pirollo, KF | 3 |
| Chang, EH | 3 |
| Chautard, E | 2 |
| De Schlichting, E | 1 |
| Dupic, G | 1 |
| Pereira, B | 1 |
| Fogli, A | 1 |
| Müller-Barthélémy, M | 1 |
| Dalloz, P | 2 |
| Khalil, T | 2 |
| Dillies, AF | 1 |
| Godfraind, C | 1 |
| Verrelle, P | 3 |
| Kamdar, MR | 1 |
| Liu, HP | 1 |
| Zheng, KB | 1 |
| Wang, JW | 3 |
| Berger, G | 1 |
| Grauwet, K | 1 |
| Hussey, AM | 1 |
| Nowicki, MO | 2 |
| Wang, DI | 1 |
| Lippard, SJ | 1 |
| Taghipour Zahir, S | 1 |
| Mortaz, M | 1 |
| Baghi Yazdi, M | 1 |
| Sefidrokh Sharahjin, N | 1 |
| Shabani, M | 1 |
| Jensen, KV | 1 |
| Cseh, O | 1 |
| Aman, A | 1 |
| Weiss, S | 5 |
| Luchman, HA | 4 |
| Lappin, H | 1 |
| Vasconcelos, G | 1 |
| Lita, A | 1 |
| Maric, D | 1 |
| Li, A | 3 |
| Celiku, O | 1 |
| Meetze, K | 1 |
| Estok, T | 1 |
| Larion, M | 1 |
| Abu-Asab, M | 1 |
| Zhuang, Z | 1 |
| Boyd, NH | 1 |
| Walker, K | 1 |
| Fried, J | 1 |
| Hackney, JR | 1 |
| McDonald, PC | 1 |
| Benavides, GA | 1 |
| Spina, R | 1 |
| Audia, A | 1 |
| Scott, SE | 1 |
| Landis, CJ | 1 |
| Tran, AN | 2 |
| Bevensee, MO | 1 |
| Griguer, C | 1 |
| Nozell, S | 1 |
| Bhat, KP | 1 |
| Bar, EE | 1 |
| Darley-Usmar, V | 1 |
| Gordon, E | 1 |
| Cooper, SJ | 1 |
| Dedhar, S | 1 |
| Hjelmeland, AB | 1 |
| Carideo, L | 1 |
| Mamede, M | 1 |
| Scaringi, C | 8 |
| Russo, I | 1 |
| Scopinaro, F | 1 |
| Cicone, F | 1 |
| Lai, SW | 1 |
| Huang, BR | 1 |
| Liu, YS | 1 |
| Tsai, CF | 2 |
| Lu, DY | 1 |
| Lin, C | 1 |
| Schecker, J | 1 |
| Würstle, S | 1 |
| Schneider, F | 1 |
| Schönfelder, M | 1 |
| Jackson, S | 1 |
| Weingart, J | 4 |
| Nduom, EK | 1 |
| Harfi, TT | 1 |
| George, RT | 1 |
| McAreavey, D | 1 |
| Anders, NM | 1 |
| Peer, C | 1 |
| Gilbert, M | 4 |
| Rudek, MA | 3 |
| Lee, JE | 1 |
| Lim, JH | 1 |
| William, D | 1 |
| Walther, M | 1 |
| Schneider, B | 2 |
| Linnebacher, M | 2 |
| Classen, CF | 2 |
| Flüh, C | 1 |
| Chitadze, G | 1 |
| Kabelitz, D | 1 |
| Lee, IC | 1 |
| Pei, C | 1 |
| Dong, T | 1 |
| Xing, W | 1 |
| Zhen, Z | 1 |
| Ren, H | 3 |
| Kurscheid, S | 2 |
| Delorenzi, M | 2 |
| Gijtenbeek, A | 1 |
| Enting, R | 3 |
| Thiessen, B | 5 |
| Hofheinz, F | 1 |
| Mutsaerts, HJMM | 1 |
| Asllani, I | 1 |
| van Osch, MJP | 1 |
| Krukowski, P | 1 |
| Gommlich, A | 1 |
| Maus, J | 1 |
| Troost, EGC | 1 |
| Gujar, AD | 1 |
| DeWees, TA | 3 |
| Lockhart, AC | 1 |
| Kim, AH | 4 |
| Duan, C | 2 |
| Dinislam, M | 1 |
| Kramer, B | 1 |
| Wischusen, J | 1 |
| Dent, R | 1 |
| Rush, A | 1 |
| Middlemiss, S | 1 |
| Ching, YW | 1 |
| Alexander, IE | 1 |
| McCowage, G | 1 |
| Jackson, WC | 1 |
| Tsien, CI | 5 |
| Junck, L | 8 |
| Hervey-Jumper, S | 1 |
| Orringer, D | 2 |
| Heth, J | 3 |
| Spratt, DE | 4 |
| Dirven, L | 3 |
| Taillibert, S | 11 |
| Sroubek, J | 2 |
| Easaw, JC | 3 |
| Kew, Y | 2 |
| Desai, R | 2 |
| Kirson, ED | 2 |
| Ghia, AJ | 1 |
| Hoang, N | 1 |
| Shang, C | 1 |
| Pan, C | 1 |
| Hong, Y | 1 |
| Mehrabian, H | 1 |
| Myrehaug, S | 1 |
| Soliman, H | 1 |
| Stanisz, GJ | 1 |
| Cheng, YC | 2 |
| Tsai, WC | 2 |
| Chang, HH | 2 |
| Tong, D | 1 |
| André-Grégoire, G | 1 |
| Bidère, N | 1 |
| Gavard, J | 1 |
| Bokstein, F | 4 |
| Brachman, DG | 6 |
| Hunter, GK | 1 |
| Shrieve, DC | 3 |
| Robinson, CG | 5 |
| Waschke, A | 1 |
| Arefian, H | 1 |
| Walter, J | 2 |
| Hartmann, M | 1 |
| Maschmann, J | 1 |
| Kalff, R | 2 |
| Akiyama, Y | 1 |
| Kimura, Y | 1 |
| Enatsu, R | 1 |
| Mikami, T | 1 |
| Wanibuchi, M | 1 |
| Mikuni, N | 1 |
| Happold, C | 5 |
| Stojcheva, N | 1 |
| Leyrer, CM | 1 |
| Parsons, M | 1 |
| Prayson, RA | 1 |
| Ahmed, EM | 1 |
| Bandopadhyay, G | 1 |
| Coyle, B | 1 |
| Grabowska, A | 1 |
| Yang, CS | 3 |
| Zhang, LZ | 1 |
| Jiang, G | 4 |
| Dréan, A | 1 |
| Rosenberg, S | 1 |
| Lejeune, FX | 1 |
| Goli, L | 1 |
| Nadaradjane, AA | 1 |
| Guehennec, J | 1 |
| Schmitt, C | 2 |
| Chen, YY | 1 |
| Ho, HL | 2 |
| Lin, SC | 3 |
| Ho, TD | 1 |
| Hsu, CY | 2 |
| Wang, HC | 2 |
| Lin, YT | 2 |
| Lin, WC | 2 |
| Ho, RW | 1 |
| Tsai, NW | 1 |
| Ho, JT | 2 |
| Lu, CH | 2 |
| Pawlowska, E | 1 |
| Szczepanska, J | 1 |
| Szatkowska, M | 1 |
| Blasiak, J | 1 |
| Qiu, G | 1 |
| Weenink, B | 1 |
| Erdem-Eraslan, L | 1 |
| Sillevis Smitt, P | 1 |
| Vos, M | 1 |
| Ryan, GF | 1 |
| Frohnapfel, L | 1 |
| Quiros, S | 1 |
| Kaina, B | 9 |
| Vallée, A | 1 |
| Lecarpentier, Y | 1 |
| Guillevin, R | 4 |
| Vallée, JN | 2 |
| Boxerman, JL | 4 |
| Safriel, Y | 3 |
| Rogg, JM | 1 |
| Wolf, RL | 1 |
| Mohan, S | 2 |
| Marques, H | 1 |
| Sorensen, AG | 6 |
| Barboriak, DP | 4 |
| Abrunhosa-Branquinho, AN | 1 |
| Bar-Deroma, R | 2 |
| Collette, S | 1 |
| Clementel, E | 1 |
| Hurkmans, CW | 1 |
| Van Beek, K | 1 |
| Weber, DC | 4 |
| Ji, P | 2 |
| Ge, S | 1 |
| Woo, P | 1 |
| Ho, J | 2 |
| Lam, S | 1 |
| Ma, E | 1 |
| Chan, D | 1 |
| Wong, WK | 1 |
| Mak, C | 1 |
| Wong, ST | 5 |
| Chan, KY | 2 |
| Feng, WY | 1 |
| Chen, ZY | 1 |
| Li, YM | 1 |
| Deng, SZ | 1 |
| Guo, ML | 1 |
| Sun, XG | 1 |
| He, MY | 1 |
| Liu, YW | 3 |
| Yusuf, M | 1 |
| Ugiliweneza, B | 1 |
| Amsbaugh, M | 1 |
| Boakye, M | 1 |
| Williams, B | 2 |
| Nelson, M | 1 |
| Hattab, EM | 1 |
| Woo, S | 1 |
| Yildirim, BA | 1 |
| Guler, OC | 1 |
| Ciner, F | 1 |
| Tufan, K | 2 |
| Zhao, P | 2 |
| Ge, M | 1 |
| Lan, C | 1 |
| Patil, VM | 1 |
| Pande, N | 1 |
| Chandrasekharan, A | 1 |
| M, C | 1 |
| Tonse, R | 1 |
| Dsouza, H | 1 |
| Vallathol, DH | 1 |
| Kwan, K | 1 |
| Schneider, JR | 2 |
| Ramalho, MJ | 1 |
| Sevin, E | 1 |
| Lima, J | 1 |
| Coelho, MAN | 1 |
| Loureiro, JA | 1 |
| Pereira, MC | 1 |
| Yamashita, S | 1 |
| Yokogami, K | 2 |
| Matsumoto, F | 1 |
| Saito, K | 6 |
| Mizuguchi, A | 1 |
| Ohta, H | 1 |
| Takeshima, H | 4 |
| Basso, J | 1 |
| Miranda, A | 1 |
| Sousa, J | 1 |
| Pais, A | 1 |
| Vitorino, C | 1 |
| Karachi, A | 2 |
| Dastmalchi, F | 2 |
| Mitchell, DA | 7 |
| Rone, JD | 1 |
| Graham, GT | 1 |
| Pannkuk, EL | 1 |
| Lamberti, G | 3 |
| Visani, M | 2 |
| Paccapelo, A | 5 |
| Mura, A | 2 |
| Tallini, G | 3 |
| Pession, A | 4 |
| De Biase, D | 3 |
| Minichillo, S | 2 |
| Tosoni, A | 18 |
| Di Battista, M | 1 |
| Cubeddu, A | 1 |
| Bartolini, S | 3 |
| Tan, D | 1 |
| Pang, FM | 1 |
| Liu, ZQ | 1 |
| Dai, B | 1 |
| Qi, N | 1 |
| Lam, FC | 1 |
| Morton, SW | 1 |
| Wyckoff, J | 1 |
| Vu Han, TL | 1 |
| Hwang, MK | 1 |
| Maffa, A | 1 |
| Balkanska-Sinclair, E | 1 |
| Yaffe, MB | 1 |
| Floyd, SR | 1 |
| Hammond, PT | 1 |
| Malakhov, N | 1 |
| Sheth, N | 1 |
| Han, P | 1 |
| Schreiber, D | 1 |
| Fujihara, T | 1 |
| Mizobuchi, Y | 2 |
| Kageji, T | 2 |
| Matsuzaki, K | 2 |
| Kitazato, KT | 2 |
| Otsuka, R | 1 |
| Hara, K | 2 |
| Mure, H | 2 |
| Okazaki, T | 2 |
| Kuwayama, K | 2 |
| Nagahiro, S | 2 |
| Takagi, Y | 2 |
| Frontiñán-Rubio, J | 1 |
| Santiago-Mora, RM | 1 |
| Nieva-Velasco, CM | 1 |
| Ferrín, G | 1 |
| Martínez-González, A | 1 |
| Gómez, MV | 1 |
| Moreno, M | 1 |
| Ariza, J | 1 |
| Lozano, E | 1 |
| Arjona-Gutiérrez, J | 1 |
| Gil-Agudo, A | 1 |
| De la Mata, M | 1 |
| Pesic, M | 2 |
| Peinado, JR | 1 |
| Villalba, JM | 1 |
| Pérez-Romasanta, L | 1 |
| Alcaín, FJ | 1 |
| Durán-Prado, M | 1 |
| Kulason, KO | 1 |
| Pramanik, B | 1 |
| Tan, K | 1 |
| Ray, A | 1 |
| Demopoulos, A | 6 |
| Matsuda, KI | 1 |
| Sakurada, K | 1 |
| Nemoto, K | 1 |
| Sonoda, Y | 6 |
| Loaiza, S | 1 |
| Carvajal, S | 1 |
| Giraldo, D | 1 |
| Galvis, A | 1 |
| Ortiz, L | 1 |
| Jin, S | 1 |
| Liang, T | 1 |
| Liang, J | 4 |
| Ni, Q | 2 |
| Abe, H | 1 |
| Natsumeda, M | 3 |
| Kanemaru, Y | 1 |
| Watanabe, J | 1 |
| Tsukamoto, Y | 2 |
| Okada, M | 2 |
| Yoshimura, J | 2 |
| Oishi, M | 1 |
| Fujii, Y | 3 |
| Xiao, X | 1 |
| Lai, X | 1 |
| Mao, G | 2 |
| Yi, G | 1 |
| Shu, S | 1 |
| Bruhn, H | 1 |
| Vrethem, M | 1 |
| Lind, J | 1 |
| Kazantseva, M | 1 |
| Eiholzer, RA | 1 |
| Mehta, S | 1 |
| Taha, A | 1 |
| Bowie, S | 1 |
| Roth, I | 1 |
| Joruiz, SM | 1 |
| Royds, JA | 1 |
| Hung, NA | 1 |
| Slatter, TL | 1 |
| Braithwaite, AW | 1 |
| Erickson, AE | 1 |
| Lan Levengood, SK | 1 |
| Chang, FC | 2 |
| Hersh, DS | 1 |
| Roos, A | 3 |
| Heath, JE | 1 |
| Legesse, T | 1 |
| Kim, AJ | 2 |
| Woodworth, GF | 2 |
| Winkles, JA | 3 |
| Harris, RJ | 2 |
| Leu, K | 1 |
| Woodworth, DC | 2 |
| Mehta, A | 1 |
| Chakhoyan, A | 1 |
| Ji, M | 1 |
| Wang, LY | 1 |
| Lü, YH | 1 |
| Lai, FF | 1 |
| Chen, XG | 1 |
| Kumagai, K | 1 |
| Takeuchi, S | 2 |
| Toyooka, T | 2 |
| Otani, N | 2 |
| Namba, H | 2 |
| Mardaleishvili, K | 1 |
| Orkodashvili, G | 1 |
| Fu, C | 1 |
| Cheng, WY | 2 |
| Shen, CC | 3 |
| Chiao, MT | 1 |
| Liang, YJ | 1 |
| Mao, TF | 1 |
| Liu, BS | 1 |
| Chen, JP | 1 |
| Sutera, P | 1 |
| Kalash, R | 1 |
| Flickinger, J | 2 |
| Engh, J | 1 |
| Heron, DE | 2 |
| Brawanski, K | 2 |
| Brockhoff, G | 1 |
| Vollmann-Zwerenz, A | 2 |
| Freyschlag, C | 1 |
| Lohmeier, A | 1 |
| Brawanski, A | 3 |
| Proescholdt, MA | 1 |
| Baratta, MG | 1 |
| Arulananda, S | 1 |
| Sem Liew, M | 1 |
| Wada, M | 1 |
| Cher, L | 7 |
| Silva, VAO | 1 |
| Rosa, MN | 1 |
| Miranda-Gonçalves, V | 1 |
| Tansini, A | 1 |
| Evangelista, AF | 1 |
| Martinho, O | 2 |
| Carloni, AC | 1 |
| Lima, JP | 1 |
| Pianowski, LF | 1 |
| Benson, R | 1 |
| Upadhyay, AD | 1 |
| Fu, L | 1 |
| Jing, W | 1 |
| Kong, L | 2 |
| Provost, C | 1 |
| Rozenblum-Beddok, L | 1 |
| Nataf, V | 1 |
| Merabtene, F | 1 |
| Prignon, A | 1 |
| Talbot, JN | 1 |
| Thanasupawat, T | 1 |
| Glogowska, A | 1 |
| Burg, M | 1 |
| Krcek, J | 1 |
| Beiko, J | 1 |
| Zhang, GJ | 1 |
| McElroy, JP | 2 |
| Fleming, J | 1 |
| Chakraborty, AR | 1 |
| Fabian, D | 1 |
| Walker, EM | 1 |
| Yu, HM | 1 |
| Schultz, CJ | 2 |
| Gray, HJ | 1 |
| Calastri, MCJ | 1 |
| Rodrigues, NLTO | 1 |
| Hatori, G | 1 |
| Gregório, ML | 1 |
| Brancati, CIFO | 1 |
| Zanovelo, EM | 1 |
| Ferraz Filho, JRL | 1 |
| Neiva, CM | 1 |
| Rodrigues Junior, ACP | 1 |
| Godoy, MF | 1 |
| Lancelloti, CLP | 1 |
| Tognola, WA | 1 |
| Souza, DRS | 1 |
| Pytel, P | 4 |
| Fitzpatrick, CA | 1 |
| Mashek, H | 1 |
| Veresezan, O | 1 |
| Gilard, V | 1 |
| David, M | 1 |
| Marinelli, A | 1 |
| Cerbone, L | 1 |
| Cordua, N | 1 |
| Buonerba, C | 1 |
| Peluso, G | 1 |
| Di Lorenzo, G | 1 |
| De Placido, S | 1 |
| Papadopoulos, KP | 1 |
| Gomez, E | 2 |
| Roberts-Rapp, L | 2 |
| Bain, E | 1 |
| Maag, D | 1 |
| Kriel, J | 1 |
| Müller-Nedebock, K | 1 |
| Maarman, G | 1 |
| Mbizana, S | 1 |
| Ojuka, E | 1 |
| Klumperman, B | 1 |
| Loos, B | 1 |
| Lok, E | 2 |
| Swanson, KD | 2 |
| Noh, H | 1 |
| Kong, LY | 1 |
| Gabrusiewicz, K | 1 |
| Hong, S | 1 |
| Heimberger, AB | 8 |
| Abdallah, MB | 1 |
| Blonski, M | 5 |
| Wantz-Mezieres, S | 2 |
| Gaudeau, Y | 2 |
| Moureaux, JM | 2 |
| de Champfleur, NM | 1 |
| Duffau, H | 10 |
| Hanif, F | 1 |
| Perveen, K | 1 |
| Malhi, SM | 1 |
| Jawed, H | 1 |
| Simjee, SU | 1 |
| Zhi, T | 1 |
| Palchetti, S | 1 |
| Digiacomo, L | 1 |
| Pozzi, D | 1 |
| Capriotti, AL | 1 |
| Frati, L | 1 |
| Tsaouli, G | 1 |
| Rota, R | 1 |
| Screpanti, I | 1 |
| Mahmoudi, M | 1 |
| Caracciolo, G | 1 |
| Ishi, Y | 1 |
| Motegi, H | 2 |
| Okamoto, M | 1 |
| Hirata, K | 1 |
| Oda, Y | 1 |
| Terasaka, S | 2 |
| Houkin, K | 2 |
| Genbrugge, E | 2 |
| Yang, G | 1 |
| Gu, D | 1 |
| Harrison, RA | 1 |
| Bai, Y | 3 |
| El Ahmadieh, TY | 1 |
| Raisanen, JM | 1 |
| Botros, J | 1 |
| Kabangu, JL | 1 |
| Pan, E | 5 |
| Gluf, W | 1 |
| Tsao, MJ | 1 |
| Bai, YH | 1 |
| Zhan, YB | 1 |
| Yu, B | 2 |
| Wang, WW | 1 |
| Zhou, JQ | 1 |
| Chen, RK | 1 |
| Zhang, FJ | 1 |
| Zhao, XW | 1 |
| Duan, WC | 1 |
| Wang, YM | 1 |
| Bao, JJ | 1 |
| Zhang, ZY | 1 |
| Liu, XZ | 1 |
| Bellu, L | 4 |
| Pambuku, A | 4 |
| Bergo, E | 1 |
| Berti, F | 5 |
| Gardiman, MP | 3 |
| Dal Pos, S | 1 |
| Buccarelli, M | 2 |
| Marconi, M | 1 |
| Pacioni, S | 1 |
| De Pascalis, I | 1 |
| D'Alessandris, QG | 4 |
| Martini, M | 3 |
| Ascione, B | 1 |
| Malorni, W | 1 |
| Larocca, LM | 5 |
| Matarrese, P | 1 |
| Kim, JY | 2 |
| Jo, Y | 1 |
| Nam, SJ | 1 |
| Clement, P | 1 |
| Iser, IC | 1 |
| Fernandes, MC | 1 |
| Spanevello, RM | 1 |
| Sévigny, J | 1 |
| Chai, RC | 1 |
| Zhang, KN | 1 |
| Liu, YQ | 3 |
| Wang, KY | 1 |
| Wang, YZ | 1 |
| Hou, S | 1 |
| Sha, LG | 1 |
| Thompson, EM | 2 |
| Landi, D | 1 |
| Ashley, D | 2 |
| Bigner, D | 1 |
| Guzauskas, GF | 1 |
| Salzberg, M | 1 |
| Wang, BC | 1 |
| López-Valero, I | 2 |
| Torres, S | 5 |
| Salazar-Roa, M | 1 |
| García-Taboada, E | 3 |
| Hernández-Tiedra, S | 3 |
| Guzmán, M | 3 |
| Velasco, G | 3 |
| Lorente, M | 3 |
| Klyuchivska, O | 1 |
| Ivasechko, I | 1 |
| Hreniukh, V | 1 |
| Ostapiuk, Y | 1 |
| Shalai, Y | 1 |
| Panchuk, R | 1 |
| Matiychuk, V | 1 |
| Obushak, M | 1 |
| Stoika, R | 1 |
| Babsky, A | 1 |
| Pessina, F | 1 |
| Cozzi, L | 1 |
| Tomatis, S | 2 |
| Reggiori, G | 1 |
| Simonelli, M | 3 |
| Santoro, A | 5 |
| Franzese, C | 1 |
| Carta, G | 1 |
| Conti Nibali, M | 1 |
| Blakeley, JO | 4 |
| Rosenfeld, MR | 7 |
| Eichler, A | 1 |
| Ribas, IG | 1 |
| Roberts, NB | 1 |
| Alqazzaz, A | 1 |
| Hwang, JR | 1 |
| Qi, X | 5 |
| Keegan, AD | 1 |
| Respondek, M | 1 |
| Beberok, A | 1 |
| Rok, J | 1 |
| Rzepka, Z | 1 |
| Wrześniok, D | 1 |
| Buszman, E | 1 |
| Zou, L | 1 |
| Navone, SE | 1 |
| Guarnaccia, L | 1 |
| Cordiglieri, C | 1 |
| Crisà, FM | 1 |
| Locatelli, M | 2 |
| Schisano, L | 1 |
| Rampini, P | 3 |
| Miozzo, M | 1 |
| La Verde, N | 1 |
| Riboni, L | 2 |
| Campanella, R | 2 |
| Marfia, G | 1 |
| Slone, SA | 1 |
| Gruber, L | 1 |
| Kumar, SS | 1 |
| Lightner, DD | 2 |
| Taylor, MA | 1 |
| Das, BC | 1 |
| Jin, T | 1 |
| Ni, L | 1 |
| Mu, H | 1 |
| Chen, MF | 1 |
| Saiz-Ladera, C | 1 |
| Rodríguez-Fornés, F | 2 |
| Barba, M | 1 |
| Dávila, D | 1 |
| Salvador-Tormo, N | 1 |
| Sánchez-Gómez, P | 1 |
| Ferreira, J | 1 |
| Ramos, AA | 1 |
| Almeida, T | 1 |
| Azqueta, A | 1 |
| Rocha, E | 1 |
| Grube, S | 1 |
| Ewald, C | 1 |
| Kögler, C | 1 |
| Lawson McLean, A | 1 |
| Barnes, JM | 1 |
| Kaushik, S | 1 |
| Bainer, RO | 1 |
| Woods, EC | 1 |
| Kai, F | 1 |
| Przybyla, L | 1 |
| Tung, JC | 1 |
| Maller, O | 1 |
| Barrett, AS | 1 |
| Lu, KV | 2 |
| Lakins, JN | 1 |
| Hansen, KC | 1 |
| Obernier, K | 1 |
| Alvarez-Buylla, A | 1 |
| Bergers, G | 2 |
| Bertozzi, CR | 1 |
| Weaver, VM | 1 |
| Marjanovic Vicentic, J | 1 |
| Garcia, I | 3 |
| Vukovic, V | 1 |
| Aldaz, P | 2 |
| Puskas, N | 1 |
| Nikolic, I | 1 |
| Tasic, G | 1 |
| Garros-Regulez, L | 2 |
| Atkinson, MJ | 1 |
| Anastasov, N | 1 |
| Han, G | 2 |
| Yue, Z | 2 |
| Ding, Z | 1 |
| Dhruv, H | 1 |
| Kwiatkowska-Piwowarczyk, A | 1 |
| Kloss, J | 2 |
| Pirrotte, P | 1 |
| Eschbacher, JM | 1 |
| Bernal Rubio, YL | 1 |
| González-Reymúndez, A | 1 |
| Wu, KH | 1 |
| Steibel, JP | 1 |
| de Los Campos, G | 1 |
| Doseff, A | 1 |
| Gallo, K | 1 |
| Vazquez, AI | 1 |
| Dho, YS | 1 |
| Cho, WK | 1 |
| Cho, O | 1 |
| El Mubarak, MA | 1 |
| Stylos, EK | 1 |
| Chatziathanasiadou, MV | 1 |
| Danika, C | 1 |
| Alexiou, GA | 1 |
| Tsekeris, P | 1 |
| Sivolapenko, GB | 1 |
| Jiapaer, S | 2 |
| Kitabayashi, T | 2 |
| Khan, UA | 1 |
| Rennert, RC | 1 |
| White, NS | 1 |
| Bartsch, H | 1 |
| Farid, N | 1 |
| Dale, AM | 1 |
| Salaroglio, IC | 2 |
| Annovazzi, L | 4 |
| Mellai, M | 4 |
| Schiffer, D | 4 |
| Melamed, JR | 1 |
| Ioele, SA | 1 |
| Hannum, AJ | 1 |
| Ullman, VM | 1 |
| Day, ES | 1 |
| Tsai, NM | 1 |
| Chang, KF | 1 |
| Dettmer, S | 1 |
| Berberich, A | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Pfaff, E | 1 |
| Brors, B | 1 |
| Eisenmenger, A | 1 |
| Jones, DTW | 1 |
| Debus, C | 1 |
| Afshar-Oromieh, A | 1 |
| Floca, R | 1 |
| Ingrisch, M | 1 |
| Knoll, M | 1 |
| Haberkorn, U | 1 |
| Gonzalez-Aguilar, A | 1 |
| Reyes-Moreno, I | 1 |
| Peiro-Osuna, RP | 1 |
| Hernandez-Hernandez, A | 1 |
| Gutierrez-Aceves, A | 1 |
| Santos-Zambrano, J | 1 |
| Guerrero-Juarez, V | 1 |
| Lopez-Martinez, M | 1 |
| Castro-Martinez, E | 1 |
| Johannessen, TC | 3 |
| Hasan-Olive, MM | 1 |
| Denisova, O | 1 |
| Grudic, A | 2 |
| Latif, MA | 1 |
| Saed, H | 1 |
| Varughese, JK | 1 |
| Røsland, GV | 1 |
| Yang, N | 2 |
| Sundstrøm, T | 1 |
| Nordal, A | 1 |
| Tronstad, KJ | 1 |
| Lund-Johansen, M | 1 |
| Janji, B | 1 |
| Westermarck, J | 1 |
| Prestegarden, L | 2 |
| Yang, HC | 1 |
| Wang, JY | 2 |
| Wang, BQ | 1 |
| Gao, YS | 1 |
| Han, SY | 1 |
| Bi, Y | 1 |
| Yi, D | 1 |
| Ward, SM | 1 |
| Skinner, M | 1 |
| Saha, B | 1 |
| Emrick, T | 1 |
| Arora, P | 1 |
| Adams, CH | 1 |
| Gudelsky, G | 1 |
| Maraka, S | 1 |
| Groves, MD | 11 |
| Mammoser, AG | 2 |
| Melguizo-Gavilanes, I | 1 |
| Conrad, CA | 6 |
| Tremont-Lukats, IW | 4 |
| Loghin, ME | 3 |
| O'Brien, BJ | 1 |
| Hess, KR | 8 |
| Alfred Yung, WK | 2 |
| Nickel, AC | 1 |
| Wan, XY | 1 |
| Saban, DV | 1 |
| Weng, YL | 1 |
| Hicks, J | 1 |
| Platt, S | 1 |
| Stewart, G | 1 |
| Senneca, C | 1 |
| Holmes, S | 1 |
| Kent, M | 1 |
| Howerth, E | 1 |
| Kaplan, J | 1 |
| Kaplan, E | 1 |
| Kumar, V | 1 |
| Radin, D | 1 |
| Leonardi, D | 1 |
| Swenson, S | 1 |
| Tuan, CD | 1 |
| Thein, TZ | 1 |
| Markland, FS | 1 |
| Eisemann, T | 1 |
| Costa, B | 2 |
| Angel, P | 1 |
| Peterziel, H | 1 |
| Kan, P | 1 |
| Yao, X | 1 |
| Pan, MH | 1 |
| Abouzid, K | 1 |
| Liu, LZ | 3 |
| Jiang, BH | 3 |
| Horibe, T | 1 |
| Torisawa, A | 1 |
| Masuda, Y | 1 |
| Kawakami, K | 1 |
| Bailey, D | 3 |
| Hsiao, E | 3 |
| Chen, XB | 1 |
| Ding, BQ | 1 |
| Liu, HL | 2 |
| He, T | 1 |
| Shao, N | 1 |
| Xue, L | 1 |
| Zhi, F | 1 |
| Donovan, LE | 2 |
| Ameratunga, M | 1 |
| Pavlakis, N | 2 |
| Grant, R | 4 |
| Dworkin, M | 1 |
| Mehan, W | 1 |
| Niemierko, A | 1 |
| Kamran, SC | 1 |
| Lamba, N | 1 |
| Martinez-Lage, M | 2 |
| Pinzi, V | 1 |
| Ciammella, P | 2 |
| Galaverni, M | 2 |
| Amelio, D | 2 |
| Scartoni, D | 1 |
| Draghini, L | 1 |
| Borzillo, V | 1 |
| Muto, P | 4 |
| Ferrarese, F | 1 |
| Fariselli, L | 6 |
| Alongi, F | 1 |
| di Monale, MB | 1 |
| Magrini, S | 1 |
| Yao, Z | 1 |
| Fabbro-Peray, P | 1 |
| Zouaoui, S | 2 |
| Fabbro, M | 5 |
| Mathieu-Daude, H | 1 |
| Bessaoud, F | 1 |
| Bauchet, F | 1 |
| Riondel, A | 1 |
| Sorbets, E | 1 |
| Charissoux, M | 2 |
| Mandonnet, E | 4 |
| Tretarre, B | 1 |
| Wei, C | 1 |
| Zhen, Y | 1 |
| Marino, A | 1 |
| Almici, E | 1 |
| Migliorin, S | 1 |
| Tapeinos, C | 1 |
| Battaglini, M | 1 |
| Cappello, V | 1 |
| Marchetti, M | 2 |
| de Vito, G | 1 |
| Cicchi, R | 1 |
| Pavone, FS | 1 |
| Ciofani, G | 1 |
| Qi, F | 1 |
| Di, J | 1 |
| Chang, J | 1 |
| Przystal, JM | 1 |
| Hajji, N | 1 |
| Khozoie, C | 1 |
| Zeng, Q | 1 |
| Abaitua, F | 1 |
| Hajitou, A | 1 |
| Suwan, K | 1 |
| Want, E | 1 |
| Bomalaski, J | 1 |
| Szlosarek, P | 1 |
| O'Neill, K | 1 |
| Atkins, RJ | 1 |
| Kurganovs, N | 1 |
| Mangiola, S | 1 |
| Nowell, CJ | 1 |
| Ware, TM | 1 |
| Corcoran, NM | 1 |
| Brown, DV | 2 |
| Morokoff, A | 1 |
| Hovens, CM | 1 |
| Dai, D | 1 |
| Zhou, M | 2 |
| Xiao, W | 2 |
| Zhu, L | 4 |
| Huang, S | 4 |
| Qi, P | 1 |
| Karlsson, I | 1 |
| Veevnik, D | 1 |
| Fedulov, A | 1 |
| Yurkshtovich, N | 1 |
| Yurkshtovich, T | 1 |
| Pejler, G | 1 |
| Lokot, I | 1 |
| Guo, S | 2 |
| Brunetti, A | 1 |
| Marinelli, O | 1 |
| Iannarelli, R | 1 |
| Russotti, D | 1 |
| Gorelick, N | 2 |
| Doglioli, M | 1 |
| Tagliaferri, V | 1 |
| Peters, M | 1 |
| Langer, R | 3 |
| Shi, HY | 1 |
| Ma, R | 2 |
| Zheng, G | 1 |
| Shao, C | 1 |
| Lee, DJ | 3 |
| Bilir, A | 3 |
| Wen, X | 1 |
| Liu, T | 3 |
| Sayour, EJ | 1 |
| Azari, H | 1 |
| Long, Y | 1 |
| Flores, C | 2 |
| Mainprize, T | 1 |
| Lipsman, N | 1 |
| Bethune, A | 1 |
| Ironside, S | 1 |
| Heyn, C | 1 |
| Alkins, R | 1 |
| Trudeau, M | 1 |
| Hynynen, K | 1 |
| Jayamanne, DT | 1 |
| Newey, A | 2 |
| Schembri, GP | 1 |
| Clarke, S | 1 |
| Bhaskaran, V | 1 |
| Idriss, M | 1 |
| Jimenez, MA | 1 |
| Lugli, G | 1 |
| Hayes, JL | 1 |
| Mahmoud, AB | 1 |
| Zane, RE | 1 |
| Passaro, C | 1 |
| Bronisz, A | 1 |
| Godlewski, J | 1 |
| Peruzzi, P | 3 |
| Carter, TC | 1 |
| Medina-Flores, R | 1 |
| Lawler, BE | 1 |
| Musah-Eroje, A | 1 |
| Watson, S | 1 |
| Pellosi, DS | 1 |
| Paula, LB | 1 |
| de Melo, MT | 1 |
| Tedesco, AC | 1 |
| Stéphanou, A | 1 |
| Ballesta, A | 1 |
| Heynckes, S | 1 |
| Daka, K | 1 |
| Franco, P | 2 |
| Gaebelein, A | 1 |
| Frenking, JH | 1 |
| Doria-Medina, R | 1 |
| Mader, I | 2 |
| Delev, D | 2 |
| Autran, D | 1 |
| Barrie, M | 7 |
| Matta, M | 2 |
| Monserrat, C | 1 |
| Campello, C | 5 |
| Petrirena, G | 1 |
| Boucard, C | 3 |
| Padovani, L | 4 |
| Loundou, A | 3 |
| Appay, R | 1 |
| Dufour, H | 5 |
| Woo, PYM | 1 |
| Ho, JMK | 1 |
| Tse, TPK | 1 |
| Lam, SW | 1 |
| Mak, CHK | 1 |
| Lee, MWY | 1 |
| Kawasaki, T | 1 |
| Miwa, K | 1 |
| Shinoda, J | 1 |
| Asano, Y | 2 |
| Takei, H | 1 |
| Ikegame, Y | 1 |
| Yokoyama, K | 1 |
| Tošić, S | 1 |
| Vitorović, J | 1 |
| Stamenković, S | 1 |
| Kostić, A | 1 |
| Vidović, N | 1 |
| Krstić, M | 1 |
| Jevtović-Stoimenov, T | 1 |
| Pavlović, D | 1 |
| Plummer, S | 1 |
| Wallace, S | 1 |
| Ball, G | 1 |
| Lloyd, R | 1 |
| Schiapparelli, P | 1 |
| Hartung, T | 1 |
| Pamies, D | 1 |
| Foltyn, M | 1 |
| Luger, AL | 1 |
| Lorenz, NI | 1 |
| Sauer, B | 1 |
| Storey, K | 1 |
| Leder, K | 1 |
| Swanson, K | 1 |
| Rockne, RC | 2 |
| Foo, J | 1 |
| Cohen, AL | 1 |
| Fink, K | 4 |
| Marcus, S | 1 |
| Danieli, D | 1 |
| Pizzolitto, S | 1 |
| Zunarelli, E | 1 |
| Di Oto, E | 1 |
| Scafati, C | 1 |
| Asioli, S | 1 |
| Lu, R | 1 |
| Lu, JJ | 1 |
| Wei, M | 2 |
| Laprie, A | 2 |
| Ken, S | 2 |
| Filleron, T | 2 |
| Vieillevigne, L | 2 |
| Tensaouti, F | 1 |
| Catalaa, I | 1 |
| Boetto, S | 1 |
| Khalifa, J | 1 |
| Attal, J | 1 |
| Peyraga, G | 1 |
| Gomez-Roca, C | 1 |
| Noel, G | 11 |
| Truc, G | 5 |
| Sunyach, MP | 3 |
| Supiot, S | 1 |
| Bernier, V | 5 |
| Mounier, M | 1 |
| Poublanc, M | 1 |
| Fabre, A | 1 |
| Delord, JP | 1 |
| Killock, D | 1 |
| Ha, W | 2 |
| Sevim-Nalkiran, H | 1 |
| Zaman, AM | 1 |
| Matsuda, K | 1 |
| Chung, L | 1 |
| Baxter, RC | 1 |
| Ornelas, AS | 1 |
| Knox, MG | 1 |
| Marks, LA | 1 |
| Wingerchuk, DM | 1 |
| O'Carroll, CB | 1 |
| Winter, SF | 1 |
| Loebel, F | 1 |
| Loeffler, J | 1 |
| Lesueur, P | 1 |
| Lequesne, J | 1 |
| Grellard, JM | 1 |
| Dugué, A | 1 |
| Coquan, E | 1 |
| Brachet, PE | 1 |
| Geffrelot, J | 1 |
| Kao, W | 1 |
| Berro, DH | 1 |
| Castera, L | 1 |
| Goardon, N | 1 |
| Lacroix, J | 1 |
| Lange, M | 1 |
| Capel, A | 1 |
| Leconte, A | 1 |
| Andre, B | 1 |
| Léger, A | 1 |
| Lelaidier, A | 1 |
| Clarisse, B | 1 |
| Stefan, D | 1 |
| Chua, J | 1 |
| Nafziger, E | 1 |
| Sabelström, H | 1 |
| Quigley, DA | 1 |
| Fenster, T | 1 |
| Foster, DJ | 1 |
| Fuchshuber, CAM | 1 |
| Saxena, S | 1 |
| Yuan, E | 1 |
| Paterno, F | 1 |
| Norling, B | 1 |
| Persson, AI | 3 |
| Weng, Z | 1 |
| Xin, Z | 2 |
| Erausquin, E | 1 |
| Mazor, G | 1 |
| Levin, L | 1 |
| Ahmadov, U | 1 |
| Carén, H | 1 |
| Borkhardt, A | 1 |
| Leprivier, G | 1 |
| Rotblat, B | 1 |
| Hettiarachchi, SD | 1 |
| Graham, RM | 1 |
| Mintz, KJ | 1 |
| Vanni, S | 1 |
| Peng, Z | 1 |
| Leblanc, RM | 1 |
| Banik, P | 1 |
| Bharti, R | 1 |
| Nayak, S | 1 |
| Ghosh, SK | 1 |
| Matusova, M | 1 |
| Baran-Schmidt, R | 1 |
| Han, N | 2 |
| Xu, HY | 1 |
| Norden, AD | 6 |
| Korytowsky, B | 1 |
| You, M | 1 |
| Kim Le, T | 1 |
| Dastani, H | 1 |
| Bobiak, S | 1 |
| Kerezoudis, P | 1 |
| Brown, DA | 1 |
| Chaichana, KL | 5 |
| Hasan, T | 1 |
| Caragher, SP | 1 |
| Dey, M | 5 |
| Zeng, X | 1 |
| Tan, X | 1 |
| Jia, L | 1 |
| Hu, M | 2 |
| Perez, JL | 1 |
| Mansour, NM | 1 |
| Szymura, SJ | 1 |
| Uppal, A | 1 |
| Raleigh, DR | 1 |
| Spretz, R | 2 |
| Nunez, L | 2 |
| Larsen, G | 1 |
| Khodarev, NN | 1 |
| Kumari, N | 1 |
| Thakur, N | 1 |
| Cho, HR | 1 |
| Goyal, A | 1 |
| Graffeo, CS | 1 |
| Lamano, JB | 1 |
| Quaggin-Smith, JA | 1 |
| Tate, MC | 1 |
| Grimm, SA | 5 |
| Kumthekar, PU | 1 |
| Bloch, O | 2 |
| Antonopoulos, M | 1 |
| Dionysiou, D | 1 |
| Graf, N | 1 |
| Stamatakos, G | 1 |
| Schipper, M | 2 |
| Umemura, Y | 1 |
| Seliger, C | 2 |
| Pang, HH | 1 |
| Chou, YW | 1 |
| Lin, CJ | 2 |
| Zhou, ZL | 1 |
| Shiue, YL | 1 |
| Yang, HW | 1 |
| Burić, SS | 1 |
| Podolski-Renić, A | 1 |
| Dinić, J | 1 |
| Stanković, T | 1 |
| Jovanović, M | 1 |
| Hadžić, S | 1 |
| Ayuso, JM | 1 |
| Virumbrales-Muñoz, M | 1 |
| Fernández, LJ | 1 |
| Ochoa, I | 1 |
| Dirkse, A | 1 |
| Buder, T | 1 |
| Brons, NHC | 1 |
| Leite, S | 1 |
| Sauvageot, N | 1 |
| Sarkisjan, D | 1 |
| Seyfrid, M | 1 |
| Fritah, S | 1 |
| Deutsch, A | 1 |
| Voss-Böhme, A | 1 |
| Brenner, A | 4 |
| Bozek, DA | 1 |
| Rajakulendran, N | 1 |
| Monteiro, V | 1 |
| Ahmadi, M | 1 |
| Steinhart, Z | 1 |
| Kushida, MM | 1 |
| Coutinho, FJ | 1 |
| Cavalli, FMG | 1 |
| Restall, I | 1 |
| Hart, T | 1 |
| Bi, N | 1 |
| Xiao, J | 1 |
| Yi, J | 1 |
| Giaccherini, L | 1 |
| Renna, I | 1 |
| Timon, G | 1 |
| Galeandro, M | 1 |
| Pisanello, A | 3 |
| Russo, M | 1 |
| Botti, A | 1 |
| Iotti, C | 1 |
| Zheng, YY | 1 |
| Liu, WL | 3 |
| Huang, GD | 1 |
| Li, WP | 1 |
| Seyfried, TN | 1 |
| Shelton, L | 1 |
| Arismendi-Morillo, G | 1 |
| Kalamian, M | 1 |
| Elsakka, A | 1 |
| Maroon, J | 1 |
| Mukherjee, P | 1 |
| Brown, C | 2 |
| Skaga, E | 1 |
| Skaga, IØ | 1 |
| Grieg, Z | 1 |
| Sandberg, CJ | 1 |
| Langmoen, IA | 1 |
| Vik-Mo, EO | 1 |
| Sohrabi, A | 1 |
| Ehsanipour, A | 1 |
| Bierman, RD | 1 |
| Nathanson, DA | 1 |
| Seidlits, SK | 1 |
| Xue, D | 1 |
| Ou-Yang, Y | 1 |
| Mai, J | 1 |
| Sheng, L | 1 |
| Xing, F | 1 |
| Yan, G | 1 |
| Zeng, T | 1 |
| Pedretti, S | 2 |
| Turco, E | 1 |
| Triggiani, L | 2 |
| Meduri, B | 1 |
| Borghetti, P | 2 |
| Pegurri, L | 1 |
| Riva, N | 1 |
| Gatta, R | 1 |
| Bruni, A | 1 |
| Megías, J | 1 |
| Martínez, A | 1 |
| San-Miguel, T | 1 |
| Gil-Benso, R | 1 |
| Muñoz-Hidalgo, L | 1 |
| Albert-Bellver, D | 1 |
| Carratalá, A | 1 |
| Gozalbo, D | 1 |
| López-Ginés, C | 1 |
| Gil, ML | 1 |
| Cerdá-Nicolás, M | 2 |
| Forte, IM | 1 |
| Indovina, P | 1 |
| Iannuzzi, CA | 1 |
| Cirillo, D | 1 |
| Di Marzo, D | 1 |
| Barone, D | 1 |
| Capone, F | 1 |
| Pentimalli, F | 1 |
| Giordano, A | 2 |
| Yin, AA | 3 |
| He, YL | 1 |
| Etcheverry, A | 2 |
| Liu, YH | 3 |
| Aubry, M | 1 |
| Liu, BL | 3 |
| Mosser, J | 3 |
| Lu, ZF | 1 |
| Jin, C | 1 |
| Liu, K | 1 |
| Di Pierro, F | 1 |
| Simonetti, G | 2 |
| Petruzzi, A | 1 |
| Bertuccioli, A | 1 |
| Botta, L | 1 |
| Bruzzone, MG | 1 |
| Cuccarini, V | 1 |
| Lamperti, E | 6 |
| van Leyen, K | 1 |
| Gruber, P | 1 |
| Remonda, L | 1 |
| Berberat, J | 2 |
| Zhao, SG | 1 |
| Chang, SL | 1 |
| Feng, FY | 1 |
| Speers, CW | 1 |
| Mihajluk, K | 1 |
| Simms, C | 1 |
| Reay, M | 1 |
| Madureira, PA | 1 |
| Howarth, A | 1 |
| Murray, P | 1 |
| Nasser, S | 1 |
| Duckworth, CA | 1 |
| Pritchard, DM | 1 |
| Pilkington, GJ | 1 |
| Hill, R | 1 |
| Aulakh, S | 1 |
| DeDeo, MR | 1 |
| Free, J | 1 |
| Rosenfeld, SS | 2 |
| Paulus, A | 1 |
| Manna, A | 1 |
| Manochakian, R | 1 |
| Chanan-Khan, AA | 1 |
| Ailawadhi, S | 1 |
| Yi, HG | 1 |
| Jeong, YH | 1 |
| Choi, YJ | 1 |
| Moon, HE | 1 |
| Kang, KS | 1 |
| Bae, M | 1 |
| Jang, J | 1 |
| Youn, H | 1 |
| Cho, DW | 1 |
| Liu, SA | 1 |
| Sullivan, T | 1 |
| Bryce, C | 1 |
| Chan, AM | 1 |
| Cilmi, S | 1 |
| Tezcan, G | 3 |
| Aksoy, SA | 1 |
| Tunca, B | 3 |
| Bekar, A | 3 |
| Mutlu, M | 1 |
| Cecener, G | 3 |
| Egeli, U | 3 |
| Kocaeli, H | 2 |
| Demirci, H | 1 |
| Taskapilioglu, MO | 3 |
| Jablonska, PA | 1 |
| Diez-Valle, R | 2 |
| Pérez-Larraya, JG | 1 |
| Moreno-Jiménez, M | 1 |
| Arbea, L | 1 |
| Tejada, S | 2 |
| Garcia de Eulate, MR | 1 |
| Ramos, L | 1 |
| Arbizu, J | 1 |
| Domínguez, P | 1 |
| Aristu, JJ | 1 |
| Zeng, W | 1 |
| Elbaroody, M | 1 |
| Ranjit, M | 2 |
| Petővári, G | 1 |
| Dankó, T | 1 |
| Krencz, I | 1 |
| Hujber, Z | 1 |
| Rajnai, H | 1 |
| Vetlényi, E | 1 |
| Raffay, R | 1 |
| Pápay, J | 1 |
| Jeney, A | 1 |
| Sebestyén, A | 1 |
| Xingyi, J | 1 |
| Guonan, C | 1 |
| Naijie, L | 1 |
| Vengoji, R | 1 |
| Macha, MA | 1 |
| Nimmakayala, RK | 1 |
| Rachagani, S | 1 |
| Siddiqui, JA | 1 |
| Mallya, K | 1 |
| Gorantla, S | 1 |
| Jain, M | 1 |
| Ponnusamy, MP | 1 |
| Batra, SK | 1 |
| Lizarte Neto, FS | 1 |
| Rodrigues, AR | 1 |
| Trevisan, FA | 1 |
| de Assis Cirino, ML | 1 |
| Matias, CCMS | 1 |
| Pereira-da-Silva, G | 1 |
| Peria, FM | 1 |
| Tirapelli, DPDC | 1 |
| Carlotti, CG | 4 |
| Chai, Y | 1 |
| Ravi, VM | 1 |
| Joseph, K | 1 |
| Wurm, J | 1 |
| Behringer, S | 1 |
| Garrelfs, N | 1 |
| d'Errico, P | 1 |
| Naseri, Y | 1 |
| Meyer-Luehmann, M | 1 |
| Sankowski, R | 1 |
| Shah, MJ | 1 |
| Follo, M | 1 |
| Beck, J | 2 |
| Hofmann, UG | 1 |
| Batalini, F | 1 |
| Kaufmann, MR | 1 |
| Aleixo, GF | 1 |
| Drews, R | 1 |
| Appelboom, G | 1 |
| Verry, C | 1 |
| Barbier, EL | 1 |
| Lux, F | 1 |
| Bräuer-Krisch, E | 2 |
| Sancey, L | 1 |
| Roux, S | 1 |
| Tillement, O | 1 |
| Friger, M | 1 |
| Geffen, DB | 1 |
| Kaisman-Elbaz, T | 1 |
| Lavrenkov, K | 1 |
| Smiljanic, S | 1 |
| Kaskun, O | 1 |
| Ghannad-Zadeh, K | 1 |
| Isaev, K | 1 |
| Morrissy, AS | 1 |
| Tong, J | 2 |
| Chan, J | 1 |
| Wilson, TM | 1 |
| Al-Omaishi, S | 1 |
| Munoz, DG | 1 |
| Moran, MF | 1 |
| Taylor, MD | 1 |
| Reimand, J | 2 |
| Domoto, T | 1 |
| Hirao, A | 1 |
| Bozzato, E | 1 |
| Joudiou, N | 1 |
| Ghiassinejad, S | 1 |
| Danhier, F | 3 |
| Gallez, B | 1 |
| Préat, V | 2 |
| Wang, MD | 1 |
| Li, RC | 1 |
| Xie, WF | 1 |
| Junold, N | 1 |
| Borchers, C | 3 |
| Gerlach, R | 1 |
| Corradini, S | 1 |
| Rottler, M | 1 |
| Förster, S | 1 |
| la Fougère, C | 3 |
| Siepmann, T | 1 |
| Schwaiger, M | 1 |
| Yu, L | 4 |
| Lei, B | 1 |
| Gong, K | 1 |
| Puliyappadamba, VT | 3 |
| Panchani, N | 1 |
| Mukherjee, B | 4 |
| Damanwalla, Z | 1 |
| Bharia, S | 1 |
| Hatanpaa, KJ | 4 |
| Gerber, DE | 2 |
| Mickey, BE | 2 |
| Patel, TR | 1 |
| Zhao, D | 2 |
| Burma, S | 6 |
| Habib, AA | 4 |
| Chung, CY | 1 |
| Gui, S | 1 |
| Fan, J | 2 |
| Qiu, B | 1 |
| Joshi, K | 2 |
| Mo, X | 1 |
| Kig, C | 1 |
| Nardini, D | 1 |
| Sobol, RW | 2 |
| Chow, LM | 1 |
| Waclaw, R | 1 |
| Beullens, M | 1 |
| Poteet, E | 1 |
| Choudhury, GR | 1 |
| Winters, A | 1 |
| Ryou, MG | 1 |
| Ghorpade, A | 1 |
| Wen, Y | 1 |
| Bigner, DD | 17 |
| Simpkins, JW | 1 |
| Kumar, S | 1 |
| Narang, J | 1 |
| Schultz, L | 3 |
| Siddiqui, S | 1 |
| Poptani, H | 2 |
| Jain, R | 2 |
| Goeppert, M | 1 |
| Jastaniyah, N | 1 |
| Murtha, A | 1 |
| Pervez, N | 1 |
| Le, D | 1 |
| Patel, S | 4 |
| Mackenzie, M | 1 |
| Fulton, D | 3 |
| Field, C | 1 |
| Fallone, G | 1 |
| Spiller, SE | 1 |
| Harrison, DK | 1 |
| Kovanda, T | 1 |
| Braca, J | 1 |
| Prabhu, V | 1 |
| Marcus, DM | 1 |
| Lowe, M | 1 |
| Khan, MK | 1 |
| Lawson, DH | 1 |
| Crocker, IR | 3 |
| Shelton, JW | 1 |
| Melton, A | 1 |
| Maynard, N | 1 |
| Delman, KA | 1 |
| Carlson, GW | 1 |
| Rizzo, M | 1 |
| Ho, AS | 2 |
| Pu, JK | 3 |
| Zhang, XQ | 5 |
| Lee, NP | 3 |
| Day, PJ | 2 |
| Lui, WM | 3 |
| Fung, CF | 2 |
| Hargrave, D | 3 |
| Geoerger, B | 2 |
| Frappaz, D | 7 |
| Gesner, L | 1 |
| Cisar, L | 1 |
| Breazna, A | 1 |
| Dorman, A | 1 |
| Cruz-Martinez, O | 1 |
| Fuster, JL | 1 |
| Rialland, X | 1 |
| Icher, C | 1 |
| Perilongo, G | 2 |
| Elliott, M | 1 |
| English, M | 1 |
| Clausen, N | 1 |
| Graus, F | 3 |
| Pardo, J | 1 |
| Escudero, D | 1 |
| Vilas, D | 1 |
| Barceló, I | 1 |
| Brell, M | 1 |
| Pascual, C | 1 |
| Crespo, JA | 1 |
| Erro, E | 1 |
| García-Romero, JC | 1 |
| Estela, J | 1 |
| Martino, J | 1 |
| García-Castaño, A | 1 |
| Mata, E | 1 |
| Lema, M | 1 |
| Gelabert, M | 1 |
| Fuentes, R | 1 |
| Pérez, P | 1 |
| Manzano, A | 1 |
| Aguas, J | 1 |
| Belenguer, A | 1 |
| Simón, A | 1 |
| Henríquez, I | 2 |
| Murcia, M | 1 |
| Vivanco, R | 1 |
| Rojas-Marcos, I | 3 |
| Muñoz-Carmona, D | 1 |
| Navas, I | 1 |
| de Andrés, P | 1 |
| Mas, G | 1 |
| Gil, M | 5 |
| Verger, E | 4 |
| Deutsch, MB | 1 |
| Gozé, C | 2 |
| Beauchesne, P | 5 |
| Baron, MH | 2 |
| Fontaine, D | 3 |
| Cen, L | 1 |
| Grogan, PT | 4 |
| Grah, JJ | 1 |
| Katalinic, D | 1 |
| Stern-Padovan, R | 1 |
| Paladino, J | 1 |
| Santek, F | 1 |
| Juretic, A | 1 |
| Zarkovic, K | 1 |
| Plestina, S | 1 |
| Supe, M | 1 |
| Czabanka, M | 2 |
| Bruenner, J | 1 |
| Parmaksiz, G | 1 |
| Broggini, T | 1 |
| Topalovic, M | 1 |
| Bayerl, SH | 1 |
| Auf, G | 1 |
| Nieminen, M | 1 |
| Jabouille, A | 1 |
| Harms, U | 1 |
| Harms, C | 1 |
| Heppner, FL | 3 |
| Misaki, K | 2 |
| Nakanuma, Y | 1 |
| Hamada, J | 2 |
| Kohsaka, S | 2 |
| Kanno, H | 4 |
| Chu, SH | 1 |
| Ma, YB | 1 |
| Feng, DF | 1 |
| Jiang, PC | 1 |
| Ilgaz, S | 1 |
| Ozdemir, M | 1 |
| Oztuna, D | 1 |
| Canpinar, H | 1 |
| Sunguroğlu, A | 1 |
| Ugur, HC | 1 |
| Barker, CA | 2 |
| Bishop, AJ | 1 |
| Chang, M | 2 |
| Beal, K | 6 |
| Chan, TA | 5 |
| Shonka, NA | 1 |
| Theeler, B | 1 |
| Cahill, D | 1 |
| Yung, A | 2 |
| Smith, L | 1 |
| Lei, X | 1 |
| Chu, PC | 1 |
| Wang, HY | 1 |
| Lu, YJ | 1 |
| Lee, PY | 1 |
| Tseng, IC | 1 |
| Yen, TC | 1 |
| Sanchez-Perez, LA | 1 |
| Archer, GE | 7 |
| Johnson, LA | 1 |
| Schmittling, RJ | 3 |
| Snyder, D | 1 |
| Murata, H | 1 |
| Amano, T | 1 |
| Nakamizo, A | 1 |
| Iwaki, T | 1 |
| Gutenberg, A | 4 |
| Lumenta, CB | 1 |
| Braunsdorf, WE | 1 |
| Mehdorn, HM | 7 |
| Guerrero-Cazares, H | 1 |
| Ford, E | 1 |
| McNutt, T | 1 |
| Chaichana, K | 1 |
| Redmond, K | 1 |
| Yeo, KK | 1 |
| Puscasiu, E | 1 |
| Keating, RF | 1 |
| Rood, BR | 1 |
| Santoni, M | 3 |
| Burattini, L | 2 |
| Berardi, R | 1 |
| Cascinu, S | 3 |
| Kruser, TJ | 1 |
| Li, RY | 1 |
| Chen, LC | 1 |
| Zhang, HY | 1 |
| Du, WZ | 1 |
| Wang, HB | 1 |
| Wen, JQ | 1 |
| Li, XF | 1 |
| Yang, DB | 1 |
| Li, YL | 1 |
| Jiang, CL | 1 |
| Hammond, SN | 1 |
| Reardon, DR | 1 |
| Fadul, CE | 3 |
| Muzikansky, A | 5 |
| Doherty, L | 3 |
| Lafrankie, D | 3 |
| Smith, K | 1 |
| Tafoya, V | 1 |
| Lis, R | 1 |
| Stack, EC | 1 |
| Hummel, TR | 1 |
| Wagner, L | 3 |
| Ahern, C | 1 |
| Reid, JM | 2 |
| McGovern, RM | 2 |
| Ames, MM | 2 |
| Gilbertson, RJ | 3 |
| Horton, T | 1 |
| Ingle, AM | 3 |
| Weigel, B | 1 |
| Merz, F | 1 |
| Dehghani, F | 1 |
| Schopow, K | 1 |
| Hellwig, C | 1 |
| Schäfer, M | 1 |
| Bauer, M | 1 |
| Stöcker, H | 1 |
| Taucher-Scholz, G | 1 |
| Durante, M | 1 |
| Martínez-Aranda, A | 1 |
| Hernández, V | 1 |
| Picón, C | 1 |
| Modolell, I | 1 |
| Sierra, A | 1 |
| Kast, RE | 7 |
| Brüning, A | 1 |
| Cappello, F | 1 |
| Chang, WW | 1 |
| Cvek, B | 1 |
| Dou, QP | 1 |
| Duenas-Gonzalez, A | 1 |
| Focosi, D | 1 |
| Ghaffari, SH | 1 |
| Ketola, K | 1 |
| Khoshnevisan, A | 1 |
| Keizman, D | 1 |
| McDonald, K | 1 |
| Muñoz, M | 2 |
| Paranjpe, A | 1 |
| Pourgholami, MH | 1 |
| Sardi, I | 2 |
| Sella, A | 1 |
| Srivenugopal, KS | 1 |
| Tuccori, M | 1 |
| Wirtz, CR | 3 |
| Massimino, M | 4 |
| Casanova, M | 1 |
| Polastri, D | 1 |
| Biassoni, V | 1 |
| Modena, P | 1 |
| Pecori, E | 1 |
| Schiavello, E | 1 |
| De Pava, MV | 1 |
| Indini, A | 1 |
| Bauer, D | 1 |
| Catania, S | 1 |
| Podda, M | 1 |
| Gandola, L | 1 |
| Quann, K | 1 |
| Gonzales, DM | 1 |
| Mercier, I | 1 |
| Sotgia, F | 1 |
| Pestell, RG | 1 |
| Lisanti, MP | 1 |
| Jasmin, JF | 1 |
| Shields, LB | 2 |
| Kadner, R | 1 |
| Vitaz, TW | 1 |
| Spalding, AC | 2 |
| Turpin, B | 1 |
| Nagarajan, R | 1 |
| Weiss, B | 1 |
| Cripe, T | 1 |
| Geller, J | 1 |
| Hart, MG | 2 |
| Garside, R | 3 |
| Rogers, G | 3 |
| Stein, K | 3 |
| Lou, E | 3 |
| Sumrall, AL | 2 |
| Coan, A | 4 |
| Bailey, L | 3 |
| Turner, S | 2 |
| Vredenburgh, JJ | 21 |
| Baldoni, A | 1 |
| De Sanctis, V | 6 |
| Enrici, RM | 8 |
| Ratai, EM | 1 |
| Snyder, BS | 3 |
| McKinstry, RC | 1 |
| Josset, E | 2 |
| Burckel, H | 2 |
| Bischoff, P | 2 |
| Bock, HC | 4 |
| Brück, W | 2 |
| Doerner, L | 1 |
| Roggendorf, W | 1 |
| Ruggiero, A | 4 |
| Rizzo, D | 2 |
| Attinà, G | 2 |
| Lazzareschi, I | 4 |
| Maurizi, P | 3 |
| Ridola, V | 4 |
| Mastrangelo, S | 2 |
| Migliorati, R | 1 |
| Bertolini, P | 1 |
| Colosimo, C | 3 |
| Riccardi, R | 5 |
| Herrmann, C | 1 |
| Becker, KA | 1 |
| Gulbins, E | 1 |
| Waters, JD | 2 |
| Rose, B | 1 |
| Gonda, DD | 2 |
| Scanderbeg, DJ | 1 |
| Russell, M | 1 |
| Alksne, JF | 1 |
| Murphy, K | 1 |
| Lawson, J | 1 |
| Van Mieghem, E | 1 |
| Wozniak, A | 1 |
| Geussens, Y | 1 |
| Van Calenbergh, F | 1 |
| Bechter, OE | 1 |
| Demaerel, P | 1 |
| Wilms, G | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 1 |
| Zwinkels, H | 3 |
| Walchenbach, R | 2 |
| Taphoorn, MJ | 19 |
| Vecht, CJ | 6 |
| Murphy, ÁC | 1 |
| Weyhenmeyer, B | 1 |
| Schmid, J | 1 |
| Kilbride, SM | 1 |
| Senft, C | 2 |
| Weissenberger, J | 1 |
| Seifert, V | 5 |
| Dunst, M | 1 |
| Kögel, D | 2 |
| Prehn, JH | 2 |
| Clark, SW | 1 |
| Taylor, J | 1 |
| Wang, DL | 1 |
| Abramson, JS | 1 |
| Gielen, PR | 1 |
| Aftab, Q | 1 |
| Ma, N | 1 |
| Chen, VC | 1 |
| Lozinsky, S | 1 |
| Naus, CC | 1 |
| Sin, WC | 1 |
| Sasajima, T | 2 |
| Shimada, N | 1 |
| Doi, Y | 2 |
| Oka, S | 2 |
| Kanagawa, M | 2 |
| Baden, A | 2 |
| Mizoi, K | 2 |
| Niibori-Nambu, A | 1 |
| Midorikawa, U | 1 |
| Mizuguchi, S | 1 |
| Hide, T | 2 |
| Nagai, M | 1 |
| Komohara, Y | 1 |
| Nagayama, M | 1 |
| Hirayama, M | 1 |
| Kobayashi, D | 1 |
| Tsubota, N | 1 |
| Takezaki, T | 2 |
| Takeya, M | 1 |
| Kuratsu, J | 3 |
| Araki, N | 1 |
| Köritzer, J | 1 |
| Boxhammer, V | 1 |
| Shimizu, T | 1 |
| Klämpfl, TG | 1 |
| Welz, C | 1 |
| Schwenk-Zieger, S | 1 |
| Morfill, GE | 1 |
| Zimmermann, JL | 1 |
| Wendland, M | 1 |
| Dipetrillo, TA | 1 |
| Gaspar, LE | 9 |
| Kavanagh, BD | 9 |
| Waziri, A | 6 |
| Damek, DM | 3 |
| Ney, D | 3 |
| Sooman, L | 1 |
| Ekman, S | 2 |
| Andersson, C | 1 |
| Kultima, HG | 1 |
| Isaksson, A | 1 |
| Johansson, F | 2 |
| Bergqvist, M | 2 |
| Blomquist, E | 2 |
| Lennartsson, J | 1 |
| Gullbo, J | 1 |
| Chu, HH | 1 |
| Ryoo, I | 2 |
| Kim, SC | 1 |
| Yeom, JA | 1 |
| Shin, H | 1 |
| Lee, AL | 1 |
| Yoon, TJ | 1 |
| Anderson, MD | 1 |
| Ejaz, S | 1 |
| Shawa, H | 1 |
| Henderson, SA | 1 |
| Habra, MA | 1 |
| Larvie, M | 2 |
| Chi, TL | 1 |
| Lopez, D | 1 |
| de la Peñas, R | 1 |
| García-Bueno, JM | 1 |
| Molina-Garrido, MJ | 1 |
| Cano, JM | 1 |
| Bugés, C | 1 |
| Sanz, SM | 1 |
| Arranz, JL | 1 |
| Rodriguez, A | 1 |
| Martin, JM | 1 |
| Benavides, M | 3 |
| Lolli, I | 2 |
| Morra, I | 1 |
| Cimmino, A | 1 |
| Trevisan, E | 2 |
| Piombino, M | 2 |
| Campanella, G | 1 |
| Gillio Tos, A | 1 |
| De Marco, L | 2 |
| Trevisan, M | 3 |
| Fiano, V | 4 |
| Penas, C | 1 |
| Pastori, C | 1 |
| Komotar, RJ | 1 |
| Bregy, A | 1 |
| Wahlestedt, C | 1 |
| Ayad, NG | 1 |
| Silver, DJ | 1 |
| Tugertimur, B | 1 |
| Deleyrolle, LP | 1 |
| Siebzehnrubl, D | 1 |
| Sarkisian, MR | 1 |
| Devers, KG | 1 |
| Yachnis, AT | 1 |
| Kupper, MD | 1 |
| Neal, D | 1 |
| Nabilsi, NH | 1 |
| Kladde, MP | 1 |
| Suslov, O | 1 |
| Brabletz, S | 1 |
| Brabletz, T | 1 |
| Reynolds, BA | 2 |
| Steindler, DA | 1 |
| Riccitelli, E | 1 |
| Di Vito, C | 1 |
| Condomitti, G | 1 |
| Galli, R | 2 |
| Viani, P | 1 |
| Lee, DY | 1 |
| Chunta, JL | 1 |
| Park, SS | 1 |
| Martinez, AA | 1 |
| Grills, IS | 1 |
| Krueger, SA | 1 |
| Wilson, GD | 1 |
| Marples, B | 1 |
| Qi, XC | 1 |
| Xie, DJ | 1 |
| Yan, QF | 1 |
| Wang, YR | 1 |
| Zhu, YX | 1 |
| Qian, C | 2 |
| Yang, SX | 1 |
| Viel, T | 1 |
| Schelhaas, S | 1 |
| Wagner, S | 1 |
| Wachsmuth, L | 1 |
| Schwegmann, K | 1 |
| Kuhlmann, M | 1 |
| Faber, C | 1 |
| Kopka, K | 1 |
| Schäfers, M | 1 |
| Jacobs, AH | 3 |
| Díez Valle, R | 1 |
| Slof, J | 1 |
| Galván, J | 1 |
| Arza, C | 1 |
| Romariz, C | 1 |
| Pezuk, JA | 1 |
| Morales, AG | 1 |
| de Oliveira, JC | 1 |
| de Paula Queiroz, RG | 2 |
| Machado, HR | 1 |
| Neder, L | 1 |
| Scrideli, CA | 3 |
| Tone, LG | 3 |
| Dilnawaz, F | 1 |
| Sahoo, SK | 1 |
| LaRiviere, MJ | 1 |
| Kang, S | 1 |
| Welp, U | 1 |
| Noriega, SE | 1 |
| Larsen, GF | 1 |
| Nicholas, MK | 4 |
| Caldera, V | 2 |
| Campia, I | 1 |
| Bosia, A | 1 |
| Ghigo, D | 1 |
| DI Cristofori, A | 1 |
| Carrabba, G | 1 |
| Lanfranchi, G | 1 |
| Menghetti, C | 1 |
| Baumann, C | 1 |
| Lorgis, V | 1 |
| Ghiringhelli, F | 4 |
| Chauffert, B | 3 |
| Pinelli, C | 1 |
| Rech, F | 1 |
| Zustovich, F | 3 |
| Landi, L | 1 |
| Porta, C | 1 |
| Galli, L | 1 |
| Fontana, A | 1 |
| Amoroso, D | 1 |
| Galli, C | 1 |
| Andreuccetti, M | 1 |
| Falcone, A | 1 |
| Hassler, MR | 1 |
| Pfeifer, W | 1 |
| Knocke-Abulesz, TH | 1 |
| Geissler, K | 1 |
| Altorjai, G | 1 |
| Raisanen, J | 1 |
| Boothman, DA | 3 |
| Cochran, B | 1 |
| Tobias, AL | 2 |
| Thaci, B | 2 |
| Auffinger, B | 3 |
| Rincón, E | 1 |
| Kim, CK | 5 |
| Aboody, KS | 2 |
| Faje, AT | 1 |
| Nachtigall, L | 1 |
| Wexler, D | 1 |
| Miller, KK | 1 |
| Klibanski, A | 1 |
| Makimura, H | 1 |
| Bruckner, T | 1 |
| Mizoe, JE | 1 |
| Kamada, T | 1 |
| Tsujii, H | 1 |
| Kieser, M | 2 |
| Ondos, J | 1 |
| Ning, H | 1 |
| Smith, S | 2 |
| Kreisl, T | 1 |
| Sul, J | 3 |
| McNeil, K | 1 |
| Krauze, A | 2 |
| Shankavaram, U | 1 |
| Fine, HA | 6 |
| Camphausen, K | 5 |
| Hayashi, T | 1 |
| Adachi, K | 1 |
| Ohba, S | 3 |
| Hirose, Y | 8 |
| Morrell, RM | 1 |
| Tooze, JA | 1 |
| Harmon, MS | 1 |
| Carter, AF | 1 |
| DeTroye, AT | 1 |
| Mullins, CS | 1 |
| Stockhammer, F | 7 |
| Krohn, M | 1 |
| Zakaria, Z | 2 |
| Fenton, E | 1 |
| Khalil, A | 1 |
| Sattar, MT | 1 |
| Molnar, P | 2 |
| Huang, TT | 1 |
| Hlavaty, J | 1 |
| Espinoza, FL | 1 |
| Martin, B | 1 |
| Petznek, H | 1 |
| Rodriguez-Aguirre, M | 1 |
| Ibañez, CE | 1 |
| Kasahara, N | 1 |
| Gunzburg, W | 1 |
| Gruber, HE | 1 |
| Pertschuk, D | 1 |
| Jolly, DJ | 1 |
| Robbins, JM | 1 |
| Balducci, M | 10 |
| De Bonis, P | 6 |
| Chiesa, S | 6 |
| Mangiola, A | 7 |
| Mattiucci, GC | 2 |
| D'Agostino, GR | 4 |
| Frascino, V | 4 |
| Mantini, G | 4 |
| Alitto, AR | 1 |
| Anile, C | 7 |
| Valentini, V | 7 |
| Kuo, LT | 2 |
| Yang, CY | 1 |
| Lin, LW | 1 |
| MacFadden, D | 2 |
| Al-Zahrani, A | 2 |
| Atenafu, E | 1 |
| Miller, BA | 1 |
| Menard, C | 3 |
| Behm, T | 1 |
| Horowski, A | 1 |
| Schneider, S | 1 |
| Mielke, D | 1 |
| Tsen, AR | 1 |
| Long, PM | 1 |
| Driscoll, HE | 1 |
| Davies, MT | 1 |
| Teasdale, BA | 1 |
| Penar, PL | 1 |
| Pendlebury, WW | 1 |
| Spees, JL | 1 |
| Viapiano, MS | 1 |
| Jaworski, DM | 1 |
| Michaelsen, SR | 2 |
| Christensen, IJ | 2 |
| Stockhausen, MT | 2 |
| Kosteljanetz, M | 2 |
| Zairi, F | 1 |
| Maurage, CA | 2 |
| Assaker, R | 1 |
| de Azambuja, E | 1 |
| Zardavas, D | 1 |
| Lemort, M | 1 |
| Rossari, J | 1 |
| Moulin, C | 1 |
| Buttice, A | 1 |
| D'Hondt, V | 1 |
| Lebrun, F | 1 |
| Lalami, Y | 1 |
| Cardoso, F | 1 |
| Sotiriou, C | 1 |
| Gil, T | 1 |
| Devriendt, D | 1 |
| Paesmans, M | 1 |
| Piccart-Gebhart, M | 1 |
| Awada, A | 1 |
| Mantwill, K | 2 |
| Naumann, U | 1 |
| Seznec, J | 1 |
| Girbinger, V | 1 |
| Lage, H | 2 |
| Surowiak, P | 1 |
| Beier, D | 5 |
| Holm, PS | 2 |
| Jin, Z | 1 |
| Dubrow, R | 2 |
| Darefsky, AS | 2 |
| Jacobs, DI | 2 |
| Park, LS | 1 |
| Rose, MG | 1 |
| Laurans, MS | 1 |
| King, JT | 2 |
| You, WC | 1 |
| Chiou, SH | 1 |
| Chiang, SF | 1 |
| Yang, CL | 1 |
| Sudhakar, JN | 1 |
| Chiang, IP | 1 |
| Lin, JC | 1 |
| Shieh, SH | 1 |
| Chow, KC | 1 |
| Mannas, JP | 1 |
| Defrates, SR | 1 |
| Pittman, T | 2 |
| Rumiato, E | 1 |
| Bertorelle, R | 5 |
| Saggioro, D | 1 |
| Farina, P | 1 |
| Sacchetto, V | 1 |
| Marcato, R | 1 |
| Amadori, A | 1 |
| Cong, ZX | 2 |
| Wang, HD | 2 |
| Pan, H | 3 |
| Zhang, DD | 1 |
| Zhang, LH | 2 |
| Cheng, JX | 2 |
| Mahajan, A | 2 |
| Erridge, S | 1 |
| Baumert, B | 1 |
| Hopkins, KI | 1 |
| Choucair, AK | 1 |
| Takeshi, N | 1 |
| Kazuhiko, S | 1 |
| Koji, I | 1 |
| Toshikazu, H | 1 |
| Kaoru, K | 1 |
| Teo, M | 1 |
| Martin, S | 3 |
| Owusu-Agyemang, K | 1 |
| Nowicki, S | 1 |
| Clark, B | 1 |
| Mackinnon, M | 1 |
| Stewart, W | 1 |
| Paul, J | 1 |
| St George, J | 1 |
| Seong, S | 1 |
| Lim, SH | 1 |
| Mozes, P | 1 |
| Szanto, E | 1 |
| Tiszlavicz, L | 1 |
| Barzo, P | 1 |
| Cserhati, A | 1 |
| Fodor, E | 1 |
| Hideghety, K | 1 |
| Aldave, G | 1 |
| Marigil, M | 1 |
| Gállego Pérez-Larraya, J | 2 |
| de Gallego, J | 1 |
| Domínguez, PD | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 2 |
| Takahashi, JC | 1 |
| Miyamoto, S | 2 |
| Mano, Y | 1 |
| Shibahara, I | 2 |
| Kawaguchi, T | 1 |
| Kato, H | 1 |
| Yamashita, Y | 3 |
| Kawagishi, J | 1 |
| Jokura, H | 1 |
| Katakura, R | 1 |
| Alnaami, IM | 1 |
| Al-Nuaimi, SK | 1 |
| Senthilselvan, A | 1 |
| Murtha, AD | 1 |
| Walling, S | 1 |
| Mehta, V | 3 |
| Gourishankar, S | 1 |
| Sarvaiya, P | 1 |
| Yi, R | 1 |
| Borovjagin, A | 1 |
| Baryshnikov, AY | 1 |
| Fan, CH | 1 |
| Wen, C | 1 |
| Habets, EJ | 1 |
| Nederend, S | 1 |
| Delgadillo, D | 1 |
| Allgeier, A | 6 |
| Seute, T | 1 |
| Gijtenbeek, AM | 1 |
| de Gans, J | 1 |
| Enting, RH | 6 |
| Tijssen, CC | 1 |
| Grossman, R | 6 |
| Brastianos, H | 2 |
| Zadnik, P | 3 |
| Hwang, L | 5 |
| Wicks, RT | 3 |
| Goodwin, RC | 1 |
| Folkert, M | 1 |
| Zumsteg, ZS | 1 |
| Gutin, PH | 3 |
| Pentsova, E | 2 |
| Snuderl, M | 1 |
| Ancukiewicz, M | 1 |
| Polaskova, P | 3 |
| Pinho, MC | 2 |
| Jennings, D | 2 |
| Eichler, AF | 4 |
| Hochberg, FH | 3 |
| Lu-Emerson, C | 1 |
| Iafrate, AJ | 2 |
| Ivy, SP | 1 |
| Rosen, BR | 2 |
| Rumanò, L | 1 |
| Pomerri, F | 1 |
| Chamberlain, MC | 23 |
| Liu, JP | 1 |
| Mao, Q | 2 |
| Tabei, Y | 2 |
| Saito, N | 5 |
| Froklage, FE | 1 |
| Oosterbaan, LJ | 1 |
| Sizoo, EM | 3 |
| de Groot, M | 2 |
| Bosma, I | 3 |
| Sanchez, E | 2 |
| Douw, L | 1 |
| Heimans, JJ | 10 |
| Lagerwaard, FJ | 2 |
| Buter, J | 4 |
| Uitdehaag, BM | 2 |
| Postma, TJ | 10 |
| Juratli, TA | 1 |
| Engellandt, K | 1 |
| Lautenschlaeger, T | 1 |
| Geiger, KD | 1 |
| von Kummer, R | 1 |
| Cerhova, J | 1 |
| Samis Zella, MA | 1 |
| Wallocha, M | 1 |
| Slotty, PJ | 2 |
| Isik, G | 1 |
| Schroeteler, J | 1 |
| Ewelt, C | 2 |
| Chou, KN | 1 |
| Lin, YC | 1 |
| Liu, MY | 1 |
| Chang, PY | 1 |
| Liu, XY | 2 |
| Ren, YJ | 1 |
| Yang, WQ | 1 |
| Ming, ZJ | 1 |
| Yang, JM | 3 |
| Teixeira, S | 1 |
| Fouse, SD | 3 |
| Nakamura, JL | 1 |
| Chang, S | 6 |
| Kim, S | 2 |
| Jo, S | 1 |
| Lee, H | 2 |
| Kim, TU | 1 |
| Kim, IC | 1 |
| Yim, JH | 1 |
| Chung, H | 1 |
| Shen, W | 1 |
| Hu, JA | 1 |
| Zheng, JS | 1 |
| Johnson, BE | 2 |
| Barnes, M | 1 |
| Aihara, K | 2 |
| McLean, CY | 1 |
| Yamamoto, S | 1 |
| Ueda, H | 1 |
| Tatsuno, K | 1 |
| Asthana, S | 1 |
| Jalbert, LE | 1 |
| Nelson, SJ | 8 |
| Bollen, AW | 1 |
| Gustafson, WC | 1 |
| Charron, E | 1 |
| Weiss, WA | 4 |
| Smirnov, IV | 1 |
| Song, JS | 1 |
| Olshen, AB | 1 |
| Cha, S | 6 |
| Moore, RA | 1 |
| Mungall, AJ | 1 |
| Jones, SJM | 1 |
| Hirst, M | 1 |
| Marra, MA | 1 |
| Aburatani, H | 2 |
| Taylor, BS | 2 |
| Magaña-Maldonado, R | 1 |
| Manoutcharian, K | 1 |
| Hernández-Pedro, NY | 1 |
| Rangel-López, E | 1 |
| Pérez-De la Cruz, V | 1 |
| Rodríguez-Balderas, C | 1 |
| Sotelo, J | 1 |
| Pineda, B | 1 |
| Tassy, L | 1 |
| Crétel, E | 1 |
| Retornaz, F | 1 |
| Rousseau, F | 1 |
| Lövey, J | 1 |
| Fedorcsák, I | 1 |
| Bajcsay, A | 1 |
| Sipos, L | 2 |
| Mangel, L | 1 |
| Kásler, M | 1 |
| Bagó, A | 1 |
| Kiss, E | 1 |
| Lahm, E | 1 |
| Vachaja, J | 1 |
| Nagy, P | 1 |
| Bazsó, P | 1 |
| Fekete, Z | 1 |
| Takácsi-Nagy, Z | 1 |
| Pápai, Z | 1 |
| Bow, H | 3 |
| Hwang, LS | 1 |
| Schildhaus, N | 1 |
| Murray, L | 1 |
| Salditch, Q | 1 |
| Rehman, A | 1 |
| Vemireddy, V | 2 |
| Souza, RF | 1 |
| Koduru, P | 1 |
| Sha, SJ | 1 |
| Wu, HP | 1 |
| Huang, PH | 1 |
| Huang, SH | 1 |
| Hsu, CT | 1 |
| Sander, A | 1 |
| Wosniok, W | 1 |
| Gabel, D | 1 |
| Bautista, F | 1 |
| Paci, A | 1 |
| Minard-Colin, V | 1 |
| Dufour, C | 2 |
| Lacroix, L | 1 |
| Valteau-Couanet, D | 1 |
| Chotai, S | 1 |
| Newton, H | 2 |
| Lamki, T | 1 |
| Tsai, JP | 1 |
| Petrescu, N | 1 |
| Casaubon, LK | 1 |
| Capdevila, L | 1 |
| Cros, S | 1 |
| Ramirez, JL | 2 |
| Romeo, M | 1 |
| Etxaniz, O | 1 |
| Massuet, A | 1 |
| Cuadra, JL | 1 |
| Balzarini, L | 1 |
| Mancini, C | 1 |
| Marvisi, M | 1 |
| Ali, AN | 1 |
| Ogunleye, T | 1 |
| Hardy, CW | 1 |
| Shu, HK | 2 |
| Low, SY | 1 |
| Yap, CT | 1 |
| Ng, WH | 3 |
| Choi, EJ | 1 |
| Cho, BJ | 1 |
| Hwang, YH | 1 |
| Chun, SH | 1 |
| Kim, HH | 1 |
| Quillien, V | 5 |
| Lavenu, A | 2 |
| Legrain, M | 2 |
| Dubus, P | 1 |
| Karayan-Tapon, L | 4 |
| Li, XQ | 2 |
| Ouyang, ZG | 2 |
| Zhang, SH | 2 |
| Shang, Y | 2 |
| Zhen, YS | 2 |
| Kim, SM | 2 |
| Woo, JS | 2 |
| Jeong, CH | 2 |
| Ryu, CH | 2 |
| Jang, JD | 1 |
| Jeun, SS | 3 |
| Eisele, G | 2 |
| Eisele, AC | 1 |
| Tonn, J | 1 |
| Ochsenbein, A | 1 |
| Neyns, B | 9 |
| Nikkhah, G | 4 |
| Picard, M | 4 |
| Donovan, P | 1 |
| Cato, K | 1 |
| Legaie, R | 1 |
| Jayalath, R | 1 |
| Olsson, G | 1 |
| Hall, B | 1 |
| Olson, S | 1 |
| Boros, S | 1 |
| Harding, A | 1 |
| Hofland, KF | 1 |
| Hansen, S | 2 |
| Sorensen, M | 1 |
| Engelholm, S | 1 |
| Schultz, HP | 1 |
| Muhic, A | 1 |
| Ask, A | 1 |
| Costa, JC | 1 |
| Kristiansen, C | 1 |
| Thomsen, C | 1 |
| Magnuson, W | 1 |
| Ian Robins, H | 1 |
| Mohindra, P | 1 |
| Howard, S | 1 |
| McNamara, MG | 4 |
| Templeton, AJ | 1 |
| Zadeh, G | 2 |
| Bernstein, M | 3 |
| Chung, C | 3 |
| Millar, BA | 5 |
| Zeng, L | 2 |
| Di, C | 1 |
| Fee, BE | 1 |
| Rivas, M | 1 |
| Adamson, DC | 2 |
| Kodama, T | 1 |
| Yokoi, S | 1 |
| Kawasaki, K | 1 |
| Hara, R | 1 |
| Tops, B | 1 |
| Jeuken, J | 2 |
| Hulleman, E | 1 |
| Boots-Sprenger, SH | 2 |
| Vandertop, WP | 1 |
| Kaspers, GJ | 1 |
| Ogura, K | 1 |
| Ogura, M | 3 |
| Sakanaka, K | 1 |
| Hiraoka, M | 1 |
| Candolfi, M | 2 |
| Yagiz, K | 1 |
| Wibowo, M | 1 |
| Ahlzadeh, GE | 1 |
| Puntel, M | 1 |
| Ghiasi, H | 1 |
| Kamran, N | 1 |
| Paran, C | 1 |
| Lowenstein, PR | 3 |
| Castro, MG | 3 |
| Panosyan, EH | 1 |
| Xia, P | 1 |
| Lee, WN | 1 |
| Pak, Y | 1 |
| Laks, DR | 1 |
| Lin, HJ | 1 |
| Moore, TB | 1 |
| Lasky, JL | 1 |
| Leccia, MT | 1 |
| Planchamp, F | 1 |
| Sassolas, B | 1 |
| Combemale, P | 1 |
| Modiano, P | 1 |
| Bedane, C | 1 |
| Cupissol, D | 1 |
| Derrey, S | 1 |
| Dygai-Cochet, I | 1 |
| Lamant, L | 1 |
| Mirabel, X | 1 |
| Mourrégot, A | 1 |
| Rougé Bugat, ME | 1 |
| Siegrist, S | 1 |
| Thariat, J | 1 |
| Tiffet, O | 1 |
| Verdoni, L | 1 |
| Mazeau-Woynar, V | 1 |
| Senetta, R | 1 |
| Castiglione, A | 1 |
| Sacerdote, C | 1 |
| Gillio-Tos, A | 1 |
| Grasso, C | 1 |
| Magistrello, M | 2 |
| Tondat, F | 1 |
| Merletti, F | 1 |
| Mason, W | 10 |
| Kavan, P | 8 |
| Cernea, D | 1 |
| Hilton, M | 2 |
| Abrey, L | 2 |
| Colman, H | 6 |
| Pugh, S | 1 |
| Jeraj, R | 1 |
| Oh, SW | 1 |
| Jee, TK | 1 |
| Allen, JE | 1 |
| Huang, SY | 1 |
| Berg, A | 1 |
| Webb, BS | 1 |
| Liu, CG | 1 |
| Lu, Z | 1 |
| El-Deiry, WS | 1 |
| Sheng, XF | 1 |
| Dai, JZ | 1 |
| She, X | 2 |
| Lei, Q | 3 |
| Xu, G | 3 |
| Badaoui, N | 1 |
| Cartalat-Carel, S | 6 |
| Jouanneau, E | 1 |
| d'Hombres, A | 2 |
| Louis-Tisserand, G | 1 |
| Archinet, A | 1 |
| Meckbach, D | 1 |
| Keim, U | 1 |
| Richter, S | 1 |
| Leiter, U | 1 |
| Eigentler, TK | 2 |
| Bauer, J | 2 |
| Pflugfelder, A | 1 |
| Büttner, P | 1 |
| Garbe, C | 3 |
| Weide, B | 1 |
| Ito, M | 3 |
| Senga, T | 1 |
| Motomura, A | 1 |
| Kato, K | 2 |
| Kato, Y | 3 |
| Soga, T | 1 |
| Arvold, ND | 3 |
| Mirlohi, S | 1 |
| Duncan, SE | 1 |
| Harmon, M | 2 |
| Case, D | 1 |
| Lesser, G | 4 |
| Dietrich, AM | 1 |
| Wachtel, MS | 1 |
| Sagiyama, K | 1 |
| Mashimo, T | 1 |
| Maher, EA | 1 |
| Sherry, AD | 1 |
| Bachoo, RM | 3 |
| Barath, M | 1 |
| Sharma, N | 1 |
| McMullin, RP | 1 |
| Wittner, BS | 1 |
| Denton-Schneider, BR | 1 |
| Hicks, D | 1 |
| Singavarapu, R | 1 |
| Moulis, S | 1 |
| Lee, J | 3 |
| Akbari, MR | 1 |
| Narod, SA | 1 |
| Ramaswamy, S | 1 |
| Sgroi, DC | 1 |
| Palmieri, D | 1 |
| Duchnowska, R | 1 |
| Woditschka, S | 1 |
| Hua, E | 1 |
| Biernat, W | 1 |
| Sosińska-Mielcarek, K | 1 |
| Stark, AM | 2 |
| Hewitt, SM | 1 |
| Liewehr, DJ | 1 |
| Jassem, J | 1 |
| Butowski, NA | 5 |
| DeSilva, AA | 1 |
| Rabbitt, JE | 1 |
| Prados, MD | 28 |
| Nieder, C | 4 |
| Marienhagen, K | 1 |
| Dalhaug, A | 1 |
| Aandahl, G | 1 |
| Haukland, E | 1 |
| Pawinski, A | 1 |
| Elicin, O | 1 |
| Inac, E | 1 |
| Uzel, EK | 1 |
| Karacam, S | 1 |
| Uzel, OE | 1 |
| Han, SJ | 4 |
| Rolston, JD | 1 |
| DeSilva, A | 1 |
| Anai, S | 1 |
| Shinojima, N | 2 |
| Yano, S | 1 |
| Munoz, JL | 3 |
| Rodriguez-Cruz, V | 2 |
| Greco, SJ | 2 |
| Rameshwar, P | 3 |
| Rubner, Y | 1 |
| Muth, C | 1 |
| Strnad, A | 1 |
| Sieber, R | 1 |
| Buslei, R | 1 |
| Melchardt, T | 1 |
| Magnes, T | 1 |
| Weiss, L | 1 |
| Grundbichler, M | 1 |
| Strasser, M | 1 |
| Hufnagl, C | 1 |
| Moik, M | 1 |
| Greil, R | 1 |
| Egle, A | 1 |
| Oborski, MJ | 1 |
| Laymon, CM | 1 |
| Hamilton, RL | 5 |
| Mountz, JM | 1 |
| Chang, AL | 1 |
| Tobias, A | 1 |
| Ricken, G | 1 |
| Budak, F | 2 |
| Tolunay, S | 1 |
| Palumbo, S | 2 |
| Toscano, M | 2 |
| Allavena, G | 1 |
| Angeletti, F | 1 |
| Manai, F | 1 |
| Comincini, S | 2 |
| Yoo, B | 1 |
| Ifediba, MA | 1 |
| Medarova, Z | 1 |
| Moore, A | 2 |
| Lim, YJ | 2 |
| Han, TJ | 1 |
| Coate, L | 1 |
| Massey, C | 1 |
| Valeriani, M | 3 |
| Osti, M | 1 |
| Bonnetain, F | 3 |
| Taillia, H | 2 |
| Schott, R | 5 |
| Guillamo, JS | 7 |
| Castera, D | 2 |
| Frenay, M | 6 |
| Dalban, C | 3 |
| Skrzypski, J | 2 |
| Cao, KI | 2 |
| Kirova, YM | 2 |
| Xie, B | 1 |
| Kalkanis, SN | 1 |
| Di Stefano, D | 2 |
| Scarpino, S | 3 |
| Villani, V | 2 |
| Salvati, M | 11 |
| Hadoux, J | 1 |
| Favier, J | 1 |
| Scoazec, JY | 1 |
| Leboulleux, S | 1 |
| Al Ghuzlan, A | 1 |
| Caramella, C | 1 |
| Déandreis, D | 1 |
| Borget, I | 2 |
| Loriot, C | 1 |
| Chougnet, C | 1 |
| Letouzé, E | 1 |
| Young, J | 1 |
| Amar, L | 1 |
| Bertherat, J | 1 |
| Libé, R | 1 |
| Dumont, F | 1 |
| Deschamps, F | 1 |
| Schlumberger, M | 1 |
| Gimenez-Roqueplo, AP | 1 |
| Baudin, E | 1 |
| Berthois, Y | 1 |
| Delfino, C | 4 |
| Fina, F | 3 |
| Nanni-Metellus, I | 2 |
| Al Aswy, H | 1 |
| Pirisi, V | 1 |
| Ouafik, L | 5 |
| Boudouresque, F | 1 |
| Smirnova, ZS | 1 |
| Ermakova, KV | 1 |
| Kubasova, IY | 1 |
| Borisova, LM | 1 |
| Kiselyova, MP | 1 |
| Oborotova, NA | 1 |
| Meerovich, GA | 1 |
| Luk'yanets, EA | 1 |
| Lebrun-Frenay, C | 1 |
| Ben Aissa, A | 1 |
| Espeli, V | 1 |
| Squiban, D | 1 |
| Dunkel, N | 1 |
| Vargas, MI | 1 |
| Mach, N | 1 |
| Schaller, K | 1 |
| Bodmer, A | 1 |
| Signore, M | 2 |
| Pelacchi, F | 1 |
| di Martino, S | 1 |
| Runci, D | 2 |
| Biffoni, M | 2 |
| Giannetti, S | 1 |
| Morgante, L | 1 |
| De Majo, M | 1 |
| Petricoin, EF | 1 |
| Stancato, L | 2 |
| De Maria, R | 2 |
| Nishida, M | 1 |
| Farkas, N | 1 |
| Dagata, JA | 1 |
| Anderson, JC | 1 |
| Duarte, CW | 1 |
| Welaya, K | 1 |
| Rohrbach, TD | 1 |
| Yang, ES | 1 |
| Choradia, NV | 1 |
| Thottassery, JV | 1 |
| Yancey Gillespie, G | 1 |
| Bonner, JA | 1 |
| Willey, CD | 1 |
| Mendola, M | 1 |
| Passeri, E | 1 |
| Ambrosi, B | 1 |
| Corbetta, S | 1 |
| Boakye-Agyeman, F | 1 |
| Kizilbash, SH | 2 |
| Reid, J | 1 |
| Li, HL | 1 |
| Cui, XL | 1 |
| Zhang, JN | 1 |
| Turner, SG | 1 |
| Gergel, T | 1 |
| Lu, S | 1 |
| Leng, C | 1 |
| Lu, F | 1 |
| Liang, S | 1 |
| Sang, DP | 1 |
| Donneau, AF | 1 |
| Mauer, M | 1 |
| Albert, A | 1 |
| Gebhardt, BJ | 1 |
| Dobelbower, MC | 2 |
| Ennis, WH | 1 |
| Bag, AK | 1 |
| Kocak, M | 2 |
| Chyla, B | 2 |
| McKeegan, E | 2 |
| Warren, KE | 1 |
| Goldman, S | 2 |
| Pollack, IF | 4 |
| Chen, A | 4 |
| Boyett, J | 1 |
| Kun, L | 1 |
| Lathia, JD | 1 |
| Flavahan, W | 1 |
| Mattson, MP | 1 |
| Rovere, RK | 1 |
| Xu, FF | 1 |
| Collins, VP | 1 |
| Di, Y | 1 |
| Pearson, D | 1 |
| Chan, R | 1 |
| Thompson, LC | 1 |
| Gabe, R | 1 |
| Stenning, SP | 1 |
| Shi, ZM | 1 |
| Jiang, CF | 1 |
| Chen, QD | 1 |
| Li, DM | 1 |
| Wang, XF | 1 |
| You, YP | 2 |
| Long, H | 1 |
| Que, T | 1 |
| Yi, L | 2 |
| Fang, W | 1 |
| Muruganandham, M | 1 |
| Clerkin, PP | 1 |
| Smith, BJ | 1 |
| Anderson, CM | 2 |
| Morris, A | 1 |
| Capizzano, AA | 1 |
| Magnotta, V | 1 |
| McGuire, SM | 1 |
| Smith, MC | 1 |
| Bayouth, JE | 1 |
| Buatti, JM | 1 |
| Mikkelson, T | 1 |
| Chang, YC | 1 |
| McAfee, Q | 1 |
| Fisher, J | 4 |
| Troxel, AB | 1 |
| Piao, S | 1 |
| Heitjan, DF | 1 |
| Tan, KS | 1 |
| Pontiggia, L | 1 |
| O'Dwyer, PJ | 1 |
| Davis, LE | 1 |
| Amaravadi, RK | 1 |
| Voss, JS | 1 |
| Hardie, J | 1 |
| Yamamoto, T | 4 |
| Tsuboi, K | 3 |
| Ikuta, S | 1 |
| Hashimoto, K | 1 |
| Uemae, Y | 1 |
| Ishihara, T | 1 |
| Matsutani, M | 4 |
| Karasawa, K | 1 |
| Nakazato, Y | 1 |
| Ohno, T | 2 |
| Mansour, J | 1 |
| Fields, B | 1 |
| Macomson, S | 1 |
| Rixe, O | 1 |
| Letarte, N | 2 |
| Gabay, MP | 1 |
| Bressler, LR | 3 |
| Long, KE | 1 |
| Stachnik, JM | 1 |
| Tan, CW | 1 |
| See, SJ | 4 |
| Tham, CK | 2 |
| Ang, AL | 1 |
| Nanegrungsunk, D | 2 |
| Onchan, W | 1 |
| Chattipakorn, N | 2 |
| Chattipakorn, SC | 2 |
| Oh, T | 1 |
| Rutkowski, MJ | 1 |
| Safaee, M | 1 |
| Sun, MZ | 1 |
| Sayegh, ET | 1 |
| Tihan, T | 4 |
| Parsa, AT | 4 |
| Smolkin, M | 1 |
| Wintermark, M | 1 |
| Shaffrey, ME | 3 |
| Lopes, MB | 1 |
| Bae, SH | 2 |
| Park, MJ | 1 |
| Lee, MM | 2 |
| Cho, SY | 1 |
| Gong, A | 1 |
| Ge, N | 1 |
| Yao, W | 1 |
| Azadi, J | 1 |
| Zhang, I | 2 |
| Joshi, A | 1 |
| Hutt-Cabezas, M | 1 |
| Martin, KL | 1 |
| Tyler, BM | 6 |
| Koekkoek, JA | 3 |
| Vos, MJ | 5 |
| Boggs, DH | 1 |
| Langer, CJ | 1 |
| Traynor, AM | 2 |
| Berkowitz, MJ | 1 |
| Patil, AA | 1 |
| Sayal, P | 1 |
| Depondt, ML | 1 |
| Beveridge, RD | 1 |
| Roylance, A | 1 |
| Kriplani, DH | 1 |
| Myers, KN | 1 |
| Cox, A | 1 |
| Jellinek, D | 1 |
| Fernando, M | 1 |
| Carroll, TA | 1 |
| Voellger, B | 1 |
| Tapia-Perez, JH | 1 |
| Rupa, R | 1 |
| Karagiannis, D | 1 |
| Kirches, E | 1 |
| Schneider, T | 1 |
| Ferrazza, P | 2 |
| Cocuzza, P | 1 |
| Fatigante, L | 2 |
| Pasqualetti, G | 1 |
| Fabbrini, MG | 1 |
| Monzani, F | 1 |
| Nguyen, SA | 2 |
| Stechishin, OD | 2 |
| Lun, XQ | 2 |
| Robbins, SM | 1 |
| Lan, J | 1 |
| Master, LM | 1 |
| Master, ZW | 1 |
| Adair, JE | 1 |
| Beard, BC | 1 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Gori, JL | 1 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 2 |
| Storer, BE | 1 |
| Rockhill, JK | 2 |
| Kiem, HP | 3 |
| Oka, H | 2 |
| Tashiro, T | 1 |
| Gutin, P | 1 |
| Karimi, S | 2 |
| Correa, DD | 1 |
| Kaley, TJ | 2 |
| Gavrilovic, IT | 3 |
| Nolan, C | 2 |
| Grommes, C | 2 |
| Baser, RE | 1 |
| Tabar, V | 1 |
| Sanchez, J | 1 |
| Barradas-Panchal, R | 1 |
| Yusubalieva, GM | 1 |
| Baklaushev, VP | 1 |
| Gurina, OI | 1 |
| Zorkina, YA | 1 |
| Gubskii, IL | 1 |
| Golanov, AV | 1 |
| Goryainov, SA | 1 |
| Gorlachev, GE | 1 |
| Konovalov, AN | 1 |
| Potapov, AA | 1 |
| Chekhonin, VP | 1 |
| Nonnenmacher, L | 3 |
| Fulda, S | 2 |
| Engelke, J | 1 |
| Simmet, T | 1 |
| Corbacioglu, S | 1 |
| Bao, ZS | 1 |
| Chen, HM | 2 |
| Yang, MY | 1 |
| Zhang, CB | 1 |
| Ye, WL | 1 |
| Hu, BQ | 1 |
| Ramakrishnan, V | 2 |
| Hu, HM | 1 |
| Li, MY | 1 |
| Yao, K | 4 |
| Qiu, XG | 1 |
| Fan, XL | 1 |
| Song, WS | 1 |
| Li, RQ | 1 |
| Su, XD | 1 |
| Shapiro, W | 2 |
| Wind, S | 1 |
| Nagaishi, M | 1 |
| Sugiura, Y | 1 |
| Takano, I | 1 |
| Tanaka, Y | 1 |
| Suzuki, K | 3 |
| Yokoo, H | 3 |
| Hyodo, A | 1 |
| Hamisch, C | 1 |
| Visser-Vandewalle, V | 1 |
| Kocher, M | 3 |
| Treuer, H | 1 |
| Voges, J | 1 |
| Ruge, MI | 1 |
| Lhermitte, B | 5 |
| Tarnawski, R | 2 |
| Rao, N | 1 |
| Thurzo, L | 1 |
| Adamska, K | 1 |
| Wiegel, T | 1 |
| Hicking, C | 3 |
| Markivskyy, A | 1 |
| Byrne, RW | 1 |
| Aiken, R | 1 |
| Lemos, AM | 1 |
| Gokaslan, A | 1 |
| Cabrera-Aldana, EE | 1 |
| Ashary, A | 1 |
| Olivi, A | 4 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 4 |
| Delgado-Goñi, T | 2 |
| Pumarola, M | 2 |
| Meng, D | 1 |
| Huai, C | 1 |
| Qin, R | 1 |
| Xu, T | 5 |
| Yun, D | 1 |
| Wojton, J | 1 |
| Meisen, WH | 1 |
| Thorne, AH | 1 |
| Hardcastle, J | 2 |
| Denton, N | 1 |
| Chu, Z | 1 |
| Dmitrieva, N | 1 |
| Marsh, R | 1 |
| Van Meir, EG | 1 |
| Kwon, CH | 1 |
| Yalcin, M | 1 |
| Sahin, S | 1 |
| Demir, C | 1 |
| Guvenc, G | 1 |
| Yilmaz, G | 1 |
| Erkan, LG | 1 |
| Malyer, H | 1 |
| Evrensel, T | 1 |
| Ferguson, M | 1 |
| Rodrigues, G | 1 |
| Bauman, G | 1 |
| König, L | 1 |
| Bostel, T | 2 |
| Harrabi, S | 1 |
| Welzel, T | 5 |
| Gabikian, P | 1 |
| Garza, M | 1 |
| Chmura, SJ | 2 |
| Fisch, MJ | 1 |
| Lagrone, LW | 1 |
| Levin, VA | 9 |
| Volas-Redd, G | 1 |
| Floyd, JD | 1 |
| Hsu, SH | 2 |
| Gonzalez, J | 2 |
| Woo, SY | 1 |
| Yung, WK | 20 |
| Ameratunga, MS | 1 |
| Omuro, AM | 4 |
| Cheng, Z | 1 |
| Kavitha, CV | 1 |
| Jain, AK | 1 |
| Agarwal, C | 1 |
| Pierce, A | 1 |
| Keating, A | 1 |
| Huber, KM | 1 |
| Serkova, NJ | 1 |
| Wempe, MF | 1 |
| Agarwal, R | 1 |
| Deep, G | 1 |
| Noack, J | 1 |
| Richter, K | 1 |
| Kopp-Schneider, A | 1 |
| Song, M | 1 |
| Mohamad, O | 1 |
| Yu, SP | 1 |
| Badiyan, SN | 2 |
| Markovina, S | 1 |
| Simpson, JR | 3 |
| DeWees, T | 1 |
| Linette, G | 3 |
| Jalalizadeh, R | 1 |
| Dacey, R | 1 |
| Rich, KM | 2 |
| Chicoine, MR | 3 |
| Dowling, JL | 2 |
| Leuthardt, EC | 2 |
| Zipfel, GJ | 2 |
| Miki, Y | 1 |
| Omata, H | 1 |
| Moritake, K | 1 |
| Hiranuma, M | 1 |
| Hironaka, C | 1 |
| Fujiwara, Y | 1 |
| Beppu, M | 1 |
| Yan, T | 2 |
| Liang, X | 1 |
| Leiss, L | 2 |
| Sakariassen, PØ | 1 |
| Skaftnesmo, KO | 2 |
| Costea, DE | 1 |
| Brynolfsson, P | 1 |
| Nilsson, D | 1 |
| Hauksson, J | 1 |
| Karlsson, M | 1 |
| Garpebring, A | 1 |
| Birgander, R | 1 |
| Trygg, J | 1 |
| Nyholm, T | 1 |
| Asklund, T | 1 |
| van Vugt, VA | 1 |
| Brown, BD | 1 |
| Brown, T | 1 |
| Saria, MG | 1 |
| Juarez, T | 1 |
| Neuwelt, AJ | 1 |
| Nguyen, TM | 1 |
| Fu, R | 1 |
| Bubalo, J | 1 |
| Tyson, RM | 1 |
| Lacy, C | 1 |
| Gahramanov, S | 2 |
| Nasseri, M | 1 |
| Barnes, PD | 1 |
| Neuwelt, EA | 4 |
| Kawano, H | 1 |
| Yunoue, S | 1 |
| Yatsushiro, K | 1 |
| Ogita, M | 1 |
| Hiraki, Y | 1 |
| Uchida, H | 1 |
| Habu, M | 1 |
| Fujio, S | 1 |
| Oyoshi, T | 1 |
| Bakhtiar, Y | 1 |
| Sugata, S | 1 |
| Yamahata, H | 1 |
| Hanaya, R | 1 |
| Tokimura, H | 1 |
| Arita, K | 1 |
| Chai, KM | 1 |
| Liaw, HJ | 1 |
| Fang, KM | 1 |
| Tzeng, SF | 1 |
| Xing, BZ | 1 |
| Upadhyay, UM | 2 |
| Patta, Y | 1 |
| Wicks, R | 1 |
| Spencer, K | 1 |
| Scott, A | 1 |
| Masi, B | 1 |
| Cima, M | 1 |
| Ling, Q | 1 |
| Xia, M | 1 |
| Jing, L | 1 |
| Jalilian, L | 1 |
| Lupo, JM | 4 |
| Ramirez, YP | 1 |
| Phillips, RM | 1 |
| Gynther, M | 1 |
| Rautio, J | 1 |
| Ross, AH | 3 |
| Wheelhouse, RT | 1 |
| Sakaria, JN | 1 |
| Lebas, N | 1 |
| Gerber, S | 1 |
| Levy, C | 1 |
| Le Scodan, R | 1 |
| Bourgier, C | 1 |
| Pierga, JY | 1 |
| Gobillion, A | 1 |
| Savignoni, A | 1 |
| Rocha, CR | 2 |
| Garcia, CC | 1 |
| Vieira, DB | 1 |
| Quinet, A | 2 |
| de Andrade-Lima, LC | 1 |
| Munford, V | 1 |
| Belizário, JE | 1 |
| Menck, CF | 3 |
| Woehrer, A | 1 |
| Hunn, MK | 1 |
| Bauer, E | 1 |
| Wood, CE | 1 |
| Gasser, O | 1 |
| Dzhelali, M | 1 |
| Ancelet, LR | 1 |
| Mester, B | 1 |
| Sharples, KJ | 1 |
| Findlay, MP | 1 |
| Hamilton, DA | 2 |
| Hermans, IF | 1 |
| Hsieh, CH | 1 |
| Wu, CP | 1 |
| Lee, HT | 1 |
| Shyu, WC | 1 |
| Wang, CC | 1 |
| Denis, JM | 1 |
| Gueulette, J | 1 |
| Slabbert, J | 1 |
| Du, W | 1 |
| Dou, Z | 1 |
| Chang, L | 1 |
| Fan, TY | 1 |
| Li, HZ | 1 |
| Lei, BX | 1 |
| Zhang, RR | 1 |
| Pointer, KB | 1 |
| Kuo, JS | 1 |
| Dempsey, RJ | 1 |
| Daniele, S | 1 |
| Zappelli, E | 1 |
| Natali, L | 1 |
| Martini, C | 2 |
| Trincavelli, ML | 1 |
| Porru, M | 1 |
| Zappavigna, S | 1 |
| Salzano, G | 1 |
| Luce, A | 1 |
| Stoppacciaro, A | 1 |
| Balestrieri, ML | 1 |
| Artuso, S | 1 |
| Lusa, S | 1 |
| De Rosa, G | 1 |
| Leonetti, C | 3 |
| Caraglia, M | 7 |
| Mason, M | 1 |
| Adeyi, O | 1 |
| Fung, S | 1 |
| Bu, G | 1 |
| Barbagallo, GM | 1 |
| Paratore, S | 1 |
| Caltabiano, R | 1 |
| Palmucci, S | 1 |
| Parra, HS | 1 |
| Privitera, G | 1 |
| Motta, F | 2 |
| Lanzafame, S | 1 |
| Scaglione, G | 1 |
| Longo, A | 1 |
| Albanese, V | 1 |
| Certo, F | 1 |
| Terrenato, I | 1 |
| Fitzner, KA | 1 |
| Bennett, CL | 1 |
| Liebling, DB | 1 |
| Luu, TH | 1 |
| Trifilio, SM | 1 |
| Fisher, MJ | 2 |
| Haleem, MS | 1 |
| Ray, PS | 1 |
| McKoy, JM | 2 |
| DeBoer, R | 2 |
| Tulas, KM | 1 |
| Deeb, M | 1 |
| Hayes, J | 1 |
| Thygesen, H | 1 |
| Tumilson, C | 1 |
| Droop, A | 1 |
| Boissinot, M | 1 |
| Hughes, TA | 1 |
| Westhead, D | 1 |
| Alder, JE | 1 |
| Shaw, L | 1 |
| Dwucet, A | 1 |
| Welscher, N | 1 |
| Hlavac, M | 1 |
| Ney, DE | 2 |
| Carlson, JA | 2 |
| Kleinschmidt-DeMasters, BK | 3 |
| Waziri, AE | 1 |
| Kaufmann, TJ | 1 |
| Peller, PJ | 2 |
| McGraw, S | 2 |
| Dahiya, S | 1 |
| Hashemi-Sadraei, N | 1 |
| Fisher, PG | 2 |
| Newton, HB | 4 |
| Brewer, C | 1 |
| Wood, L | 1 |
| Prayson, R | 1 |
| Elson, P | 3 |
| Purchiaroni, F | 1 |
| Begini, P | 1 |
| Gallina, S | 1 |
| Delle Fave, G | 1 |
| Marignani, M | 1 |
| Zhou, R | 3 |
| Gong, C | 1 |
| Cai, T | 2 |
| Tan, C | 1 |
| Zanotto-Filho, A | 1 |
| Klafke, K | 1 |
| Terra, SR | 1 |
| Paludo, FJ | 1 |
| Morrone, M | 1 |
| Bristot, IJ | 1 |
| Battastini, AM | 2 |
| Forcelini, CM | 1 |
| Bishop, AJR | 1 |
| Gelain, DP | 1 |
| Moreira, JCF | 1 |
| Pérès, EA | 2 |
| Gérault, AN | 1 |
| Valable, S | 2 |
| Roussel, S | 2 |
| Toutain, J | 2 |
| Divoux, D | 2 |
| Bernaudin, M | 3 |
| Petit, E | 2 |
| Bochenek-Cibor, J | 1 |
| Krupa, M | 1 |
| Moskała, M | 1 |
| Trojanowski, T | 1 |
| Girão, H | 1 |
| Meyer, M | 1 |
| Lan, X | 1 |
| Head, R | 2 |
| Kushida, M | 1 |
| Bayani, J | 1 |
| Pressey, JC | 1 |
| Lionel, AC | 1 |
| Clarke, ID | 2 |
| Cusimano, M | 1 |
| Squire, JA | 1 |
| Scherer, SW | 1 |
| Woodin, MA | 1 |
| Bader, GD | 1 |
| Verhoeff, JJ | 1 |
| Richel, DJ | 2 |
| van Furth, WR | 2 |
| Verheul, HM | 1 |
| Schuster, J | 1 |
| Lai, RK | 1 |
| Paleologos, NA | 3 |
| Jensen, R | 1 |
| Cruickshank, S | 1 |
| Green, JA | 1 |
| Prager, AJ | 1 |
| Young, RJ | 2 |
| Kim, HR | 1 |
| Kim, KH | 1 |
| Jansen, NL | 1 |
| Linn, J | 2 |
| Kretzschmar, H | 1 |
| Janssen, H | 1 |
| Pöpperl, G | 2 |
| Kreth, FW | 6 |
| Miao, W | 1 |
| Lian, S | 1 |
| Paff, M | 1 |
| Alexandru-Abrams, D | 1 |
| Hsu, FP | 1 |
| Shao, Q | 1 |
| Speirs, CK | 2 |
| Dacey, RG | 1 |
| Messaoudi, K | 3 |
| Lemaire, L | 1 |
| Benoit, JP | 1 |
| Lagarce, F | 3 |
| Schmainda, KM | 1 |
| Prah, M | 1 |
| Hosein, AN | 1 |
| Lim, YC | 1 |
| Day, B | 1 |
| Stringer, B | 1 |
| Rose, S | 1 |
| Cosgrove, L | 1 |
| Martin, JH | 1 |
| Kästner, B | 1 |
| Sabel, MC | 4 |
| Homicsko, K | 3 |
| Kollias, S | 1 |
| Hüsing, J | 1 |
| Chang-Halpenny, CN | 1 |
| Yeh, J | 1 |
| Lien, WW | 1 |
| Pan, SJ | 2 |
| Wu, YB | 1 |
| Pan, YX | 2 |
| Bian, LG | 2 |
| Sun, QF | 2 |
| Coons, SW | 1 |
| Ryu, S | 2 |
| Blaes, J | 3 |
| Rübmann, P | 1 |
| Milford, D | 1 |
| Urban, S | 1 |
| Jestaedt, L | 1 |
| Heiland, S | 1 |
| Hertenstein, A | 4 |
| Pfenning, PN | 1 |
| Ruiz de Almodóvar, C | 1 |
| Weiler, M | 4 |
| Curran, W | 5 |
| Gao, H | 3 |
| Lei, T | 2 |
| Sayari, AJ | 2 |
| Iaccarino, C | 1 |
| Orlandi, E | 1 |
| Ruggeri, F | 1 |
| Nicoli, D | 1 |
| Torricelli, F | 1 |
| Maggi, M | 1 |
| Cerasti, D | 1 |
| Pedrazzi, G | 1 |
| Froio, E | 1 |
| Crafa, P | 1 |
| D'Abbiero, N | 1 |
| Michiara, M | 2 |
| Ghadirpour, R | 1 |
| Servadei, F | 2 |
| van Thuijl, HF | 1 |
| Kloezeman, JJ | 2 |
| Lamfers, ML | 2 |
| Ylstra, B | 1 |
| Favero, F | 1 |
| McGranahan, N | 1 |
| Salm, M | 1 |
| Birkbak, NJ | 1 |
| Sanborn, JZ | 1 |
| Benz, SC | 1 |
| Becq, J | 1 |
| Peden, JF | 1 |
| Kingsbury, Z | 1 |
| Grocok, RJ | 1 |
| Humphray, S | 1 |
| Bentley, D | 1 |
| Spencer-Dene, B | 1 |
| Gutteridge, A | 1 |
| Roger, S | 1 |
| Forshew, T | 1 |
| Gerlinger, M | 1 |
| Rowan, A | 1 |
| Stamp, G | 1 |
| Eklund, AC | 1 |
| Szallasi, Z | 1 |
| Swanton, C | 1 |
| Hager, MO | 1 |
| Ouédraogo, ZG | 1 |
| Lemaire, JJ | 1 |
| Turner, KM | 1 |
| Bernard, B | 1 |
| Cogdell, DE | 1 |
| Shmulevich, I | 1 |
| Fuller, GN | 2 |
| Cominelli, M | 1 |
| Grisanti, S | 2 |
| Mazzoleni, S | 1 |
| Branca, C | 1 |
| Buttolo, L | 1 |
| Furlan, D | 1 |
| Liserre, B | 1 |
| Bonetti, MF | 1 |
| Medicina, D | 1 |
| Pellegrini, V | 1 |
| Liserre, R | 2 |
| Pellegatta, S | 1 |
| Dalerba, P | 1 |
| Facchetti, F | 1 |
| Pizzi, M | 1 |
| Poliani, PL | 1 |
| Clavreul, A | 2 |
| Daniel, PM | 1 |
| D'Abaco, GM | 1 |
| Gogos, A | 1 |
| Ng, W | 2 |
| Lai, IC | 2 |
| Wong, TT | 3 |
| Shiau, CY | 1 |
| Hu, YW | 1 |
| Ho, DM | 3 |
| Chang, KP | 2 |
| Guo, WY | 2 |
| Liang, ML | 2 |
| Lee, YY | 1 |
| Yen, SH | 1 |
| Chen, YW | 1 |
| Elhag, R | 1 |
| Mazzio, EA | 1 |
| Soliman, KF | 1 |
| Naz, A | 1 |
| Thompson, DH | 1 |
| Irudayaraj, J | 1 |
| Stephen, ZR | 2 |
| Kievit, FM | 1 |
| Chiu, DT | 1 |
| Press, OW | 1 |
| Mazurkiewicz, M | 1 |
| Depenni, R | 2 |
| Pojo, M | 1 |
| Gonçalves, CS | 1 |
| Xavier-Magalhães, A | 1 |
| Oliveira, AI | 1 |
| Gonçalves, T | 1 |
| Correia, S | 1 |
| Rodrigues, AJ | 1 |
| Pinto, L | 1 |
| Pinto, AA | 1 |
| Lopes, JM | 2 |
| Rocha, M | 1 |
| Sousa, N | 1 |
| Shih, PH | 1 |
| Yao, CJ | 1 |
| Wang-Peng, J | 1 |
| Lui, TN | 1 |
| Chuang, SE | 1 |
| Hu, TS | 1 |
| Lai, TY | 1 |
| Lai, GM | 1 |
| Ampie, L | 1 |
| Kusne, Y | 1 |
| Sanai, N | 1 |
| Tsuboi, A | 2 |
| Chiba, Y | 2 |
| Izumoto, S | 1 |
| Kijima, N | 1 |
| Oka, Y | 2 |
| Morimoto, S | 1 |
| Nakajima, H | 1 |
| Morita, S | 1 |
| Sakamoto, J | 1 |
| Nishida, S | 2 |
| Hosen, N | 2 |
| Oji, Y | 2 |
| Arita, N | 1 |
| Yoshimine, T | 5 |
| Sugiyama, H | 2 |
| Fontanella, MM | 1 |
| Spena, G | 2 |
| Poliani, LP | 1 |
| Gipponi, S | 1 |
| Spiazzi, L | 1 |
| Deibert, CP | 1 |
| Zussman, BM | 1 |
| Engh, JA | 1 |
| Goldwirt, L | 1 |
| Beccaria, K | 1 |
| Levasseur, C | 1 |
| Labussiere, M | 1 |
| Milane, A | 1 |
| Farinotti, R | 1 |
| Fernandez, C | 1 |
| Valtorta, S | 1 |
| Raccagni, I | 1 |
| Belloli, S | 1 |
| Gianelli, U | 1 |
| Vaira, V | 1 |
| Politi, LS | 1 |
| Bosari, S | 1 |
| Moresco, RM | 1 |
| Parisi, S | 3 |
| Corsa, P | 1 |
| Raguso, A | 1 |
| Perrone, A | 1 |
| Cossa, S | 1 |
| Munafò, T | 1 |
| Sanpaolo, G | 1 |
| Donno, E | 1 |
| Clemente, MA | 1 |
| Parisi, F | 1 |
| Valle, G | 1 |
| Grieco, A | 1 |
| Tafuri, MA | 1 |
| Biolato, M | 1 |
| Diletto, B | 3 |
| Di Napoli, N | 1 |
| Balducci, N | 1 |
| Vecchio, FM | 1 |
| Miele, L | 1 |
| Dong, F | 1 |
| Eibach, M | 1 |
| Dolga, AM | 1 |
| Schlomann, U | 1 |
| Conrad, C | 2 |
| Schieber, S | 1 |
| Schilling, O | 1 |
| Biniossek, ML | 1 |
| Strik, H | 2 |
| Koller, G | 1 |
| Carl, B | 1 |
| Thomas, TA | 1 |
| Narayan, S | 1 |
| Curran, WP | 1 |
| Tanguturi, SK | 1 |
| Aizer, AA | 1 |
| Christianson, LW | 1 |
| Horvath, MC | 1 |
| Dunn, IF | 1 |
| Johnson, MD | 2 |
| Claus, EB | 1 |
| Rutledge, WC | 1 |
| Tchoghandjian, A | 1 |
| Denicolai, E | 2 |
| Nanni, I | 2 |
| Ma, G | 1 |
| Cui, L | 1 |
| Liang, W | 1 |
| Sesen, J | 2 |
| Dahan, P | 1 |
| Scotland, SJ | 2 |
| Saland, E | 1 |
| Dang, VT | 1 |
| Lemarié, A | 1 |
| Toulas, C | 1 |
| Sarry, JE | 1 |
| Skuli, N | 2 |
| Berghauser Pont, LM | 1 |
| Dirven, CM | 1 |
| Chong, DQ | 1 |
| Toh, XY | 1 |
| Ho, IA | 1 |
| Sia, KC | 1 |
| Newman, JP | 1 |
| Yulyana, Y | 1 |
| Lai, SH | 1 |
| Ho, MM | 1 |
| Dinesh, N | 1 |
| Lam, PY | 1 |
| Hao, S | 2 |
| Battaglia, L | 1 |
| Chirio, D | 1 |
| Melcarne, A | 2 |
| Ono, M | 1 |
| Sørensen, MD | 1 |
| Fosmark, S | 1 |
| Hellwege, S | 1 |
| Kristensen, BW | 1 |
| Beier, CP | 5 |
| Rapkins, RW | 2 |
| Nguyen, HN | 1 |
| Hitchins, MP | 2 |
| Sadat, H | 1 |
| Santos, F | 1 |
| Panet-Raymond, V | 4 |
| Owen, S | 3 |
| Patyka, M | 1 |
| Shenouda, G | 3 |
| Ening, G | 1 |
| Osterheld, F | 1 |
| Schmieder, K | 4 |
| Brenke, C | 1 |
| Prabhu, RS | 1 |
| Brick, W | 1 |
| Blaker, BD | 1 |
| Heideman, BE | 1 |
| Boltes, P | 1 |
| Kelly, R | 1 |
| Symanowski, JT | 1 |
| Wiggins, WF | 1 |
| Norton, HJ | 1 |
| Asher, AL | 2 |
| Cattaneo, M | 1 |
| Storaci, AM | 1 |
| De Blasio, P | 1 |
| Biunno, I | 1 |
| Bryukhovetskiy, I | 1 |
| Bryukhovetsky, A | 1 |
| Khotimchenko, Y | 1 |
| Mischenko, P | 1 |
| Tolok, E | 1 |
| Khotimchenko, R | 1 |
| Shao, H | 1 |
| Chung, J | 1 |
| Min, C | 1 |
| Breakefield, XO | 1 |
| Weissleder, R | 3 |
| Zhou, D | 2 |
| Yan, Q | 2 |
| Mo, L | 2 |
| Wan, Y | 3 |
| Xie, D | 3 |
| Xie, J | 3 |
| Rivoirard, R | 1 |
| Falk, AT | 1 |
| Chargari, C | 3 |
| Guy, JB | 1 |
| Mery, B | 1 |
| Nuti, C | 3 |
| Peoc'h, M | 3 |
| Forest, F | 3 |
| Garin, C | 1 |
| Adjabi, A | 1 |
| Hoarau, D | 1 |
| Kawaye, S | 1 |
| Almokhles, H | 1 |
| Fournel, P | 1 |
| Kim, T | 1 |
| Joo, JD | 2 |
| Yun, CH | 1 |
| D'Alimonte, I | 1 |
| Nargi, E | 1 |
| Zuccarini, M | 1 |
| Lanuti, P | 1 |
| Di Iorio, P | 1 |
| Giuliani, P | 1 |
| Caciagli, F | 1 |
| Ciccarelli, R | 1 |
| Fourniols, T | 1 |
| Randolph, LD | 1 |
| Staub, A | 1 |
| Vanvarenberg, K | 1 |
| Leprince, JG | 1 |
| des Rieux, A | 1 |
| Yazaki, T | 1 |
| Katayama, M | 2 |
| Kimura, T | 5 |
| Fujiwara, H | 1 |
| Ohira, T | 1 |
| Kourelis, TV | 1 |
| Gangat, N | 1 |
| Patnaik, MM | 1 |
| Kovic, B | 1 |
| Xie, F | 1 |
| Theodore-Oklota, C | 1 |
| Ravelo, A | 1 |
| Tieu, MT | 1 |
| Lovblom, LE | 1 |
| Kiehl, TR | 1 |
| Perkins, BA | 1 |
| Knippen, S | 1 |
| Lahmer, G | 1 |
| Semrau, S | 1 |
| Rösche, J | 1 |
| Piek, J | 1 |
| Hildebrandt, G | 1 |
| Grossmann, A | 1 |
| Kirschstein, T | 1 |
| Benecke, R | 1 |
| Fathallah-Shaykh, HM | 3 |
| Mohile, N | 3 |
| Lager, JJ | 1 |
| Laird, AD | 1 |
| Egile, C | 1 |
| Mayer, A | 1 |
| Schwanbeck, C | 1 |
| Sommer, C | 2 |
| Stockinger, M | 1 |
| Renovanz, M | 1 |
| Vaupel, P | 1 |
| Schmidberger, H | 1 |
| Mullen, DF | 1 |
| Fergus, S | 1 |
| Dunn, G | 1 |
| Belda-Iniesta, C | 1 |
| Reynés, G | 5 |
| Capellades, J | 3 |
| Ordoñez, JM | 1 |
| La Orden, B | 1 |
| Krossa, S | 1 |
| Schmitt, AD | 1 |
| Fritsch, J | 1 |
| Scheidig, AJ | 1 |
| Lewis, S | 1 |
| Churi, S | 1 |
| Padmavati, A | 1 |
| Shetty, P | 1 |
| Welzel, G | 1 |
| Gehweiler, J | 1 |
| Appelt, JU | 1 |
| Seiz-Rosenhagen, M | 1 |
| Shen, Y | 1 |
| Nitta, M | 2 |
| Steed, T | 1 |
| Treiber, JM | 1 |
| Taich, Z | 1 |
| Stevens, D | 1 |
| Wykosky, J | 1 |
| Chen, HZ | 1 |
| Becher, OJ | 1 |
| Kennedy, R | 1 |
| Esashi, F | 1 |
| Desai, A | 1 |
| Trouve, C | 1 |
| Le Meunier, F | 1 |
| Solomalalarivelo, F | 1 |
| Delentaigne Delogivieres, X | 1 |
| Drouard, M | 1 |
| Suguenot, R | 1 |
| Lecuyer, E | 1 |
| Bentayeb, H | 1 |
| Rault, I | 1 |
| Douadi, Y | 1 |
| Dayen, C | 1 |
| Vanaclocha, V | 1 |
| Sureda, M | 1 |
| Azinovic, I | 1 |
| Rebollo, J | 1 |
| Cañón, R | 1 |
| Sapena, NS | 1 |
| Cases, FG | 1 |
| Brugarolas, A | 1 |
| Yan, C | 1 |
| Pramanik, PP | 1 |
| Parmar, HA | 1 |
| Junck, LR | 1 |
| Atif, F | 1 |
| Patel, NR | 1 |
| Yousuf, S | 1 |
| Stein, DG | 1 |
| Bleeker, FE | 1 |
| Moutinho, C | 1 |
| Falcomatà, C | 1 |
| Siravegna, G | 1 |
| Milione, M | 1 |
| De Braud, F | 1 |
| Venesio, T | 1 |
| de Witt Hamer, P | 1 |
| Esteller, M | 2 |
| Rosenthal, MA | 9 |
| Dally, M | 1 |
| Drummond, K | 1 |
| Murphy, M | 1 |
| Thursfield, V | 1 |
| Ströbele, S | 1 |
| Schneele, L | 1 |
| Karpel-Massle, G | 1 |
| Bourgon, R | 1 |
| Moore, N | 2 |
| Kharbanda, S | 1 |
| Peale, F | 1 |
| Hegde, P | 1 |
| Phillips, HS | 2 |
| Bais, C | 1 |
| Raub, TJ | 1 |
| Wishart, GN | 1 |
| Kulanthaivel, P | 1 |
| Staton, BA | 1 |
| Ajamie, RT | 1 |
| Sawada, GA | 1 |
| Gelbert, LM | 2 |
| Sanchez-Martinez, C | 1 |
| De Dios, A | 1 |
| Yahyanejad, S | 2 |
| van Hoof, SJ | 2 |
| Theys, J | 2 |
| Barbeau, LM | 2 |
| Granton, PV | 2 |
| Paesmans, K | 1 |
| Verhaegen, F | 2 |
| Vooijs, M | 2 |
| Moukhlissi, M | 1 |
| Naciri, F | 1 |
| Towner, RA | 1 |
| Ihnat, M | 1 |
| Saunders, D | 1 |
| Bastian, A | 1 |
| Pavana, RK | 1 |
| Xie, G | 2 |
| Yao, G | 1 |
| Krauze, AV | 1 |
| Myrehaug, SD | 1 |
| Chang, MG | 1 |
| Holdford, DJ | 1 |
| Shih, J | 1 |
| Tofilon, PJ | 4 |
| Middleton, MR | 3 |
| Friedlander, P | 1 |
| Hamid, O | 1 |
| Daud, A | 1 |
| Plummer, R | 1 |
| Falotico, N | 1 |
| Mostafa, NM | 1 |
| Zhu, M | 1 |
| McKee, M | 1 |
| Giranda, VL | 1 |
| McArthur, GA | 1 |
| Walker, ND | 1 |
| Scotto, KW | 1 |
| Prust, MJ | 1 |
| Jafari-Khouzani, K | 1 |
| Farace, C | 1 |
| Oliver, JA | 2 |
| Alvarez, P | 1 |
| Bandiera, P | 1 |
| Rama, AR | 1 |
| Malaguarnera, G | 1 |
| Madeddu, R | 2 |
| Giridhar, P | 1 |
| Haresh, KP | 2 |
| Burger, P | 1 |
| Soudry, E | 1 |
| Gallia, GL | 1 |
| Sidransky, D | 1 |
| Lan, F | 2 |
| Xia, T | 1 |
| Yue, X | 2 |
| Arevalo-Perez, J | 1 |
| Lyo, J | 1 |
| Peck, KK | 1 |
| Emmons, G | 1 |
| Garcia Ribas, I | 1 |
| Komori, K | 1 |
| Yanagisawa, R | 1 |
| Miyairi, Y | 1 |
| Sakashita, K | 1 |
| Shiohara, M | 1 |
| Fujihara, I | 1 |
| Morita, D | 1 |
| Nakamura, T | 2 |
| Ogiso, Y | 1 |
| Sano, K | 1 |
| Shirahata, M | 2 |
| Fukuoka, K | 1 |
| Shigeta, H | 1 |
| Gurda, D | 1 |
| Głodowicz, P | 1 |
| Nowak, S | 1 |
| Tai, P | 1 |
| Dubey, A | 2 |
| Salim, M | 1 |
| Vu, K | 1 |
| Koul, R | 1 |
| St-Coeur, PD | 1 |
| Poitras, JJ | 1 |
| Cuperlovic-Culf, M | 1 |
| Touaibia, M | 1 |
| Morin, P | 1 |
| Bosa, C | 1 |
| Franchino, F | 1 |
| DeMarco, J | 1 |
| Chen, CM | 1 |
| Syu, JP | 1 |
| Way, TD | 1 |
| Huang, LJ | 1 |
| Kuo, SC | 1 |
| Lin, CT | 1 |
| Ben Harrabi, S | 1 |
| Mohr, A | 1 |
| Koelsche, C | 2 |
| Diehl, C | 2 |
| Shen, D | 1 |
| Qiu, ZK | 1 |
| Yang, QY | 1 |
| Chen, YS | 1 |
| Panasci, L | 1 |
| Boccard, SG | 1 |
| Marand, SV | 1 |
| Geraci, S | 1 |
| Pycroft, L | 1 |
| Berger, FR | 1 |
| Pelletier, LA | 1 |
| Lu, P | 1 |
| Lee, IH | 3 |
| Jung, YS | 1 |
| Nam, SH | 1 |
| Kim, BS | 2 |
| Joo, KM | 3 |
| Li, RH | 1 |
| Hou, XY | 1 |
| Tang, JQ | 1 |
| Bertucci, A | 1 |
| Prasetyanto, EA | 1 |
| Septiadi, D | 1 |
| Manicardi, A | 2 |
| Brognara, E | 2 |
| Gambari, R | 2 |
| Corradini, R | 2 |
| De Cola, L | 1 |
| Duerinck, J | 1 |
| Du Four, S | 1 |
| Sander, W | 1 |
| Van Binst, AM | 1 |
| Everaert, H | 2 |
| Michotte, A | 4 |
| Alshami, J | 1 |
| Gibson, N | 1 |
| Solca, F | 1 |
| Muanza, T | 2 |
| Rizzato, S | 1 |
| Anghileri, E | 1 |
| Nicolotto, E | 1 |
| Bazzoli, E | 1 |
| Fabi, A | 3 |
| Gurrieri, L | 1 |
| Dall'Agata, M | 1 |
| Bai, GR | 1 |
| An, JB | 1 |
| Wang, XY | 1 |
| Li, SM | 1 |
| Yan, KJ | 1 |
| Lü, FR | 1 |
| Gu, N | 1 |
| Griffin, AN | 1 |
| Sun, BY | 1 |
| Wang, GC | 1 |
| Zhou, SP | 1 |
| Liu, CX | 1 |
| Tai, L | 1 |
| Gandhi, AK | 1 |
| Sharma, DN | 1 |
| Wang, TJ | 1 |
| Jani, A | 1 |
| Estrada, JP | 1 |
| Chow, DS | 1 |
| Soun, JE | 1 |
| Saad, S | 1 |
| Qureshi, YH | 1 |
| Gartrell, R | 1 |
| Isaacson, SR | 1 |
| Cheng, SK | 1 |
| McKhann, GM | 1 |
| Bruce, JN | 1 |
| Bulik, M | 1 |
| Kazda, T | 1 |
| Slampa, P | 2 |
| Jancalek, R | 1 |
| Ahmed, KA | 1 |
| Fulp, WJ | 1 |
| Eschrich, S | 1 |
| Torres-Roca, JF | 1 |
| Caudell, JJ | 1 |
| Babu, R | 1 |
| Komisarow, JM | 1 |
| Agarwal, VJ | 1 |
| Rahimpour, S | 1 |
| Iyer, A | 1 |
| Britt, D | 1 |
| Karikari, IO | 1 |
| Grossi, PM | 1 |
| Thomas, S | 2 |
| Friedman, AH | 20 |
| Adamson, C | 1 |
| Neagu, MR | 1 |
| Guan, DG | 1 |
| Liao, SF | 1 |
| Zhao, TZ | 1 |
| Groves, M | 2 |
| Loghin, M | 1 |
| Liu, D | 1 |
| Rademaker, A | 2 |
| Vaillant, B | 1 |
| Rudnick, J | 1 |
| Chamberlain, M | 3 |
| Vick, N | 1 |
| Ellsworth, S | 1 |
| Guo, A | 1 |
| Faure, G | 1 |
| Quetin, P | 2 |
| Carnin, C | 1 |
| Pedeux, R | 1 |
| Trotti, AM | 1 |
| Cavaliere, R | 2 |
| Shelton, BJ | 1 |
| Shearer, AJ | 1 |
| Sun, DA | 1 |
| Parsons, S | 1 |
| Bourne, TD | 1 |
| LaRocca, R | 2 |
| Wehbe, M | 1 |
| Strutt, D | 1 |
| Masin, D | 1 |
| Anantha, M | 1 |
| Walker, D | 1 |
| Chu, F | 1 |
| Backstrom, I | 1 |
| Kalra, J | 1 |
| Waterhouse, D | 1 |
| Yapp, DT | 1 |
| Bally, MB | 1 |
| Sugiyama, S | 3 |
| Benedetti, E | 1 |
| Antonosante, A | 1 |
| d'Angelo, M | 1 |
| Cristiano, L | 1 |
| Galzio, R | 1 |
| Destouches, D | 1 |
| Florio, TM | 1 |
| Dhez, AC | 1 |
| Astarita, C | 1 |
| Fidoamore, A | 1 |
| Rosati, F | 1 |
| Ippoliti, R | 1 |
| Courty, J | 1 |
| Cimini, A | 1 |
| Murphy, SF | 1 |
| Varghese, RT | 1 |
| Lamouille, S | 1 |
| Pridham, KJ | 1 |
| Kanabur, P | 1 |
| Osimani, AM | 1 |
| Jourdan, J | 1 |
| Rodgers, CM | 1 |
| Simonds, GR | 1 |
| Gourdie, RG | 1 |
| Sheng, Z | 2 |
| Ananta, JS | 1 |
| Carra, E | 1 |
| Barbieri, F | 1 |
| Würth, R | 1 |
| Parodi, F | 1 |
| Pattarozzi, A | 1 |
| Carosio, R | 1 |
| Florio, T | 1 |
| Chakrabarti, M | 1 |
| Martínez-Sales, V | 1 |
| Vila, V | 1 |
| Palomero, I | 1 |
| Fleitas, T | 1 |
| Reche, E | 1 |
| Wyss, MT | 1 |
| Crippa, F | 1 |
| Azevedo, H | 1 |
| Moreira-Filho, CA | 1 |
| Glantz, M | 3 |
| Field, KM | 1 |
| Sawkins, K | 1 |
| Wickström, M | 1 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 1 |
| Sandén, E | 1 |
| Kool, M | 1 |
| Kogner, P | 1 |
| Baryawno, N | 1 |
| Johnsen, JI | 1 |
| Ramiro, S | 1 |
| Lladó, S | 1 |
| Toro, S | 1 |
| Coveñas, R | 1 |
| Arita, H | 2 |
| Yonezawa, M | 1 |
| Fukushima, S | 2 |
| Takami, H | 2 |
| Poon, MW | 2 |
| Zhuang, JT | 2 |
| Zhuang, Y | 1 |
| Tivnan, A | 1 |
| Flanagan, L | 1 |
| Murray, DW | 1 |
| Boyd, AW | 1 |
| O'Brien, DF | 1 |
| Steinberg, DM | 1 |
| Henson, JW | 3 |
| Engelhard, HH | 2 |
| Tran, ND | 1 |
| Ortega, A | 1 |
| Sarmiento, JM | 1 |
| Ly, D | 1 |
| Nuño, M | 3 |
| Mukherjee, D | 3 |
| Black, KL | 4 |
| Patil, CG | 3 |
| Ghoochani, A | 2 |
| Yakubov, E | 1 |
| Sehm, T | 2 |
| Fan, Z | 2 |
| Hock, S | 1 |
| Buchfelder, M | 2 |
| Eyüpoglu, IY | 3 |
| Savaskan, NE | 2 |
| Yazici, G | 1 |
| Zorlu, F | 1 |
| Cengiz, M | 1 |
| Ozyigit, G | 1 |
| Eren, G | 1 |
| Yüce, D | 1 |
| Varan, A | 2 |
| Akyuz, C | 2 |
| Akalan, N | 1 |
| Gurkaynak, M | 1 |
| Younis, SG | 1 |
| Khedr, RA | 1 |
| El-Shorbagy, SH | 1 |
| Jhaveri, N | 4 |
| Agasse, F | 1 |
| Armstrong, D | 1 |
| Commins, D | 1 |
| Rosenstein-Sisson, R | 1 |
| Vaikari, VP | 2 |
| Santiago, SV | 1 |
| Santos, T | 1 |
| Durand, T | 1 |
| Jacob, S | 1 |
| Lebouil, L | 1 |
| Douzane, H | 1 |
| Lestaevel, P | 1 |
| Rahimian, A | 1 |
| Leclercq, D | 1 |
| Brochet, B | 1 |
| Tamarat, R | 1 |
| Milliat, F | 1 |
| Benderitter, M | 1 |
| Vayatis, N | 1 |
| Bernier, MO | 1 |
| Muldoon, LL | 1 |
| Pagel, MA | 1 |
| Netto, JP | 1 |
| Fabbri, E | 1 |
| Montagner, G | 1 |
| Gasparello, J | 1 |
| Bianchi, N | 1 |
| Finotti, A | 1 |
| Breveglieri, G | 1 |
| Borgatti, M | 1 |
| Lampronti, I | 1 |
| Milani, R | 1 |
| Dechecchi, MC | 1 |
| Cabrini, G | 1 |
| Park, M | 1 |
| Choi, KH | 1 |
| Xu, HU | 1 |
| Bihari, F | 1 |
| Whitehead, S | 1 |
| Wong, E | 1 |
| Schmid, S | 1 |
| Hebb, MO | 1 |
| Mendez, JS | 1 |
| Govindan, A | 1 |
| Leong, J | 1 |
| Egan, G | 1 |
| Cervone, KA | 1 |
| Philips, PC | 1 |
| Belasco, JB | 1 |
| Finlay, JL | 1 |
| Gardner, SL | 1 |
| Strowd, RE | 2 |
| Abuali, I | 1 |
| Henaine, AM | 1 |
| Paubel, N | 1 |
| Diebold, G | 1 |
| Aulagner, G | 1 |
| Hartmann, D | 1 |
| Armoiry, X | 1 |
| Ensign, SP | 1 |
| Mathews, IT | 2 |
| Tuncali, S | 2 |
| Symons, MH | 1 |
| Nitta, Y | 1 |
| Shimizu, S | 4 |
| Shishido-Hara, Y | 2 |
| Shiokawa, Y | 3 |
| Kang, W | 1 |
| Paddison, PJ | 1 |
| Kim, M | 1 |
| Hwang, YI | 1 |
| Hegi, M | 2 |
| Dhar, S | 1 |
| Pozzi, E | 1 |
| Schmid, RS | 1 |
| Simon, JM | 5 |
| Vitucci, M | 1 |
| McNeill, RS | 1 |
| Bash, RE | 1 |
| Werneke, AM | 1 |
| Huey, L | 1 |
| White, KK | 1 |
| Álvarez de Eulate-Beramendi, S | 1 |
| Álvarez-Vega, MA | 1 |
| Balbin, M | 1 |
| Sanchez-Pitiot, A | 1 |
| Vallina-Alvarez, A | 1 |
| Martino-González, J | 1 |
| Ouyang, M | 1 |
| White, EE | 1 |
| Yanyan, S | 1 |
| Da Fonseca, A | 1 |
| Manuel, ER | 1 |
| Vonderfecht, SL | 1 |
| Alizadeh, D | 1 |
| Berlin, JM | 1 |
| Badie, B | 2 |
| Redjal, N | 1 |
| Reinshagen, C | 1 |
| Le, A | 1 |
| Walcott, BP | 1 |
| McDonnell, E | 1 |
| Nahed, BV | 2 |
| Qian, L | 1 |
| O'Leary, B | 1 |
| Mandeville, HC | 1 |
| Fersht, N | 1 |
| Solda, F | 1 |
| Mycroft, J | 1 |
| Zacharoulis, S | 3 |
| Vaidya, S | 2 |
| Gil-Gil, MJ | 1 |
| Vieitez, JM | 1 |
| Garcia, A | 1 |
| Vazquez-Estevez, S | 1 |
| Fernandez, I | 1 |
| De la Cruz, JJ | 1 |
| Giner, P | 1 |
| Kushal, S | 1 |
| Kota, R | 1 |
| Yeh, TS | 1 |
| Groshen, SL | 1 |
| Olenyuk, BZ | 1 |
| Xia, L | 1 |
| Ling, Z | 1 |
| Arrizabalaga, O | 1 |
| Moncho-Amor, V | 1 |
| Carrasco-Garcia, E | 1 |
| Manterola, L | 1 |
| Moreno-Cugnon, L | 1 |
| Barrena, C | 1 |
| Villanua, J | 1 |
| Ruiz, I | 1 |
| Pollard, S | 1 |
| Lovell-Badge, R | 1 |
| Conway, GE | 1 |
| Casey, A | 1 |
| Milosavljevic, V | 1 |
| Howe, O | 1 |
| Cullen, PJ | 1 |
| Curtin, JF | 1 |
| Kristensen, LS | 1 |
| Dyrbye, H | 1 |
| Aslan, D | 1 |
| Grønbæk, K | 1 |
| Radoul, M | 1 |
| Chaumeil, MM | 1 |
| Eriksson, P | 1 |
| Wang, AS | 1 |
| Ronen, SM | 2 |
| Berglund, A | 1 |
| Kenchappa, RS | 1 |
| Forsyth, PA | 2 |
| Mulé, JJ | 1 |
| Koukourakis, MI | 1 |
| Mitrakas, AG | 1 |
| Giatromanolaki, A | 1 |
| Paul-Samojedny, M | 1 |
| Pudełko, A | 1 |
| Kowalczyk, M | 1 |
| Fila-Daniłow, A | 1 |
| Suchanek-Raif, R | 1 |
| Borkowska, P | 1 |
| Kowalski, J | 1 |
| Qin, Q | 1 |
| Han, D | 1 |
| Hsieh, TH | 1 |
| Ng, KH | 1 |
| Tsai, YN | 1 |
| Chao, ME | 1 |
| Liu, DJ | 1 |
| Chu, SS | 1 |
| Liu, YR | 1 |
| Yang, MH | 1 |
| Parker, NR | 1 |
| Hudson, AL | 1 |
| Khong, P | 1 |
| Parkinson, JF | 2 |
| Dwight, T | 1 |
| Ikin, RJ | 1 |
| Cheng, ZJ | 1 |
| Vafaee, F | 1 |
| Wheeler, HR | 3 |
| Howell, VM | 1 |
| Ermani, M | 12 |
| Sturiale, C | 2 |
| Pavesi, G | 1 |
| Urbini, B | 1 |
| Crisi, G | 1 |
| Cavallo, MA | 1 |
| Dazzi, C | 1 |
| Biasini, C | 1 |
| Bertolini, F | 1 |
| Mucciarini, C | 1 |
| Pasini, G | 1 |
| Baruzzi, A | 2 |
| Bromberg, JE | 7 |
| Buckner, J | 3 |
| Xipell, E | 1 |
| Aragón, T | 1 |
| Martínez-Velez, N | 1 |
| Vera, B | 1 |
| Martínez-Irujo, JJ | 1 |
| Garzón, AG | 1 |
| Gonzalez-Huarriz, M | 1 |
| Acanda, AM | 1 |
| Lang, FF | 2 |
| Fueyo, J | 2 |
| Gomez-Manzano, C | 2 |
| Peng, C | 1 |
| Qiu, W | 1 |
| Luo, H | 2 |
| Ferguson, SD | 1 |
| Srinivasan, VM | 1 |
| Ghali, MG | 1 |
| Proske, J | 1 |
| Walter, L | 1 |
| Bumes, E | 1 |
| Hutterer, M | 1 |
| Miller, K | 1 |
| Dixit, S | 5 |
| Bredlau, AL | 1 |
| McKinnon, E | 1 |
| Broome, AM | 1 |
| Jakacki, RI | 3 |
| Cohen, KJ | 2 |
| Buxton, A | 2 |
| Krailo, MD | 2 |
| Burger, PC | 3 |
| Brat, DJ | 2 |
| Eckel, SP | 1 |
| Lavey, RS | 2 |
| Gorospe Sarasúa, L | 1 |
| Ureña-Vacas, A | 1 |
| Muñoz Del Toro, JR | 1 |
| Raj, S | 1 |
| Pandit, PN | 1 |
| Kishor, K | 1 |
| Seystahl, K | 1 |
| Ortega-Martorell, S | 1 |
| Ciezka, M | 1 |
| Olier, I | 1 |
| Fernández, F | 1 |
| Lisboa, PJ | 1 |
| An, Y | 1 |
| Bo, C | 1 |
| Rauh, M | 1 |
| Engelhorn, T | 1 |
| Minakaki, G | 1 |
| Dörfler, A | 1 |
| Klucken, J | 1 |
| Savaskan, N | 1 |
| Chawla, S | 1 |
| Verma, G | 1 |
| Skolnik, A | 1 |
| Apaijai, N | 1 |
| Yarana, C | 1 |
| Sripetchwandee, J | 1 |
| Limpastan, K | 1 |
| Watcharasaksilp, W | 1 |
| Vaniyapong, T | 1 |
| Ma, ZX | 1 |
| Sidlauskas, K | 1 |
| Zhang, EE | 1 |
| Ohtsu, N | 1 |
| Echizenya, S | 1 |
| Otsuguro, S | 1 |
| Ogura, R | 1 |
| Isogawa, M | 1 |
| Aoki, H | 3 |
| Ichikawa, S | 1 |
| Sakaitani, M | 1 |
| Matsuda, A | 1 |
| Maenaka, K | 1 |
| D'Alessandro, G | 1 |
| Grimaldi, A | 1 |
| Chece, G | 1 |
| Porzia, A | 1 |
| Mainiero, F | 1 |
| Ragozzino, D | 1 |
| Di Angelantonio, S | 1 |
| Wulff, H | 1 |
| Catalano, M | 1 |
| Limatola, C | 1 |
| Mirjolet, C | 1 |
| Mazoyer, F | 1 |
| Blanchard, N | 1 |
| Lagneau, É | 1 |
| Maingon, P | 1 |
| Drachsler, M | 1 |
| Kleber, S | 1 |
| Mateos, A | 1 |
| Volk, K | 1 |
| Mohr, N | 1 |
| Cirovic, B | 1 |
| Tüttenberg, J | 1 |
| Gieffers, C | 1 |
| Sykora, J | 1 |
| Martin-Villalba, A | 1 |
| Garcia, L | 1 |
| Gruslova, A | 1 |
| Cavazos, D | 1 |
| Garcia, M | 1 |
| Strom, AM | 1 |
| Gustafsson, JA | 1 |
| Vandraas, K | 1 |
| Tjønnfjord, GE | 1 |
| Johannesen, TB | 2 |
| Stetson, LC | 1 |
| Dazard, JE | 1 |
| Steuve, J | 1 |
| Hamou, MF | 4 |
| Kosch, M | 1 |
| Farina, M | 1 |
| Castelli, J | 1 |
| Haoming, QC | 2 |
| Berger, A | 2 |
| Gutierrez, FL | 1 |
| Morandi, X | 1 |
| Le Reste, PJ | 1 |
| Thillays, F | 2 |
| Loussouarn, D | 1 |
| Nouhaud, E | 1 |
| Crehange, G | 1 |
| Antoni, D | 2 |
| de Crevoisier, R | 2 |
| Bailey, BJ | 1 |
| Reza Saadatzadeh, M | 1 |
| Ding, J | 1 |
| Tonsing-Carter, E | 1 |
| Georgiadis, TM | 1 |
| Zachary Gunter, T | 1 |
| Long, EC | 1 |
| Minto, RE | 1 |
| Gordon, KR | 1 |
| Sen, SE | 1 |
| Eitel, JA | 1 |
| Waning, DL | 1 |
| Bringman, LR | 1 |
| Wells, CD | 1 |
| Murray, ME | 1 |
| Jones, DR | 1 |
| Cohen-Gadol, AA | 1 |
| Mayo, LD | 1 |
| Carceller, F | 1 |
| Fowkes, LA | 1 |
| Khabra, K | 1 |
| Moreno, L | 2 |
| Burford, A | 1 |
| Mackay, A | 1 |
| Jones, DT | 1 |
| Hovestadt, V | 1 |
| Mandeville, H | 1 |
| Jerome, N | 1 |
| Bridges, LR | 1 |
| Laxton, R | 1 |
| Al-Sarraj, S | 1 |
| Pearson, AD | 2 |
| Koh, DM | 1 |
| Morr, S | 1 |
| Prasad, D | 1 |
| King, H | 1 |
| Iglesias, VS | 1 |
| Groot, AJ | 1 |
| Habets, R | 1 |
| Prickaerts, J | 1 |
| Eekers, DB | 1 |
| Florange, J | 1 |
| Badakhshi, H | 1 |
| Grün, A | 1 |
| Ghadjar, P | 1 |
| Exner, S | 1 |
| Budach, V | 2 |
| Rusthoven, CG | 1 |
| Koshy, M | 1 |
| Sher, DJ | 2 |
| Jones, BL | 1 |
| Karam, SD | 1 |
| Youssef, AS | 1 |
| Weitzel, DH | 1 |
| Tovmasyan, A | 1 |
| Ashcraft, KA | 1 |
| Boico, A | 1 |
| Birer, SR | 1 |
| Roy Choudhury, K | 1 |
| Herndon, J | 1 |
| Rodriguiz, RM | 1 |
| Wetsel, WC | 1 |
| Spasojevic, I | 1 |
| Batinic-Haberle, I | 1 |
| Dewhirst, MW | 1 |
| Hernandez-Lain, A | 1 |
| Hilario, A | 1 |
| Cantero, D | 1 |
| Ramos, A | 1 |
| Paquette, B | 1 |
| Vernerey, D | 1 |
| Dabakuyo, S | 1 |
| Anota, A | 1 |
| Stavrovskaya, AA | 2 |
| Shushanov, SS | 1 |
| Rybalkina, EY | 2 |
| Hu, P | 1 |
| Tang, F | 1 |
| Lian, H | 1 |
| Cazzato, E | 1 |
| Ladewig, E | 1 |
| Frattini, V | 1 |
| Rosenbloom, DI | 1 |
| Zairis, S | 1 |
| Abate, F | 1 |
| Elliott, O | 1 |
| Shin, YJ | 1 |
| Lee, JK | 1 |
| Blumberg, AJ | 1 |
| Lasorella, A | 1 |
| Rotta, JM | 1 |
| de Oliveira, MF | 1 |
| Reis, RC | 1 |
| Botelho, RV | 1 |
| Yang, YR | 1 |
| Chen, MH | 2 |
| Wang, XD | 2 |
| Sun, LL | 1 |
| Wang, FZ | 1 |
| Wang, DC | 1 |
| Weatherbee, JL | 2 |
| Kraus, JL | 1 |
| Grzmil, M | 1 |
| Seebacher, J | 1 |
| Hess, D | 1 |
| Behe, M | 1 |
| Schibli, R | 1 |
| Moncayo, G | 1 |
| Frank, S | 1 |
| Hemmings, BA | 1 |
| Horiguchi, H | 1 |
| Nakata, S | 1 |
| Nobusawa, S | 2 |
| Uyama, S | 1 |
| Miyamoto, T | 1 |
| Ueta, H | 1 |
| Fujimoto, N | 1 |
| Chandler, JP | 2 |
| Ferrarese, R | 1 |
| Levy, RM | 2 |
| Rosenow, J | 1 |
| Paton, M | 1 |
| Moiseeva, NI | 1 |
| Susova, OY | 1 |
| Mitrofanov, AA | 1 |
| Panteleev, DY | 1 |
| Pavlova, GV | 1 |
| Pustogarov, NA | 1 |
| Matsumura, N | 1 |
| Nakajima, N | 1 |
| Yamazaki, T | 1 |
| Nagano, T | 1 |
| Kagoshima, K | 1 |
| Ikota, H | 1 |
| Bracci, S | 1 |
| Hitchcock, K | 1 |
| Duran-Peña, A | 1 |
| Navarro, S | 1 |
| Chevalier, A | 1 |
| Jacob, J | 1 |
| Troussier, I | 1 |
| Jastaniah, Z | 1 |
| Gaultier, C | 1 |
| Ahle, G | 1 |
| Couchot, J | 1 |
| Atlani, D | 2 |
| Clavier, JB | 2 |
| Srour, R | 1 |
| Chaussemy, D | 1 |
| Kajitani, GS | 1 |
| Fortunato, RS | 1 |
| Gil Del Alcazar, CR | 1 |
| Todorova, PK | 1 |
| Barone, TA | 1 |
| Burkhart, CA | 1 |
| Safina, A | 1 |
| Haderski, G | 1 |
| Gurova, KV | 1 |
| Purmal, AA | 1 |
| Gudkov, AV | 1 |
| Plunkett, RJ | 1 |
| Cho, YH | 1 |
| Yoon, SM | 1 |
| Lee, KH | 3 |
| Kang, SH | 2 |
| Kang, MK | 1 |
| Chung, DS | 2 |
| Hwang, SC | 1 |
| Song, JH | 1 |
| Cho, SJ | 1 |
| Lee, SI | 1 |
| Lee, YS | 1 |
| Ahn, KJ | 1 |
| Gwak, HS | 1 |
| Xiao, S | 1 |
| Lv, R | 1 |
| Berenguer-Daizé, C | 1 |
| Astorgues-Xerri, L | 1 |
| Odore, E | 1 |
| Cayol, M | 1 |
| Cvitkovic, E | 1 |
| Noel, K | 1 |
| Bekradda, M | 1 |
| MacKenzie, S | 1 |
| Rezai, K | 1 |
| Lokiec, F | 1 |
| Riveiro, ME | 1 |
| Nolen, SC | 1 |
| Lee, B | 1 |
| Shantharam, S | 1 |
| Yu, HJ | 1 |
| Billimek, J | 1 |
| Holla, FK | 1 |
| Blankenstein, MA | 1 |
| van Mierlo, TJM | 1 |
| Uitdehaag, BMJ | 1 |
| Hielscher, T | 2 |
| Menn, O | 1 |
| Kim, C | 1 |
| Pledl, HW | 1 |
| Zorn, M | 1 |
| Jugold, M | 1 |
| Green, E | 1 |
| Löw, S | 1 |
| Ott, M | 1 |
| Steffen, AC | 1 |
| Qi, L | 1 |
| Ding, L | 1 |
| Lv, P | 1 |
| Hu, Q | 1 |
| Kamamoto, D | 1 |
| Mizutani, K | 1 |
| Cai, Z | 1 |
| Hu, G | 1 |
| Heo, DS | 3 |
| Kim, DG | 5 |
| Jung, HW | 5 |
| Lorimer, CF | 1 |
| Brock, J | 1 |
| Bielecka, AM | 1 |
| Song, G | 1 |
| Colamaio, M | 1 |
| Tosti, N | 1 |
| Puca, F | 1 |
| Mari, A | 1 |
| Gattordo, R | 1 |
| Kuzay, Y | 1 |
| Federico, A | 1 |
| Pepe, A | 1 |
| Sarnataro, D | 1 |
| Ragozzino, E | 1 |
| Raia, M | 1 |
| Hirata, H | 1 |
| Gemei, M | 1 |
| Mimori, K | 1 |
| Del Vecchio, L | 1 |
| Battista, S | 1 |
| Diesler, K | 1 |
| Majhen, D | 1 |
| Steigerwald, C | 1 |
| Berte, N | 2 |
| Freund, H | 1 |
| Stojanović, N | 1 |
| Osmak, M | 1 |
| Ambriović-Ristov, A | 1 |
| Hiddinga, BI | 1 |
| Pauwels, P | 1 |
| Janssens, A | 1 |
| van Meerbeeck, JP | 1 |
| Weyhenmeyer, BC | 1 |
| Noonan, J | 1 |
| Würstle, ML | 1 |
| Lincoln, FA | 1 |
| Johnston, G | 1 |
| Shimokawa, A | 1 |
| Kobayashi, K | 2 |
| Higuchi, F | 1 |
| Uzuka, T | 3 |
| Otani, R | 1 |
| Tamura, K | 1 |
| Sumita, K | 1 |
| Ishibashi, K | 1 |
| Kodama, Y | 1 |
| Tomogane, Y | 1 |
| Fukai, J | 1 |
| Fujita, K | 1 |
| Terakawa, Y | 1 |
| Tsuyuguchi, N | 1 |
| Shibuya, M | 1 |
| Maehara, T | 1 |
| Kawahara, N | 1 |
| Miyaoka, E | 1 |
| Kerloeguen, Y | 1 |
| Zhan, SK | 1 |
| Olson, M | 2 |
| Crane, JC | 1 |
| Molinaro, A | 2 |
| Roy, R | 2 |
| Joly, MO | 1 |
| Rivet, P | 2 |
| Entz-Werle, N | 2 |
| Zalcman, EL | 1 |
| Levallet, G | 2 |
| Escande, F | 1 |
| Ramirez, C | 3 |
| Chiforeanu, D | 1 |
| Hoja, S | 1 |
| Schulze, M | 1 |
| Rehli, M | 1 |
| Toren, A | 1 |
| Pismenyuk, T | 1 |
| Yalon, M | 1 |
| Freedman, S | 1 |
| Simon, AJ | 1 |
| Fisher, T | 1 |
| Moshe, I | 1 |
| Reichardt, JK | 1 |
| Constantini, S | 1 |
| Daniels, D | 1 |
| Assoulin, M | 1 |
| Mehrian-Shai, R | 1 |
| Smith, KA | 1 |
| Stea, B | 1 |
| Wilson, TJ | 1 |
| Zamler, DB | 1 |
| Doherty, R | 1 |
| Haas-Kogan, DA | 4 |
| Dayal, M | 1 |
| Nelson, S | 1 |
| Kadambi, AK | 1 |
| Park, I | 2 |
| Crane, J | 1 |
| Koh, I | 1 |
| Jeon, JY | 1 |
| Yun, M | 1 |
| Huh, YM | 1 |
| Lee, SJ | 2 |
| Pollak, M | 1 |
| Kim, P | 1 |
| Cheong, JH | 1 |
| Vartanian, A | 1 |
| Agnihotri, S | 2 |
| Wilson, MR | 1 |
| Burrell, KE | 1 |
| Tonge, PD | 1 |
| Alamsahebpour, A | 1 |
| Jalali, S | 1 |
| Taccone, MS | 1 |
| Mansouri, S | 1 |
| Arnal, AV | 1 |
| Wang, SH | 2 |
| Odia, Y | 1 |
| Lokan, S | 1 |
| Eich, M | 1 |
| Trusheim, J | 1 |
| Dunbar, E | 1 |
| Battiste, J | 1 |
| Connelly, J | 1 |
| Tomabechi, M | 1 |
| Sasaki, M | 1 |
| Polewski, MD | 1 |
| Reveron-Thornton, RF | 1 |
| Cherryholmes, GA | 1 |
| Marinov, GK | 1 |
| Cassady, K | 1 |
| Pinheiro, R | 1 |
| Santos, G | 1 |
| Bronze, MR | 1 |
| Falcão, AS | 1 |
| Bao, S | 1 |
| Bromberg, JEC | 1 |
| Ryan, G | 4 |
| Hassel, MB | 2 |
| Reni, M | 10 |
| Kantor, G | 2 |
| Smits, A | 1 |
| Hartmann, C | 8 |
| Rossiter, JP | 1 |
| Dif, N | 1 |
| Bravo-Marques, J | 1 |
| Nordal, RA | 3 |
| Lacombe, D | 8 |
| Lee, JW | 2 |
| Koh, YC | 1 |
| Chung, YG | 1 |
| Kim, JM | 1 |
| Kim, CH | 3 |
| Ikawa, F | 1 |
| Ishifuro, M | 1 |
| Nishibuchi, I | 1 |
| Amiri, A | 1 |
| Moquin, A | 1 |
| Machkalyan, G | 1 |
| Gillard, JW | 1 |
| Yoganathan, N | 1 |
| Maysinger, D | 1 |
| Hartmann, R | 1 |
| Schröter, F | 1 |
| Suwala, AK | 1 |
| Krüger, AC | 1 |
| Willbold, D | 1 |
| He, P | 1 |
| Yue, J | 1 |
| Boop, FA | 1 |
| Pfeffer, SR | 1 |
| da Fonseca, AC | 1 |
| Amaral, R | 1 |
| Garcia, C | 2 |
| Geraldo, LH | 2 |
| Lima, FR | 2 |
| Zha, Y | 1 |
| Vaios, EJ | 1 |
| Fathi, AT | 1 |
| Cheng, G | 1 |
| Cefalu, M | 1 |
| Zigler, C | 1 |
| Schrag, D | 1 |
| Dominici, F | 1 |
| Tian, T | 1 |
| Mingyi, M | 1 |
| Qiu, Y | 1 |
| Nagel, ZD | 1 |
| Joughin, BA | 1 |
| Chaim, IA | 1 |
| Mazzucato, P | 1 |
| Lauffenburger, DA | 1 |
| Samson, LD | 1 |
| Kim, BR | 1 |
| Park, SW | 1 |
| Yang, JP | 1 |
| Jing, SY | 1 |
| Fan, B | 1 |
| Sun, GZ | 1 |
| Sahuc, P | 1 |
| Nguyen, AT | 1 |
| Fouet, B | 1 |
| Wybrecht, D | 1 |
| Faivre, A | 1 |
| Alla, P | 1 |
| Dagain, A | 1 |
| Schliesser, MG | 1 |
| Claus, R | 1 |
| Grimm, C | 1 |
| Weichenhan, D | 1 |
| Schramm, J | 1 |
| Weiß, EK | 1 |
| Baer, C | 1 |
| Plass, C | 1 |
| Ikeda, T | 1 |
| Suzuki, J | 1 |
| Norizuki, M | 1 |
| Okabe, T | 1 |
| Sasahara, T | 1 |
| Toshima, M | 1 |
| Yokota, H | 1 |
| Hatakeyama, S | 1 |
| Morisawa, Y | 1 |
| Watanabe, S | 1 |
| Kuwabara, Y | 1 |
| Tanaka, M | 3 |
| Tanaka, A | 1 |
| Ohue, S | 1 |
| Araki, H | 1 |
| Ismaila, N | 1 |
| Lovely, M | 1 |
| Mumber, MP | 1 |
| Shi, H | 1 |
| Gui, Q | 1 |
| Lee, CC | 2 |
| Chang, CK | 1 |
| Di, H | 1 |
| Gebhart, RN | 1 |
| Jeon, M | 1 |
| Blair, AA | 1 |
| Ellenbogen, RG | 1 |
| Silber, JR | 5 |
| Frikeche, J | 1 |
| Lott, T | 1 |
| Felder, R | 1 |
| Eisinger-Mathason, TSK | 1 |
| Fisher, JL | 2 |
| Hampton, TH | 2 |
| Christensen, BC | 1 |
| Tsongalis, GJ | 1 |
| Rahme, GJ | 1 |
| Whipple, CA | 1 |
| Steel, SE | 1 |
| Davis, MC | 1 |
| Gaur, AB | 1 |
| Lewis, LD | 1 |
| Ernstoff, MS | 3 |
| Cahill, DP | 4 |
| Dolinskas, CA | 1 |
| Barger, GR | 1 |
| Shih, H | 1 |
| Brachman, D | 2 |
| Schultz, C | 2 |
| Hunter, G | 1 |
| Di Tommaso, L | 1 |
| Baretti, M | 1 |
| Corredor, AG | 1 |
| Peddi, P | 1 |
| Ajit, NE | 1 |
| Burton, GV | 1 |
| El-Osta, H | 1 |
| Zwirner, K | 1 |
| Paulsen, F | 1 |
| Schittenhelm, J | 1 |
| Skardelly, M | 1 |
| Zips, D | 1 |
| Eckert, F | 1 |
| Sheng, R | 1 |
| Lee, TY | 1 |
| Khoury, T | 1 |
| Abu Rmeileh, A | 1 |
| Daher, S | 1 |
| Yaari, S | 1 |
| Benson, AA | 1 |
| Cohen, J | 1 |
| Mizrahi, M | 1 |
| Peng, R | 1 |
| Munasinghe, W | 1 |
| Zeng, B | 1 |
| Zheng, W | 1 |
| Deng, X | 1 |
| Fei, S | 1 |
| Xie, CY | 1 |
| Pinel, B | 1 |
| Duchesne, M | 1 |
| Godet, J | 2 |
| Milin, S | 1 |
| Wager, M | 2 |
| Klimowicz, AC | 1 |
| Magliocco, A | 1 |
| Robe, P | 1 |
| Salavaggione, AL | 1 |
| Lee, RJ | 1 |
| Inge, LJ | 1 |
| Hartman, LK | 1 |
| Chow, D | 1 |
| Millard, N | 1 |
| Yin, HH | 1 |
| Yung, AW | 1 |
| Liang, F | 1 |
| Bao, L | 1 |
| Zhao, YS | 1 |
| Zhang, SM | 1 |
| Zhang, SQ | 1 |
| Absalyamova, OV | 1 |
| Ryzhova, MV | 1 |
| Poddubskiy, AA | 1 |
| Inozemtseva, MV | 1 |
| Lodygina, KS | 1 |
| Shi, F | 1 |
| Cho, JH | 1 |
| Marsoner, T | 1 |
| Schmidt, OP | 1 |
| Triemer, T | 1 |
| Luedtke, NW | 1 |
| Dal-Cim, T | 1 |
| Ludka, FK | 1 |
| Peng, WX | 1 |
| Han, X | 1 |
| Zhang, CL | 1 |
| Ge, L | 1 |
| Du, FY | 1 |
| Gong, AH | 1 |
| Xu, XK | 1 |
| Li, JL | 1 |
| Kong, KK | 1 |
| Ge, XS | 1 |
| Li, FC | 1 |
| Achari, R | 1 |
| Arunsingh, M | 1 |
| Badgami, RK | 1 |
| Saha, A | 1 |
| Shrimali, RK | 1 |
| Arun, B | 2 |
| Gokturk, D | 1 |
| Kelebek, H | 1 |
| Ceylan, S | 1 |
| Yilmaz, DM | 1 |
| Feng, E | 1 |
| Sui, C | 1 |
| Nachbichler, SB | 1 |
| Schupp, G | 1 |
| Ballhausen, H | 1 |
| Kwintkiewicz, J | 1 |
| Tech, K | 1 |
| Frady, LN | 1 |
| Bautista, W | 1 |
| Moon, SI | 1 |
| MacDonald, J | 1 |
| Cenci, T | 2 |
| Kim, BT | 1 |
| Bogdańska, MU | 1 |
| Bodnar, M | 1 |
| Belmonte-Beitia, J | 1 |
| Qiao, W | 2 |
| Guo, B | 1 |
| Xu, W | 3 |
| Liang, Y | 1 |
| Dong, B | 1 |
| Reardon, D | 1 |
| Peters, K | 3 |
| Xu, K | 1 |
| Pei, H | 1 |
| Ramachandran, R | 1 |
| Junnuthula, VR | 1 |
| Gowd, GS | 1 |
| Ashokan, A | 1 |
| Thomas, J | 1 |
| Peethambaran, R | 1 |
| Thomas, A | 1 |
| Unni, AK | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Ben Abdallah, M | 1 |
| Chandran, M | 1 |
| Shah, D | 1 |
| Yadav, VN | 1 |
| Koschmann, C | 1 |
| Asad, AS | 1 |
| Takahashi, W | 1 |
| Tomita, H | 1 |
| Ho, ASW | 1 |
| Cheng, YS | 1 |
| Pu, JKS | 1 |
| Leung, GKK | 1 |
| Sardaro, A | 1 |
| Iannalfi, A | 1 |
| Meattini, I | 1 |
| Leonulli, BG | 1 |
| Borghesi, S | 1 |
| Martinelli, F | 1 |
| Bordi, L | 1 |
| Ammannati, F | 1 |
| Biti, G | 3 |
| Yaman, E | 2 |
| Buyukberber, S | 2 |
| Uner, A | 1 |
| Coskun, U | 2 |
| Akmansu, M | 2 |
| Benekli, M | 2 |
| Yamac, D | 1 |
| Ozturk, B | 2 |
| Kaya, AO | 2 |
| Yildiz, R | 2 |
| Ozkan, S | 1 |
| Gunel, N | 1 |
| Roberge, D | 4 |
| Shakibnia, L | 1 |
| Lambert, C | 1 |
| Leblanc, R | 1 |
| Del Maestro, R | 1 |
| Sirachainan, N | 1 |
| Pakakasama, S | 1 |
| Visudithbhan, A | 1 |
| Chiamchanya, S | 1 |
| Tuntiyatorn, L | 1 |
| Dhanachai, M | 1 |
| Laothamatas, J | 1 |
| Hongeng, S | 1 |
| Murat, A | 1 |
| Migliavacca, E | 1 |
| Lambiv, WL | 2 |
| Shay, T | 1 |
| de Tribolet, N | 4 |
| Kouwenhoven, MC | 5 |
| Hainfellner, JA | 2 |
| Zimmer, Y | 1 |
| Janzer, RC | 5 |
| Domany, E | 1 |
| Huang, F | 2 |
| Markovic, Y | 1 |
| Kobayashi, I | 1 |
| Ujiie, H | 1 |
| Yokoyama, T | 1 |
| Iwado, E | 1 |
| Kondo, Y | 3 |
| Georgescu, MM | 2 |
| Sawaya, R | 4 |
| Kawamura, H | 1 |
| Hashimoto, Y | 1 |
| Urata, Y | 1 |
| Fujiwara, T | 1 |
| Kondo, S | 1 |
| Maschio, M | 2 |
| Albani, F | 1 |
| Jandolo, B | 2 |
| Zarabla, A | 1 |
| Contin, M | 1 |
| Dinapoli, L | 2 |
| Maira, G | 5 |
| Sica, G | 1 |
| Lama, G | 1 |
| Lauriola, L | 1 |
| Röhrl, S | 1 |
| Pillai, DR | 1 |
| Schwarz, S | 1 |
| Kunz-Schughart, LA | 1 |
| Leukel, P | 1 |
| Bogdahn, U | 7 |
| Trampe-Kieslich, A | 1 |
| Giebel, B | 1 |
| Wischhusen, J | 1 |
| Régnard, P | 1 |
| Troprès, I | 1 |
| Keyriläinen, J | 1 |
| Bravin, A | 1 |
| Beule, AC | 1 |
| Bromberg, J | 1 |
| Ernemann, U | 2 |
| Rorden, C | 1 |
| Karnath, HO | 1 |
| Maxwell, JA | 1 |
| Johnson, SP | 2 |
| McLendon, RE | 12 |
| Lister, DW | 1 |
| Horne, KS | 1 |
| Rasheed, A | 1 |
| Quinn, JA | 10 |
| Ali-Osman, F | 1 |
| Modrich, PL | 2 |
| Sauvageot, CM | 1 |
| Winters, SE | 1 |
| Barnes, J | 2 |
| Dellagatta, J | 1 |
| Ramakrishna, NR | 1 |
| Stiles, CD | 1 |
| Kung, AL | 3 |
| Kieran, MW | 3 |
| Schaich, M | 1 |
| Kestel, L | 1 |
| Pfirrmann, M | 1 |
| Robel, K | 1 |
| Illmer, T | 1 |
| Kramer, M | 1 |
| Dill, C | 1 |
| Ehninger, G | 1 |
| Dall'oglio, S | 2 |
| D'Amico, A | 1 |
| Pioli, F | 1 |
| Gabbani, M | 1 |
| Pasini, F | 1 |
| Passarin, MG | 2 |
| Talacchi, A | 1 |
| Turazzi, S | 1 |
| Maluta, S | 2 |
| Solheim, K | 1 |
| Polley, MY | 8 |
| Lamborn, KR | 12 |
| Page, M | 4 |
| Fedoroff, A | 3 |
| Rabbitt, J | 5 |
| Georgescu, G | 1 |
| Isola, IM | 1 |
| Youssef, S | 1 |
| Adachi, J | 2 |
| Rolston, K | 1 |
| Hadjipanayis, CG | 1 |
| Fellows-Mayle, W | 1 |
| Deluca, NA | 1 |
| Rizek, P | 1 |
| Cashman, R | 1 |
| Morrison, M | 2 |
| Morrison, T | 1 |
| Muni, R | 3 |
| Rasio, D | 1 |
| Osti, MF | 3 |
| Cantore, GP | 2 |
| Maurizi Enrici, R | 3 |
| Kang, GS | 1 |
| Mohler, ML | 1 |
| Kirichenko, OV | 1 |
| Patil, R | 1 |
| Orr, WE | 1 |
| Miller, DD | 1 |
| Geisert, EE | 1 |
| Pédeboscq, S | 2 |
| L'Azou, B | 2 |
| Passagne, I | 1 |
| De Giorgi, F | 1 |
| Ichas, F | 1 |
| Pometan, JP | 2 |
| Cambar, J | 2 |
| Berkey, B | 1 |
| Macdonald, D | 3 |
| Jenkins, R | 1 |
| Herman, J | 1 |
| Biggs, C | 1 |
| Bracht, LK | 1 |
| Meyerhardt, JA | 1 |
| Kulke, MH | 1 |
| Hornick, JL | 1 |
| Redston, M | 1 |
| LaFrankie, DC | 2 |
| Black, PM | 3 |
| Norden, A | 2 |
| Fichtner, I | 1 |
| Lemm, M | 1 |
| Lienau, P | 1 |
| Hess-Stumpp, H | 1 |
| Rotgeri, A | 1 |
| Hofmann, B | 1 |
| Klar, U | 1 |
| Atkins, MB | 2 |
| Sosman, JA | 2 |
| Agarwala, S | 1 |
| Logan, T | 1 |
| Clark, JI | 1 |
| Lawson, D | 1 |
| Dutcher, JP | 1 |
| Weiss, G | 2 |
| Curti, B | 1 |
| Margolin, KA | 2 |
| Narayana, A | 2 |
| Golfinos, JG | 2 |
| Fischer, I | 1 |
| Raza, S | 2 |
| Kelly, P | 1 |
| Parker, E | 2 |
| Knopp, EA | 1 |
| Medabalmi, P | 1 |
| Zagzag, D | 2 |
| Eagan, P | 2 |
| Gruber, ML | 2 |
| Hamilton, M | 1 |
| Tersak, J | 1 |
| Voss, SD | 1 |
| Dancey, JE | 2 |
| Adamson, PC | 2 |
| Addeo, R | 6 |
| De Rosa, C | 1 |
| Faiola, V | 4 |
| Leo, L | 1 |
| Cennamo, G | 3 |
| Montella, L | 5 |
| Guarrasi, R | 2 |
| Del Prete, S | 5 |
| Ang, KK | 1 |
| Zhang, HZ | 1 |
| Hammond, E | 1 |
| Piert, M | 2 |
| Gomez-Hassan, D | 2 |
| Hayman, J | 1 |
| Ten Haken, RK | 2 |
| Sridhar, T | 1 |
| Gore, A | 1 |
| Boiangiu, I | 1 |
| Machin, D | 1 |
| Symonds, RP | 1 |
| Somerville, M | 2 |
| Takahashi, H | 5 |
| Yoshida, J | 5 |
| McGirt, MJ | 1 |
| Gathinji, M | 1 |
| Than, K | 1 |
| Weingart, JD | 1 |
| Quiñones-Hinojosa, AR | 1 |
| Sadones, J | 2 |
| Veld, P | 1 |
| Chaskis, C | 3 |
| Joossens, EJ | 1 |
| Strauven, T | 2 |
| D'Hondt, LA | 1 |
| Sartenaer, D | 1 |
| Califice, SF | 1 |
| Bierau, K | 1 |
| Svensson, C | 1 |
| De Grève, J | 1 |
| Guilleminault, L | 1 |
| Carré, P | 1 |
| de Luca, K | 1 |
| Beau Salinas, F | 1 |
| Autret-Leca, E | 1 |
| Narciso, B | 1 |
| Diot, P | 1 |
| Speer, TW | 1 |
| de Paiva, TF | 1 |
| de Barros e Silva, MJ | 1 |
| Rinck, JA | 1 |
| Fanelli, MF | 1 |
| Gimenes, DL | 1 |
| Chua, C | 1 |
| Zaiden, N | 1 |
| Chong, KH | 1 |
| Wong, MC | 2 |
| Linnebank, M | 1 |
| Da Costa, L | 1 |
| Auger, N | 1 |
| Jullien, M | 1 |
| Bhangoo, R | 1 |
| Prabhakara, S | 1 |
| Kalia, VK | 1 |
| Kim, KB | 1 |
| Hwu, WJ | 5 |
| Papadopoulos, NE | 1 |
| Bedikian, AY | 1 |
| Camacho, LH | 1 |
| Ng, C | 1 |
| Hernandez, IM | 1 |
| Frost, AM | 1 |
| Jack, MA | 1 |
| Hwu, P | 1 |
| Anderson, J | 2 |
| Margolis, J | 1 |
| Gutierrez, J | 1 |
| Croteau, D | 4 |
| Hasselbach, L | 1 |
| Avedissian, R | 2 |
| Hassouna, I | 1 |
| Sperling, S | 1 |
| Schulz-Schaeffer, W | 1 |
| Rave-Fränk, M | 1 |
| Hasselblatt, M | 1 |
| Jelkmann, W | 1 |
| Ehrenreich, H | 1 |
| Frommolt, P | 1 |
| Borberg, SK | 1 |
| Rühl, U | 1 |
| Steingräber, M | 1 |
| Niewald, M | 2 |
| Staar, S | 1 |
| Becker, G | 1 |
| Fischedick, AR | 1 |
| Grauthoff, H | 1 |
| Müller, RP | 2 |
| Ningaraj, NS | 2 |
| Sankpal, UT | 2 |
| Khaitan, D | 2 |
| Meister, EA | 2 |
| Vats, T | 1 |
| Nozue, K | 2 |
| Miyazaki, H | 1 |
| Kurita, H | 1 |
| Homori, M | 1 |
| Goldhoff, P | 1 |
| Warrington, NM | 1 |
| Limbrick, DD | 1 |
| Hope, A | 1 |
| Woerner, BM | 1 |
| Jackson, E | 1 |
| Piwnica-Worms, D | 1 |
| Rubin, JB | 1 |
| Mathieu, V | 3 |
| De Nève, N | 1 |
| Le Mercier, M | 5 |
| Dewelle, J | 1 |
| Gaussin, JF | 2 |
| Dehoux, M | 1 |
| Kiss, R | 9 |
| Yang, TM | 1 |
| Chang, WN | 1 |
| Chang, HW | 1 |
| Guzel, A | 2 |
| Tatli, M | 1 |
| Senturk, S | 2 |
| Guzel, E | 1 |
| Cayli, SR | 1 |
| Dinca, EB | 3 |
| Pieper, RO | 3 |
| Vandenberg, SR | 3 |
| Parvataneni, R | 3 |
| Carliner, H | 1 |
| Kabuubi, P | 1 |
| Ayers-Ringler, J | 3 |
| Sneed, PK | 2 |
| Vandenberg, S | 2 |
| Stokoe, D | 1 |
| Heymann, S | 1 |
| Karamanoukian, D | 1 |
| Wang, CH | 1 |
| Hsu, TR | 1 |
| Peca, C | 1 |
| Pacelli, R | 1 |
| Elefante, A | 1 |
| Del Basso De Caro, ML | 1 |
| Vergara, P | 1 |
| Mariniello, G | 1 |
| Giamundo, A | 1 |
| Maiuri, F | 1 |
| Rosso, L | 1 |
| Brock, CS | 4 |
| Saleem, A | 2 |
| Price, PM | 2 |
| Turkheimer, FE | 1 |
| Aboagye, EO | 2 |
| Macklin, EA | 1 |
| Ciampa, A | 3 |
| Bradshaw, J | 1 |
| Levy, B | 1 |
| Radakovic, G | 1 |
| Ramakrishna, N | 4 |
| de Oliveira, MS | 1 |
| Cechim, G | 1 |
| Santos, DG | 1 |
| Meurer, L | 1 |
| de Castro, CG | 1 |
| Brunetto, AL | 1 |
| Schwartsmann, G | 2 |
| Schwarstmann, G | 1 |
| Roesler, R | 1 |
| Watkins, JM | 1 |
| Marshall, DT | 1 |
| Herrin, AE | 1 |
| Garrett-Mayer, E | 1 |
| Jenrette, JM | 2 |
| Russo, AL | 1 |
| Kwon, HC | 1 |
| Burgan, WE | 2 |
| Carter, D | 2 |
| Beam, K | 2 |
| Weizheng, X | 1 |
| Slusher, BS | 1 |
| De Ridder, M | 2 |
| McCann, CM | 1 |
| Waterman, P | 2 |
| Figueiredo, JL | 1 |
| Aikawa, E | 1 |
| Chen, JW | 1 |
| Blatt, V | 5 |
| Amistà, P | 4 |
| Gardiman, M | 3 |
| Labianca, R | 1 |
| Bianchini, C | 1 |
| Scheurer, ME | 1 |
| Vera-Bolaños, E | 1 |
| Manning, R | 1 |
| Okcu, MF | 1 |
| Bondy, M | 1 |
| Dohmen-Scheufler, H | 1 |
| Volk, B | 1 |
| Ostertag, CB | 1 |
| Sotti, G | 4 |
| Frezza, G | 2 |
| Spagnolli, F | 2 |
| Binello, E | 2 |
| Jiang, SX | 4 |
| Gururangan, S | 11 |
| Walker, A | 2 |
| Rampling, R | 4 |
| Armand, JP | 2 |
| Kletzl, H | 1 |
| Klughammer, B | 1 |
| Maurer, GD | 1 |
| Tritschler, I | 1 |
| Adams, B | 1 |
| Banissi, C | 1 |
| McNamara, MB | 1 |
| Hoorens, A | 1 |
| Pascher, C | 2 |
| Jauch, T | 2 |
| Codd, PJ | 2 |
| Ludwin, SK | 2 |
| Fisher, B | 4 |
| Gijtenbeek, J | 1 |
| Eisenhauer, E | 4 |
| Roon, K | 1 |
| Jeurissen, FJ | 1 |
| Hop, WC | 1 |
| Ingold, B | 1 |
| Schraml, P | 1 |
| Moch, H | 1 |
| Kadoch, C | 1 |
| Voicu, R | 2 |
| Nguyen, D | 1 |
| Parikh, S | 1 |
| Karrim, J | 1 |
| Shuman, MA | 1 |
| Lowell, CA | 1 |
| Treseler, PA | 1 |
| Rubenstein, JL | 1 |
| Sonabend, AM | 1 |
| Nandi, S | 1 |
| Khramtsov, A | 1 |
| Bell, D | 1 |
| Méhes, G | 1 |
| Akbar, U | 1 |
| Jones, T | 2 |
| Winestone, J | 1 |
| Michael, M | 1 |
| Duntsch, C | 1 |
| De Jesus, A | 1 |
| Paun, O | 1 |
| Kaliberova, LN | 1 |
| Krendelchtchikova, V | 1 |
| Harmon, DK | 1 |
| Stockard, CR | 1 |
| Petersen, AS | 1 |
| Grizzle, WE | 1 |
| Buchsbaum, DJ | 2 |
| Kaliberov, SA | 1 |
| Wyss, M | 1 |
| Bruehlmeier, M | 1 |
| Hefti, M | 1 |
| Uhlmann, C | 1 |
| Bärtschi, E | 1 |
| Buettner, UW | 1 |
| Virrey, JJ | 1 |
| Golden, EB | 2 |
| Sivakumar, W | 2 |
| Pen, L | 1 |
| Koukourakis, GV | 1 |
| Kouloulias, V | 1 |
| Zacharias, G | 1 |
| Papadimitriou, C | 1 |
| Pantelakos, P | 1 |
| Maravelis, G | 1 |
| Fotineas, A | 1 |
| Beli, I | 1 |
| Chaldeopoulos, D | 1 |
| Kouvaris, J | 1 |
| Kim, DW | 1 |
| Wiemels, JL | 2 |
| Wilson, D | 1 |
| Patil, C | 1 |
| Patoka, J | 1 |
| McCoy, L | 1 |
| Rice, T | 2 |
| Schwartzbaum, J | 1 |
| Heimberger, A | 1 |
| Wiencke, JK | 2 |
| Wrensch, M | 1 |
| Oshiro, S | 2 |
| Tsugu, H | 2 |
| Komatsu, F | 2 |
| Ohmura, T | 1 |
| Ohta, M | 1 |
| Sakamoto, S | 1 |
| Fukushima, T | 6 |
| McEllin, B | 2 |
| Camacho, CV | 2 |
| Tomimatsu, N | 2 |
| Sirasanagandala, S | 1 |
| Nannepaga, S | 1 |
| Mickey, B | 1 |
| Madden, C | 1 |
| Maher, E | 1 |
| Yuki, K | 2 |
| Yokoyama, H | 1 |
| Chansakul, P | 1 |
| Kim, SU | 1 |
| Tilleul, P | 1 |
| Brignone, M | 1 |
| Hassani, Y | 1 |
| Sarma, N | 1 |
| Panageas, K | 1 |
| Nolan, CP | 3 |
| Gavrilovic, I | 1 |
| Ogino, A | 3 |
| Yachi, K | 3 |
| Ohta, T | 3 |
| Watanabe, T | 3 |
| Katayama, Y | 4 |
| Okamoto, Y | 3 |
| Naruse, N | 2 |
| Sano, E | 3 |
| Heery, CR | 1 |
| Benevento, F | 1 |
| Scopece, L | 2 |
| Mazzocchi, V | 1 |
| Bacci, A | 1 |
| Agati, R | 1 |
| Calbucci, F | 2 |
| Kawase, T | 2 |
| Sano, H | 2 |
| Dunn, J | 1 |
| Baborie, A | 1 |
| Alam, F | 1 |
| Joyce, K | 1 |
| Moxham, M | 1 |
| Sibson, R | 1 |
| Crooks, D | 1 |
| Husband, D | 1 |
| Shenoy, A | 1 |
| Brodbelt, A | 1 |
| Wong, H | 1 |
| Liloglou, T | 1 |
| Haylock, B | 1 |
| Walker, C | 1 |
| Gauden, AJ | 1 |
| Hunn, A | 1 |
| Erasmus, A | 1 |
| Waites, P | 1 |
| Gauden, SJ | 1 |
| Seery, TE | 1 |
| Cevenini, G | 2 |
| Vannini, M | 1 |
| Oliveri, G | 1 |
| Marsili, S | 1 |
| Mourmouras, V | 1 |
| Russillo, M | 1 |
| Metro, G | 1 |
| Vidiri, A | 3 |
| Di Giovanni, S | 1 |
| Cognetti, F | 1 |
| Lageman, SK | 1 |
| Locke, DE | 1 |
| Nakamura, M | 1 |
| Shimada, K | 1 |
| Konishi, N | 1 |
| Montano, N | 3 |
| Zheng, CQ | 1 |
| Ji, SP | 1 |
| Li, AM | 1 |
| Tai, JL | 1 |
| Zhang, YP | 1 |
| Piantadosi, S | 3 |
| Jeon, HJ | 2 |
| Park, KB | 2 |
| Park, K | 5 |
| Kim, ST | 5 |
| Kim, WS | 5 |
| Raut, N | 1 |
| Arora, B | 1 |
| Dutta, D | 1 |
| Munshi, A | 2 |
| Kurkure, P | 1 |
| Fabrini, MG | 2 |
| Perrone, F | 2 |
| De Franco, L | 1 |
| Grespi, S | 1 |
| Vannozzi, R | 1 |
| Cionini, L | 1 |
| Najim, N | 1 |
| Podmore, ID | 1 |
| McGown, A | 1 |
| Estlin, EJ | 1 |
| D'Elia, A | 2 |
| Formichella, AI | 1 |
| Frati, A | 2 |
| Perez Segura, P | 1 |
| Garcia Lopez, J | 1 |
| Yaya, R | 2 |
| Rodríguez, J | 1 |
| Iglesias, L | 1 |
| Liu, VH | 1 |
| Hunter, K | 1 |
| Meyers, C | 2 |
| Platta, CS | 1 |
| Khuntia, D | 2 |
| Morganti, AG | 4 |
| Romanelli, P | 2 |
| Ferro, M | 2 |
| Calista, F | 1 |
| Digesù, C | 1 |
| Macchia, G | 2 |
| Ianiri, M | 1 |
| Deodato, F | 2 |
| Cilla, S | 2 |
| Piermattei, A | 1 |
| Cellini, N | 2 |
| Dresemann, G | 1 |
| Wedding, U | 1 |
| Wagner, W | 1 |
| Engel, E | 1 |
| Heinrich, B | 1 |
| Karup-Hansen, A | 1 |
| Fluge, O | 1 |
| Nowak, A | 1 |
| Schleyer, E | 1 |
| Olver, IN | 1 |
| Hosius, C | 1 |
| Sieder, C | 1 |
| Sorenson, G | 1 |
| Parker, R | 1 |
| Ballman, KA | 1 |
| Manfrida, S | 3 |
| De Renzi, F | 1 |
| Colicchio, G | 2 |
| Apicella, G | 1 |
| De Bari, B | 3 |
| Pompucci, A | 2 |
| Shibamoto, Y | 2 |
| Sugie, C | 1 |
| Iwata, H | 1 |
| Rhee, DJ | 1 |
| Suh, YL | 3 |
| Song, SY | 1 |
| Hilverda, K | 1 |
| Peter Vandertop, W | 1 |
| Cetica, V | 1 |
| Buccoliero, AM | 1 |
| Giunti, L | 1 |
| Genitori, L | 1 |
| Aricò, M | 1 |
| Vats, TS | 1 |
| Wu, PF | 1 |
| Kuo, KT | 1 |
| Lee, WC | 1 |
| Lu, YS | 1 |
| Wu, RM | 1 |
| Tu, YK | 1 |
| Tasi, JC | 1 |
| Tseng, HM | 1 |
| Tseng, SH | 2 |
| Cheng, AL | 1 |
| Crinò, L | 3 |
| Danova, M | 1 |
| Salvagni, S | 1 |
| Schiavetto, I | 1 |
| Vitali, M | 1 |
| Bajetta, E | 1 |
| Brandsma, D | 3 |
| Inamasu, J | 1 |
| Kuramae, T | 1 |
| Nakatsukasa, M | 1 |
| Yang, I | 3 |
| Otero, JJ | 2 |
| Ahn, BJ | 2 |
| Kimple, RJ | 1 |
| Grabowski, S | 1 |
| Papez, M | 1 |
| Collichio, F | 1 |
| Morris, DE | 1 |
| Song, SW | 2 |
| Roldán, GB | 2 |
| Scott, JN | 1 |
| McIntyre, JB | 1 |
| Dharmawardene, M | 1 |
| de Robles, PA | 1 |
| Magliocco, AM | 1 |
| Yan, ES | 2 |
| Oh, J | 2 |
| Bilbao, JM | 1 |
| Tsao, MN | 3 |
| Fazl, M | 1 |
| Del Maestro, RF | 1 |
| Cao, VT | 1 |
| Jung, S | 3 |
| Jin, SG | 1 |
| Moon, KS | 3 |
| Kim, IY | 3 |
| Kang, SS | 2 |
| Park, CS | 2 |
| Chae, HJ | 1 |
| Wiewrodt, D | 1 |
| Meyermann, R | 4 |
| Barazzuol, L | 1 |
| Burnet, NG | 1 |
| Jena, R | 1 |
| Jones, B | 3 |
| Jefferies, SJ | 1 |
| Kirkby, NF | 1 |
| Rotilio, A | 2 |
| Scienza, R | 2 |
| Pastorelli, D | 1 |
| Blanchard, S | 1 |
| Synold, TW | 1 |
| Moretto, G | 1 |
| Musso, AM | 1 |
| Ottaviani, S | 1 |
| Masotto, B | 1 |
| Iuzzolino, P | 2 |
| Buffone, E | 1 |
| Vattemi, E | 1 |
| Pedersini, R | 1 |
| Park, TS | 1 |
| Suh, B | 1 |
| Jang, SJ | 1 |
| Lee, CH | 1 |
| Choi, JR | 1 |
| Ma, B | 1 |
| Kim, TG | 3 |
| Park, SD | 2 |
| Xing, JZ | 1 |
| Small, C | 1 |
| Kortmann, R | 2 |
| Miriamanoff, R | 1 |
| Okunieff, P | 2 |
| Jeremic, B | 1 |
| Iliadis, G | 3 |
| Selviaridis, P | 3 |
| Kalogera-Fountzila, A | 1 |
| Fragkoulidi, A | 1 |
| Baltas, D | 1 |
| Tselis, N | 1 |
| Chatzisotiriou, A | 2 |
| Misailidou, D | 3 |
| Zamboglou, N | 1 |
| Fountzilas, G | 7 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Koeppen, S | 1 |
| Wiestler, OD | 1 |
| Poelen, J | 1 |
| Prick, MJ | 1 |
| Jeuken, JW | 2 |
| Bernsen, HJ | 1 |
| van Marion, R | 2 |
| van Heuvel, I | 5 |
| Zonnenberg, BA | 3 |
| Zonnenberg, CB | 2 |
| Gijtenbeek, JM | 2 |
| Boogerd, W | 6 |
| Groenendijk, FH | 2 |
| Smitt, PA | 1 |
| Dinjens, WN | 2 |
| Shepard, DR | 1 |
| Brewer, CJ | 1 |
| Agarwal, N | 1 |
| Stevens, GH | 1 |
| Weil, RJ | 1 |
| Fotovati, A | 2 |
| Cote, G | 1 |
| Guns, E | 1 |
| Toyota, B | 2 |
| Faury, D | 1 |
| Jabado, N | 1 |
| Dunn, SE | 2 |
| Sheehan, J | 1 |
| Cifarelli, CP | 1 |
| Dassoulas, K | 1 |
| Olson, C | 1 |
| Rainey, J | 1 |
| Qian, ZZ | 1 |
| Wang, HQ | 1 |
| Liu, XM | 1 |
| Yang, SY | 1 |
| Guillaume, DJ | 1 |
| Doolittle, ND | 1 |
| Hedrick, NA | 1 |
| Delashaw, JB | 1 |
| Kataoka, H | 1 |
| Schild, SE | 1 |
| Behl, D | 1 |
| Markovic, SN | 1 |
| Sande, JR | 1 |
| Deming, RL | 1 |
| Rowland, KM | 1 |
| Bearden, JD | 1 |
| Hoffmann, AL | 1 |
| Buhk, JH | 1 |
| Verhoeff, JJC | 1 |
| Lavini, C | 1 |
| Stalpers, LJA | 1 |
| Majoie, CBLM | 1 |
| Lamoral-Theys, D | 1 |
| Le Calvé, B | 2 |
| Rynkowski, MA | 1 |
| Bruyère, C | 3 |
| Decaestecker, C | 4 |
| Haibe-Kains, B | 4 |
| Bontempi, G | 4 |
| Dubois, J | 1 |
| Cho, KH | 1 |
| Moon, SH | 1 |
| Kim, TH | 1 |
| Shin, KH | 1 |
| Yoon, M | 1 |
| Pyo, HR | 1 |
| Kracht, LW | 1 |
| Burghaus, L | 1 |
| Ullrich, RT | 1 |
| Backes, H | 1 |
| Brunn, A | 1 |
| Heiss, WD | 1 |
| Doherty, LM | 2 |
| Sceppa, C | 1 |
| Gerard, M | 1 |
| Phan, P | 1 |
| Young, G | 1 |
| Weiss, SE | 2 |
| Spiegl-Kreinecker, S | 3 |
| Pirker, C | 2 |
| Filipits, M | 1 |
| Lötsch, D | 1 |
| Buchroithner, J | 2 |
| Silye, R | 2 |
| Micksche, M | 3 |
| Berger, W | 3 |
| Holm, DA | 1 |
| Okollie, B | 1 |
| Artemov, D | 1 |
| Linz, U | 1 |
| Hristova-Kazmierski, M | 2 |
| Musib, L | 1 |
| Nicol, SJ | 2 |
| Thornton, DE | 2 |
| Marucci, G | 1 |
| Brandes, A | 1 |
| Dong, SM | 1 |
| Symons, S | 2 |
| Aviv, R | 2 |
| Lam, K | 2 |
| Davey, P | 2 |
| Recinos, VR | 2 |
| Bekelis, K | 1 |
| Sunshine, SB | 1 |
| Vellimana, A | 1 |
| Li, KW | 2 |
| Chahal, M | 1 |
| Lesniak, D | 1 |
| Graham, K | 1 |
| Famulski, K | 1 |
| Christensen, JG | 1 |
| Aghi, M | 2 |
| Jacques, A | 1 |
| Murray, D | 1 |
| Harrison, C | 1 |
| Donatello, RS | 1 |
| Korones, DN | 3 |
| Cruickshanks, N | 1 |
| Shervington, L | 1 |
| Patel, R | 1 |
| Munje, C | 1 |
| Thakkar, D | 1 |
| Shervington, A | 1 |
| Kekan, MS | 1 |
| Johnson, MJ | 1 |
| Meleth, S | 1 |
| Kuo, H | 1 |
| Gladson, CL | 1 |
| Ng, K | 1 |
| Kung, A | 1 |
| D'Andrea, A | 2 |
| Seiz, M | 4 |
| Nölte, I | 1 |
| Pechlivanis, I | 1 |
| Tuettenberg, J | 5 |
| Hashizume, R | 1 |
| Gupta, N | 2 |
| Banerjee, A | 1 |
| Easaw, J | 2 |
| Shields, C | 1 |
| Kirby, S | 1 |
| Pouliot, JF | 2 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Elias, DA | 1 |
| Quang, TS | 1 |
| Gracely, EJ | 1 |
| Emrich, JG | 1 |
| Yaeger, TE | 1 |
| Cohen, SC | 1 |
| Black, P | 1 |
| Brady, LW | 1 |
| Slaby, O | 1 |
| Lakomy, R | 1 |
| Fadrus, P | 1 |
| Hrstka, R | 1 |
| Kren, L | 1 |
| Lzicarova, E | 1 |
| Smrcka, M | 1 |
| Svoboda, M | 1 |
| Dolezalova, H | 1 |
| Novakova, J | 1 |
| Valik, D | 1 |
| Vyzula, R | 1 |
| Michalek, J | 1 |
| Murao, A | 1 |
| Gabelloni, P | 1 |
| Da Pozzo, E | 1 |
| Bendinelli, S | 1 |
| Nuti, E | 1 |
| Casalini, F | 1 |
| Orlandini, E | 1 |
| Rossello, A | 1 |
| Blough, MD | 2 |
| Westgate, MR | 2 |
| Beauchamp, D | 1 |
| Kelly, JJ | 2 |
| Stechishin, O | 1 |
| Ramirez, AL | 1 |
| Müerköster, SS | 1 |
| Penfold, ME | 1 |
| Schall, TJ | 1 |
| Mentlein, R | 1 |
| Zhang, YH | 2 |
| Yue, ZJ | 2 |
| McDonald, MW | 1 |
| Dowling, A | 3 |
| Kalnins, R | 1 |
| Algar, E | 1 |
| Wong, N | 1 |
| Benson, A | 1 |
| Woods, AM | 2 |
| Hasselbalch, B | 1 |
| Holmberg, M | 1 |
| Sørensen, M | 1 |
| Tsumoto, K | 2 |
| Guimarães, I | 1 |
| Jaraquemada, T | 1 |
| Augusto, I | 1 |
| Castro, L | 1 |
| Honavar, M | 1 |
| Resende, M | 1 |
| Braga, F | 1 |
| Silva, A | 1 |
| Pardal, F | 1 |
| Amorim, J | 1 |
| Nabiço, R | 1 |
| Almeida, R | 1 |
| Alegria, C | 1 |
| Pires, M | 1 |
| Pinheiro, C | 1 |
| Carvalho, E | 1 |
| Costa, P | 1 |
| Damasceno, M | 1 |
| Doyle, TJ | 1 |
| Sure, D | 1 |
| Dunn, I | 1 |
| Anderson, WS | 1 |
| Birol Sarica, F | 1 |
| Cekinmez, M | 1 |
| Sen, O | 1 |
| Cem Onal, H | 1 |
| Erdogan, B | 1 |
| Nur Altinors, M | 1 |
| Chua, D | 1 |
| Krzakowski, M | 1 |
| Chouaid, C | 1 |
| Pallotta, MG | 1 |
| Martinez, JI | 1 |
| Gottfried, M | 1 |
| Throuvalas, N | 2 |
| Grabenbauer, GG | 1 |
| Ochsenbein, AF | 2 |
| Diserens, AC | 4 |
| Pica, A | 5 |
| Hermisson, M | 1 |
| Krueger, S | 1 |
| Marcello, J | 4 |
| Janney, D | 2 |
| Morlan, BW | 1 |
| Parot-Schinkel, E | 1 |
| Loiseau, H | 1 |
| Jacquet, G | 1 |
| Plotkin, M | 1 |
| Blechschmidt, C | 1 |
| Bobola, MS | 3 |
| Kolstoe, DD | 2 |
| Blank, A | 3 |
| Sierra del Rio, M | 1 |
| Khayal, IS | 1 |
| Jalbert, L | 1 |
| Elkhaled, A | 1 |
| Garbossa, D | 1 |
| Barletta, L | 1 |
| Prevost, C | 1 |
| Versari, P | 1 |
| Toda, H | 1 |
| Iwamizu, H | 1 |
| Sugita, T | 1 |
| Hachisu, R | 1 |
| Watanabe, R | 2 |
| Bankiewicz, K | 1 |
| Márquez-Rivas, J | 1 |
| Ramirez, G | 1 |
| Ollero-Ortiz, A | 1 |
| Giménez-Pando, J | 1 |
| Emmerich, J | 1 |
| Quiroga-Cantero, E | 1 |
| Rivas, E | 1 |
| Gómez-González, E | 1 |
| Qadeer, ZA | 1 |
| Uzzaman, M | 1 |
| Mangla, R | 1 |
| Singh, G | 1 |
| Ziegelitz, D | 1 |
| Zhong, J | 1 |
| Ekholm, SE | 1 |
| Hahm, B | 1 |
| Wesolowski, JR | 1 |
| Rajdev, P | 1 |
| Mukherji, SK | 1 |
| Pentheroudakis, G | 2 |
| del Rio, MS | 1 |
| Hainsworth, JD | 2 |
| Ervin, T | 1 |
| Friedman, E | 1 |
| Priego, V | 1 |
| Murphy, PB | 1 |
| Clark, BL | 1 |
| Lamar, RE | 1 |
| Srivastava, A | 2 |
| Jain, A | 2 |
| Jha, P | 3 |
| Sharma, MC | 2 |
| Puri, T | 1 |
| Gupta, DK | 1 |
| Sarkar, C | 2 |
| Beauchamp, DC | 1 |
| Muti, P | 1 |
| Salazar, AM | 1 |
| Yokosawa, M | 1 |
| Nishihara, M | 2 |
| Satoh, T | 1 |
| Yokoyama, M | 1 |
| Franz, K | 4 |
| Blasel, S | 1 |
| Oszvald, A | 2 |
| Rathert, J | 1 |
| Gasser, T | 1 |
| Oner, Y | 1 |
| Uncu, D | 1 |
| Palomo, JM | 1 |
| Rahmathulla, G | 1 |
| McGraw, M | 1 |
| Donze, J | 1 |
| Kang, HC | 1 |
| Choe, GY | 1 |
| Pan, T | 2 |
| Eto, T | 1 |
| Nakashima, S | 1 |
| Okada, Y | 1 |
| Ogo, E | 1 |
| Sugita, Y | 1 |
| Tokutomi, T | 1 |
| Shigemori, M | 2 |
| Bertoni, F | 2 |
| Mantovani, C | 2 |
| Tombolini, V | 3 |
| De Renzis, C | 3 |
| Lioce, M | 2 |
| Cipressi, S | 2 |
| Piroth, MD | 3 |
| Pinkawa, M | 3 |
| Holy, R | 2 |
| Klotz, J | 1 |
| Nussen, S | 1 |
| Coenen, HH | 2 |
| Kaiser, HJ | 2 |
| Eble, MJ | 3 |
| Bobustuc, GC | 1 |
| Bekele, BN | 1 |
| Piersiak, T | 1 |
| Nariata, Y | 1 |
| Hosono, A | 1 |
| Makimoto, A | 1 |
| Song, KS | 1 |
| Phi, JH | 1 |
| Cho, BK | 2 |
| Wang, KC | 2 |
| Lee, JY | 2 |
| Ahn, HS | 1 |
| Redelman-Sidi, G | 1 |
| Papanicolaou, G | 1 |
| Łata, S | 1 |
| Molczyk, A | 1 |
| Buttarelli, F | 1 |
| De Santi, MS | 1 |
| Abbruzzese, A | 2 |
| Parlato, C | 3 |
| Carraturo, M | 2 |
| Genovese, M | 1 |
| Kwon, KH | 1 |
| Puchner, MJ | 1 |
| Lohmann, F | 1 |
| Schütze, M | 1 |
| Koll, S | 1 |
| Buchalla, R | 1 |
| Rainov, N | 1 |
| Kantelhardt, SR | 1 |
| Goldbecker, A | 1 |
| Tryc, AB | 1 |
| Raab, P | 1 |
| Worthmann, H | 1 |
| Herrmann, J | 1 |
| Weissenborn, K | 1 |
| Rusthoven, KE | 2 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Gilbert, CA | 1 |
| Daou, MC | 1 |
| Moser, RP | 1 |
| Pedretti, M | 1 |
| Verpelli, C | 1 |
| Mårlind, J | 1 |
| Bertani, G | 1 |
| Sala, C | 1 |
| Neri, D | 1 |
| Priester, P | 1 |
| Slovácek, L | 1 |
| Petera, J | 2 |
| Kopecký, O | 1 |
| Macingova, Z | 1 |
| Nakai, K | 2 |
| Tanaka, H | 1 |
| Sasayama, T | 1 |
| Arai, A | 1 |
| Kawamura, A | 1 |
| Kanomata, N | 1 |
| Itoh, T | 2 |
| Kohmura, E | 1 |
| Tzadok, S | 1 |
| Beery, E | 1 |
| Israeli, M | 1 |
| Uziel, O | 1 |
| Lahav, M | 1 |
| Fenig, E | 1 |
| Gil-Ad, I | 1 |
| Weizman, A | 1 |
| Nordenberg, J | 1 |
| Barone, G | 2 |
| Tang, GS | 1 |
| Habermehl, D | 2 |
| Jäkel, O | 1 |
| Nikoghosyan, A | 1 |
| Haselmann, R | 2 |
| Doyle, CL | 1 |
| Rynkowski, M | 1 |
| Lonez, C | 2 |
| Gras, T | 1 |
| Ruysschaert, JM | 2 |
| Dosa, E | 1 |
| Kraemer, DF | 1 |
| Gerstein, J | 2 |
| Fraunholz, I | 1 |
| Weiss, C | 3 |
| Rödel, C | 2 |
| McLendon, R | 4 |
| Threatt, S | 3 |
| Amichetti, M | 1 |
| Schubert, AD | 1 |
| Vassella, E | 2 |
| Mariani, L | 3 |
| Grasbon-Frodl, EM | 1 |
| Lutz, J | 2 |
| Kreth, S | 3 |
| Kretzschmar, HA | 2 |
| Moon, S | 1 |
| Pothiawala, S | 1 |
| Hsu, MY | 1 |
| Ibrahimi, OA | 1 |
| Zauderer, M | 1 |
| Krug, LM | 1 |
| Pietanza, MC | 1 |
| O'Rourke, D | 1 |
| Nestler, U | 1 |
| Kern, BC | 1 |
| Vince, GH | 2 |
| Pichlmeier, U | 1 |
| Robischon, M | 1 |
| Stuhr, K | 2 |
| Malkin, MG | 5 |
| Torres-Trejo, A | 1 |
| Schwartz, F | 1 |
| Dawirs, S | 1 |
| Hedderich, J | 2 |
| Dörner, L | 1 |
| Nabavi, A | 2 |
| Laffaire, J | 1 |
| Paris, S | 2 |
| Boisselier, B | 1 |
| Ganswindt, U | 1 |
| Schwarz, SB | 2 |
| Geisler, J | 1 |
| Ertl, L | 1 |
| Siefert, A | 1 |
| Fields, EC | 1 |
| Liu, AK | 1 |
| Kirkpatrick, JP | 2 |
| Friedman, A | 1 |
| Essock-Burns, E | 2 |
| Fassan, M | 1 |
| Tassone, E | 1 |
| Onisto, M | 1 |
| Armosini, V | 1 |
| Caporello, P | 3 |
| Mei, M | 1 |
| Maurizi, RE | 1 |
| Shawky, H | 1 |
| Abo Hamar, AH | 1 |
| Zakaria, F | 1 |
| El-Shorbagy, D | 1 |
| Ang, C | 1 |
| Ramanakumar, AV | 1 |
| Maio, M | 1 |
| Yim, SY | 1 |
| Lee, AR | 1 |
| Pathak, P | 1 |
| Suri, A | 1 |
| Gupta, D | 1 |
| Chattopadhyay, P | 1 |
| Jo, MY | 1 |
| Kim, JK | 1 |
| Ahn, JM | 1 |
| Yoon, MJ | 1 |
| Tran, A | 2 |
| Solis, OE | 2 |
| Selch, M | 2 |
| Filka, E | 2 |
| Yong, WH | 3 |
| Black, K | 1 |
| Green, RM | 3 |
| Spier, CE | 1 |
| Kolevska, T | 1 |
| Polikoff, J | 1 |
| Fehrenbacher, L | 1 |
| Elashoff, R | 1 |
| Schmittling, R | 1 |
| Petritsch, C | 1 |
| Itsara, M | 1 |
| Sim, FJ | 1 |
| Auvergne, R | 1 |
| Goldenberg, DD | 1 |
| Nguyen, KN | 1 |
| Yakovenko, S | 1 |
| Nishiyama, A | 1 |
| Stallcup, WB | 1 |
| McKnight, TR | 1 |
| Goldman, SA | 1 |
| van der Holt, B | 1 |
| Sillevis Smitt, PA | 4 |
| Paravati, AJ | 1 |
| Landsittel, D | 1 |
| Flickinger, JC | 1 |
| Mintz, A | 1 |
| Chen, YF | 1 |
| Huq, MS | 1 |
| Takahashi, K | 3 |
| Nishihara, H | 4 |
| Katoh, M | 1 |
| Yoshinaga, T | 1 |
| Mahabir, R | 1 |
| Tanino, M | 5 |
| Ikeda, J | 2 |
| Sawamura, Y | 5 |
| Nagashima, K | 2 |
| Scott, AW | 1 |
| Masi, BC | 2 |
| Patta, YR | 1 |
| Basaldella, L | 1 |
| Langer, RS | 1 |
| Cima, MJ | 2 |
| Salazar, M | 1 |
| Barcia, J | 1 |
| Vargo, JA | 1 |
| Snelling, BM | 1 |
| Ghareeb, ER | 1 |
| John, K | 1 |
| Frame, JN | 1 |
| Schmidt, JH | 1 |
| Adair, J | 1 |
| Moldovan, K | 1 |
| Yeoh, HK | 1 |
| Starke, RM | 1 |
| Pouratian, N | 2 |
| Chaponis, D | 1 |
| Barnes, JW | 1 |
| Dellagatta, JL | 1 |
| Fast, E | 1 |
| Sauvageot, C | 1 |
| Panagrahy, D | 1 |
| Greene, ER | 1 |
| Stiles, C | 1 |
| Louie, SG | 3 |
| Miyahara, H | 1 |
| Yajima, N | 1 |
| Toyoshima, Y | 1 |
| Kakita, A | 1 |
| Chansriwong, P | 1 |
| Sirisinha, T | 1 |
| Froelich, S | 1 |
| Gaub, MP | 1 |
| Boyer, P | 1 |
| Fischer-Lokou, D | 1 |
| Dufour, P | 1 |
| Kehrli, P | 1 |
| Maitrot, D | 1 |
| Payer, F | 3 |
| Prasad, G | 1 |
| Sottero, T | 1 |
| Ozawa, T | 2 |
| Aftab, DT | 1 |
| Takahashi, J | 2 |
| Zhuang, D | 1 |
| Luan, S | 1 |
| Wei, ZP | 1 |
| Pei, DS | 1 |
| Zheng, JN | 1 |
| Tashiro, H | 1 |
| Mitsuya, K | 1 |
| Ito, I | 1 |
| Nakasu, S | 1 |
| Nakajima, T | 1 |
| Matuschek, C | 1 |
| Bölke, E | 1 |
| Nawatny, J | 1 |
| Hoffmann, TK | 1 |
| Peiper, M | 1 |
| Orth, K | 1 |
| Gerber, PA | 1 |
| Rusnak, E | 1 |
| Lammering, G | 1 |
| Gui, J | 1 |
| Côté, AL | 1 |
| Holmes, EJ | 1 |
| Heideman, RL | 2 |
| Hingorani, M | 4 |
| Achawal, S | 1 |
| Scott, I | 1 |
| Schwartz, PH | 1 |
| Linskey, ME | 1 |
| DiBiase, S | 1 |
| Meisenberg, B | 1 |
| Flannery, T | 1 |
| Patel, A | 1 |
| Dhople, A | 1 |
| Cheston, S | 1 |
| Amin, P | 1 |
| Giampieri, S | 1 |
| Worku, M | 1 |
| Alcaide-German, M | 1 |
| Sioftanos, G | 1 |
| Bourne, S | 1 |
| Lio, KI | 1 |
| Shaked-Rabi, M | 1 |
| Martindale, C | 1 |
| Ledderose, C | 1 |
| Hinske, LC | 2 |
| Zeman, F | 1 |
| Tang, JB | 1 |
| Svilar, D | 1 |
| Trivedi, RN | 1 |
| Wang, XH | 1 |
| Goellner, EM | 1 |
| Moore, B | 1 |
| Banze, LA | 1 |
| Brown, AR | 1 |
| Burnett Iii, OL | 1 |
| Hyatt, MD | 1 |
| Moroz, MA | 1 |
| Kochetkov, T | 1 |
| Thaler, H | 1 |
| de Stanchina, E | 1 |
| Gamez, I | 1 |
| Ryan, RP | 1 |
| Blasberg, RG | 1 |
| Topuk, S | 1 |
| Oymak, E | 1 |
| Parlak, C | 1 |
| Mijatovic, T | 4 |
| De Salvo, M | 1 |
| Maresca, G | 1 |
| D'agnano, I | 1 |
| Marchese, R | 1 |
| Stigliano, A | 1 |
| Gagliassi, R | 1 |
| Brunetti, E | 1 |
| Raza, GH | 1 |
| De Paula, U | 2 |
| Bucci, B | 1 |
| Zheng, YR | 1 |
| Wang, JJ | 1 |
| Wu, ZC | 1 |
| Sun, JH | 1 |
| Löffler, M | 1 |
| de La Motte Rouge, T | 1 |
| Zeaiter, A | 1 |
| Phillips, H | 1 |
| Modrusan, Z | 1 |
| Kawaguchi, H | 1 |
| Komatsu, M | 1 |
| Nabeshima, K | 1 |
| Mohri, M | 1 |
| Kyritsis, AP | 1 |
| Tian, XH | 1 |
| Lin, XN | 1 |
| Huang, ZC | 1 |
| Ren, L | 1 |
| Diao, Y | 1 |
| Malkoun, N | 2 |
| Fotso, MJ | 2 |
| Cartier, L | 2 |
| Auberdiac, P | 2 |
| Thorin, J | 2 |
| Pacaut, C | 2 |
| Schmitt, T | 2 |
| Kogias, E | 1 |
| Osterberg, N | 1 |
| Baumer, B | 1 |
| Psarras, N | 1 |
| Koentges, C | 1 |
| Papazoglou, A | 1 |
| Saavedra, JE | 1 |
| Keefer, LK | 1 |
| Kawabata, S | 1 |
| Miyatake, S | 1 |
| Hiramatsu, R | 1 |
| Hirota, Y | 1 |
| Miyata, S | 1 |
| Takekita, Y | 1 |
| Kuroiwa, T | 1 |
| Kirihata, M | 1 |
| Sakurai, Y | 1 |
| Maruhashi, A | 1 |
| Ono, K | 1 |
| Saikali, S | 1 |
| Lesimple, T | 2 |
| Hamlat, A | 2 |
| Wolf, A | 1 |
| Munoz, DM | 1 |
| Smith, CJ | 1 |
| Gajadhar, A | 1 |
| Restrepo, A | 1 |
| McGlade, CJ | 1 |
| Stanford, WL | 1 |
| Hawkins, C | 1 |
| Guha, A | 1 |
| Kishida, Y | 1 |
| Higashi, H | 1 |
| Wakai, K | 1 |
| Colin, C | 1 |
| Tchogandjian, A | 1 |
| Coulibaly, B | 1 |
| Cuneo, KC | 1 |
| Willett, CG | 1 |
| Herzog, H | 1 |
| Lohr, F | 2 |
| Enomoto, T | 1 |
| Morishita, Y | 1 |
| Wachsberger, PR | 1 |
| Lawrence, RY | 1 |
| Andersen, B | 1 |
| Dicker, AP | 2 |
| Hu, A | 1 |
| Kim, RY | 1 |
| Nguyen, A | 1 |
| Zachenhofer, I | 1 |
| Maier, R | 1 |
| Eiter, H | 1 |
| Muxel, M | 1 |
| Muxel, B | 1 |
| Cejna, M | 1 |
| DeVries, A | 1 |
| Roessler, K | 1 |
| Bok, R | 1 |
| Vigneron, DB | 1 |
| Vasishta, RK | 1 |
| Gupta, K | 1 |
| Sharma, SC | 1 |
| Patel, F | 1 |
| Mathuriya, SN | 1 |
| Jackson, EF | 1 |
| Menuel, C | 1 |
| Costalat, R | 1 |
| Abud, L | 1 |
| Habas, C | 1 |
| De Marco, G | 1 |
| Chiras, J | 1 |
| Chiarion-Sileni, V | 1 |
| Ridolfi, L | 1 |
| Romanini, A | 1 |
| Del Bianco, P | 1 |
| Pigozzo, J | 1 |
| Brugnara, S | 1 |
| Colucci, G | 1 |
| Ridolfi, R | 1 |
| Inaba, N | 1 |
| Kimura, M | 1 |
| Fujioka, K | 1 |
| Ikeda, K | 1 |
| Somura, H | 1 |
| Akiyoshi, K | 1 |
| Inoue, Y | 1 |
| Nomura, M | 1 |
| Saito, Y | 1 |
| Saito, H | 1 |
| Manome, Y | 1 |
| Nandipati, S | 1 |
| Rivera, AL | 2 |
| Rocque, BG | 2 |
| Weaver, SA | 2 |
| Kamar, FG | 2 |
| Jhanwar, SC | 2 |
| Schönsteiner, SS | 1 |
| Bommer, M | 1 |
| Haenle, MM | 1 |
| Klaus, B | 1 |
| Scheuerle, A | 1 |
| Schmid, M | 1 |
| Catry-Thomas, I | 1 |
| Monjour, A | 1 |
| Huchet, A | 2 |
| Tanguy, ML | 1 |
| Holzmüller, R | 1 |
| Haczek, C | 1 |
| Rognoni, E | 1 |
| Anton, M | 1 |
| Kasajima, A | 1 |
| Weichert, W | 1 |
| Treue, D | 1 |
| Schuster, T | 1 |
| Gänsbacher, B | 1 |
| Ziegler, DS | 1 |
| Keating, J | 1 |
| Fast, EM | 1 |
| Zawel, L | 1 |
| Veldhuijzen van Zanten, SE | 1 |
| Andrási, M | 1 |
| Törzsök, B | 1 |
| Klekner, Á | 1 |
| Gáspár, A | 1 |
| Coan, AD | 1 |
| Salameire, D | 1 |
| Carraway, H | 1 |
| Lashkari, HP | 1 |
| Saso, S | 1 |
| Athanasiou, T | 1 |
| Berkhof, J | 1 |
| Hoekstra, OS | 1 |
| Sanchez-Perez, L | 1 |
| Snyder, DJ | 1 |
| Congdon, KL | 1 |
| Herbet, G | 1 |
| Maldonado, IL | 1 |
| Moritz-Gasser, S | 1 |
| Kerr, C | 2 |
| Tichy, J | 1 |
| Thanendrarajan, S | 1 |
| Stuplich, M | 2 |
| Rieger, J | 2 |
| Boström, J | 1 |
| Tashiro, S | 1 |
| Fujimoto, Y | 1 |
| Miyazaki, Y | 1 |
| Yakushijin, T | 1 |
| Takehara, T | 1 |
| Luchin, EI | 1 |
| Ievleva, AG | 1 |
| Bakholdin, DV | 1 |
| Abysheva, SN | 1 |
| Zavgorodniaia, EV | 1 |
| Potapova, ON | 1 |
| Imianitov, EN | 1 |
| Ulitin, AIu | 1 |
| Matsko, DE | 1 |
| Ananda, S | 1 |
| Rogers, S | 1 |
| Bodis, S | 2 |
| Demir, H | 1 |
| Yamada, R | 2 |
| Ray-Chaudhury, A | 1 |
| Aguilar, LK | 1 |
| Bell, SD | 1 |
| McGregor, J | 1 |
| Lo, S | 1 |
| Ray-Chaudhuri, A | 1 |
| Harris, KS | 1 |
| Grossman, RG | 1 |
| Trask, TW | 1 |
| Monterroso, C | 1 |
| Manzanera, AG | 1 |
| Aguilar-Cordova, E | 1 |
| Guckenberger, M | 1 |
| Mayer, M | 2 |
| Buttmann, M | 1 |
| Demir, HA | 1 |
| Yalçin, B | 1 |
| Kutluk, T | 1 |
| Büyükpamukçu, M | 1 |
| Rossetti, AO | 1 |
| Brower, V | 1 |
| Pieper, R | 1 |
| Nicole, A | 1 |
| Hsieh, E | 1 |
| Bianchi, F | 2 |
| Lauretti, L | 1 |
| Doglietto, F | 1 |
| Javaherian, K | 1 |
| Cho, H | 1 |
| Petasis, NA | 2 |
| Wong, TS | 1 |
| Ng, GK | 1 |
| Duri, S | 1 |
| Gaviani, P | 5 |
| Milanesi, I | 2 |
| Casali, C | 2 |
| Di Meco, F | 2 |
| Conti, A | 1 |
| Pontoriero, A | 1 |
| Arpa, D | 1 |
| Siragusa, C | 1 |
| Tomasello, C | 1 |
| Cardali, S | 1 |
| Granata, F | 1 |
| Tomasello, F | 1 |
| Botturi, A | 4 |
| Ferrari, D | 1 |
| Schulz, JB | 2 |
| Albanese, A | 1 |
| Micciche', F | 1 |
| De Rose, F | 2 |
| Cheung, T | 1 |
| Proulx, A | 1 |
| Fraser, JA | 1 |
| Catalán-Uribarrena, G | 1 |
| Bilbao-Barandica, G | 1 |
| Pomposo-Gaztelu, I | 1 |
| Undabeitia-Huertas, J | 1 |
| Ruiz de Gopegui-Ruiz, E | 1 |
| Galbarriatu-Gutiérrez, L | 1 |
| Canales-Llantada, M | 1 |
| Aurrecoechea-Obieta, J | 1 |
| Igartua-Azkune, A | 1 |
| Carbayo-Lozano, G | 1 |
| Berdel, C | 1 |
| Fleckenstein, J | 1 |
| Licht, N | 1 |
| Rübe, C | 1 |
| Ueno, H | 1 |
| SongTao, Q | 1 |
| Si, G | 1 |
| YanQing, D | 1 |
| HuiXia, H | 1 |
| XueLin, Z | 1 |
| LanXiao, W | 1 |
| Fei, Y | 1 |
| Gruber, D | 1 |
| Kunnakkat, S | 1 |
| Van Nifterik, KA | 2 |
| Van den Berg, J | 3 |
| Lafleur, MV | 2 |
| Andre, N | 1 |
| Gentet, JC | 1 |
| Figarella Branger, D | 1 |
| Scavarda, D | 1 |
| Verschuur, A | 1 |
| Cowen, D | 1 |
| Muracciole, X | 4 |
| Normolle, D | 1 |
| Chenevert, T | 1 |
| Lawrence, T | 1 |
| Pu, P | 1 |
| Pesce, GA | 1 |
| Klingbiel, D | 1 |
| Ribi, K | 1 |
| Zouhair, A | 1 |
| von Moos, R | 1 |
| Schlaeppi, M | 1 |
| Caspar, CB | 1 |
| Fischer, N | 1 |
| Anchisi, S | 1 |
| Peters, S | 1 |
| Cathomas, R | 1 |
| Bernhard, J | 1 |
| Kotrubczik, NM | 1 |
| D'Addario, G | 1 |
| Pilop, C | 1 |
| Pless, M | 1 |
| Shih, YL | 1 |
| Lin, YF | 1 |
| Arivazhagan, A | 1 |
| Kumar, DM | 1 |
| Sagar, V | 1 |
| Patric, IR | 1 |
| Sridevi, S | 1 |
| Thota, B | 1 |
| Srividya, MR | 1 |
| Prasanna, K | 1 |
| Thennarasu, K | 1 |
| Mondal, N | 1 |
| Hegde, AS | 1 |
| Chandramouli, BA | 1 |
| Santosh, V | 1 |
| Rao, MR | 1 |
| Kondaiah, P | 1 |
| Cao, JQ | 1 |
| Bauman, GS | 1 |
| Megyesi, JF | 1 |
| Watling, CJ | 2 |
| Alksne, J | 1 |
| Mundt, AJ | 1 |
| Murphy, KT | 1 |
| Cornell, M | 1 |
| Lawson, JD | 1 |
| Smolczyk, DR | 1 |
| Janzen, E | 1 |
| Céfaro, GA | 1 |
| Genovesi, D | 1 |
| Vinciguerra, A | 1 |
| Trignani, M | 1 |
| Taraborrelli, M | 1 |
| Augurio, A | 1 |
| Buonaguidi, R | 1 |
| Galzio, RJ | 1 |
| Di Nicola, M | 1 |
| Afzal, P | 1 |
| Campbell, AP | 1 |
| Gunjur, A | 2 |
| Lau, E | 1 |
| Taouk, Y | 1 |
| Borges, KS | 2 |
| Castro-Gamero, AM | 2 |
| Moreno, DA | 2 |
| da Silva Silveira, V | 1 |
| de Oliveira, HF | 2 |
| Macneil, M | 1 |
| Urva, S | 1 |
| McIntosh, L | 1 |
| Tu, Q | 1 |
| Kanai, R | 1 |
| Sgubin, D | 1 |
| Zaupa, CM | 1 |
| Sleire, L | 1 |
| Devito, N | 1 |
| Kilickap, S | 2 |
| Oztoprak, I | 1 |
| Yucel, B | 1 |
| Kotoula, V | 3 |
| Televantou, D | 3 |
| Eleftheraki, AG | 1 |
| Lambaki, S | 2 |
| Rock, K | 1 |
| McArdle, O | 1 |
| Forde, P | 1 |
| Dunne, M | 1 |
| Fitzpatrick, D | 1 |
| O'Neill, B | 1 |
| Faul, C | 1 |
| Korytova, LI | 1 |
| Meshechkin, AV | 1 |
| Zhabuna, RM | 1 |
| Masliukova, EA | 1 |
| Ivanov, VG | 1 |
| Yabroff, KR | 1 |
| Harlan, L | 1 |
| Zeruto, C | 1 |
| Abrams, J | 1 |
| Mann, B | 1 |
| Packer, RJ | 2 |
| Martinet, D | 1 |
| Besuchet Schmutz, N | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Audrain, O | 1 |
| Gamboa-Vignolle, C | 1 |
| Ferrari-Carballo, T | 1 |
| Arrieta, Ó | 1 |
| Mohar, A | 1 |
| Lai, C | 1 |
| Gharib, M | 1 |
| Stoffregen, C | 1 |
| Decker, R | 1 |
| Meinel, T | 1 |
| Martus, P | 1 |
| Jakobs, O | 1 |
| Liu, ZF | 1 |
| Li, HQ | 1 |
| Tao, RJ | 1 |
| Mattox, AK | 1 |
| Lark, AL | 1 |
| Calderaro, F | 1 |
| Estrada-Bernal, A | 1 |
| Palanichamy, K | 3 |
| Ray Chaudhury, A | 1 |
| Van Brocklyn, JR | 1 |
| Lechapt-Zalcman, E | 1 |
| Dugué, AE | 1 |
| Vital, A | 1 |
| Diebold, MD | 1 |
| Peruzzy, P | 1 |
| Chapon, F | 1 |
| Reich, M | 1 |
| Comet, B | 1 |
| Sathornsumetee, S | 4 |
| van de Bergh, J | 1 |
| Gu, K | 1 |
| Roldán Urgoiti, GB | 2 |
| Singh, AD | 1 |
| Siu, IM | 1 |
| Thomale, UW | 1 |
| Jallo, GI | 1 |
| Ruban, A | 1 |
| Berkutzki, T | 1 |
| Cooper, I | 1 |
| Mohar, B | 1 |
| Teichberg, VI | 1 |
| Sarganas, G | 1 |
| Orzechowski, HD | 1 |
| Klimpel, A | 1 |
| Thomae, M | 1 |
| Kauffmann, W | 1 |
| Herbst, H | 1 |
| Bronder, E | 1 |
| Garbe, E | 1 |
| Segers-van Rijn, JM | 1 |
| van der Rijt, CC | 3 |
| Onofri, A | 1 |
| Velasco, R | 1 |
| Blasco, J | 1 |
| Kim, YS | 1 |
| Jensen, SA | 1 |
| Jaekel, O | 1 |
| Strik, HM | 1 |
| Nagasawa, DT | 1 |
| Chow, F | 1 |
| Yew, A | 1 |
| Kim, W | 1 |
| Cremer, N | 1 |
| Shin, BJ | 1 |
| Burkhardt, JK | 1 |
| Riina, HA | 1 |
| McGrane, J | 1 |
| Bedford, T | 1 |
| Kelly, S | 1 |
| Oikawa, M | 1 |
| Ozaki, Y | 1 |
| Murata, J | 3 |
| Kato, M | 1 |
| Kubota, K | 1 |
| McPherson, CM | 1 |
| Gerena-Lewis, M | 1 |
| Breneman, JC | 1 |
| Warnick, RE | 1 |
| Marschall, V | 1 |
| Karl, S | 1 |
| Cristofanon, S | 1 |
| Zobel, K | 1 |
| Deshayes, K | 1 |
| Vucic, D | 1 |
| McCoy, LS | 1 |
| Smirnov, I | 1 |
| Patoka, JS | 1 |
| Hansen, HM | 1 |
| Fridley, BL | 1 |
| Madden, MH | 1 |
| Browning, JE | 1 |
| Egan, KM | 1 |
| Wrensch, MR | 1 |
| Hobbs, J | 1 |
| Nikiforova, MN | 1 |
| Fardo, DW | 1 |
| Bortoluzzi, S | 1 |
| Cieply, K | 1 |
| Schmitt, M | 1 |
| Ling, Y | 1 |
| Zou, F | 1 |
| Sk, UH | 1 |
| Huber-Keener, KJ | 1 |
| Sun, YW | 1 |
| Amin, S | 1 |
| Sharma, AK | 1 |
| Hashem, SA | 1 |
| Salem, A | 1 |
| Al-Rashdan, A | 1 |
| Ezam, N | 1 |
| Nour, A | 1 |
| Alsharbaji, A | 1 |
| Rejeeth, C | 1 |
| Mohamad, I | 1 |
| Sughayer, M | 1 |
| Elyan, M | 1 |
| Al-Hussaini, M | 1 |
| Addasi, A | 1 |
| Almousa, A | 1 |
| Schipper, MH | 1 |
| van Duinen, SG | 1 |
| Kloet, A | 1 |
| Wiggenraad, RG | 2 |
| Falchi, L | 1 |
| Gunnellini, M | 1 |
| Ferranti, L | 1 |
| Liberati, AM | 1 |
| Olsen, J | 1 |
| Galbán, S | 1 |
| Lemasson, B | 1 |
| Williams, TM | 1 |
| Heist, KA | 1 |
| Johnson, TD | 1 |
| Leopold, JS | 1 |
| Chenevert, TL | 2 |
| Galbán, CJ | 1 |
| Ross, BD | 2 |
| Saieva, C | 1 |
| Morigaki, R | 1 |
| Schriefer, B | 1 |
| Weis, J | 1 |
| Fairchild, A | 1 |
| Gulyban, A | 1 |
| Fenton, PA | 1 |
| Schmidt, N | 1 |
| Florea, AM | 1 |
| Hoadley, K | 1 |
| Kushwaha, D | 1 |
| Ra, YS | 1 |
| Baek, HJ | 1 |
| Choi, HS | 1 |
| Braun, C | 1 |
| Silvano, G | 1 |
| Savio, G | 1 |
| Bonizzoni, E | 1 |
| Perrone, T | 1 |
| Janouskova, H | 1 |
| Maglott, A | 1 |
| Leger, DY | 1 |
| Bossert, C | 1 |
| Noulet, F | 1 |
| Guerin, E | 1 |
| Guenot, D | 1 |
| Pinel, S | 1 |
| Chastagner, P | 1 |
| Plenat, F | 1 |
| Lehmann-Che, J | 1 |
| Teisinger, J | 1 |
| Dontenwill, M | 1 |
| Williams, M | 1 |
| Liu, ZW | 1 |
| Woolf, D | 1 |
| Hargreaves, S | 1 |
| Michalarea, V | 1 |
| Menashy, R | 1 |
| Kooner, I | 1 |
| Maire, JP | 1 |
| Henzen, C | 1 |
| Missohou, F | 1 |
| Bondiau, PY | 1 |
| Collin, P | 1 |
| Vinchon-Petit, S | 1 |
| Lagrange, JL | 1 |
| Quick, J | 1 |
| Szelényi, A | 1 |
| Dagıstan, Y | 1 |
| Karaca, I | 1 |
| Bozkurt, ER | 1 |
| Ozar, E | 1 |
| Yagmurlu, K | 1 |
| Toklu, A | 1 |
| Miccichè, F | 1 |
| Gambacorta, MA | 1 |
| Den, RB | 1 |
| Kamrava, M | 1 |
| Dougherty, E | 1 |
| Marinucchi, M | 1 |
| Lawrence, YR | 1 |
| Hegarty, S | 1 |
| Hyslop, T | 1 |
| Friedman, DP | 1 |
| Green, MR | 1 |
| Chou, JF | 1 |
| Hadizadeh, DR | 1 |
| Kuchelmeister, K | 1 |
| Scorzin, J | 1 |
| Filss, C | 1 |
| Schüller, H | 1 |
| Yoon, WS | 1 |
| Park, KY | 1 |
| Lim, JY | 1 |
| Shih, KC | 1 |
| Shepard, GC | 1 |
| Tillinghast, GW | 1 |
| Brinker, BT | 1 |
| Spigel, DR | 1 |
| Goldenberg, F | 1 |
| Tao, BB | 1 |
| Zhao, ZY | 1 |
| Hu, GH | 1 |
| Ding, XH | 1 |
| Sheng, P | 1 |
| Lu, YC | 1 |
| Harasaki, Y | 1 |
| Tallet, A | 1 |
| Kirova, Y | 1 |
| Kamoshima, Y | 1 |
| Chan, HL | 1 |
| Li, CH | 1 |
| Raghavan, D | 1 |
| Boxerman, J | 2 |
| Jeyapalan, S | 2 |
| Rogg, J | 1 |
| Plummer, AB | 1 |
| Tatar, Z | 1 |
| Planchat, E | 1 |
| Gimbergues, P | 2 |
| Gadea, E | 1 |
| Abrial, C | 1 |
| Villalva, C | 1 |
| Cortes, U | 1 |
| Tourani, JM | 1 |
| Marquant, C | 1 |
| Turhan, AG | 1 |
| Baker, L | 1 |
| Walmsley, V | 1 |
| Yu, TS | 1 |
| McKay, RM | 1 |
| Burns, DK | 1 |
| Kernie, SG | 1 |
| Parada, LF | 1 |
| Langsenlehner, T | 1 |
| Groll, MJ | 1 |
| Quehenberger, F | 1 |
| Mokry, M | 1 |
| Kapp, KS | 1 |
| Rønning, PA | 1 |
| Helseth, E | 1 |
| Sanchez, C | 1 |
| Sahin, A | 1 |
| Scheer, JK | 1 |
| Morse, B | 1 |
| Marsh, N | 1 |
| Furfine, E | 1 |
| Carvajal, I | 1 |
| Newman, SB | 1 |
| Jovanovic, B | 1 |
| Abacioglu, U | 1 |
| Rosell, J | 1 |
| Lee, WJ | 1 |
| Yi, KS | 1 |
| Mansard, S | 1 |
| Daste, A | 1 |
| Brocard, L | 1 |
| Sperlongano, P | 1 |
| Iodice, P | 1 |
| Russo, P | 1 |
| Salzano, A | 1 |
| Lombardi, A | 1 |
| Sperlongano, R | 1 |
| Prete, SD | 1 |
| Massaccesi, M | 1 |
| Lu, XY | 1 |
| Cao, K | 1 |
| Li, QY | 1 |
| Yuan, ZC | 1 |
| Lu, PS | 1 |
| Fortin, MA | 1 |
| Falchetti, ML | 1 |
| Annibali, D | 1 |
| Savino, M | 1 |
| Pierconti, F | 1 |
| Nasi, S | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Graham, TA | 1 |
| Yi, A | 1 |
| Elramsisy, A | 2 |
| Irvin, DK | 1 |
| Bannykh, SI | 2 |
| Kuhn, JG | 2 |
| Espinoza-Delgado, I | 1 |
| Tseng, J | 1 |
| Leong, MN | 1 |
| Goldkorn, A | 1 |
| Ramachandran, C | 1 |
| Nair, SM | 1 |
| Escalon, E | 1 |
| Melnick, SJ | 1 |
| Olivier, J | 1 |
| Tiwari, S | 1 |
| Kuroiwa-Trzmielina, J | 1 |
| Brewer, J | 1 |
| Geng, J | 1 |
| Reyngold, M | 1 |
| Safdie, F | 1 |
| Brandhorst, S | 1 |
| Hwang, S | 1 |
| Conti, PS | 1 |
| Longo, VD | 1 |
| Negretti, L | 1 |
| Bergström, S | 1 |
| Oosterkamp, HM | 1 |
| Oosterkamp, RM | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Nagy, KA | 1 |
| Török, E | 1 |
| Vághy, R | 1 |
| Vargáné Tamás, R | 1 |
| Puskásné Szatmári, K | 1 |
| Yamada, A | 1 |
| Moritake, H | 1 |
| Shimonodan, H | 1 |
| Marutsuka, K | 1 |
| Nunoi, H | 1 |
| Bressel, M | 1 |
| Triscott, J | 1 |
| Berns, R | 1 |
| Pambid, M | 1 |
| Luk, M | 1 |
| Kong, E | 1 |
| Toyota, E | 1 |
| Nadkarni, A | 1 |
| Shrivastav, M | 1 |
| Schwingler, PM | 1 |
| Gray, LA | 1 |
| Shinomiya, N | 1 |
| Shimazaki, H | 1 |
| Nakanishi, K | 1 |
| Nagatani, K | 1 |
| Osada, H | 1 |
| Uozumi, Y | 1 |
| Matsuo, H | 1 |
| Nawashiro, H | 1 |
| Alonso-Llamazares, A | 1 |
| Vega-Castro, A | 1 |
| Beitia-Mazuecos, JM | 1 |
| Mateo-Borrega, B | 1 |
| Cardenas-Contreras, R | 1 |
| Shinomiya, A | 1 |
| Kawai, N | 1 |
| Tamiya, T | 1 |
| Vajtai, I | 2 |
| Hewer, E | 1 |
| Kappeler, A | 2 |
| Reinert, MM | 1 |
| Tsuno, NH | 1 |
| Chou, AP | 2 |
| Selfridge, J | 2 |
| Zurayk, M | 2 |
| Lou, JJ | 2 |
| Everson, RG | 1 |
| Wu, KC | 1 |
| Faull, KF | 1 |
| Carico, C | 1 |
| Dantis, J | 1 |
| Corroyer-Dulmont, A | 1 |
| Varoqueaux, N | 1 |
| MacKenzie, ET | 1 |
| Delamare, J | 1 |
| Ibazizène, M | 1 |
| Lecocq, M | 1 |
| Barré, L | 1 |
| Popa, AM | 1 |
| Valla, K | 1 |
| Radhakrishnan, L | 1 |
| Cuellar, S | 1 |
| Safdar, S | 1 |
| Payne, CA | 1 |
| Tu, NH | 1 |
| Taite, LJ | 1 |
| Ji, XJ | 1 |
| Li, WC | 1 |
| Falco, T | 1 |
| Teufel, J | 1 |
| Hoepner, I | 1 |
| Rasper, M | 1 |
| Koeritzer, J | 1 |
| Yuan, S | 1 |
| Keating, MJ | 1 |
| Xu, RH | 1 |
| Huang, P | 1 |
| Marrinan, J | 1 |
| Frishman, C | 1 |
| Sampath, P | 1 |
| Bartolotti, M | 1 |
| Moseley, CK | 1 |
| Carlin, SM | 1 |
| Neelamegam, R | 1 |
| Kahn, SA | 1 |
| Biasoli, D | 1 |
| Sobrinho, M | 1 |
| Frauches, AC | 1 |
| Romão, L | 1 |
| Soletti, RC | 1 |
| Assunção, Fdos S | 1 |
| Tovar-Moll, F | 1 |
| de Souza, JM | 1 |
| Anderluh, G | 1 |
| Morana, G | 1 |
| Piccardo, A | 1 |
| Garrè, ML | 3 |
| Nozza, P | 1 |
| Consales, A | 1 |
| Rossi, A | 1 |
| Yuzawa, S | 1 |
| Mohri, H | 1 |
| Hatanaka, Y | 1 |
| Chiumento, C | 1 |
| Caivano, R | 1 |
| Cozzolino, M | 1 |
| Pedicini, P | 1 |
| Paulsson, AK | 1 |
| McMullen, KP | 1 |
| Peiffer, AM | 1 |
| Hinson, WH | 1 |
| Kearns, WT | 1 |
| Johnson, AJ | 1 |
| Ellis, TL | 1 |
| Tatter, SB | 1 |
| Debinski, W | 1 |
| Shaw, EG | 1 |
| Chan, MD | 1 |
| Vellimana, AK | 1 |
| Fowers, KD | 1 |
| Okonma, S | 1 |
| Eberhart, CG | 1 |
| Kerschbaumer, J | 1 |
| Bauer, R | 1 |
| Obwegeser, AA | 1 |
| Schubert, GA | 1 |
| Lu, JQ | 1 |
| Wilson, BA | 1 |
| Pugh, J | 1 |
| Salvant, C | 1 |
| Heguy, A | 1 |
| Kaufman, A | 1 |
| Golubovskaya, VM | 1 |
| Ho, B | 1 |
| Yemma, M | 1 |
| Morrison, CD | 1 |
| Eliceiri, BP | 1 |
| Cance, WG | 1 |
| González, B | 1 |
| Concha, A | 1 |
| Alvarez, PJ | 1 |
| López, R | 1 |
| Rodríguez-Serrano, F | 1 |
| Aránega, A | 1 |
| Karkavelas, G | 1 |
| Hytiroglou, P | 1 |
| Lampaki, S | 1 |
| Polyzoidis, KS | 1 |
| Tysnes, BB | 1 |
| Walker, GV | 1 |
| Prabhu, SS | 2 |
| Momiyama, M | 1 |
| Suetsugu, A | 1 |
| Chishima, T | 1 |
| Bouvet, M | 1 |
| Endo, I | 1 |
| Hoffman, RM | 2 |
| Franceries, X | 1 |
| Simon, L | 1 |
| Supper, C | 1 |
| Lotterie, JA | 1 |
| Berry, I | 1 |
| Cassol, E | 1 |
| Delannes, M | 1 |
| Celsis, P | 1 |
| Cohen-Jonathan, EM | 1 |
| Chang-Chien, YC | 1 |
| Yen, YS | 1 |
| Karavasilis, V | 1 |
| Chrisafi, S | 1 |
| Bobos, M | 1 |
| Blackwood, R | 1 |
| Brown, M | 1 |
| Lovato, J | 1 |
| Yalcinkaya, T | 1 |
| Aguilera, D | 1 |
| Mazewski, C | 2 |
| Fangusaro, J | 1 |
| MacDonald, TJ | 2 |
| McNall-Knapp, RY | 1 |
| Hayes, LL | 1 |
| Castellino, RC | 1 |
| Suazo, VK | 1 |
| Fujinami, MM | 1 |
| de Paula Gomes Queiroz, R | 1 |
| Berhorn, T | 1 |
| Schroeter, M | 1 |
| Jang, WY | 1 |
| Jeong, EH | 1 |
| Hirst, TC | 1 |
| Vesterinen, HM | 1 |
| Sena, ES | 1 |
| Egan, KJ | 1 |
| Macleod, MR | 1 |
| Whittle, IR | 1 |
| Bowersock, J | 1 |
| Johnson, A | 1 |
| Liao, K | 1 |
| Bi, ZF | 1 |
| Liu, YM | 1 |
| Lalezari, S | 1 |
| Khanlou, N | 1 |
| Chowdhury, R | 1 |
| Sanchez, DE | 1 |
| Wilson, RW | 1 |
| Lalezari, J | 1 |
| Ormiston, L | 1 |
| Ancheta, K | 1 |
| Hanna, R | 1 |
| Buchanan, C | 1 |
| Wang, HJ | 1 |
| Elashoff, RM | 1 |
| Jiang, R | 1 |
| Limbeck, E | 1 |
| Schütz, SV | 1 |
| Hoefig, K | 1 |
| Albanese, C | 1 |
| Alzani, R | 1 |
| Amboldi, N | 1 |
| Degrassi, A | 1 |
| Festuccia, C | 1 |
| Fiorentini, F | 1 |
| Gravina, G | 1 |
| Mercurio, C | 1 |
| Pastori, W | 1 |
| Brasca, M | 1 |
| Pesenti, E | 1 |
| Galvani, A | 1 |
| Ciomei, M | 1 |
| Solero, CL | 1 |
| Maccagnano, C | 1 |
| Guzzetti, S | 1 |
| Pollo, B | 1 |
| Ciusani, E | 2 |
| Dimeco, F | 1 |
| Tsuchiya, K | 1 |
| Aguilar, HN | 1 |
| Hung, RW | 1 |
| Kotylak, T | 1 |
| Sherriff, J | 1 |
| Tamangani, J | 1 |
| Senthil, L | 1 |
| Spooner, D | 1 |
| Brookes, C | 1 |
| Donahue, J | 1 |
| Goldman, M | 1 |
| Kinsella, T | 1 |
| Dipetrillo, T | 1 |
| Evans, D | 1 |
| Constantinou, M | 1 |
| Stopa, E | 1 |
| Puthawala, Y | 1 |
| Santaniello, A | 1 |
| Oyelese, A | 1 |
| Mantripragada, K | 1 |
| Rosati, K | 1 |
| Isdale, D | 1 |
| De Filippo, L | 1 |
| Autorino, R | 1 |
| Rinaldi, C | 1 |
| Fersino, S | 1 |
| Matteucci, P | 1 |
| Ciurlia, E | 1 |
| Alacacioglu, A | 1 |
| Unal, S | 1 |
| Canpolat, S | 1 |
| Yurt, A | 1 |
| Oztekin, O | 1 |
| Coskun, A | 1 |
| Karatas, A | 1 |
| Postaci, H | 1 |
| Sop, G | 1 |
| Salvage, D | 1 |
| Rajaraman, C | 1 |
| Rowland-Hill, C | 1 |
| Sperduto, PW | 1 |
| Schell, MC | 1 |
| Komaki, R | 1 |
| Buyyounouski, MK | 1 |
| Demas, W | 1 |
| Shah, SA | 1 |
| Nedzi, LA | 1 |
| Perry, G | 1 |
| Danson, SJ | 1 |
| Trent, S | 1 |
| Kong, A | 1 |
| Traish, D | 2 |
| Ashley, S | 2 |
| Dowe, A | 1 |
| Hines, F | 2 |
| Bocangel, DB | 1 |
| Finkelstein, S | 1 |
| Schold, SC | 4 |
| Bhakat, KK | 1 |
| Kokkinakis, DM | 2 |
| Antonadou, D | 2 |
| Paraskevaidis, M | 2 |
| Sarris, G | 1 |
| Coliarakis, N | 1 |
| Economou, I | 1 |
| Karageorgis, P | 2 |
| Schoeler, KD | 1 |
| Haroldson, PD | 1 |
| Huynh, MB | 1 |
| Tentori, L | 3 |
| Portarena, I | 2 |
| Torino, F | 1 |
| Scerrati, M | 1 |
| Navarra, P | 1 |
| Graziani, G | 3 |
| Lerro, KA | 1 |
| Lacy, J | 1 |
| Gaya, A | 1 |
| Greenstein, A | 1 |
| Stebbing, J | 1 |
| Frick, S | 1 |
| Lischner, S | 1 |
| Rosien, F | 1 |
| Haacke, TC | 1 |
| Schäfer, F | 1 |
| Christophers, E | 1 |
| Hauschild, A | 2 |
| Gollob, JA | 2 |
| McDermott, DF | 1 |
| Tutin, L | 1 |
| Sorokin, P | 1 |
| Parker, RA | 1 |
| Mier, JW | 1 |
| Islam, R | 1 |
| Isaacson, BJ | 1 |
| Zickerman, PM | 1 |
| Ratanawong, C | 1 |
| Tipping, SJ | 1 |
| Teixeira, MM | 1 |
| Portela, I | 1 |
| Cernuda, M | 1 |
| Oliveira, C | 1 |
| Albano, J | 1 |
| Lima, L | 1 |
| Zheludkova, OG | 1 |
| Tarasova, IS | 1 |
| Gorbatykh, SV | 1 |
| Belogurova, MB | 1 |
| Kumirova, EV | 1 |
| Borodina, ID | 1 |
| Prityko, AG | 1 |
| Melikian, AG | 1 |
| Shcherbenko, OI | 1 |
| Conill, C | 5 |
| Puig, S | 5 |
| Toscas, I | 1 |
| Castel, T | 5 |
| Lashford, LS | 1 |
| Thiesse, P | 1 |
| Couanet, D | 2 |
| Griffiths, PD | 1 |
| Doz, F | 1 |
| Ironside, J | 1 |
| Robson, K | 1 |
| Hobson, R | 1 |
| Dugan, M | 6 |
| Vassal, G | 2 |
| Ebert, BL | 1 |
| Niemierko, E | 1 |
| Shaffer, K | 1 |
| Salgia, R | 1 |
| Barkhof, F | 1 |
| Baayen, HC | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Bravo Marques, J | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Benita-Weiss, M | 1 |
| Coyle, TE | 1 |
| Bushunow, P | 2 |
| Evans, B | 1 |
| Friedman, H | 3 |
| Chahlavi, A | 1 |
| Kanner, A | 1 |
| Staugaitis, SM | 1 |
| Barnett, G | 1 |
| Figul, M | 1 |
| Söling, A | 1 |
| Dong, HJ | 1 |
| Chou, TC | 2 |
| Rainov, NG | 2 |
| Houghton, PJ | 4 |
| Litofsky, NS | 1 |
| Brown, GD | 1 |
| Brady, F | 1 |
| Osman, S | 2 |
| Luthra, SK | 1 |
| Ranicar, AS | 1 |
| Stevens, MF | 2 |
| Newlands, E | 2 |
| Price, P | 2 |
| Dziadziuszko, R | 1 |
| Ardizzoni, A | 1 |
| Postmus, PE | 1 |
| Smit, EF | 1 |
| Price, A | 2 |
| Debruyne, C | 1 |
| Legrand, C | 1 |
| Giaccone, G | 1 |
| Bodell, WJ | 1 |
| Gaikwad, NW | 1 |
| Miller, D | 1 |
| Vecht, ChJ | 1 |
| Newlands, ES | 11 |
| Foster, T | 2 |
| Zaknoen, S | 4 |
| Krown, SE | 3 |
| Menell, JH | 2 |
| Merrell, J | 2 |
| Lamb, LA | 2 |
| Williams, LJ | 2 |
| Quinn, CJ | 1 |
| Chapman, PB | 2 |
| Livingston, PO | 2 |
| Wolchok, JD | 2 |
| Houghton, AN | 3 |
| Panetta, JC | 1 |
| Kirstein, MN | 3 |
| Gajjar, A | 3 |
| Nair, G | 1 |
| Wilkinson, M | 1 |
| Stewart, CF | 5 |
| Riccardi, A | 1 |
| Mazzarella, G | 2 |
| Cefalo, G | 2 |
| Barone, C | 1 |
| Sandri, A | 2 |
| Caldarelli, M | 2 |
| Madon, E | 2 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Stelea, A | 1 |
| Mundt, A | 1 |
| Piccirilli, M | 2 |
| Caroli, E | 1 |
| Brogna, C | 1 |
| Artizzu, S | 1 |
| Mizutani, T | 2 |
| Ishikawa, M | 1 |
| Bouffet, E | 3 |
| Gammon, J | 2 |
| Becker, L | 1 |
| Rutka, J | 1 |
| Baruchel, S | 2 |
| Scarsella, M | 2 |
| D'Amati, G | 1 |
| Vergati, M | 2 |
| Kalish, V | 1 |
| Zupi, G | 1 |
| Nagasubramanian, R | 1 |
| Dolan, ME | 2 |
| Viviers, L | 2 |
| Abson, C | 2 |
| Britton, J | 1 |
| Sardell, S | 1 |
| Gonsalves, A | 1 |
| Wilkins, P | 1 |
| Westbury, C | 1 |
| Galiè, E | 1 |
| Carosi, M | 1 |
| Telera, S | 1 |
| Cianciulli, AM | 1 |
| Canalini, P | 1 |
| Giannarelli, D | 1 |
| Vera, K | 1 |
| Djafari, L | 2 |
| Faivre, S | 1 |
| Djazouli, K | 1 |
| Osorio, M | 1 |
| Parker, F | 1 |
| Cioloca, C | 1 |
| Raymond, E | 2 |
| Lodi, R | 1 |
| Setola, E | 1 |
| Ambrosetto, P | 1 |
| Barbiroli, B | 1 |
| Cortelli, P | 1 |
| Theodosopoulos, P | 1 |
| Lamborn, K | 2 |
| Malec, M | 3 |
| Greenberg, HS | 1 |
| Kuhn, J | 4 |
| Chua, SL | 1 |
| Wong, SS | 1 |
| Cher, LM | 1 |
| Murphy, PS | 1 |
| Rowland, IJ | 1 |
| Dzik-Jurasz, AS | 1 |
| Maccagnano, E | 1 |
| Broggi, G | 3 |
| Boiardi, A | 5 |
| Tsao-Wei, DD | 2 |
| Godard, S | 1 |
| Ostermann, S | 5 |
| Otten, P | 1 |
| Van Melle, G | 1 |
| Fernández-Ibiza, J | 1 |
| Malvehy, J | 4 |
| Fine, H | 2 |
| Greenberg, H | 3 |
| Hess, K | 1 |
| Schold, C | 1 |
| Tarhini, AA | 1 |
| Agarwala, SS | 3 |
| Ashley, DL | 3 |
| González-Cao, M | 1 |
| Jorcano, S | 2 |
| Martí, R | 2 |
| Basso, U | 3 |
| Vastola, F | 1 |
| Cavallo, G | 3 |
| Ferreri, AJ | 3 |
| Panucci, MG | 1 |
| Monfardini, S | 3 |
| Michielin, O | 1 |
| Udry, E | 1 |
| Périard, D | 1 |
| Matzinger, O | 1 |
| Lobrinus, JA | 1 |
| Dvorak, J | 1 |
| Melichar, B | 1 |
| Zizka, J | 1 |
| Hadzi-Nikolov, D | 1 |
| Frauger, E | 1 |
| Palmari, J | 1 |
| Braguer, D | 4 |
| Moktari, K | 1 |
| Peragut, JC | 2 |
| Martin, PM | 4 |
| Grisoli, F | 3 |
| Lebrun, C | 1 |
| Ramaioli, A | 1 |
| Vandenbos, F | 1 |
| Chanalet, S | 1 |
| Lonjon, M | 1 |
| Michiels, JF | 1 |
| Paquis, P | 1 |
| Chatel, M | 1 |
| Kirkwood, JM | 2 |
| Gore, M | 1 |
| Dreno, B | 1 |
| Thatcher, N | 2 |
| Czarnetski, B | 1 |
| Atkins, M | 1 |
| Buzaid, A | 1 |
| Skarlos, D | 3 |
| Rankin, EM | 1 |
| Csajka, C | 1 |
| Buclin, T | 2 |
| Leyvraz, S | 7 |
| Lejeune, F | 3 |
| Decosterd, LA | 2 |
| Seiferheld, W | 1 |
| Share, R | 1 |
| Atkins, J | 1 |
| Choucair, A | 1 |
| Kresl, J | 1 |
| Thoron, L | 1 |
| Cairncross, G | 2 |
| Dolinskas, C | 1 |
| Barger, G | 1 |
| Ataman, F | 1 |
| Poortmans, P | 1 |
| Verschuur, AC | 1 |
| Lelouch-Tubiana, A | 1 |
| Kalifa, C | 1 |
| Napolitano, M | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 2 |
| Levin, N | 2 |
| Gomori, JM | 1 |
| Kleber, M | 1 |
| Kujas, M | 3 |
| Lejeune, J | 4 |
| Polivka, M | 2 |
| Crinière, E | 2 |
| Marie, Y | 3 |
| Broët, P | 1 |
| Paz, MF | 1 |
| Yaya-Tur, R | 3 |
| Pollan, M | 1 |
| Aguirre-Cruz, L | 1 |
| García-Lopez, JL | 1 |
| Piquer, J | 1 |
| Safont, MJ | 1 |
| Sanchez-Cespedes, M | 1 |
| García-Villanueva, M | 1 |
| Arribas, L | 1 |
| Balzarotti, M | 1 |
| Calatozzolo, C | 1 |
| Croci, D | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Bafaloukos, D | 4 |
| Tsoutsos, D | 2 |
| Linardou, H | 2 |
| Christodoulou, C | 4 |
| Kalofonos, HP | 1 |
| Briassoulis, E | 2 |
| Panagiotou, P | 2 |
| Hatzichristou, H | 1 |
| Gogas, H | 3 |
| Triebels, VH | 1 |
| Stege, EB | 1 |
| Mäenpää, HO | 1 |
| Aaltonen, K | 1 |
| Mäntylä, R | 1 |
| Minn, H | 1 |
| Kufe, DW | 1 |
| Aryan, HE | 1 |
| Meltzer, HS | 1 |
| Lu, DC | 1 |
| Ozgur, BM | 1 |
| Levy, ML | 1 |
| Bruce, DA | 1 |
| Larson, D | 1 |
| Wara, W | 1 |
| Sneed, P | 1 |
| Wasserfallen, JB | 3 |
| Villemure, JG | 1 |
| Bringas, JR | 1 |
| Panner, A | 1 |
| Tamas, M | 1 |
| Bankiewicz, KS | 1 |
| Bartolomei, M | 2 |
| Mazzetta, C | 1 |
| Handkiewicz-Junak, D | 1 |
| Bodei, L | 1 |
| Rocca, P | 1 |
| Grana, C | 1 |
| Villa, G | 1 |
| Paganelli, G | 1 |
| Everaert, E | 1 |
| Joosens, E | 1 |
| Branle, F | 1 |
| Küker, W | 1 |
| Dichgans, J | 1 |
| Spence, AM | 3 |
| Scharnhorst, JD | 1 |
| Rostomily, RC | 1 |
| Ravizza, R | 1 |
| Cereda, E | 1 |
| Monti, E | 1 |
| Gariboldi, MB | 1 |
| Grobholz, R | 1 |
| Korn, T | 1 |
| Erber, R | 1 |
| Valduga, F | 1 |
| Nicolardi, L | 1 |
| Vicini, P | 2 |
| Orlansky, A | 1 |
| Pulfer, S | 1 |
| Bookman, MA | 1 |
| Guo, P | 3 |
| Fang, HB | 1 |
| Tian, GL | 1 |
| Bowman, FD | 1 |
| Stewart, PW | 1 |
| Sen, PK | 1 |
| Helms, RW | 1 |
| Banik, NL | 2 |
| Viñolas, N | 1 |
| Pujol, T | 1 |
| Quintó, L | 1 |
| Roitberg, B | 2 |
| Vitanovics, D | 1 |
| Afra, D | 1 |
| Byrne, TN | 1 |
| López-Pousa, A | 1 |
| García, JL | 1 |
| Martín-Broto, J | 1 |
| Ballester, R | 1 |
| Balart, J | 1 |
| Kopf, B | 1 |
| De Giorgi, U | 1 |
| Zago, S | 1 |
| Carminati, O | 1 |
| Rosti, G | 1 |
| Marangolo, M | 1 |
| Menniti, A | 1 |
| Moschettoni, L | 1 |
| Liccardo, G | 1 |
| Lunardi, P | 1 |
| Voloschin, AD | 1 |
| Cosgrove, GR | 1 |
| Aravantinos, G | 1 |
| Bamias, A | 2 |
| Carina, M | 1 |
| Klouvas, G | 1 |
| Su, YW | 1 |
| Chang, MC | 1 |
| Chiang, MF | 1 |
| Hsieh, RK | 1 |
| Aksoy, S | 1 |
| Abali, H | 1 |
| Güler, N | 1 |
| Kunze, S | 1 |
| Eich, HT | 1 |
| Semrau, R | 1 |
| Curschmann, J | 2 |
| Athanassiou, H | 1 |
| Synodinou, M | 1 |
| Maragoudakis, E | 1 |
| Verigos, C | 1 |
| Saris, G | 1 |
| Beroukas, K | 1 |
| Panagiotou, IE | 1 |
| Brountzos, EN | 1 |
| Kelekis, DA | 1 |
| Papathanasiou, MA | 1 |
| Bafaloukos, DI | 1 |
| Xu, GW | 1 |
| Mymryk, JS | 1 |
| Kiebert, G | 1 |
| Olson, J | 3 |
| Lonardi, S | 1 |
| Shirato, H | 1 |
| Couprie, C | 1 |
| Legha, SS | 2 |
| Lis, E | 2 |
| James, S | 1 |
| Camby, I | 1 |
| Darro, F | 1 |
| Brotchi, J | 1 |
| Gabius, J | 1 |
| Khong, HT | 1 |
| Wheeler, CJ | 1 |
| Gutwein, S | 1 |
| Schulz-Ertner, D | 6 |
| van Kampen, M | 1 |
| Thilmann, C | 1 |
| Edler, L | 4 |
| Wannenmacher, MM | 1 |
| Seiter, K | 1 |
| Ryken, T | 1 |
| Tatro, DS | 1 |
| Ten Haken, R | 1 |
| Kessler, ML | 1 |
| Palmieri, C | 1 |
| Brock, C | 4 |
| van der Rijt, CD | 1 |
| Costanzo, R | 1 |
| Marra, M | 1 |
| Palmieri, G | 1 |
| Budillon, A | 1 |
| Grillone, F | 1 |
| Venuta, S | 1 |
| Tagliaferri, P | 1 |
| Giorgio, CG | 1 |
| Giuffrida, D | 1 |
| Pappalardo, A | 1 |
| Russo, A | 1 |
| Santini, D | 1 |
| Salice, P | 1 |
| Blanco, G | 1 |
| Castorina, S | 1 |
| Failla, G | 1 |
| Bordonaro, R | 2 |
| Vredenburgh, J | 2 |
| Badruddoja, M | 1 |
| Provenzale, J | 1 |
| Dowell, JM | 1 |
| Burkart, JL | 1 |
| Toubiana, T | 1 |
| Lang, P | 1 |
| Martikainen, JA | 1 |
| Kivioja, A | 1 |
| Hallinen, T | 1 |
| Vihinen, P | 1 |
| Lewis, KD | 1 |
| Gibbs, P | 1 |
| O'Day, S | 1 |
| Richards, J | 1 |
| Weber, J | 2 |
| Anderson, C | 1 |
| Baron, A | 1 |
| Russ, P | 1 |
| Gonzalez, R | 1 |
| Nerio, E | 1 |
| Hofmann, M | 1 |
| Kiecker, F | 1 |
| Wurm, R | 1 |
| Schlenger, L | 1 |
| Sterry, W | 1 |
| Trefzer, U | 2 |
| Tortoriello, A | 1 |
| Pisano, A | 1 |
| Comella, P | 1 |
| Formato, R | 1 |
| Quattrin, S | 1 |
| Iaffaioli, RV | 1 |
| Delaney, SM | 1 |
| Rich, J | 2 |
| Pegg, AE | 1 |
| Moschel, RC | 1 |
| Birch, R | 1 |
| Provenzale, JM | 2 |
| Maxwell, J | 2 |
| Tourt-Uhlig, S | 1 |
| Chintagumpala, M | 1 |
| Krasin, MJ | 1 |
| Bowers, DC | 1 |
| Iacono, LC | 1 |
| Merchant, TE | 1 |
| Kun, LE | 2 |
| Ledet, D | 1 |
| Tanaka, R | 1 |
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Pazdur, R | 1 |
| Stamatakos, GS | 1 |
| Antipas, VP | 1 |
| Uzunoglu, NK | 1 |
| Leimgruber, A | 1 |
| Yeon, EJ | 1 |
| Buff, E | 1 |
| Maeder, PP | 1 |
| Meuli, RA | 1 |
| Wemmert, S | 1 |
| Rahnenführer, J | 1 |
| Beerenwinkel, N | 1 |
| Strowitzki, M | 1 |
| Feiden, W | 1 |
| Lengauer, T | 1 |
| Zang, KD | 1 |
| Meese, E | 1 |
| Steudel, WI | 1 |
| Urbschat, S | 1 |
| Keyaerts, M | 1 |
| Veld, PI | 1 |
| Gregor, A | 1 |
| Therasse, P | 1 |
| Pruitt, AA | 1 |
| Muzi, A | 1 |
| Forini, O | 1 |
| Lacal, PM | 1 |
| Ruffini, F | 1 |
| Gold, B | 1 |
| Koch, D | 5 |
| Di Rocco, C | 1 |
| Abate, ME | 1 |
| Clerico, A | 1 |
| Simmons, C | 1 |
| Danielpour, M | 1 |
| Osoba, D | 5 |
| Groshen, S | 1 |
| Son, MJ | 2 |
| Kim, JS | 3 |
| Kim, MH | 1 |
| Song, HS | 1 |
| Kim, JT | 2 |
| Shin, T | 1 |
| Park, SY | 1 |
| Chan, YL | 1 |
| Barbarisi, M | 1 |
| Moraci, M | 1 |
| Moraci, A | 1 |
| González Cao, M | 1 |
| Martín, M | 1 |
| Carrera, C | 1 |
| Herrero, J | 1 |
| Gascón, P | 1 |
| Mellado, B | 1 |
| Ron, IG | 1 |
| Sarid, D | 1 |
| Ryvo, L | 1 |
| Sapir, EE | 1 |
| Schneebaum, S | 1 |
| Metser, U | 1 |
| Asna, N | 1 |
| Inbar, MJ | 1 |
| Safra, T | 1 |
| Kapadia, A | 1 |
| Page, MS | 1 |
| Kelley, SK | 1 |
| Rehman, S | 1 |
| Lavon, I | 2 |
| Zelikovitsh, B | 1 |
| Fellig, Y | 1 |
| Tamburrini, G | 1 |
| Itasaka, S | 1 |
| Donson, AM | 1 |
| Addo-Yobo, SO | 1 |
| Handler, MH | 1 |
| Gore, L | 1 |
| Foreman, NK | 1 |
| Hunter, C | 1 |
| Smith, R | 1 |
| Stephens, P | 1 |
| Stevens, C | 2 |
| Teague, J | 1 |
| Greenman, C | 1 |
| Edkins, S | 1 |
| Bignell, G | 1 |
| Davies, H | 1 |
| O'Meara, S | 1 |
| Parker, A | 1 |
| Avis, T | 1 |
| Barthorpe, S | 1 |
| Brackenbury, L | 1 |
| Buck, G | 1 |
| Butler, A | 1 |
| Clements, J | 1 |
| Cole, J | 1 |
| Dicks, E | 1 |
| Forbes, S | 1 |
| Gorton, M | 1 |
| Gray, K | 1 |
| Halliday, K | 1 |
| Harrison, R | 1 |
| Hills, K | 1 |
| Hinton, J | 1 |
| Jenkinson, A | 1 |
| Kosmidou, V | 1 |
| Laman, R | 1 |
| Lugg, R | 1 |
| Menzies, A | 1 |
| Petty, R | 1 |
| Raine, K | 1 |
| Richardson, D | 1 |
| Shepherd, R | 1 |
| Small, A | 1 |
| Solomon, H | 1 |
| Tofts, C | 1 |
| Varian, J | 1 |
| West, S | 1 |
| Widaa, S | 1 |
| Yates, A | 2 |
| Easton, DF | 1 |
| Riggins, G | 1 |
| Roy, JE | 1 |
| Levine, KK | 2 |
| Stratton, MR | 2 |
| Futreal, PA | 2 |
| Wooster, R | 1 |
| Liu, V | 1 |
| Partap, S | 1 |
| Schuetze, S | 1 |
| Domingo-Doménech, J | 1 |
| Gallego, R | 1 |
| Vilella, R | 1 |
| Gupta, V | 1 |
| Su, YS | 1 |
| Kardosh, A | 1 |
| Liebes, LF | 1 |
| Dehdashti, AR | 1 |
| Heeger, S | 1 |
| Ganière, V | 1 |
| Christen, G | 1 |
| Bally, F | 1 |
| Guillou, L | 1 |
| de Ribaupierre, S | 1 |
| Doh, LS | 1 |
| Amato, R | 1 |
| Paulino, AC | 1 |
| Teh, BS | 1 |
| Cortot, AB | 1 |
| Gerinière, L | 1 |
| Robinet, G | 1 |
| Breton, JL | 1 |
| Corre, R | 1 |
| Falchero, L | 1 |
| Berard, H | 1 |
| Gimenez, C | 1 |
| Chavaillon, JM | 1 |
| Perol, M | 1 |
| Bombaron, P | 1 |
| Mercier, C | 1 |
| Souquet, PJ | 1 |
| Hassler, M | 1 |
| Stockhammer, G | 1 |
| Abuja, B | 1 |
| Deinsberger, R | 1 |
| Batista, LF | 1 |
| Naumann, SC | 1 |
| Frank, B | 1 |
| Möhle, R | 1 |
| Charnley, N | 1 |
| West, CM | 1 |
| Barnett, CM | 1 |
| Bydder, GM | 1 |
| Glaser, M | 2 |
| Swindell, R | 1 |
| Matthews, J | 2 |
| Schwarzmaier, HJ | 1 |
| Eickmeyer, F | 1 |
| von Tempelhoff, W | 1 |
| Fiedler, VU | 1 |
| Niehoff, H | 1 |
| Ulrich, SD | 1 |
| Ulrich, F | 1 |
| Taliansky-Aronov, A | 1 |
| Ngo, L | 1 |
| Nei, M | 1 |
| Kim, MK | 1 |
| Lee, TK | 1 |
| Kang, JK | 1 |
| Kim, MC | 1 |
| Diezi, M | 1 |
| Stempak, D | 1 |
| Moghrabi, A | 1 |
| Coppes, MJ | 1 |
| Fernandez, CV | 1 |
| Rivera, E | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Broglio, K | 1 |
| Yin, G | 1 |
| Hortobagyi, GN | 1 |
| Buchholz, T | 1 |
| Biemond-ter Stege, EM | 1 |
| Graveland, WJ | 1 |
| Mutter, N | 1 |
| Glantz, MJ | 3 |
| Chalmers, L | 2 |
| Van Horn, A | 1 |
| Sloan, AE | 1 |
| Bonaldi, L | 2 |
| Maruno, M | 1 |
| Fujimaki, T | 1 |
| Kochi, M | 1 |
| Hori, T | 1 |
| Polyzos, A | 1 |
| Stavrinidis, I | 1 |
| Frangia, K | 1 |
| Markopoulos, C | 1 |
| Papadopoulos, O | 1 |
| Pectasides, D | 1 |
| Mantzourani, M | 1 |
| Middleton, M | 1 |
| Vaiopoulos, G | 1 |
| Loeser, S | 1 |
| Blaschke, B | 2 |
| Tan, TC | 1 |
| Mabasa, VH | 1 |
| Taylor, SC | 1 |
| Niedzwiecki, D | 1 |
| Hodgson, L | 1 |
| Haluska, FG | 1 |
| Schadendorf, D | 1 |
| Ugurel, S | 1 |
| Thoelke, A | 1 |
| Egberts, F | 1 |
| Kreissig, M | 1 |
| Linse, R | 1 |
| Vogt, T | 1 |
| Tilgen, W | 1 |
| Mohr, P | 1 |
| Eoh, W | 1 |
| Gioia, V | 1 |
| Biscuola, M | 1 |
| Kemper, EM | 1 |
| Leenders, W | 1 |
| Küsters, B | 1 |
| Lyons, S | 1 |
| Buckle, T | 1 |
| Heerschap, A | 2 |
| Beijnen, JH | 1 |
| van Tellingen, O | 1 |
| Siker, ML | 1 |
| Boor, S | 1 |
| Banna, GL | 1 |
| Bettio, D | 1 |
| Rodriguez Baena, R | 1 |
| Aimar, E | 1 |
| Gaetani, P | 1 |
| Colombo, P | 1 |
| Rognone, F | 1 |
| Liu, TJ | 1 |
| Peterson, P | 2 |
| Stevens, QE | 1 |
| Howes, G | 1 |
| Dickerman, RD | 1 |
| Nardone, EM | 1 |
| Contreras Martínez, J | 1 |
| Azcoaga Blasco, JM | 1 |
| Delgado Rico, R | 1 |
| Wals Zurita, A | 1 |
| Villanueva Alvarez, A | 1 |
| Rivas Sánchez, D | 1 |
| Herruzo Cabrera, I | 1 |
| Gasco, J | 1 |
| Park, JA | 2 |
| Joe, YA | 1 |
| Zeltzman, M | 1 |
| Parisi, MA | 1 |
| Liguoro, D | 1 |
| Piao, Y | 1 |
| Larkin, JM | 1 |
| Hughes, SA | 1 |
| Beirne, DA | 1 |
| Patel, PM | 1 |
| Gibbens, IM | 1 |
| Bate, SC | 1 |
| Thomas, K | 1 |
| Eisen, TG | 1 |
| Gore, ME | 1 |
| de Gast, GC | 1 |
| Dalesio, O | 1 |
| Ishii, N | 1 |
| Iwasaki, Y | 1 |
| Zhang, JP | 1 |
| Shi, HL | 1 |
| Yue, WY | 1 |
| Mu, YG | 1 |
| Everhard, S | 1 |
| Thillet, J | 1 |
| Taniguchi, T | 1 |
| Pitini, V | 1 |
| Baldari, S | 1 |
| Altavilla, G | 1 |
| Arrigo, C | 1 |
| Naro, C | 1 |
| Perniciaro, F | 1 |
| Capasso, E | 1 |
| Caserta, L | 1 |
| Pradilla, G | 1 |
| Legnani, F | 1 |
| Caplan, J | 1 |
| Nuthalapati, S | 1 |
| Mineo, JF | 1 |
| Bordron, A | 1 |
| Baroncini, M | 1 |
| Blond, S | 1 |
| Dam-Hieu, P | 1 |
| Sohn, HJ | 1 |
| Marg, E | 1 |
| Rudolph, R | 1 |
| Rauch, M | 1 |
| Rieckmann, P | 1 |
| Schuth, J | 1 |
| Koch, H | 1 |
| Zaja, F | 1 |
| Mazza, E | 2 |
| Spina, M | 1 |
| Ilariucci, F | 1 |
| Corazzelli, G | 1 |
| Manno, P | 1 |
| Candela, M | 1 |
| Abbadessa, A | 1 |
| Stelitano, C | 1 |
| Latte, G | 1 |
| Kamen, BA | 1 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Fehlauer, F | 1 |
| Muench, M | 1 |
| Richter, E | 1 |
| Allen, JC | 1 |
| Phillips, PC | 1 |
| Watral, MA | 1 |
| Krauser, JM | 1 |
| Mora, A | 1 |
| Prada, F | 1 |
| Borsa, S | 1 |
| Martinelli-Boneschi, F | 1 |
| Saladino, A | 1 |
| Gaini, SM | 1 |
| de la Fuente, BP | 1 |
| Dalmau, J | 1 |
| Greenberger, NJ | 1 |
| Gigas, DC | 2 |
| Rabkin, S | 1 |
| Betensky, RA | 1 |
| Romany, CA | 1 |
| Reavie, LB | 1 |
| Goldman, B | 1 |
| Choong, NW | 1 |
| Mauer, AM | 1 |
| Hoffman, PC | 1 |
| Rudin, CM | 1 |
| Winegarden, JD | 1 |
| Kozloff, M | 1 |
| Wade, JL | 1 |
| Sciortino, DF | 1 |
| Szeto, L | 1 |
| Vokes, EE | 1 |
| Dellinger, CA | 1 |
| O'Toole, L | 1 |
| Khanduri, S | 2 |
| Gerrard, GE | 1 |
| Vajramani, GV | 1 |
| Dambatta, S | 1 |
| Walker, M | 1 |
| Grundy, PL | 1 |
| Fuentes, S | 1 |
| Eudes, N | 1 |
| Lancelot, S | 1 |
| Amiel-Benouaich, A | 1 |
| Gatta, G | 1 |
| Vecht, C | 1 |
| Pore, N | 1 |
| Cerniglia, GJ | 1 |
| Mick, R | 1 |
| Bernhard, EJ | 1 |
| Hahn, SM | 1 |
| Gupta, AK | 1 |
| Maity, A | 1 |
| McConville, P | 1 |
| Moody, JB | 1 |
| Leopold, WR | 1 |
| Kreger, AR | 1 |
| Woolliscroft, MJ | 1 |
| Powathil, G | 1 |
| Kohandel, M | 1 |
| Sivaloganathan, S | 1 |
| Oza, A | 1 |
| Milosevic, M | 1 |
| Menon, H | 2 |
| Gujral, S | 1 |
| Diakite, F | 1 |
| Renard, MA | 1 |
| Iraqi, W | 1 |
| Jordan, JT | 1 |
| Hussain, SF | 2 |
| DeAngulo, G | 1 |
| Kudo, M | 1 |
| Singhal, N | 1 |
| Selva-Nayagam, S | 1 |
| Brown, MP | 1 |
| Ang, EL | 1 |
| Lim, CC | 1 |
| Chan, SP | 1 |
| Ty, A | 1 |
| Tsuno, T | 1 |
| Katsumata, S | 1 |
| Mizuno, M | 1 |
| Fujita, M | 1 |
| Osawa, H | 1 |
| Nakahara, N | 1 |
| Satoh, Y | 1 |
| Inagaki, M | 1 |
| Fiumani, A | 2 |
| Falcone, C | 2 |
| Filippini, G | 2 |
| Khaw, SL | 1 |
| Coleman, LT | 1 |
| Downie, PA | 1 |
| Heath, JA | 1 |
| Kouvaris, JR | 1 |
| Miliadou, A | 1 |
| Kouloulias, VE | 1 |
| Kolokouris, D | 1 |
| Balafouta, MJ | 1 |
| Papacharalampous, XN | 1 |
| Vlahos, LJ | 1 |
| Gerrard, G | 1 |
| Majer, M | 1 |
| Jensen, RL | 1 |
| Watson, GA | 1 |
| Leachman, SA | 1 |
| Boucher, KM | 1 |
| Samlowski, WE | 1 |
| Tartarone, A | 1 |
| Ardito, R | 1 |
| Romano, C | 1 |
| Kruh, GD | 1 |
| Dancey, J | 1 |
| Crott, R | 2 |
| Cornelissen, SJ | 1 |
| Vriezen, M | 1 |
| Dekkers, MM | 1 |
| Errami, A | 1 |
| Sijben, A | 1 |
| Nicholson, HS | 1 |
| Kretschmar, CS | 1 |
| Krailo, M | 1 |
| Kadota, R | 1 |
| Harris, MB | 1 |
| Tedeschi-Blok, N | 1 |
| Sato, J | 1 |
| Reaman, GH | 1 |
| Yin, LT | 1 |
| Fu, YJ | 1 |
| Xu, QL | 1 |
| Liu, ZL | 1 |
| Liang, AH | 1 |
| Fan, XJ | 1 |
| Xu, CG | 1 |
| Ishii, D | 1 |
| Hatano, H | 1 |
| Takeuchi, H | 1 |
| Shimato, S | 1 |
| Fujii, M | 1 |
| Sawrie, SM | 1 |
| Guthrie, BL | 1 |
| Spencer, SA | 1 |
| Meredith, RF | 1 |
| Cloud, GA | 1 |
| Nojima, K | 1 |
| Pyrko, P | 1 |
| Lee, AS | 1 |
| Galanopoulos, N | 1 |
| Rawlani, V | 1 |
| Veerapong, J | 1 |
| Bickenbach, K | 1 |
| Taylor, RE | 1 |
| Hulsebos, TJ | 1 |
| Wagner, J | 2 |
| Bischof, M | 4 |
| Wagner, F | 2 |
| Pitt, M | 1 |
| Anderson, R | 1 |
| Dyer, M | 1 |
| Mealing, S | 1 |
| Clarkson, A | 1 |
| McKenzie, CA | 1 |
| Biggs, MT | 1 |
| Little, NS | 1 |
| Cook, RJ | 1 |
| Messina, M | 1 |
| Robinson, BG | 1 |
| Wallace, D | 1 |
| Danks, MK | 1 |
| Boyett, JM | 1 |
| Gagel, B | 1 |
| Stanzel, S | 1 |
| Asadpour, B | 1 |
| Katsuki, H | 1 |
| Metha, M | 1 |
| Robins, IH | 1 |
| Sijens, PE | 1 |
| Heesters, MA | 1 |
| van der Graaf, WT | 1 |
| Potze, JH | 1 |
| Irwan, R | 1 |
| Meiners, LC | 1 |
| Oudkerk, M | 1 |
| Karakis, I | 1 |
| McGeeney, B | 1 |
| Demierre, MF | 1 |
| Thiele, JJ | 1 |
| Wolpowitz, D | 1 |
| Bhawan, J | 1 |
| Goel, A | 1 |
| Crutcher, L | 1 |
| Hassenbusch, SJ | 1 |
| Schmittling, B | 1 |
| Kunwar, S | 1 |
| Shaffrey, M | 1 |
| Parker, K | 1 |
| Grahn, AY | 1 |
| Sherman, JW | 1 |
| Husain, SR | 1 |
| Claes, A | 1 |
| Maass, C | 1 |
| Leenders, WP | 1 |
| Lamers, LM | 1 |
| Al, MJ | 1 |
| Mittmann, N | 1 |
| Jin Seung, S | 1 |
| Uyl-de Groot, CA | 1 |
| Johansson, M | 1 |
| Bergström, P | 1 |
| Bergenheim, AT | 1 |
| Avutu, B | 1 |
| Barker, FG | 1 |
| Shono, T | 1 |
| Kil, WJ | 1 |
| Cerna, D | 1 |
| Balmaceda, C | 1 |
| Cheung, YK | 1 |
| Alavi, J | 1 |
| Sisti, M | 1 |
| Fine, RL | 1 |
| Filippone, F | 1 |
| Rausch, R | 2 |
| Zabel-du Bois, A | 1 |
| Fathi, AR | 1 |
| Novoa, E | 1 |
| El-Koussy, M | 1 |
| Solari, A | 1 |
| da Fonseca, CO | 1 |
| Nagel, J | 1 |
| Futuro, D | 1 |
| Quirico-Santos, T | 1 |
| Gattass, CR | 1 |
| Debeir, O | 1 |
| Kunz-Schughart, L | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Bael, TE | 1 |
| Peterson, BL | 1 |
| Nakamura, O | 1 |
| McGibbon, B | 1 |
| Graham, C | 1 |
| Mischel, P | 1 |
| Bergsneider, M | 1 |
| Pope, W | 1 |
| Lagattuta, TF | 1 |
| Egorin, MJ | 1 |
| Salvado, AJ | 1 |
| Wei-Tsao, DD | 1 |
| Lin, SH | 1 |
| Steckley, JL | 1 |
| Mitchell, SB | 1 |
| Tsai, JS | 1 |
| Adam, M | 1 |
| Nagy, M | 1 |
| Katz, RL | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Longtine, JA | 1 |
| Weaver, S | 1 |
| Laforme, A | 1 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Benveniste, RJ | 1 |
| Manzano, G | 1 |
| Petito, CK | 1 |
| Andreoli, A | 1 |
| Leonardi, M | 1 |
| Gujrati, M | 1 |
| Scheithauer, BW | 1 |
| Zambrano, SC | 1 |
| Jost, SC | 1 |
| Raghavan, R | 1 |
| Cochran, EJ | 1 |
| Stalpers, L | 1 |
| Hof, H | 1 |
| Oertel, S | 1 |
| Salgaller, ML | 1 |
| Oliver, PG | 1 |
| Belenky, ML | 1 |
| Timmerman, R | 1 |
| Flom, L | 1 |
| Plowman, J | 1 |
| Waud, WR | 1 |
| Koutsoukos, AD | 1 |
| Rubinstein, LV | 1 |
| Moore, TD | 1 |
| Grever, MR | 1 |
| McVie, JG | 1 |
| O'Reilly, SM | 3 |
| Glaser, MG | 3 |
| Brampton, M | 1 |
| Rice-Edwards, JM | 2 |
| Illingworth, RD | 2 |
| Richards, PG | 2 |
| Kennard, C | 1 |
| Colquhoun, IR | 1 |
| Lewis, P | 3 |
| Devineni, D | 1 |
| Klein-Szanto, A | 1 |
| Buzaid, AC | 1 |
| Bower, M | 3 |
| Evans, H | 3 |
| Brampton, MH | 4 |
| Colquhoun, I | 3 |
| Wedge, SR | 2 |
| Porteous, JK | 1 |
| Marcus, K | 1 |
| Bleehen, NM | 1 |
| Begent, RJ | 1 |
| Calvert, H | 2 |
| Roddie, M | 1 |
| Rustin, GJ | 1 |
| Marzolini, C | 2 |
| Gander, M | 3 |
| Biollaz, J | 2 |
| Izbicka, E | 1 |
| Soda, H | 1 |
| Gerson, SL | 1 |
| Von Hoff, DD | 1 |
| Kerby, T | 2 |
| Bigner, SH | 1 |
| Henry, AJ | 1 |
| Krischer, J | 1 |
| Lovell, S | 1 |
| Rasheed, K | 1 |
| Marchev, F | 1 |
| Seman, AJ | 1 |
| Cokgor, I | 1 |
| Stewart, E | 1 |
| Colvin, OM | 1 |
| Haglund, MM | 1 |
| Sankar, A | 1 |
| Thomas, DG | 1 |
| Darling, JL | 1 |
| Decosterd, L | 1 |
| Bonfanti, M | 1 |
| Liénard, D | 1 |
| Perey, L | 1 |
| Colella, G | 1 |
| Yarosh, D | 1 |
| Belanich, M | 1 |
| D'Incalci, M | 1 |
| Miller, JL | 1 |
| Albright, R | 1 |
| O'Neill, AM | 1 |
| Bruner, J | 3 |
| Yue, N | 3 |
| Judson, I | 1 |
| Beale, P | 1 |
| Moore, S | 1 |
| Reidenberg, P | 1 |
| Statkevich, P | 1 |
| Batra, V | 1 |
| Cutler, D | 1 |
| Young, H | 1 |
| Middlemas, DS | 1 |
| Poquette, C | 1 |
| Brent, TP | 2 |
| Landoni, C | 1 |
| Villa, E | 1 |
| MacConnachie, AM | 1 |
| van Rijn, J | 1 |
| van der Valk, P | 1 |
| Albright, RE | 1 |
| Fredericks, R | 1 |
| Spence, A | 1 |
| Hohl, RJ | 1 |
| Selker, RG | 1 |
| Vick, NA | 1 |
| Phillips, P | 1 |
| Cheshire, PJ | 1 |
| Richmond, LB | 1 |
| Poquette, CA | 1 |
| Hulette, C | 1 |
| Kosmidis, P | 2 |
| Samantas, E | 2 |
| Papakostas, P | 1 |
| Karabelis, A | 2 |
| Bacoyiannis, C | 1 |
| Skarlos, DV | 1 |
| Pinna, G | 1 |
| Dirix, LY | 1 |
| Bravo-Marques, JM | 1 |
| Rao, S | 1 |
| Bosik, ME | 1 |
| Honore, S | 1 |
| Frenkel, EP | 1 |
| Wick, JB | 1 |
| Dinnes, J | 2 |
| Cave, C | 2 |
| Major, K | 1 |
| Milne, R | 2 |
| Harris, MT | 1 |
| Lutterbach, J | 1 |
| Liegibel, J | 1 |
| Madlinger, A | 1 |
| Frommhold, H | 1 |
| Keime-Guibert, F | 1 |
| Eskens, FA | 1 |
| Biasco, G | 1 |
| Pantaleo, MA | 1 |
| Casadei, S | 1 |
| Fels, C | 1 |
| Droege, JW | 1 |
| Schäfer, C | 1 |
| Olson, JD | 1 |
| Mack, M | 1 |
| Rodavitch, A | 1 |
| Boutros, DY | 1 |
| Benjelloun, A | 1 |
| Delavelle, J | 1 |
| Lazeyras, F | 1 |
| Khan, RB | 1 |
| Bazylewicz, KA | 1 |
| Georgoulias, V | 1 |
| Kalofonos, Ch | 1 |
| Santi, M | 1 |
| Ostermann Kraljevic, S | 1 |
| Maillard, I | 1 |
| Maeder, P | 1 |
| Meuli, R | 1 |
| Janzer, R | 1 |
| Pizzolato, G | 1 |
| Miralbell, R | 1 |
| Porchet, F | 1 |
| Paul, MJ | 1 |
| Summers, Y | 1 |
| Calvert, AH | 1 |
| Rustin, G | 1 |
| Margolin, K | 1 |
| Atkins, B | 1 |
| Thompson, A | 1 |
| Ernstoff, S | 1 |
| Flaherty, L | 1 |
| Clark, I | 1 |
| Sosman, J | 1 |
| II Smith, W | 1 |
| Dutcher, P | 1 |
| Gollob, J | 1 |
| Longmate, J | 1 |
| Johnson, D | 1 |
| Sterba, J | 1 |
| Pavelka, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma[NCT02590263] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2015-08-24 | Completed | ||
| Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM[NCT00977431] | Phase 1 | 36 participants (Actual) | Interventional | 2009-09-17 | Completed | ||
| A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas[NCT02766270] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2016-09-26 | Recruiting | ||
| A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT02853565] | Phase 1 | 10 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide[NCT03687957] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2019-01-04 | Recruiting | ||
| Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.[NCT00626990] | Phase 3 | 751 participants (Actual) | Interventional | 2007-12-31 | Active, not recruiting | ||
| A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma[NCT02667587] | Phase 3 | 716 participants (Actual) | Interventional | 2016-05-09 | Active, not recruiting | ||
| The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial[NCT04547621] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma[NCT04471844] | 950 participants (Anticipated) | Interventional | 2020-12-08 | Recruiting | |||
| SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study[NCT03477110] | Early Phase 1 | 30 participants (Actual) | Interventional | 2018-05-04 | Active, not recruiting | ||
| A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)[NCT00045968] | Phase 3 | 348 participants (Anticipated) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery[NCT03190967] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2018-04-18 | Terminated (stopped due to The phase II portion was never started as we could no longer get the drug from the manufacturer.) | ||
| A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, or Peduncular High-Grade Glioma[NCT01390948] | Phase 2 | 124 participants (Actual) | Interventional | 2011-10-18 | Completed | ||
| Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients[NCT02227576] | Phase 2 | 20 participants (Actual) | Interventional | 2014-07-10 | Terminated (stopped due to Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.) | ||
| INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group[NCT02343406] | Phase 2 | 266 participants (Actual) | Interventional | 2015-02-17 | Completed | ||
| A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)[NCT01514201] | Phase 1/Phase 2 | 66 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409] | Phase 3 | 700 participants (Anticipated) | Interventional | 2009-06-30 | Completed | ||
| Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)[NCT01502241] | Phase 3 | 412 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma[NCT01220271] | Phase 1/Phase 2 | 75 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.[NCT02209948] | Phase 2 | 166 participants (Actual) | Interventional | 2014-08-22 | Completed | ||
| A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma[NCT02017717] | Phase 3 | 529 participants (Actual) | Interventional | 2014-02-07 | Active, not recruiting | ||
| Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data[NCT04792437] | 120 participants (Anticipated) | Observational | 2021-03-10 | Recruiting | |||
| A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients[NCT00482677] | Phase 3 | 562 participants (Actual) | Interventional | 2007-11-14 | Completed | ||
| Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients[NCT01149109] | Phase 3 | 141 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma[NCT02617745] | Phase 2 | 244 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study[NCT03119064] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2017-11-30 | Terminated (stopped due to lack of response to study therapy) | ||
| A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma[NCT01812603] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma[NCT01812616] | Phase 1/Phase 2 | 21 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas[NCT01991977] | Phase 2 | 91 participants (Actual) | Interventional | 2013-12-31 | Active, not recruiting | ||
| A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations[NCT05588141] | Phase 1/Phase 2 | 96 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | ||
| A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment[NCT01480050] | Phase 1 | 28 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme With Rapid Early Progression Patients Prior to Adjuvant Oncological Therapy (GlioMET)[NCT05608395] | Phase 2 | 71 participants (Anticipated) | Interventional | 2020-12-04 | Recruiting | ||
| The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021] | 710 participants (Actual) | Observational | 2017-08-31 | Active, not recruiting | |||
| Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739] | 500 participants (Anticipated) | Observational | 2021-12-30 | Recruiting | |||
| A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma[NCT00588523] | Phase 2 | 60 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT01591577] | Phase 2 | 50 participants (Actual) | Interventional | 2012-12-07 | Active, not recruiting | ||
| Nitroglycerin Plus Whole Intracranial Radiotherapy for Brain Metastases in Non-small Cell Lung Cancer Patients: a Phase II Open Randomized Clinical Trial[NCT04338867] | Phase 2 | 96 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2[NCT05521048] | Phase 1/Phase 2 | 19 participants (Anticipated) | Interventional | 2022-09-19 | Recruiting | ||
| An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma[NCT01480479] | Phase 3 | 745 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)[NCT02573324] | Phase 3 | 691 participants (Actual) | Interventional | 2015-01-04 | Completed | ||
| [NCT00967330] | Phase 2 | 182 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma[NCT01062399] | Phase 1/Phase 2 | 279 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer[NCT04892472] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-07-12 | Recruiting | ||
| ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer[NCT03940196] | Phase 3 | 540 participants (Actual) | Interventional | 2019-03-22 | Active, not recruiting | ||
| EF-33: An Open-Label Pilot Study of OPTUNE® (TTFields, 200 Khz) With High Density Transducer Arrays for the Treatment of Recurrent Glioblastoma[NCT04492163] | Phase 2 | 25 participants (Anticipated) | Interventional | 2020-07-14 | Recruiting | ||
| A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarci[NCT04281576] | 28 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | |||
| Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma[NCT00887146] | Phase 3 | 360 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study[NCT00182819] | Phase 3 | 709 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas[NCT00114140] | Phase 2 | 136 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme[NCT01800695] | Phase 1 | 202 participants (Actual) | Interventional | 2013-04-02 | Completed | ||
| Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial[NCT01164189] | Phase 2 | 155 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Safety of Intensity-modulated Radiotherapy Treatment With Inhomogeneous Dose Distribution in Patients With Relapsed High-grade Gliomas.[NCT04610229] | 12 participants (Actual) | Interventional | 2016-02-01 | Completed | |||
| An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme[NCT04446416] | 6 participants (Actual) | Interventional | 2020-07-21 | Completed | |||
| A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin[NCT02343991] | 10 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135] | Phase 2 | 23 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost[NCT01507506] | Phase 3 | 180 participants (Actual) | Interventional | 2011-03-15 | Terminated | ||
| Ependymomics: Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents[NCT05151718] | 370 participants (Anticipated) | Observational | 2021-09-30 | Recruiting | |||
| Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397] | 10 participants (Anticipated) | Interventional | 2023-02-17 | Recruiting | |||
| Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients[NCT03212742] | Phase 1/Phase 2 | 91 participants (Anticipated) | Interventional | 2017-09-04 | Recruiting | ||
| Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Refractory Brain Metastases: A Single-arm, Single-center Phase II Trial[NCT02654106] | Phase 2 | 65 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System[NCT03626896] | 6 participants (Actual) | Interventional | 2018-08-17 | Completed | |||
| Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)[NCT03956706] | 0 participants (Actual) | Interventional | 2018-12-24 | Withdrawn (stopped due to no partipants enrolled and investigator left the institution) | |||
| A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors[NCT01076530] | Phase 1 | 27 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis[NCT05554302] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| A Modified Ketogenic, Anti-Inflammatory Diet for Patients With High-Grade Gliomas[NCT05373381] | 10 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | |||
| Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma[NCT03072134] | Phase 1 | 12 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| Glioblastoma Multiforme Patients in Clinical Trials: An Examination of Their Clinical Trial Experiences[NCT05958485] | 500 participants (Anticipated) | Observational | 2024-08-31 | Not yet recruiting | |||
| Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT00304031] | Phase 3 | 1,173 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT01790503] | Phase 1/Phase 2 | 65 participants (Actual) | Interventional | 2013-07-18 | Completed | ||
| Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic[NCT05504681] | 200 participants (Anticipated) | Observational | 2021-11-03 | Recruiting | |||
| Validity and Reliability Evaluation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for Adult-type Diffuse Gliomas Patients in Chinese Population[NCT05486923] | 450 participants (Anticipated) | Observational | 2022-09-19 | Recruiting | |||
| A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs[NCT00662506] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques[NCT00756106] | 15 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Funding ended) | |||
| A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain[NCT00841555] | Phase 1 | 9 participants (Actual) | Interventional | 2009-02-13 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patie[NCT00943826] | Phase 3 | 921 participants (Actual) | Interventional | 2009-06-29 | Completed | ||
| Precoce Medical Care by the Mobil Support for Patients With Glioblastoma Receiving Specific Medical Oncology Treatment[NCT04516733] | 35 participants (Actual) | Interventional | 2019-05-10 | Completed | |||
| Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT00884741] | Phase 3 | 637 participants (Actual) | Interventional | 2009-04-15 | Completed | ||
| Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867] | Phase 1 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened) | ||
| A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation[NCT00525525] | Phase 2 | 74 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma[NCT00619112] | Phase 2 | 60 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide[NCT01022918] | Phase 2 | 134 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma[NCT00884416] | Phase 1 | 17 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Phase I/II Trial of Hydroxychloroquine in Conjunction With Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00486603] | Phase 1/Phase 2 | 92 participants (Actual) | Interventional | 2007-10-29 | Completed | ||
| A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients[NCT00632203] | Phase 2 | 53 participants (Actual) | Interventional | 2008-03-04 | Terminated | ||
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Thera[NCT00689221] | Phase 3 | 545 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme[NCT00112502] | Phase 2 | 178 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer[NCT00875355] | Phase 2 | 100 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma[NCT05425004] | Phase 2 | 24 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | ||
| A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00458601] | Phase 2 | 82 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas[NCT04143425] | 50 participants (Anticipated) | Observational | 2020-02-06 | Recruiting | |||
| An Italian Multicenter Phase II Trial of Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study[NCT05554003] | Phase 2 | 46 participants (Anticipated) | Interventional | 2022-01-14 | Recruiting | ||
| Phase 1/2 Open Single-arm Monocentric Study Evaluating the Tolerance and Interest of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SONOCLOUD® Implantable Medical Device in Mild Alzheimer's Disease Patients (MMSE [NCT03119961] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2017-06-26 | Completed | ||
| A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00305864] | Phase 1/Phase 2 | 118 participants (Actual) | Interventional | 2006-02-09 | Completed | ||
| A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era[NCT03138642] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-07-01 | Recruiting | ||
| Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521] | Phase 3 | 406 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas[NCT00979017] | Phase 2 | 41 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status[NCT03519412] | Phase 2 | 102 participants (Anticipated) | Interventional | 2019-01-23 | Active, not recruiting | ||
| An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366] | Phase 2 | 21 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients) | ||
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma[NCT00804908] | Phase 2 | 346 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Restrictive Use of Dexamethasone in Glioblastoma[NCT04266977] | 50 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | |||
| Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma[NCT03377491] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-02-10 | Active, not recruiting | ||
| HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma[NCT03128047] | Phase 1 | 6 participants (Actual) | Interventional | 2017-04-06 | Active, not recruiting | ||
| HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)[NCT03606590] | Phase 2 | 25 participants (Actual) | Interventional | 2019-02-15 | Active, not recruiting | ||
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).[NCT02831959] | Phase 3 | 270 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure[NCT02973789] | Phase 3 | 276 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| EPIBRAINRAD : Study of Neurological Complication After Radiotherapy for Glioblastoma High Grade[NCT02544178] | 200 participants (Anticipated) | Observational | 2015-04-30 | Recruiting | |||
| Simultaneous Integrated Boost FDOPA PET Guided in Patients With Partially- or Non-operated Glioblastoma[NCT05653622] | Phase 2 | 75 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)[NCT05553041] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-08-07 | Recruiting | ||
| [NCT01702610] | 50 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235] | Phase 2 | 23 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas[NCT00033280] | Phase 2 | 42 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00002545] | Phase 3 | 200 participants (Anticipated) | Interventional | 1994-02-28 | Completed | ||
| Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma[NCT00187486] | Phase 2 | 66 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme[NCT00086879] | Phase 2 | 110 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| Spatial Analysis and Validation of Glioblastoma on 7 T MRI[NCT02062372] | 5 participants (Actual) | Interventional | 2014-12-10 | Terminated (stopped due to Expectation that within the set time period insufficient patients will be included, so endpoints will not be achieved) | |||
| Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma[NCT03232424] | Phase 1 | 12 participants (Actual) | Interventional | 2017-07-26 | Completed | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme[NCT00943462] | 0 participants (Actual) | Observational | 2009-06-30 | Withdrawn (stopped due to No eligible patients could be recruited.) | |||
| Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors[NCT02740933] | Phase 1 | 40 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma[NCT03291314] | Phase 2 | 52 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Retrospective Evaluation of Prognostic and/or Predictive Profile of Melanocortin Receptor-4 Gene Polymorphisms in Patient With a Diagnosis of Glioblastoma Treated With Upfront Concomitant Radio-chemotherapy or Chemotherapy[NCT02458508] | 65 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Effect of stRess and exeRcize on the Outcome After Chemo-Radiation[NCT05431348] | 40 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme[NCT01464177] | Phase 2 | 40 participants (Anticipated) | Interventional | 2011-10-31 | Active, not recruiting | ||
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer[NCT01679743] | Phase 2 | 0 participants (Actual) | Interventional | 2012-08-29 | Withdrawn | ||
| Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.[NCT00831545] | Phase 2 | 162 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| Phase I/II Study on Concomitant and Adjuvant Temozolomide and Radiotherapy With or Without PTK787/ZK222584 in Newly Diagnosed GBM[NCT00128700] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System[NCT00068666] | Phase 2 | 41 participants (Actual) | Interventional | 2004-01-31 | Terminated | ||
| A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter[NCT02928575] | Phase 2 | 45 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)[NCT04209790] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | ||
| The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma[NCT00392171] | Phase 2 | 120 participants (Actual) | Interventional | 2006-06-09 | Completed | ||
| A Phase II Study o the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody Radiolabeled With I-125 for High Grade Gliomas[NCT00589706] | Phase 2 | 11 participants (Actual) | Interventional | 1985-01-31 | Completed | ||
| A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer[NCT00076856] | Phase 2 | 95 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493] | Phase 2 | 32 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab[NCT04681677] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-02 | Recruiting | ||
| A Pilot Study of Patients With Recurrent Glioblastoma Treated With Maximal Safe Neurosurgical Resection, Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® Electronic Brachytherapy System[NCT04763031] | 1 participants (Actual) | Interventional | 2021-03-05 | Terminated (stopped due to No potential patients enrolled since first enrollment on 06/27/2022.) | |||
| A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme[NCT00544817] | Phase 2 | 47 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Phase I Study of In Situ Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Prior To Radical Prostatectomy[NCT03262103] | Phase 1 | 13 participants (Actual) | Interventional | 2017-06-16 | Completed | ||
| A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00262730] | Phase 2 | 97 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults[NCT04672291] | Phase 1 | 43 participants (Actual) | Interventional | 2021-07-21 | Completed | ||
| Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma[NCT04525859] | Phase 1 | 19 participants (Anticipated) | Interventional | 2020-08-19 | Recruiting | ||
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC): A Phase II Clinical Study[NCT01984892] | Phase 2 | 8 participants (Actual) | Interventional | 2013-11-30 | Terminated (stopped due to PI discretion, low enrollment) | ||
| Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma[NCT01165671] | 100 participants (Actual) | Interventional | 2010-07-31 | Completed | |||
| A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma[NCT00385853] | Phase 1 | 19 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma[NCT00553150] | Phase 1/Phase 2 | 122 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII[NCT00643097] | Phase 2 | 40 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas[NCT00822887] | Phase 1 | 13 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors[NCT02013297] | 61 participants (Actual) | Interventional | 2013-12-03 | Completed | |||
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Phase II, Multicenter, Study for Newly Diagnosed Glioblastomas Using Boron Neutron Capture Therapy, Additional X-ray Treatment and Chemotherapy[NCT00974987] | Phase 2 | 32 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas[NCT00369590] | Phase 2 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT00626483] | Phase 1 | 34 participants (Actual) | Interventional | 2007-04-24 | Completed | ||
| A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma[NCT00501891] | Phase 2 | 32 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas[NCT00751270] | Phase 1 | 15 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Valproic Acid for Children With Recurrent and Progressive Brain Tumors[NCT01861990] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to Feasibility of the trial was proven to be absent.) | ||
| A Multi-center, Prospective, Observational Study of Analysis of Q Cell Markers in Patients With Newly Diagnosed Primary Glioblastoma (Phase IV)[NCT02047058] | 240 participants (Anticipated) | Observational [Patient Registry] | 2014-03-31 | Not yet recruiting | |||
| Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial[NCT00238251] | Phase 2 | 59 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| IMRT Combined With Erlotinib Compared With Whole-brain Radiotherapy for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases[NCT02556593] | Phase 2 | 12 participants (Actual) | Interventional | 2015-09-30 | Terminated | ||
| A Phase I Study of Temozolomide and RAD001C in Patients With Malignant Glioblastoma Multiforme[NCT00387400] | Phase 1 | 32 participants (Actual) | Interventional | 2007-03-20 | Completed | ||
| Phase II Randomized Study: Whole Brain Radiotherapy and Concomitant Temozolomide, Compared With Whole Brain Radiotherapy for Brain Metastases Treatment[NCT01015534] | Phase 2 | 55 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas[NCT00516607] | Phase 1 | 28 participants (Actual) | Interventional | 2007-07-31 | Active, not recruiting | ||
| Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme[NCT05775458] | 50 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors[NCT04592354] | 40 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | |||
| A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme[NCT04450160] | Phase 2 | 80 participants (Anticipated) | Interventional | 2020-12-31 | Not yet recruiting | ||
| A Randomized Double Blind Placebo Controlled Trial to Determine the Effects of Oxaloacetate on Improving Fatigue in ME/CFS[NCT05273372] | 80 participants (Anticipated) | Interventional | 2022-03-15 | Enrolling by invitation | |||
| Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)[NCT02082119] | 82 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)[NCT00792012] | Phase 1 | 37 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00085254] | Phase 1/Phase 2 | 112 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-line of Treatment of Patients With Glioblastoma Multiforme[NCT00805961] | Phase 2 | 68 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients[NCT01819233] | 38 participants (Actual) | Interventional | 2013-03-08 | Completed | |||
| Can Fasting Decrease the Side Effects of Chemotherapy?[NCT04027478] | 39 participants (Anticipated) | Interventional | 2019-09-01 | Enrolling by invitation | |||
| A Phase II Study of Hypofractionated Stereotactic Radiotherapy Combined With Anlotinib in Patients With Recurrent High-Grade Glioma[NCT04197492] | Phase 2 | 32 participants (Anticipated) | Interventional | 2019-12-16 | Recruiting | ||
| A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma[NCT00498927] | Phase 2 | 47 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study[NCT01402063] | Phase 2 | 63 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Phase II Study of TEMOZOLOMIDE in Advanced Non-Small Cell Lung Cancer With and Without Brain Metastases[NCT00003062] | Phase 2 | 70 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
| First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial[NCT00003731] | Phase 2 | 39 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer[NCT06017284] | Phase 3 | 100 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma[NCT00005815] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-12-31 | Completed | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| Using Genomic Analysis to Guide Individual Treatment in Glioblastoma[NCT02725684] | 36 participants (Actual) | Observational | 2015-03-12 | Completed | |||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)[NCT00004259] | Phase 3 | 230 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| [NCT05491928] | 0 participants | Expanded Access | Available | ||||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)[NCT05163080] | Phase 2 | 265 participants (Anticipated) | Interventional | 2021-11-18 | Recruiting | ||
| Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)[NCT01349660] | Phase 1/Phase 2 | 88 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.[NCT05831631] | 200 participants (Anticipated) | Observational | 2022-08-01 | Recruiting | |||
| Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma[NCT02942264] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2016-12-14 | Completed | ||
| Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM[NCT04838782] | 250 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | |||
| Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.[NCT01345370] | 300 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope[NCT01006044] | Phase 2 | 26 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in Combination With N-Acetylcysteine Amid (NACA) and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma[NCT06169280] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | ||
| Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas[NCT01849952] | 200 participants (Anticipated) | Observational | 2020-02-28 | Recruiting | |||
| Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.[NCT01700569] | Phase 1 | 24 participants (Actual) | Interventional | 2013-01-31 | Terminated (stopped due to changing the standard of care) | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Prospective, Randomized Controlled Trial of Surgical Resection Prior to Bevacizumab Therapy for Recurrent Glioblastoma Multiforme[NCT01413438] | Phase 2 | 0 participants (Actual) | Interventional | 2011-07-15 | Withdrawn | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy[NCT01465347] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients[NCT04115761] | Phase 2 | 24 participants (Anticipated) | Interventional | 2019-06-06 | Recruiting | ||
| Re-irradiation of High Grade Gliomas: a Quality of Life Study[NCT01711580] | 0 participants (Actual) | Observational | 2013-03-31 | Withdrawn (stopped due to Another study was commenced for this patient group) | |||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide[NCT00004068] | Phase 2 | 53 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263] | Phase 1 | 46 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| A Phase II Study in Relapsing Glioblastoma of Intraarterial Concurrent Chemoradiation Therapy Using IA Carboplatin[NCT03672721] | Phase 1/Phase 2 | 35 participants (Anticipated) | Interventional | 2018-07-10 | Recruiting | ||
| Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme[NCT00006358] | Phase 2 | 44 participants (Actual) | Interventional | 2000-06-13 | Completed | ||
| Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent[NCT01956734] | Phase 1 | 31 participants (Anticipated) | Interventional | 2013-09-30 | Completed | ||
| Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma[NCT03536039] | Phase 2 | 28 participants (Actual) | Interventional | 2016-01-27 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)[NCT01735747] | Phase 2 | 16 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents[NCT03557359] | Phase 2 | 20 participants (Actual) | Interventional | 2018-06-12 | Active, not recruiting | ||
| A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas[NCT00027625] | Phase 1 | 0 participants | Interventional | 2002-01-28 | Completed | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| A Phase I/II Trial Of Temozolomide And Vinorelbine For Patients With Recurrent Brain Metastases[NCT00026494] | Phase 1/Phase 2 | 49 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma[NCT00006025] | Phase 1 | 0 participants | Interventional | 2001-01-05 | Completed | ||
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma[NCT00354068] | Phase 1 | 65 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting[NCT00047294] | Phase 2 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas[NCT00006024] | Phase 1 | 32 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071] | Phase 1 | 9 participants (Actual) | Interventional | 2009-09-22 | Completed | ||
| A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma[NCT00004113] | Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD was defined as the highest afatinib dose level, at which no more than 1 out of 6 patients experienced drug-related DLT, i.e. the highest afatinib dose with a DLT incidence ≤17%. A separate MTD was determined for afatinib and RT (Regimen U), and for afatinib, TMZ, and RT (Regimen M). (NCT00977431)
Timeframe: 6 weeks
| Intervention | Milligram (mg) (Number) |
|---|---|
| Total - Regimen M | 30 |
| Total - Regimen U | 40 |
"Adverse event (AE) related to afatinib with any one criteria; Hematological: Common terminology criteria for adverse events (CTCAE) Grade 4 neutropenia (Absolute neutrophil count, including bands <500/cubic millimeter (mm³)) for >7 days, CTCAE Grade 3 or 4 neutropenia of any duration associated with fever >38.3 Celsius, CTCAE Grade 3 thrombocytopenia (platelet count <50000 - 25000/mm³), All other toxicities of CTCAE Grade ≥3 leading interruption of treatment > 14 days.~Non-hematological: CTCAE Grade ≥3 nausea or vomiting despite appropriate use of standard anti-emetics for ≥3 days, CTCAE Grade ≥3 diarrhea despite appropriate use of standard anti-diarrheal therapy for ≥3 days, CTCAE Grade ≥3 rash despite standard medical management and lasting >7 days, CTCAE Grade ≥2 cardiac left ventricular function, CTCAE Grade ≥2 worsening of renal function as measured by serum creatinine, newly developed proteinuria or decrease in glomerular filtration rate, All other toxicities of CTCAE Grade ≥3. (NCT00977431)
Timeframe: 6 weeks
| Intervention | Participants (Number) |
|---|---|
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 1 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 0 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 2 |
| Afatinib 20 mg, Radiotherapy - Regimen U | 0 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 1 |
Concentration of afatinib in plasma at steady state pre-dose (Cpre,ss) on days 8, 15 and 29. (NCT00977431)
Timeframe: Pharmacokinetic blood sample were taken at 5 minutes before drug on days 8, 15 and 29 and 1, 3 and 6 hours after drug administration on day 15
| Intervention | nanograms per milliliter (ng/mL) (Geometric Mean) | ||
|---|---|---|---|
| Cpre, ss, 8 | Cpre, ss, 15 | Cpre, ss, 29 | |
| Afatinib 20 mg, Radiotherapy - Regimen U | 4.9 | 4.4 | 5.0 |
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 4.4 | 5.6 | 5.3 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 10.7 | 9.6 | 17.8 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 16.7 | 18.9 | 16.1 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 15.7 | 16.8 | 17.4 |
Incidence and intensity of adverse events (AE) according to Common Terminology Criteria of Adverse Events (CTCAE v.3.0). The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE). (NCT00977431)
Timeframe: From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Afatinib 20 mg, Radiotherapy - Regimen U | 0 | 1 | 2 | 0 | 0 |
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 0 | 0 | 4 | 3 | 0 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 0 | 2 | 4 | 0 | 0 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 1 | 2 | 5 | 2 | 3 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 1 | 1 | 4 | 1 | 0 |
Objective response was defined as a best overall response of complete response (CR) or partial response (PR). The best overall response was the best overall response to trial medication according to the Macdonald criteria recorded since the first administration of trial medication and until the earliest of disease progression, death, or start of further anti-cancer treatment. Tumour response was assessed based on local radiological image evaluation by the investigators according to the Macdonald criteria: Complete Response (CR): Disappearance of all enhancing tumour on consecutive Magnetic resonance imaging (MRI) scans at least 28 days apart, off steroids, and neurologically stable or improved. Partial Response (PR): At least 50% reduction in size of enhancing tumour on consecutive MRI scans at least 28 days apart, steroids stable or reduced, and neurologically stable or improved. (NCT00977431)
Timeframe: From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| No | Yes | Missing | |
| Afatinib 20 mg, Radiotherapy - Regimen U | 3 | 0 | 0 |
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 5 | 2 | 0 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 3 | 3 | 0 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 10 | 1 | 2 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 5 | 0 | 2 |
The duration of survival is the time interval between randomization and the date of death due to any cause. Patients not reported dead or lost to follow up will be censored at the date of the last follow up examination. (NCT00626990)
Timeframe: from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)
| Intervention | Months (Median) |
|---|---|
| Absence of Concomitant Temozolomide (TMZ) | 60.42 |
| Presence of Concomitant Temozolomide (TMZ) | 66.92 |
| Absence of Adjuvant Temozolomide (TMZ) | 46.92 |
| Presence of Adjuvant Temozolomide (TMZ) | 82.33 |
Disease progression is defined as radiological or neurological/clinical progression (whichever occurs first); progression free survival (PFS) is the time interval between the date of randomization and the date of disease progression or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination. Radiological progression was defined as increase of contrast enhancing area on MRI or CT scans of more than 25% as measured by two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique. The appearance of new lesions with or without contrast enhancement Neurological/clinical progression was defined as:decrease in WHO performance status,deterioration of neurological functions,appearance of signs/symptoms of increased intracranial pressure,and/or start of corticosteroid or increase of corticosteroid dosage by 50% for control of neurological symptoms. (NCT00626990)
Timeframe: from randomization till the date of disease progression or death (time till death is up to 10.9 years after patient enrollment in the study)
| Intervention | Months (Median) |
|---|---|
| Absence of Concomitant TMZ | 20.9 |
| Presence of Concomitant TMZ | 33.02 |
| Absence of Adjuvant TMZ | 19.09 |
| Presence of Adjuvant TMZ | 42.81 |
Overall Survival (OS) rate is defined as the percentage of participants surviving at 12 months (NCT02667587)
Timeframe: From randomization to 12 months after first dose
| Intervention | percentage of participants (Number) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 82.7 |
| Radiotherapy, Temozolomide Plus Placebo | 87.7 |
Overall Survival (OS) rate is defined as the percentage of participants surviving at 24 months (NCT02667587)
Timeframe: From randomization to 24 months after first dose
| Intervention | percentage of participants (Number) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 55.9 |
| Radiotherapy, Temozolomide Plus Placebo | 63.3 |
The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by investigator assessment based Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease. (NCT02667587)
Timeframe: From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 14.09 |
| Radiotherapy, Temozolomide Plus Placebo | 15.18 |
The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by a Blinded Independent Central Review (BICR) assessed based on Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease. (NCT02667587)
Timeframe: From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 10.64 |
| Radiotherapy, Temozolomide Plus Placebo | 10.32 |
The time from the date of randomization to the date of death. who have not died by the end of the study will be censored to last known date alive. OS is assessed in the randomized population with no corticosteroids at baseline population and in the overall randomized population. (NCT02667587)
Timeframe: From randomization to date of death (up to approximately 4.5 years)
| Intervention | Months (Median) | |
|---|---|---|
| All randomized participants | All randomized participants without baseline corticosteroids | |
| Radiotherapy, Temozolomide Plus Nivolumab | 28.91 | 31.34 |
| Radiotherapy, Temozolomide Plus Placebo | 32.07 | 32.99 |
Maximum tolerated dose of TMZ when used in combination with T-DM1. MTD is defined as the dose level at which 0 or 1 participant in 6 has a dose limiting toxicity (DLT). A DLT is defined as grade 3 or higher non-hematologic adverse events excluding grade 3 hypertension controlled with anti-hypertensive therapy; or grade 3 asymptomatic electrolytes imbalance; grade 3 endocrinopathy; grade 3 asymptomatic increase in aspartate aminotransferase or alanine aminotransferase; and transient (lasting less than <48 hours) nausea, emesis, or diarrhea if corrected with conservative measures within 24-48 hours. A hematologic grade 4 neutropenia of ≥ 7 days duration, grade ≥ 3 thrombocytopenia, and all other grade 4 hematologic toxicities excluding grade 4 lymphopenia, or leukopenia in the absence of grade 3 or higher neutropenia. Grade 3 is severe. Grade 4 is life-threatening. (NCT03190967)
Timeframe: first 21 days of treatment
| Intervention | mg/m^2 (Number) |
|---|---|
| All Participants | 40 |
Median amount of time participants survives after therapy. Survival compared between the two arms and Kaplan-Meier curves constructed with a two-tailed log-rank test used to compare the arms. (NCT03190967)
Timeframe: From date of first therapy until death, an average of 40.79 months
| Intervention | Months (Median) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 37.8 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 48.4 |
| Level 3 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 38.5 |
Number of participants with DLTs at each dose level 30 days after treatment. A DLT is defined as grade 3 or higher non-hematologic adverse events excluding grade 3 hypertension controlled with anti-hypertensive therapy; or grade 3 asymptomatic electrolytes imbalance; grade 3 endocrinopathy; grade 3 asymptomatic increase in aspartate aminotransferase or alanine aminotransferase; and transient (lasting less than <48 hours) nausea, emesis, or diarrhea if corrected with conservative measures within 24-48 hours. A hematologic grade 4 neutropenia of ≥ 7 days duration, grade ≥ 3 thrombocytopenia, and all other grade 4 hematologic toxicities excluding grade 4 lymphopenia, or leukopenia in the absence of grade 3 or higher neutropenia. Grade 3 is severe. Grade 4 is life-threatening. (NCT03190967)
Timeframe: After first cycle of treatment, up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 0 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 0 |
| Level 3 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 0 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT03190967)
Timeframe: Date treatment consent signed to date off study, approximately 44 months and 27 days for level 1, 28 months and 10 days for level 2, and 40 months and 8 days for level 3.
| Intervention | Participants (Count of Participants) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 3 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 3 |
| Level 3 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 6 |
TTP is the time between the first day of treatment to the day of disease progression. Progression was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 25% increase in the sum of products of all measurable lesions over smallest sum observed, clear worsening of any evaluable disease, appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition. (NCT03190967)
Timeframe: From first day of treatment to the day of disease progression, an average of 15 months.
| Intervention | Months (Mean) |
|---|---|
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 6.95 |
| Level 2 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 16.26 |
| Level 3 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 17.46 |
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is severe. Grade 4 is life-threatening. (NCT03190967)
Timeframe: Evaluated at the beginning of every cycle while on study, for an average of 9.6 months (range 2.8-33.9 months).
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 Anemia | Grade 3 Aspartate aminotransferase increased | Grade 3 CD4 lymphocytes decreased | Grade 3 Dysphasia | Grade 3 Hypokalemia | Grade 3 Lymphocyte count decreased | Grade 3 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Malignant Neoplasm-CML | Grade 3 Neutrophil count decreased | Grade 3 Platelet count decreased | Grade 3 Surgical and medical procedures - Other, Lap Cholecystectomy/Hernia Repair | Grade 3 White blood cell decreased | Grade 4 White blood cell decreased | Grade 4 CD4 lymphocytes decreased | Grade 4 Lymphocyte count decreased | Grade 5 | |
| Level 1 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 30 mg/m^2 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Level 2 Phase I: Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 40 mg/m^2 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Level 3 Phase I:Ado-trastuzumab (T-DMI) 3.6 mg/kg + Temozolomide (TMZ) 50 mg/m^2 | 0 | 1 | 5 | 0 | 1 | 5 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 0 |
Concordance is presented as the percentage of participants with concordance between assessments. EFS concordance was defined as event Structural assessment and Diffusion Perfusion assessment occurs within 28 days or no event Structural and no Diffusion Perfusion. (NCT01390948)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 96.6 |
| Chemoradiation + Bevacizumab + TMZ | 87.1 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non-HGG malignancy or death attributable to any cause. Tumor assessments were conducted using MRI and reviewed by the investigator using RANO criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the participant on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: From the time of randomization to the date of any defined event (up to 12 months)
| Intervention | months (Median) |
|---|---|
| Chemoradiation + TMZ | 11.79 |
| Chemoradiation + Bevacizumab + TMZ | 11.27 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non- HGG malignancy or death attributable to any cause. Tumor assessments were conducted using magnetic resonance imaging (MRI) and reviewed by the site-independent CRRC using Response Assessment in Neuro-Oncology (RANO) criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the subject on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: From the time of randomization to the date of any defined event (up to 12 months)
| Intervention | months (Median) |
|---|---|
| Chemoradiation + TMZ | 11.79 |
| Chemoradiation + Bevacizumab + TMZ | 8.21 |
The Wechsler Intelligence Scale for Children version IV (WISC-IV) was used to generate a full scale intelligence quotient (IQ) which represents a child's general intellectual ability. The average IQ score is 100, with lower scores representing lower intellectual ability. (NCT01390948)
Timeframe: End of treatment (approximately 58 weeks post-baseline)
| Intervention | units on a scale (Mean) |
|---|---|
| Chemoradiation + TMZ | 92.0 |
| Chemoradiation + Bevacizumab + TMZ | 97.0 |
Number of doses were assessed for the concurrent phase, which is the treatment period after the initial treatment phase and including the subsequent treatment break of approximately 4 weeks. (NCT01390948)
Timeframe: Beginning of the concurrent phase to end of treatment break (10 weeks)
| Intervention | Grays (Median) |
|---|---|
| Chemoradiation + TMZ | 54.0 |
| Chemoradiation + Bevacizumab + TMZ | 54.0 |
ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) determined on two consecutive occasions >/= 4 weeks apart. Tumor assessments were conducted using MRI and reviewed by the site-independent CRRC using RANO criteria. The following were needed to qualify as CR: complete disappearance of all measurable enhancing lesions sustained for at least 4 weeks by MRI, no steroids above physiological levels, clinical status stable or improved compared to baseline. The following were needed to qualify as PR: ≥ 50% decrease from baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks by MRI, steroid dose not increased compared to baseline, clinical status stable or improved compared to baseline. (NCT01390948)
Timeframe: From the time of randomization to the date of any defined event (up to 12 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 40 |
| Chemoradiation + Bevacizumab + TMZ | 41.7 |
Overall Survival was defined as the time of diagnosis to the date of death due to any cause. Overall Survival was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: From the time of randomization to the date of death (up to approximately 60 months)
| Intervention | months (Median) |
|---|---|
| Chemoradiation + TMZ | 20.27 |
| Chemoradiation + Bevacizumab + TMZ | 18.30 |
1-year survival was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: 1 year after end of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 67.69 |
| Chemoradiation + Bevacizumab + TMZ | 74.83 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT01390948)
Timeframe: From the time of randomization of the first participant to the date of clinical cutoff (approximately 60 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 100 |
| Chemoradiation + Bevacizumab + TMZ | 98.3 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non- HGG malignancy or death attributable to any cause. Tumor assessments were conducted using MRI and reviewed by the site-independent CRRC using RANO criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the subject on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 48.37 |
| Chemoradiation + Bevacizumab + TMZ | 38.28 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non- HGG malignancy or death attributable to any cause. Tumor assessments were conducted using MRI and reviewed by the site-independent CRRC using RANO criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the subject on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 66.46 |
| Chemoradiation + Bevacizumab + TMZ | 68.43 |
HUI is a preference-based, multi-attitude, health-related instrument specifically developed for use with children. HUI consists of eight attributes of health status: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain. Each attribute had 5 or 6 levels varying from highly impaired to normal. Each of the eight health dimensions was tested separately and a composite score ranging between 1 (perfect health) and 0 (death) was obtained for participants aged 5 years or older. (NCT01390948)
Timeframe: Baseline, Cycle 6 of the adjuvant phase, end of treatment (approximately 58 weeks post-baseline), and yearly during the follow-up period (maximum 5 years in follow-up)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Cycle 6, Day 1 | End of Treatment | Yearly Follow-Up 1 | Yearly Follow-up 2 | Additional Safety Follow-Up (Visit 2) | Additional Safety Follow-Up (Visit 4) | Additional Safety Follow-Up (Visit 6) | Additional Safety Follow-Up (Visit 8) | End of Study | |
| Chemoradiation + Bevacizumab + TMZ | 0.730 | 0.779 | 0.820 | 0.926 | 0.793 | 0.901 | 0.830 | 0.490 | 0.930 | 0.790 |
HUI is a preference-based, multi-attitude, health-related instrument specifically developed for use with children. HUI consists of eight attributes of health status: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain. Each attribute had 5 or 6 levels varying from highly impaired to normal. Each of the eight health dimensions was tested separately and a composite score ranging between 1 (perfect health) and 0 (death) was obtained for participants aged 5 years or older. (NCT01390948)
Timeframe: Baseline, Cycle 6 of the adjuvant phase, end of treatment (approximately 58 weeks post-baseline), and yearly during the follow-up period (maximum 5 years in follow-up)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Cycle 6, Day 1 | End of Treatment | Yearly Follow-Up 1 | Yearly Follow-up 2 | Additional Safety Follow-Up (Visit 2) | Additional Safety Follow-Up (Visit 4) | Additional Safety Follow-Up (Visit 6) | End of Study | |
| Chemoradiation + TMZ | 0.713 | 0.785 | 0.832 | 0.906 | 0.737 | 0.784 | 0.814 | 1.000 | 0.647 |
Number of doses were assessed for the concurrent phase, which is the treatment period after the initial treatment phase and including the subsequent treatment break of approximately 4 weeks. (NCT01390948)
Timeframe: Beginning of the concurrent phase to end of treatment break (10 weeks)
| Intervention | number of dose administrations (Median) | |
|---|---|---|
| TMZ | Bevacizumab | |
| Chemoradiation + Bevacizumab + TMZ | 42.0 | 6.0 |
| Chemoradiation + TMZ | 42.0 | NA |
(NCT01390948)
Timeframe: From the time of randomization of the first participant to the date of clinical cutoff (approximately 60 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Radiotherapy | TMZ | |
| Chemoradiation + Bevacizumab + TMZ | 98.3 | 88.3 |
| Chemoradiation + TMZ | 94.6 | 85.7 |
(NCT01390948)
Timeframe: From the time of randomization of the first participant to the date of clinical cutoff (approximately 60 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| AE leading to dose modification/interruption | AE leading to withdrawal from treatment | |
| Chemoradiation + Bevacizumab + TMZ | 71.7 | 21.7 |
| Chemoradiation + TMZ | 60.7 | 5.4 |
The objective response rate (ORR) included best overall responses - complete response (CR) and partial response (PR) - assessed by the independent review committee per response assessment in neurooncology criteria (RANO) criteria from the date of randomization until disease progression or death, whichever came first. All objective responses (CR and PR) must be have been confirmed by repeat MRI 4 weeks after the first time when CR or PR is identified. Any subject who did not meet CR or PR including those who did not have post-baseline radiological assessments was considered a nonresponder. (NCT02343406)
Timeframe: Every 8 weeks at each assessment of disease, up to 28 months
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414/Temozolomide | 14.3 |
| ABT-414_adult | 7.7 |
| Control (Temozolomide/Lomustine) | 4.4 |
AUC is a measure of how long and how much drug is present in the body after dosing. The AUC of depatuxizumab mafodotin (ABT-414) in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 3170 |
AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. The AUC of Cys-mcMMAF, a toxic metabolite of depatuxizumab mafodotin, in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 14.1 |
Half-life is the calculated time it takes for half of the drug to leave the body. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 9.0 |
Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body. CysmcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 11.2 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose. Cys-mcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 0.272 |
Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 31.4 |
The severity of each adverse event was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) (NCT02343406)
Timeframe: From participant's first visit until 49 days after the participant's last dose of study drug, up to 63 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414_ Pediatric | 100 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine). (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months.
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 4.6 | 7.9 | 15.5 |
| ABT-414/Temozolomide | 5.7 | 9.6 | 16.9 |
| Control (Temozolomide/Lomustine) | 4.9 | 8.2 | 12.6 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine) for all randomized participants that had the Epidermal Growth Factor Receptor (EGFRvIII) mutation. (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 5.0 | 8.4 | 13.9 |
| ABT-414/Temozolomide | 6.3 | 9.4 | 14.4 |
| Control (Temozolomide/Lomustine) | 4.7 | 7.5 | 12.4 |
Progression-free survival was assessed per response assessment in neuro-oncology criteria (RANO) criteria and assessed by an independent review committee and was defined as the length of time during and after the treatment of a disease, that the participant lived with the disease but did not get worse. (NCT02343406)
Timeframe: Measured every 8 weeks from date of randomization until the date of first objective progression or subject's death, whichever occurred first, up to 2 years
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 1.5 | 1.9 | 3.5 |
| ABT-414/Temozolomide | 1.8 | 2.7 | 4.9 |
| Control (Temozolomide/Lomustine) | 1.6 | 1.9 | 4.2 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | L/m^2 (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 75.4 |
| Phase I, Dose Level 2 (65 mg) | 56.1 |
| Phase I, Dose Level 3 (85 mg) | 63.9 |
| Phase II (MTD) | 73.1 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. Cmax measures the highest concentration of drug. (NCT01514201)
Timeframe: Day 1
| Intervention | μM (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 2.12 |
| Phase I, Dose Level 2 (65 mg) | 3.45 |
| Phase I, Dose Level 3 (85 mg) | 4.40 |
| Phase II (MTD) | 3.45 |
The traditional 3+3 dose finding algorithm was used to estimate the maximum-tolerated dose of veliparib given concurrently with radiation therapy. The dose-limiting toxicity observation period was the first 10 weeks of therapy. Dose-limiting toxicities included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with a few exceptions (see section 5.2.1.2 of the protocol document), any grade 2 non-hematologic toxicity that persisted for >7 days and considered medically significant that required treatment interruption; grade 3 or higher thrombocytopenia or grade 4 neutropenia; and any Veliparib related adverse event that led to a dose reduction or the permanent cessation of therapy. (NCT01514201)
Timeframe: 10 weeks
| Intervention | mg/m2/dose BID (Number) |
|---|---|
| Phase I Patients | 65 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | L/m^2/h (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 16.1 |
| Phase I, Dose Level 2 (65 mg) | 13.2 |
| Phase I, Dose Level 3 (85 mg) | 15.8 |
| Phase II (MTD) | 11.7 |
DLTs were defined as any of the following adverse events that were at least possibly attributable to Veliparib observed during the dose finding phase (the first 10 weeks of therapy). Hematologic dose limiting toxicities included grade 3 and higher thrombocytopenia or grade 4 neutropenia. Non-hematologic dose limiting toxicities included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., nausea and vomiting of <5 days; fever or infection of <5 days; hypophosphatemia, hypokalemia, hypocalcemia or hypomagnesemia responsive to oral supplementation; elevation of transaminases that return to levels meeting eligibility criteria within 7 days), or any grade non-hematologic toxicity that persisted for >7 days and considered medically significant or sufficiently intolerable by patients that required treatment interruption. (NCT01514201)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 1 |
| Phase I, Dose Level 2 (65 mg) | 0 |
| Phase I, Dose Level 3 (85 mg) | 3 |
Overall survival was defined as the interval from date on treatment to date of death from any cause or to date of last follow-up. Patients who had not failed (died) at the time of analyses were censored at their last date of contact. The method of Kaplan and Meier was used to estimate overall survival. The 3-year estimate with a 95% confidence interval is reported. (NCT01514201)
Timeframe: Time from initiation of therapy to the date of death from any cause or to the date patient was known to be alive for surviving patients, assessed to up to 3 years
| Intervention | Percent probability (Number) |
|---|---|
| Phase II Patients + Phase I MTD Patients | 5.3 |
Unacceptable toxicities during maintenance included events at least possibly attributable to Veliparib and temozolomide (TMZ) such as any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., grade 3 nausea/vomiting <5 days, grade 3 fever or infection <5 days), grade 3+ thrombocytopenia, grade 4 neutropenia, delay >14 days in starting subsequent cycle due to neutrophil <1,000/mm3 or platelet <100,000/mm3. Maintenance therapy was initiated with 25 mg/m2 Veliparib and 135 mg/m2 of TMZ, with the possibility to escalate TMZ to 175 mg/m2 and 200 mg/m2 in courses 2 and 3, respectively, if no unacceptable toxicities occurred following one course of treatment at each of the dose levels to be tested. Intra-patient dose escalation to a given dose (135, 175, or 200 mg/m2) was halted based on rules employed in 3+3 designs. This dose escalation was intended for all patients but was halted early, during the phase I portion, as it was not well tolerated. (NCT01514201)
Timeframe: 28 days per treatment cycle
| Intervention | % of participants (Number) |
|---|---|
| Dose Level 1 (135 mg/m2) | 9 |
| Dose Level 2 (175 mg/m2) | 40 |
| Dose Level 3 (200 mg/m2) | 67 |
Blood samples were collected from patients and assessed pre- and post-Veliparib to assess treatment-induced changes. A significant change in PBMC PARP level was arbitrarily defined as a >50% increase or decrease from the pre-treatment level, documented at week 6 and/or week 11 after starting protocol therapy. (NCT01514201)
Timeframe: Baseline and up to 11 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 100 |
| Phase I, Dose Level 2 (65 mg) | 100 |
| Phase I, Dose Level 3 (85 mg) | 75 |
| Phase II (MTD) | 36 |
For participants that showed possible tumor progression (pseudo progression) on magnetic resonance imaging (MRI) during the first 6 months of therapy, treating physicians had the option of allowing patients to remain on therapy and repeating the disease assessment in 4-6 weeks. If the repeat MRI at 4-6 weeks showed disease progression, the patient was noted to have true disease progression (and the progression date corresponded to that of the first MRI). If the repeat MRI at 4-6 weeks did not show disease progression, then the patient was noted to have pseudo progression. The percentage of patients observed to have experienced pseudo progression was provided with a 95% confidence interval. (NCT01514201)
Timeframe: Up to 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 33.3 |
| Phase I, Dose Level 2 (65 mg) | 16.7 |
| Phase I, Dose Level 3 (85 mg) | 0 |
| Phase II (MTD) | 12.8 |
PFS was defined as the interval from date of treatment initiation to date of first event (disease progression or relapse, second malignancy or death from any cause). Patients who had not failed at the time of analyses were censored at their last date of contact. The method of Kaplan and Meier was used to estimate PFS. A 3-year estimate with a 95% confidence interval is reported. (NCT01514201)
Timeframe: Time from initiation of treatment to the earliest date of failure (disease progression, death from any cause, or second malignancy), assessed up to 3 years
| Intervention | Percent probability (Number) |
|---|---|
| Phase II Patients + Phase I MTD Patients | 2.9 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | Hour (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 5.18 |
| Phase I, Dose Level 2 (65 mg) | 2.62 |
| Phase I, Dose Level 3 (85 mg) | 4.45 |
| Phase II (MTD) | 2.18 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | ng/mL (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 58 |
| Phase I, Dose Level 2 (65 mg) | 140 |
| Phase I, Dose Level 3 (85 mg) | 163 |
| Phase II (MTD) | 84 |
Urine samples were analyzed for a panel of biomarkers. Netrin-1 levels were determined by ELISA. Levels of matrix metalloproteinase 3 (MMP3) and basic fibroblast growth factor (bFGF) were analyzed using custom Luminex® screening assays. Tissue inhibitor of metalloproteinase 1 (TIMP1) levels were analyzed using a Luminex® performance assay. Protein concentrations are given in picograms per microgram (pg/μg), and were determined by dividing the concentration of the target protein in the sample (pg/mL) by the concentration of total protein in the sample (μg/mL) as a normalization measure. (NCT01514201)
Timeframe: Baseline to up to 3 years
| Intervention | pg/μg (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMP3 at pre-study | MMP3 at week 10-11 | MMP3 at week 18 | MMP3 at week 26 | Netrin-1 at pre-study | Netrin-1 at week 10-11 | Netrin-1 at week 18 | Netrin-1 at week 26 | TIMP1 at pre-study | TIMP1 at week 10-11 | TIMP1 at week 18 | TIMP1 at week 26 | bFGF at pre-study | bFGF at week 10-11 | bFGF at week 18 | bFGF at week 26 | |
| Phase I, Dose Level 1 (50 mg) | 2.0 | 1.4 | 4.3 | 2.9 | 0.1 | 0.1 | 0.3 | 0.4 | 3.4 | 6.2 | 10.7 | 7.3 | 3.1 | 3.6 | 10.3 | 7.7 |
| Phase I, Dose Level 2 (65 mg) | 1.0 | 1.0 | 1.7 | 0.4 | 0.1 | 0.1 | 0.1 | 0.2 | 9.9 | 11.9 | 7.7 | 5.2 | 1.9 | 2.1 | 3.5 | 0.9 |
| Phase I, Dose Level 3 (85 mg) | 0.0 | 0.8 | 0.7 | 1.0 | 0.1 | 0.1 | 0.0 | 0.0 | 10.8 | 12.3 | 14.8 | 32.8 | 1.2 | 1.8 | 1.3 | 1.1 |
| Phase II (MTD) | 1.1 | 2.6 | 2.3 | 3.0 | 0.1 | 0.0 | 0.1 | 0.0 | 7.3 | 7.5 | 7.1 | 10.7 | 4.5 | 3.5 | 4.4 | 4.5 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. Cmax measures the highest concentration of drug. (NCT01514201)
Timeframe: Up to day 4
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 1, Cmax (ng/mL) | Day 4, Cmax (ng/mL) | |
| Phase I, Dose Level 1 (50 mg) | 519 | 409 |
| Phase I, Dose Level 2 (65 mg) | 843 | 788 |
| Phase I, Dose Level 3 (85 mg) | 1074 | 954 |
| Phase II (MTD) | 844 | 717 |
Median OS depending on treatment arm in patients with methylated MGMT (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 20.7 |
| Without Treatment | 27.1 |
Median Progression Free Survival depending on treatment arm in patients with MGMT methylation (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 11.4 |
| Without Treatment | 8.5 |
Time between start of treatment and death (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 18.2 |
| Without Treatment | 23.3 |
It will be measured following Response assessment in neuro-oncology (RANO) guidelines: progression-free survival (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 9.5 |
| Without Treatment | 7.77 |
"Percentage of patients without progression of disease and time between start of treatment and progression of disease.~The progression disease is defined as the time from the date of randomization to the date of progression defined according to the RANO criteria." (NCT02209948)
Timeframe: 6 month
| Intervention | percentage of patients (Number) |
|---|---|
| Temozolomide | 61.3 |
| Without Treatment | 55.7 |
Total number of patients presenting adverse events, stratified by type of event and grade. Adverse Events of special interest: Only relevant differences in toxicity by arm. (NCT02209948)
Timeframe: Through the whole study. 4 years
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphopenia72025836 | Lymphopenia72025835 | Thrombocytopenia72025835 | Thrombocytopenia72025836 | Nausea and vomiting72025835 | Nausea and vomiting72025836 | Fatigue72025836 | Fatigue72025835 | Leucopenia72025835 | Leucopenia72025836 | |||||||||||||||||||||
| Grade 1-2 | Grade 3-4 | not affected | ||||||||||||||||||||||||||||
| Temozolomide | 52 | |||||||||||||||||||||||||||||
| Without Treatment | 33 | |||||||||||||||||||||||||||||
| Temozolomide | 3 | |||||||||||||||||||||||||||||
| Temozolomide | 25 | |||||||||||||||||||||||||||||
| Without Treatment | 46 | |||||||||||||||||||||||||||||
| Temozolomide | 36 | |||||||||||||||||||||||||||||
| Without Treatment | 17 | |||||||||||||||||||||||||||||
| Temozolomide | 2 | |||||||||||||||||||||||||||||
| Temozolomide | 42 | |||||||||||||||||||||||||||||
| Without Treatment | 62 | |||||||||||||||||||||||||||||
| Temozolomide | 30 | |||||||||||||||||||||||||||||
| Without Treatment | 10 | |||||||||||||||||||||||||||||
| Without Treatment | 0 | |||||||||||||||||||||||||||||
| Temozolomide | 50 | |||||||||||||||||||||||||||||
| Without Treatment | 69 | |||||||||||||||||||||||||||||
| Temozolomide | 35 | |||||||||||||||||||||||||||||
| Without Treatment | 21 | |||||||||||||||||||||||||||||
| Temozolomide | 0 | |||||||||||||||||||||||||||||
| Temozolomide | 45 | |||||||||||||||||||||||||||||
| Without Treatment | 58 | |||||||||||||||||||||||||||||
| Temozolomide | 29 | |||||||||||||||||||||||||||||
| Without Treatment | 20 | |||||||||||||||||||||||||||||
| Temozolomide | 1 | |||||||||||||||||||||||||||||
| Without Treatment | 59 | |||||||||||||||||||||||||||||
"ORR was measured by the percentage of participants whose best overall response (BOR) is confirmed Complete Response (CR) or Partial Response (PR) divided by response evaluable participants. The best overall response (BOR) is determined once all the data for the participant is known. BOR is defined as the best response designation, as determined by investigators, recorded between the date of randomization and the date of objectively documented progression per RANO criteria, the date of subsequent therapy, or date of surgical resection, whichever occurs first.~Confidence interval based on the Clopper and Pearson method. For the comparison of the odds ratio of Nivolumab over Bevacizumab, the Cochran-Mantel-Haenszel (CMH) method of weighting was utilized." (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to approximately 31 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 7.8 |
| Cohort 2: Arm B | 23.1 |
OS(12) is measured as the percentage of participants alive at 12 months per Kaplan-Meier curve of OS. Z test with variance estimation based on Greenwood formula using log(-log) transformation. (NCT02017717)
Timeframe: From randomization to 12 months following randomization
| Intervention | Percentage of Participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 41.8 |
| Cohort 2: Arm B | 42.4 |
"OS was measured in months from the time of randomization to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. P-value from log-rank test stratified by presence of measurable lesions at baseline per IVRS." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 9.77 |
| Cohort 2: Arm B | 10.05 |
"OS was measured in months from the time of randomization (Part B) or time of treatment (Part A) to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.08 |
| Part A Cohort 1d: Arm N3+RT | 14.41 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 15.95 |
| Part B Cohort 1d: Arm N3+RT | 13.96 |
PFS was measured in months from the time of randomization to the date of the first documented tumor progression or death due to any cause. Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 1.51 |
| Cohort 2: Arm B | 3.61 |
The percentage of participants who experienced an adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 10.0 | 70.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 20.0 | 30.0 | 40.0 | 10.0 | 0 |
| Cohort 1b: Arm N3+I1 | 5.0 | 25.0 | 50.0 | 20.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.5 | 12.9 | 58.1 | 22.6 | 0 |
| Part A Cohort 1d: Arm N3+RT | 13.3 | 26.7 | 33.3 | 20.0 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 | 28.6 | 50.0 | 10.7 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 17.9 | 25.0 | 35.7 | 21.4 | 0 |
The percentage of participants who experienced a drug-related adverse event leading to drug discontinuation by worst grade (grade 5 being the worst) prior to complete four-dose treatment. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 16.7 | 33.3 | 0 |
| Cohort 1: Arm N3 | 0 | 0 | 0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 0 | 0 | 0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 66.7 | 0 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1d: Arm N3+RT | 0 | 0 | 50.0 | 0 | 0 |
The percentage of participants who experienced a serious adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 60.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 0 | 10.0 | 40.0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 5.0 | 35.0 | 15.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.2 | 0 | 45.2 | 16.1 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 16.7 | 16.7 | 16.7 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 3.6 | 35.7 | 3.6 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 0 | 10.7 | 32.1 | 14.3 | 0 |
"The percentage of participants who experienced a laboratory abnormality of the liver in each treatment arm.~MedDRA Version: 24.1~Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Denominator corresponds to participants with at least on one treatment measurement of the corresponding laboratory parameter. Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ALT OR AST > 3*ULN | ALT OR AST > 5*ULN | ALT OR AST > 10*ULN | ALT OR AST > 20*ULN | TOTAL BILIRUBIN (Tbili) > 2*ULN | ALP > 1.5*ULN | ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 1.5*ULN within 30 days | ALT or AST > 3xULN w/ Tbili > 2*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 2*ULN within 30 days | |
| Cohort 1: Arm N1+I3 | 30.0 | 20.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| Cohort 1: Arm N3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 15.8 | 10.5 | 5.3 | 5.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.6 | 12.9 | 6.5 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1d: Arm N3+RT | 10.0 | 3.3 | 3.3 | 3.3 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 18.5 | 11.1 | 3.7 | 0.0 | 7.4 | 0.0 | 3.7 | 3.7 | 3.7 | 3.7 |
| Part B Cohort 1d: Arm N3+RT | 14.8 | 3.7 | 3.7 | 3.7 | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
"The percentage of participants who experienced a laboratory abnormality of the thyroid in each treatment arm.~MedDRA Version: 24.1~Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN)~(A) Within a 2-week window after the abnormal TSH test date. (B) Includes participants with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnormal value(s) from only one of the two tests and no value from the other test." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN | TSH > ULN, WITH TSH <= ULN AT BASELINE | TSH > ULN, WITH AT LEAST ONE FT3/FT4 TEST < LLN | TSH > ULN, WITH ALL OTHER FT3/FT4 TEST >= LLN | TSH > ULN, WITH FT3/FT4 TEST MISSING | TSH < LLN | TSH < LLN, WITH TSH >= LLN AT BASELINE | TSH | TSH < LLN, WITH ALL OTHER FT3/FT4 TEST <= ULN | TSH < LLN, WITH FT3/FT4 TEST MISSING | |
| Cohort 1: Arm N1+I3 | 20.0 | 20.0 | 20.0 | 0.0 | 0.0 | 60.0 | 60.0 | 30.0 | 20.0 | 10.0 |
| Cohort 1: Arm N3 | 50.0 | 30.0 | 30.0 | 10.0 | 10.0 | 30.0 | 30.0 | 10.0 | 20.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 10.5 | 10.5 | 10.5 | 0.0 | 0.0 | 31.6 | 31.6 | 15.8 | 10.5 | 5.3 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 23.3 | 20.0 | 13.3 | 6.7 | 3.3 | 43.3 | 33.3 | 10.0 | 30.0 | 3.3 |
| Part A Cohort 1d: Arm N3+RT | 16.7 | 16.7 | 13.3 | 0.0 | 3.3 | 40.0 | 40.0 | 13.3 | 16.7 | 10.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 | 11.1 | 7.4 | 3.7 | 0.0 | 22.2 | 18.5 | 11.1 | 11.1 | 0.0 |
| Part B Cohort 1d: Arm N3+RT | 7.4 | 7.4 | 0.0 | 7.4 | 0.0 | 33.3 | 18.5 | 0.0 | 29.6 | 3.7 |
Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 13.47 |
| Radiation | 7.69 |
Time from date of randomization to the date of death of any causes, or censored at last known alive date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 9.33 |
| Radiation | 7.62 |
Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 5.29 |
| Radiation | 3.94 |
To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. (NCT03119064)
Timeframe: Every two weeks for 4 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| All Participants | 50 |
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT03119064)
Timeframe: Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years.
| Intervention | participants (Number) | |
|---|---|---|
| Partial Response | Progressive Disease | |
| Dose 1 | 1 | 8 |
| Dose 2 | 1 | 2 |
Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4 (NCT03119064)
Timeframe: Baseline through 30 days post off study treatment
| Intervention | events (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | ALT/AST | Hypokalemia | Hypophosphatemia | Nausea | Fatigue | Diarrhea | Anorexia | Dehydration | Urticaria | |
| Dose 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 |
| Dose 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 0 |
"The proportion of Grade IV MGMT un-methylated patients that experience confirmed-progression-free survival at 6 months (CPFS6). Progression is defined by any of the following:~≥25% increase in the sum of products of perpendicular diameters of enhancing lesions compared to the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids~Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events~Any new lesion~Clear clinical deterioration not attributable to other causes apart from the tumor or changes in corticosteroid dose.~Failure to return for evaluation due to death or deteriorating condition~Clear progression of non-measurable disease" (NCT01991977)
Timeframe: Time from registration to the confirmed disease progression, assessed at 6 months
| Intervention | proportion of participants (Number) |
|---|---|
| Diagnostic (PET, pMRI, DTI, IMRT, Temozolomide) | 0.795 |
(NCT00588523)
Timeframe: up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 60 |
To determine the duration of disease control of newly diagnosed pure and mixed anaplastic oligodendrogliomas treated with dose-intensive chemotherapy requiring hematopoietic stem cell support. (NCT00588523)
Timeframe: 2 years
| Intervention | % of participants without progression (Number) |
|---|---|
| Participants With Newly Diagnosed Anaplastic Oligodendroglioma | 85.7 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom severity score is defined as average over 13 core symptom items and 9 brain tumor symptom items, with a total score of 0 to 10, with higher score indicating worse symptoms/interference. Changes in symptom severity score were classified into 3 categories: improved (≤ -1), stable (> -1 and < 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom severity score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 11.0 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 6.1 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom interference score is defined as an average of 6 interference items, with a total score of 0 to 10, where higher scores indicate worse interference. Changes in symptom interference score were classified into 3 categories: improved (≤ -1), stable (> -1 and < 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom interference score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 9.7 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 6.1 |
The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. When scoring the HVLT-R, the 3 learning trials are combined to calculate a total recall score (range -12 to 60). Deterioration is defined as satisfying the deterioration criteria (i.e., decrease in HVLT-R total recall score by 5 units) without further improvement within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 13.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 10.7 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 18.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 19.8 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | NA |
| Depatuxizumab Mafodotin, Radiation and TMZ | 25.4 |
"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.~Unmethylated MGMT promoter is associated with a worse prognosis in GBM" (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 16.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 16.1 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 18.7 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 18.9 |
PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria or to the date of death, if disease progression does not occur. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 5.9 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 8.3 |
PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria (see Wen et al. J Clin Oncol. 2010 Apr 10;28(11):1963-72) or to the date of death, if disease progression does not occur. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 6.3 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 8.0 |
KPS is an 11-level score (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100) which ranges between 0 (death) to 100 (complete healthy status); a higher score represents a higher ability to perform daily tasks. Deterioration in KPS was defined as decrease of 20 or more points in KPS score. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Bevacizumab + Irinotecan | -3.3399 |
| Temozolomide | -5.4909 |
Overall survival was defined as the time from randomization to death from any cause. OS was estimated using Kaplan-Meier method. (NCT00967330)
Timeframe: From baseline until death (up to 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Irinotecan | 16.64 |
| Temozolomide | 17.30 |
Progression-free survival was defined as the time from randomization to objective tumor progression or death from any cause, whichever came first. Progression was defined as 25 percent (%) increase in size of enhancing tumor or any new tumor on gadolinium contrast agent magnetic resonance imaging (Gd-MRI) scans, or neurologically worse, and steroids stable or increased. Percentage of participants achieving PFS without disease progression or death was reported. (NCT00967330)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + Irinotecan | 79.31 |
| Temozolomide | 42.59 |
Participants used corticosteroids for the glioblastoma condition. Corticosteroids included dexamethasone, methylprednisone, fortecortin, hydrocortisone, urbason, and prednisolone. (NCT00967330)
Timeframe: From baseline to Month 6
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + Irinotecan | 80.0 |
| Temozolomide | 78.7 |
Progression-free survival was defined as the time from randomization to objective tumor progression or death from any cause, whichever came first. Progression was defined as 25% increase in size of enhancing tumor or any new tumor on Gd-MRI scans, or neurologically worse, and steroids stable or increased. PFS was estimated using Kaplan-Meier method. (NCT00967330)
Timeframe: From baseline to the end of the study (up to 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Irinotecan | 9.74 |
| Temozolomide | 5.99 |
(NCT00967330)
Timeframe: From baseline until end of study (up to 4.5 years)
| Intervention | years (Median) |
|---|---|
| Bevacizumab + Irinotecan | NA |
| Temozolomide | NA |
EORTC QLQ-BN20 consisted of 20 items assessing visual disorders, motor dysfunction, communication deficit, various disease symptoms (e.g. headaches and seizures), treatment toxicities (e.g. hair loss) and future uncertainty. All of the 20 items are rated on a 4 point Likert scale from 1=not at all, 2=a little, 3=quite a bit and 4=very much, and were linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Future uncertainty | Visual disorder | Motor dysfunction | Communication deficit | Headaches | Drowsines | Hair loss | Itchy skin | Weakness of legs | Bladder control | |
| Bevacizumab + Irinotecan | -5.2779 | -2.0869 | 5.4416 | 4.7440 | 4.3905 | 11.7204 | 11.9235 | 5.4882 | 8.9586 | 1.5020 |
| Temozolomide | -8.5478 | -3.202 | 6.5429 | 4.6431 | -3.9389 | 8.2805 | 7.3328 | 6.4690 | 7.9245 | 1.9710 |
The MMSE briefly measures orientation to time and place, immediate recall, short-term verbal memory, calculation, language and construct ability. Each area tested had a designated point value, the total score can range from 0 to 30, with a higher score indicating better function. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Orientation to time and place | Immediate recall | Repetitions required | Calculations | Short-term verbal memory | Language and construct ability | Total Score | |
| Bevacizumab + Irinotecan | -0.01771 | -0.00264 | -0.05763 | -0.2153 | 0.2012 | -0.1254 | -0.2871 |
| Temozolomide | -0.2110 | -0.03219 | 0.08530 | -0.2120 | 0.1634 | -0.2057 | -0.5999 |
The EORTC QLQ-C30 incorporates: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score for Global Qol/functional scales=better level of functioning or a higher score for symptom scale=greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Role Functioning | Emotional Functioning | Cognitive Functioning | Social Functioning | Global health Status /QoL (ql) | Fatique | Nausea/Vomitting | Pain | Dyspnoea | Insomnia | Appetite loss | Constipation | Diarrhoea | Financial Problems | |
| Bevacizumab + Irinotecan | -8.3513 | -0.7635 | 2.2774 | -2.0188 | -6.2324 | -3.1134 | 5.5228 | 8.9557 | 10.6876 | 3.7134 | -2.6266 | 13.7423 | 8.0230 | 6.0230 | 4.8435 |
| Temozolomide | -6.2511 | -2.2339 | 2.2547 | -3.8401 | -4.6198 | 0.3855 | 2.1779 | 4.7597 | 1.5926 | 0.5046 | -7.5026 | 10.9601 | 4.0855 | -0.1455 | 2.1140 |
BOR was defined as the best response observed for a participant during assessment. Number of participants who had BOR as CR and number of participants who had BOR as CR or PR were reported. Complete response was defined as disappearance of all enhancing tumor on consecutive Gd-MRI scans at least 1 month apart, off steroids, and neurologically stable or improved. Partial response was defined as 50% reduction in size of enhancing tumor on consecutive Gd-MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. (NCT00967330)
Timeframe: 4 week after radiotherapy (RT) (up to Week 4), >4 Week after RT (up to Week 8) and Month 6
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| CR at 4 weeks after RT (n=110,46) | CR at >4 weeks after RT (n=95,35) | CR at Month 6 (n=91,28) | CR or PR at 4 Week after RT (n=110,46) | CR or PR at >4 Week after RT (n=95,35) | CR or PR at Month 6 (n=91,28) | |
| Bevacizumab + Irinotecan | 11 | 11 | 3 | 42 | 18 | 5 |
| Temozolomide | 2 | 1 | 1 | 6 | 3 | 3 |
Discontinuation was defined as the percentage of participants who permanently discontinued treatment in either treatment arm. Percentage of participant with individual discontinuation reason are reported. CNS: central nervous system; CTCAE: Common Terminology Criteria for Adverse Events . Other reason refers to any other reason than the specified ones. (NCT00967330)
Timeframe: From baseline until death (up to 4.5 years)
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Persisting non-hematological toxicity CTCAE Grade3 | CNS hemorrhagic event (CTCAE Grade >1) | Gastro-intestinal perforation (CTCAE Grade 1-4) | Other | Participant's wish | Progressive disease | Proteinuria (nephrotic syndrome) (CTCAE Grade 4) | Regular | Repeated CTCAE Grade 4 hematological toxicity | Venous thrombosis/embolism | Wound dehiscence requiring medical intervention | Wound dehiscence requiring surgical intervention | |
| Bevacizumab + Irinotecan | 0 | 0.9 | 0.9 | 9.5 | 6 | 74.1 | 0.9 | 1.7 | 0 | 0.9 | 0.9 | 4.3 |
| Temozolomide | 1.9 | 0 | 0 | 5.6 | 5.6 | 57.4 | 0 | 27.8 | 0.9 | 0 | 0 | 0 |
"FLAIR lesions were determined as stable, progressive or decreased. FLAIR lesions was determined as progressive only if they were not be attributed to causes apart from tumor infiltration (sequelae of radiation therapy, demyelination, ischemia, infection, seizures, or other treatment effects). Percentage of participants are based on ITT population.~Dis.=Discontinuation." (NCT00967330)
Timeframe: At screening, Baseline, Month 6 and Therapy Discontinuation (Up to 4.5 years)
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening: Initial Flair Lesion (n=116,54) | Screening:Stable Flair Lesion (n=116,54) | Baseline:Decreased FLAIR Lesions (n=105,46) | Baseline:Initial FLAIR Lesions (n=105,46) | Baseline:Progressive FLAIR Lesions (n=105,46) | Baseline: Stable FLAIR Lesions (n=105,46) | Month 6:Progressive FLAIR Lesions (n=91,28) | Month 6: Stable FLAIR Lesions (n=91,28) | Therapy Dis.:Decreased FLAIR Lesions (n=55,31) | Therapy Dis.:Progressiv FLAIR Lesions (n=55,31) | Therapy Dis.:Stable FLAIR Lesions (n=55,31) | |
| Bevacizumab + Irinotecan | 72.4 | 17.2 | 16.4 | 18.1 | 14.7 | 41.4 | 16.4 | 62.1 | 0.9 | 29.3 | 17.2 |
| Temozolomide | 72.2 | 16.7 | 20.4 | 18.5 | 11.1 | 35.2 | 22.2 | 29.6 | 0.0 | 27.8 | 29.6 |
DLT is defined as any of the following events occurring during the first 8 weeks of treatment with RAD001 and temozolomide and attributable to the study drugs: any grade 3 or 4 thrombocytopenia, grade 4 anemia, or grade 4 neutropenia lasting more than 7 days; any non-hematologic grade 3 or greater adverse event (AE), excluding alopecia, despite maximal medical therapy; any grade 4 radiation-induced skin changes; failure to recover from adverse events to be eligible for re-treatment with RAD001 and temozolomide within 14 days of the last dose of either drug; or any episode of non-infectious pneumonitis grade 2, 3, or 4 of any duration. Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE (NCT01062399)
Timeframe: From start of treatment to eight weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ph I: RT + TMZ + RAD001 2.5 mg/Day | 2 |
| Ph I: RT + TMZ + RAD001 5 mg/Day | 2 |
| Ph I: RT + TMZ + RAD001 10 mg/Day | 2 |
Overall survival time is defined as time from/randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | months (Median) |
|---|---|
| Ph II: RT + TMZ | 21.2 |
| Ph II: RT + TMZ + RAD001 | 16.5 |
Using the Response Assessment in Neuro- Oncology (RANO) criteria, the progression is defined by any of the following: > 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared to the smallest tumor measurement obtained either at baseline (if no decrease) or best response, on stable or increasing doses of corticosteroids; Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events; Any new lesion; Clear clinical deterioration not attributable to other causes apart from the tumor or changes in corticosteroid dose; Failure to return for evaluation due to death or deteriorating condition; Clear progression of non-measurable disease. PFS time is defined as time from registration to date of progression, death, or last known follow-up (censored). PFS rates are estimated using the Kaplan-Meier method. (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | months (Median) |
|---|---|
| Ph II: RT + TMZ | 10.2 |
| Ph II: RT + TMZ + RAD001 | 8.2 |
"AE reporting in Phase I was split up by treatment timing: concurrent treatment (RT, TMZ, RAD001); post-RT treatment (TMZ, RAD001) along with all AE's reported in follow-up.~The worst/highest grade of any adverse event reported in each time period was determined for each patient. The percentage of patients in each grade level is reported. Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE." (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Concurrent treatment: Grade 1 | Concurrent treatment: Grade 2 | Concurrent treatment: Grade 3 | Concurrent treatment: Grade 4 | Concurrent treatment: Grade 5 | Post-RT treatment: Grade 1 | Post-RT treatment: Grade 2 | Post-RT treatment: Grade 3 | Post-RT treatment: Grade 4 | Post-RT treatment: Grade 5 | |
| Ph I: RT + TMZ + RAD001 10 mg/Day | 12.5 | 0.0 | 87.5 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| Ph I: RT + TMZ + RAD001 2.5 mg/Day | 0.0 | 0.0 | 50.0 | 50.0 | 0.0 | 0.0 | 0.0 | 71.4 | 14.3 | 14.3 |
| Ph I: RT + TMZ + RAD001 5 mg/Day | 11.1 | 33.3 | 44.4 | 11.1 | 0.0 | 0.0 | 42.9 | 28.6 | 0.0 | 0.0 |
The worst/highest grade of any adverse event reported was determined for each patient. The percentage of patients in each grade level is reported. Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Ph II: RT + TMZ | 0 | 0 | 3 | 3 | 2 |
| Ph II: RT + TMZ + RAD001 | 0 | 3 | 5 | 0 | 1 |
Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 3 years. (NCT00114140)
Timeframe: Registration to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Temozolomide + Radiation Therapy (RT) | 73.1 |
"Progressive Disease (PD) is defined as 25% or > increase in the cross-sectional area of enhancing or non-enhancing tumor on consecutive MRI scans, or any new area(s) of tumor. Under exceptional circumstances, disease progression may be declared in the absence of an increase in tumor size based on clinical deterioration including the need for increasing doses of steroid and/or a worsening Karnofsky Performance Status(KPS) / Neurologic Function Score(NFS). Progression-free survival time is defined as time from registration to date of progressive disease or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Median survival time is reported." (NCT00114140)
Timeframe: From registration to last follow-up, up to 7.1 years. Analysis occurs after all patients have been on study for at least 3 years.
| Intervention | years (Median) |
|---|---|
| Temozolomide + Radiation Therapy (RT) | 4.5 |
"Hopkins Verbal Learning Test (HVLT) is a test measuring learning memory retrieval, and memory consolidation processes.; Controlled Oral Word Association Test (COWAT) is a test of phonemic verbal fluency. The patient produces as many words as possible in 1 min. (each) for a specific letter (C, F, L or P, R, W).; Trail Making Test (TMT) is a measure of visuospatial scanning, attention, sequencing, and speed in Part A (TMT A) and executive function in Part B (TMT B). Patients must connect the dots either in a numbered sequence or alternating letters and numbers. Difference between pre-treatment baseline and follow-up assessment scores determined by the reliable change (RC) index, using a 90% confidence interval to designate statistically significant change." (NCT00114140)
Timeframe: Baseline, 6 months, and 12 months.
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HVLT Recall Status: Deterioration | HVLT Recall Status: No change | HVLT Recall Status: Improvement | COWA Status: Deterioration | COWA Status: No change | COWA Status: Improvement | TMT A Status: Deterioration | TMT A Status: No change | TMT A Status: Improvement | TMT B Status: Deterioration | TMT B Status: No change | TMT B Status: Improvement | |
| Temozolomide + Radiation Therapy (RT) at 12 Months | 8 | 22 | 15 | 3 | 28 | 12 | 7 | 24 | 14 | 7 | 22 | 15 |
| Temozolomide + Radiation Therapy (RT) at 6 Months | 11 | 26 | 13 | 1 | 42 | 6 | 15 | 24 | 11 | 11 | 27 | 11 |
Functional Assessment of Cancer Therapy Scale with brain module (FACT-BR): a 50-question self-report questionnaire contains the following domains (scales): Physical well-being (7 questions totalling 0-28), social/family well-being (7 questions totalling 0-28), emotional well-being (6 questions totalling 0-24), functional well-being (7 questions totalling 0-28) and brain cancer subscale which contains concerns relevant to patients with brain tumors (19 questions totalling 0-76). Each question has a value 0-4. For some questions a higher indicates better outcome and others are the opposite. The former are summed as is, the latter are reversed in value before adding, such that each domain ranges from 0 to 4 multiplied by the number of questions in the domain, with 0 indicating worst and the highest possible value indicating best outcome. The FACT-Br total (0-184) is obtained by adding all domains together if the overall question response rate is greater than 80%. (NCT00114140)
Timeframe: Baseline, 6 months, and 12 months.
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Physical Well-Being | Social/Family Well-Being | Emotional Well-Being | Functional Well-Being | Brain Cancer Subscale | FACT-Br Total | |
| Temozolomide + Radiation Therapy (RT) at 12 Months | 23 | 24.3 | 23.0 | 19.5 | 59.0 | 140.0 |
| Temozolomide + Radiation Therapy (RT) at 6 Months | 22 | 24.0 | 20.0 | 18.0 | 52.0 | 129.9 |
| Temozolomide + Radiation Therapy (RT) at Baseline | 23 | 24.5 | 18.5 | 17.0 | 54.0 | 135.3 |
"Survival time is defined as time from registration to date of death from any cause. Progressive Disease (PD) is defined as 25% or > increase in the cross-sectional area of enhancing or non-enhancing tumor on consecutive MRI scans, or any new area(s) of tumor. Under exceptional circumstances, disease progression may be declared in the absence of an increase in tumor size based on clinical deterioration including the need for increasing doses of steroid and/or a worsening Karnofsky Performance Status(KPS) / Neurologic Function Score(NFS). Survival and progression-free survival are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact." (NCT00114140)
Timeframe: Registration to 3 years
| Intervention | years (Median) | |
|---|---|---|
| Overall Survival | Progression-free Survival | |
| Temozolomide + Radiation Therapy (RT) - Methylated | NA | NA |
| Temozolomide + Radiation Therapy (RT) - Unmethylated | 3.0 | 2.0 |
Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 7.1 |
Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 1.7 |
Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| DSF-Cu | 2 |
Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| DSF-Cu | 14 |
ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete response | Partial Response | |
| DSF-Cu | 0 | 0 |
Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| DSF-Cu | 61 | 35 |
Median overall survival (NCT03072134)
Timeframe: Two years
| Intervention | Months (Median) |
|---|---|
| Total Cohort | 18.4 |
Using a 3+3 dose escalation design, three to six patients were to be enrolled per dose in each of the 3 cohorts. If no patients in the cohort experienced a dose-limiting toxicity (DLT), then the next cohort enrolled a minimum of 3 patients. If one of three patients experienced a DLT, then 3 more patients were evaluated at that dose level. If none of these three additional patients experienced a DLT, then dose escalation occurs, unless this is the highest dose, in which case dose escalation is stopped and the highest dose is declared the MTD. If 1 or more of these additional 3 patients had a DLT, then three additional patients may be entered, after discussion with the sponsor, at the next lowest does level if only three patients were treated previously at that dose. If two or more patients experienced a DLT Dose escalation will be stopped; 3 more patients could be added with sponsor approval at the next lower dose level. (NCT03072134)
Timeframe: Two years
| Intervention | Percentage of dose-limiting toxicities (Number) |
|---|---|
| Arm B/Cohort 1 | 0 |
| Arm B/Cohort 2 | 0 |
| ArmB/Cohort 3 | 17 |
Median progression-free survival (NCT03072134)
Timeframe: two years
| Intervention | Months (Median) |
|---|---|
| Total Cohort | 9.1 |
Per Response Assessment in Neuro-Oncology Criteria (RANO, 2017) for target lesions as assessed by MRI: Complete Response (CR): The enhancing tumor is no longer seen by neuroimaging; Partial Response (PR): Decrease of ≥ 50% in the product of two diameters with the patient on a stable or decreasing dose of steroids; Minor Response (MR): Decrease in diameter products of < 50% with the patient on a stable or decreasing dose of steroids; Stable Disease (SD): The scan shows no change. Patients should be receiving stable or decreasing doses of steroids; Progression (P): Increase of > 25% in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. A concomitant decrease in steroid dose will rule out a progression designation during the first two months after completion of radiation; Pseudoprogression (PP): Radiological changes without concomitant neurological changes. (NCT03072134)
Timeframe: Two years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Percentage of participants with tumor response: Partial | Percentage of participants with tumor response: Pseudoprogression | Percentage of participants with tumor response: Stable disease | |
| Total Cohort | 8 | 8 | 84 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30 subscales are calculated as the mean of component items, then standardized such that subscale scores range from 0 to 100. A high score for a functional scale represents a healthy level of functioning. Controlled Oral Word Association (COWA) score is the sum of correct responses with a range of 0 to infinity. A higher score indicates better functioning. Hopkins Verbal Learning Test - Revised (HVLT-R) score ranges from 0 to 36 for total recall is 0 to 36, 0 to 12 for delayed recall, and -12 to 12 for recognition. A higher score indicates better functioning. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Both Arms Combined | 17.5 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline." (NCT00304031)
Timeframe: Baseline and mid-cycle 1 (approximately 12 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -4.58 |
| Dose-dense Adjuvant TMZ | -2.63 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline." (NCT00304031)
Timeframe: Baseline and mid-cycle 4 (approximately 24 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -2.78 |
| Dose-dense Adjuvant TMZ | -0.72 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. (NCT00304031)
Timeframe: Baseline and mid-cycle 1 (approximately 12 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 0.48 |
| Dose-dense Adjuvant TMZ | 0.39 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. (NCT00304031)
Timeframe: Baseline and mid-cycle 4 (approximately 24 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -0.23 |
| Dose-dense Adjuvant TMZ | 0.19 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best)." (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 73.3 |
| Dose-dense Adjuvant TMZ | 69.7 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 1.17 |
| Dose-dense Adjuvant TMZ | 1.18 |
The NCF Composite score is the arithmetic mean of the Hopkins Verbal Learning Test - Revised (HVLT-R) (Free Recall, Delayed Recall, Delayed Recognition), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB), and Controlled Oral Word Association (COWA) test scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function. (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -0.95 |
| Dose-dense Adjuvant TMZ | -1.19 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Conventional Adjuvant TMZ | 16.6 |
| Dose-dense Adjuvant TMZ | 14.9 |
Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Conventional Adjuvant TMZ | 5.5 |
| Dose-dense Adjuvant TMZ | 6.7 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (did not interfere) to 10 (interfered completely). The symptom interference score is the average of the symptom interference items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. (NCT00304031)
Timeframe: baseline and cycle 4 (approximately 22 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Conventional Adjuvant TMZ | 7 |
| Dose-dense Adjuvant TMZ | 13 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. (NCT00304031)
Timeframe: baseline and cycle 4 (approximately 22 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Conventional Adjuvant TMZ | 5 |
| Dose-dense Adjuvant TMZ | 11 |
Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| No Progression at 6 Months | 20.7 |
| Progression at 6 Months | 10.1 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline was calculated as time point value - baseline value with a positive change value indicating improved QOL from baseline." (NCT00304031)
Timeframe: Baseline, 10,12, 22, 24, and 46 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 10 (Cycle 1) | Week 12 (Cycle 1.5) | Week 22 (Cycle 4) | Week 24 (Cycle 4.5) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | 0.0 | -4.6 | 3.9 | -2.8 | 5.4 |
| Dose-dense Adjuvant TMZ | -2.9 | -2.7 | -4.4 | -0.7 | -1.9 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. (NCT00304031)
Timeframe: Baseline, 10, 12, 22, 24, and 46 weeks
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 10 (Cycle 1) | Week 12 (Cycle 1.5) | Week 22 (Cycle 4) | Week 24 (Cycle 4.5) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | 1.3 | 1.4 | 1.6 | 1.0 | 1.0 | 1.2 |
| Dose-dense Adjuvant TMZ | 1.1 | 1.4 | 1.5 | 1.2 | 1.1 | 1.1 |
The NCF Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function. (NCT00304031)
Timeframe: Baseline, 10, 22, and 46 weeks
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | Week 10 (Cycle 1) | Week 22 (Cycle 4) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | -1.2 | -1.3 | -1.1 | -1.0 |
| Dose-dense Adjuvant TMZ | -1.5 | -1.45 | -1.3 | -1.2 |
Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) | |
|---|---|---|
| Unmethylated MGMT | Methylated MGMT | |
| Conventional Adjuvant TMZ | 14.6 | 21.4 |
| Dose-dense Adjuvant TMZ | 13.3 | 20.2 |
Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) | |
|---|---|---|
| Unmethylated MGMT | Methylated MGMT | |
| Conventional Adjuvant TMZ | 5.1 | 6.5 |
| Dose-dense Adjuvant TMZ | 6.0 | 10.1 |
mPFS was based on model parameters estimated by maximum likelihood with a Newton-Raphson algorithm. The Radiation Therapy Oncology Group (RTOG) 0525 study was the main historical control used for statistical analysis. Additionally, RTOG-0825 was also used to support this outcome measure. (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
| Intervention | months (Median) |
|---|---|
| RP2D | 7.7 |
| RP2D-0525 (Cycle 1, Day 1) | 7.6 |
| RP2D-0825 | 7.0 |
| RP2D-0525 (Rest Period, Day 15) | 6.1 |
Overall Survival was calculated using a parametric model. The Radiation Therapy Oncology Group (RTOG) 0525 study was the main historical control used for statistical analysis. Additionally, RTOG-0825 was also used to support this outcome measure (NCT01790503)
Timeframe: Assessed from date of first dose administered to the date of death from any cause, assessed up to 4 years 4 months.
| Intervention | months (Median) |
|---|---|
| RP2D | 18.8 |
| RP2D-0525 (Cycle 1, Day 1) | 20.2 |
| RP2D-0825 | 17.0 |
| RP2D-0525 (Rest Period, Day 15) | 16.9 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | Neutropenia | Anaemia | Lymphopenia | AST increased | Platelet count decreased | Neutrophil count decreased | Leukopenia | Febrile neutropenia | ALT increased | Bone marrow failure | Haemolysis | White blood cell decreased | Lymphocyte count decreased | |
| Phase 1b Dose Escalation - 600 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/1000 mg | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/600 mg | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/800 mg | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg (5 Days) | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Phase 1b Dose Escalation - 800 mg/1000 mg | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/600 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/800 mg | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escation - 800 mg (No Adjuvant Therapy) | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | ALT increased | AST increased | Platelet count decreased | Lymphopenia | White blood cell count decreased | Neutrophil count decreased | Leukopenia | Febrile neutropenia | Lymphocyte count decreased | Blood alkaline phosphatase increased | Blood creatinine increased | DRESS | Liver function test abnormal | Bone marrow failure | Haemolysis | Blood bilirubin increased | Blood iron decreased | |
| Combined 800 mg, 5 Days/Week | 9 | 6 | 7 | 8 | 8 | 7 | 4 | 5 | 2 | 2 | 2 | 3 | 3 | 3 | 1 | 1 | 0 | 1 | 1 | 1 |
| Phase 2 - 800 mg | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Phase 2 - 800 mg/800 mg | 6 | 3 | 5 | 2 | 2 | 4 | 2 | 4 | 2 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Phase 2 Total | 7 | 4 | 6 | 7 | 6 | 5 | 3 | 5 | 2 | 2 | 1 | 2 | 3 | 3 | 1 | 1 | 0 | 0 | 1 | 1 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General Disorders and Administrative Site | Nervous System Disorders | Skin and Subcutaneous Tissue Disorders | Gastrointestinal Disorders | Metabolism and Nutrition Disorders | Psychiatric Disorders | Infections and Infestations | Investigations | Respiratory, Thoracic, and Mediastinal Disorders | Musculoskeletal and Connective Tissue Disorders | Blood and Lymphatic Tissue Disorders | Vascular Disorders | Renal and Urinary Disorders | Eye Disorders | Injury, Poisoning, and Procedural Complications | Ear and Labyrinth | Endocrine Disorders | Cardiac Disorders | Hepatobiliary Disorders | Reproductive System and Breast Disorders | Immune System Disorders | Neoplasms Benign, Malignant, and Unspecified | |
| Phase 1b Dose Escalation - 600 mg | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/1000 mg | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/600 mg | 2 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/800 mg | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg | 5 | 4 | 4 | 3 | 2 | 1 | 1 | 2 | 3 | 3 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/1000 mg | 5 | 5 | 5 | 5 | 4 | 3 | 5 | 4 | 3 | 2 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/600 mg | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/800 mg | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escation - 800 mg | 3 | 2 | 1 | 2 | 2 | 1 | 3 | 3 | 2 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General Disorders and Administration Site | Skin and Subcutaneous Tissue Disorders | Nervous System Disorders | Gastrointestinal Disorders | Metabolism and Nutrition Disorders | Psychiatric Disorders | Investigations | Musculoskeletal and Connective Tissue Disorders | Blood and Lymphatic System Disorders | Injury, Poisoning, and Procedural Complications | Eye Disorders | Vascular Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Renal and Urinary Disorders | Cardiac Disorders | Endocrine Disorders | Ear and Labyrinth Disorders | Reproductive System and Breast Disorders | Neoplasms Benign, Malignant, and Unspecified | Hepatobiliary Disorders | Immune System Disorders | |
| Combined 800 mg, 5 Days/Week | 47 | 45 | 43 | 41 | 30 | 27 | 27 | 25 | 18 | 18 | 16 | 18 | 16 | 13 | 8 | 7 | 5 | 3 | 2 | 1 | 1 |
| Phase 2 - 800 mg | 13 | 12 | 12 | 12 | 8 | 6 | 9 | 7 | 2 | 6 | 6 | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 0 |
| Phase 2 - 800 mg/800 mg | 24 | 24 | 22 | 21 | 16 | 17 | 12 | 13 | 14 | 10 | 7 | 9 | 7 | 7 | 5 | 5 | 3 | 2 | 2 | 0 | 1 |
| Phase 2 Total | 37 | 36 | 34 | 33 | 24 | 23 | 21 | 20 | 16 | 16 | 13 | 13 | 10 | 9 | 7 | 6 | 4 | 2 | 2 | 1 | 1 |
"Progression was determined by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS) was analyzed based on the non-parametric Kaplan-Meier method. mPFS was analyzed by age group, extent of surgery, baseline Karnofsky Performance Status (KPS), and O6-methylguanine-DNA methyltransferase status (MGMT).~The scale range for the baseline Karnofsky Performance Status is from 0-100, with 0 indicating that the participant is dead and 100 indicating that the participant is Normal no complaints, no evidence of disease. The higher the number, the better the outcome." (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
| Intervention | months (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Age: 18-64 years | Age: 65+ years | Extent of surgery: complete resection | Extent of surgery: partial resection | Baseline KPS: 70-89 | Baseline KPS: 90-100 | MGMT status: methylated | MGMT status: unmethylated | |
| Combined 800 mg, 5 Days/Week | 6 | 10 | 6 | 9 | 4 | 11 | 10 | 4 |
Progression was determined by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS) was analyzed based on the non-parametric Kaplan-Meier method. (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
| Intervention | months (Median) | |
|---|---|---|
| mITT RP2D | PP RP2D | |
| Combined 800 mg, 5 Days/Week | 6.7 | 6.9 |
"Overall Survival was calculated using a non-parametric Kaplan-Meier analysis method. Median OS was analyzed by age group, extent of surgery, baseline Karnofsky Performance Status (KPS), and O6-methylguanine-DNA methyltransferase status (MGMT).~The scale range for the baseline Karnofsky Performance Status is from 0-100, with 0 indicating that the participant is dead and 100 indicating that the participant is Normal no complaints, no evidence of disease. The higher the number, the better the outcome." (NCT01790503)
Timeframe: Assessed from date of first dose administered to the date of death from any cause, assessed up to 4 years 4 months.
| Intervention | months (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Age group: 18-64 years | Age group: 65+ years | Extent of surgery: complete resection | Extent of surgery: partial resection | Basline KPS: 70-89 | Baseline KPS: 90-100 | MGMT status: methylated | MGMT: unmethylated | |
| Combined 800 mg, 5 Days/Week | 14.3 | 11 | 14 | 13 | 8 | 24 | 15 | 12 |
Overall Survival (OS) was defined as the number of days from the first day of treatment (C1D1) to the date of death and analyzed using a non-parametric Kaplan Meier method. (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of death from any cause, assessed up to 4 years 4 months
| Intervention | months (Median) | |
|---|---|---|
| mITT RP2D | PP RP2D | |
| Combined 800 mg, 5 Days/Week | 13.1 | 12.4 |
Best Overall Response (based on the RANO response) was defined as the highest overall response recorded from the start of study treatment until the end of treatment. Per the Response Assessment in Neuro-Oncology (RANO) criteria for measurable lesions and assessed by Cranial MRI scan, summarized as: Complete Response (CR), Disappearance of all enhancing disease (measurable and non-measurable); Partial Response (PR), >=50% decrease of all measurable enhancing lesions; Stable disease, does not qualify for complete response, partial response, or progression, and progression, >25% increase in enhancing lesions despite stable or increasing steroid use or any new lesions. (NCT01790503)
Timeframe: Assessed from Baseline and every 8 weeks, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age group: 18-64 years72008643 | Age group: 65+ years72008643 | Complete resection72008643 | Partial resection72008643 | Baseline KPS: 70-8972008643 | Baseline KPS: 90-10072008643 | MGMT status: methylated72008643 | MGMT status: unmethylated72008643 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Complete response (CR) | Partial response (PR) | CR+PR | Stable disease | Progressive disease | Unable to access | Unknown | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
"Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue. ADC was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | mm2/s (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.00110 | 0.00113 | 0.00106 | 0.00110 | 0.00118 | 0.00122 | 0.00125 | 0.00125 | 0.00132 | 0.00127 | 0.00108 | 0.00133 | 0.00148 | 0.00179 | 0.00140 |
"Permeability-surface Area Product (Ktrans). Ktrans reflects the efflux rate of contrast from blood plasma into the tissue extravascular extracellular space (EES). Ktrans was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | min ^-1 (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.053 | 0.039 | 0.055 | 0.048 | 0.055 | 0.053 | 0.058 | 0.059 | 0.063 | 0.042 | 0.050 | 0.058 | 0.056 | 0.060 | 0.032 |
"Relative cerebral blood flow (rCBF) is the blood flow rate (the volume of blood passing through the specified are over a specified period of time) in the region of interest (ROI) divided by the blood flow rate in the symmetrical region on the other side of the normal brain (control region). CBF was assessed using spin-echo post-contrast T1-weighted images. CBF was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.83 | 0.86 | 0.92 | 0.94 | 0.80 | 0.79 | 0.83 | 0.73 | 0.63 | 0.59 | 0.60 | 0.60 | 0.52 | 0.47 | 0.37 |
"Relative cerebral blood volume (rCBV) is the blood volume in the region of interest (ROI) divided by the blood volume in the symmetrical region on the other side of the normal brain (control region). CBV was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.88 | 0.90 | 0.95 | 1.0 | 0.88 | 0.83 | 0.86 | 0.76 | 0.68 | 0.61 | 0.59 | 0.65 | 0.61 | 0.64 | 0.32 |
This study is designed as a phase I dose escalation trial using the Standard Method of dose escalation of three patients per dose level to determine the MTD of TMZ (up to 75 mg/m 2 /day) when TMZ is used with HIMRT for patients with glioblastoma multiforme(GBM) or Anaplastic Astrocytoma(AA)of the brain. The 3 dose levels will be evaluated using the standard method to determine if either represents an MTD based on DLT. If DLT is not observed at all doses level, the greater of the three levels will be recommended for phase II evaluations of treatment effect. (NCT00841555)
Timeframe: up to 12-16 months
| Intervention | mg/m^2 (Number) |
|---|---|
| Hypofractionation Radiotherapy+Temozolomide | 75 |
All patients will be followed to death. Active follow-up with disease evaluation with scans will be terminated if the patient's physician deems it in the patient's interest not to continue or upon patient request. (NCT00841555)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Hypofractionation Radiotherapy+Temozolomide | 12.7 |
Time spent in a KPS ≥70 was calculated from the date of diagnosis of Karonofsky Performance Status decline (KPS<70) or censored at the last date the patient was known with KPS ≥70. The KPS higher scores indicates normal activity status. (NCT00841555)
Timeframe: up to 12-16 months
| Intervention | months (Median) |
|---|---|
| Hypofractionation Radiotherapy+Temozolomide | 8.1 |
Overall Survival was defined as the time from randomization to death due to any cause. (NCT00943826)
Timeframe: Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT + Temozolomide | 16.8 |
| Placebo + RT + Temozolomide | 16.7 |
PFS is defined as time from randomization to disease progression (PD) or death. PD was assessed using adapted Macdonald response criteria (modified World Health Organization [WHO] criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging [MRI] scans,neurological assessment and changes in corticosteroid use. PD is assessed as greater than or equal to(>=) 25% increase in sum of products of the longest diameters of all index lesions (enhancing,measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing,non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment. (NCT00943826)
Timeframe: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT + Temozolomide | 10.6 |
| Placebo + RT + Temozolomide | 6.2 |
KM estimate of one year overall survival (probability to survive for at least 1 year) was reported. Corresponding 95% confidence interval (CI) was calculated using Greenwood's formula. (NCT00943826)
Timeframe: Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | probability of being alive (Number) |
|---|---|
| Bevacizumab + RT + Temozolomide | 0.72 |
| Placebo + RT + Temozolomide | 0.66 |
KM estimate of two year overall survival was reported (probability to survive for at least 2 years). Corresponding 95% CI was calculated using Greenwood's formula. (NCT00943826)
Timeframe: Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | probability of being alive (Number) |
|---|---|
| Bevacizumab + RT + Temozolomide | 0.34 |
| Placebo + RT + Temozolomide | 0.30 |
An Independent Review Facility reviewed the MRI scans used by investigator to evaluate radiological tumor response. PFS is defined as time from randomization to PD or death. PD was assessed using adapted Macdonald response (modified WHO) criteria based on 3 components: radiological tumor assessments using MRI scans, neurological assessment and changes in corticosteroid use. PD is assessed as >=25% increase in sum of products of the longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing, non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment. (NCT00943826)
Timeframe: Randomization until PFS Event (Until data cutoff= 31 March 2012 [up to 29.5 months])
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT +Temozolomide | 8.4 |
| Placebo + RT + Temozolomide | 4.3 |
An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as AE.A serious adverse event (SAE) is any experience that suggests a significant hazard,contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Non-serious adverse events (Non-SAEs) included all AEs except SAEs (non-SAEs = all AEs - SAEs). Nine participants randomized to the Placebo+RT+Temozolomide arm incorrectly received at least 1 dose of bevacizumab and were added to the Bevacizumab+RT+Temozolomide arm for Safety. (NCT00943826)
Timeframe: Randomization until study completion (Until data cutoff= 09 Sep 2015 [up to 64 months])
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Non-SAEs | SAEs | Death | |
| Bevacizumab + RT + Temozolomide | 437 | 179 | 335 |
| Placebo + RT + Temozolomide | 412 | 115 | 337 |
EORTC QLQ-C30: 30 items; 5 functional scales; 9 symptom scales; & global health status. Most questions used 4-point scale (1:Not at all, 4:Very much), 2 questions used 7-point scale (1:very poor, 7:Excellent). EORTC QLQ-BN20: 20 items rated on a 4 point scale (1:not at all, 4:very much). EORTC QLQ-C30 and BN20 scores were transformed to a 0-100 scale, higher score=better functioning/global health (C30) or more severe symptoms (BN20). Stable HRQoL: change from baseline (BL) within 10 points. Improved HRQoL: an increase from BL >/=10 points for functioning/global health status, & decrease of >/=10 points for symptoms. PFS is reported for participants with Stable/Improved global health; physical, social functioning (C30); motor dysfunction & communication deficit (BN20). PFS: randomization to PD or death. PD: >=25% increase in sum of products of longest diameters of index lesions; or progression of existing non-index lesions; or appearance of new lesions; or neurological worsening. (NCT00943826)
Timeframe: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
| Intervention | Months (Median) | ||||
|---|---|---|---|---|---|
| Global health status (n=354, 309) | Physical functioning (n=353, 318) | Social functioning (n=352, 327) | Motor dysfunction (n=361, 314) | Communication deficit (n=365, 329) | |
| Bevacizumab + RT + Temozolomide | 8 | 7 | 8 | 7 | 8 |
| Placebo + RT + Temozolomide | 4 | 5 | 4 | 4 | 4 |
AEs are graded by using CTCAE 3.0. The difference between the two randomized arms in the percentage of patients with grade 3 or higher toxicities reported as possibly/probably/definitely related to protocol treatment will be tested using a chi square test. (NCT00884741)
Timeframe: Up to 30 days
| Intervention | participants (Number) |
|---|---|
| Randomized Arm 1: TMZ+RT + Placebo | 87 |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 97 |
Survival time was defined as time from randomization to date of death from any cause and was estimated by the Kaplan-Meier method. Patients last known to be alive were censored at the date of last contact. This analysis was planned to occur when 390 deaths had been reported. (NCT00884741)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all 390 deaths have been reported.
| Intervention | months (Median) |
|---|---|
| Randomized Arm 1: TMZ+RT + Placebo | 16.1 |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 15.7 |
Progression-free survival was defined as time from randomization to date of progression, death, or last follow-up, and was estimated by the Kaplan-Meier method. Patients last known to be alive were censored at the date of last contact. This analysis was planned to occur when 390 deaths had been reported. (NCT00884741)
Timeframe: From randomization to date of progression, death, or last follow-up for progression-free survival. Analysis occurs after all 390 deaths have been reported.
| Intervention | months (Median) |
|---|---|
| Randomized Arm 1: TMZ+RT + Placebo | 7.3 |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 10.7 |
Overall survival was defined from the date of diagnosis to date of death from any cause (NCT00525525)
Timeframe: Approximately 6-24 months
| Intervention | months (Median) |
|---|---|
| Efficacy Group | 19.8 |
Progression-free survival was defined from the date of diagnosis to the date that progressive disease was first observed on imaging, or the date at which nonreversible neurologic progression or permanently increased corticosteroid requirement, death from any cause, or early discontinuation of treatment. Imaging guidelines were used to evaluate progression: (i) 25% increase in the sum of products of all measurable lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline; (ii) clear worsening of any assessable disease; (iii) appearance of any new lesion/site; and (iv) clear clinical worsening or failure to return for evaluation as a result of death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00525525)
Timeframe: Approximately 6 months to 1 year
| Intervention | months (Median) |
|---|---|
| Efficacy Group | 13.5 |
Unexpected severe study-related adverse events (NCT00525525)
Timeframe: Within 8 weeks of initiating study therapy
| Intervention | Events (Number) |
|---|---|
| Safety Lead-in Group | 0 |
Efficacy of dose-intense temozolomide treatment schedule, as measured by 6 months progression-free survival (NCT00619112)
Timeframe: First day of treatment until progression or until 6 months mark
| Intervention | percentage of patients (Number) |
|---|---|
| Glioblastoma | 10 |
| Grade III Glioma | 50 |
(NCT00619112)
Timeframe: up to 2 years after treatment
| Intervention | weeks (Median) |
|---|---|
| Glioblastoma | 21.6 |
| Grade III Glioma | 100.6 |
(NCT00619112)
Timeframe: From beginning of voluntarily temozolomide discontinued up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 4 |
| Grade III Glioma | 4 |
(NCT00619112)
Timeframe: After two first-line adjuvant courses of temozolomide
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 3 |
| Grade III Glioma | 0 |
(NCT00619112)
Timeframe: Within 6 months after 6th adjuvant course of temozolomide
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 4 |
| Grade III Glioma | 1 |
PCR analysis of tumor tissue for microsatellite instability (MSI). Tissue was obtained during surgeries prior this study. (NCT00619112)
Timeframe: prior to start of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 0 |
| Grade III Glioma | 0 |
Progression-free survival data (obtained for Primary Outcome Measure) was correlated with tumor MGMT (O(6)-methylguanine-DNA methyltransferase) promoter methylation status, obtained from patients as part of the study. (NCT00619112)
Timeframe: First day of treatment until progression or until 6 months mark
| Intervention | weeks (Median) |
|---|---|
| Glioblastoma With Methylated MGMT | 8.14 |
| Glioblastoma With Unmethylated MGMT | 7.57 |
| Grade III Glioma With Methylated MGMT | 38.1 |
| Grade III Glioma With Unmethylated MGMT | 48.6 |
Dose limiting toxicity defined as: Any DLT must be a toxicity considered at least possibly related to HCQ. DLTs will include any possibly, probably, or definitely HCQ-related Grade 3 or 4 toxicity. Known or reasonably suspected TMZ hematological toxicities will not be considered dose limiting unless the treating physician considers the toxicity to be exacerbated by HCQ. Nonhematological toxicities: Any Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis) (NCT00486603)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1: RT+TMZ+HCQ - 200mg | 0 |
| Phase 1: RT+TMZ+HCQ - 400mg | 0 |
| Phase 1: RT+TMZ+HCQ - 600mg | 0 |
| Phase 1: RT+TMZ+HCQ - 800mg | 3 |
Number of participants experiencing Grade 3 and 4 toxicity, as defined by CTCAE v3.0, with a possible, probable or definite relationship to HCQ, TMZ or both (NCT00486603)
Timeframe: up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 22 |
Number of months alive after end of study participation (NCT00486603)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 15.6 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | hour (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 1.06 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | Liters (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 963 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | hours (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 0.51 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | L/hr (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 11.85 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | Liters (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 483.96 |
Number of participants who tolerated doses of HCQ without dose limiting toxicity. The highest dose at which participants did not experience dose limiting toxicity was determined as the MTD. (NCT00486603)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 200mg | 400mg | 600mg | 800mg | |
| Phase 1 - Dose Finding | 3 | 7 | 3 | 0 |
Autophagy inhibition is represented by an increase in autophagic vacuoles (AV) in participants with at least 2 peripheral blood mononuclear cell samples that were amenable to EM. (NCT00486603)
Timeframe: up to 9 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AV Increase | No AV Increase | |
| HCQ Cmax <= 1785 ng/mL | 10 | 12 |
| HCQ Cmax>1785 ng/mL | 12 | 6 |
Brain Metastases were defined as radiological evidence of brain metastases on magnetic resonance imaging (MRI). (NCT00632203)
Timeframe: Up to 12 months (as measured from day 1 of cycle 1 of standard first-line systemic chemotherapy)
| Intervention | participants (Number) |
|---|---|
| Temozolomide Treatment | 4 |
| Observation | 3 |
The overall survival was analyzed using the Kaplan-Meier method. (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up
| Intervention | months (Median) |
|---|---|
| Temozolomide Treatment | 27.14 |
| Observation | 22.54 |
"The time to progression (per response evaluation criteria in solid tumors [RECIST]) was analyzed using the Kaplan-Meier method.~Definitions of response per RECIST:~Complete Response (CR): Disappearance of all target lesions.~Partial Response (PR): A decrease of at least 30% in the sum of the longest~diameter of target lesions.~Progressive Disease (PD): An increase of at least 20% in the sum of the longest~diameter of target lesions.~Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease." (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to progression or up to 6 cycles (168 days) of study treatment
| Intervention | months (Median) |
|---|---|
| Temozolomide Treatment | 11.70 |
| Observation | 10.68 |
"Defined as CNS progression as measured by MRI.~Time to CNS progression was analyzed using the Kaplan-Meier method." (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to radiological progression or the last known CNS progression-free date
| Intervention | months (Median) |
|---|---|
| Temozolomide Treatment | NA |
| Observation | NA |
Tolerability was defined as number of participants with any adverse event leading to study discontinuation and/or study drug discontinuation. (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)
| Intervention | participants (Number) |
|---|---|
| Temozolomide Treatment | 5 |
| Observation | NA |
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
The AUC (0-6) for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1. (NCT00689221)
Timeframe: Day 1 of Week -1
| Intervention | hour*ng/mL (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 295171.2 |
The EuroQuol-5D (EQ-5D) questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.594 (death) and the highest is 1.00 (full health). (NCT00689221)
Timeframe: Up to 50 months
| Intervention | units on a scale (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 0.598 |
| Temozolomide + Radiotherapy | 0.623 |
The Cmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1. (NCT00689221)
Timeframe: Day 1 of Week -1
| Intervention | nanogram per milliliter (ng/mL) (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 167363.2 |
The OS time is defined as the time (in months) from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00689221)
Timeframe: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)
| Intervention | Months (Median) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 26.3 |
| Temozolomide + Radiotherapy | 26.3 |
The Tmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1. (NCT00689221)
Timeframe: Day 1 of Week -1
| Intervention | hours (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 1.029 |
The QLQ-BN20 is a questionnaire specifically designed as the QLQ-C30 supplement for the evaluation of quality of life in brain tumor participants. It includes 4 multi-item sub-scales: future uncertainty, visual disorder, motor dysfunction, communication deficits, and 7 single-item scales: headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All items are rated on a 4-point Likert-type scale ('1=not at all', '2=a little', '3=quite a bit' and '4=very much'), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms. (NCT00689221)
Timeframe: Up to 50 months
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Future Uncertainty (n=68, 86) | Visual Disorder (n=68, 85) | Motor Dysfunction (n=68, 86) | Communication Deficit (n=68, 86) | Headaches (n=68, 86) | Seizures (n=68, 87) | Drowsiness (n=66, 87) | Itchy Skin (n=68, 86) | Hair Loss (n=66, 86) | Weakness of Legs (n=67, 85) | Bladder Control (n=67, 85) | |
| Cilengitide + Temozolomide + Radiotherapy | 44.49 | 12.99 | 27.45 | 26.14 | 25.98 | 9.31 | 38.38 | 9.80 | 13.13 | 24.38 | 19.40 |
| Temozolomide + Radiotherapy | 39.31 | 17.78 | 23.39 | 19.96 | 21.71 | 8.05 | 35.25 | 13.57 | 15.12 | 20.39 | 10.20 |
The EORTC QLQ-C30 is a questionnaire including following sub-scales: global health status, functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social activity), symptom scales (fatigue, nausea and vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better quality of life on global health status and functional scales and worse quality of life on symptom scales and financial difficulty scale. (NCT00689221)
Timeframe: Up to 50 months
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status (n=71, 92) | Physical Functioning (n=71, 92) | Role Functioning (n=71, 92) | Emotional Functioning (n=71, 93) | Cognitive Functioning (n=70, 93) | Social Activity (n=71, 93) | Fatigue (n=71, 92) | Nausea and Vomiting (n=71, 93) | Pain (n=71, 93) | Dyspnoea (n=71, 92) | Insomnia (n=71, 91) | Appetite Loss (n=71, 92) | Constipation (n=71, 93) | Diarrhoea (n=70, 92) | Financial Difficulties (n=71, 93) | |
| Cilengitide + Temozolomide + Radiotherapy | 54.34 | 65.70 | 56.34 | 67.49 | 64.05 | 56.34 | 44.37 | 10.33 | 22.30 | 15.96 | 20.66 | 21.13 | 18.78 | 6.67 | 27.23 |
| Temozolomide + Radiotherapy | 55.43 | 67.46 | 56.34 | 67.00 | 65.41 | 62.72 | 39.73 | 7.71 | 24.37 | 13.04 | 20.51 | 15.94 | 13.98 | 4.35 | 22.94 |
An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. Treatment-emergent AEs are the events between first dose of study drug and up to 28 days after last dose of study treatment. A Serious AE is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-related AEs are the AEs which are suspected to be reasonably related to the study treatment (cilengitide, or radiotherapy, or temozolomide) as per investigator assessment. The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome. (NCT00689221)
Timeframe: Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| AEs | Serious AEs | Treatment-related AEs | Treatment-Related Serious AEs | AEs leading to death | Treatment-related AEs leading to death | AEs with NCI-CTC toxicity Grade 3 or 4 | Treatment-related AEs of Grade 3 or 4 | |
| Cilengitide + Temozolomide + Radiotherapy | 261 | 138 | 229 | 55 | 11 | 3 | 169 | 100 |
| Temozolomide + Radiotherapy | 253 | 115 | 222 | 47 | 9 | 3 | 158 | 101 |
Thromboembolic events (standardized MedDRA query [SMQ]) Grade 3 or 4 AEs encompassed hemiparesis and cerebrovascular accident, pulmonary embolism, and deep vein thrombosis. Thromboembolic events (SMQ) of any grade and of Grade 3 or 4 were generally more frequent in the Cilengitide + Temozolomide/Radiotherapy group than in the Temozolomide/Radiotherapy group but were still in the expected range of this patient population The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome. (NCT00689221)
Timeframe: Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)
| Intervention | Participants (Number) | |
|---|---|---|
| SMQ:Thromboembolic events | SMQ: Hemorrhage | |
| Cilengitide + Temozolomide + Radiotherapy | 35 | 4 |
| Temozolomide + Radiotherapy | 23 | 4 |
Number of participants with change from baseline in work status (working full time [FT], part-time [PT], unemployed/retired [U/R]) at end of study (EOS) (up to cut-off date, [19 Nov 2012]) was reported. For the category 'part-time', the following sub-categories were defined: part-time due to basic disease (PT1); part-time not due to basic disease (PT2); part-time reason not known (PT3). (NCT00689221)
Timeframe: Baseline, End of study (up to cut-off date, [19 Nov 2012])
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: FT, EOS: FT | Baseline: FT, EOS: PT1 | Baseline: FT, EOS: PT2 | Baseline: FT, EOS: PT3 | Baseline: FT, EOS: U/R | Baseline: PT1, EOS: FT | Baseline: PT1, EOS: PT1 | Baseline: PT1, EOS: PT2 | Baseline: PT1, EOS: PT3 | Baseline: PT1, EOS: U/R | Baseline: PT2, EOS: FT | Baseline: PT2, EOS: PT1 | Baseline: PT2, EOS: PT2 | Baseline: PT2, EOS: PT3 | Baseline: PT2, EOS: U/R | Baseline: PT3, EOS: FT | Baseline: PT3, EOS: PT1 | Baseline: PT3, EOS: PT2 | Baseline: PT3, EOS: PT3 | Baseline: PT3, EOS: U/R | Baseline: U/R, EOS: FT | Baseline: U/R, EOS: PT1 | Baseline: U/R, EOS: PT2 | Baseline: U/R, EOS: PT3 | Baseline: U/R, EOS: U/R | Baseline: Missing, EOS: FT | Baseline: Missing, EOS: PT1 | Baseline: Missing, EOS: PT2 | Baseline: Missing, EOS: PT3 | Baseline: Missing, EOS: U/R | Baseline: Missing, EOS: Missing | |
| Cilengitide + Temozolomide + Radiotherapy | 3 | 2 | 1 | 0 | 24 | 3 | 3 | 0 | 0 | 9 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 1 | 0 | 199 | 0 | 0 | 0 | 0 | 1 | 1 |
| Temozolomide + Radiotherapy | 6 | 1 | 0 | 0 | 22 | 2 | 1 | 0 | 0 | 12 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 8 | 7 | 1 | 0 | 191 | 0 | 0 | 0 | 0 | 1 | 1 |
"The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause. Investigator read is the assessment of all imaging by the treating physician at the local trial site and Independent Read is the assessment of all imaging centrally by an Independent Review Committee (IRC). Investigator's assessed progression according to MacDonald criteria and IRC by Response Assessment in Neuro-Oncology Working Group (RANO) criteria using Gadolinium-enhanced magnetic resonance imaging.~Investigator and IRC read: Progression is defined as greater than 25 percent increase in the sum of the product of the largest perpendicular diameters of enhancing tumor compared to the smallest prior sum, or Worsening of an evaluable lesion(s),or Marked increase in T2/FLAIR non-enhancing lesions (IRC only) or Any new lesion" (NCT00689221)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)
| Intervention | Months (Median) | |
|---|---|---|
| PFS Time: Investigator read | PFS Time: Independent read | |
| Cilengitide + Temozolomide + Radiotherapy | 13.5 | 10.6 |
| Temozolomide + Radiotherapy | 10.7 | 7.9 |
Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 20.2 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 17.1 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 17.0 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 20.1 |
Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and ARM VIII | 17.1 |
| No Isotretinoin: Arm I, Arm II, Arm III and ARM VI | 19.9 |
Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 18.3 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 17.4 |
Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 8.3 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 7.4 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 8.3 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 8.2 |
Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and Arm VIII | 6.6 |
| No Isotretinoin: Arm I, Arm II, Arm III and Arm VI | 9.1 |
Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 7.6 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 8.7 |
Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 10.5 |
| Arm II: TMZ + Thalidomide | 7.7 |
| Arm III: TMZ + Celecoxib | 13.4 |
| Arm IV: TMZ + Isotretinoin | 6.5 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 11.6 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 7.9 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 6.2 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 5.8 |
Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 21.2 |
| Arm II: TMZ + Thalidomide | 17.4 |
| Arm III: TMZ + Celecoxib | 18.1 |
| Arm IV: TMZ + Isotretinoin | 11.7 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 23.1 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 20.2 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 17.9 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 18.5 |
"Patients were to be followed for a minimum of 90 days from the start of radiation therapy (RT) and carefully evaluated with respect to treatment morbidity. A dose limiting toxicity (DLT) was defined as a grade 4 neurologic adverse event (AE) considered to be related to treatment occurring within 21 days of the conclusion of RT. For each dose level, up to seven patients were to be accrued to assure that there would be six eligible for treatment adverse event evaluation. A dose level of MGd was considered acceptable if no more than 1 patient of the 6 experience a DLT. If the current level was considered acceptable, then dose escalation occurred. Otherwise, the preceding dose level would be declared the maximum tolerated dose (MTD). The MTD would be used for the Phase II arm.~Rating scale: 0 = not the MTD, 1 = MTD" (NCT00305864)
Timeframe: From start of radiation therapy to 90 days,
| Intervention | units on a scale (Number) |
|---|---|
| Phase I: MGd 3 mg/kg | 0 |
| Phase I: MGd 4 mg/kg | 0 |
| Phase I: 5 mg/kg | 1 |
Survival time was defined as the time from baseline to date of death from any cause. Patients last known to be alive are censored at date of last contact. (NCT00305864)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for at least 18 months. Patients were followed up to 54.3 months
| Intervention | Months (Median) |
|---|---|
| All MGd 5mg/kg Patients (Phase I and II Arms Combined) | 15.6 |
Progression will be defined as a > 25% increase in tumor area. Progression-free survival time was defined as the time from baseline to date of death from any cause. Patients last known to be alive are censored at date of last contact. (NCT00305864)
Timeframe: From randomization to date of progression, death, or last follow-up. Analysis occurs after all patients have been potentially followed for at least 18 months. Patients were followed up to 54.3 months.
| Intervention | months (Median) |
|---|---|
| All MGd 5mg/kg Patients (Phase I and II Arms Combined) | 7.6 |
Time in months from the start of study treatment to the date of death due to any cause. Patients alive as of the last follow-up had OS censored at the last follow-up date. Median OS was estimated using a Kaplan-Meier curve. (NCT00979017)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Avastin in Combination With Temozolomide and Irinotecan | 12 |
Time in months from the start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause. Per RANO, progression is a ≥ 25% increase in the sum of the products of perpendicular diameters of enhancing lesions, worsening T2/FLAIR, any new lesion, or clinical deterioration. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. (NCT00979017)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Avastin in Combination With Temozolomide and Irinotecan | 8.6 |
The percentage of participants with a complete or partial response as determined by a modification of the Response Assessment in Neuro-Oncology (RANO) criteria. Complete Response (CR) was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses) and accompanied by a stable or improving neurologic examination. Partial Response (PR) was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids and accompanied by a stable or improving neurologic examination. Per the criteria, confirmation of response was required. Response rate = CR+PR. (NCT00979017)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| Avastin in Combination With Temozolomide and Irinotecan | 22 |
Incidence and severity of CNS hemorrhage and systemic hemorrhage- The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov. (NCT00979017)
Timeframe: 4 months
| Intervention | participants (Number) | |
|---|---|---|
| CNS hemorrhage (grade 3) | Systemic hemorrhage (all grade 3) | |
| Avastin in Combination With Temozolomide and Irinotecan | 1 | 3 |
Incidence of treatment-related, grade ≥ 4 hematologic and ≥ grade 3 non-hematologic toxicities- The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov. (NCT00979017)
Timeframe: 4 months
| Intervention | participants (Number) | |
|---|---|---|
| Grade > or = to 4 hematologic toxicity | Grade > or = to 3 non-hematologic toxicity | |
| Avastin in Combination With Temozolomide and Irinotecan | 7 | 17 |
The 12-month overall survival rate was defined as the percentage of participants surviving at 12 months. The distribution of 12-month OS rate was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Per protocol, survival was to be assessed every 4 weeks or as needed after participant is registered as off-study for up to 18 months. The maximum observed follow-up at the overall survival analysis time was 21.0 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 52.6 |
| ABT-888 20 mg BID + TMZ QD | 43.5 |
| ABT-888 40 mg BID + TMZ QD | 54.1 |
The 6-month progression-free survival rate was defined as the percentage of participants without disease progression at 6 months.The distribution of 6-month progression-free survival rate, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 19.1 |
| ABT-888 20 mg BID + TMZ QD | 32.8 |
| ABT-888 40 mg BID + TMZ QD | 30.7 |
The disease control rate was defined as the percentage of participants who had at least stable disease (complete response, partial response, or stable disease) through the end of Week 8. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 48.7 |
| ABT-888 20 mg BID + TMZ QD | 62.9 |
| ABT-888 40 mg BID + TMZ QD | 59.1 |
The objective response rate was defined as the percentage of participants with a confirmed CR or PR per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by computed tomography (CT) scan: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 7.0 |
| ABT-888 20 mg BID + TMZ QD | 10.3 |
| ABT-888 40 mg BID + TMZ QD | 9.6 |
OS was defined as the number of days from the date the participant was randomized to the date of death. All deaths were included, whether the participant was still taking or had discontinued study drug. If a participant had not died and was lost to follow-up, then data were censored at the last study visit or contact date, or date the participant was last known to be alive, whichever was later; if the participant was not lost to follow-up, then data were censored at the last study visit or contact date, whichever was later. The distribution of OS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the OS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints. (NCT00804908)
Timeframe: Per protocol, survival follow-up information was to be obtained every 3 months for up to 18 months after the final visit for the subject. The maximum observed follow-up at the overall survival analysis time was 21.0 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 204 | 327 | NA |
| ABT-888 40 mg BID + TMZ QD | 181 | 412 | NA |
| Placebo for ABT-888 BID + TMZ QD | 207 | 390 | 559 |
PFS: the number of days from the date that the participant was randomized to the date the participant experienced a confirmed event of disease progression (radiological, as determined by the central imaging center; or clinical, as determined by the investigator), or to the date of death (all causes of mortality) if disease progression was not reached. All events were included whether the participant was still taking or had discontinued study drug. Events of death were included for participants who had not experienced a confirmed event of disease progression, provided the death occurred within 8 weeks of the last available disease progression assessment. The distribution of PFS, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% confidence intervals (95% CIs) for the quartiles for the PFS distribution are provided. (NCT00804908)
Timeframe: Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th Percentile | 75th Percentile | |
| ABT-888 20 mg BID + TMZ QD | 56 | 113 | 225 |
| ABT-888 40 mg BID + TMZ QD | 53 | 110 | 226 |
| Placebo for ABT-888 BID + TMZ QD | 54 | 60 | 163 |
The distribution of time to disease progression, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every Cycle (28 Days), until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 56 | 113 | 225 |
| ABT-888 40 mg BID + TMZ QD | 53 | 110 | 226 |
| Placebo for ABT-888 BID + TMZ QD | 54 | 60 | 163 |
Time to neurological/brain metastases progression, defined as the number of days from the date of randomization to the date the participant experienced an event of neurological/brain metastases progression, was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the distribution are provided. All events of progression were included, regardless of whether the event occurred while the participant was still taking study drug. If a participant did not experience an event, data were censored at the date of the last available brain CT scan. For participants with no postbaseline brain CT scans, data were censored at randomization. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 119 | NA | NA |
| ABT-888 40 mg BID + TMZ QD | 184 | 184 | NA |
| Placebo for ABT-888 BID + TMZ QD | 60 | NA | NA |
Patients were monitored until death (NCT00187486)
Timeframe: assessment of survival was every 2 months, up to 181 weeks
| Intervention | months (Median) |
|---|---|
| Temodar Plus Tarceva Plus Radiotherapy | 19 |
Progression based on MR imaging using the Modified McDonnald Criteria defined as 25% increase in sum of products of all measured lesions or any new lesion (NCT00187486)
Timeframe: every 2 months measure by MR imaging, up to 39 months
| Intervention | months (Median) |
|---|---|
| Temodar Plus Tarceva Plus Radiotherapy | 8.2 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Progression-free survival as determined by Kaplan-Meier method. (NCT00392171)
Timeframe: 6 months
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Anaplastic Glioma (n=28) | Early Glioblastoma Multiforme (GBM) (n=33) | Extended Glioblastoma Multiforme (GBM) (n=27) | Rechallenge Glioblastoma Multiforme (GBM) (n=28) | |
| Temozolomide | 35.7 | 27.3 | 7.4 | 35.7 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Sorafenib + Temozolomide | 9.4 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug*H/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 45309.7 |
| EIAEDs-Day 28 | 47148.2 |
| Non-EIAEDs-Day 1 | 45238.7 |
| Non-EIAEDs-Day 28 | 128820.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 3397.3 |
| EIAEDs-Day 28 | 3813.9 |
| Non-EIAEDs-Day 1 | 3155.1 |
| Non-EIAEDs-Day 28 | 8118.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | hours (Median) |
|---|---|
| EIAEDs-Day 1 | 8.2 |
| EIAEDs-Day 28 | 2.1 |
| Non-EIAEDs-Day 1 | 24.0 |
| Non-EIAEDs-Day 28 | 4.2 |
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months
| Intervention | participants (Number) |
|---|---|
| Sorafenib + Temozolomide | 19 |
"The number of patients with complete or partial responses measured from the time of initial response to documented tumor progression. Radiologic response was defined using the Macdonald criteria.~The Macdonald criteria divides response into 4 types of response based on imaging (MRI) and clinical features, as follows: 1) complete response (CR); 2) partial response (PR); 3) stable disease (SD); and 4) progression (PD).~Criteria:~CR: disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions. No corticosteroids, clinically stable or improved.~PR: >=50% decrease of all measurable enhancing lesions, sustained for at least 4 weeks, no new lesions. Stable or reduced corticosteroids, clinically stable or improved.~SD: does not qualify for complete response, partial response or progression. Clinically stable.~PD: >= 25% increase in enhancing lesions, any new lesions. Clinical deterioration." (NCT00544817)
Timeframe: every 8 weeks until disease progression, estimated 18 months
| Intervention | participants (Number) |
|---|---|
| Combination Therapy | 13 |
Defined as Day 1 of protocol treatment to date of death from any cause. (NCT00544817)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 12 |
Defined as the duration of time from start of treatment to time of progression or death, whichever comes first. (NCT00544817)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 6 |
survival time is defined from time of histological diagnosis to death occurrence. (NCT00262730)
Timeframe: 30 months
| Intervention | months (Mean) |
|---|---|
| Treatment Arm - All Subjects | 17.2 |
Patients who are alive on the date of closing follow-up, or 30 months after completing all study treatments, will be censored on that date (NCT01984892)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants With Stage 4 Cancer | 8 |
"Progression-free survival defined as the time in weeks from study entry until tumor progression defined using the Wolchok criteria or death. Patients who are alive and free from progression on the date of closing follow-up will be censored on that date.~In order to minimize the potential for misdiagnosis of pseudoprogression, related to early inflammation, tumor measurement for determination of progression will be made at the earliest at 26 weeks." (NCT01984892)
Timeframe: average 52 weeks
| Intervention | weeks (Number) |
|---|---|
| Participants With Stage 4 Cancer | 41 |
Patients were assessed during RT for dose-limiting toxicities (DLT), which were defined as failure to deliver greater than 75% of the planned doses of TMZ or RAD001 during RT, interruption of RT for more than 5 days because of toxicity, or the following: >= Grade 3 diarrhea or skin rash; >= Grade 4 neutropenia, leukopenia, or thrombocytopenia; >= Grade 4 hypertriglyceridemia, hypercholesterolemia, or hyperglycemia despite optimal medial management, other >= 3 non-hematologic events; or >= Grade 4 radiation dermatitis. Maximum tolerated dose (MTD) was defined a priori as the highest dose level at which 0 or 1 of 6 patients developed DLTs. The number of patients who developed DLTs are reported here by dose level, with the MTD reported in the statistical analysis section. (NCT00553150)
Timeframe: Up to 49 days
| Intervention | participants who developed DLTs (Number) |
|---|---|
| Phase I: Dose Level 0 | 1 |
| Phase I: Dose Level 1 | 1 |
| Phase I: Dose Level 2 | 1 |
"The primary endpoint is overall survival at 12 months (OS12) after entry into this study. The proportion of successes will be estimated using the binomial point estimator (number of successes divided by the total number of evaluable patients) and the binomial 95% confidence interval estimated. A patient who is evaluable and survive more than 12 months (i.e. 365 days or more) after start of therapy will be classified as a success. Patients who die within 12 months after start of therapy will be considered to have failed." (NCT00553150)
Timeframe: at 12 months
| Intervention | proportion of participants (Number) |
|---|---|
| Phase II | 0.64 |
Overall survival: The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier method. (NCT00553150)
Timeframe: Up to 15 years
| Intervention | months (Median) |
|---|---|
| Phase II | 15.8 |
Progression-free-survival at 6 months: is the proportion of patients alive and progression-free at 6 months after start of regimen. This proportion will be estimated using the binomial point estimator and the binomial 95% confidence interval estimated. Progression is defined as at least a 25% increase in product of perpendicular diameters of contrast enhancement or mass or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians or appearance of new lesions. (NCT00553150)
Timeframe: at 6 months
| Intervention | proportion of participants (Number) |
|---|---|
| Phase II | 0.52 |
The response rate is defined as the percentage of patients receiving F-fluorothymidine positron emission tomography (FLT-PET) imaging whose cancer shrinks or disappears after treatment. A reduction in standardized uptake value (SUV) of 30% or greater in the T1-post-gadolinium scan volume of interest (T1-gad VOI) or the total tumor VOI will be considered a responsive tumor. (NCT00553150)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 44.4 |
Time-to-disease progression is defined as the time from start of study therapy to documentation of disease progression. Patients who die without documentation of progression will be considered to have had tumor progression at the time of death unless there is documented evidence that no progression occurred before death. Patients who fail to return for evaluation after beginning therapy will be censored for progression on the last day of therapy. Patients who experience major treatment violations will be censored for progression on the date of treatment violation occurred. The time-to-progression distribution will be estimated using the Kaplan-Meier method. Progression is defined as at least a 25% increase in product of perpendicular diameters of contrast enhancement or mass or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians or appearance of new lesions. (NCT00553150)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Phase II | 6.4 |
"Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve.~Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator)." (NCT00643097)
Timeframe: 58 months
| Intervention | months (Median) |
|---|---|
| Arm I (ACTIVATE) | 14.2 |
| Arm II (ACT II STD) | 12.1 |
| Arm III (ACT II DI) | 11.6 |
Number of patients that developed a delayed-type hypersensitivity (DTH) response at following vaccination. Any skin reaction in response to the intradermal injection of the antigen was measured and recorded. A positive skin test was defined as > 5 mm induration (swelling). (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 3 |
| Arm II (ACT II STD) | 0 |
| Arm III (ACT II DI) | 7 |
The objective is to assess the duration of immunosuppressive cytokine secretion and to identify a receptive interval for active immunotherapy. Immunosuppression will determined by monitoring a panel of immunosuppressive serum/plasma cytokines longitudinally and by determining the response of each patient to Recombivax Hepatitis B (HB) vaccination. Response is defined as seropositive or seronegative to the Hepatitis B surface antigen. (NCT00643097)
Timeframe: 26 months
| Intervention | Months (Mean) |
|---|---|
| Arm I (ACTIVATE) | NA |
| Arm II (ACT II STD) | NA |
| Arm III (ACT II DI) | NA |
To assess for any potential toxicity to the PEP-3 vaccine immunization in patients with newly diagnosed glioblastoma, Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was used to tabulate any toxicities attributable to PEP-3. The number of patients with toxicity attributable to vaccine while on study are tabulated. (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 4 |
| Arm II (ACT II STD) | 1 |
| Arm III (ACT II DI) | 7 |
all patients alive as of the last contact were censored for survival on the basis of that contact date (NCT00369590)
Timeframe: 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 55 |
| Arm 2 - Glioblastoma | 39 |
"pts with confirmed radiographic response and their rate of progression (PFS).~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: up to 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 45 |
| Arm 2 - Glioblastoma | 23 |
"This design yields 85% power to detect a true 30% 6-month PFS rate, while maintaining .91 probability of rejecting for a true 15% 6-month PFS rate.~pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression.~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 25 |
| Arm 2 - Glioblastoma | 7.7 |
number of patients who experienced toxicity that led to being taken off treatment (NCT00369590)
Timeframe: Approximately 1 year (start of treatment - end of treatment)
| Intervention | participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 8 |
| Arm 2 - Glioblastoma | 6 |
number of cycles patient was able to have before developing a toxicity that required removing the patient from treatment. Treatment: Aflibercept 4mg/kg intravenously on day 1 of every 14-day cycle - 2 week cycle. (NCT00369590)
Timeframe: Start to End of treatment 39 cycles or 1yr 7.5months (78 weeks)
| Intervention | cycles (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 5 |
| Arm 2 - Glioblastoma | 3.5 |
"pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression. All responders were centrally reviewed for confirmation~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: Up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Complete Response | Partial Response | |
| Arm 2 - Glioblastoma | 0 | 7 |
| Arm I - Anaplastic Glioma | 1 | 6 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. [Optional: Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).] (NCT00501891)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab and Metronomic Temozolomide | 18.8 |
The number of participants with complete or partial response as determined by a modification of the Macdonald criteria. Complete response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. (NCT00501891)
Timeframe: 27 months
| Intervention | Number of participants (Number) |
|---|---|
| Bevacizumab and Metronomic Temozolomide | 9 |
Number of participants experiencing a Central Nervous System (CNS) hemorrhage or systemic hemorrhage (NCT00501891)
Timeframe: 27 months
| Intervention | participants (Number) | |
|---|---|---|
| CNS Hemorrhage | Systemic Hemorrhage | |
| Bevacizumab and Metronomic Temozolomide | 0 | 0 |
Number of participants experiencing a grade ≥4 hematologic or grade ≥3 non-hematologic toxicity (NCT00501891)
Timeframe: 27 months
| Intervention | participants (Number) | |
|---|---|---|
| Grade ≥ 4 hematologic toxicities | Grade ≥ 3 non-hematologic toxicities | |
| Bevacizumab and Metromonic Temozolomide | 0 | 14 |
"Objective Response (OR) encompassed the number of participants with Complete Response (CR) and the number of participants with Partial Response (PR). CR is the disappearance of all brain metastases, assessed between two or more cranial MRI. PR is at least a 30% decrease in the sum of the longest diameter of the brain metastases, taking as reference the baseline sum longest diameter, assessed between two or more cranial MRI.~Objective Response Rate (ORR) is the ratio between the number of participants with objective response and the total number of participants." (NCT01015534)
Timeframe: 90 days
| Intervention | Percentage of participants with OR (Number) |
|---|---|
| Whole Brain Irradiation and Temozolomide | 78.6 |
| Whole Brain Irradiation | 48.1 |
Overall survival:Time in months measured from treatment initiation until the date of death or the date of last follow-up. (NCT01015534)
Timeframe: 1 year
| Intervention | Months of Overall Survival (Median) |
|---|---|
| Whole Brain Irradiation and Temozolomide | 8 |
| Whole Brain Irradiation | 8.1 |
Progression free survival of brain metastases is the survival of participants without progressive brain metastases or without neurological symptoms. The progressive brain metastases (PBM) were evaluated with cranial MRI. The PBM were defined as an increase of at least 20% in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new metastases. (NCT01015534)
Timeframe: at 90 days
| Intervention | Percentage of Participants (Number) |
|---|---|
| Whole Brain Irradiation and Temozolomide | 88.7 |
| Whole Brain Irradiation | 83.7 |
"AE, evaluated and graded according to the NCI common terminology criteria (NCI-CTCAE) v3.0~Grade 3 Severe AE.~Grade 4 Life-threatening or disabling AE." (NCT01015534)
Timeframe: 4 months
| Intervention | Events (Number) | ||||
|---|---|---|---|---|---|
| Leukopenia | Lymphopenia | Nausea-Vomiting | Neutropenia | Platelets | |
| Whole Brain Irradiation | 0 | 6 | 0 | 1 | 0 |
| Whole Brain Irradiation and Temozolomide | 1 | 11 | 1 | 1 | 3 |
Progression free survival is defined by any of the following: ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR non-enhancing lesions on stable or increasing dose of corticosteroids compared with baseline scan or best response after initial of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of non-measurable lesions; or definite clinical deterioration not attributable to another causes apart from the tumor, or to decrease in corticosteroid dose. (NCT02082119)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High Grade Glioma | 82 |
"pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)~DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting.~Nonhematological toxicities Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis)" (NCT00085254)
Timeframe: 10 weeks
| Intervention | participants (Number) |
|---|---|
| Arm 1 500mg (Safety Run In) | 0 |
| ARM 2 1000mg (Safety run-in) | 0 |
| Arm 3 2000mg (Safety Run-In) | 0 |
The proportion of patients with grade 3 and grade 4 hematologic and non hematologic adverse events per CTCAE 4.0 (NCT00085254)
Timeframe: Up to 1 year
| Intervention | Number of grade 3 or 4 events (Number) |
|---|---|
| Arm 1- Phase 2 (500mg) | 48 |
| Arm 2 - Phase 2 (2000mg) | 35 |
"pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review any dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (safety run-in)~DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting.~cohorts at these 3 defined doses: 500mg, 1000mg and 2000mg MTD defined as: dose producing DLT in 2 out of 6 patients or dose level below the dose which produced DLT in >/= 2 out of 3 patients, or in >/= 3 out of 6 patients If no MTD (maximum tolerable dose) was defined through 3 steps of dose escalation, phase 2 will proceed with a randomized treatment allocation of the two pre-specified dosage arms: low dose; 500mg and high dose; 2000mg" (NCT00085254)
Timeframe: 10 weeks
| Intervention | mg (Number) |
|---|---|
| Arm 1 - Safety Run In | NA |
The overall survival is calculated from time of histological diagnosis to death occurance - median based on all 112 patients, all dose levels (NCT00085254)
Timeframe: up to 36 months
| Intervention | months (Median) |
|---|---|
| Arm 4 (Overall Study) | 19.7 |
survival calculated from date of initial histologic diagnosis and occurence of death. Pts at 500mg dose compared against Pts treated at 2000mg dose. Calculated using median (NCT00085254)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Arm 1 - Phase 2 (Treatment 1) | 17.4 |
| Arm 2 - Phase 2 (Treatment 2) | 20.8 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00805961)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Overall Study | 53 |
Response to treatment was assessed by MRI using the MacDonald criteria based on the assessment of the MRI scan for measurable, evaluable, and new lesions. The objective response rate is defined as the proportion of patients with improvement and or decreased extent of lesions compared to baseline. (NCT00805961)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Overall Study | 31 |
Overall survival was defined as the interval from the first day of study treatment until the date of death. (NCT00805961)
Timeframe: 18 months
| Intervention | Months (Number) |
|---|---|
| Overall Study | 13.9 |
Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. (NCT00805961)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Overall Study | 11.3 |
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in body fat (Mean) |
|---|---|
| Behavioral Dietary Intervention | -3.1 |
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in BMI (Mean) |
|---|---|
| Behavioral Dietary Intervention | -1.2 |
Assessed via mixed-effects regression. (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | beats per minute (Mean) |
|---|---|
| Behavioral Dietary Intervention | 67.3 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%. (NCT01819233)
Timeframe: Up to week 12
| Intervention | participants (Number) |
|---|---|
| Behavioral Dietary Intervention | 28 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much) (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | score on a scale (Mean) |
|---|---|
| Behavioral Dietary Intervention | 0.8 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
All patients will have their tumor measurements recorded at baseline and at the time of each MRI scan. Lesions must be measured in two dimensions. The dose of gadolinium must be held constant from scan to scan. Macdonald criteria will be used for assessment of tumor response. (NCT00498927)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide | 7 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00498927)
Timeframe: at 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Temozolomide | 19 |
"MRI response evaluated by RANO criteria~Complete Response (CR): Circumstance when the enhancing tumor is no longer seen by neuroimaging, with the patient off all steroids or on adrenal maintenance only; CR will be coded only if confirmed by a second CT/MR scan performed a minimum of 4 weeks after the initial scan coding a response.~Partial Response (PR): Decrease of > 50% in the product of two diameters. Patients should be receiving stable or decreasing doses of steroids. PR will be coded only if confirmed by a second CT/MR scan performed a minimum of 4 weeks after the initial scan.~Progression (P): A > 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. This will not need a confirmatory scan. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of XRT." (NCT01402063)
Timeframe: Q 3 months on study then Q3 months in f/u for yr 1, q 4 months yr 2, q 6 months for approximately 4 ys.
| Intervention | participants (Number) |
|---|---|
| Radiation Plus PPX(CT2103 | 31 |
| Radiation + Temozolomide | 15 |
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Radiation Therapy + Temozolomide (TMZ) | 3.9 |
| RT + BCNU/CCNU | 3.8 |
Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Progression-free survival time is defined as time from randomization to date of progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Methylated MGMT | 4.0 |
| Unmthylated MGMT | 2.1 |
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Methylated MGMT | 7.2 |
| Unmthylated MGMT | 3.1 |
Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | months (Median) |
|---|---|
| Radiation Therapy + Temozolomide (TMZ) | 45.4 |
| RT + BCNU/CCNU | 54.7 |
Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (< 25,000 for 5 days), neutropenia (< 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU. (NCT00004259)
Timeframe: From start of treatment to 3 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Subjects with Pulmonary DLT | Subjects with Hematologic DLT | |
| Pilot Arm #1: RT+TMZ+BCNU | 1 | 4 |
| Pilot Arm #2: RT+TMZ+BCNU | 0 | 3 |
Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | participants (Number) | |
|---|---|---|
| Overall toxicity | Non-hematologic toxicity | |
| Radiation Therapy + Temozolomide (TMZ) | 46 | 31 |
| RT + BCNU/CCNU | 75 | 34 |
Two groups of patients in the Phase II trial will be considered separately, 1) participants who have not received previous bevacizumab and 2) participants who have received bevacizumab as part of first-line treatment. Overall survival is measured as the interval from first study treatment until date of death, or date last known alive. (NCT01349660)
Timeframe: every 12 weeks for up to 60 months
| Intervention | months (Median) |
|---|---|
| Phase II Participants - Prior Bevacizumab | 6.6 |
| Phase II Participants - Bevacizumab Naive | 10.8 |
Two groups of patients in the Phase II trial will be considered separately, 1) participants who have not received previous bevacizumab and 2) participants who have received bevacizumab as part of first-line treatment. PFS is measured from the date of first protocol treatment until date of disease progression or death occurs, or date of last adequate tumor assessment using RANO or McDonald criteria. McDonald disease progression criteria: a 25% or greater increase in sum of the diameters of lesions, new lesions, or clinical deterioration (McDonald et al, 1990). RANO disease progression criteria: a 25% or greater increase in the enhancing lesions sum compared with smallest tumor measurement, significant increase in T2/FLAIR nonenhancing lesion on stable or increasing corticosteroids, new lesions, or clinical deterioration (Wen et al 2010) (NCT01349660)
Timeframe: every 8 weeks for up to 33 months
| Intervention | months (Median) |
|---|---|
| Phase II Patients With Prior Bevacizumab Treatment. | 2.8 |
| Phase II Patients Without Prior Bevacizumab Treatment | 5.3 |
The optimal dose of BKM120 to administer in combination with standard dose bevacizumab determined as the dose at which ≤1 of 6 patients experiences a DLT assessed using NCI CTCAE v4.03 during Cycle 1 (28 days). The optimal dose of BKM120 was determined to be 60 mg by mouth (PO), once a day for each 28 day cycle along with bevacizumab, administered 10 mg/kg intravenously (IV) on Day 1 and Day 15 of each 28 day cycle. (NCT01349660)
Timeframe: Collected from day of first dose to the end of the first treatment cycle, up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I Dose Level 1 (60 mg BKM120, 10mg/kg Bevacizumab) | 0 |
| Phase I Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab) | 3 |
Two groups of participants in the Phase II trial will be considered separately, 1) those who have not received previous bevacizumab and 2) those who have received bevacizumab as part of first-line treatment. Overall Response (OR) = number of patients with complete or partial responses (CR or PR) per McDonald or RANO criteria. McDonald: CR as disappearance of all disease for at least four weeks, no new lesions, no steroids; PR as 50% or greater decrease in the sum of all lesions compared with baseline for at least four weeks, no new lesions, stable or reduced steroids (McDonald 1990). RANO: CR as disappearance of all disease for at least 4 weeks, no new lesions, stable or improved nonenhancing lesions, and no steroid usage; and PR as a 50% or greater decrease in the sum of all lesions compared with baseline measurement for at least four weeks, no new lesions, stable or improved nonenhancing lesions on same or lower steroid dose compared to baseline (Wen 2010). (NCT01349660)
Timeframe: every 8 weeks, projected 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase II Participants - Prior Bevacizumab. | 1 |
| Phase II Participants - Bevacizumab Naive | 18 |
Defined as the number of participants with treatment-emergent grade 3/4/5 adverse events/serious adverse events utilizing the National Cancer Institute Common Technology Criteria for Adverse Events (NCI CTCAE) v4.03 (NCT01349660)
Timeframe: every 4 weeks for up to 5.2 years
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Confusion | Hyperglycemia | Diarrhea | Alanine aminotransferase increased | Hypertension | Seizure | Asthenia | Aspartate Aminotransferase Increased | Hypertriglyceridemia | Abdominal pain | Altered Mental Status | Gait Disturbance | Ataxia | Lipase Increased | Muscle Weakness | Pneumonia | Sepsis | Respiratory Failure | Thrombocytopenia | Hypercholesterolemia | Mucositis | Anorexia | Memory Impairment | Pruritis | Vomiting | Mood Alteration | Weight Loss | Neutropenia | Dehydration | Dyspnea | Hemorrhage | Somnolence | Taste Alteration | Agitation | Dysarthria | Fall | Hypermagnesemia | Ejection Fraction Decreased | Elevated Liver Enzymes | Hypoalbuminemia | Hypophosphatemia | Psychosis | Suicidal Ideation | Thromboembolic Event | Akathisia | Cellulitis | Chronic Obstructive Pulmonary Disease | Delirium | Diabetic Ketoacidosis | Enteritis | Female Genital Tract Fistula | Gastrointestinal Infection | Hyperlipidemia | Intracranial Hemorrhage | Left Ventricular Systolic Dysfunction | Necrotizing Fasciitis | Palsy | Paralysis | Personality Change | Syncope | Transaminitis | Urine Output Decreased | Vaginal Fistula | Volume Depletion | Headache | Hypokalemia | Hyponatremia | Nausea | Proteinuria | Rash | Urinary Tract Infection | |
| Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 2 |
| Phase II - (60 mg BKM120, 10mg/kg Bevacizumab) | 8 | 8 | 5 | 5 | 5 | 6 | 6 | 4 | 5 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 4 | 3 | 1 | 3 | 2 | 2 |
We first determined the MTDs in each ARM and we then performed the cohort expansion at the MTD in both ARMs separately, until we treated a total of 18 participants at this dose in each ARM. PFS is defined as the duration of time from start of registration to time of progression or death, whichever comes first. Progression was assessed by the Response Assessment in Neuro-Oncology Criteria (RANO). Progression is ≥25% increase in tumor volume compared to baseline in the sum of the products of perpendicular diameters of enhancing lesions compared with the smallest measurement obtained either at baseline or best response with the participant on stable or increasing doses of steroids. Significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) non-enhancing lesions with the participant on stable or increasing doses of steroids (not caused by comorbid events). Any new lesions. (NCT02942264)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 25 |
We first determined the maximum tolerated dose (MTDs) in each ARM and we then performed the cohort expansion at the MTD in both ARMs separately, until we treated a total of 18 participants at this dose in each ARM. PFS is defined as the duration of time from start of registration to time of progression or death, whichever comes first. Progression was assessed by the Response Assessment in Neuro-Oncology Criteria (RANO). Progression is ≥25% increase in tumor volume compared to baseline in the sum of the products of perpendicular diameters of enhancing lesions compared with the smallest measurement obtained either at baseline or best response with the participant on stable or increasing doses of steroids. Significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) non-enhancing lesions with the participant on stable or increasing doses of steroids (not caused by comorbid events). Any new lesions. (NCT02942264)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 40 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02942264)
Timeframe: Date treatment consent signed to date off study, approximately 15mo(m)/8days(d), 26m, 7m/26d, 13m/17d, 11m/30d, 12m/6d, 19m/11d, 9m/28d and 18m/21d for Group 1-9 respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 Dose Level 0 - (Starting Dose) | 6 |
| ARM 1 Dose Level 1 - (Dose Escalation) | 13 |
| ARM 2 Dose Level 0 (Starting Dose) | 3 |
| ARM 2 Dose 1 - (Dose Escalation) | 6 |
| ARM 2 Dose 0 - (Dose De-escalation) | 3 |
| ARM 2 Dose Level II - (Dose Escalation) | 2 |
| ARM 2 Dose Level I - (Dose De-escalation) | 7 |
| ARM 1 Dose Level 1 (MTD Level in ARM1) | 6 |
| ARM 2 Dose Level 1 (MTD Level in ARM2) | 7 |
Maximum tolerated dose of metronomic (mn) Zotiraciclib (TG02) was assessed using the Bayesian Optimal Interval (BOIN) design. The MTD is defined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.35. If there are ties, we select the higher dose level when the isotonic estimate is lower than the target toxicity rate; and we select the lower dose level when the isotonic estimate is greater than the target toxicity rate of 0.35. (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | mg/day (Number) |
|---|---|
| All Participants | 250 |
Maximum tolerated dose of Zotiraciclib (TG02) in combination with dose dense Temozolomide (TMZ) was assessed using the Bayesian Optimal Interval (BOIN) design. The MTD is defined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.35. If there are ties, we select the higher dose level when the isotonic estimate is lower than the target toxicity rate; and we select the lower dose level when the isotonic estimate is greater than the target toxicity rate of 0.35. (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | mg/day (Number) |
|---|---|
| All Participants | 250 |
DLT is defined as any adverse events attributed to the study drug. For example, Grade 4 neutropenia lasting 5 days or more. Febrile neutropenia defined as grade 3-4 neutropenia with fever ≥38.5ºC and/or infection requiring antibiotic or antifungal treatment. Nausea or vomiting that responds to symptomatic therapy and lasts ≤7 days. Fatigue that responds to symptomatic therapy and lasts ≤7 days. And weight gain (in patients on steroids). (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 Dose Level 0 - (Starting Dose) | 1 |
| ARM 1 Dose Level 1 - (Dose Escalation) | 3 |
| ARM 2 Dose Level 0 (Starting Dose) | 0 |
| ARM 2 Dose 1 - (Dose Escalation) | 3 |
| ARM 2 Dose 0 - (Dose De-escalation) | 1 |
| ARM 2 Dose Level II - (Dose Escalation) | 1 |
| ARM 2 Dose Level I - (Dose De-escalation) | 4 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
Number of Participants in Phase 1 with Dose Limiting Toxicities (DLTs) (NCT01465347)
Timeframe: During phase 1
| Intervention | Participants (Count of Participants) |
|---|---|
| TSC 0.25 mg/kg - 9 Dose Group | 0 |
The sum of the product of the diameters of the tumor (using recorded tumor diameter measurements made from brain MRI images) was used to express tumor size. Results were summarized for actual and percentage change from baseline. Individual subjects results were listed, including tumor volume and tumor response from independent reviewers. Investigator data were listed but not used in the analysis. Percent response (according to independent reviewer assessments) by percentage tumor reduction from tumor resection or definitive biopsy to the last MRI were summarized. (NCT01465347)
Timeframe: From Baseline to Week 110
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| tumor not reduced | 0 to 39% tumor reduction | 40 to 63% tumor reduction | 64 to 93% tumor reduction | 94 to 99% tumor reduction | 100% tumor reduction | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 10 | 6 | 2 | 6 | 2 | 11 |
| TSC 0.25mg/kg - 9 Dose Group - Phase 1 | 1 | 0 | 0 | 0 | 0 | 2 |
Participants in phase 2 (18 dose group, 6 weeks treatment with TSC) were monitored for up to 3 years (last follow-up - February 16, 2016). Overall Survival (OS) was defined as the length of time from the date of tumor resection surgery or definitive biopsy to the date of death. The OS analyses were performed using the Kaplan-Meier estimate method. The OS rates at 6, 12, 18 and 24 months were estimated. Median OS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. The length of OS (in months) was calculated as follows: date of death or censored - date of surgery or definitive biopsy / 30.4375. (NCT01465347)
Timeframe: 6, 12, 18, 24 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| 6 month OS | 12 month OS | 18 month OS | 24 month OS | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 89.3 | 71.2 | 43.8 | 36.3 |
The PFS analyses were performed using the Kaplan-Meier estimate method. The PFS rates at 6, 12, 18 and 24 months were estimated. Median PFS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. Time to disease progression (in months) was calculated as follows: date of event* or censoring - date of surgery or definitive biopsy / 30.4375; *event = first tumor progression or death. (NCT01465347)
Timeframe: 6,12,18, 24 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| 6 months | 12 months | 18 months | 24 months | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 30.9 | 9.9 | 4.0 | 0.0 |
All patients will have their tumor measurements recorded at baseline and at the time of each MRI scan. Lesions must be measured in two dimensions. (NCT00026494)
Timeframe: 2 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Stable Disease (SD) | Progression of Disease (POD) | Partial Response (PR) | Minor Response (MR) | Complete Response (CR) | |
| 15mg/m2 - Vinorelbine | 3 | 2 | 0 | 0 | 0 |
| 20mg/m2 - Vinorelbine | 2 | 1 | 1 | 0 | 0 |
| 25mg/m2 - Vinorelbine | 4 | 11 | 0 | 1 | 0 |
| 30mg/m2 - Vinorelbine | 3 | 12 | 0 | 0 | 1 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
372 reviews available for temozolomide and Brain Neoplasms
| Article | Year |
|---|---|
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; D | 2021 |
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; D | 2021 |
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; D | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review.
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Invasive Pulmonary Aspergillosis; Male; Risk Factors; T | 2021 |
Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review.
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Invasive Pulmonary Aspergillosis; Male; Risk Factors; T | 2021 |
Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review.
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Invasive Pulmonary Aspergillosis; Male; Risk Factors; T | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modalit | 2021 |
Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modalit | 2021 |
Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modalit | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Progression-F | 2022 |
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Progression-F | 2022 |
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Progression-F | 2022 |
Newly Diagnosed Glioblastoma in Elderly Patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pre | 2022 |
Newly Diagnosed Glioblastoma in Elderly Patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pre | 2022 |
Newly Diagnosed Glioblastoma in Elderly Patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pre | 2022 |
Oxamate targeting aggressive cancers with special emphasis to brain tumors.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glycolysis; Humans; L-Lactate Dehydrogenase; Mitochondri | 2022 |
Oxamate targeting aggressive cancers with special emphasis to brain tumors.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glycolysis; Humans; L-Lactate Dehydrogenase; Mitochondri | 2022 |
Oxamate targeting aggressive cancers with special emphasis to brain tumors.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glycolysis; Humans; L-Lactate Dehydrogenase; Mitochondri | 2022 |
Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Topics: Adult; Brain Neoplasms; Brain Stem; Dacarbazine; Glioblastoma; Humans; Male; Pyridines; Temozolomide | 2022 |
Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Topics: Adult; Brain Neoplasms; Brain Stem; Dacarbazine; Glioblastoma; Humans; Male; Pyridines; Temozolomide | 2022 |
Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Topics: Adult; Brain Neoplasms; Brain Stem; Dacarbazine; Glioblastoma; Humans; Male; Pyridines; Temozolomide | 2022 |
Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Immunologic Factors; Immunotherapy; Lymp | 2022 |
Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Immunologic Factors; Immunotherapy; Lymp | 2022 |
Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Immunologic Factors; Immunotherapy; Lymp | 2022 |
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2022 |
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2022 |
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2022 |
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Obser | 2022 |
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Obser | 2022 |
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Obser | 2022 |
Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Temozolomide | 2022 |
Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Temozolomide | 2022 |
Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Temozolomide | 2022 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Glioblastoma | 2023 |
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Glioblastoma | 2023 |
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Glioblastoma | 2023 |
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Neoplastic Stem Cells; Temozolomide | 2022 |
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Neoplastic Stem Cells; Temozolomide | 2022 |
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Neoplastic Stem Cells; Temozolomide | 2022 |
Optimal managements of elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Tem | 2022 |
Optimal managements of elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Tem | 2022 |
Optimal managements of elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Tem | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastom | 2022 |
Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastom | 2022 |
Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastom | 2022 |
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Retrospective | 2022 |
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Retrospective | 2022 |
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Retrospective | 2022 |
Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Guanine; Humans; Temozolomide | 2022 |
Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Guanine; Humans; Temozolomide | 2022 |
Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Guanine; Humans; Temozolomide | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Temozolomid | 2022 |
Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Temozolomid | 2022 |
Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Temozolomid | 2022 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2022 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2022 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2022 |
Nanomedicine for glioblastoma: Progress and future prospects.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanomedicine; Temozolomide | 2022 |
Nanomedicine for glioblastoma: Progress and future prospects.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanomedicine; Temozolomide | 2022 |
Nanomedicine for glioblastoma: Progress and future prospects.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanomedicine; Temozolomide | 2022 |
Updates in the Management of Recurrent Glioblastoma Multiforme.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Updates in the Management of Recurrent Glioblastoma Multiforme.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Updates in the Management of Recurrent Glioblastoma Multiforme.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Glioblastoma and Methionine Addiction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Epigenesis, Genetic; Glioblastoma; Humans; Methi | 2022 |
Glioblastoma and Methionine Addiction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Epigenesis, Genetic; Glioblastoma; Humans; Methi | 2022 |
Glioblastoma and Methionine Addiction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Epigenesis, Genetic; Glioblastoma; Humans; Methi | 2022 |
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Topics: Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2022 |
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Topics: Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2022 |
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Topics: Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2022 |
Intracranial dissemination of glioblastoma multiforme: a case report and literature review.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Glioblastoma; Humans; Tem | 2022 |
Intracranial dissemination of glioblastoma multiforme: a case report and literature review.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Glioblastoma; Humans; Tem | 2022 |
Intracranial dissemination of glioblastoma multiforme: a case report and literature review.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Glioblastoma; Humans; Tem | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Immune Checkpoint Inhibi | 2022 |
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Immune Checkpoint Inhibi | 2022 |
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Immune Checkpoint Inhibi | 2022 |
Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Delayed-Act | 2022 |
Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Delayed-Act | 2022 |
Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Delayed-Act | 2022 |
Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Signal Transduction; Temozolomide | 2022 |
Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Signal Transduction; Temozolomide | 2022 |
Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Signal Transduction; Temozolomide | 2022 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
Tumor treating fields with radiation for glioblastoma: a narrative review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Temozol | 2022 |
Tumor treating fields with radiation for glioblastoma: a narrative review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Temozol | 2022 |
Tumor treating fields with radiation for glioblastoma: a narrative review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Temozol | 2022 |
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; COVID-19; Glioblastoma; Humans; Middle Aged; Pan | 2022 |
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; COVID-19; Glioblastoma; Humans; Middle Aged; Pan | 2022 |
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; COVID-19; Glioblastoma; Humans; Middle Aged; Pan | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Organoids; Temozolomide | 2022 |
Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Organoids; Temozolomide | 2022 |
Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Organoids; Temozolomide | 2022 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
Injectable local drug delivery systems for glioblastoma: a systematic review and
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Glioblastoma; Liposomes; Temozolomide | 2023 |
Injectable local drug delivery systems for glioblastoma: a systematic review and
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Glioblastoma; Liposomes; Temozolomide | 2023 |
Injectable local drug delivery systems for glioblastoma: a systematic review and
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Glioblastoma; Liposomes; Temozolomide | 2023 |
Modeling glioblastoma complexity with organoids for personalized treatments.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2023 |
Modeling glioblastoma complexity with organoids for personalized treatments.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2023 |
Modeling glioblastoma complexity with organoids for personalized treatments.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know.
Topics: Brain Neoplasms; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neurosurgeons; RNA, L | 2023 |
The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know.
Topics: Brain Neoplasms; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neurosurgeons; RNA, L | 2023 |
The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know.
Topics: Brain Neoplasms; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neurosurgeons; RNA, L | 2023 |
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lymphopenia; Radiotherapy; Temozolomide; Treatment Outcome | 2023 |
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lymphopenia; Radiotherapy; Temozolomide; Treatment Outcome | 2023 |
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lymphopenia; Radiotherapy; Temozolomide; Treatment Outcome | 2023 |
Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme.
Topics: Adult; Autophagy; Brain Neoplasms; Glioblastoma; Humans; MicroRNAs; Temozolomide; Tumor Microenviron | 2023 |
Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme.
Topics: Adult; Autophagy; Brain Neoplasms; Glioblastoma; Humans; MicroRNAs; Temozolomide; Tumor Microenviron | 2023 |
Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme.
Topics: Adult; Autophagy; Brain Neoplasms; Glioblastoma; Humans; MicroRNAs; Temozolomide; Tumor Microenviron | 2023 |
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.
Topics: Brain Neoplasms; Glioblastoma; Humans; Indoles; Temozolomide | 2023 |
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.
Topics: Brain Neoplasms; Glioblastoma; Humans; Indoles; Temozolomide | 2023 |
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.
Topics: Brain Neoplasms; Glioblastoma; Humans; Indoles; Temozolomide | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Isocitrate Dehydrogenase; Mutation; Prognosis; | 2023 |
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Isocitrate Dehydrogenase; Mutation; Prognosis; | 2023 |
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Isocitrate Dehydrogenase; Mutation; Prognosis; | 2023 |
Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioblastoma; Humans; Pyroptos | 2023 |
Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioblastoma; Humans; Pyroptos | 2023 |
Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioblastoma; Humans; Pyroptos | 2023 |
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Precision Medicine; Prognosis; T | 2023 |
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Precision Medicine; Prognosis; T | 2023 |
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Precision Medicine; Prognosis; T | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; End | 2023 |
Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; End | 2023 |
Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; End | 2023 |
The impact of survivorship bias in glioblastoma research.
Topics: Aged; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Repair Enzymes; Glioblas | 2023 |
The impact of survivorship bias in glioblastoma research.
Topics: Aged; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Repair Enzymes; Glioblas | 2023 |
The impact of survivorship bias in glioblastoma research.
Topics: Aged; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Repair Enzymes; Glioblas | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; Male; Molecular Targeted Therapy; | 2019 |
Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; Male; Molecular Targeted Therapy; | 2019 |
Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; Male; Molecular Targeted Therapy; | 2019 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chemistry, Pharmaceutical; Dendrimers; | 2020 |
Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chemistry, Pharmaceutical; Dendrimers; | 2020 |
Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chemistry, Pharmaceutical; Dendrimers; | 2020 |
Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Disease-Free Survival; Glioblastoma; Humans; Prospective | 2021 |
Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Disease-Free Survival; Glioblastoma; Humans; Prospective | 2021 |
Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Disease-Free Survival; Glioblastoma; Humans; Prospective | 2021 |
Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood-Brain Barrier; Bra | 2020 |
Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood-Brain Barrier; Bra | 2020 |
Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood-Brain Barrier; Bra | 2020 |
Management of glioblastomas in the elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Prospective Studies; | 2020 |
Management of glioblastomas in the elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Prospective Studies; | 2020 |
Management of glioblastomas in the elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Prospective Studies; | 2020 |
MGMT Status as a Clinical Biomarker in Glioblastoma.
Topics: Biomarkers, Tumor; Brain Neoplasms; Clinical Decision-Making; DNA Methylation; DNA Mismatch Repair; | 2020 |
MGMT Status as a Clinical Biomarker in Glioblastoma.
Topics: Biomarkers, Tumor; Brain Neoplasms; Clinical Decision-Making; DNA Methylation; DNA Mismatch Repair; | 2020 |
MGMT Status as a Clinical Biomarker in Glioblastoma.
Topics: Biomarkers, Tumor; Brain Neoplasms; Clinical Decision-Making; DNA Methylation; DNA Mismatch Repair; | 2020 |
Management of glioblastoma: State of the art and future directions.
Topics: Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastom | 2020 |
Management of glioblastoma: State of the art and future directions.
Topics: Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastom | 2020 |
Management of glioblastoma: State of the art and future directions.
Topics: Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastom | 2020 |
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Humans; Nanotechnology; Temozo | 2021 |
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Humans; Nanotechnology; Temozo | 2021 |
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Humans; Nanotechnology; Temozo | 2021 |
The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Ra | 2020 |
The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Ra | 2020 |
The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Ra | 2020 |
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cl | 2020 |
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cl | 2020 |
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cl | 2020 |
Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Disease-Free Survival; Glioblastoma; Huma | 2020 |
Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Disease-Free Survival; Glioblastoma; Huma | 2020 |
Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Disease-Free Survival; Glioblastoma; Huma | 2020 |
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Immunoth | 2021 |
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Immunoth | 2021 |
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Immunoth | 2021 |
Management of elderly patients with glioblastoma: current status with a focus on the post-operative radiation therapy.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Quality of Life; Temozolomid | 2020 |
Management of elderly patients with glioblastoma: current status with a focus on the post-operative radiation therapy.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Quality of Life; Temozolomid | 2020 |
Management of elderly patients with glioblastoma: current status with a focus on the post-operative radiation therapy.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Quality of Life; Temozolomid | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen | 2020 |
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen | 2020 |
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen | 2020 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Gr | 2021 |
Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Gr | 2021 |
Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Gr | 2021 |
Treatments of gliosarcoma of the brain: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2021 |
Treatments of gliosarcoma of the brain: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2021 |
Treatments of gliosarcoma of the brain: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2021 |
Update on the management of elderly patients with glioblastoma: a narrative review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Ran | 2021 |
Update on the management of elderly patients with glioblastoma: a narrative review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Ran | 2021 |
Update on the management of elderly patients with glioblastoma: a narrative review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Ran | 2021 |
Radiation-Associated Glioblastoma after Prophylactic Cranial Irradiation in a Patient of ALL: Review of Literature and Report of a Rare Case.
Topics: Brain Neoplasms; Child, Preschool; Cranial Irradiation; Glioblastoma; Humans; Male; Neoplasm Recurre | 2020 |
Radiation-Associated Glioblastoma after Prophylactic Cranial Irradiation in a Patient of ALL: Review of Literature and Report of a Rare Case.
Topics: Brain Neoplasms; Child, Preschool; Cranial Irradiation; Glioblastoma; Humans; Male; Neoplasm Recurre | 2020 |
Radiation-Associated Glioblastoma after Prophylactic Cranial Irradiation in a Patient of ALL: Review of Literature and Report of a Rare Case.
Topics: Brain Neoplasms; Child, Preschool; Cranial Irradiation; Glioblastoma; Humans; Male; Neoplasm Recurre | 2020 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
Natural substances to potentiate canonical glioblastoma chemotherapy.
Topics: Anthraquinones; Biological Products; Brain Neoplasms; Catechols; Cell Cycle; Dose-Response Relations | 2021 |
Natural substances to potentiate canonical glioblastoma chemotherapy.
Topics: Anthraquinones; Biological Products; Brain Neoplasms; Catechols; Cell Cycle; Dose-Response Relations | 2021 |
Natural substances to potentiate canonical glioblastoma chemotherapy.
Topics: Anthraquinones; Biological Products; Brain Neoplasms; Catechols; Cell Cycle; Dose-Response Relations | 2021 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; | 2021 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; | 2021 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; | 2021 |
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cohort Studies; CpG Islands; DNA Me | 2021 |
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cohort Studies; CpG Islands; DNA Me | 2021 |
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cohort Studies; CpG Islands; DNA Me | 2021 |
Novel Radiation Approaches.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
Novel Radiation Approaches.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
Novel Radiation Approaches.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene E | 2021 |
Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene E | 2021 |
Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene E | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; DNA Modification Methylases; DNA | 2021 |
Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; DNA Modification Methylases; DNA | 2021 |
Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; DNA Modification Methylases; DNA | 2021 |
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Topics: Adult; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; DNA Damage; | 2022 |
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Topics: Adult; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; DNA Damage; | 2022 |
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Topics: Adult; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; DNA Damage; | 2022 |
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; DNA Damage; DNA Repair; | 2021 |
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; DNA Damage; DNA Repair; | 2021 |
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; DNA Damage; DNA Repair; | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
Topics: Animals; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Cancer-Associated Fibroblasts; Carcinogenes | 2021 |
Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
Topics: Animals; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Cancer-Associated Fibroblasts; Carcinogenes | 2021 |
Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
Topics: Animals; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Cancer-Associated Fibroblasts; Carcinogenes | 2021 |
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Quality | 2021 |
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Quality | 2021 |
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Quality | 2021 |
Progress and prospect in tumor treating fields treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Th | 2021 |
Progress and prospect in tumor treating fields treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Th | 2021 |
Progress and prospect in tumor treating fields treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Th | 2021 |
Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2021 |
Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2021 |
Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2021 |
Antioxidant responses related to temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Antioxidant responses related to temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Antioxidant responses related to temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cam | 2021 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cam | 2021 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cam | 2021 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Managing Glioblastoma in the Elderly Patient: New Opportunities.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disea | 2017 |
Managing Glioblastoma in the Elderly Patient: New Opportunities.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disea | 2017 |
Managing Glioblastoma in the Elderly Patient: New Opportunities.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disea | 2017 |
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Humans; Isocitrate Dehydroge | 2017 |
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Humans; Isocitrate Dehydroge | 2017 |
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Humans; Isocitrate Dehydroge | 2017 |
Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2017 |
Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2017 |
Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Topics: Animals; Brain Neoplasms; Cause of Death; Chemoradiotherapy; Combined Modality Therapy; Disease Mana | 2018 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Topics: Animals; Brain Neoplasms; Cause of Death; Chemoradiotherapy; Combined Modality Therapy; Disease Mana | 2018 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Topics: Animals; Brain Neoplasms; Cause of Death; Chemoradiotherapy; Combined Modality Therapy; Disease Mana | 2018 |
Glioblastoma in the elderly: initial management.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, P | 2017 |
Glioblastoma in the elderly: initial management.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, P | 2017 |
Glioblastoma in the elderly: initial management.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, P | 2017 |
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2017 |
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2017 |
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2017 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca | 2017 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca | 2017 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca | 2017 |
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Topics: Aging; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide; Treat | 2018 |
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Topics: Aging; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide; Treat | 2018 |
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Topics: Aging; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide; Treat | 2018 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Bra | 2017 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Bra | 2017 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Bra | 2017 |
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mod | 2018 |
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mod | 2018 |
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mod | 2018 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy | 2018 |
Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy | 2018 |
Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescen | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescen | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescen | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Repurposing drugs for glioblastoma: From bench to bedside.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Repositioning; Drug Resistanc | 2018 |
Repurposing drugs for glioblastoma: From bench to bedside.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Repositioning; Drug Resistanc | 2018 |
Repurposing drugs for glioblastoma: From bench to bedside.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Repositioning; Drug Resistanc | 2018 |
Temozolomide for immunomodulation in the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunomodulation; Prognosi | 2018 |
Temozolomide for immunomodulation in the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunomodulation; Prognosi | 2018 |
Temozolomide for immunomodulation in the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunomodulation; Prognosi | 2018 |
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2018 |
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2018 |
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2018 |
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cholesterol; Drug Resistance, Neopla | 2018 |
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cholesterol; Drug Resistance, Neopla | 2018 |
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cholesterol; Drug Resistance, Neopla | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Treatment of Glioblastoma in the Elderly.
Topics: Aged; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine | 2018 |
Treatment of Glioblastoma in the Elderly.
Topics: Aged; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine | 2018 |
Treatment of Glioblastoma in the Elderly.
Topics: Aged; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine | 2018 |
Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.
Topics: Antineoplastic Agents; Autophagosomes; Autophagy; Brain Neoplasms; Cell Death; Drug Resistance, Neop | 2018 |
Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.
Topics: Antineoplastic Agents; Autophagosomes; Autophagy; Brain Neoplasms; Cell Death; Drug Resistance, Neop | 2018 |
Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.
Topics: Antineoplastic Agents; Autophagosomes; Autophagy; Brain Neoplasms; Cell Death; Drug Resistance, Neop | 2018 |
Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplas | 2018 |
Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplas | 2018 |
Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplas | 2018 |
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; | 2018 |
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; | 2018 |
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; | 2018 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Evidence-Based Practice; Glioblastoma; Humans; T | 2019 |
Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Evidence-Based Practice; Glioblastoma; Humans; T | 2019 |
Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Evidence-Based Practice; Glioblastoma; Humans; T | 2019 |
Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Prognos | 2019 |
Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Prognos | 2019 |
Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Prognos | 2019 |
From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM.
Topics: Brain Neoplasms; Glioblastoma; Humans; Receptors, Calcitriol; Temozolomide; Tretinoin; Vitamin D | 2019 |
From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM.
Topics: Brain Neoplasms; Glioblastoma; Humans; Receptors, Calcitriol; Temozolomide; Tretinoin; Vitamin D | 2019 |
From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM.
Topics: Brain Neoplasms; Glioblastoma; Humans; Receptors, Calcitriol; Temozolomide; Tretinoin; Vitamin D | 2019 |
Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Reoperation; Temozolomide; | 2019 |
Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Reoperation; Temozolomide; | 2019 |
Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Reoperation; Temozolomide; | 2019 |
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Topics: Brain Neoplasms; Cell Death; DNA Repair; Humans; Nitrosourea Compounds; Precision Medicine; Temozolo | 2019 |
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Topics: Brain Neoplasms; Cell Death; DNA Repair; Humans; Nitrosourea Compounds; Precision Medicine; Temozolo | 2019 |
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
Topics: Brain Neoplasms; Cell Death; DNA Repair; Humans; Nitrosourea Compounds; Precision Medicine; Temozolo | 2019 |
Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regul | 2019 |
Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regul | 2019 |
Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regul | 2019 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
Essential role of Gli proteins in glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hedgeh | 2013 |
Essential role of Gli proteins in glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hedgeh | 2013 |
Essential role of Gli proteins in glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hedgeh | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2013 |
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Topics: Brain Neoplasms; Dacarbazine; Humans; Isocitrate Dehydrogenase; Mutation; Oligodendroglioma; Temozol | 2013 |
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Topics: Brain Neoplasms; Dacarbazine; Humans; Isocitrate Dehydrogenase; Mutation; Oligodendroglioma; Temozol | 2013 |
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Topics: Brain Neoplasms; Dacarbazine; Humans; Isocitrate Dehydrogenase; Mutation; Oligodendroglioma; Temozol | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory N | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory N | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory N | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; | 2013 |
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; | 2013 |
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; | 2013 |
Elderly patients with glioblastoma: the treatment challenge.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2013 |
Elderly patients with glioblastoma: the treatment challenge.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2013 |
Elderly patients with glioblastoma: the treatment challenge.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, | 2014 |
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, | 2014 |
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, | 2014 |
Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methyl | 2014 |
Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methyl | 2014 |
Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methyl | 2014 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
Treatment options and outcomes for glioblastoma in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2014 |
Treatment options and outcomes for glioblastoma in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2014 |
Treatment options and outcomes for glioblastoma in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Straying from the path in neuro-oncology.
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Medical Oncology; Temozolomide | 2014 |
Straying from the path in neuro-oncology.
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Medical Oncology; Temozolomide | 2014 |
Straying from the path in neuro-oncology.
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Medical Oncology; Temozolomide | 2014 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Predictive biomarkers investigated in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Daca | 2014 |
Predictive biomarkers investigated in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Daca | 2014 |
Predictive biomarkers investigated in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Daca | 2014 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Me | 2014 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Me | 2014 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Me | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Treatment of brain metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2014 |
Treatment of brain metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2014 |
Treatment of brain metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Emerging therapies for glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell- and Tissue-Based Therapy; Dacarbazine; Glioblas | 2014 |
Emerging therapies for glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell- and Tissue-Based Therapy; Dacarbazine; Glioblas | 2014 |
Emerging therapies for glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell- and Tissue-Based Therapy; Dacarbazine; Glioblas | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Glioblastoma survival: has it improved? Evidence from population-based studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Community Health Planning; Dacarbazine; Glioblas | 2014 |
Glioblastoma survival: has it improved? Evidence from population-based studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Community Health Planning; Dacarbazine; Glioblas | 2014 |
Glioblastoma survival: has it improved? Evidence from population-based studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Community Health Planning; Dacarbazine; Glioblas | 2014 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2015 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2015 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2015 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Glioblastoma in the elderly.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repa | 2015 |
Glioblastoma in the elderly.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repa | 2015 |
Glioblastoma in the elderly.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repa | 2015 |
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2014 |
[Elderly patients with glioblastoma: state of the art].
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab | 2015 |
[Elderly patients with glioblastoma: state of the art].
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab | 2015 |
[Elderly patients with glioblastoma: state of the art].
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab | 2015 |
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug De | 2015 |
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug De | 2015 |
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug De | 2015 |
Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Ch | 2015 |
Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Ch | 2015 |
Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Ch | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Ther | 2015 |
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Ther | 2015 |
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Ther | 2015 |
Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Re | 2015 |
Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Re | 2015 |
Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug Re | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Therapeutic management of gliosarcoma in the temozolomide era.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Management; Gliosarcoma; Hu | 2015 |
Therapeutic management of gliosarcoma in the temozolomide era.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Management; Gliosarcoma; Hu | 2015 |
Therapeutic management of gliosarcoma in the temozolomide era.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Management; Gliosarcoma; Hu | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2016 |
Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2016 |
Intracranial fibrosarcoma treated with adjuvant radiation and temozolomide: Report of a case and review of all published cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2016 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
Comparison of the effectiveness of whole-brain radiotherapy plus temozolomide versus whole-brain radiotherapy in treating brain metastases based on a systematic review of randomized controlled trials.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2016 |
Comparison of the effectiveness of whole-brain radiotherapy plus temozolomide versus whole-brain radiotherapy in treating brain metastases based on a systematic review of randomized controlled trials.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2016 |
Comparison of the effectiveness of whole-brain radiotherapy plus temozolomide versus whole-brain radiotherapy in treating brain metastases based on a systematic review of randomized controlled trials.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2016 |
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2015 |
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2015 |
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2015 |
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol | 2015 |
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol | 2015 |
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol | 2015 |
Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party.
Topics: Adult; Africa, Northern; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Medical Oncology; Medit | 2016 |
Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party.
Topics: Adult; Africa, Northern; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Medical Oncology; Medit | 2016 |
Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party.
Topics: Adult; Africa, Northern; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Medical Oncology; Medit | 2016 |
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumo | 2016 |
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumo | 2016 |
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumo | 2016 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell S | 2016 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell S | 2016 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell S | 2016 |
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2016 |
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2016 |
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2016 |
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2016 |
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2016 |
Brain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2016 |
Low-grade and anaplastic oligodendroglioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methyl | 2016 |
Low-grade and anaplastic oligodendroglioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methyl | 2016 |
Low-grade and anaplastic oligodendroglioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methyl | 2016 |
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Hu | 2016 |
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Hu | 2016 |
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Hu | 2016 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascu | 2016 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascu | 2016 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascu | 2016 |
Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
Effects of Temozolomide and Radiotherapy on Brain Metastatic Tumor: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
Problems of Glioblastoma Multiforme Drug Resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine | 2016 |
Problems of Glioblastoma Multiforme Drug Resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine | 2016 |
Problems of Glioblastoma Multiforme Drug Resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modali | 2016 |
A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modali | 2016 |
A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Combined Modali | 2016 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2017 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2017 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2017 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Microglia in Cancer: For Good or for Bad?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cytokines; Dacarbazine; ErbB | 2016 |
Microglia in Cancer: For Good or for Bad?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cytokines; Dacarbazine; ErbB | 2016 |
Microglia in Cancer: For Good or for Bad?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cytokines; Dacarbazine; ErbB | 2016 |
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Sur | 2016 |
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Sur | 2016 |
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Sur | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Prote | 2017 |
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Prote | 2017 |
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Prote | 2017 |
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Consensus; Cranial Ir | 2017 |
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Consensus; Cranial Ir | 2017 |
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Consensus; Cranial Ir | 2017 |
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2017 |
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2017 |
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recu | 2008 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recu | 2008 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recu | 2008 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cognition; Dacarbazine; Humans; Neoplasm Metastasis; Pr | 2010 |
Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cognition; Dacarbazine; Humans; Neoplasm Metastasis; Pr | 2010 |
Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cognition; Dacarbazine; Humans; Neoplasm Metastasis; Pr | 2010 |
Radiotherapy for metastatic brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cra | 2009 |
Radiotherapy for metastatic brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cra | 2009 |
Radiotherapy for metastatic brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cra | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Humans; Tem | 2010 |
Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Humans; Tem | 2010 |
Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Humans; Tem | 2010 |
Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioblastoma; | 2009 |
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioblastoma; | 2009 |
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioblastoma; | 2009 |
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 2010 |
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 2010 |
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 2010 |
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DN | 2010 |
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DN | 2010 |
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DN | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age | 2011 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age | 2011 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age | 2011 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2011 |
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2011 |
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
[Glioblastoma in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2011 |
[Glioblastoma in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2011 |
[Glioblastoma in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2011 |
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2011 |
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2011 |
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2012 |
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2012 |
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2012 |
Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool | 2012 |
Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool | 2012 |
Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool | 2012 |
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemica | 2012 |
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemica | 2012 |
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemica | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; | 2012 |
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; | 2012 |
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; | 2012 |
Cellular-based immunotherapies for patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Cancer Vaccines; Cell Extracts; Clinical Trials as Topic; Combined Modality T | 2012 |
Cellular-based immunotherapies for patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Cancer Vaccines; Cell Extracts; Clinical Trials as Topic; Combined Modality T | 2012 |
Cellular-based immunotherapies for patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Cancer Vaccines; Cell Extracts; Clinical Trials as Topic; Combined Modality T | 2012 |
Cerebral ganglioneuroblastoma of adult onset: two patients and a review of the literature.
Topics: Adult; Age of Onset; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; C | 2012 |
Cerebral ganglioneuroblastoma of adult onset: two patients and a review of the literature.
Topics: Adult; Age of Onset; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; C | 2012 |
Cerebral ganglioneuroblastoma of adult onset: two patients and a review of the literature.
Topics: Adult; Age of Onset; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; C | 2012 |
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Recent medical management of glioblastoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Tr | 2012 |
Recent medical management of glioblastoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Tr | 2012 |
Recent medical management of glioblastoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Tr | 2012 |
The efficacy of temozolomide for recurrent glioblastoma multiforme.
Topics: Administration, Metronomic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Pha | 2013 |
The efficacy of temozolomide for recurrent glioblastoma multiforme.
Topics: Administration, Metronomic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Pha | 2013 |
The efficacy of temozolomide for recurrent glioblastoma multiforme.
Topics: Administration, Metronomic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Pha | 2013 |
Potential usefulness of radiosensitizers in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Potential usefulness of radiosensitizers in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Potential usefulness of radiosensitizers in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
[Brain metastases from breast cancer: prognostic factors and tailored management].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
[Brain metastases from breast cancer: prognostic factors and tailored management].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
[Brain metastases from breast cancer: prognostic factors and tailored management].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antin | 2012 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antin | 2012 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antin | 2012 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Top | 2012 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Top | 2012 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Top | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiothera | 2013 |
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiothera | 2013 |
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiothera | 2013 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agent | 2013 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agent | 2013 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agent | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
[Whole brain radiation therapy plus temozolomide in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dac | 2012 |
[Whole brain radiation therapy plus temozolomide in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dac | 2012 |
[Whole brain radiation therapy plus temozolomide in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dac | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
Chemotherapy for the treatment of metastatic brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carboplatin; Clinical Trials as Topic; Dacarbazine; Humans; | 2002 |
Chemotherapy for the treatment of metastatic brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carboplatin; Clinical Trials as Topic; Dacarbazine; Humans; | 2002 |
Chemotherapy for the treatment of metastatic brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carboplatin; Clinical Trials as Topic; Dacarbazine; Humans; | 2002 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The role of chemotherapy in brain metastases.
Topics: Anticonvulsants; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Ther | 2003 |
The role of chemotherapy in brain metastases.
Topics: Anticonvulsants; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Ther | 2003 |
The role of chemotherapy in brain metastases.
Topics: Anticonvulsants; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modality Ther | 2003 |
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2003 |
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2003 |
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neop | 2004 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neop | 2004 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neop | 2004 |
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Arachnoid Cysts; Astrocytoma; Brain Neoplasms; Child; Child, Pres | 2005 |
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Arachnoid Cysts; Astrocytoma; Brain Neoplasms; Child; Child, Pres | 2005 |
Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Arachnoid Cysts; Astrocytoma; Brain Neoplasms; Child; Child, Pres | 2005 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Research news and notes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cost-Benefit Analysis; Dac | 2005 |
Research news and notes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cost-Benefit Analysis; Dac | 2005 |
Research news and notes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cost-Benefit Analysis; Dac | 2005 |
Response of low-grade oligodendroglial tumors to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Controlled Clinical | 2004 |
Response of low-grade oligodendroglial tumors to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Controlled Clinical | 2004 |
Response of low-grade oligodendroglial tumors to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Controlled Clinical | 2004 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
[Highly quality-controlled radiation therapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2005 |
[Highly quality-controlled radiation therapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2005 |
[Highly quality-controlled radiation therapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2005 |
[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2005 |
[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2005 |
[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
[Standards and new developments in the chemotherapy of glioblastomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[Standards and new developments in the chemotherapy of glioblastomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[Standards and new developments in the chemotherapy of glioblastomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide.
Topics: Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Radiosurgery; Radiotherapy; Temozol | 2003 |
Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide.
Topics: Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Radiosurgery; Radiotherapy; Temozol | 2003 |
Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide.
Topics: Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; Radiosurgery; Radiotherapy; Temozol | 2003 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
Treatment of astrocytomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Therapy; Humans; | 2005 |
Treatment of astrocytomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Therapy; Humans; | 2005 |
Treatment of astrocytomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Therapy; Humans; | 2005 |
[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; | 2005 |
[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; | 2005 |
[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; | 2005 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
Advances in the treatment of primary brain tumors: dawn of a new era?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2006 |
Advances in the treatment of primary brain tumors: dawn of a new era?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2006 |
Advances in the treatment of primary brain tumors: dawn of a new era?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2006 |
The evolution of chemoradiation for glioblastoma: a modern success story.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2006 |
The evolution of chemoradiation for glioblastoma: a modern success story.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2006 |
The evolution of chemoradiation for glioblastoma: a modern success story.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2006 |
Temozolomide: a milestone in the pharmacotherapy of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; T | 2005 |
Temozolomide: a milestone in the pharmacotherapy of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; T | 2005 |
Temozolomide: a milestone in the pharmacotherapy of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; T | 2005 |
Role of temozolomide in pediatric brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Ther | 2006 |
Role of temozolomide in pediatric brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Ther | 2006 |
Role of temozolomide in pediatric brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Ther | 2006 |
Treatment options for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cytotoxins; Dacarbazin | 2006 |
Treatment options for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cytotoxins; Dacarbazin | 2006 |
Treatment options for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cytotoxins; Dacarbazin | 2006 |
Autophagy, the Trojan horse to combat glioblastomas.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Brain Neoplasms; Cell Movement; Dacarbazine; Drug Resi | 2006 |
Autophagy, the Trojan horse to combat glioblastomas.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Brain Neoplasms; Cell Movement; Dacarbazine; Drug Resi | 2006 |
Autophagy, the Trojan horse to combat glioblastomas.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Brain Neoplasms; Cell Movement; Dacarbazine; Drug Resi | 2006 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methy | 2006 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methy | 2006 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methy | 2006 |
The role of chemotherapy in the treatment of malignant astrocytomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2006 |
The role of chemotherapy in the treatment of malignant astrocytomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2006 |
The role of chemotherapy in the treatment of malignant astrocytomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2006 |
Radiation therapy in the management of brain metastases from renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Dacarbazine; Humans; Kidney Neoplasms; Metalloporphyrins; Ne | 2006 |
Radiation therapy in the management of brain metastases from renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Dacarbazine; Humans; Kidney Neoplasms; Metalloporphyrins; Ne | 2006 |
Radiation therapy in the management of brain metastases from renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Dacarbazine; Humans; Kidney Neoplasms; Metalloporphyrins; Ne | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modif | 2005 |
Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modif | 2005 |
Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modif | 2005 |
Chemotherapy for malignant gliomas.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cl | 2006 |
Chemotherapy for malignant gliomas.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cl | 2006 |
Chemotherapy for malignant gliomas.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cl | 2006 |
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant; | 2006 |
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant; | 2006 |
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant; | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; | 2007 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; | 2007 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
Anaplastic astrocytoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical T | 2007 |
Anaplastic astrocytoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical T | 2007 |
Anaplastic astrocytoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical T | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Cranial Irrad | 2007 |
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Cranial Irrad | 2007 |
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Cranial Irrad | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
Diagnosis and treatment of high-grade astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Dacarbazine; Diagnosis, Differen | 2007 |
Diagnosis and treatment of high-grade astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Dacarbazine; Diagnosis, Differen | 2007 |
Diagnosis and treatment of high-grade astrocytoma.
Topics: Antineoplastic Agents; Astrocytoma; Brachytherapy; Brain Neoplasms; Dacarbazine; Diagnosis, Differen | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2006 |
Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2006 |
Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2006 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain | 2006 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain | 2006 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain | 2006 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2000 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2000 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2001 |
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2001 |
Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2001 |
Temozolomide for treating brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemothera | 2001 |
Temozolomide for treating brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemothera | 2001 |
Temozolomide for treating brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemothera | 2001 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2002 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2002 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2002 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
513 trials available for temozolomide and Brain Neoplasms
| Article | Year |
|---|---|
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Gliob | 2021 |
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Gliob | 2021 |
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Gliob | 2021 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Brain Neoplasms; Combined | 2021 |
Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Brain Neoplasms; Combined | 2021 |
Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Brain Neoplasms; Combined | 2021 |
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Renin-Ang | 2022 |
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Renin-Ang | 2022 |
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Renin-Ang | 2022 |
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2022 |
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2022 |
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2022 |
The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Levetiracetam | 2022 |
The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Levetiracetam | 2022 |
The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Levetiracetam | 2022 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; DNA Modification Methylas | 2023 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; DNA Modification Methylas | 2023 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; DNA Modification Methylas | 2023 |
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA | 2022 |
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA | 2022 |
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA | 2022 |
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Dacarbaz | 2022 |
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Dacarbaz | 2022 |
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Dacarbaz | 2022 |
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2022 |
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2022 |
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2022 |
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cerebellar Neoplasms; | 2022 |
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cerebellar Neoplasms; | 2022 |
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cerebellar Neoplasms; | 2022 |
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Female; Glioblastoma; Hum | 2023 |
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Female; Glioblastoma; Hum | 2023 |
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Female; Glioblastoma; Hum | 2023 |
A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Quali | 2022 |
A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Quali | 2022 |
A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Quali | 2022 |
A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as | 2022 |
A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as | 2022 |
A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as | 2022 |
Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Human | 2023 |
Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Human | 2023 |
Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Human | 2023 |
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric | 2022 |
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric | 2022 |
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric | 2022 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DN | 2023 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DN | 2023 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DN | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomus | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomus | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomus | 2023 |
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Topics: Ado-Trastuzumab Emtansine; Brain Neoplasms; Breast Neoplasms; Cell-Free Nucleic Acids; Female; Human | 2023 |
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Topics: Ado-Trastuzumab Emtansine; Brain Neoplasms; Breast Neoplasms; Cell-Free Nucleic Acids; Female; Human | 2023 |
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Topics: Ado-Trastuzumab Emtansine; Brain Neoplasms; Breast Neoplasms; Cell-Free Nucleic Acids; Female; Human | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studi | 2023 |
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studi | 2023 |
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studi | 2023 |
Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as T | 2023 |
Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as T | 2023 |
Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as T | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2023 |
Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2023 |
Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; ErbB Receptor | 2020 |
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; ErbB Receptor | 2020 |
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; ErbB Receptor | 2020 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Fema | 2020 |
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Fema | 2020 |
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Fema | 2020 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Electric Stimulation | 2020 |
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Electric Stimulation | 2020 |
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Electric Stimulation | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Drug Synergism; Fe | 2020 |
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Drug Synergism; Fe | 2020 |
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Drug Synergism; Fe | 2020 |
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Cytoreduction Surgical Procedures; Female; Glioblas | 2020 |
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Cytoreduction Surgical Procedures; Female; Glioblas | 2020 |
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Cytoreduction Surgical Procedures; Female; Glioblas | 2020 |
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Thera | 2020 |
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Thera | 2020 |
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Thera | 2020 |
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; | 2020 |
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; | 2020 |
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Gene Amplificat | 2020 |
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Gene Amplificat | 2020 |
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Gene Amplificat | 2020 |
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2020 |
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2020 |
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2020 |
Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes | 2020 |
Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes | 2020 |
Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes | 2020 |
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neopl | 2020 |
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neopl | 2020 |
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neopl | 2020 |
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up Studi | 2020 |
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up Studi | 2020 |
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up Studi | 2020 |
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Topics: Adult; Brain Neoplasms; Humans; Isocitrate Dehydrogenase; Oligodendroglioma; Progression-Free Surviv | 2021 |
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Topics: Adult; Brain Neoplasms; Humans; Isocitrate Dehydrogenase; Oligodendroglioma; Progression-Free Surviv | 2021 |
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Topics: Adult; Brain Neoplasms; Humans; Isocitrate Dehydrogenase; Oligodendroglioma; Progression-Free Surviv | 2021 |
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Chemoradiotherapy; Fe | 2021 |
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Chemoradiotherapy; Fe | 2021 |
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Chemoradiotherapy; Fe | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Topics: Adolescent; Adult; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Humans; Lapatini | 2021 |
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Topics: Adolescent; Adult; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Humans; Lapatini | 2021 |
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Topics: Adolescent; Adult; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Humans; Lapatini | 2021 |
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2021 |
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2021 |
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2021 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
Initial Results of a Phase 2 Trial of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunologi | 2021 |
Initial Results of a Phase 2 Trial of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunologi | 2021 |
Initial Results of a Phase 2 Trial of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunologi | 2021 |
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bayes Theorem; Brain Neoplasms; Dacarba | 2021 |
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bayes Theorem; Brain Neoplasms; Dacarba | 2021 |
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bayes Theorem; Brain Neoplasms; Dacarba | 2021 |
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; DNA Methylation; DNA Modificatio | 2021 |
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; DNA Methylation; DNA Modificatio | 2021 |
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; DNA Methylation; DNA Modificatio | 2021 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
The need for geriatric scales in glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastom | 2021 |
The need for geriatric scales in glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastom | 2021 |
The need for geriatric scales in glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastom | 2021 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cel | 2017 |
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cel | 2017 |
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cel | 2017 |
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra | 2017 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2017 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2017 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2017 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Dacar | 2017 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Dacar | 2017 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Dacar | 2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combi | 2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combi | 2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combi | 2017 |
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2018 |
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2018 |
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2018 |
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2018 |
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2018 |
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2018 |
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2018 |
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2018 |
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbaz | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbaz | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbaz | 2018 |
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; DNA Methy | 2018 |
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; DNA Methy | 2018 |
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; DNA Methy | 2018 |
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2018 |
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2018 |
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2018 |
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
Efficacy and safety of temozolomide plus whole-brain radiotherapy in the treatment of intracranial metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial I | 2017 |
Efficacy and safety of temozolomide plus whole-brain radiotherapy in the treatment of intracranial metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial I | 2017 |
Efficacy and safety of temozolomide plus whole-brain radiotherapy in the treatment of intracranial metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial I | 2017 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Anti | 2018 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Anti | 2018 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Anti | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper; | 2018 |
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper; | 2018 |
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper; | 2018 |
Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Topics: Brain Neoplasms; Child; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; | 2018 |
Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Topics: Brain Neoplasms; Child; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; | 2018 |
Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Topics: Brain Neoplasms; Child; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cost-Benefit Ana | 2018 |
Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cost-Benefit Ana | 2018 |
Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cost-Benefit Ana | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Follow-U | 2018 |
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Follow-U | 2018 |
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Follow-U | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; | 2018 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Su | 2019 |
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Su | 2019 |
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Su | 2019 |
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
Topics: Benzamides; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Glioblastoma; Hum | 2019 |
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
Topics: Benzamides; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Glioblastoma; Hum | 2019 |
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
Topics: Benzamides; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Glioblastoma; Hum | 2019 |
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2019 |
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2019 |
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2019 |
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2019 |
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2019 |
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2019 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Tria | 2019 |
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Tria | 2019 |
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Tria | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dendriti | 2019 |
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dendriti | 2019 |
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dendriti | 2019 |
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases.
Topics: Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Dr | 2019 |
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases.
Topics: Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Dr | 2019 |
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases.
Topics: Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Dr | 2019 |
Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; H | 2019 |
Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; H | 2019 |
Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; H | 2019 |
A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Edema | 2019 |
A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Edema | 2019 |
A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Edema | 2019 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2019 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2019 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; C | 2013 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; C | 2013 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; C | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tu | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tu | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tu | 2013 |
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2013 |
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2013 |
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; A | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; A | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; A | 2013 |
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Mod | 2013 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Mod | 2013 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Mod | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Be | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Be | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Be | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therap | 2013 |
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therap | 2013 |
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therap | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Daca | 2013 |
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; | 2015 |
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; | 2015 |
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; | 2015 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2013 |
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2014 |
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2014 |
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Borohydrides; Boron Compounds; Boron Neutron Capture | 2014 |
Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Borohydrides; Boron Compounds; Boron Neutron Capture | 2014 |
Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Borohydrides; Boron Compounds; Boron Neutron Capture | 2014 |
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain N | 2014 |
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain N | 2014 |
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain N | 2014 |
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2014 |
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2014 |
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2016 |
Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2016 |
Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2016 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin | 2014 |
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin | 2014 |
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Child; Child, | 2014 |
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Child; Child, | 2014 |
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Child; Child, | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neo | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neo | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neo | 2014 |
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combin | 2014 |
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combin | 2014 |
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combin | 2014 |
Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Early Termination of Clin | 2014 |
Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Early Termination of Clin | 2014 |
Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Early Termination of Clin | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combinatio | 2015 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combinatio | 2015 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combinatio | 2015 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cele | 2015 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cele | 2015 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cele | 2015 |
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Combined Modality | 2015 |
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Combined Modality | 2015 |
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Combined Modality | 2015 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Mo | 2015 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Mo | 2015 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Mo | 2015 |
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblas | 2015 |
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblas | 2015 |
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblas | 2015 |
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chro | 2015 |
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chro | 2015 |
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chro | 2015 |
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Surv | 2015 |
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Surv | 2015 |
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Surv | 2015 |
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Chemoradiot | 2015 |
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Chemoradiot | 2015 |
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Chemoradiot | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phyt | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phyt | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phyt | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-F | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-F | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-F | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylatio | 2015 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylatio | 2015 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylatio | 2015 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Stud | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Stud | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Stud | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Dacarbaz | 2015 |
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Dacarbaz | 2015 |
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Dacarbaz | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbaz | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbaz | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbaz | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2015 |
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Hu | 2015 |
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Hu | 2015 |
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Hu | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain; Brain Neoplasms; Ch | 2015 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain; Brain Neoplasms; Ch | 2015 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain; Brain Neoplasms; Ch | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female | 2015 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA | 2016 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA | 2016 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA | 2016 |
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2016 |
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2016 |
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2016 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brai | 2016 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brai | 2016 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brai | 2016 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2016 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2016 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2016 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Carb | 2016 |
Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Carb | 2016 |
Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brain Neoplasms; Carb | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Che | 2016 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Che | 2016 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Che | 2016 |
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Meth | 2016 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Meth | 2016 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Meth | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Ch | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Ch | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Ch | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2016 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2017 |
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2017 |
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2017 |
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarke | 2017 |
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarke | 2017 |
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarke | 2017 |
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant | 2017 |
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant | 2017 |
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Da | 2017 |
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Da | 2017 |
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Da | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients].
Topics: Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Da | 2016 |
[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients].
Topics: Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Da | 2016 |
[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients].
Topics: Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Da | 2016 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm | 2008 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm | 2008 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Topics: Adult; Adult Stem Cells; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2008 |
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Topics: Adult; Adult Stem Cells; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2008 |
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Topics: Adult; Adult Stem Cells; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbamazepine; Dacarbazi | 2008 |
Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbamazepine; Dacarbazi | 2008 |
Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbamazepine; Dacarbazi | 2008 |
Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; M | 2008 |
Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; M | 2008 |
Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; M | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome | 2009 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome | 2009 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome | 2009 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; | 2008 |
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Carcinoma, | 2008 |
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Carcinoma, | 2008 |
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Carcinoma, | 2008 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined | 2009 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined | 2009 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined | 2009 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2009 |
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2009 |
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2009 |
Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2008 |
Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2008 |
Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Thera | 2009 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Thera | 2009 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Thera | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2009 |
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplas | 2009 |
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplas | 2009 |
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplas | 2009 |
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2009 |
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2009 |
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2009 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2009 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2009 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2009 |
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Ra | 2010 |
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Ra | 2010 |
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Ra | 2010 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2009 |
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2009 |
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2009 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Neopl | 2010 |
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Neopl | 2010 |
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Neopl | 2010 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Co | 2009 |
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Co | 2009 |
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Co | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2010 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2010 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2010 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl | 2010 |
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl | 2010 |
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combin | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combin | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combin | 2010 |
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2010 |
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2010 |
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2010 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mo | 2010 |
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mo | 2010 |
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mo | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos | 2010 |
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos | 2010 |
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial | 2010 |
Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial | 2010 |
Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial | 2010 |
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com | 2010 |
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com | 2010 |
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality T | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality T | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality T | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free | 2011 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free | 2011 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free | 2011 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2010 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon; Combined Modality Therapy; D | 2010 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon; Combined Modality Therapy; D | 2010 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon; Combined Modality Therapy; D | 2010 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adju | 2010 |
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adju | 2010 |
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adju | 2010 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2011 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2011 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2009 |
The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2009 |
The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2009 |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child | 2011 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child | 2011 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child | 2011 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brai | 2011 |
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brai | 2011 |
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brai | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Dacarbazine; | 2011 |
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Dacarbazine; | 2011 |
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Dacarbazine; | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Al | 2011 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Al | 2011 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Al | 2011 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2011 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Fe | 2012 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Fe | 2012 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Fe | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2012 |
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2012 |
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car | 2012 |
Going past the data for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2012 |
Going past the data for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2012 |
Going past the data for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2012 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2012 |
A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2012 |
A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2012 |
Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2012 |
Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2012 |
Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2012 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2012 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2012 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazin | 2012 |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modali | 2012 |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modali | 2012 |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modali | 2012 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Sur | 2012 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Sur | 2012 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Sur | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; | 2013 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; | 2013 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; | 2013 |
Chemosensitized radiosurgery for recurrent brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
Chemosensitized radiosurgery for recurrent brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
Chemosensitized radiosurgery for recurrent brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2012 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2012 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2012 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarba | 2013 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarba | 2013 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarba | 2013 |
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2014 |
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2014 |
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2014 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2015 |
Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2015 |
Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2015 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Smal | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Smal | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Smal | 2013 |
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2002 |
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2002 |
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2002 |
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2002 |
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2002 |
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2003 |
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2003 |
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Avai | 2003 |
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Avai | 2003 |
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Avai | 2003 |
Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Brain | 2003 |
Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Brain | 2003 |
Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Brain | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progres | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progres | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progres | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Con | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Con | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Con | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosph | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosph | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosph | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modalit | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modalit | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modalit | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2004 |
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modalit | 2004 |
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modalit | 2004 |
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modalit | 2004 |
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2004 |
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2004 |
Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradia | 2005 |
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradia | 2005 |
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradia | 2005 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2004 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2004 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2004 |
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2004 |
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2004 |
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2004 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2005 |
Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2005 |
Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2005 |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2005 |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2005 |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2005 |
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small | 2005 |
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small | 2005 |
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2005 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2005 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2005 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Mag | 2006 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Mag | 2006 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Mag | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neopla | 2005 |
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adult; Anaplasia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cyclophosphamide; | 2006 |
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adult; Anaplasia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cyclophosphamide; | 2006 |
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adult; Anaplasia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cyclophosphamide; | 2006 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2006 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2006 |
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2006 |
Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2006 |
Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2006 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dac | 2006 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dac | 2006 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dac | 2006 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2006 |
Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2006 |
Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug | 2006 |
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug | 2006 |
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Dose-R | 2006 |
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Dose-R | 2006 |
Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Dose-R | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Ch | 2006 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Ch | 2006 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Ch | 2006 |
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2006 |
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2006 |
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2006 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2006 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2007 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2007 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2007 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life.
Topics: Aged; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; H | 2007 |
Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life.
Topics: Aged; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; H | 2007 |
Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life.
Topics: Aged; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; H | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide as salvage treatment in primary brain lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2007 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cam | 2006 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cam | 2006 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cam | 2006 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Do | 2007 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Do | 2007 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Do | 2007 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; | 2008 |
Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; | 2008 |
Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; | 2008 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; | 2008 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; | 2008 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; F | 2008 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; F | 2008 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; F | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.
Topics: Administration, Oral; Antineoplastic Agents; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Dose- | 1993 |
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.
Topics: Administration, Oral; Antineoplastic Agents; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Dose- | 1993 |
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.
Topics: Administration, Oral; Antineoplastic Agents; Astrocytoma; Brain; Brain Neoplasms; Dacarbazine; Dose- | 1993 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 1999 |
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 1999 |
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2000 |
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2000 |
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2000 |
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Evaluation; Femal | 2001 |
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Evaluation; Femal | 2001 |
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Evaluation; Femal | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2001 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2001 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2001 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relations | 2000 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relations | 2000 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relations | 2000 |
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; M | 2001 |
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; M | 2001 |
Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; M | 2001 |
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2001 |
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2001 |
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2001 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2002 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2002 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Combined Modalit | 2002 |
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Combined Modalit | 2002 |
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Combined Modalit | 2002 |
2387 other studies available for temozolomide and Brain Neoplasms
| Article | Year |
|---|---|
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Topics: Animals; Area Under Curve; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Design; Enzyme Inhibit | 2019 |
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Topics: Animals; Area Under Curve; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Design; Enzyme Inhibit | 2019 |
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Topics: Animals; Area Under Curve; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Design; Enzyme Inhibit | 2019 |
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; | 2019 |
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; | 2019 |
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; | 2019 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2019 |
The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2019 |
The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2019 |
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2020 |
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2020 |
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2020 |
Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Brain Neoplasms; Cell Proliferation; Cell Sur | 2021 |
Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Brain Neoplasms; Cell Proliferation; Cell Sur | 2021 |
Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Brain Neoplasms; Cell Proliferation; Cell Sur | 2021 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationshi | 2021 |
Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationshi | 2021 |
Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationshi | 2021 |
Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Lin | 2021 |
Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Lin | 2021 |
Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Lin | 2021 |
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclot | 2022 |
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclot | 2022 |
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclot | 2022 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
An international perspective on the management of glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Internationality; Temozolomide | 2021 |
An international perspective on the management of glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Internationality; Temozolomide | 2021 |
An international perspective on the management of glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Internationality; Temozolomide | 2021 |
Radiotherapy intensification for glioblastoma: enhancing the backbone of treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Radiotherapy, Intensity-Mo | 2021 |
Radiotherapy intensification for glioblastoma: enhancing the backbone of treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Radiotherapy, Intensity-Mo | 2021 |
Radiotherapy intensification for glioblastoma: enhancing the backbone of treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Radiotherapy, Intensity-Mo | 2021 |
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Indoles; Quinolines; Temozolomide | 2021 |
Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Indoles; Quinolines; Temozolomide | 2021 |
Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Indoles; Quinolines; Temozolomide | 2021 |
Interplay of m
Topics: Adenosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Interplay of m
Topics: Adenosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Interplay of m
Topics: Adenosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Size; DNA Methylation; D | 2021 |
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Size; DNA Methylation; D | 2021 |
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Size; DNA Methylation; D | 2021 |
Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Glioblastoma; Humans; Mice | 2022 |
Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Glioblastoma; Humans; Mice | 2022 |
Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Glioblastoma; Humans; Mice | 2022 |
Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Da | 2022 |
Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Da | 2022 |
Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Da | 2022 |
The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female | 2021 |
The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female | 2021 |
The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female | 2021 |
Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; C | 2021 |
Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; C | 2021 |
Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; C | 2021 |
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, | 2021 |
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, | 2021 |
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chenopodiu | 2021 |
Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chenopodiu | 2021 |
Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chenopodiu | 2021 |
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2021 |
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2021 |
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
Related expression of TRKA and P75 receptors and the changing copy number of
Topics: Brain Neoplasms; Cisplatin; DNA Copy Number Variations; Humans; In Situ Hybridization, Fluorescence; | 2020 |
Related expression of TRKA and P75 receptors and the changing copy number of
Topics: Brain Neoplasms; Cisplatin; DNA Copy Number Variations; Humans; In Situ Hybridization, Fluorescence; | 2020 |
Related expression of TRKA and P75 receptors and the changing copy number of
Topics: Brain Neoplasms; Cisplatin; DNA Copy Number Variations; Humans; In Situ Hybridization, Fluorescence; | 2020 |
NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2021 |
NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2021 |
NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2021 |
Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2021 |
Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2021 |
Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2021 |
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2021 |
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2021 |
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2021 |
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2021 |
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2021 |
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Fo | 2021 |
Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Fo | 2021 |
Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Fo | 2021 |
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2021 |
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2021 |
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2021 |
[MGMT and temozolomide sensibility].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Mo | 2021 |
[MGMT and temozolomide sensibility].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Mo | 2021 |
[MGMT and temozolomide sensibility].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Mo | 2021 |
Nanomedicine in the treatment of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanom | 2021 |
Nanomedicine in the treatment of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanom | 2021 |
Nanomedicine in the treatment of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanom | 2021 |
Hematological adverse events in the management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Randomized Controlled Tria | 2022 |
Hematological adverse events in the management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Randomized Controlled Tria | 2022 |
Hematological adverse events in the management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Randomized Controlled Tria | 2022 |
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasm | 2022 |
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasm | 2022 |
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasm | 2022 |
Temporal Trends in Glioblastoma Survival: Progress then Plateau.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Temozolomide | 2022 |
Temporal Trends in Glioblastoma Survival: Progress then Plateau.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Temozolomide | 2022 |
Temporal Trends in Glioblastoma Survival: Progress then Plateau.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Temozolomide | 2022 |
RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level.
Topics: Brain Neoplasms; Exome Sequencing; Glioblastoma; Humans; Sequence Analysis, RNA; Temozolomide | 2022 |
RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level.
Topics: Brain Neoplasms; Exome Sequencing; Glioblastoma; Humans; Sequence Analysis, RNA; Temozolomide | 2022 |
RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level.
Topics: Brain Neoplasms; Exome Sequencing; Glioblastoma; Humans; Sequence Analysis, RNA; Temozolomide | 2022 |
Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Follow-Up Studies; Frailty; G | 2022 |
Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Follow-Up Studies; Frailty; G | 2022 |
Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Follow-Up Studies; Frailty; G | 2022 |
Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy.
Topics: Brain Neoplasms; Carbocyanines; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Nanoparticle | 2022 |
Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy.
Topics: Brain Neoplasms; Carbocyanines; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Nanoparticle | 2022 |
Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy.
Topics: Brain Neoplasms; Carbocyanines; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Nanoparticle | 2022 |
Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Genistein; Glioblastoma; Hu | 2022 |
Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Genistein; Glioblastoma; Hu | 2022 |
Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Genistein; Glioblastoma; Hu | 2022 |
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor | 2021 |
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor | 2021 |
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor | 2021 |
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Frail Elderly; Glioblastoma; Human | 2022 |
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Frail Elderly; Glioblastoma; Human | 2022 |
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Frail Elderly; Glioblastoma; Human | 2022 |
GPR17 signaling activation by CHBC agonist induced cell death via modulation of MAPK pathway in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tu | 2022 |
GPR17 signaling activation by CHBC agonist induced cell death via modulation of MAPK pathway in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tu | 2022 |
GPR17 signaling activation by CHBC agonist induced cell death via modulation of MAPK pathway in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tu | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Leukoencephalopathy, Progressive Multifocal; Temozolomide | 2022 |
Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Leukoencephalopathy, Progressive Multifocal; Temozolomide | 2022 |
Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Leukoencephalopathy, Progressive Multifocal; Temozolomide | 2022 |
Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferat | 2022 |
Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferat | 2022 |
Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferat | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Mo | 2022 |
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Mo | 2022 |
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Mo | 2022 |
Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2022 |
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2022 |
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Recurrent oligodendroglioma with changed 1p/19q status.
Topics: Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosome | 2022 |
Recurrent oligodendroglioma with changed 1p/19q status.
Topics: Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosome | 2022 |
Recurrent oligodendroglioma with changed 1p/19q status.
Topics: Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosome | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Topics: Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferati | 2022 |
Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Topics: Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferati | 2022 |
Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Topics: Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferati | 2022 |
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2022 |
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2022 |
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study.
Topics: Adult; Brain Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Oligodendrogli | 2022 |
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study.
Topics: Adult; Brain Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Oligodendrogli | 2022 |
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study.
Topics: Adult; Brain Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Oligodendrogli | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Topics: Amino Acid Transport System A; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lin | 2022 |
Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Topics: Amino Acid Transport System A; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lin | 2022 |
Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Topics: Amino Acid Transport System A; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lin | 2022 |
Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Gliobl | 2022 |
Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Gliobl | 2022 |
Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Gliobl | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2022 |
The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2022 |
The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2022 |
Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2022 |
Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2022 |
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; E | 2022 |
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; E | 2022 |
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; E | 2022 |
Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Endothelial Cells; Glioblas | 2022 |
Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Endothelial Cells; Glioblas | 2022 |
Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Endothelial Cells; Glioblas | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Glioblastoma; Humans; NF-ka | 2022 |
Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Glioblastoma; Humans; NF-ka | 2022 |
Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Glioblastoma; Humans; NF-ka | 2022 |
Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, | 2022 |
Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, | 2022 |
Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, | 2022 |
Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cymenes; Glioblastoma; Humans; Mice; | 2022 |
Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cymenes; Glioblastoma; Humans; Mice; | 2022 |
Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cymenes; Glioblastoma; Humans; Mice; | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle | 2022 |
Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle | 2022 |
Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle | 2022 |
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2022 |
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2022 |
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fat | 2022 |
Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fat | 2022 |
Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fat | 2022 |
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
Topics: Acceleration; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modific | 2022 |
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
Topics: Acceleration; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modific | 2022 |
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
Topics: Acceleration; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modific | 2022 |
Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lipos | 2022 |
TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lipos | 2022 |
TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lipos | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
Topics: Brain Neoplasms; Child; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Retrosp | 2022 |
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
Topics: Brain Neoplasms; Child; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Retrosp | 2022 |
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
Topics: Brain Neoplasms; Child; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Retrosp | 2022 |
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Gliobl | 2022 |
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Gliobl | 2022 |
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Gliobl | 2022 |
Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Vesicles; Glioblastoma; | 2022 |
Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Vesicles; Glioblastoma; | 2022 |
Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Vesicles; Glioblastoma; | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Mo | 2022 |
Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Mo | 2022 |
Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Mo | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Republi | 2022 |
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Republi | 2022 |
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Republi | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2022 |
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2022 |
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness.
Topics: Acetazolamide; Antioxidants; Brain Neoplasms; Ditiocarb; Glioblastoma; Humans; Hydroxyurea; Melatoni | 2021 |
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness.
Topics: Acetazolamide; Antioxidants; Brain Neoplasms; Ditiocarb; Glioblastoma; Humans; Hydroxyurea; Melatoni | 2021 |
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness.
Topics: Acetazolamide; Antioxidants; Brain Neoplasms; Ditiocarb; Glioblastoma; Humans; Hydroxyurea; Melatoni | 2021 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
Topics: Brain Neoplasms; Chromosome Aberrations; Humans; Oligodendroglioma; Retrospective Studies; Survivors | 2022 |
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
Topics: Brain Neoplasms; Chromosome Aberrations; Humans; Oligodendroglioma; Retrospective Studies; Survivors | 2022 |
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
Topics: Brain Neoplasms; Chromosome Aberrations; Humans; Oligodendroglioma; Retrospective Studies; Survivors | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Modification M | 2022 |
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Modification M | 2022 |
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Modification M | 2022 |
Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, High | 2022 |
Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, High | 2022 |
Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, High | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Poor Prognostic Factors and Future Perspectives].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pro | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Poor Prognostic Factors and Future Perspectives].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pro | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Poor Prognostic Factors and Future Perspectives].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pro | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Topics: Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Hydrogels; Laminin; Spheroids, Cellu | 2023 |
Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Topics: Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Hydrogels; Laminin; Spheroids, Cellu | 2023 |
Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Topics: Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Hydrogels; Laminin; Spheroids, Cellu | 2023 |
MGMT in glial carcinogenesis. Roles from prevention to treatment.
Topics: Brain Neoplasms; Carcinogenesis; Carcinogens; Dacarbazine; DNA; DNA Methylation; DNA Modification Me | 2022 |
MGMT in glial carcinogenesis. Roles from prevention to treatment.
Topics: Brain Neoplasms; Carcinogenesis; Carcinogens; Dacarbazine; DNA; DNA Methylation; DNA Modification Me | 2022 |
MGMT in glial carcinogenesis. Roles from prevention to treatment.
Topics: Brain Neoplasms; Carcinogenesis; Carcinogens; Dacarbazine; DNA; DNA Methylation; DNA Modification Me | 2022 |
PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; Glioblastoma; Humans; Rad | 2022 |
Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; Glioblastoma; Humans; Rad | 2022 |
Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; Glioblastoma; Humans; Rad | 2022 |
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2022 |
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2022 |
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2022 |
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apolipoproteins E; Artesunate; Brain Neoplasms; Cell Lin | 2022 |
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apolipoproteins E; Artesunate; Brain Neoplasms; Cell Lin | 2022 |
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apolipoproteins E; Artesunate; Brain Neoplasms; Cell Lin | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.
Topics: Brain Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Glioblastoma; Humans; Proteomi | 2022 |
Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.
Topics: Brain Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Glioblastoma; Humans; Proteomi | 2022 |
Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.
Topics: Brain Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Glioblastoma; Humans; Proteomi | 2022 |
SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Suppr | 2022 |
SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Suppr | 2022 |
SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Suppr | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Glioblasto | 2022 |
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Glioblasto | 2022 |
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Glioblasto | 2022 |
Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplas | 2022 |
Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplas | 2022 |
Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplas | 2022 |
Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; DNA Modif | 2022 |
GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; DNA Modif | 2022 |
GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; DNA Modif | 2022 |
Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Dru | 2022 |
Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Dru | 2022 |
Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Dru | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressi | 2022 |
A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressi | 2022 |
A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressi | 2022 |
PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2022 |
PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2022 |
PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2022 |
The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
Topics: Brain Neoplasms; Clinical Trials as Topic; Cohort Studies; Glioblastoma; Humans; Prognosis; Temozolo | 2022 |
The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
Topics: Brain Neoplasms; Clinical Trials as Topic; Cohort Studies; Glioblastoma; Humans; Prognosis; Temozolo | 2022 |
The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
Topics: Brain Neoplasms; Clinical Trials as Topic; Cohort Studies; Glioblastoma; Humans; Prognosis; Temozolo | 2022 |
TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell Li | 2022 |
TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell Li | 2022 |
TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell Li | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free S | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free S | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free S | 2022 |
ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Re | 2022 |
ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Re | 2022 |
ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Re | 2022 |
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Topics: Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2022 |
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Topics: Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2022 |
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Topics: Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2022 |
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type 2; DNA | 2022 |
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type 2; DNA | 2022 |
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type 2; DNA | 2022 |
Mechanism-based design of agents that selectively target drug-resistant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2022 |
Mechanism-based design of agents that selectively target drug-resistant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2022 |
Mechanism-based design of agents that selectively target drug-resistant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2022 |
MIR99AHG/miR-204-5p/TXNIP/Nrf2/ARE Signaling Pathway Decreases Glioblastoma Temozolomide Sensitivity.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, | 2022 |
MIR99AHG/miR-204-5p/TXNIP/Nrf2/ARE Signaling Pathway Decreases Glioblastoma Temozolomide Sensitivity.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, | 2022 |
MIR99AHG/miR-204-5p/TXNIP/Nrf2/ARE Signaling Pathway Decreases Glioblastoma Temozolomide Sensitivity.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, | 2022 |
ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide.
Topics: Adenosine Deaminase; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; NF-kappa B; RNA-Bindin | 2022 |
ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide.
Topics: Adenosine Deaminase; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; NF-kappa B; RNA-Bindin | 2022 |
ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide.
Topics: Adenosine Deaminase; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; NF-kappa B; RNA-Bindin | 2022 |
Characterization and comparison of human glioblastoma models.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Temozolomide | 2022 |
Characterization and comparison of human glioblastoma models.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Temozolomide | 2022 |
Characterization and comparison of human glioblastoma models.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Temozolomide | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
GMI, Ganoderma microsporum protein, suppresses cell mobility and increases temozolomide sensitivity through induction of Slug degradation in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance | 2022 |
GMI, Ganoderma microsporum protein, suppresses cell mobility and increases temozolomide sensitivity through induction of Slug degradation in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance | 2022 |
GMI, Ganoderma microsporum protein, suppresses cell mobility and increases temozolomide sensitivity through induction of Slug degradation in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Downregulated ferroptosis-related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fer | 2022 |
Downregulated ferroptosis-related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fer | 2022 |
Downregulated ferroptosis-related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fer | 2022 |
Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism.
Topics: Animals; Brain Neoplasms; Contrast Media; Fumarates; Glioblastoma; Humans; Magnetic Resonance Imagin | 2022 |
Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism.
Topics: Animals; Brain Neoplasms; Contrast Media; Fumarates; Glioblastoma; Humans; Magnetic Resonance Imagin | 2022 |
Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism.
Topics: Animals; Brain Neoplasms; Contrast Media; Fumarates; Glioblastoma; Humans; Magnetic Resonance Imagin | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
MicroRNA-640 Inhibition Enhances the Chemosensitivity of Human Glioblastoma Cells to Temozolomide by Targeting Bcl2 Modifying Factor.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2023 |
MicroRNA-640 Inhibition Enhances the Chemosensitivity of Human Glioblastoma Cells to Temozolomide by Targeting Bcl2 Modifying Factor.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2023 |
MicroRNA-640 Inhibition Enhances the Chemosensitivity of Human Glioblastoma Cells to Temozolomide by Targeting Bcl2 Modifying Factor.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2023 |
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer | 2022 |
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer | 2022 |
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Endothelial Cells; Glioblastoma; Humans; Hypoxia; Macrophages; Ph | 2022 |
Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Endothelial Cells; Glioblastoma; Humans; Hypoxia; Macrophages; Ph | 2022 |
Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Endothelial Cells; Glioblastoma; Humans; Hypoxia; Macrophages; Ph | 2022 |
Tissue Niche Miniature of Glioblastoma Patient Treated with Nano-Awakeners to Induce Suicide of Cancer Stem Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Nanomedicine; Neoplastic Stem Cells; Temozo | 2022 |
Tissue Niche Miniature of Glioblastoma Patient Treated with Nano-Awakeners to Induce Suicide of Cancer Stem Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Nanomedicine; Neoplastic Stem Cells; Temozo | 2022 |
Tissue Niche Miniature of Glioblastoma Patient Treated with Nano-Awakeners to Induce Suicide of Cancer Stem Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Nanomedicine; Neoplastic Stem Cells; Temozo | 2022 |
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.
Topics: Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tumor; Drug Res | 2022 |
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.
Topics: Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tumor; Drug Res | 2022 |
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.
Topics: Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tumor; Drug Res | 2022 |
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local | 2022 |
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local | 2022 |
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Glioblas | 2022 |
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Glioblas | 2022 |
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Glioblas | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Shape; Drug Resistance, N | 2023 |
Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Shape; Drug Resistance, N | 2023 |
Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Shape; Drug Resistance, N | 2023 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2022 |
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Isocitrate Deh | 2022 |
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Isocitrate Deh | 2022 |
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Isocitrate Deh | 2022 |
Inhibition of human peptide deformylase by actinonin sensitizes glioblastoma cells to temozolomide chemotherapy.
Topics: Amidohydrolases; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Mitochon | 2022 |
Inhibition of human peptide deformylase by actinonin sensitizes glioblastoma cells to temozolomide chemotherapy.
Topics: Amidohydrolases; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Mitochon | 2022 |
Inhibition of human peptide deformylase by actinonin sensitizes glioblastoma cells to temozolomide chemotherapy.
Topics: Amidohydrolases; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Mitochon | 2022 |
Apatinib and temozolomide in children with recurrent ependymoma: A case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Ependymoma; Humans; Male | 2022 |
Apatinib and temozolomide in children with recurrent ependymoma: A case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Ependymoma; Humans; Male | 2022 |
Apatinib and temozolomide in children with recurrent ependymoma: A case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Ependymoma; Humans; Male | 2022 |
Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
Topics: Acridine Orange; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Chick Embryo; Em | 2022 |
Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
Topics: Acridine Orange; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Chick Embryo; Em | 2022 |
Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
Topics: Acridine Orange; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Chick Embryo; Em | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.
Topics: Agar; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Telomerase; Temoz | 2022 |
Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.
Topics: Agar; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Telomerase; Temoz | 2022 |
Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.
Topics: Agar; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Telomerase; Temoz | 2022 |
Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2023 |
Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2023 |
Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2023 |
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Glioblastoma; Human | 2023 |
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Glioblastoma; Human | 2023 |
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Glioblastoma; Human | 2023 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Topics: Animals; Anticonvulsants; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2022 |
Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Topics: Animals; Anticonvulsants; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2022 |
Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Topics: Animals; Anticonvulsants; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2022 |
Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dioxolanes; Drug Resistance, N | 2022 |
Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dioxolanes; Drug Resistance, N | 2022 |
Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dioxolanes; Drug Resistance, N | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzamides; Brain Neoplasms; Caspase 6; Caspase 8; Caspase 9; | 2022 |
Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzamides; Brain Neoplasms; Caspase 6; Caspase 8; Caspase 9; | 2022 |
Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzamides; Brain Neoplasms; Caspase 6; Caspase 8; Caspase 9; | 2022 |
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle | 2022 |
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle | 2022 |
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle | 2022 |
Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
Topics: Adult; Brain Neoplasms; Feasibility Studies; Female; Glioblastoma; Humans; Male; Prospective Studies | 2022 |
Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
Topics: Adult; Brain Neoplasms; Feasibility Studies; Female; Glioblastoma; Humans; Male; Prospective Studies | 2022 |
Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
Topics: Adult; Brain Neoplasms; Feasibility Studies; Female; Glioblastoma; Humans; Male; Prospective Studies | 2022 |
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA; DNA Methylation; DNA Repair Enzymes; Gliobl | 2022 |
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA; DNA Methylation; DNA Repair Enzymes; Gliobl | 2022 |
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA; DNA Methylation; DNA Repair Enzymes; Gliobl | 2022 |
Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Repositioning; Glioblastoma; Humans; Temozolomide | 2023 |
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Repositioning; Glioblastoma; Humans; Temozolomide | 2023 |
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Repositioning; Glioblastoma; Humans; Temozolomide | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
Molecular Docking and Molecular Dynamics Studies Reveal Secretory Proteins as Novel Targets of Temozolomide in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Molecular Docking and Molecular Dynamics Studies Reveal Secretory Proteins as Novel Targets of Temozolomide in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Molecular Docking and Molecular Dynamics Studies Reveal Secretory Proteins as Novel Targets of Temozolomide in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours.
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Humans; Magnetic Phenomena; Magnetics; Mice; Temozo | 2023 |
Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours.
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Humans; Magnetic Phenomena; Magnetics; Mice; Temozo | 2023 |
Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours.
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Humans; Magnetic Phenomena; Magnetics; Mice; Temozo | 2023 |
A Comparison of Three Different Deep Learning-Based Models to Predict the MGMT Promoter Methylation Status in Glioblastoma Using Brain MRI.
Topics: Adult; Brain; Brain Neoplasms; Deep Learning; DNA Methylation; DNA Modification Methylases; DNA Repa | 2023 |
A Comparison of Three Different Deep Learning-Based Models to Predict the MGMT Promoter Methylation Status in Glioblastoma Using Brain MRI.
Topics: Adult; Brain; Brain Neoplasms; Deep Learning; DNA Methylation; DNA Modification Methylases; DNA Repa | 2023 |
A Comparison of Three Different Deep Learning-Based Models to Predict the MGMT Promoter Methylation Status in Glioblastoma Using Brain MRI.
Topics: Adult; Brain; Brain Neoplasms; Deep Learning; DNA Methylation; DNA Modification Methylases; DNA Repa | 2023 |
Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Male; Middle Aged; Neoplas | 2022 |
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Male; Middle Aged; Neoplas | 2022 |
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Male; Middle Aged; Neoplas | 2022 |
A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; H | 2023 |
A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; H | 2023 |
A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; H | 2023 |
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Topics: Adult; Brain Neoplasms; East Asian People; Female; Glioblastoma; Humans; Male; Middle Aged; Prospect | 2023 |
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Topics: Adult; Brain Neoplasms; East Asian People; Female; Glioblastoma; Humans; Male; Middle Aged; Prospect | 2023 |
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Topics: Adult; Brain Neoplasms; East Asian People; Female; Glioblastoma; Humans; Male; Middle Aged; Prospect | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Patterns of failure in glioblastoma multiforme following Standard (60 Gy) or Short course (40 Gy) radiation and concurrent temozolomide.
Topics: Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Retrospective Studies; Temozolomide; Treat | 2023 |
Patterns of failure in glioblastoma multiforme following Standard (60 Gy) or Short course (40 Gy) radiation and concurrent temozolomide.
Topics: Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Retrospective Studies; Temozolomide; Treat | 2023 |
Patterns of failure in glioblastoma multiforme following Standard (60 Gy) or Short course (40 Gy) radiation and concurrent temozolomide.
Topics: Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Retrospective Studies; Temozolomide; Treat | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study.
Topics: Adolescent; Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Middle Aged; Prognosis; | 2023 |
Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study.
Topics: Adolescent; Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Middle Aged; Prognosis; | 2023 |
Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study.
Topics: Adolescent; Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Middle Aged; Prognosis; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma.
Topics: Brain; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Radiation Dose Hypofractionation; T | 2023 |
Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma.
Topics: Brain; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Radiation Dose Hypofractionation; T | 2023 |
Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma.
Topics: Brain; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Radiation Dose Hypofractionation; T | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, | 2023 |
Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, | 2023 |
Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, | 2023 |
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2023 |
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2023 |
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2023 |
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Nanoparticles; Peptide Nuclei | 2023 |
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Nanoparticles; Peptide Nuclei | 2023 |
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Nanoparticles; Peptide Nuclei | 2023 |
Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Glioblastoma; Glyco | 2023 |
Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Glioblastoma; Glyco | 2023 |
Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Glioblastoma; Glyco | 2023 |
Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Topics: Brain Neoplasms; Glioblastoma; Gliosarcoma; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Progn | 2023 |
Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Topics: Brain Neoplasms; Glioblastoma; Gliosarcoma; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Progn | 2023 |
Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Topics: Brain Neoplasms; Glioblastoma; Gliosarcoma; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Progn | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Pilot Projects; Tem | 2023 |
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Pilot Projects; Tem | 2023 |
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Pilot Projects; Tem | 2023 |
RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Radiosurgery; R | 2022 |
RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Radiosurgery; R | 2022 |
RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Radiosurgery; R | 2022 |
Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem | 2023 |
Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem | 2023 |
Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2023 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2023 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2023 |
Letter to the editor regarding "The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies".
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2023 |
Letter to the editor regarding "The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies".
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2023 |
Letter to the editor regarding "The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies".
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Prognosis; Signal Transduction; Temozolomid | 2023 |
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Prognosis; Signal Transduction; Temozolomid | 2023 |
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Prognosis; Signal Transduction; Temozolomid | 2023 |
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Mutation; Temozolomide | 2023 |
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Mutation; Temozolomide | 2023 |
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Mutation; Temozolomide | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Liposomes; Liquid Crystals; Polyethylene Gl | 2023 |
Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Liposomes; Liquid Crystals; Polyethylene Gl | 2023 |
Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Liposomes; Liquid Crystals; Polyethylene Gl | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.
Topics: Albumins; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Hum | 2023 |
Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.
Topics: Albumins; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Hum | 2023 |
Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.
Topics: Albumins; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Hum | 2023 |
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; | 2023 |
Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; | 2023 |
Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes.
Topics: Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Glioblastoma; Mice; Nanotubes, Carbon; Temoz | 2023 |
Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes.
Topics: Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Glioblastoma; Mice; Nanotubes, Carbon; Temoz | 2023 |
Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes.
Topics: Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Glioblastoma; Mice; Nanotubes, Carbon; Temoz | 2023 |
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Hydroge | 2023 |
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Hydroge | 2023 |
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Hydroge | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2023 |
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2023 |
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolom | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolom | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolom | 2023 |
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplast | 2023 |
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplast | 2023 |
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplast | 2023 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzyme | 2023 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzyme | 2023 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzyme | 2023 |
Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; DNA Modification Me | 2023 |
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; DNA Modification Me | 2023 |
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; DNA Modification Me | 2023 |
Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasm Recurre | 2023 |
Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasm Recurre | 2023 |
Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasm Recurre | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Male; Mental Disorders; Quality of Life; Retrospec | 2023 |
Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Male; Mental Disorders; Quality of Life; Retrospec | 2023 |
Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Male; Mental Disorders; Quality of Life; Retrospec | 2023 |
Acetogenins-Rich Fractions of
Topics: Acetogenins; Annona; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gliobl | 2023 |
Acetogenins-Rich Fractions of
Topics: Acetogenins; Annona; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gliobl | 2023 |
Acetogenins-Rich Fractions of
Topics: Acetogenins; Annona; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gliobl | 2023 |
ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.
Topics: ADAM17 Protein; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Down-Regulatio | 2023 |
ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.
Topics: ADAM17 Protein; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Down-Regulatio | 2023 |
ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.
Topics: ADAM17 Protein; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Down-Regulatio | 2023 |
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Topics: Animals; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopl | 2023 |
UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Topics: Animals; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopl | 2023 |
UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Topics: Animals; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopl | 2023 |
Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Ribonucleotide R | 2023 |
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Ribonucleotide R | 2023 |
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Ribonucleotide R | 2023 |
GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Dacarbazine; DNA Modification Methyla | 2023 |
GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Dacarbazine; DNA Modification Methyla | 2023 |
GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Dacarbazine; DNA Modification Methyla | 2023 |
AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
LncRNA CASC2 Inhibits Progression of Glioblastoma by Regulating the Expression of AKT in T98G Cell Line, Treated by TMZ and Thiosemicarbazone Complex.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
LncRNA CASC2 Inhibits Progression of Glioblastoma by Regulating the Expression of AKT in T98G Cell Line, Treated by TMZ and Thiosemicarbazone Complex.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
LncRNA CASC2 Inhibits Progression of Glioblastoma by Regulating the Expression of AKT in T98G Cell Line, Treated by TMZ and Thiosemicarbazone Complex.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Dopamine D2 Receptor Antagonists; Drug Resistance, Neo | 2023 |
The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Dopamine D2 Receptor Antagonists; Drug Resistance, Neo | 2023 |
The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Dopamine D2 Receptor Antagonists; Drug Resistance, Neo | 2023 |
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2023 |
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2023 |
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
The interplay of solvent-drug-protein interactions during albumin nanoparticles formulations for temozolomide delivery to brain cancer cells.
Topics: Acetone; Brain Neoplasms; Cell Line, Tumor; Ethanol; Glioblastoma; Humans; Nanoparticles; Serum Albu | 2023 |
The interplay of solvent-drug-protein interactions during albumin nanoparticles formulations for temozolomide delivery to brain cancer cells.
Topics: Acetone; Brain Neoplasms; Cell Line, Tumor; Ethanol; Glioblastoma; Humans; Nanoparticles; Serum Albu | 2023 |
The interplay of solvent-drug-protein interactions during albumin nanoparticles formulations for temozolomide delivery to brain cancer cells.
Topics: Acetone; Brain Neoplasms; Cell Line, Tumor; Ethanol; Glioblastoma; Humans; Nanoparticles; Serum Albu | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Tem | 2023 |
Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Tem | 2023 |
Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Tem | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fee | 2023 |
HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fee | 2023 |
HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fee | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
The Impact of O6-Methylguanine-DNA Methyltransferase (
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Methylation; DNA Modificat | 2023 |
The Impact of O6-Methylguanine-DNA Methyltransferase (
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Methylation; DNA Modificat | 2023 |
The Impact of O6-Methylguanine-DNA Methyltransferase (
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Methylation; DNA Modificat | 2023 |
Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance; Glioblastoma; Humans; Nanog Homeobox Protein; Ne | 2023 |
Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance; Glioblastoma; Humans; Nanog Homeobox Protein; Ne | 2023 |
Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance; Glioblastoma; Humans; Nanog Homeobox Protein; Ne | 2023 |
Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mesenchymal Stem | 2023 |
Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mesenchymal Stem | 2023 |
Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mesenchymal Stem | 2023 |
[Regional variation in usage of TTF (Optune)].
Topics: Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Temozolomide | 2023 |
[Regional variation in usage of TTF (Optune)].
Topics: Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Temozolomide | 2023 |
[Regional variation in usage of TTF (Optune)].
Topics: Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Temozolomide | 2023 |
The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2023 |
The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2023 |
The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2023 |
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2023 |
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2023 |
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2023 |
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Topics: Animals; Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Immunotherapy; Interleukin-15 | 2023 |
A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Topics: Animals; Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Immunotherapy; Interleukin-15 | 2023 |
A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Topics: Animals; Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Immunotherapy; Interleukin-15 | 2023 |
Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Mental Disorders; Temozolomide | 2023 |
Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Mental Disorders; Temozolomide | 2023 |
Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Mental Disorders; Temozolomide | 2023 |
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Immune Checkpoint Inhibitors; I | 2023 |
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Immune Checkpoint Inhibitors; I | 2023 |
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Immune Checkpoint Inhibitors; I | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Age | 2023 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Age | 2023 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Age | 2023 |
Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation | 2023 |
Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation | 2023 |
Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation | 2023 |
Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; RNA Interference | 2023 |
Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; RNA Interference | 2023 |
Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; RNA Interference | 2023 |
TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice | 2023 |
TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice | 2023 |
TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice | 2023 |
The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Neoplas | 2023 |
The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Neoplas | 2023 |
The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Neoplas | 2023 |
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Isocitrate Dehydrogenase; Middle Aged; Positron-Emission Tomo | 2023 |
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Isocitrate Dehydrogenase; Middle Aged; Positron-Emission Tomo | 2023 |
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Isocitrate Dehydrogenase; Middle Aged; Positron-Emission Tomo | 2023 |
FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Feedback; | 2023 |
FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Feedback; | 2023 |
FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Feedback; | 2023 |
Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mice; Mice, | 2023 |
Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mice; Mice, | 2023 |
Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mice; Mice, | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Child; Cisplatin; Gl | 2023 |
Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Child; Cisplatin; Gl | 2023 |
Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Child; Cisplatin; Gl | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Temozol | 2023 |
Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Temozol | 2023 |
Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Humans; Temozol | 2023 |
5-lipoxygenase as a target to sensitize glioblastoma to temozolomide treatment via β-catenin-dependent pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2023 |
5-lipoxygenase as a target to sensitize glioblastoma to temozolomide treatment via β-catenin-dependent pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2023 |
5-lipoxygenase as a target to sensitize glioblastoma to temozolomide treatment via β-catenin-dependent pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Ma | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Ma | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Ma | 2023 |
NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CCAAT-Binding Factor; Cell Line, Tumor; Cell Pro | 2023 |
NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CCAAT-Binding Factor; Cell Line, Tumor; Cell Pro | 2023 |
NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CCAAT-Binding Factor; Cell Line, Tumor; Cell Pro | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Epigenomics; ErbB Receptors; Genes, erbB-1; Glioblastoma; Humans; | 2023 |
Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Epigenomics; ErbB Receptors; Genes, erbB-1; Glioblastoma; Humans; | 2023 |
Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Epigenomics; ErbB Receptors; Genes, erbB-1; Glioblastoma; Humans; | 2023 |
The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; CD8-Positive T-Lymphocytes; Glioblastoma; Histocompatibility Antigens | 2023 |
The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; CD8-Positive T-Lymphocytes; Glioblastoma; Histocompatibility Antigens | 2023 |
The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; CD8-Positive T-Lymphocytes; Glioblastoma; Histocompatibility Antigens | 2023 |
Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Metallocenes; Reactive Oxygen Species; Temo | 2023 |
Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Metallocenes; Reactive Oxygen Species; Temo | 2023 |
Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Metallocenes; Reactive Oxygen Species; Temo | 2023 |
Comparative Analysis of IDH Wild-Type Multifocal and Unifocal Glioblastomas: Prognostic Factors and Survival Outcomes in Focus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; | 2023 |
Comparative Analysis of IDH Wild-Type Multifocal and Unifocal Glioblastomas: Prognostic Factors and Survival Outcomes in Focus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; | 2023 |
Comparative Analysis of IDH Wild-Type Multifocal and Unifocal Glioblastomas: Prognostic Factors and Survival Outcomes in Focus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; | 2023 |
A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2023 |
A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2023 |
A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2023 |
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Glioblastoma; Humans; Temozolomide; Trifluoper | 2023 |
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Glioblastoma; Humans; Temozolomide; Trifluoper | 2023 |
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Glioblastoma; Humans; Temozolomide; Trifluoper | 2023 |
Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Membrane Proteins; Neoplastic Processes; Receptors, Progester | 2023 |
Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Membrane Proteins; Neoplastic Processes; Receptors, Progester | 2023 |
Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Membrane Proteins; Neoplastic Processes; Receptors, Progester | 2023 |
Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tu | 2023 |
Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tu | 2023 |
Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tu | 2023 |
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2023 |
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2023 |
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Ra | 2023 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Ra | 2023 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Ra | 2023 |
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Modification Methylas | 2024 |
CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Modification Methylas | 2024 |
CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Modification Methylas | 2024 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Treatment of glioblastoma in Greenlandic patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glio | 2023 |
Treatment of glioblastoma in Greenlandic patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glio | 2023 |
Treatment of glioblastoma in Greenlandic patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glio | 2023 |
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoin | 2023 |
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoin | 2023 |
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoin | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cathepsin B; Cell Line, Tumor; Cell Survival; Do | 2019 |
miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cathepsin B; Cell Line, Tumor; Cell Survival; Do | 2019 |
miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cathepsin B; Cell Line, Tumor; Cell Survival; Do | 2019 |
Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Casein Kinase II; Enzyme Inhibitors; Humans; Med | 2019 |
Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Casein Kinase II; Enzyme Inhibitors; Humans; Med | 2019 |
Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Casein Kinase II; Enzyme Inhibitors; Humans; Med | 2019 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Administration S | 2019 |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Administration S | 2019 |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Administration S | 2019 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2020 |
Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2020 |
Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2020 |
Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Neoplasm; Drug Synergism; | 2019 |
Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Neoplasm; Drug Synergism; | 2019 |
Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Neoplasm; Drug Synergism; | 2019 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
Synergistic combination of chemo‑phototherapy based on temozolomide/ICG‑loaded iron oxide nanoparticles for brain cancer treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
Synergistic combination of chemo‑phototherapy based on temozolomide/ICG‑loaded iron oxide nanoparticles for brain cancer treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
Synergistic combination of chemo‑phototherapy based on temozolomide/ICG‑loaded iron oxide nanoparticles for brain cancer treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
A local combination therapy to inhibit GBM recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Glioblastoma; | 2019 |
A local combination therapy to inhibit GBM recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Glioblastoma; | 2019 |
A local combination therapy to inhibit GBM recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Glioblastoma; | 2019 |
Temozolomide has anti-tumor effects through the phosphorylation of cPLA
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblasto | 2019 |
Temozolomide has anti-tumor effects through the phosphorylation of cPLA
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblasto | 2019 |
Temozolomide has anti-tumor effects through the phosphorylation of cPLA
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblasto | 2019 |
TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Early Grow | 2020 |
TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Early Grow | 2020 |
TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Early Grow | 2020 |
Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cyclin-D | 2019 |
Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cyclin-D | 2019 |
Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cyclin-D | 2019 |
Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cerebrovascular | 2020 |
Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cerebrovascular | 2020 |
Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cerebrovascular | 2020 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2019 |
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2019 |
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2019 |
Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
Topics: Aged; Algorithms; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Female; G | 2020 |
Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
Topics: Aged; Algorithms; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Female; G | 2020 |
Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
Topics: Aged; Algorithms; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Female; G | 2020 |
MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin.
Topics: 3' Untranslated Regions; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2019 |
MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin.
Topics: 3' Untranslated Regions; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2019 |
MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin.
Topics: 3' Untranslated Regions; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2019 |
The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2019 |
The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2019 |
The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2019 |
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2019 |
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2019 |
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD47 Antigen; Cell Line, Tumor; Combine | 2020 |
Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD47 Antigen; Cell Line, Tumor; Combine | 2020 |
Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD47 Antigen; Cell Line, Tumor; Combine | 2020 |
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capillary | 2020 |
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capillary | 2020 |
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capillary | 2020 |
Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Brain Neoplasms; Drug Resistance, Neoplasm; Drug Sy | 2019 |
Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Brain Neoplasms; Drug Resistance, Neoplasm; Drug Sy | 2019 |
Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Brain Neoplasms; Drug Resistance, Neoplasm; Drug Sy | 2019 |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Topics: Adult; Aged; Brain; Brain Neoplasms; Cell Nucleus; Chemoradiotherapy, Adjuvant; Cyclin D2; Female; G | 2020 |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Topics: Adult; Aged; Brain; Brain Neoplasms; Cell Nucleus; Chemoradiotherapy, Adjuvant; Cyclin D2; Female; G | 2020 |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Topics: Adult; Aged; Brain; Brain Neoplasms; Cell Nucleus; Chemoradiotherapy, Adjuvant; Cyclin D2; Female; G | 2020 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
Personalized oncology with artificial intelligence: The case of temozolomide.
Topics: Algorithms; Artificial Intelligence; Bayes Theorem; Brain Neoplasms; Computer Simulation; Dose-Respo | 2019 |
Personalized oncology with artificial intelligence: The case of temozolomide.
Topics: Algorithms; Artificial Intelligence; Bayes Theorem; Brain Neoplasms; Computer Simulation; Dose-Respo | 2019 |
Personalized oncology with artificial intelligence: The case of temozolomide.
Topics: Algorithms; Artificial Intelligence; Bayes Theorem; Brain Neoplasms; Computer Simulation; Dose-Respo | 2019 |
Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Res | 2019 |
Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Res | 2019 |
Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Res | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Brain | 2020 |
ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Brain | 2020 |
ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Brain | 2020 |
A new chance for EGFR inhibition in glioblastoma?
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2019 |
A new chance for EGFR inhibition in glioblastoma?
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2019 |
A new chance for EGFR inhibition in glioblastoma?
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2019 |
Treatment strategies for glioblastoma in older patients: age is just a number.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Stu | 2019 |
Treatment strategies for glioblastoma in older patients: age is just a number.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Stu | 2019 |
Treatment strategies for glioblastoma in older patients: age is just a number.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Stu | 2019 |
Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; Humans | 2019 |
Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; Humans | 2019 |
Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; Humans | 2019 |
Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Chaperone-Mediated Autophagy; Cytoplasm; Dr | 2019 |
Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Chaperone-Mediated Autophagy; Cytoplasm; Dr | 2019 |
Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Chaperone-Mediated Autophagy; Cytoplasm; Dr | 2019 |
Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain N | 2019 |
Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain N | 2019 |
Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain N | 2019 |
Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carnosine; Cell Survival; Female; Glioblas | 2019 |
Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carnosine; Cell Survival; Female; Glioblas | 2019 |
Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carnosine; Cell Survival; Female; Glioblas | 2019 |
Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Eukaryotic Initiation Factors; Humans; Neoplasm Protei | 2020 |
Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Eukaryotic Initiation Factors; Humans; Neoplasm Protei | 2020 |
Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Eukaryotic Initiation Factors; Humans; Neoplasm Protei | 2020 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
A man with weak limbs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Craniotomy; Glioblastoma; Humans; Magnetic Reson | 2019 |
A man with weak limbs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Craniotomy; Glioblastoma; Humans; Magnetic Reson | 2019 |
A man with weak limbs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Craniotomy; Glioblastoma; Humans; Magnetic Reson | 2019 |
Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Comb | 2020 |
Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Comb | 2020 |
Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Comb | 2020 |
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
Topics: Aged; Brain Neoplasms; Brain Stem; Glioblastoma; Humans; Supratentorial Neoplasms; Temozolomide | 2020 |
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
Topics: Aged; Brain Neoplasms; Brain Stem; Glioblastoma; Humans; Supratentorial Neoplasms; Temozolomide | 2020 |
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
Topics: Aged; Brain Neoplasms; Brain Stem; Glioblastoma; Humans; Supratentorial Neoplasms; Temozolomide | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 4; Antineoplastic Agents, Alkylating | 2019 |
ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 4; Antineoplastic Agents, Alkylating | 2019 |
ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 4; Antineoplastic Agents, Alkylating | 2019 |
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2019 |
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2019 |
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2019 |
Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
Topics: Antagomirs; Antimicrobial Cationic Peptides; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2019 |
Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
Topics: Antagomirs; Antimicrobial Cationic Peptides; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2019 |
Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
Topics: Antagomirs; Antimicrobial Cationic Peptides; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2019 |
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Gonanes; Humans; Phosphatidyl | 2019 |
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Gonanes; Humans; Phosphatidyl | 2019 |
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Gonanes; Humans; Phosphatidyl | 2019 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Molecular Evolution of
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2020 |
Molecular Evolution of
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2020 |
Molecular Evolution of
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2020 |
LQB‑118 compound inhibits migration and induces cell death in glioblastoma cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2020 |
LQB‑118 compound inhibits migration and induces cell death in glioblastoma cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2020 |
LQB‑118 compound inhibits migration and induces cell death in glioblastoma cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
[RAD51 promotes proliferation and migration of glioblastoma cells and decreases sensitivity of cells to temozolomide].
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Tech | 2019 |
[RAD51 promotes proliferation and migration of glioblastoma cells and decreases sensitivity of cells to temozolomide].
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Tech | 2019 |
[RAD51 promotes proliferation and migration of glioblastoma cells and decreases sensitivity of cells to temozolomide].
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Tech | 2019 |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Brain Neopla | 2019 |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Brain Neopla | 2019 |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Brain Neopla | 2019 |
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Contr | 2020 |
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Contr | 2020 |
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Contr | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisot | 2019 |
Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisot | 2019 |
Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisot | 2019 |
Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2019 |
Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2019 |
Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2019 |
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Topics: Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Dose-Response Relation | 2019 |
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Topics: Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Dose-Response Relation | 2019 |
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Topics: Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Dose-Response Relation | 2019 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Di | 2020 |
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Di | 2020 |
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Di | 2020 |
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Topics: Antineoplastic Agents, Alkylating; Benzene Derivatives; Brain Neoplasms; Cell Line, Tumor; Cell Surv | 2019 |
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Topics: Antineoplastic Agents, Alkylating; Benzene Derivatives; Brain Neoplasms; Cell Line, Tumor; Cell Surv | 2019 |
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Topics: Antineoplastic Agents, Alkylating; Benzene Derivatives; Brain Neoplasms; Cell Line, Tumor; Cell Surv | 2019 |
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2019 |
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2019 |
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Drug Resistance, Neoplasm | 2020 |
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Drug Resistance, Neoplasm | 2020 |
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Drug Resistance, Neoplasm | 2020 |
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2020 |
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2020 |
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2020 |
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2019 |
Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2019 |
Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2019 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Brain Neoplasms; Cell Cycle; Cell M | 2020 |
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Brain Neoplasms; Cell Cycle; Cell M | 2020 |
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Brain Neoplasms; Cell Cycle; Cell M | 2020 |
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain | 2020 |
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain | 2020 |
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain | 2020 |
Survey of treatment recommendations for elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasm | 2020 |
Survey of treatment recommendations for elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasm | 2020 |
Survey of treatment recommendations for elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasm | 2020 |
IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2020 |
IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2020 |
IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2020 |
Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2020 |
Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2020 |
A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, T | 2020 |
A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, T | 2020 |
A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, T | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Polymerase III; D | 2020 |
ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Polymerase III; D | 2020 |
ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Polymerase III; D | 2020 |
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; BRCA1 Protein; DNA Mismatch Repai | 2020 |
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; BRCA1 Protein; DNA Mismatch Repai | 2020 |
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; BRCA1 Protein; DNA Mismatch Repai | 2020 |
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; G | 2020 |
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; G | 2020 |
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; G | 2020 |
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Drug Compounding; Drugs, Generi | 2020 |
Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Drug Compounding; Drugs, Generi | 2020 |
Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Drug Compounding; Drugs, Generi | 2020 |
Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neo | 2020 |
Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neo | 2020 |
Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neo | 2020 |
Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, | 2020 |
Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, | 2020 |
Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, | 2020 |
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combin | 2020 |
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combin | 2020 |
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combin | 2020 |
A Common Rule for Resection of Glioblastoma in the Molecular Era.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2020 |
A Common Rule for Resection of Glioblastoma in the Molecular Era.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2020 |
A Common Rule for Resection of Glioblastoma in the Molecular Era.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2020 |
Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemoradiothe | 2020 |
Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemoradiothe | 2020 |
Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemoradiothe | 2020 |
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Copy Number Variations; D | 2020 |
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Copy Number Variations; D | 2020 |
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Copy Number Variations; D | 2020 |
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Cohort Studies; DNA Methylation; DNA | 2020 |
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Cohort Studies; DNA Methylation; DNA | 2020 |
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Cohort Studies; DNA Methylation; DNA | 2020 |
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
Topics: Adult; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Disulfides; DNA Modification Methylase | 2020 |
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
Topics: Adult; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Disulfides; DNA Modification Methylase | 2020 |
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
Topics: Adult; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Disulfides; DNA Modification Methylase | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2020 |
Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2020 |
Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2020 |
Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A.
Topics: Biomarkers, Tumor; Brain Neoplasms; Calpain; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ce | 2020 |
Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A.
Topics: Biomarkers, Tumor; Brain Neoplasms; Calpain; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ce | 2020 |
Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A.
Topics: Biomarkers, Tumor; Brain Neoplasms; Calpain; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ce | 2020 |
Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy.
Topics: Animals; Anxiety; Behavior, Animal; Brain Neoplasms; CA1 Region, Hippocampal; Combined Modality Ther | 2020 |
Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy.
Topics: Animals; Anxiety; Behavior, Animal; Brain Neoplasms; CA1 Region, Hippocampal; Combined Modality Ther | 2020 |
Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy.
Topics: Animals; Anxiety; Behavior, Animal; Brain Neoplasms; CA1 Region, Hippocampal; Combined Modality Ther | 2020 |
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Discoidin Domain Rece | 2020 |
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Discoidin Domain Rece | 2020 |
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Discoidin Domain Rece | 2020 |
A troublesome burden, the amplification of EGFR in glioblastoma!
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Lomustine; | 2020 |
A troublesome burden, the amplification of EGFR in glioblastoma!
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Lomustine; | 2020 |
A troublesome burden, the amplification of EGFR in glioblastoma!
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Lomustine; | 2020 |
STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; | 2020 |
STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; | 2020 |
STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2020 |
Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2020 |
Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2020 |
A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; A | 2020 |
A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; A | 2020 |
A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; A | 2020 |
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; H | 2021 |
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; H | 2021 |
The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gliosarcoma; H | 2021 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Glioblast | 2020 |
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Glioblast | 2020 |
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Glioblast | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
Control of brain tumor growth by reactivating myeloid cells with niacin.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Neoplastic | 2020 |
Control of brain tumor growth by reactivating myeloid cells with niacin.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Neoplastic | 2020 |
Control of brain tumor growth by reactivating myeloid cells with niacin.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Neoplastic | 2020 |
[Dosimetry of tumor treating fields: energy per unit correlates with oncological endpoints in patients with glioblastoma in the EF-14 trial].
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiometry; Temozolomide | 2020 |
[Dosimetry of tumor treating fields: energy per unit correlates with oncological endpoints in patients with glioblastoma in the EF-14 trial].
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiometry; Temozolomide | 2020 |
[Dosimetry of tumor treating fields: energy per unit correlates with oncological endpoints in patients with glioblastoma in the EF-14 trial].
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiometry; Temozolomide | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2021 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Topics: Adult; Aged; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Ne | 2020 |
Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Topics: Adult; Aged; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Ne | 2020 |
Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Topics: Adult; Aged; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Ne | 2020 |
Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2020 |
Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2020 |
Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2020 |
Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Topics: Animals; Antibodies, Neoplasm; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Brain Neopl | 2020 |
Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Topics: Animals; Antibodies, Neoplasm; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Brain Neopl | 2020 |
Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Topics: Animals; Antibodies, Neoplasm; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Brain Neopl | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Drug Resista | 2020 |
The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Drug Resista | 2020 |
The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Drug Resista | 2020 |
Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine | 2020 |
Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine | 2020 |
Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine | 2020 |
Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Coho | 2020 |
Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Coho | 2020 |
Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Coho | 2020 |
The limitations of targeting MEK signalling in Glioblastoma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Deat | 2020 |
The limitations of targeting MEK signalling in Glioblastoma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Deat | 2020 |
The limitations of targeting MEK signalling in Glioblastoma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Deat | 2020 |
Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2020 |
Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2020 |
Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2020 |
Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hippocampu | 2020 |
Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hippocampu | 2020 |
Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hippocampu | 2020 |
NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature.
Topics: Astrocytoma; Brain Neoplasms; Cell Proliferation; Child; Humans; NF-kappa B; Temozolomide | 2020 |
NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature.
Topics: Astrocytoma; Brain Neoplasms; Cell Proliferation; Child; Humans; NF-kappa B; Temozolomide | 2020 |
NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma and concise review of the current literature.
Topics: Astrocytoma; Brain Neoplasms; Cell Proliferation; Child; Humans; NF-kappa B; Temozolomide | 2020 |
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Craniotomy; Fatal Outcome; Female; Gliobl | 2020 |
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Craniotomy; Fatal Outcome; Female; Gliobl | 2020 |
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Craniotomy; Fatal Outcome; Female; Gliobl | 2020 |
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Temoz | 2020 |
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Temoz | 2020 |
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Temoz | 2020 |
Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
Topics: Antimalarials; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance | 2020 |
Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
Topics: Antimalarials; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance | 2020 |
Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
Topics: Antimalarials; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance | 2020 |
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Prolif | 2020 |
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Prolif | 2020 |
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Prolif | 2020 |
LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Oncolytic V | 2020 |
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Oncolytic V | 2020 |
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Oncolytic V | 2020 |
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modifica | 2020 |
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modifica | 2020 |
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modifica | 2020 |
Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes.
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiation Dose Hypofractionation; Radiosurgery; Temozolomide | 2020 |
Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes.
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiation Dose Hypofractionation; Radiosurgery; Temozolomide | 2020 |
Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes.
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiation Dose Hypofractionation; Radiosurgery; Temozolomide | 2020 |
The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Modification | 2020 |
The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Modification | 2020 |
The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Modification | 2020 |
Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cells, Cultured; Diffuse Intrinsic Pont | 2020 |
Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cells, Cultured; Diffuse Intrinsic Pont | 2020 |
Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cells, Cultured; Diffuse Intrinsic Pont | 2020 |
A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2020 |
A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2020 |
A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2020 |
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2020 |
MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2020 |
MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2020 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
Brain metastases from esophageal cancer: A case report.
Topics: Administration, Oral; Aftercare; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined | 2020 |
Brain metastases from esophageal cancer: A case report.
Topics: Administration, Oral; Aftercare; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined | 2020 |
Brain metastases from esophageal cancer: A case report.
Topics: Administration, Oral; Aftercare; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA | 2020 |
The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA | 2020 |
The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA | 2020 |
Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Diabetes Insipidus, Neurogenic; Humans; M | 2020 |
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Diabetes Insipidus, Neurogenic; Humans; M | 2020 |
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Diabetes Insipidus, Neurogenic; Humans; M | 2020 |
Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Topics: Adult; Apoptosis; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Differentiation; | 2020 |
Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Topics: Adult; Apoptosis; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Differentiation; | 2020 |
Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Topics: Adult; Apoptosis; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Differentiation; | 2020 |
Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2020 |
Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2020 |
Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2020 |
A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methyl | 2020 |
A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methyl | 2020 |
A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methyl | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Conventional Treatment of Glioblastoma Reveals Persistent CD44
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma; Humans; Hyaluronan Re | 2020 |
Conventional Treatment of Glioblastoma Reveals Persistent CD44
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma; Humans; Hyaluronan Re | 2020 |
Conventional Treatment of Glioblastoma Reveals Persistent CD44
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma; Humans; Hyaluronan Re | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Survival; Cells, Cul | 2020 |
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Survival; Cells, Cul | 2020 |
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Survival; Cells, Cul | 2020 |
Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2020 |
Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2020 |
Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2020 |
Glioblastoma and bevacizumab in elderly patients: Monocentric study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; G | 2021 |
Glioblastoma and bevacizumab in elderly patients: Monocentric study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; G | 2021 |
Glioblastoma and bevacizumab in elderly patients: Monocentric study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; G | 2021 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Combination Therapy with Nanomicellar-Curcumin and Temozolomide for In Vitro Therapy of Glioblastoma Multiforme via Wnt Signaling Pathways.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2020 |
Combination Therapy with Nanomicellar-Curcumin and Temozolomide for In Vitro Therapy of Glioblastoma Multiforme via Wnt Signaling Pathways.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2020 |
Combination Therapy with Nanomicellar-Curcumin and Temozolomide for In Vitro Therapy of Glioblastoma Multiforme via Wnt Signaling Pathways.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Ce | 2020 |
Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Ce | 2020 |
Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Ce | 2020 |
HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliob | 2021 |
HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliob | 2021 |
HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliob | 2021 |
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
Vascularized Temporoparietal Fascial Flap: A Novel Surgical Technique to Bypass the Blood-Brain Barrier in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Chemoradiotherapy, Adjuvant | 2020 |
Vascularized Temporoparietal Fascial Flap: A Novel Surgical Technique to Bypass the Blood-Brain Barrier in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Chemoradiotherapy, Adjuvant | 2020 |
Vascularized Temporoparietal Fascial Flap: A Novel Surgical Technique to Bypass the Blood-Brain Barrier in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Chemoradiotherapy, Adjuvant | 2020 |
Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2020 |
Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2020 |
Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2020 |
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carcinogenesis; Cell | 2020 |
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carcinogenesis; Cell | 2020 |
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carcinogenesis; Cell | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Confidence Intervals; Female; | 2021 |
Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Confidence Intervals; Female; | 2021 |
Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Confidence Intervals; Female; | 2021 |
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; B | 2021 |
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; B | 2021 |
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; B | 2021 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Topics: Actin Cytoskeleton; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; | 2020 |
NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Topics: Actin Cytoskeleton; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; | 2020 |
NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Topics: Actin Cytoskeleton; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fem | 2020 |
Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fem | 2020 |
Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fem | 2020 |
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Isocitrate Dehydrogenase; | 2020 |
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Isocitrate Dehydrogenase; | 2020 |
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Isocitrate Dehydrogenase; | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2020 |
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2020 |
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2020 |
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Topics: Adult; Brain Neoplasms; Chitinase-3-Like Protein 1; DNA Methylation; DNA Modification Methylases; DN | 2020 |
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Topics: Adult; Brain Neoplasms; Chitinase-3-Like Protein 1; DNA Methylation; DNA Modification Methylases; DN | 2020 |
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Topics: Adult; Brain Neoplasms; Chitinase-3-Like Protein 1; DNA Methylation; DNA Modification Methylases; DN | 2020 |
Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Losartan; Quercetin; Temozolomide | 2020 |
Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Losartan; Quercetin; Temozolomide | 2020 |
Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Losartan; Quercetin; Temozolomide | 2020 |
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Pr | 2021 |
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Pr | 2021 |
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Pr | 2021 |
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Modification M | 2020 |
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Modification M | 2020 |
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Modification M | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Neoplasm | 2020 |
Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Neoplasm | 2020 |
Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Neoplasm | 2020 |
An interview with Buddy Ratner.
Topics: Brain Neoplasms; Glioblastoma; Humans; Polyesters; Temozolomide | 2020 |
An interview with Buddy Ratner.
Topics: Brain Neoplasms; Glioblastoma; Humans; Polyesters; Temozolomide | 2020 |
An interview with Buddy Ratner.
Topics: Brain Neoplasms; Glioblastoma; Humans; Polyesters; Temozolomide | 2020 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Me | 2020 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Me | 2020 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Me | 2020 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mesenchymal Stem Cells; Mice; Mice | 2020 |
A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mesenchymal Stem Cells; Mice; Mice | 2020 |
A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mesenchymal Stem Cells; Mice; Mice | 2020 |
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling.
Topics: Adaptor Proteins, Signal Transducing; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2021 |
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling.
Topics: Adaptor Proteins, Signal Transducing; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2021 |
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling.
Topics: Adaptor Proteins, Signal Transducing; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2021 |
Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Diab | 2021 |
Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Diab | 2021 |
Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Diab | 2021 |
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Brazil; Chemoradiotherapy; Chemotherapy, Adjuvan | 2020 |
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Brazil; Chemoradiotherapy; Chemotherapy, Adjuvan | 2020 |
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Brazil; Chemoradiotherapy; Chemotherapy, Adjuvan | 2020 |
Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2020 |
Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2020 |
Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2020 |
Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Pr | 2020 |
Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Pr | 2020 |
Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Pr | 2020 |
A case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Histones; Humans; Magnetic Resona | 2020 |
A case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Histones; Humans; Magnetic Resona | 2020 |
A case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Histones; Humans; Magnetic Resona | 2020 |
Z-scan method to measure the nonlinear optical behavior of cells for evaluating the cytotoxic effects of chemotherapy and hyperthermia treatments.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Humans; Hyperthermia, Induced; Nonlinear D | 2021 |
Z-scan method to measure the nonlinear optical behavior of cells for evaluating the cytotoxic effects of chemotherapy and hyperthermia treatments.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Humans; Hyperthermia, Induced; Nonlinear D | 2021 |
Z-scan method to measure the nonlinear optical behavior of cells for evaluating the cytotoxic effects of chemotherapy and hyperthermia treatments.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Humans; Hyperthermia, Induced; Nonlinear D | 2021 |
Survival benefit of concomitant chemoradiation in adult supratentorial primary glioblastoma. A propensity score weighted population-based analysis.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Propensity Score; Supratentoria | 2022 |
Survival benefit of concomitant chemoradiation in adult supratentorial primary glioblastoma. A propensity score weighted population-based analysis.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Propensity Score; Supratentoria | 2022 |
Survival benefit of concomitant chemoradiation in adult supratentorial primary glioblastoma. A propensity score weighted population-based analysis.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Propensity Score; Supratentoria | 2022 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
Central diabetes insipidus induced by temozolomide: A report of two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Deamino Arginine Vasopressin; Diabetes In | 2021 |
Central diabetes insipidus induced by temozolomide: A report of two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Deamino Arginine Vasopressin; Diabetes In | 2021 |
Central diabetes insipidus induced by temozolomide: A report of two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Deamino Arginine Vasopressin; Diabetes In | 2021 |
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplas | 2020 |
Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplas | 2020 |
Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplas | 2020 |
Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2020 |
Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2020 |
Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2020 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
Topics: Brain Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Res | 2020 |
LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
Topics: Brain Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Res | 2020 |
LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
Topics: Brain Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Res | 2020 |
Penetrating the brain tumor space with DNA damage response inhibitors.
Topics: Brain Neoplasms; DNA Damage; Glioblastoma; Humans; Phthalazines; Piperazines; Temozolomide | 2020 |
Penetrating the brain tumor space with DNA damage response inhibitors.
Topics: Brain Neoplasms; DNA Damage; Glioblastoma; Humans; Phthalazines; Piperazines; Temozolomide | 2020 |
Penetrating the brain tumor space with DNA damage response inhibitors.
Topics: Brain Neoplasms; DNA Damage; Glioblastoma; Humans; Phthalazines; Piperazines; Temozolomide | 2020 |
Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice; Neoplasm | 2021 |
Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice; Neoplasm | 2021 |
Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice; Neoplasm | 2021 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2021 |
Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2021 |
Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2021 |
Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Caspase 9; Cell Line, Tumor; Cell Surv | 2020 |
Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Caspase 9; Cell Line, Tumor; Cell Surv | 2020 |
Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Caspase 9; Cell Line, Tumor; Cell Surv | 2020 |
Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Resista | 2020 |
Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Resista | 2020 |
Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Resista | 2020 |
Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Drug | 2020 |
Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Drug | 2020 |
Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Drug | 2020 |
Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Cell Surv | 2020 |
Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Cell Surv | 2020 |
Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Cell Surv | 2020 |
Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplas | 2020 |
Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplas | 2020 |
Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplas | 2020 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Encapsulation of Small Drugs in a Supramolecule Enhances Solubility, Stability, and Therapeutic Efficacy Against Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glioblasto | 2021 |
Encapsulation of Small Drugs in a Supramolecule Enhances Solubility, Stability, and Therapeutic Efficacy Against Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glioblasto | 2021 |
Encapsulation of Small Drugs in a Supramolecule Enhances Solubility, Stability, and Therapeutic Efficacy Against Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glioblasto | 2021 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; D | 2021 |
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; D | 2021 |
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; D | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy | 2020 |
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy | 2020 |
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy | 2020 |
[Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis].
Topics: Brain Neoplasms; Cathepsins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation | 2020 |
[Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis].
Topics: Brain Neoplasms; Cathepsins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation | 2020 |
[Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis].
Topics: Brain Neoplasms; Cathepsins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation | 2020 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell S | 2020 |
Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell S | 2020 |
Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell S | 2020 |
Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Topics: Animals; Brain Neoplasms; Female; Glioblastoma; Humans; Mice; Mice, Nude; Protein Serine-Threonine K | 2020 |
Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Topics: Animals; Brain Neoplasms; Female; Glioblastoma; Humans; Mice; Mice, Nude; Protein Serine-Threonine K | 2020 |
Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Topics: Animals; Brain Neoplasms; Female; Glioblastoma; Humans; Mice; Mice, Nude; Protein Serine-Threonine K | 2020 |
Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Machine Learning; Magnetic Resonan | 2020 |
Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Machine Learning; Magnetic Resonan | 2020 |
Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Machine Learning; Magnetic Resonan | 2020 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell P | 2021 |
Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell P | 2021 |
Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell P | 2021 |
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromatography, High Pressure Liquid; CpG | 2020 |
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromatography, High Pressure Liquid; CpG | 2020 |
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromatography, High Pressure Liquid; CpG | 2020 |
Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Rats; Spectrometry, X-Ray E | 2020 |
Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Rats; Spectrometry, X-Ray E | 2020 |
Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Rats; Spectrometry, X-Ray E | 2020 |
Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Fema | 2021 |
Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Fema | 2021 |
Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Fema | 2021 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Su | 2021 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Su | 2021 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Su | 2021 |
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolog | 2020 |
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolog | 2020 |
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolog | 2020 |
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis.
Topics: Adult; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Meningeal Neoplasms; P | 2021 |
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis.
Topics: Adult; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Meningeal Neoplasms; P | 2021 |
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis.
Topics: Adult; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Meningeal Neoplasms; P | 2021 |
Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, N | 2020 |
Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, N | 2020 |
Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, N | 2020 |
Flunarizine, a drug approved for treating migraine and vertigo, exhibits cytotoxicity in GBM cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulato | 2021 |
Flunarizine, a drug approved for treating migraine and vertigo, exhibits cytotoxicity in GBM cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulato | 2021 |
Flunarizine, a drug approved for treating migraine and vertigo, exhibits cytotoxicity in GBM cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulato | 2021 |
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Clustered Regularly Interspaced Short Palindromic | 2020 |
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Clustered Regularly Interspaced Short Palindromic | 2020 |
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Clustered Regularly Interspaced Short Palindromic | 2020 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
Topics: Apoptosis; Astrocytes; Brain; Brain Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; | 2021 |
The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
Topics: Apoptosis; Astrocytes; Brain; Brain Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; | 2021 |
The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
Topics: Apoptosis; Astrocytes; Brain; Brain Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; | 2021 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Class Ia Phosphatidy | 2021 |
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Class Ia Phosphatidy | 2021 |
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Class Ia Phosphatidy | 2021 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality | 2020 |
Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality | 2020 |
Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality | 2020 |
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Neoplasm Recurrence, Local; Radiotherapy, Ad | 2021 |
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Neoplasm Recurrence, Local; Radiotherapy, Ad | 2021 |
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Neoplasm Recurrence, Local; Radiotherapy, Ad | 2021 |
Regorafenib in glioblastoma recurrence: A case report.
Topics: Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2021 |
Regorafenib in glioblastoma recurrence: A case report.
Topics: Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2021 |
Regorafenib in glioblastoma recurrence: A case report.
Topics: Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2021 |
Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Lung Neo | 2020 |
Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Lung Neo | 2020 |
Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Lung Neo | 2020 |
Final Results of the Prospective Biomarker Trial PETra: [
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Final Results of the Prospective Biomarker Trial PETra: [
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Final Results of the Prospective Biomarker Trial PETra: [
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Ma | 2021 |
Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Ma | 2021 |
Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Ma | 2021 |
Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Prol | 2021 |
Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Prol | 2021 |
Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Prol | 2021 |
Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain N | 2021 |
Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain N | 2021 |
Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain N | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Desquamative skin rash associated with temozolomide in a patient with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Exanthema; Glioblastoma; Humans; Temozolomide | 2021 |
Desquamative skin rash associated with temozolomide in a patient with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Exanthema; Glioblastoma; Humans; Temozolomide | 2021 |
Desquamative skin rash associated with temozolomide in a patient with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Exanthema; Glioblastoma; Humans; Temozolomide | 2021 |
Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Electron Tr | 2021 |
Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Electron Tr | 2021 |
Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Electron Tr | 2021 |
Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Deoxyribonuclease I; Drug Resistanc | 2021 |
Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Deoxyribonuclease I; Drug Resistanc | 2021 |
Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Deoxyribonuclease I; Drug Resistanc | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; COVID | 2021 |
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; COVID | 2021 |
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; COVID | 2021 |
Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2021 |
Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2021 |
Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2021 |
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2021 |
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2021 |
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Humans; Lomustine; Pro | 2021 |
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Humans; Lomustine; Pro | 2021 |
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Humans; Lomustine; Pro | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
Topics: Brain Neoplasms; Dacarbazine; Humans; Oligodendroglioma; Temozolomide | 2021 |
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
Topics: Brain Neoplasms; Dacarbazine; Humans; Oligodendroglioma; Temozolomide | 2021 |
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
Topics: Brain Neoplasms; Dacarbazine; Humans; Oligodendroglioma; Temozolomide | 2021 |
Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemistry, Pharmaceutical; | 2021 |
Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemistry, Pharmaceutical; | 2021 |
Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemistry, Pharmaceutical; | 2021 |
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Data Science; Dimethyl Sulfoxide; DNA Repair; Drug Resis | 2021 |
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Data Science; Dimethyl Sulfoxide; DNA Repair; Drug Resis | 2021 |
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Data Science; Dimethyl Sulfoxide; DNA Repair; Drug Resis | 2021 |
Multicentric non-enhancing lesions in glioblastoma: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Multicentric non-enhancing lesions in glioblastoma: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Multicentric non-enhancing lesions in glioblastoma: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclin-Depende | 2021 |
The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclin-Depende | 2021 |
The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclin-Depende | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Cannabinoids in glioblastoma multiforme-hype or hope?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Proliferation; Ce | 2021 |
Cannabinoids in glioblastoma multiforme-hype or hope?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Proliferation; Ce | 2021 |
Cannabinoids in glioblastoma multiforme-hype or hope?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Proliferation; Ce | 2021 |
Predictive value of MGMT promoter methylation on the survival of TMZ treated
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2021 |
Predictive value of MGMT promoter methylation on the survival of TMZ treated
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2021 |
Predictive value of MGMT promoter methylation on the survival of TMZ treated
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2021 |
Telomerase reverse transcriptase promoter mutation- and O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Telomerase reverse transcriptase promoter mutation- and O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Telomerase reverse transcriptase promoter mutation- and O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2021 |
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2021 |
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2021 |
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylat | 2021 |
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylat | 2021 |
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylat | 2021 |
The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; Brain | 2021 |
The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; Brain | 2021 |
The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; Brain | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Lateral Ventricles; Progno | 2021 |
Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Lateral Ventricles; Progno | 2021 |
Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Lateral Ventricles; Progno | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Cycle Proteins; Chemoradiotherapy; Cranioto | 2021 |
Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Cycle Proteins; Chemoradiotherapy; Cranioto | 2021 |
Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Cycle Proteins; Chemoradiotherapy; Cranioto | 2021 |
CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
Topics: B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; Brain Neoplasms; CDC2 Protein Kinase; Cell | 2021 |
CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
Topics: B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; Brain Neoplasms; CDC2 Protein Kinase; Cell | 2021 |
CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
Topics: B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; Brain Neoplasms; CDC2 Protein Kinase; Cell | 2021 |
The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Brain Neoplasms; Carbazoles; Cell Line, T | 2021 |
The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Brain Neoplasms; Carbazoles; Cell Line, T | 2021 |
The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Brain Neoplasms; Carbazoles; Cell Line, T | 2021 |
MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regul | 2021 |
MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regul | 2021 |
MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regul | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Hy | 2021 |
Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Hy | 2021 |
Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Hy | 2021 |
Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2021 |
Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2021 |
Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2021 |
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Cancer-specific loss of
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Prol | 2021 |
Cancer-specific loss of
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Prol | 2021 |
Cancer-specific loss of
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Prol | 2021 |
Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2021 |
Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2021 |
Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2021 |
Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2021 |
Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atlases as Topic; Brain Neoplasms; Female; Gene Expr | 2021 |
Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atlases as Topic; Brain Neoplasms; Female; Gene Expr | 2021 |
Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atlases as Topic; Brain Neoplasms; Female; Gene Expr | 2021 |
PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Class Ib Phosphatidylinositol 3-Kinase; Drug Resi | 2021 |
PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Class Ib Phosphatidylinositol 3-Kinase; Drug Resi | 2021 |
PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Class Ib Phosphatidylinositol 3-Kinase; Drug Resi | 2021 |
De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhib | 2021 |
De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhib | 2021 |
De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhib | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Administra | 2021 |
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Administra | 2021 |
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Administra | 2021 |
Dual-triggered biomimetic vehicles enable treatment of glioblastoma through a cancer stem cell therapeutic strategy.
Topics: Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Neoplastic Stem Cells; Temozol | 2021 |
Dual-triggered biomimetic vehicles enable treatment of glioblastoma through a cancer stem cell therapeutic strategy.
Topics: Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Neoplastic Stem Cells; Temozol | 2021 |
Dual-triggered biomimetic vehicles enable treatment of glioblastoma through a cancer stem cell therapeutic strategy.
Topics: Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Neoplastic Stem Cells; Temozol | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging | 2021 |
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging | 2021 |
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell C | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell C | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell C | 2021 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Plastic | 2021 |
CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Plastic | 2021 |
CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Plastic | 2021 |
EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability.
Topics: Brain Neoplasms; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; G | 2021 |
EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability.
Topics: Brain Neoplasms; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; G | 2021 |
EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability.
Topics: Brain Neoplasms; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; G | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2021 |
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2021 |
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2021 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
[Glioblastoma].
Topics: Brain Neoplasms; Glioblastoma; Humans; Japan; Neoplasm Recurrence, Local; Temozolomide | 2021 |
[Glioblastoma].
Topics: Brain Neoplasms; Glioblastoma; Humans; Japan; Neoplasm Recurrence, Local; Temozolomide | 2021 |
[Glioblastoma].
Topics: Brain Neoplasms; Glioblastoma; Humans; Japan; Neoplasm Recurrence, Local; Temozolomide | 2021 |
A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug De | 2021 |
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug De | 2021 |
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug De | 2021 |
Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Nucl | 2021 |
Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Nucl | 2021 |
Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Nucl | 2021 |
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell | 2021 |
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell | 2021 |
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell | 2021 |
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Research Design; Retrospective Studi | 2021 |
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Research Design; Retrospective Studi | 2021 |
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Research Design; Retrospective Studi | 2021 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Apraxias; Brain Neoplasms; Chemoradiotherapy, Adjuvan | 2021 |
Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Apraxias; Brain Neoplasms; Chemoradiotherapy, Adjuvan | 2021 |
Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Apraxias; Brain Neoplasms; Chemoradiotherapy, Adjuvan | 2021 |
Prediction of Glioma Stemlike Cell Infiltration in the Non-Contrast-Enhancing Area by Quantitative Measurement of Lactate on Magnetic Resonance Spectroscopy in Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Prediction of Glioma Stemlike Cell Infiltration in the Non-Contrast-Enhancing Area by Quantitative Measurement of Lactate on Magnetic Resonance Spectroscopy in Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Prediction of Glioma Stemlike Cell Infiltration in the Non-Contrast-Enhancing Area by Quantitative Measurement of Lactate on Magnetic Resonance Spectroscopy in Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Glioblastoma; Ho | 2021 |
17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Glioblastoma; Ho | 2021 |
17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Glioblastoma; Ho | 2021 |
Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2021 |
Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2021 |
Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2021 |
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Heterografts; Humans; Mic | 2022 |
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Heterografts; Humans; Mic | 2022 |
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Heterografts; Humans; Mic | 2022 |
Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Neurosurgical Procedures; Prognosis; Retrospective Stud | 2022 |
Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Neurosurgical Procedures; Prognosis; Retrospective Stud | 2022 |
Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Neurosurgical Procedures; Prognosis; Retrospective Stud | 2022 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Contrast Media; Craniotomy; Female; Glioblastoma | 2021 |
Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Contrast Media; Craniotomy; Female; Glioblastoma | 2021 |
Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Contrast Media; Craniotomy; Female; Glioblastoma | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Exo | 2021 |
Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Exo | 2021 |
Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Exo | 2021 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Ac | 2022 |
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Ac | 2022 |
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Ac | 2022 |
Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Male; | 2021 |
Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Male; | 2021 |
Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Male; | 2021 |
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Topics: Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Gadolinium; Glioblastoma; Humans; Temozolomide; Tre | 2021 |
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Topics: Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Gadolinium; Glioblastoma; Humans; Temozolomide; Tre | 2021 |
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Topics: Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Gadolinium; Glioblastoma; Humans; Temozolomide; Tre | 2021 |
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2022 |
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2022 |
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2022 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; D | 2021 |
Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; D | 2021 |
Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; D | 2021 |
Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
Topics: Adenosine; Aerobiosis; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Agents, Alkylat | 2021 |
Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
Topics: Adenosine; Aerobiosis; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Agents, Alkylat | 2021 |
Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
Topics: Adenosine; Aerobiosis; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Agents, Alkylat | 2021 |
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2021 |
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2021 |
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2021 |
Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Drug Resistance; Drug Resistance, Neoplasm | 2022 |
Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Drug Resistance; Drug Resistance, Neoplasm | 2022 |
Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Drug Resistance; Drug Resistance, Neoplasm | 2022 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Epigenetic instability may alter cell state transitions and anticancer drug resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Epigenetic instability may alter cell state transitions and anticancer drug resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Epigenetic instability may alter cell state transitions and anticancer drug resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2022 |
Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2022 |
Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2022 |
Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviva | 2021 |
Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviva | 2021 |
Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviva | 2021 |
Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2021 |
Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2021 |
Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2021 |
The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Brain Neoplasms; | 2021 |
The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Brain Neoplasms; | 2021 |
The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Brain Neoplasms; | 2021 |
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Caspase 3; Cell Line, Tumor; Ce | 2021 |
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Caspase 3; Cell Line, Tumor; Ce | 2021 |
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Caspase 3; Cell Line, Tumor; Ce | 2021 |
Proton therapy for newly diagnosed glioblastoma: more room for investigation.
Topics: Brain Neoplasms; Glioblastoma; Humans; Proton Therapy; Temozolomide | 2021 |
Proton therapy for newly diagnosed glioblastoma: more room for investigation.
Topics: Brain Neoplasms; Glioblastoma; Humans; Proton Therapy; Temozolomide | 2021 |
Proton therapy for newly diagnosed glioblastoma: more room for investigation.
Topics: Brain Neoplasms; Glioblastoma; Humans; Proton Therapy; Temozolomide | 2021 |
Answer to the comment of Hai Lu et al. regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
Answer to the comment of Hai Lu et al. regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
Answer to the comment of Hai Lu et al. regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Prolif | 2017 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Prolif | 2017 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Prolif | 2017 |
MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; H | 2017 |
MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; H | 2017 |
MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; H | 2017 |
Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma.
Topics: Adipocytes; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma.
Topics: Adipocytes; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma.
Topics: Adipocytes; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Ch | 2017 |
Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Ch | 2017 |
Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Ch | 2017 |
Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Brain Neoplasms; Cell Line | 2017 |
Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Brain Neoplasms; Cell Line | 2017 |
Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Brain Neoplasms; Cell Line | 2017 |
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Topics: Aged; Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2017 |
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Topics: Aged; Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2017 |
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Topics: Aged; Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2017 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2017 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2017 |
Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2017 |
Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2017 |
Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Sex as a biological variable in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Mice; Sex Factors; Surviv | 2017 |
Sex as a biological variable in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Mice; Sex Factors; Surviv | 2017 |
Sex as a biological variable in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Mice; Sex Factors; Surviv | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2017 |
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2017 |
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2017 |
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tum | 2017 |
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tum | 2017 |
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tum | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery.
Topics: Adult; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Dacarbazine; Humans; Int | 2017 |
A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery.
Topics: Adult; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Dacarbazine; Humans; Int | 2017 |
A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery.
Topics: Adult; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Dacarbazine; Humans; Int | 2017 |
Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Nucleus; Chemotherapy, Adjuvan | 2018 |
Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Nucleus; Chemotherapy, Adjuvan | 2018 |
Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Nucleus; Chemotherapy, Adjuvan | 2018 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Expression and function of ABCG2 and XIAP in glioblastomas.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Su | 2017 |
Expression and function of ABCG2 and XIAP in glioblastomas.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Su | 2017 |
Expression and function of ABCG2 and XIAP in glioblastomas.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Su | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytokines; Dacarbaz | 2017 |
EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytokines; Dacarbaz | 2017 |
EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytokines; Dacarbaz | 2017 |
Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Biochemical Phenomena; Brain; Brain Ne | 2017 |
Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Biochemical Phenomena; Brain; Brain Ne | 2017 |
Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Biochemical Phenomena; Brain; Brain Ne | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diseas | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diseas | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diseas | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; N | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; N | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; N | 2017 |
Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2018 |
Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2018 |
Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2018 |
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Daca | 2017 |
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Daca | 2017 |
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Daca | 2017 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2016 |
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2016 |
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2016 |
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2017 |
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2017 |
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2017 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2017 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2017 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, | 2017 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, | 2017 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, | 2017 |
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; CpG Islands; Dacarbazine; DNA | 2017 |
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; CpG Islands; Dacarbazine; DNA | 2017 |
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; CpG Islands; Dacarbazine; DNA | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heter | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heter | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heter | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornit | 2017 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornit | 2017 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornit | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Mode | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Mode | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Mode | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, | 2017 |
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2017 |
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2017 |
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2017 |
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2017 |
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progres | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progres | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progres | 2017 |
Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dose-Respons | 2018 |
Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dose-Respons | 2018 |
Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dose-Respons | 2018 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connective | 2017 |
Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connective | 2017 |
Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connective | 2017 |
New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Carriers; | 2017 |
New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Carriers; | 2017 |
New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Carriers; | 2017 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2017 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2017 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2017 |
Liposomal temozolomide drug delivery using convection enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Convection; Dacarbazine; Drug Delivery | 2017 |
Liposomal temozolomide drug delivery using convection enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Convection; Dacarbazine; Drug Delivery | 2017 |
Liposomal temozolomide drug delivery using convection enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Convection; Dacarbazine; Drug Delivery | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resis | 2017 |
Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resis | 2017 |
Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resis | 2017 |
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, | 2017 |
Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, | 2017 |
Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, | 2017 |
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case | 2017 |
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case | 2017 |
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case | 2017 |
A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glio | 2017 |
A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glio | 2017 |
A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glio | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Di | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Di | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Di | 2017 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2017 |
FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2017 |
FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2017 |
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2018 |
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2018 |
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2018 |
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2017 |
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2017 |
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2017 |
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Topics: Animals; Brain Neoplasms; Cells, Cultured; CRISPR-Cas Systems; Dacarbazine; Dependovirus; DNA Mutati | 2017 |
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Topics: Animals; Brain Neoplasms; Cells, Cultured; CRISPR-Cas Systems; Dacarbazine; Dependovirus; DNA Mutati | 2017 |
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Topics: Animals; Brain Neoplasms; Cells, Cultured; CRISPR-Cas Systems; Dacarbazine; Dependovirus; DNA Mutati | 2017 |
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazi | 2016 |
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazi | 2016 |
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazi | 2016 |
Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modi | 2017 |
Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modi | 2017 |
Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modi | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2017 |
Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2017 |
Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2017 |
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; | 2018 |
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; | 2018 |
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; | 2018 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacar | 2017 |
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacar | 2017 |
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacar | 2017 |
Identification of WISP1 as a novel oncogene in glioblastoma.
Topics: Brain Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Prolife | 2017 |
Identification of WISP1 as a novel oncogene in glioblastoma.
Topics: Brain Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Prolife | 2017 |
Identification of WISP1 as a novel oncogene in glioblastoma.
Topics: Brain Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Prolife | 2017 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Survival improvements with adjuvant therapy in patients with glioblastoma.
Topics: Adult; Aged; Analysis of Variance; Australia; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort S | 2018 |
Survival improvements with adjuvant therapy in patients with glioblastoma.
Topics: Adult; Aged; Analysis of Variance; Australia; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort S | 2018 |
Survival improvements with adjuvant therapy in patients with glioblastoma.
Topics: Adult; Aged; Analysis of Variance; Australia; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort S | 2018 |
Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.
Topics: Brain Neoplasms; Cell Death; Cell Differentiation; Cell Self Renewal; Dacarbazine; Drug Resistance, | 2017 |
Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.
Topics: Brain Neoplasms; Cell Death; Cell Differentiation; Cell Self Renewal; Dacarbazine; Drug Resistance, | 2017 |
Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro.
Topics: Brain Neoplasms; Cell Death; Cell Differentiation; Cell Self Renewal; Dacarbazine; Drug Resistance, | 2017 |
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Culture Media, | 2017 |
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Culture Media, | 2017 |
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Culture Media, | 2017 |
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Doubl | 2017 |
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Doubl | 2017 |
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Doubl | 2017 |
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2018 |
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2018 |
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2018 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2018 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2018 |
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Femal | 2017 |
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Femal | 2017 |
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Femal | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; | 2017 |
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; DNA Repl | 2018 |
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; DNA Repl | 2018 |
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; DNA Repl | 2018 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2017 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2017 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2017 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2018 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2018 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2018 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cisplatin | 2018 |
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cisplatin | 2018 |
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cisplatin | 2018 |
Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication.
Topics: Analgesics, Opioid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cell Lin | 2018 |
Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication.
Topics: Analgesics, Opioid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cell Lin | 2018 |
Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication.
Topics: Analgesics, Opioid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cell Lin | 2018 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neopla | 2017 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neopla | 2017 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neopla | 2017 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Glio | 2018 |
Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Glio | 2018 |
Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Glio | 2018 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarb | 2018 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarb | 2018 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarb | 2018 |
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Ge | 2018 |
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Ge | 2018 |
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Ge | 2018 |
Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2018 |
Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2018 |
Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2018 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Pr | 2018 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Pr | 2018 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Pr | 2018 |
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2018 |
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2018 |
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2018 |
MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Dacarbazine; Databases, G | 2018 |
MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Dacarbazine; Databases, G | 2018 |
MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Dacarbazine; Databases, G | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Coordin | 2018 |
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Coordin | 2018 |
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Coordin | 2018 |
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; | 2018 |
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; | 2018 |
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; | 2018 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation | 2017 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation | 2017 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation | 2017 |
Novel Targeting of Transcription and Metabolism in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain; Brain Neoplasms; Cell Lin | 2018 |
Novel Targeting of Transcription and Metabolism in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain; Brain Neoplasms; Cell Lin | 2018 |
Novel Targeting of Transcription and Metabolism in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain; Brain Neoplasms; Cell Lin | 2018 |
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; DNA Da | 2017 |
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; DNA Da | 2017 |
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; DNA Da | 2017 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, | 2018 |
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, | 2018 |
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, | 2018 |
High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell D | 2018 |
Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell D | 2018 |
Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell D | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell | 2018 |
Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell | 2018 |
Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell | 2018 |
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA-Binding Prote | 2018 |
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA-Binding Prote | 2018 |
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA-Binding Prote | 2018 |
Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cerebrova | 2018 |
Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cerebrova | 2018 |
Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cerebrova | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Where does O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; O(6)-Meth | 2018 |
Where does O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; O(6)-Meth | 2018 |
Where does O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; O(6)-Meth | 2018 |
Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Respo | 2018 |
Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Respo | 2018 |
Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Respo | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Drug | 2018 |
Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Drug | 2018 |
Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Drug | 2018 |
Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Disease Progression; Female; Gamma Rays; | 2018 |
Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Disease Progression; Female; Gamma Rays; | 2018 |
Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Disease Progression; Female; Gamma Rays; | 2018 |
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Mov | 2018 |
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Mov | 2018 |
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Mov | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Chemotherapy, Adjuva | 2018 |
A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Chemotherapy, Adjuva | 2018 |
A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Chemotherapy, Adjuva | 2018 |
Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Extracellular Vesicles; Female; Glioblastoma; Huma | 2018 |
Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Extracellular Vesicles; Female; Glioblastoma; Huma | 2018 |
Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Extracellular Vesicles; Female; Glioblastoma; Huma | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2018 |
Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2018 |
Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Topics: AC133 Antigen; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cisp | 2018 |
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Topics: AC133 Antigen; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cisp | 2018 |
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Topics: AC133 Antigen; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cisp | 2018 |
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Brain Neopl | 2018 |
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Brain Neopl | 2018 |
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Brain Neopl | 2018 |
Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients.
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression R | 2018 |
Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients.
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression R | 2018 |
Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients.
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression R | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2018 |
Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2018 |
Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2018 |
XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA- | 2018 |
XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA- | 2018 |
XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA- | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; An | 2018 |
Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; An | 2018 |
Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; An | 2018 |
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2018 |
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2018 |
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2018 |
Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Dacarbazine; Down-Regul | 2018 |
Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Dacarbazine; Down-Regul | 2018 |
Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Dacarbazine; Down-Regul | 2018 |
Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2018 |
Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2018 |
Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; D | 2018 |
Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; D | 2018 |
Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; D | 2018 |
Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Temozolomide | 2018 |
Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Temozolomide | 2018 |
Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Temozolomide | 2018 |
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell P | 2018 |
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell P | 2018 |
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell P | 2018 |
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Li | 2018 |
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Li | 2018 |
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Li | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magn | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magn | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magn | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Databases, Fa | 2018 |
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Databases, Fa | 2018 |
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Databases, Fa | 2018 |
Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2018 |
Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2018 |
Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2018 |
Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydrogen Pe | 2018 |
Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydrogen Pe | 2018 |
Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydrogen Pe | 2018 |
Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemoradiotherapy, Adj | 2018 |
Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemoradiotherapy, Adj | 2018 |
Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemoradiotherapy, Adj | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolo | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolo | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolo | 2018 |
Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2018 |
Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2018 |
Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Topics: Adenine Phosphoribosyltransferase; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2018 |
Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Topics: Adenine Phosphoribosyltransferase; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2018 |
Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Topics: Adenine Phosphoribosyltransferase; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbaz | 2018 |
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbaz | 2018 |
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Dacarbaz | 2018 |
miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; G | 2018 |
miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; G | 2018 |
miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; G | 2018 |
Improved survival of Swedish glioblastoma patients treated according to Stupp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2018 |
Improved survival of Swedish glioblastoma patients treated according to Stupp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2018 |
Improved survival of Swedish glioblastoma patients treated according to Stupp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2018 |
Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; | 2018 |
Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; | 2018 |
Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; | 2018 |
Fabrication and Characterization of Chitosan-Hyaluronic Acid Scaffolds with Varying Stiffness for Glioblastoma Cell Culture.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chitosan; Glioblastoma | 2018 |
Fabrication and Characterization of Chitosan-Hyaluronic Acid Scaffolds with Varying Stiffness for Glioblastoma Cell Culture.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chitosan; Glioblastoma | 2018 |
Fabrication and Characterization of Chitosan-Hyaluronic Acid Scaffolds with Varying Stiffness for Glioblastoma Cell Culture.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chitosan; Glioblastoma | 2018 |
The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Move | 2018 |
The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Move | 2018 |
The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Move | 2018 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
Tumor-treating fields: time for demystification.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimulation | 2018 |
Tumor-treating fields: time for demystification.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimulation | 2018 |
Tumor-treating fields: time for demystification.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimulation | 2018 |
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neopla | 2018 |
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neopla | 2018 |
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neopla | 2018 |
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2018 |
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2018 |
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2018 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.
Topics: Adult; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2018 |
Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.
Topics: Adult; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2018 |
Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.
Topics: Adult; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2018 |
Getting to the brain.
Topics: Animals; Antineoplastic Agents; Azepines; Blood-Brain Barrier; Brain; Brain Neoplasms; Drug Carriers | 2018 |
Getting to the brain.
Topics: Animals; Antineoplastic Agents; Azepines; Blood-Brain Barrier; Brain; Brain Neoplasms; Drug Carriers | 2018 |
Getting to the brain.
Topics: Animals; Antineoplastic Agents; Azepines; Blood-Brain Barrier; Brain; Brain Neoplasms; Drug Carriers | 2018 |
Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2018 |
Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2018 |
Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2018 |
Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Cell Prolif | 2019 |
Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Cell Prolif | 2019 |
Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Cell Prolif | 2019 |
Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Syste | 2019 |
Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Syste | 2019 |
Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Syste | 2019 |
Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Brain Neoplasms; Carcinoma, | 2018 |
Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Brain Neoplasms; Carcinoma, | 2018 |
Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Brain Neoplasms; Carcinoma, | 2018 |
[
Topics: Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; | 2019 |
[
Topics: Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; | 2019 |
[
Topics: Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; | 2019 |
C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Topics: Adiponectin; Antineoplastic Agents, Alkylating; Apoptosis; bcl-X Protein; Brain Neoplasms; Caspase 3 | 2018 |
C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Topics: Adiponectin; Antineoplastic Agents, Alkylating; Apoptosis; bcl-X Protein; Brain Neoplasms; Caspase 3 | 2018 |
C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Topics: Adiponectin; Antineoplastic Agents, Alkylating; Apoptosis; bcl-X Protein; Brain Neoplasms; Caspase 3 | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Female | 2019 |
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Female | 2019 |
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Female | 2019 |
Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Brain Neoplasms; Cell Line, Tumor; Ce | 2018 |
Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Brain Neoplasms; Cell Line, Tumor; Ce | 2018 |
Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Brain Neoplasms; Cell Line, Tumor; Ce | 2018 |
Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2018 |
Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2018 |
Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2018 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2018 |
Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2018 |
Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2018 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apolipoproteins; Blood-Brain Barrier; Brain; Brain Neoplasms; Cel | 2018 |
Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apolipoproteins; Blood-Brain Barrier; Brain; Brain Neoplasms; Cel | 2018 |
Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apolipoproteins; Blood-Brain Barrier; Brain; Brain Neoplasms; Cel | 2018 |
Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Dehydroepiandrosterone; DNA Damage; Dr | 2019 |
Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Dehydroepiandrosterone; DNA Damage; Dr | 2019 |
Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Dehydroepiandrosterone; DNA Damage; Dr | 2019 |
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2020 |
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2020 |
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2020 |
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 2018 |
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 2018 |
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 2018 |
A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2019 |
A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2019 |
A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2019 |
Modulation of Cell State to Improve Drug Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Mo | 2018 |
Modulation of Cell State to Improve Drug Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Mo | 2018 |
Modulation of Cell State to Improve Drug Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Mo | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Longitudin | 2018 |
Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Longitudin | 2018 |
Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Longitudin | 2018 |
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazin | 2018 |
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazin | 2018 |
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazin | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hematol | 2018 |
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hematol | 2018 |
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hematol | 2018 |
Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Kaplan-Meier | 2018 |
Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Kaplan-Meier | 2018 |
Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Kaplan-Meier | 2018 |
Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tu | 2018 |
Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tu | 2018 |
Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tu | 2018 |
Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Topics: 5'-Nucleotidase; Adenosine; Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Move | 2019 |
CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Topics: 5'-Nucleotidase; Adenosine; Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Move | 2019 |
CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Topics: 5'-Nucleotidase; Adenosine; Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Move | 2019 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Female; | 2018 |
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Female; | 2018 |
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Female; | 2018 |
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival | 2018 |
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival | 2018 |
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Proapoptotic effects of novel thiazole derivative on human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Doxoru | 2019 |
Proapoptotic effects of novel thiazole derivative on human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Doxoru | 2019 |
Proapoptotic effects of novel thiazole derivative on human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Doxoru | 2019 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Su | 2018 |
MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Su | 2018 |
MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Su | 2018 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplas | 2018 |
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplas | 2018 |
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplas | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Pro | 2018 |
FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Pro | 2018 |
FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Pro | 2018 |
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carr | 2018 |
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carr | 2018 |
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carr | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Line, Tu | 2018 |
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Line, Tu | 2018 |
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Line, Tu | 2018 |
Achievable Central Nervous System Concentrations of the Green Tea Catechin EGCG Induce Stress in Glioblastoma Cells in Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Catechin; Cen | 2018 |
Achievable Central Nervous System Concentrations of the Green Tea Catechin EGCG Induce Stress in Glioblastoma Cells in Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Catechin; Cen | 2018 |
Achievable Central Nervous System Concentrations of the Green Tea Catechin EGCG Induce Stress in Glioblastoma Cells in Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Catechin; Cen | 2018 |
A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Feedback, Physiological; | 2018 |
A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Feedback, Physiological; | 2018 |
A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Feedback, Physiological; | 2018 |
SOX3 can promote the malignant behavior of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2019 |
SOX3 can promote the malignant behavior of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2019 |
SOX3 can promote the malignant behavior of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2019 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Female; Focal Adhesion Kinase 2; Gene Exp | 2018 |
PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Female; Focal Adhesion Kinase 2; Gene Exp | 2018 |
PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Female; Focal Adhesion Kinase 2; Gene Exp | 2018 |
Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Copy Number Variations; DNA Methylatio | 2018 |
Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Copy Number Variations; DNA Methylatio | 2018 |
Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Copy Number Variations; DNA Methylatio | 2018 |
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Modification Methylases; DNA R | 2018 |
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Modification Methylases; DNA R | 2018 |
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Modification Methylases; DNA R | 2018 |
Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Chemical Prec | 2019 |
Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Chemical Prec | 2019 |
Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Chemical Prec | 2019 |
Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Femal | 2018 |
Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Femal | 2018 |
Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Femal | 2018 |
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carbonic Anhydras | 2018 |
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carbonic Anhydras | 2018 |
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carbonic Anhydras | 2018 |
Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug C | 2018 |
Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug C | 2018 |
Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug C | 2018 |
Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Li | 2018 |
Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Li | 2018 |
Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Li | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Brain Neoplasms; | 2019 |
Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Brain Neoplasms; | 2019 |
Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Brain Neoplasms; | 2019 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2019 |
Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2019 |
Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2019 |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor | 2019 |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor | 2019 |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor | 2019 |
A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice.
Topics: Animals; Brachytherapy; Brain Neoplasms; Cell Proliferation; Cell Survival; Disintegrins; Drug Syner | 2018 |
A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice.
Topics: Animals; Brachytherapy; Brain Neoplasms; Cell Proliferation; Cell Survival; Disintegrins; Drug Syner | 2018 |
A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice.
Topics: Animals; Brachytherapy; Brain Neoplasms; Cell Proliferation; Cell Survival; Disintegrins; Drug Syner | 2018 |
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cel | 2019 |
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cel | 2019 |
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cel | 2019 |
Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance | 2018 |
Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance | 2018 |
Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance | 2018 |
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Topics: Animals; Antagomirs; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-A | 2018 |
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Topics: Animals; Antagomirs; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-A | 2018 |
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Topics: Animals; Antagomirs; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-A | 2018 |
Functional analysis of protein disulfide isomerase P5 in glioblastoma cells as a novel anticancer target.
Topics: Anacardic Acids; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Scree | 2019 |
Functional analysis of protein disulfide isomerase P5 in glioblastoma cells as a novel anticancer target.
Topics: Anacardic Acids; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Scree | 2019 |
Functional analysis of protein disulfide isomerase P5 in glioblastoma cells as a novel anticancer target.
Topics: Anacardic Acids; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Scree | 2019 |
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell | 2019 |
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell | 2019 |
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell | 2019 |
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Humans; | 2019 |
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Humans; | 2019 |
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Humans; | 2019 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2020 |
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2020 |
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2020 |
Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Child; Disease Progression; Dru | 2019 |
PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Child; Disease Progression; Dru | 2019 |
PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Child; Disease Progression; Dru | 2019 |
Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Barium Compounds; Blood-Brain Barrier; Brain Neoplasms | 2019 |
Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Barium Compounds; Blood-Brain Barrier; Brain Neoplasms | 2019 |
Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Barium Compounds; Blood-Brain Barrier; Brain Neoplasms | 2019 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Brain | 2018 |
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Brain | 2018 |
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Brain | 2018 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cel | 2019 |
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cel | 2019 |
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cel | 2019 |
Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2018 |
Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2018 |
Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2018 |
Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Autophagy; Autophagy-Related Protein | 2019 |
The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Autophagy; Autophagy-Related Protein | 2019 |
The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Autophagy; Autophagy-Related Protein | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Biological Tra | 2019 |
Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Biological Tra | 2019 |
Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Biological Tra | 2019 |
Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Su | 2019 |
Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Su | 2019 |
Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Su | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Gliobl | 2019 |
Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Gliobl | 2019 |
Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Gliobl | 2019 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Female; Glioblastoma; Human | 2019 |
Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Female; Glioblastoma; Human | 2019 |
Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Female; Glioblastoma; Human | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
[Temozolomide (TMZ)].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Temozolomide | 2016 |
[Temozolomide (TMZ)].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Temozolomide | 2016 |
[Temozolomide (TMZ)].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Temozolomide | 2016 |
Increased Expression of GRP78 Correlates with Adverse Outcome in Recurrent Glioblastoma Multiforme Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherap | 2020 |
Increased Expression of GRP78 Correlates with Adverse Outcome in Recurrent Glioblastoma Multiforme Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherap | 2020 |
Increased Expression of GRP78 Correlates with Adverse Outcome in Recurrent Glioblastoma Multiforme Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherap | 2020 |
MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neo | 2019 |
MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neo | 2019 |
MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neo | 2019 |
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2019 |
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2019 |
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2019 |
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response R | 2019 |
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response R | 2019 |
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response R | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2019 |
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2019 |
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2019 |
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Hyp | 2019 |
A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Hyp | 2019 |
A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Hyp | 2019 |
Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chemotherapy, Adj | 2019 |
Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chemotherapy, Adj | 2019 |
Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chemotherapy, Adj | 2019 |
pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Computer Simulation; Cytoplasm | 2019 |
pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Computer Simulation; Cytoplasm | 2019 |
pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Computer Simulation; Cytoplasm | 2019 |
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; Gene Expression | 2019 |
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; Gene Expression | 2019 |
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; Gene Expression | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Stu | 2019 |
Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Stu | 2019 |
Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Stu | 2019 |
Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
The Impact of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
The Impact of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
The Impact of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2019 |
A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2019 |
A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2019 |
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2019 |
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2019 |
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2019 |
Glioblastoma Recurrence and the Role of O
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; DNA Meth | 2019 |
Glioblastoma Recurrence and the Role of O
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; DNA Meth | 2019 |
Glioblastoma Recurrence and the Role of O
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; DNA Meth | 2019 |
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2019 |
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2019 |
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2019 |
Improving survival in molecularly selected glioblastoma.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes; | 2019 |
Improving survival in molecularly selected glioblastoma.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes; | 2019 |
Improving survival in molecularly selected glioblastoma.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes; | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; DNA Methylation; DNA Modification Methylases; | 2019 |
Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; DNA Methylation; DNA Modification Methylases; | 2019 |
Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; DNA Methylation; DNA Modification Methylases; | 2019 |
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Topics: Aged; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modifi | 2019 |
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Topics: Aged; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modifi | 2019 |
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Topics: Aged; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modifi | 2019 |
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimul | 2019 |
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimul | 2019 |
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimul | 2019 |
High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Self Renewal; Drug Resista | 2019 |
High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Self Renewal; Drug Resista | 2019 |
High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Self Renewal; Drug Resista | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2019 |
HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2019 |
HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2019 |
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mes | 2019 |
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mes | 2019 |
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mes | 2019 |
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplas | 2019 |
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplas | 2019 |
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplas | 2019 |
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors.
Topics: Brain Neoplasms; Carbon; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Sy | 2019 |
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors.
Topics: Brain Neoplasms; Carbon; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Sy | 2019 |
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors.
Topics: Brain Neoplasms; Carbon; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Sy | 2019 |
Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell P | 2019 |
Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell P | 2019 |
Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell P | 2019 |
D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro.
Topics: Adult; Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2019 |
D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro.
Topics: Adult; Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2019 |
D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro.
Topics: Adult; Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2019 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2019 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2019 |
Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Topics: Animals; Apoptosis; Biological Transport; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Topics: Animals; Apoptosis; Biological Transport; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Topics: Animals; Apoptosis; Biological Transport; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dose-Response Rela | 2019 |
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dose-Response Rela | 2019 |
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dose-Response Rela | 2019 |
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Plasticity; Drug Resistance, Neopla | 2019 |
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Plasticity; Drug Resistance, Neopla | 2019 |
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Plasticity; Drug Resistance, Neopla | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
How to integrate immunotherapy into standard of care in glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Standard of Care; T-Lymphocytes; Temozolomide | 2019 |
How to integrate immunotherapy into standard of care in glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Standard of Care; T-Lymphocytes; Temozolomide | 2019 |
How to integrate immunotherapy into standard of care in glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Standard of Care; T-Lymphocytes; Temozolomide | 2019 |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Gene Knoc | 2019 |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Gene Knoc | 2019 |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Gene Knoc | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Colitis; Cytomegalovirus Infections; Female; Glioblastoma; | 2019 |
Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Colitis; Cytomegalovirus Infections; Female; Glioblastoma; | 2019 |
Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Colitis; Cytomegalovirus Infections; Female; Glioblastoma; | 2019 |
Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, | 2019 |
Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, | 2019 |
Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, | 2019 |
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2020 |
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2020 |
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2020 |
miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
Bioengineering fluorescent virus-like particle/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors.
Topics: Animals; Apolipoproteins E; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Movement; C | 2019 |
Bioengineering fluorescent virus-like particle/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors.
Topics: Animals; Apolipoproteins E; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Movement; C | 2019 |
Bioengineering fluorescent virus-like particle/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors.
Topics: Animals; Apolipoproteins E; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Movement; C | 2019 |
Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma
Topics: Animals; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Male; Mice; | 2019 |
Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma
Topics: Animals; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Male; Mice; | 2019 |
Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma
Topics: Animals; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Male; Mice; | 2019 |
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
Topics: Animals; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Cell Line, Tumor; Cell Plastici | 2019 |
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
Topics: Animals; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Cell Line, Tumor; Cell Plastici | 2019 |
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
Topics: Animals; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Cell Line, Tumor; Cell Plastici | 2019 |
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain | 2019 |
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain | 2019 |
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain | 2019 |
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, | 2019 |
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, | 2019 |
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2019 |
Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2019 |
Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2019 |
Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Topics: Adult; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chondroitin Sulfate Proteoglycan | 2019 |
Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Topics: Adult; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chondroitin Sulfate Proteoglycan | 2019 |
Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Topics: Adult; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chondroitin Sulfate Proteoglycan | 2019 |
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?
Topics: Brain Neoplasms; Glioblastoma; Glucose; Glutamine; Humans; Ketone Bodies; Mitochondria; Standard of | 2019 |
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?
Topics: Brain Neoplasms; Glioblastoma; Glucose; Glutamine; Humans; Ketone Bodies; Mitochondria; Standard of | 2019 |
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?
Topics: Brain Neoplasms; Glioblastoma; Glucose; Glutamine; Humans; Ketone Bodies; Mitochondria; Standard of | 2019 |
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Female; Fol | 2020 |
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Female; Fol | 2020 |
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Female; Fol | 2020 |
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap | 2019 |
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap | 2019 |
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap | 2019 |
Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Ext | 2020 |
Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Ext | 2020 |
Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Ext | 2020 |
R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm | 2019 |
R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm | 2019 |
R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm | 2019 |
Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell | 2019 |
Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell | 2019 |
Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell | 2019 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Lnc-TALC promotes O
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modificati | 2019 |
Lnc-TALC promotes O
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modificati | 2019 |
Lnc-TALC promotes O
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modificati | 2019 |
Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1.
Topics: 3' Untranslated Regions; Adult; Aged; Antagomirs; Brain Neoplasms; Case-Control Studies; Cell Line, | 2019 |
Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1.
Topics: 3' Untranslated Regions; Adult; Aged; Antagomirs; Brain Neoplasms; Case-Control Studies; Cell Line, | 2019 |
Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1.
Topics: 3' Untranslated Regions; Adult; Aged; Antagomirs; Brain Neoplasms; Case-Control Studies; Cell Line, | 2019 |
Pam
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Sur | 2020 |
Pam
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Sur | 2020 |
Pam
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Sur | 2020 |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, N | 2019 |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, N | 2019 |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, N | 2019 |
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Female; Gliobl | 2019 |
Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Female; Gliobl | 2019 |
Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Female; Gliobl | 2019 |
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
Survival trends in glioblastoma and association with treating facility volume.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Databases, Fact | 2019 |
Survival trends in glioblastoma and association with treating facility volume.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Databases, Fact | 2019 |
Survival trends in glioblastoma and association with treating facility volume.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Databases, Fact | 2019 |
A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy.
Topics: Bioprinting; Brain; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Combinations; Drug Ev | 2019 |
A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy.
Topics: Bioprinting; Brain; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Combinations; Drug Ev | 2019 |
A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy.
Topics: Bioprinting; Brain; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Combinations; Drug Ev | 2019 |
Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Aspergillosis; Brain Abscess; Brain Neoplasms; Combined Modality | 2019 |
Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Aspergillosis; Brain Abscess; Brain Neoplasms; Combined Modality | 2019 |
Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Aspergillosis; Brain Abscess; Brain Neoplasms; Combined Modality | 2019 |
Oleuropein modulates glioblastoma miRNA pattern different from
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Line, Tu | 2019 |
Oleuropein modulates glioblastoma miRNA pattern different from
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Line, Tu | 2019 |
Oleuropein modulates glioblastoma miRNA pattern different from
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Line, Tu | 2019 |
Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studi | 2019 |
Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studi | 2019 |
Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studi | 2019 |
Bufothionine Promotes Apoptosis via Triggering ER Stress and Synergizes with Temozolomide in Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug | 2019 |
Bufothionine Promotes Apoptosis via Triggering ER Stress and Synergizes with Temozolomide in Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug | 2019 |
Bufothionine Promotes Apoptosis via Triggering ER Stress and Synergizes with Temozolomide in Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug | 2019 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Neoplastic Stem Cells; | 2019 |
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Neoplastic Stem Cells; | 2019 |
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Neoplastic Stem Cells; | 2019 |
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor | 2019 |
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor | 2019 |
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor | 2019 |
microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Brazil; DNA Methylation; DNA Modificati | 2019 |
microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Brazil; DNA Methylation; DNA Modificati | 2019 |
microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Brazil; DNA Methylation; DNA Modificati | 2019 |
MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Drug Resistance, Neoplasm; Fe | 2019 |
MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Drug Resistance, Neoplasm; Fe | 2019 |
MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Drug Resistance, Neoplasm; Fe | 2019 |
Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Brain; Brain Neoplasms; Cell Movement; Cell Proliferatio | 2019 |
Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Brain; Brain Neoplasms; Cell Movement; Cell Proliferatio | 2019 |
Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Brain; Brain Neoplasms; Cell Movement; Cell Proliferatio | 2019 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Female; Glio | 2019 |
The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Female; Glio | 2019 |
The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Female; Glio | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru | 2019 |
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru | 2019 |
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru | 2019 |
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery | 2019 |
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery | 2019 |
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery | 2019 |
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium-Calmodulin-Dependent Protein Kina | 2020 |
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium-Calmodulin-Dependent Protein Kina | 2020 |
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium-Calmodulin-Dependent Protein Kina | 2020 |
Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromobox Protein Homolog 5; Cytoplasmi | 2019 |
Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromobox Protein Homolog 5; Cytoplasmi | 2019 |
Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromobox Protein Homolog 5; Cytoplasmi | 2019 |
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell | 2019 |
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell | 2019 |
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell | 2019 |
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Topics: Amphiregulin; Antibodies, Blocking; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neop | 2019 |
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Topics: Amphiregulin; Antibodies, Blocking; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neop | 2019 |
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Topics: Amphiregulin; Antibodies, Blocking; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neop | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Dacarbazine; For | 2013 |
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Dacarbazine; For | 2013 |
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Dacarbazine; For | 2013 |
Reversing the Warburg effect as a treatment for glioblastoma.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2013 |
Reversing the Warburg effect as a treatment for glioblastoma.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2013 |
Reversing the Warburg effect as a treatment for glioblastoma.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2013 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance | 2013 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance | 2013 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance | 2013 |
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Biomarkers, Tumor; Brain Neoplasms; Che | 2013 |
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Biomarkers, Tumor; Brain Neoplasms; Che | 2013 |
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Biomarkers, Tumor; Brain Neoplasms; Che | 2013 |
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Blepharoptosis; Brain Neoplasms; Chemoradiothera | 2013 |
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Blepharoptosis; Brain Neoplasms; Chemoradiothera | 2013 |
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Blepharoptosis; Brain Neoplasms; Chemoradiothera | 2013 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Steroid management in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2013 |
Steroid management in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2013 |
Steroid management in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2013 |
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2013 |
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2013 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality T | 2013 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality T | 2013 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality T | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevaci | 2014 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevaci | 2014 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevaci | 2014 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Gli | 2013 |
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Gli | 2013 |
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Gli | 2013 |
Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2013 |
Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2013 |
Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Ne | 2013 |
Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Ne | 2013 |
Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Ne | 2013 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, | 2013 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, | 2013 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, | 2013 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive | 2013 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive | 2013 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive | 2013 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; M | 2013 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; M | 2013 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; M | 2013 |
Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2013 |
Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2013 |
Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2013 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brai | 2013 |
Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brai | 2013 |
Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brai | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbon; Cell Proliferation; Da | 2013 |
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbon; Cell Proliferation; Da | 2013 |
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbon; Cell Proliferation; Da | 2013 |
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Caspase 12; Caspase 3; | 2013 |
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Caspase 12; Caspase 3; | 2013 |
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Caspase 12; Caspase 3; | 2013 |
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Da | 2013 |
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Da | 2013 |
Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Da | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemot | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemot | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemot | 2013 |
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Dacarbazine; D | 2013 |
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Dacarbazine; D | 2013 |
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Dacarbazine; D | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neopl | 2013 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neopl | 2013 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neopl | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Case-Control Studies; Chemo | 2013 |
Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Case-Control Studies; Chemo | 2013 |
Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Case-Control Studies; Chemo | 2013 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradi | 2013 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradi | 2013 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradi | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Apoptotic | 2013 |
Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Apoptotic | 2013 |
Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Apoptotic | 2013 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphom | 2013 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphom | 2013 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphom | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2013 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2013 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dif | 2013 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dif | 2013 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dif | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; D | 2014 |
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; D | 2014 |
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; D | 2014 |
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Small Cell; Dacarbazine; Female; Huma | 2013 |
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Small Cell; Dacarbazine; Female; Huma | 2013 |
Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Small Cell; Dacarbazine; Female; Huma | 2013 |
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA M | 2013 |
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA M | 2013 |
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA M | 2013 |
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neo | 2013 |
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neo | 2013 |
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neo | 2013 |
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irra | 2013 |
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irra | 2013 |
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irra | 2013 |
LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DN | 2013 |
LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DN | 2013 |
LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DN | 2013 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazin | 2013 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazin | 2013 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazin | 2013 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacar | 2013 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacar | 2013 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacar | 2013 |
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cel | 2013 |
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cel | 2013 |
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cel | 2013 |
Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model.
Topics: Acridine Orange; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cu | 2013 |
Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model.
Topics: Acridine Orange; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cu | 2013 |
Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model.
Topics: Acridine Orange; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cu | 2013 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2013 |
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2013 |
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2013 |
Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor | 2013 |
Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor | 2013 |
Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor | 2013 |
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2014 |
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2014 |
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2014 |
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; C | 2013 |
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; C | 2013 |
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; C | 2013 |
Central diabetes insipidus: a previously unreported side effect of temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Diabetes Insipi | 2013 |
Central diabetes insipidus: a previously unreported side effect of temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Diabetes Insipi | 2013 |
Central diabetes insipidus: a previously unreported side effect of temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Diabetes Insipi | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neopla | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neopla | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neopla | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarb | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarb | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarb | 2013 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2017 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2017 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2017 |
Glioblastoma management in the temozolomide era: have we improved outcome?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Glioblastoma management in the temozolomide era: have we improved outcome?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Glioblastoma management in the temozolomide era: have we improved outcome?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2013 |
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2013 |
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2013 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cra | 2014 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cra | 2014 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cra | 2014 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; ATPases Associated with Diverse Cellul | 2013 |
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; ATPases Associated with Diverse Cellul | 2013 |
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; ATPases Associated with Diverse Cellul | 2013 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regul | 2014 |
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regul | 2014 |
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regul | 2014 |
A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; Chemor | 2013 |
A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; Chemor | 2013 |
A case of adult onset medulloblastoma during maintenance chemotherapy for anaplastic astrocytoma one year after radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cerebellar Neoplasms; Chemor | 2013 |
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Ce | 2013 |
Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Ce | 2013 |
Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Ce | 2013 |
Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.
Topics: Adult; Brain Neoplasms; Cell Transformation, Neoplastic; Cerebrospinal Fluid; Chemotherapy, Adjuvant | 2014 |
Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.
Topics: Adult; Brain Neoplasms; Cell Transformation, Neoplastic; Cerebrospinal Fluid; Chemotherapy, Adjuvant | 2014 |
Clinical course of central neurocytoma with malignant transformation-an indication for craniospinal irradiation.
Topics: Adult; Brain Neoplasms; Cell Transformation, Neoplastic; Cerebrospinal Fluid; Chemotherapy, Adjuvant | 2014 |
High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2013 |
High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2013 |
High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2013 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modificati | 2014 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modificati | 2014 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modificati | 2014 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Treatment results of glioblastoma during the last 30 years in a single institute.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2013 |
Treatment results of glioblastoma during the last 30 years in a single institute.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2013 |
Treatment results of glioblastoma during the last 30 years in a single institute.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2013 |
Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Female; G | 2013 |
Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Female; G | 2013 |
Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Female; G | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.
Topics: Aged; Astrocytoma; Brain Neoplasms; Cognition Disorders; Cohort Studies; Dacarbazine; DNA Modificati | 2014 |
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.
Topics: Aged; Astrocytoma; Brain Neoplasms; Cognition Disorders; Cohort Studies; Dacarbazine; DNA Modificati | 2014 |
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.
Topics: Aged; Astrocytoma; Brain Neoplasms; Cognition Disorders; Cohort Studies; Dacarbazine; DNA Modificati | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female | 2014 |
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female | 2014 |
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female | 2014 |
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Therapy, Combination; Ependymom | 2013 |
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Therapy, Combination; Ependymom | 2013 |
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Therapy, Combination; Ependymom | 2013 |
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2014 |
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2014 |
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2014 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromo | 2013 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromo | 2013 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromo | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; | 2014 |
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; | 2014 |
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; | 2014 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Hu | 2014 |
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Hu | 2014 |
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Hu | 2014 |
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Chem | 2014 |
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Chem | 2014 |
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Chem | 2014 |
Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.
Topics: Antineoplastic Agents; Base Sequence; Benzofurans; Brain Neoplasms; Cell Line, Tumor; Comet Assay; D | 2013 |
Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.
Topics: Antineoplastic Agents; Base Sequence; Benzofurans; Brain Neoplasms; Cell Line, Tumor; Comet Assay; D | 2013 |
Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.
Topics: Antineoplastic Agents; Base Sequence; Benzofurans; Brain Neoplasms; Cell Line, Tumor; Comet Assay; D | 2013 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
[Results of postoperative radiochemotherapy of glioblastoma multiforme].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disea | 2013 |
[Results of postoperative radiochemotherapy of glioblastoma multiforme].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disea | 2013 |
[Results of postoperative radiochemotherapy of glioblastoma multiforme].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disea | 2013 |
[Our experience with targeted therapy in glioblastoma multiforme].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2013 |
[Our experience with targeted therapy in glioblastoma multiforme].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2013 |
[Our experience with targeted therapy in glioblastoma multiforme].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2013 |
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neo | 2014 |
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neo | 2014 |
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neo | 2014 |
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epidermal Growth Factor; ErbB Receptors; Gene Expres | 2015 |
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epidermal Growth Factor; ErbB Receptors; Gene Expres | 2015 |
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epidermal Growth Factor; ErbB Receptors; Gene Expres | 2015 |
Extraneural metastases of anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic M | 2014 |
Extraneural metastases of anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic M | 2014 |
Extraneural metastases of anaplastic oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic M | 2014 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Concomitant viral and bacterial encephalitis after temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Encephalitis, Viral; Glioblastoma; | 2014 |
Concomitant viral and bacterial encephalitis after temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Encephalitis, Viral; Glioblastoma; | 2014 |
Concomitant viral and bacterial encephalitis after temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Encephalitis, Viral; Glioblastoma; | 2014 |
A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Gas Analysis; Brain Neoplasms; Bronchoalveolar Lavage | 2014 |
A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Gas Analysis; Brain Neoplasms; Bronchoalveolar Lavage | 2014 |
A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Gas Analysis; Brain Neoplasms; Bronchoalveolar Lavage | 2014 |
Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dac | 2014 |
Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dac | 2014 |
Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dac | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Notificatio | 2014 |
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Notificatio | 2014 |
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Notificatio | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Daca | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Daca | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Daca | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2014 |
Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2014 |
Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2014 |
Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2014 |
The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Topics: Adherens Junctions; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain | 2014 |
The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Topics: Adherens Junctions; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain | 2014 |
The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Topics: Adherens Junctions; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain | 2014 |
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2014 |
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2014 |
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2014 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; | 2013 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; | 2013 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; | 2013 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; | 2014 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; | 2014 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; | 2014 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia | 2014 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia | 2014 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
Bevacizumab in glioblastoma--still much to learn.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazin | 2014 |
Bevacizumab in glioblastoma--still much to learn.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazin | 2014 |
Bevacizumab in glioblastoma--still much to learn.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazin | 2014 |
Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2014 |
Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2014 |
Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2014 |
The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Drug | 2014 |
The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Drug | 2014 |
The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Drug | 2014 |
miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
Topics: Actins; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Mo | 2014 |
miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
Topics: Actins; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Mo | 2014 |
miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
Topics: Actins; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Mo | 2014 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neop | 2014 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neop | 2014 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neop | 2014 |
Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Ne | 2014 |
Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Ne | 2014 |
Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Ne | 2014 |
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Mice; Mice, SCID | 2014 |
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Mice; Mice, SCID | 2014 |
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Mice; Mice, SCID | 2014 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA | 2014 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA | 2014 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA | 2014 |
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; B | 2014 |
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; B | 2014 |
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; B | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dac | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dac | 2014 |
Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Dac | 2014 |
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; | 2014 |
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; | 2014 |
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged; | 2014 |
Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2014 |
Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2014 |
Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coloring Agents; Connexin 43; Dacarbazine; Drug Re | 2014 |
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coloring Agents; Connexin 43; Dacarbazine; Drug Re | 2014 |
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coloring Agents; Connexin 43; Dacarbazine; Drug Re | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioblastoma; Huma | 2014 |
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioblastoma; Huma | 2014 |
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioblastoma; Huma | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Drug Resistan | 2014 |
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Drug Resistan | 2014 |
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Drug Resistan | 2014 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cell | 2014 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cell | 2014 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cell | 2014 |
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Iron; | 2014 |
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Iron; | 2014 |
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Iron; | 2014 |
Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2015 |
Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2015 |
Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2015 |
Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evidence-Based Medicine; Glioblasto | 2014 |
Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evidence-Based Medicine; Glioblasto | 2014 |
Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evidence-Based Medicine; Glioblasto | 2014 |
Glioblastoma treatment in the elderly in the temozolomide therapy era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Coho | 2014 |
Glioblastoma treatment in the elderly in the temozolomide therapy era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Coho | 2014 |
Glioblastoma treatment in the elderly in the temozolomide therapy era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Coho | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers; Brain Neoplasms; Chemoradio | 2014 |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers; Brain Neoplasms; Chemoradio | 2014 |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers; Brain Neoplasms; Chemoradio | 2014 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor | 2014 |
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor | 2014 |
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor | 2014 |
Experimental study of combined therapy for malignant glioma.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2014 |
Experimental study of combined therapy for malignant glioma.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2014 |
Experimental study of combined therapy for malignant glioma.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; | 2014 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; | 2014 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; D | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; D | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; D | 2014 |
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2014 |
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2014 |
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2014 |
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cereb | 2014 |
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cereb | 2014 |
Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cereb | 2014 |
Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined M | 2014 |
Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined M | 2014 |
Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined M | 2014 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacar | 2014 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacar | 2014 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacar | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradi | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradi | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradi | 2014 |
Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com | 2014 |
Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com | 2014 |
Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com | 2014 |
Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; | 2014 |
Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; | 2014 |
Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; | 2014 |
Longitudinal quality of life data: a comparison of continuous and ordinal approaches.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appetite; Brain Neoplas | 2014 |
Longitudinal quality of life data: a comparison of continuous and ordinal approaches.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appetite; Brain Neoplas | 2014 |
Longitudinal quality of life data: a comparison of continuous and ordinal approaches.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appetite; Brain Neoplas | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2014 |
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; C | 2014 |
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; C | 2014 |
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; C | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasm | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasm | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasm | 2014 |
Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation | 2014 |
Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation | 2014 |
Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; C | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; C | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; C | 2014 |
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2014 |
miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2014 |
miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2014 |
Analyzing temozolomide medication errors: potentially fatal.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarba | 2014 |
Analyzing temozolomide medication errors: potentially fatal.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarba | 2014 |
Analyzing temozolomide medication errors: potentially fatal.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarba | 2014 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leuke | 2014 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leuke | 2014 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leuke | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neopla | 2015 |
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neopla | 2015 |
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neopla | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
Survival in granular cell astrocytomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2015 |
Survival in granular cell astrocytomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2015 |
Survival in granular cell astrocytomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2015 |
Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2014 |
Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2014 |
Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2014 |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain | 2014 |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain | 2014 |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2014 |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2014 |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2014 |
Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neopl | 2014 |
Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neopl | 2014 |
Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neopl | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; | 2015 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; | 2015 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; | 2015 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain | 2014 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain | 2014 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain | 2014 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; | 2014 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; | 2014 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; | 2014 |
Primary brain tumors: introduction.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2014 |
Primary brain tumors: introduction.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2014 |
Primary brain tumors: introduction.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2014 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Abscess; Brain Neoplasms; Dacarbazine; Humans; | 2015 |
Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Abscess; Brain Neoplasms; Dacarbazine; Humans; | 2015 |
Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Abscess; Brain Neoplasms; Dacarbazine; Humans; | 2015 |
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain; Brain Neoplasms; Dacarbazine; Female; Glio | 2014 |
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain; Brain Neoplasms; Dacarbazine; Female; Glio | 2014 |
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain; Brain Neoplasms; Dacarbazine; Female; Glio | 2014 |
Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2014 |
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2014 |
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2015 |
Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2015 |
Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2015 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Cell Line, Tum | 2014 |
Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Cell Line, Tum | 2014 |
Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Cell Line, Tum | 2014 |
Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; E | 2015 |
Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; E | 2015 |
Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; E | 2015 |
A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramide | 2014 |
A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramide | 2014 |
A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramide | 2014 |
Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Dacarbazine; Drug Resi | 2014 |
Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Dacarbazine; Drug Resi | 2014 |
Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Dacarbazine; Drug Resi | 2014 |
Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2014 |
Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2014 |
Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
Topics: Astrocytes; Brain Neoplasms; Cell Compartmentation; Cell Count; Cell Line, Tumor; Cell Survival; Coc | 2014 |
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
Topics: Astrocytes; Brain Neoplasms; Cell Compartmentation; Cell Count; Cell Line, Tumor; Cell Survival; Coc | 2014 |
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
Topics: Astrocytes; Brain Neoplasms; Cell Compartmentation; Cell Count; Cell Line, Tumor; Cell Survival; Coc | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2015 |
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2015 |
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2015 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2015 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2015 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2015 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capsules; | 2014 |
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capsules; | 2014 |
Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capsules; | 2014 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neo | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neo | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neo | 2015 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Protein | 2015 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Protein | 2015 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Protein | 2015 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain N | 2015 |
Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain N | 2015 |
Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain N | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell | 2015 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member | 2014 |
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member | 2014 |
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2014 |
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2014 |
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2014 |
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Topics: Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Apoptosis; Brain Neoplasms; Cell Dif | 2014 |
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Topics: Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Apoptosis; Brain Neoplasms; Cell Dif | 2014 |
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Topics: Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Apoptosis; Brain Neoplasms; Cell Dif | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; D | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; D | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; D | 2014 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver | 2014 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver | 2014 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver | 2014 |
Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; CDC2 Protein Kina | 2015 |
Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; CDC2 Protein Kina | 2015 |
Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; CDC2 Protein Kina | 2015 |
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2014 |
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2014 |
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2014 |
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Br | 2015 |
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Br | 2015 |
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Br | 2015 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Topics: Aged; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Databases, Genetic; Female; Gene Expression Pr | 2015 |
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Topics: Aged; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Databases, Genetic; Female; Gene Expression Pr | 2015 |
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Topics: Aged; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Databases, Genetic; Female; Gene Expression Pr | 2015 |
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Topics: Antineoplastic Agents, Alkylating; Antipsychotic Agents; Apoptosis; Benzodiazepines; Blotting, Weste | 2015 |
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Topics: Antineoplastic Agents, Alkylating; Antipsychotic Agents; Apoptosis; Benzodiazepines; Blotting, Weste | 2015 |
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Topics: Antineoplastic Agents, Alkylating; Antipsychotic Agents; Apoptosis; Benzodiazepines; Blotting, Weste | 2015 |
Glioblastoma multiforme and hepatitis B: do the right thing(s).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hepatitis B; Hepatiti | 2014 |
Glioblastoma multiforme and hepatitis B: do the right thing(s).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hepatitis B; Hepatiti | 2014 |
Glioblastoma multiforme and hepatitis B: do the right thing(s).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hepatitis B; Hepatiti | 2014 |
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene K | 2015 |
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene K | 2015 |
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene K | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survi | 2015 |
Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survi | 2015 |
Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survi | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gliob | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gliob | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gliob | 2015 |
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gl | 2015 |
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gl | 2015 |
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gl | 2015 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2015 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2015 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2015 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dr | 2016 |
Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dr | 2016 |
Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dr | 2016 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporte | 2015 |
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporte | 2015 |
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporte | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2015 |
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2015 |
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2015 |
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2015 |
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Combined | 2015 |
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Combined | 2015 |
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Combined | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine | 2015 |
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine | 2015 |
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2015 |
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2015 |
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Epithelial-Mesenc | 2015 |
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Epithelial-Mesenc | 2015 |
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Epithelial-Mesenc | 2015 |
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy, Needle; Brain Neoplasms; Chemoth | 2015 |
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy, Needle; Brain Neoplasms; Chemoth | 2015 |
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy, Needle; Brain Neoplasms; Chemoth | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Huma | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Huma | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Huma | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Topics: Administration, Metronomic; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Topics: Administration, Metronomic; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Topics: Administration, Metronomic; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Topics: AC133 Antigen; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Ge | 2015 |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Topics: AC133 Antigen; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Ge | 2015 |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Topics: AC133 Antigen; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Ge | 2015 |
Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Chemotherapy | 2015 |
Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Chemotherapy | 2015 |
Treatment results and prognostic factors for intracranial nongerminomatous germ cell tumors: single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Chemotherapy | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompa | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompa | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompa | 2015 |
Temozolomide nanoparticles for targeted glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug | 2015 |
Temozolomide nanoparticles for targeted glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug | 2015 |
Temozolomide nanoparticles for targeted glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug | 2015 |
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression; Glioblastoma; Homeodomai | 2015 |
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression; Glioblastoma; Homeodomai | 2015 |
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression; Glioblastoma; Homeodomai | 2015 |
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; | 2015 |
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; | 2015 |
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middl | 2015 |
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middl | 2015 |
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middl | 2015 |
Focused ultrasound with microbubbles increases temozolomide delivery in U87 transfected mice.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2015 |
Focused ultrasound with microbubbles increases temozolomide delivery in U87 transfected mice.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2015 |
Focused ultrasound with microbubbles increases temozolomide delivery in U87 transfected mice.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogen | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogen | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogen | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Topics: ADAM Proteins; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Separation; Cell Surv | 2015 |
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Topics: ADAM Proteins; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Separation; Cell Surv | 2015 |
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Topics: ADAM Proteins; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Separation; Cell Surv | 2015 |
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2015 |
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2015 |
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition | 2015 |
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; D | 2015 |
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; D | 2015 |
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; D | 2015 |
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Brain Neoplasms; China; C | 2015 |
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Brain Neoplasms; China; C | 2015 |
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Brain Neoplasms; China; C | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine | 2015 |
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine | 2015 |
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine | 2015 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2015 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2015 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2015 |
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neopla | 2015 |
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neopla | 2015 |
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neopla | 2015 |
Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2015 |
Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2015 |
Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Da | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Da | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Da | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasm | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasm | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasm | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, | 2015 |
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplas | 2015 |
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplas | 2015 |
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplas | 2015 |
miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; | 2015 |
miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; | 2015 |
miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; | 2015 |
Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; He | 2015 |
Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; He | 2015 |
Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; He | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2015 |
Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
Topics: Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apopto | 2015 |
Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
Topics: Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apopto | 2015 |
Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
Topics: Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apopto | 2015 |
Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2015 |
Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2015 |
Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marr | 2015 |
Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marr | 2015 |
Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marr | 2015 |
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Brain Neoplasms; Dacarbazine; De | 2015 |
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Brain Neoplasms; Dacarbazine; De | 2015 |
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Brain Neoplasms; Dacarbazine; De | 2015 |
A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagoni | 2015 |
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagoni | 2015 |
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagoni | 2015 |
Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradi | 2015 |
Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradi | 2015 |
Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradi | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; CD11b Antigen; | 2015 |
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; CD11b Antigen; | 2015 |
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; CD11b Antigen; | 2015 |
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Chemoradiotherapy; Comor | 2015 |
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Chemoradiotherapy; Comor | 2015 |
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Chemoradiotherapy; Comor | 2015 |
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; | 2015 |
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; | 2015 |
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; | 2015 |
[A pleural transudate with a 0 g/L protein level].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Catheters, | 2015 |
[A pleural transudate with a 0 g/L protein level].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Catheters, | 2015 |
[A pleural transudate with a 0 g/L protein level].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Catheters, | 2015 |
Photodynamic therapy in the treatment of brain tumours. A feasibility study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dihematoporphyrin | 2015 |
Photodynamic therapy in the treatment of brain tumours. A feasibility study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dihematoporphyrin | 2015 |
Photodynamic therapy in the treatment of brain tumours. A feasibility study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dihematoporphyrin | 2015 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; D | 2015 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; D | 2015 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; D | 2015 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dac | 2015 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dac | 2015 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dac | 2015 |
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2015 |
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2015 |
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Management of glioblastoma in Victoria, Australia (2006-2008).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female | 2015 |
Management of glioblastoma in Victoria, Australia (2006-2008).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female | 2015 |
Management of glioblastoma in Victoria, Australia (2006-2008).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female | 2015 |
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2015 |
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2015 |
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2015 |
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasm | 2015 |
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasm | 2015 |
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasm | 2015 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brai | 2015 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brai | 2015 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brai | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Co | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Co | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Co | 2015 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2015 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2015 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, | 2015 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, | 2015 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, | 2015 |
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Topics: Brain Neoplasms; Chondroitin Sulfate Proteoglycans; Dacarbazine; Decorin; Glioblastoma; Humans; Kera | 2015 |
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Topics: Brain Neoplasms; Chondroitin Sulfate Proteoglycans; Dacarbazine; Decorin; Glioblastoma; Humans; Kera | 2015 |
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Topics: Brain Neoplasms; Chondroitin Sulfate Proteoglycans; Dacarbazine; Decorin; Glioblastoma; Humans; Kera | 2015 |
Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; D | 2015 |
Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; D | 2015 |
Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; D | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosi | 2015 |
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosi | 2015 |
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosi | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contr | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contr | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contr | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine | 2015 |
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child, Preschool; Dacarbazine; DNA Modification | 2016 |
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child, Preschool; Dacarbazine; DNA Modification | 2016 |
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child, Preschool; Dacarbazine; DNA Modification | 2016 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
Diagnosis and Management of Spinal Metastasis of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2015 |
Diagnosis and Management of Spinal Metastasis of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2015 |
Diagnosis and Management of Spinal Metastasis of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2015 |
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Fema | 2016 |
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Fema | 2016 |
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Fema | 2016 |
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2015 |
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2015 |
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2015 |
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents; Autophagy; Brain Neoplasms; Carbazoles; Cell Cycle Checkpoints; Cell Line, Tu | 2015 |
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents; Autophagy; Brain Neoplasms; Carbazoles; Cell Cycle Checkpoints; Cell Line, Tu | 2015 |
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents; Autophagy; Brain Neoplasms; Carbazoles; Cell Cycle Checkpoints; Cell Line, Tu | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; D | 2015 |
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; D | 2015 |
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; D | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Co | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Co | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Co | 2015 |
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2015 |
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2015 |
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2015 |
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2015 |
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2015 |
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2015 |
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2015 |
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2015 |
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2015 |
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Da | 2015 |
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Da | 2015 |
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Da | 2015 |
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Brain Neoplasms; Combined Modali | 2016 |
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Brain Neoplasms; Combined Modali | 2016 |
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Brain Neoplasms; Combined Modali | 2016 |
The radiosensitivity index predicts for overall survival in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2015 |
The radiosensitivity index predicts for overall survival in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2015 |
The radiosensitivity index predicts for overall survival in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2015 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2016 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2016 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2016 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Differentiation; Cell Line, | 2016 |
Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Differentiation; Cell Line, | 2016 |
Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Differentiation; Cell Line, | 2016 |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2015 |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2015 |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2015 |
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2015 |
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2015 |
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2015 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumo | 2015 |
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumo | 2015 |
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumo | 2015 |
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Brain Neoplasms; Cell | 2016 |
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Brain Neoplasms; Cell | 2016 |
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Brain Neoplasms; Cell | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Prolife | 2016 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Prolife | 2016 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Prolife | 2016 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2016 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2016 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2016 |
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calmodul | 2015 |
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calmodul | 2015 |
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calmodul | 2015 |
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial | 2016 |
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial | 2016 |
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial | 2016 |
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modifica | 2016 |
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modifica | 2016 |
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modifica | 2016 |
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplas | 2016 |
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplas | 2016 |
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplas | 2016 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2016 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2016 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Ad | 2016 |
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Ad | 2016 |
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Ad | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug | 2016 |
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug | 2016 |
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2016 |
In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2016 |
In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2016 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2016 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2016 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Cost | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Cost | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Cost | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokine TWEAK; | 2016 |
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokine TWEAK; | 2016 |
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokine TWEAK; | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DEAD-box RNA Helicases; Dr | 2016 |
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DEAD-box RNA Helicases; Dr | 2016 |
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DEAD-box RNA Helicases; Dr | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resi | 2016 |
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resi | 2016 |
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resi | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemothera | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemothera | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemothera | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Ant | 2016 |
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Ant | 2016 |
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Ant | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2016 |
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2016 |
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastom | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastom | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastom | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Dr | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Dr | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Dr | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2016 |
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2016 |
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2016 |
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2016 |
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2016 |
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2016 |
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarb | 2016 |
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarb | 2016 |
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarb | 2016 |
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2016 |
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2016 |
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplas | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplas | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplas | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; D | 2016 |
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; D | 2016 |
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; D | 2016 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2016 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2016 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2016 |
Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2016 |
Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2016 |
Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2016 |
A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2016 |
A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2016 |
A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Da | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Da | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Da | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Crea | 2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Crea | 2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Crea | 2016 |
Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Calcium Ch | 2016 |
Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Calcium Ch | 2016 |
Bevacizumab is superior to Temozolomide in causing mitochondrial dysfunction in human brain tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Calcium Ch | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell | 2016 |
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell | 2016 |
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis | 2016 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis | 2016 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbaz | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbaz | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbaz | 2016 |
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Brain Neoplasms; Caspase 3; Cell Line, Tumor | 2016 |
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Brain Neoplasms; Caspase 3; Cell Line, Tumor | 2016 |
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Brain Neoplasms; Caspase 3; Cell Line, Tumor | 2016 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarb | 2016 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarb | 2016 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarb | 2016 |
Protein Markers Predict Survival in Glioma Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastom | 2016 |
Protein Markers Predict Survival in Glioma Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastom | 2016 |
Protein Markers Predict Survival in Glioma Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastom | 2016 |
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2016 |
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2016 |
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2016 |
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Mode | 2017 |
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Mode | 2017 |
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Mode | 2017 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, T | 2016 |
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, T | 2016 |
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, T | 2016 |
Accelerated hyperfractionation plus temozolomide in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2016 |
Accelerated hyperfractionation plus temozolomide in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2016 |
Accelerated hyperfractionation plus temozolomide in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2016 |
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2016 |
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2016 |
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2016 |
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Brain; Brain Neoplasms; Cell Line, Tumor; Cisplati | 2016 |
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Brain; Brain Neoplasms; Cell Line, Tumor; Cisplati | 2016 |
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Brain; Brain Neoplasms; Cell Line, Tumor; Cisplati | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2016 |
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2016 |
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2016 |
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Ev | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Ev | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Ev | 2016 |
Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2016 |
Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2016 |
Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2016 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2016 |
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2016 |
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Adult-onset atypical teratoid/rhabdoid tumor featuring long spindle cells with nuclear palisading and perivascular pseudorosettes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined M | 2017 |
Adult-onset atypical teratoid/rhabdoid tumor featuring long spindle cells with nuclear palisading and perivascular pseudorosettes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined M | 2017 |
Adult-onset atypical teratoid/rhabdoid tumor featuring long spindle cells with nuclear palisading and perivascular pseudorosettes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined M | 2017 |
Connection between Proliferation Rate and Temozolomide Sensitivity of Primary Glioblastoma Cell Culture and Expression of YB-1 and LRP/MVP.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression | 2016 |
Connection between Proliferation Rate and Temozolomide Sensitivity of Primary Glioblastoma Cell Culture and Expression of YB-1 and LRP/MVP.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression | 2016 |
Connection between Proliferation Rate and Temozolomide Sensitivity of Primary Glioblastoma Cell Culture and Expression of YB-1 and LRP/MVP.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression | 2016 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cranial Irradiation; Da | 2017 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cranial Irradiation; Da | 2017 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cranial Irradiation; Da | 2017 |
Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Cranial Irrad | 2016 |
Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Cranial Irrad | 2016 |
Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Cranial Irrad | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modificati | 2016 |
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modificati | 2016 |
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modificati | 2016 |
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Pr | 2017 |
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Pr | 2017 |
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Pr | 2017 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2017 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2017 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2017 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood- | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood- | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood- | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Diseas | 2016 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Diseas | 2016 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Diseas | 2016 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrova | 2017 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrova | 2017 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrova | 2017 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; | 2016 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; | 2016 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; | 2016 |
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Pr | 2017 |
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Pr | 2017 |
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Pr | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2016 |
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2016 |
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2016 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neop | 2016 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neop | 2016 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neop | 2016 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; | 2017 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; | 2017 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; | 2017 |
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2016 |
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2016 |
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2016 |
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2016 |
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2016 |
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2017 |
Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2017 |
Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2017 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Combin | 2016 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Combin | 2016 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Combin | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Chol | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Chol | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Chol | 2016 |
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification | 2016 |
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification | 2016 |
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associat | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associat | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associat | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2016 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cho | 2017 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cho | 2017 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cho | 2017 |
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2016 |
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2016 |
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; B | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; B | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; B | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant | 2017 |
Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant | 2017 |
Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant | 2017 |
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Topics: Acetazolamide; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhyd | 2016 |
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Topics: Acetazolamide; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhyd | 2016 |
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Topics: Acetazolamide; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhyd | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Choline; Choline Kinase; Dacarbazine; Energy Metab | 2016 |
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Choline; Choline Kinase; Dacarbazine; Energy Metab | 2016 |
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Choline; Choline Kinase; Dacarbazine; Energy Metab | 2016 |
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2016 |
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2016 |
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2016 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Ne | 2017 |
Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Ne | 2017 |
Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Ne | 2017 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2016 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2016 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2016 |
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2017 |
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2017 |
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2017 |
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2016 |
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2016 |
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2016 |
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Meth | 2016 |
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Meth | 2016 |
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Meth | 2016 |
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DN | 2017 |
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DN | 2017 |
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DN | 2017 |
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2016 |
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2016 |
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2016 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Aged; Aspergillosis; Brain Neoplasms; Combined Modality Therapy; Dacarbazin | 2017 |
Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Aged; Aspergillosis; Brain Neoplasms; Combined Modality Therapy; Dacarbazin | 2017 |
Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Aged; Aspergillosis; Brain Neoplasms; Combined Modality Therapy; Dacarbazin | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Guanosine; Humans; Hydrogen-Ion Concen | 2017 |
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Guanosine; Humans; Hydrogen-Ion Concen | 2017 |
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Guanosine; Humans; Hydrogen-Ion Concen | 2017 |
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brain Neoplasms; Cell Lin | 2017 |
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brain Neoplasms; Cell Lin | 2017 |
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brain Neoplasms; Cell Lin | 2017 |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherap | 2017 |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherap | 2017 |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherap | 2017 |
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dia | 2016 |
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dia | 2016 |
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dia | 2016 |
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Autoimmunity; Brain Neoplasms; Chemical and Dru | 2016 |
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Autoimmunity; Brain Neoplasms; Chemical and Dru | 2016 |
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Autoimmunity; Brain Neoplasms; Chemical and Dru | 2016 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiosur | 2017 |
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiosur | 2017 |
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiosur | 2017 |
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
Acute liver injury induced by levetiracetam and temozolomide co-treatment.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studi | 2017 |
Acute liver injury induced by levetiracetam and temozolomide co-treatment.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studi | 2017 |
Acute liver injury induced by levetiracetam and temozolomide co-treatment.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studi | 2017 |
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Topics: 3' Untranslated Regions; Antagomirs; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplas | 2017 |
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Topics: 3' Untranslated Regions; Antagomirs; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplas | 2017 |
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Topics: 3' Untranslated Regions; Antagomirs; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplas | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2017 |
The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2017 |
The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2017 |
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA | 2017 |
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA | 2017 |
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA | 2017 |
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Aurintricarboxylic Acid; Brain Neoplasms; Cell Line, Tum | 2017 |
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Aurintricarboxylic Acid; Brain Neoplasms; Cell Line, Tum | 2017 |
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Aurintricarboxylic Acid; Brain Neoplasms; Cell Line, Tum | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2017 |
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2017 |
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Coh | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Coh | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Coh | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2017 |
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2017 |
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2017 |
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Contra | 2017 |
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Contra | 2017 |
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Contra | 2017 |
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Br | 2018 |
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Br | 2018 |
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Br | 2018 |
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dose-Respon | 2017 |
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dose-Respon | 2017 |
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dose-Respon | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2017 |
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2017 |
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azep | 2017 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azep | 2017 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azep | 2017 |
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarb | 2017 |
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarb | 2017 |
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarb | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Daca | 2017 |
A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Daca | 2017 |
A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Daca | 2017 |
Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell | 2017 |
Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell | 2017 |
Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell | 2017 |
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarb | 2017 |
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarb | 2017 |
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarb | 2017 |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, | 2009 |
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, | 2009 |
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, | 2009 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; G | 2008 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; G | 2008 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; G | 2008 |
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; C | 2008 |
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; C | 2008 |
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; C | 2008 |
Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvan | 2008 |
Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvan | 2008 |
Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvan | 2008 |
Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Combined | 2008 |
Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Combined | 2008 |
Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Combined | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2009 |
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2009 |
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2009 |
Quality of life in low-grade glioma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 2009 |
Quality of life in low-grade glioma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 2009 |
Quality of life in low-grade glioma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H | 2009 |
Disseminated salmonellosis in a patient treated with temozolomide.
Topics: Adult; Anti-Infective Agents; Antineoplastic Agents, Alkylating; Arthritis, Infectious; Astrocytoma; | 2008 |
Disseminated salmonellosis in a patient treated with temozolomide.
Topics: Adult; Anti-Infective Agents; Antineoplastic Agents, Alkylating; Arthritis, Infectious; Astrocytoma; | 2008 |
Disseminated salmonellosis in a patient treated with temozolomide.
Topics: Adult; Anti-Infective Agents; Antineoplastic Agents, Alkylating; Arthritis, Infectious; Astrocytoma; | 2008 |
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Convection; | 2008 |
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Convection; | 2008 |
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Convection; | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Benzothiazoles; Blood | 2009 |
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Benzothiazoles; Blood | 2009 |
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Benzothiazoles; Blood | 2009 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lineage; Combined Modality Therapy; Dacarba | 2008 |
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lineage; Combined Modality Therapy; Dacarba | 2008 |
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lineage; Combined Modality Therapy; Dacarba | 2008 |
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2009 |
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2009 |
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2009 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dac | 2009 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dac | 2009 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dac | 2009 |
[Alveolo-interstitial pneumonia due to Temozolamide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Bronchoalveolar Lavage; Dacarbazine; Female; Gli | 2008 |
[Alveolo-interstitial pneumonia due to Temozolamide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Bronchoalveolar Lavage; Dacarbazine; Female; Gli | 2008 |
[Alveolo-interstitial pneumonia due to Temozolamide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Bronchoalveolar Lavage; Dacarbazine; Female; Gli | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant | 2009 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant | 2009 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant | 2009 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradi | 2008 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradi | 2008 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradi | 2008 |
Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.
Topics: Acridine Orange; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line | 2008 |
Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.
Topics: Acridine Orange; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line | 2008 |
Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine.
Topics: Acridine Orange; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line | 2008 |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Dacar | 2009 |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Dacar | 2009 |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Dacar | 2009 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-U | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-U | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-U | 2008 |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Combined Modal | 2009 |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Combined Modal | 2009 |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Combined Modal | 2009 |
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Li | 2008 |
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Li | 2008 |
Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Li | 2008 |
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2008 |
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2008 |
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Pituitary carcinoma presenting with multiple metastases: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Humans; Magnetic Res | 2008 |
Pituitary carcinoma presenting with multiple metastases: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Humans; Magnetic Res | 2008 |
Pituitary carcinoma presenting with multiple metastases: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Female; Humans; Magnetic Res | 2008 |
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2008 |
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2008 |
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2008 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neop | 2009 |
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neop | 2009 |
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neop | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Repair; Enzyme | 2009 |
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Repair; Enzyme | 2009 |
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Repair; Enzyme | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modificat | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modificat | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modificat | 2009 |
Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2009 |
Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2009 |
Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2009 |
Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Squamous Cell; Dacarbazine; Glioblast | 2009 |
Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Squamous Cell; Dacarbazine; Glioblast | 2009 |
Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Squamous Cell; Dacarbazine; Glioblast | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2009 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2008 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2008 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2008 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
Topics: Animals; Brain Neoplasms; Cell Polarity; Dacarbazine; DNA Modification Methylases; DNA Repair Enzyme | 2009 |
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
Topics: Animals; Brain Neoplasms; Cell Polarity; Dacarbazine; DNA Modification Methylases; DNA Repair Enzyme | 2009 |
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.
Topics: Animals; Brain Neoplasms; Cell Polarity; Dacarbazine; DNA Modification Methylases; DNA Repair Enzyme | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; F | 2009 |
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; F | 2009 |
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; F | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2009 |
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2009 |
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 2009 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 2009 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 2009 |
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA | 2009 |
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA | 2009 |
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA | 2009 |
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Re | 2009 |
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Re | 2009 |
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Re | 2009 |
Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2009 |
Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2009 |
Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemo | 2009 |
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemo | 2009 |
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemo | 2009 |
Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neop | 2009 |
Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neop | 2009 |
Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neop | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
FEN1 is overexpressed in testis, lung and brain tumors.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Brain Neoplasms; Cisplatin; Dacarbazine; Flap Endon | 2009 |
FEN1 is overexpressed in testis, lung and brain tumors.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Brain Neoplasms; Cisplatin; Dacarbazine; Flap Endon | 2009 |
FEN1 is overexpressed in testis, lung and brain tumors.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Brain Neoplasms; Cisplatin; Dacarbazine; Flap Endon | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progre | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progre | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progre | 2009 |
Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dac | 2010 |
Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dac | 2010 |
Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dac | 2010 |
Comment re: Temozolomide preferentially depletes cancer stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Reso | 2009 |
Comment re: Temozolomide preferentially depletes cancer stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Reso | 2009 |
Comment re: Temozolomide preferentially depletes cancer stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Reso | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemoth | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemoth | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemoth | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2009 |
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2009 |
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2009 |
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Surviv | 2010 |
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Surviv | 2010 |
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Surviv | 2010 |
Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2009 |
Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2009 |
Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2009 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Di | 2010 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Di | 2010 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Di | 2010 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2010 |
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2010 |
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2010 |
Glioblastoma masquerading as a hypertensive putaminal hemorrhage: a diagnostic pitfall.
Topics: Antihypertensive Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Di | 2009 |
Glioblastoma masquerading as a hypertensive putaminal hemorrhage: a diagnostic pitfall.
Topics: Antihypertensive Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Di | 2009 |
Glioblastoma masquerading as a hypertensive putaminal hemorrhage: a diagnostic pitfall.
Topics: Antihypertensive Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Di | 2009 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2010 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2010 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2010 |
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
Recurrent PNET with MGMT methylation responds to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2009 |
Recurrent PNET with MGMT methylation responds to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2009 |
Recurrent PNET with MGMT methylation responds to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2009 |
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2009 |
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2009 |
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2009 |
A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, | 2010 |
A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, | 2010 |
A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytar | 2010 |
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytar | 2010 |
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytar | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemothe | 2009 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemothe | 2009 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemothe | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans | 2009 |
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans | 2009 |
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans | 2009 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; | 2009 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; | 2009 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; | 2009 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined | 2010 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined | 2010 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined M | 2009 |
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined M | 2009 |
Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined M | 2009 |
Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2010 |
Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2010 |
Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2010 |
Up-front temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modifi | 2010 |
Up-front temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modifi | 2010 |
Up-front temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modifi | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplas | 2010 |
Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplas | 2010 |
Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplas | 2010 |
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Dideox | 2010 |
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Dideox | 2010 |
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Dideox | 2010 |
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Blotting, West | 2010 |
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Blotting, West | 2010 |
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Blotting, West | 2010 |
Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carbon Radioisotopes; Cell Lin | 2010 |
Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carbon Radioisotopes; Cell Lin | 2010 |
Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carbon Radioisotopes; Cell Lin | 2010 |
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase I | 2010 |
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase I | 2010 |
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase I | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2010 |
Patent watch.
Topics: Antineoplastic Agents, Alkylating; Antiparkinson Agents; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2010 |
Patent watch.
Topics: Antineoplastic Agents, Alkylating; Antiparkinson Agents; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2010 |
Patent watch.
Topics: Antineoplastic Agents, Alkylating; Antiparkinson Agents; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture | 2009 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture | 2009 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture | 2009 |
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central | 2010 |
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central | 2010 |
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central | 2010 |
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Huma | 2010 |
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Huma | 2010 |
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Huma | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.
Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methyla | 2010 |
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.
Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methyla | 2010 |
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.
Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methyla | 2010 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasm | 2010 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasm | 2010 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasm | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tum | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tum | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tum | 2010 |
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemota | 2010 |
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemota | 2010 |
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemota | 2010 |
Sensitivity to temozolomide in brain tumor initiating cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Dacarbazine; Glioblastoma; Humans | 2010 |
Sensitivity to temozolomide in brain tumor initiating cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Dacarbazine; Glioblastoma; Humans | 2010 |
Sensitivity to temozolomide in brain tumor initiating cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Dacarbazine; Glioblastoma; Humans | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combi | 2011 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combi | 2011 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combi | 2011 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Fem | 2010 |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Fem | 2010 |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Fem | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Me | 2010 |
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Me | 2010 |
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Me | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Corp | 2010 |
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Corp | 2010 |
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Corp | 2010 |
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2010 |
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2010 |
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Da | 2010 |
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Da | 2010 |
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Da | 2010 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Depe | 2010 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Depe | 2010 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Depe | 2010 |
Temozolomide (Temodar).
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2010 |
Temozolomide (Temodar).
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2010 |
Temozolomide (Temodar).
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2011 |
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2011 |
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2011 |
MGMT gene promoter methylation in pediatric glioblastomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2010 |
MGMT gene promoter methylation in pediatric glioblastomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2010 |
MGMT gene promoter methylation in pediatric glioblastomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2010 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Combined Modality Therapy; C | 2010 |
Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Combined Modality Therapy; C | 2010 |
Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Combined Modality Therapy; C | 2010 |
Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Brain Neopl | 2010 |
Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Brain Neopl | 2010 |
Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Brain Neopl | 2010 |
Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magne | 2010 |
Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magne | 2010 |
Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magne | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Res | 2010 |
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Res | 2010 |
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Res | 2010 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineopla | 2010 |
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineopla | 2010 |
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineopla | 2010 |
Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line.
Topics: Apoptosis; Astrocytoma; Blotting, Western; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazin | 2010 |
Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line.
Topics: Apoptosis; Astrocytoma; Blotting, Western; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazin | 2010 |
Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line.
Topics: Apoptosis; Astrocytoma; Blotting, Western; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazin | 2010 |
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Female; Frontal | 2010 |
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Female; Frontal | 2010 |
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Female; Frontal | 2010 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2010 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2010 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2010 |
Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bordetella bronchiseptica; Bordetella Infections; Brain | 2011 |
Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bordetella bronchiseptica; Bordetella Infections; Brain | 2011 |
Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bordetella bronchiseptica; Bordetella Infections; Brain | 2011 |
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2010 |
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2010 |
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2010 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2011 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2011 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2011 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
Hepatic encephalopathy after treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2011 |
Hepatic encephalopathy after treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2011 |
Hepatic encephalopathy after treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2010 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2010 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2010 |
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gliobla | 2010 |
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gliobla | 2010 |
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gliobla | 2010 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea | 2010 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea | 2010 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; | 2010 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antineoplastic Agents, A | 2010 |
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antineoplastic Agents, A | 2010 |
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antineoplastic Agents, A | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Urticarial hypersensitivity reaction caused by temozolomide.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Da | 2010 |
Urticarial hypersensitivity reaction caused by temozolomide.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Da | 2010 |
Urticarial hypersensitivity reaction caused by temozolomide.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Da | 2010 |
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Mal | 2010 |
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Mal | 2010 |
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Mal | 2010 |
High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2011 |
High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2011 |
High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2011 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolo | 2010 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolo | 2010 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolo | 2010 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2011 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2011 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mod | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mod | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mod | 2011 |
Clinical significance of molecular biomarkers in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neo | 2010 |
Clinical significance of molecular biomarkers in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neo | 2010 |
Clinical significance of molecular biomarkers in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neo | 2010 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2011 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2011 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2011 |
Neuro-oncology, a decade of temozolomide and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Quality of Life; Temozolomide; Treatmen | 2010 |
Neuro-oncology, a decade of temozolomide and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Quality of Life; Temozolomide; Treatmen | 2010 |
Neuro-oncology, a decade of temozolomide and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Quality of Life; Temozolomide; Treatmen | 2010 |
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer | 2011 |
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer | 2011 |
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer | 2011 |
Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Taming glioblastoma by targeting angiogenesis: 3 years later.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Taming glioblastoma by targeting angiogenesis: 3 years later.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Taming glioblastoma by targeting angiogenesis: 3 years later.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Non-stem cell origin for oligodendroglioma.
Topics: Animals; Antigens; Benzamides; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; | 2010 |
Non-stem cell origin for oligodendroglioma.
Topics: Animals; Antigens; Benzamides; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; | 2010 |
Non-stem cell origin for oligodendroglioma.
Topics: Animals; Antigens; Benzamides; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; | 2010 |
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chromosom | 2011 |
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chromosom | 2011 |
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chromosom | 2011 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chi-Square Distributio | 2011 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chi-Square Distributio | 2011 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chi-Square Distributio | 2011 |
Case of atypical teratoid/rhabdoid tumor in an adult, with long survival.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosomal Proteins, Non-Histone; Combined Modality Ther | 2011 |
Case of atypical teratoid/rhabdoid tumor in an adult, with long survival.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosomal Proteins, Non-Histone; Combined Modality Ther | 2011 |
Case of atypical teratoid/rhabdoid tumor in an adult, with long survival.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosomal Proteins, Non-Histone; Combined Modality Ther | 2011 |
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Topics: Animals; Brain; Brain Neoplasms; Capsules; Dacarbazine; Disease Models, Animal; Drug Delivery System | 2011 |
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Topics: Animals; Brain; Brain Neoplasms; Capsules; Dacarbazine; Disease Models, Animal; Drug Delivery System | 2011 |
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Topics: Animals; Brain; Brain Neoplasms; Capsules; Dacarbazine; Disease Models, Animal; Drug Delivery System | 2011 |
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Growth Pro | 2011 |
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Growth Pro | 2011 |
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Growth Pro | 2011 |
Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2011 |
Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2011 |
Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytom | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neo | 2010 |
Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neo | 2010 |
Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neo | 2010 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Ce | 2011 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Ce | 2011 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Ce | 2011 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2011 |
O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2011 |
O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2011 |
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Brain Neoplasms; Combined Modality Ther | 2011 |
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Brain Neoplasms; Combined Modality Ther | 2011 |
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Brain Neoplasms; Combined Modality Ther | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2011 |
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2011 |
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2011 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepine | 2011 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepine | 2011 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepine | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; | 2011 |
Radiation-induced astrocytoma with rapid malignant transformation: case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Basal Ganglia; Brain Neoplasms; Cell Transformation, | 2011 |
Radiation-induced astrocytoma with rapid malignant transformation: case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Basal Ganglia; Brain Neoplasms; Cell Transformation, | 2011 |
Radiation-induced astrocytoma with rapid malignant transformation: case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Basal Ganglia; Brain Neoplasms; Cell Transformation, | 2011 |
MGMT promoter methylation and temozolomide response in choroid plexus carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Choroid Plex | 2011 |
MGMT promoter methylation and temozolomide response in choroid plexus carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Choroid Plex | 2011 |
MGMT promoter methylation and temozolomide response in choroid plexus carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Choroid Plex | 2011 |
Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine; Microscopy, Electron, Transmissio | 2011 |
Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine; Microscopy, Electron, Transmissio | 2011 |
Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine; Microscopy, Electron, Transmissio | 2011 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2011 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2011 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2011 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase I | 2011 |
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase I | 2011 |
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase I | 2011 |
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2011 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2011 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2011 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; | 2011 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; | 2011 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; | 2011 |
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vacc | 2011 |
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vacc | 2011 |
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vacc | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Electroencephal | 2011 |
Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Electroencephal | 2011 |
Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Electroencephal | 2011 |
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
Topics: Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modif | 2011 |
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
Topics: Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modif | 2011 |
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
Topics: Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modif | 2011 |
Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain | 2011 |
Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain | 2011 |
Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain | 2011 |
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Isotopes; Cell Line, Tumor; Daca | 2011 |
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Isotopes; Cell Line, Tumor; Daca | 2011 |
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Isotopes; Cell Line, Tumor; Daca | 2011 |
Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Care Facilities; Combined Modality | 2011 |
Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Care Facilities; Combined Modality | 2011 |
Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Care Facilities; Combined Modality | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
Rare phenomenon: liver metastases from glioblastoma multiforme.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; | 2011 |
Rare phenomenon: liver metastases from glioblastoma multiforme.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; | 2011 |
Rare phenomenon: liver metastases from glioblastoma multiforme.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2011 |
Immunotherapy for glioblastoma: the devil is in the details.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Clinica | 2011 |
Immunotherapy for glioblastoma: the devil is in the details.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Clinica | 2011 |
Immunotherapy for glioblastoma: the devil is in the details.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Clinica | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, A | 2012 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, A | 2012 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, A | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography.
Topics: Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Chromatography, Micellar Electrokinetic Cap | 2011 |
Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography.
Topics: Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Chromatography, Micellar Electrokinetic Cap | 2011 |
Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography.
Topics: Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Chromatography, Micellar Electrokinetic Cap | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Fr | 2011 |
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Fr | 2011 |
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Fr | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.
Topics: Antineoplastic Agents, Alkylating; Antiviral Agents; Astrocytoma; Brain Neoplasms; Carrier State; Ch | 2012 |
Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.
Topics: Antineoplastic Agents, Alkylating; Antiviral Agents; Astrocytoma; Brain Neoplasms; Carrier State; Ch | 2012 |
Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.
Topics: Antineoplastic Agents, Alkylating; Antiviral Agents; Astrocytoma; Brain Neoplasms; Carrier State; Ch | 2012 |
[Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant | 2011 |
[Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant | 2011 |
[Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2011 |
Method for novel anti-cancer drug development using tumor explants of surgical specimens.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Flow Cytometr | 2011 |
Method for novel anti-cancer drug development using tumor explants of surgical specimens.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Flow Cytometr | 2011 |
Method for novel anti-cancer drug development using tumor explants of surgical specimens.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Flow Cytometr | 2011 |
Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2011 |
Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2011 |
Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2011 |
Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2012 |
Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2012 |
Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2012 |
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line | 2011 |
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line | 2011 |
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line | 2011 |
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2011 |
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2011 |
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2011 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiother | 2011 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiother | 2011 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiother | 2011 |
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Isocitrate Dehydro | 2011 |
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Isocitrate Dehydro | 2011 |
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Isocitrate Dehydro | 2011 |
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Dacarbazine; Drug Resistance, Neopla | 2011 |
Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Dacarbazine; Drug Resistance, Neopla | 2011 |
Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Dacarbazine; Drug Resistance, Neopla | 2011 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2011 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2011 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2011 |
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; | 2012 |
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; | 2012 |
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; | 2012 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Primary central nervous system lymphoma presenting as Parinaud syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Dacarbazine; D | 2011 |
Primary central nervous system lymphoma presenting as Parinaud syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Dacarbazine; D | 2011 |
Primary central nervous system lymphoma presenting as Parinaud syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Dacarbazine; D | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Pr | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Pr | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Pr | 2011 |
Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Gliob | 2011 |
Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Gliob | 2011 |
Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Gliob | 2011 |
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Base Sequence; Biomarkers, Tumor; Brain Neoplasms; D | 2012 |
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Base Sequence; Biomarkers, Tumor; Brain Neoplasms; D | 2012 |
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Base Sequence; Biomarkers, Tumor; Brain Neoplasms; D | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2011 |
Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2011 |
Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2011 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2011 |
Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2011 |
Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2011 |
Glioblastoma survival in the United States before and during the temozolomide era.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dac | 2012 |
Glioblastoma survival in the United States before and during the temozolomide era.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dac | 2012 |
Glioblastoma survival in the United States before and during the temozolomide era.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dac | 2012 |
Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2012 |
Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2012 |
Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Pro | 2012 |
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Pro | 2012 |
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Pro | 2012 |
Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherap | 2012 |
Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherap | 2012 |
Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherap | 2012 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adj | 2011 |
Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adj | 2011 |
Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adj | 2011 |
Temozolomide induced liver injury.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemorad | 2011 |
Temozolomide induced liver injury.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemorad | 2011 |
Temozolomide induced liver injury.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemorad | 2011 |
Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2011 |
Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2011 |
Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2011 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, | 2012 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, | 2012 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, | 2012 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2012 |
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2012 |
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2012 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-F | 2012 |
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-F | 2012 |
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-F | 2012 |
Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2012 |
Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2012 |
Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2012 |
[Brain metastasis in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
[Brain metastasis in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
[Brain metastasis in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Da | 2012 |
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Da | 2012 |
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Da | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2012 |
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2012 |
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2012 |
[Protracted low-dose temozolomide combined with concomitant whole brain radiotherapy for brain metastases from non-small cell lung cancer].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Sma | 2011 |
[Protracted low-dose temozolomide combined with concomitant whole brain radiotherapy for brain metastases from non-small cell lung cancer].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Sma | 2011 |
[Protracted low-dose temozolomide combined with concomitant whole brain radiotherapy for brain metastases from non-small cell lung cancer].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Sma | 2011 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Ce | 2012 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Ce | 2012 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Ce | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
Cotard's syndrome with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Co | 2012 |
Cotard's syndrome with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Co | 2012 |
Cotard's syndrome with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Co | 2012 |
Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating | 2012 |
Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating | 2012 |
Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazi | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazi | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazi | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Admi | 2012 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Admi | 2012 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Admi | 2012 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; | 2012 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; | 2012 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; | 2012 |
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-F | 2012 |
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-F | 2012 |
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-F | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2012 |
Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; | 2012 |
Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; | 2012 |
Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; | 2012 |
Expression of O⁶-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2012 |
Expression of O⁶-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2012 |
Expression of O⁶-methylguanine DNA methyltransferase (MGMT) and immunohistochemical analysis of 12 pineal parenchymal tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2012 |
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic | 2013 |
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic | 2013 |
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic | 2013 |
SSBP2 variants are associated with survival in glioblastoma patients.
Topics: Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Genome-Wide Association Study; Glioblast | 2012 |
SSBP2 variants are associated with survival in glioblastoma patients.
Topics: Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Genome-Wide Association Study; Glioblast | 2012 |
SSBP2 variants are associated with survival in glioblastoma patients.
Topics: Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Genome-Wide Association Study; Glioblast | 2012 |
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasm | 2012 |
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasm | 2012 |
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasm | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2012 |
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2012 |
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2012 |
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neopla | 2012 |
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neopla | 2012 |
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neopla | 2012 |
MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Hum | 2012 |
MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Hum | 2012 |
MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Hum | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherap | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherap | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherap | 2012 |
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2012 |
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2012 |
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2012 |
Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Base Sequence; Blotting, Western; Brain Neoplasms; | 2012 |
Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Base Sequence; Blotting, Western; Brain Neoplasms; | 2012 |
Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Base Sequence; Blotting, Western; Brain Neoplasms; | 2012 |
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification | 2012 |
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification | 2012 |
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification | 2012 |
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; | 2012 |
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; | 2012 |
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; | 2012 |
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification | 2012 |
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification | 2012 |
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Treatment of elderly patients with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
Treatment of elderly patients with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
Treatment of elderly patients with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Humans; Male; | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Equ | 2012 |
Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Equ | 2012 |
Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Delivery Systems; Equ | 2012 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2012 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2012 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemotherapy, Adjuvant; Combine | 2012 |
Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemotherapy, Adjuvant; Combine | 2012 |
Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemotherapy, Adjuvant; Combine | 2012 |
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2012 |
Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2012 |
Initial treatment patterns over time for anaplastic oligodendroglial tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2012 |
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2012 |
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2012 |
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2012 |
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2012 |
Knockdown of CDK6 enhances glioma sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2012 |
Knockdown of CDK6 enhances glioma sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2012 |
Knockdown of CDK6 enhances glioma sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2012 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Ther | 2013 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Ther | 2013 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Ther | 2013 |
MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Mo | 2012 |
MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Mo | 2012 |
MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Mo | 2012 |
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Daca | 2012 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Daca | 2012 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Daca | 2012 |
Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Gli | 2012 |
Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Gli | 2012 |
Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Gli | 2012 |
A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined M | 2012 |
Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined M | 2012 |
Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined M | 2012 |
Glioblastoma therapy in the elderly: one age does not fit all.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Glioblastoma therapy in the elderly: one age does not fit all.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Glioblastoma therapy in the elderly: one age does not fit all.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2012 |
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2012 |
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Ma | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Ma | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Ma | 2012 |
Prognosis of patients with multifocal glioblastoma: a case-control study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cohort Studies; Combined Modalit | 2012 |
Prognosis of patients with multifocal glioblastoma: a case-control study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cohort Studies; Combined Modalit | 2012 |
Prognosis of patients with multifocal glioblastoma: a case-control study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cohort Studies; Combined Modalit | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2012 |
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2013 |
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2013 |
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2013 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Decision making and management of gliomas: practical considerations.
Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA | 2012 |
Decision making and management of gliomas: practical considerations.
Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA | 2012 |
Decision making and management of gliomas: practical considerations.
Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA | 2012 |
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2012 |
Prime time for molecular marker diagnostics in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Meth | 2012 |
Prime time for molecular marker diagnostics in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Meth | 2012 |
Prime time for molecular marker diagnostics in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Meth | 2012 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Com | 2013 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Com | 2013 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Com | 2013 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms | 2012 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms | 2012 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms | 2012 |
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Blott | 2012 |
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Blott | 2012 |
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Blott | 2012 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; D | 2013 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; D | 2013 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; D | 2013 |
Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amino Acid Transport System y+; Antineoplastic Agents, | 2013 |
Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amino Acid Transport System y+; Antineoplastic Agents, | 2013 |
Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amino Acid Transport System y+; Antineoplastic Agents, | 2013 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2013 |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2013 |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2013 |
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2013 |
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2013 |
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2013 |
Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tu | 2012 |
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tu | 2012 |
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tu | 2012 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Neuro-oncology: treatment decisions in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; | 2012 |
Neuro-oncology: treatment decisions in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; | 2012 |
Neuro-oncology: treatment decisions in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; | 2012 |
An efficient and practical radiosynthesis of [11C]temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Molecular Str | 2012 |
An efficient and practical radiosynthesis of [11C]temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Molecular Str | 2012 |
An efficient and practical radiosynthesis of [11C]temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Molecular Str | 2012 |
Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cni | 2012 |
Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cni | 2012 |
Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cni | 2012 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Immunohistochemical molecular gene expression profile of metastatic brain tumor as a potent personalized medicine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA | 2013 |
Immunohistochemical molecular gene expression profile of metastatic brain tumor as a potent personalized medicine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA | 2013 |
Immunohistochemical molecular gene expression profile of metastatic brain tumor as a potent personalized medicine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA | 2013 |
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2013 |
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2013 |
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine | 2012 |
Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine | 2012 |
Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine | 2012 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dac | 2012 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dac | 2012 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dac | 2012 |
Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Bystander | 2013 |
Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Bystander | 2013 |
Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Bystander | 2013 |
DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Topics: Apoptosis; Brain Neoplasms; Dacarbazine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Glio | 2013 |
DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Topics: Apoptosis; Brain Neoplasms; Dacarbazine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Glio | 2013 |
DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Topics: Apoptosis; Brain Neoplasms; Dacarbazine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Glio | 2013 |
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Antineoplastic Agents, Alkylating; Blotti | 2013 |
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Antineoplastic Agents, Alkylating; Blotti | 2013 |
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Antineoplastic Agents, Alkylating; Blotti | 2013 |
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2013 |
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2013 |
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnet | 2013 |
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnet | 2013 |
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnet | 2013 |
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assis | 2013 |
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assis | 2013 |
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assis | 2013 |
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2013 |
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2013 |
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell | 2013 |
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell | 2013 |
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell | 2013 |
Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2013 |
Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2013 |
Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured | 2013 |
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methy | 2013 |
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methy | 2013 |
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methy | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques | 2013 |
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques | 2013 |
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2013 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2013 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Breast metastasis of anaplastic oligodendroglioma: a case report.
Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiothera | 2012 |
Breast metastasis of anaplastic oligodendroglioma: a case report.
Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiothera | 2012 |
Breast metastasis of anaplastic oligodendroglioma: a case report.
Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiothera | 2012 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine | 2013 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine | 2013 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine | 2013 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2013 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2013 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2013 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; | 2002 |
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; | 2002 |
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cystitis; Dacarbazine; Female; | 2002 |
Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cystitis; Dacarbazine; Female; | 2002 |
Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Cystitis; Dacarbazine; Female; | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Bra | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Bra | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Bra | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2003 |
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2003 |
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbaz | 2003 |
Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbaz | 2003 |
Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbaz | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm | 2003 |
Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Leukemi | 2003 |
Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Leukemi | 2003 |
Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Leukemi | 2003 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inh | 2003 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inh | 2003 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inh | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2003 |
Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2003 |
Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2003 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; D | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; D | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; D | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci | 2004 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci | 2004 |
Long-term outcome of oligodendrogliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III a | 2004 |
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III a | 2004 |
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III a | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; C | 2004 |
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; C | 2004 |
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; C | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Li | 2004 |
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Li | 2004 |
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Li | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Ben | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Ben | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Ben | 2004 |
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2004 |
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2004 |
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarba | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarba | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarba | 2004 |
Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Esthesioneuroblastoma, Olfactory; F | 2004 |
Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Esthesioneuroblastoma, Olfactory; F | 2004 |
Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Esthesioneuroblastoma, Olfactory; F | 2004 |
The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Cell Cycle; Cyclic N-Ox | 2004 |
The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Cell Cycle; Cyclic N-Ox | 2004 |
The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Cell Cycle; Cyclic N-Ox | 2004 |
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2005 |
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2005 |
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2005 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simu | 2004 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simu | 2004 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simu | 2004 |
Hierarchical models for tumor xenograft experiments in drug development.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2004 |
Hierarchical models for tumor xenograft experiments in drug development.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2004 |
Hierarchical models for tumor xenograft experiments in drug development.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2004 |
Making inferences about projected completors in longitudinal studies.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2004 |
Making inferences about projected completors in longitudinal studies.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2004 |
Making inferences about projected completors in longitudinal studies.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combin | 2004 |
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Pr | 2004 |
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Pr | 2004 |
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Pr | 2004 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycy | 2004 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycy | 2004 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycy | 2004 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Gliobl | 2005 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Gliobl | 2005 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Gliobl | 2005 |
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromos | 2005 |
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromos | 2005 |
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromos | 2005 |
Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Chondrosarcoma, Mesenchym | 2005 |
Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Chondrosarcoma, Mesenchym | 2005 |
Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Chondrosarcoma, Mesenchym | 2005 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2005 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2005 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
Treatment of brain metastases from melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Endpoint | 2005 |
Treatment of brain metastases from melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Endpoint | 2005 |
Treatment of brain metastases from melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Endpoint | 2005 |
Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cimetidine; Dac | 2005 |
Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cimetidine; Dac | 2005 |
Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cimetidine; Dac | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Gene Silenc | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Gene Silenc | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Gene Silenc | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Fertility; Huma | 2005 |
Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Fertility; Huma | 2005 |
Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Fertility; Huma | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
Modeling antitumor activity in xenograft tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Computer Sim | 2005 |
Modeling antitumor activity in xenograft tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Computer Sim | 2005 |
Modeling antitumor activity in xenograft tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Computer Sim | 2005 |
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Current therapies for glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cranial Irradiation; Craniotomy; D | 2004 |
Current therapies for glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cranial Irradiation; Craniotomy; D | 2004 |
Current therapies for glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cranial Irradiation; Craniotomy; D | 2004 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G | 2006 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G | 2006 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G | 2006 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2005 |
Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2005 |
Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2005 |
Salvage temozolomide for prior temozolomide responders.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2005 |
Salvage temozolomide for prior temozolomide responders.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2005 |
Salvage temozolomide for prior temozolomide responders.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2005 |
Efficiency, quality and bureaucracy: not always in the same bag!!
Topics: Antineoplastic Agents, Alkylating; Biomedical Research; Brain Neoplasms; Clinical Trials as Topic; D | 2005 |
Efficiency, quality and bureaucracy: not always in the same bag!!
Topics: Antineoplastic Agents, Alkylating; Biomedical Research; Brain Neoplasms; Clinical Trials as Topic; D | 2005 |
Efficiency, quality and bureaucracy: not always in the same bag!!
Topics: Antineoplastic Agents, Alkylating; Biomedical Research; Brain Neoplasms; Clinical Trials as Topic; D | 2005 |
10 questions about temozolomide and the treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Temozolomide | 2005 |
10 questions about temozolomide and the treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Temozolomide | 2005 |
10 questions about temozolomide and the treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Temozolomide | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Dacarbazine; Drug Over | 2006 |
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Dacarbazine; Drug Over | 2006 |
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Dacarbazine; Drug Over | 2006 |
A congenital brain tumor associated with assisted in vitro fertilization. Case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2005 |
A congenital brain tumor associated with assisted in vitro fertilization. Case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2005 |
A congenital brain tumor associated with assisted in vitro fertilization. Case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Dacarbazine; Fe | 2005 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Chemotherapy for glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2006 |
Chemotherapy for glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2006 |
Chemotherapy for glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Humans; | 2006 |
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Humans; | 2006 |
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Humans; | 2006 |
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pai | 2006 |
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pai | 2006 |
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pai | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Complications of a temozolomide overdose: a case report.
Topics: Antineoplastic Agents, Alkylating; Bacterial Infections; Brain Neoplasms; Combined Modality Therapy; | 2006 |
Complications of a temozolomide overdose: a case report.
Topics: Antineoplastic Agents, Alkylating; Bacterial Infections; Brain Neoplasms; Combined Modality Therapy; | 2006 |
Complications of a temozolomide overdose: a case report.
Topics: Antineoplastic Agents, Alkylating; Bacterial Infections; Brain Neoplasms; Combined Modality Therapy; | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combi | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combi | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combi | 2006 |
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2006 |
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2006 |
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2006 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comorbidity; Dacarbazine | 2006 |
Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comorbidity; Dacarbazine | 2006 |
Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comorbidity; Dacarbazine | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2007 |
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2007 |
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2007 |
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Division; Cel | 2006 |
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Division; Cel | 2006 |
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Division; Cel | 2006 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adj | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adj | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adj | 2007 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Drug | 2007 |
Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Drug | 2007 |
Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Drug | 2007 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2007 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2007 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modali | 2007 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modali | 2007 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modali | 2007 |
Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cross-Priming; Dacarbazine; Dendritic C | 2007 |
Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cross-Priming; Dacarbazine; Dendritic C | 2007 |
Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cross-Priming; Dacarbazine; Dendritic C | 2007 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Binding, Competitive; Brain Neoplasms; Carrier Proteins; Cell Lin | 2007 |
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Binding, Competitive; Brain Neoplasms; Carrier Proteins; Cell Lin | 2007 |
O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Binding, Competitive; Brain Neoplasms; Carrier Proteins; Cell Lin | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacar | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacar | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacar | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA, Viral; Glioblastoma; Hepatitis | 2007 |
Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA, Viral; Glioblastoma; Hepatitis | 2007 |
Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA, Viral; Glioblastoma; Hepatitis | 2007 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2007 |
Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2007 |
Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2007 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; | 2006 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; | 2006 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; | 2006 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcom | 2007 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcom | 2007 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcom | 2007 |
A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therap | 2007 |
A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therap | 2007 |
A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therap | 2007 |
Multiple gangliogliomas of the optic pathway.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ganglioglioma; Humans; | 2006 |
Multiple gangliogliomas of the optic pathway.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ganglioglioma; Humans; | 2006 |
Multiple gangliogliomas of the optic pathway.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ganglioglioma; Humans; | 2006 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Stagin | 2007 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Stagin | 2007 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Stagin | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Int | 2007 |
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Int | 2007 |
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Int | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Com | 2007 |
Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Com | 2007 |
Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Com | 2007 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neo | 2007 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neo | 2007 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neo | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; | 2007 |
Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; | 2007 |
Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; | 2007 |
Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2007 |
Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2007 |
Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2007 |
Salvage chemotherapy in progressive high-grade astrocytoma.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; R | 2007 |
Salvage chemotherapy in progressive high-grade astrocytoma.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; R | 2007 |
Salvage chemotherapy in progressive high-grade astrocytoma.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; R | 2007 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Temozolomide in pediatric low-grade glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati | 2007 |
Temozolomide in pediatric low-grade glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati | 2007 |
Temozolomide in pediatric low-grade glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; H | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; H | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; H | 2007 |
Prophylactic radiotherapy for glioblastoma in the elderly.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2007 |
Prophylactic radiotherapy for glioblastoma in the elderly.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2007 |
Prophylactic radiotherapy for glioblastoma in the elderly.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2007 |
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Models, Ani | 2007 |
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Models, Ani | 2007 |
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Models, Ani | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2008 |
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2008 |
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2008 |
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dac | 2007 |
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dac | 2007 |
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dac | 2007 |
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2008 |
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2008 |
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2008 |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2008 |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2008 |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2008 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; | 2007 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; | 2007 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Acquired hypopigmentation (leukoderma) as a presenting feature of metastatic amelanotic melanoma with brain involvement.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; De | 2007 |
Acquired hypopigmentation (leukoderma) as a presenting feature of metastatic amelanotic melanoma with brain involvement.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; De | 2007 |
Acquired hypopigmentation (leukoderma) as a presenting feature of metastatic amelanotic melanoma with brain involvement.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; De | 2007 |
Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2007 |
Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2007 |
Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2007 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2008 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2008 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-B | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-B | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-B | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Chemother | 2008 |
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Chemother | 2008 |
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Chemother | 2008 |
[Treatment of marignant brain tumor: today and tomorrow].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Dacarbazine; Genetic Therapy; H | 2008 |
[Treatment of marignant brain tumor: today and tomorrow].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Dacarbazine; Genetic Therapy; H | 2008 |
[Treatment of marignant brain tumor: today and tomorrow].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Dacarbazine; Genetic Therapy; H | 2008 |
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2008 |
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2008 |
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2008 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2008 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2008 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up.
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2008 |
Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up.
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2008 |
Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up.
Topics: Antibodies, Antinuclear; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X | 2008 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X | 2008 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X | 2008 |
[Temozolomide: Temodal].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dac | 2008 |
[Temozolomide: Temodal].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dac | 2008 |
[Temozolomide: Temodal].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dac | 2008 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
[The sodium pump could constitute a new target to combat glioblastomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; | 2008 |
[The sodium pump could constitute a new target to combat glioblastomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; | 2008 |
[The sodium pump could constitute a new target to combat glioblastomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; | 2008 |
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Com | 2008 |
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Com | 2008 |
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Com | 2008 |
Low grade astrocytoma presenting with visual loss.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Daca | 2008 |
Low grade astrocytoma presenting with visual loss.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Daca | 2008 |
Low grade astrocytoma presenting with visual loss.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Daca | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Br | 2007 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Br | 2007 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Br | 2007 |
Multifocal glioblastoma multiforme with synchronous spontaneous hemorrhage: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cerebral Hemorr | 2008 |
Multifocal glioblastoma multiforme with synchronous spontaneous hemorrhage: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cerebral Hemorr | 2008 |
Multifocal glioblastoma multiforme with synchronous spontaneous hemorrhage: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cerebral Hemorr | 2008 |
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Reg | 2008 |
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Reg | 2008 |
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Reg | 2008 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; C | 2008 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; C | 2008 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; C | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Admini | 2008 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Admini | 2008 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Admini | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1994 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1994 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1994 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine | 1993 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine | 1993 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine | 1993 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Moda | 1997 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Moda | 1997 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Moda | 1997 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; | 1996 |
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; | 1996 |
Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Guanine; | 1996 |
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; DNA, Neopl | 1998 |
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; DNA, Neopl | 1998 |
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; DNA, Neopl | 1998 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R | 1999 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R | 1999 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R | 1999 |
Oral temozolomide approved for refractory brain tumor.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 1999 |
Oral temozolomide approved for refractory brain tumor.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 1999 |
Oral temozolomide approved for refractory brain tumor.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 1999 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch | 2000 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch | 2000 |
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch | 2000 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lym | 2000 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lym | 2000 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lym | 2000 |
Temozolomide (Temodal) for treatment of primary brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Monitoring; Glioblastoma; Huma | 2000 |
Temozolomide (Temodal) for treatment of primary brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Monitoring; Glioblastoma; Huma | 2000 |
Temozolomide (Temodal) for treatment of primary brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Monitoring; Glioblastoma; Huma | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Temozolomide for refractory anaplastic astrocytoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinic | 1999 |
Temozolomide for refractory anaplastic astrocytoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinic | 1999 |
Temozolomide for refractory anaplastic astrocytoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinic | 1999 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
Temozolomide chemotherapy in recurrent oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence | 2001 |
Temozolomide chemotherapy in recurrent oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence | 2001 |
Temozolomide chemotherapy in recurrent oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Reso | 2001 |
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Reso | 2001 |
Possible efficacy of temozolomide in a patient with gliomatosis cerebri.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Humans; Magnetic Reso | 2001 |
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2001 |
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2001 |
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2001 |
NICE verdict on Temozolomide: where next?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2002 |
NICE verdict on Temozolomide: where next?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2002 |
NICE verdict on Temozolomide: where next?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2002 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |